<SEC-DOCUMENT>0001410578-23-000324.txt : 20230322
<SEC-HEADER>0001410578-23-000324.hdr.sgml : 20230322
<ACCEPTANCE-DATETIME>20230322080036
ACCESSION NUMBER:		0001410578-23-000324
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230322
DATE AS OF CHANGE:		20230322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Marker Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001094038
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880277072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37939
		FILM NUMBER:		23751448

	BUSINESS ADDRESS:	
		STREET 1:		4551 KENNEDY COMMERCE DR.
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77032
		BUSINESS PHONE:		(713) 400-6400

	MAIL ADDRESS:	
		STREET 1:		4551 KENNEDY COMMERCE DR.
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77032

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC.
		DATE OF NAME CHANGE:	20170629

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TAPIMMUNE INC
		DATE OF NAME CHANGE:	20070628

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENEMAX CORP
		DATE OF NAME CHANGE:	20020718
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrkr-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/22/2023 11:51:18 AM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: ac7eb4b8-7da2-44b8-b324-d3b763b73079 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:mrkr="http://www.tapimmune.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" xs:nil="true" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" name="us-gaap:PreferredStockValue" id="Hidden_bxX6QbSpekC8G-HwtQb90Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" xs:nil="true" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" name="us-gaap:PreferredStockValue" id="Hidden_eDcSIFJbBkiEl4pe1p3BoA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" id="Hidden_FuIPzOWfjEuw7JcSqUHBnw">4704611</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" id="Hidden_b9x6r4ODwECU40jh-cbSzg">11134913</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityCentralIndexKey" id="Tc_EF5PdThRwEmKAfFPFR4CbQ_2_1">0001094038</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:CurrentFiscalYearEndDate" id="Tc_fw8kQSq4vkaOYAk0XfPjMA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:DocumentFiscalYearFocus" id="Tc_XbDIQYM06k-eAlvH8-NlXA_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_QXUcs95exkKn0GsePHHGng_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:AmendmentFlag" id="Tc_XdWKaixp50qBJOya_RlCUA_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:IcfrAuditorAttestationFlag" id="Tc_BeV59xUVLEuI-GjO_48wvw_7_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" name="us-gaap:CommonStockSharesIssued" id="Hidden_XJzDz4-ELkOS8norAoOL8w">8300000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_J5UYgV3izECAEBRrpVGnhg">8400000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_lhALYDffbEuklraKG2XQmQ" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" id="Hidden_VRXEGsrXjkaiFVGne_HW4A">3513544</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_hMFFrHQHMkq7-EVZp3BQdw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-6" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_1HJlOWutCU21PJuZ_5nO2w">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mrkr-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_12_2022_To_12_12_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kp85NnJBBUmUhXIRR_MpQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-12</xbrli:startDate><xbrli:endDate>2022-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_DRQziVPupkyucYZQUxu7CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F6wReus0oEaCdo351uy7TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_21_2021_To_4_21_2021_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_ZclhqIbMvU-O8EfMWIhhgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-21</xbrli:startDate><xbrli:endDate>2021-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HZfAycR2kk-ZXkhm82bVPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_j-Tt7k3AAEelDRzuTV__kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_lYIjNL0t2E6NNbd5622y6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmkYNaQrdkaCT93Kx5jgTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GdnjYANna0qQFgzGMImcPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egIQ7QghbkGRIjamiNWiUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FBFeOkr3ykuSOy5dBngOrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1uzjGStWO06DZSlcFGbVsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GInYc9c9Y0moOPtffvDIDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8cq4aMH20Sb7VO8y3pJew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_npaXz9T0mUaUNEGeD_jgZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_S5Q4yNrC5UKGn_ImsQmXDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_24_2022_To_5_24_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ubwm1qD4wE-HsJvlsJGJpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-24</xbrli:startDate><xbrli:endDate>2022-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ZEI3kl26Pk2zgb9tiZo19w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_OptionIndexedToIssuersEquityTypeAxis_mrkr_NonEmployeeStockOptionMember_gbP12LhguU6WycZv51CdaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">mrkr:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A-AeQilLX0WzYGhiZT07Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3OQQVZE1uEm384QeLqzj-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_U85KQ1vJe0u5uT4iGCYd1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAwards2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_F-6NSFyNk0uhy-tFDHx2jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAwards2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_kUuUrHRKk0G10jpx1s-bkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_yIinahL4sEGqxYXSIhjnhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_pVnVS7CZdEWMB5iww4KJeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrkr:NonExecutiveEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_meicGgKvzUadt_zzSUx2eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ltpSYmw2Ck-js4TXpUSbpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_GhcbliHPX0GLe0R12grctQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_CgqUPlC4VU6qTAV9KfQcqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_pGIzcYnvJEiT9dhMXsElQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_JUDa3cw9BUK0ZTYPzI9s9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2022-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_AxyTiy7MlUuwc7GAnr3jLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4Mlx9tG1EEGFYz6EXdp5Vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mhcEIpDJQkmXGgO5cKQZuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_J2wzhp4PQ0yD55El3XelKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-17</xbrli:startDate><xbrli:endDate>2022-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2022_To_1_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_JbX3ZgrhrUCG3fxE5SiYMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OcBdsIpxMk6PRtghWozW-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_14_2023_To_3_14_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_AllovirIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1XuOmQ5XPUeNbdcsl4Y23g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:AllovirIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ServiceMember_sVgjmKoubkywnwtNRRNxpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_lhALYDffbEuklraKG2XQmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_Z55ugQPT_kKUAhzu1ioV8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_QveB1kU3tkucob1EUaCgcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mrkr:OperationalCostReductionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_8-nrYuOdiEO8hicagC8Wcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_92UkqyWHCkqZKAb3ohfj-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_BMzNUjdDhUG_b5P76LRATw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_I0FgPzQc2EedkO5jGv2oEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_FG_G8klQXUmj79kiu1yNMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_awMWjIqo90CWdC9K0cfcDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_sQrTMozyWEyU4ra-AUAZ2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_McT4zbJriU6hB34bDlJjeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_eEnb8GgPoU6evepNcjl2rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NXup2CJ02USDTLUpDls9hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_iRDTtaZteEiLcISmCUciWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TLp-qtPIB02goeZcg_RReg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mMYtiCFfIEK_bdrpJ5dMRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_qtmbiBYUXEGhAeHMenyf7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_VtFCZtpzqUS4hInYPoLNNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nqoFwEJHwUmDvKu-C4t_AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kiI02v_yr0miZEzODZfWew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_zKhfppn7GEWXbnJMKir-Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_jSWMIRhbp0WIJO4zq_1XRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:ExerciseOfStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_VP3-b6HOUk2DKLQ51VCCBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtmAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_us-gaap_SubsequentEventMember_Yue1bky0HUK0DiPiPA1ZmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_EA2qnlAMxUapgXjRK0-39A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_l66B3TClFEmlIWsk1ybpMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_G1H72RYOhku1flLkvnmwxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6tRxU7Rie0-8urQAVoZMJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JKGI8Nx-2kSnc6KA5Cd6jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_NlI_rrXrCkWSdi8cy_jNIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_9_2023_To_1_9_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tgbt7OSC3EulA327h83DEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_sD7iYvHxZkqwyKox7Z0qJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mrkr:OperationalCostReductionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_elmgfz9S-0W_ZDXK3WDiaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_73WDhaJFhk26kf_aw8N7qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_de53l1GX8kGkNWjZK3KpnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_McFGqwTRbE2KSZ_az8T4DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_yhp5Hv7lwkaZQV2FAXpIpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_w84Uaz3YUEqYjRHmFPZttg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6ka_iEmMjE2aQAOD6iwO8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_XPzhwj-erUqIBzQu-ulhQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RangeAxis_srt_MinimumMember_PZ0RPJnwKk65BP6T537-EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_RangeAxis_srt_MaximumMember_dikyAbnEbkGQJoXUA7yMkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_EhfaszvU3UinGypAqqyo6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:ExerciseOfStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_5W-EffSPAk-sIjPcaw3pDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NGUNmIMxGkq1Z8jXaWqHoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_I0jHwwB580SqyJF3TUAQmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_93kl4ltjMUiFOgjh_0uOaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbjncsNOXUKlnyjr3E54gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2023_To_1_26_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oBMB2ozYCUm78jnnAf9ERw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-26</xbrli:startDate><xbrli:endDate>2023-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_RYoECPvlqUm2SecYEAk3nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_xLzOljk2o0KBWMLiKybJag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_WhoS9ltZXk6NBcS9AfdoJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-21</xbrli:startDate><xbrli:endDate>2022-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_75w7V3-2uEiEHBbWok-lEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_E_6jM-m13kOR5Fzj9eeTUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2021_To_3_11_2021_ipD27hsbDkSP-aqaxEKH-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-11</xbrli:startDate><xbrli:endDate>2021-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_y6evzTYbj0ikSh5RHLTXHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2022-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_YqaWefj0tk20njxWAVYeyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_uGqtaqdy20eQ6t52skgzRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrkr:NonExecutiveEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-17</xbrli:startDate><xbrli:endDate>2022-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_UIJSoFc-BEakDbs6zOJBIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrkr:NonExecutiveEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-11</xbrli:startDate><xbrli:endDate>2021-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_9_2022_To_3_9_2022_mHWNE8BszkWyzvOf2FXUaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-09</xbrli:startDate><xbrli:endDate>2022-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_13_2022_To_9_13_2022_w0iIOXYe5U2sofHNZfyE-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-13</xbrli:startDate><xbrli:endDate>2022-09-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-13</xbrli:startDate><xbrli:endDate>2023-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7NoYkmU3T0yNAjX5qvt6FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_d7Z-oISLakWWyRl9aSgT8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_JT2ojtlpfUiPgirbtHOffA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OtJ-a1ZIt0GTo1DBVaijBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bQJrMgrRIEih2ZZ5LZh_Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DbSC03W-N0uqTlyKBJ9KHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RBkehlwI7UK7Hw7PXAvVhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_rJJmBdCj7EOIPmbz9BOYyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_sdKnf_W3b06nZ9jMBEsNJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2022_To_3_24_2022_IbGXbqvguEioxE6sArNnqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-24</xbrli:startDate><xbrli:endDate>2022-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_13_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_UoBREzfn7kO2CeAdFJzHPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_4_2023_To_1_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uUaeHZ6WLE2MqQaG64NZzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-04</xbrli:startDate><xbrli:endDate>2023-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_LiJpe6ByN0awpAG6BNal_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2023_76HOzdeFcEmvS3bm87KgOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001094038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw"><xbrli:measure>mrkr:installment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 15pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:48.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_80d2fa41_025d_4d4d_9e41_d1da1929010f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:DocumentType" id="Narr_aFuDoL2z9kaAPt2E7r0BQw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ac7c0859_eda2_4f03_8547_effe1ab84986"></a><a id="Tc_X0954KZUPU6XrmbmolkWFQ_0_1"></a><a id="Tc_S3XAM3ff-E6Y6oxl1t1Nvw_2_0"></a><a id="Tc_iEquFsC16EmtA4jNAWGYVw_4_1"></a><a id="Tc_Iwn11CBQpUO5X0X1YnufJA_6_1"></a><a id="Tc_XZ4t4zZZVUqlNSz2lxHxyg_8_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:DocumentAnnualReport" id="Tc_ibzjZI3SIkuByPlvtYINuA_0_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the Fiscal Year Ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:DocumentPeriodEndDate" id="Narr_OM_fOHw7vkm04Zgcq55WIg"><b style="font-size:7pt;font-weight:bold;">December 31, 2022</b></ix:nonNumeric></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:DocumentTransitionReport" id="Tc_PrrRKs5ZbkShw_ZKMOGvrQ_6_0"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">For the transition period from _______________ to ______________.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityFileNumber" id="Narr_igKbb5PLx0OeCsQAjV6ZJQ"><b style="font-size:7pt;font-weight:bold;">001-37939</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><img src="mrkr-20221231x10k001.jpg" alt="Graphic" style="display:inline-block;height:47.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:177.84pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityRegistrantName" id="Narr_Yfq2b0KUGkm1J6huij49lw"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MARKER THERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_11ec842d_d288_4c27_b8c1_6be4f6168352"></a><a id="Tc_hCCC9bEzXEKY7ppk3A3GvQ_1_0"></a><a id="Tc_DKW5YM5iX0uZx9ohF724ng_1_2"></a><a id="Tc_P-yACkujtUeGCgOmiEIasg_3_0"></a><a id="Narr_NICzw0pFqE23GJU-nzEEew"></a><a id="Tc_vGwQ7gST6USKpYcExTNZ3A_4_0"></a><a id="Tc_ZKD0QimIvUCIX7ViOkU4BA_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_mj3qO2Iu6UqzHtSKdgHZqA_0_0"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityTaxIdentificationNumber" id="Tc_h3KgBaB-pU-QenO3WPNJRA_0_2"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">45-4497941</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(State or other jurisdiction of<br />incorporation)</p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityAddressAddressLine1" id="Narr_oBs65FQ9oEi6S_lRh_fXCg"><b style="font-size:7pt;font-weight:bold;">4551 Kennedy Commerce Drive</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityAddressCityOrTown" id="Narr_qMXioG5j7EuidT6GazGKeQ"><b style="font-size:7pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityAddressStateOrProvince" id="Narr_Nt1ltKW3IES4RPjqEh5IdQ"><b style="font-size:7pt;font-weight:bold;">Texas</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityAddressPostalZipCode" id="Tc_FriPNodcYUOdsr4XHAwXog_3_2"><b style="font-size:7pt;font-weight:bold;">77032</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:52.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:CityAreaCode" id="Narr_XfLthzsVokqDn2TwWqHDLQ"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">713</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:LocalPhoneNumber" id="Narr_-MPvI-fK70airuy1DCpYzA"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">400-6400</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">(Telephone Number)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.91%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">3200 Southwest Freeway, Suite 2500, Houston, Texas, 77027</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Former name, former address and former fiscal year, if changed since last report)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;text-transform:uppercase;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_30fd9b93_e51f_4292_9f56_eefebf830d65"></a><a id="Tc_O1VhQc1SrkGEAFRLyEbmyQ_1_0"></a><a id="Tc_i41TmCQcmkeUwTdjhpwe8Q_1_2"></a><a id="Tc_ZpNOz6xchkqTM0s49U5Nqg_1_4"></a><a id="Tc_eaDnykj-KUqOIMSOThIdxA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:0.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:29.07%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:0.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:33.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:bottom;width:35.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:Security12bTitle" id="Tc_DtfRfvt7g0mhsd86qiTfyw_2_0"><span style="font-size:7pt;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.07%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:TradingSymbol" id="Tc_7PYDcYKU80aDR8quPGhjPw_2_2"><span style="font-size:7pt;">MRKR</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:0.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:SecurityExchangeName" id="Narr_ed5SITrnJ0C_JFb3hB2UJQ"><span style="font-size:7pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:7pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_uxoL9U4ozEiSekr4-yxhPQ"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 of Section&#160;15(d)&#160;of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityVoluntaryFilers" id="Narr_Gd4KlgJ5yUutc3Ep7Mgndw"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityCurrentReportingStatus" id="Narr_0vHAcwq150a4NxkV2AiHeg"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityInteractiveDataCurrent" id="Narr_G5NIjIrrKEqZD2vpOFDkFw"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8328f2dc_9b0a_4e2e_92e1_9eeb50d1cfd8"></a><a id="Tc_tHYa3Aq_7Um7U1bpS3PMow_1_0"></a><a id="Tc_H4c7JixJIkaTV8KVJQbTuQ_1_1"></a><a id="Tc_LZBFQdfct0OxIXYXY1Ky0A_1_2"></a><a id="Tc_f56fN49h8E6bpNRVXCsaow_1_3"></a><a id="Tc_o5rqnPgHAUqT7pWdkkQNWw_2_1"></a><a id="Tc_L6ju9IXzrUKlqpqT_L2W7Q_2_2"></a><a id="Tc_alEiCL1zCEuoO3HNm0aICQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityFilerCategory" id="Tc_JrH6cZRRE0iDJroZr1fXkQ_2_0"><span style="font-size:7pt;">Non-accelerated filer </span></ix:nonNumeric></p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntitySmallBusiness" id="Tc_Rg3paNmquUe1tgULphdmLg_2_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityEmergingGrowthCompany" id="Tc_SWxieoZpb0a11kptj5gZ5g_3_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:IcfrAuditorAttestationFlag" id="Narr_Of-JJ9qKz02tarEA2JHaMQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. [&#160;&#160;&#160;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). [&#160;&#160;&#160;]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;">Indicate by checkmark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;No </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:EntityShellCompany" id="Narr_7B_Wj0M_GEuns2PoF-AJeA"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June&#160;30, 2022 (the last day of the registrant&#8217;s most recently completed second fiscal quarter) based on the closing sale price of $3.30 as reported on the Nasdaq Capital Market as of that date was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2022_LiJpe6ByN0awpAG6BNal_g" decimals="0" name="dei:EntityPublicFloat" id="Narr_pdVFRMThikW8dOUsd8eFhg">22,800,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">The registrant had <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_17_2023_76HOzdeFcEmvS3bm87KgOQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_8Qlztl1x8UajNF3WNNiDdw">8,798,829</ix:nonFraction> shares of common stock outstanding as of March 17, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Documents Incorporated By Reference</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Portions of the registrant&#8217;s proxy statement relating to registrant&#8217;s 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120&#160;days after the close of the registrant&#8217;s fiscal&#160;year, are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K. Except with respect to information specifically incorporated by reference in this Annual Report on Form&#160;10-K, the Proxy Statement is not deemed to be filed as part of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2736262a_5841_4826_80f5_a5c6b280c735"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#FORWARDLOOKINGSTATEMENTS_197689"><span style="font-style:normal;font-weight:normal;">FORWARD&#160;LOOKING&#160;STATEMENTS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">ii</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTI_513007"><b style="font-style:normal;font-weight:bold;">Part I</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1BUSINESS_525596"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUSINESS_525596"><span style="font-style:normal;font-weight:normal;">Business&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_686864"><span style="font-style:normal;font-weight:normal;">Item 1a.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_686864"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"><span style="font-style:normal;font-weight:normal;">Item 1b.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM2PROPERTIES_338462"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2PROPERTIES_338462"><span style="font-style:normal;font-weight:normal;">Properties&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_282506"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_282506"><span style="font-style:normal;font-weight:normal;">Legal Proceedings&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURE_456568"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURE_456568"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosure&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTII_862782"><b style="font-style:normal;font-weight:bold;">Part II</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><span style="font-style:normal;font-weight:normal;">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_944586"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6RESERVED"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion And Analysis Of Financial Condition And Results Of Operations&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item 7a.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative And Qualitative Disclosures About Market Risk&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTS_684464"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTS_684464"><span style="font-style:normal;font-weight:normal;">Financial Statements&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><span style="font-style:normal;font-weight:normal;">Changes In And Disagreements With Accountants On Accounting And Financial Disclosure&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_136839"><span style="font-style:normal;font-weight:normal;">Item 9a.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9ACONTROLSANDPROCEDURES_136839"><span style="font-style:normal;font-weight:normal;">Controls And Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_833436"><span style="font-style:normal;font-weight:normal;">Item 9b.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_833436"><span style="font-style:normal;font-weight:normal;">Other Information&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;">Item 9c</span></a>.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM9CDISCLOSUREREGARDINGFOREIGNJURISDIC"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIII_534190"><b style="font-style:normal;font-weight:bold;">Part III</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers And Corporate Governance&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_899018"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_899018"><span style="font-style:normal;font-weight:normal;">Executive Compensation&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><span style="font-style:normal;font-weight:normal;">Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><span style="font-style:normal;font-weight:normal;">Certain Relationships And Related Transactions, And Director Independence&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees And Services&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIV_855523"><b style="font-style:normal;font-weight:bold;">Part IV</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_680075"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM16FORM10KSUMMARY_680075"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary&#160;</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_77138615_8a8e_4708_bd07_c2b6e2b3b569"></a><a id="FORWARDLOOKINGSTATEMENTS_197689"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORWARD LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This annual report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part&#160;I, Item&#160;1:&#160;&#8220;Business,&#8221; Part&#160;I, Item&#160;1A: &#8220;Risk Factors,&#8221; and Part&#160;2, Item&#160;7: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this annual report. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;intend&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221; or &#8220;continue&#8221;, the negative of such terms or other comparable terminology. These statements speak only as of the date of this Annual Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.&#160;We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations.&#160; Forward-looking statements in this annual report include statements as to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue as a going concern;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the timing, progress and results of clinical trials of multi tumor associated antigen (<span style="font-family:'Symbol';">&#8220;</span>multiTAA<span style="font-family:'Symbol';">&#8221;</span>)-specific T cell therapies and our other product candidates, including statements regarding the timing of initiation and completion of preclinical studies or clinical trials or related preparatory work, the period during which the results of the trials will become available and our research and development programs;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the timing of any submission of filings for regulatory approval of product candidates and our ability to obtain and maintain regulatory approvals for product candidates for any indication;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to successfully commercialize product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our expectations regarding the size of the patient populations, market acceptance and opportunity for and clinical utility of product candidates, if approved for commercial use;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our manufacturing capabilities and strategy, including the ease, scalability and commercial viability of our manufacturing methods and processes;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our expectations regarding the scope of any approved indications for product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the potential benefits of and our ability to maintain our relationships and collaborations with the Baylor College of Medicine and other potential collaboration or strategic relationships;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to use the multiTAA-specific T cell platform to develop future product candidates;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional funding;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to identify, recruit and retain key personnel;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our ability to protect and enforce our intellectual property position for our product candidates, and the scope of such protection;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our financial performance;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">our competitive position and the development of and projections relating to our competitors or our industry; and</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the impact of laws and regulations.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should refer to &#8220;Item&#160;1A. Risk Factors&#8221; in this annual report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this annual report represent our views as of the date of this annual report. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this report all references to (i) &#8220;Marker&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221; mean Marker Therapeutics, Inc. and its wholly-owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals, Inc., which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) &#8220;SEC&#8221; refers to the Securities and Exchange Commission; (iii) &#8220;Securities Act&#8221; refers to the United States <i style="font-style:italic;">Securities Act of 1933</i>, as amended; (iv) &#8220;Exchange Act&#8221; refers to the United States <i style="font-style:italic;">Securities Exchange Act of 1934</i>, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_feeff9d6_39bc_4e65_b508_bdbf9233087a"></a><a id="PARTI_513007"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART I</b></p><a id="ITEM1BUSINESS_525596"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1. BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens, or TAAs. MultiTAA-specific T cells are able to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. When infused into a cancer patient, the multiTAA-specific T cells are designed to kill cancer cells expressing the TAA and potentially recruit the patient&#8217;s immune system to participate in the cancer killing process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We licensed the underlying technology for multiTAA-specific T cell therapy from Baylor College of Medicine, or BCM, in March 2018. BCM had utilized the therapy in seven exploratory clinical trials. In these studies, BCM treated over 150 patients suffering from a variety of cancers including lymphoma, multiple myeloma, acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, pancreatic cancer, breast cancer and various sarcomas. In those studies, BCM saw evidence of clinical benefit, expansion of infused cells epitope spreading, and decreased toxicity compared to other cellular therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are advancing three product candidates as part of our multiTAA-specific T cell program for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">autologous treatment of lymphoma, and selected solid tumors </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allogeneic T cells for the treatment of AML</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">off-the-shelf products in various indications</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not genetically engineer our multiTAA-specific T cell therapies and we believe that our product candidates are superior to T cells engineered with chimeric antigen receptors, or CAR-T, for several reasons including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple targets &#8594; enhanced tumoricidal effect&#8594; minimized tumor immune escape</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Epitope spreading &#8594; broad patient T cell expansion &#8594; durable endogenous antitumor immune response</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical safety &#8594; no reported cytokine release syndrome (CRS) or other severe adverse effects (SAEs) in our clinical trials to date</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Standard IV administration &#8594; outpatient treatment &#8594; enhanced accessibility</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-engineered &#8594; reduced manufacturing complexity &#8594; lower cost</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:206.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20221231x10k002.jpg" alt="Graphic" style="display:inline-block;height:206.22pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:362.95pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For these reasons, we believe our endogenous T cell receptor-based therapies may provide meaningful clinical benefit and safety to patients with both liquid and solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the simplicity of our manufacturing process allows additional modifications to expand multiTAA-specific T cell recognition of cancer targets. For example, we are currently analyzing the potential for a 12-antigen multiTAA-specific T cell therapy. We are also assessing the potential of combining multiTAA-specific T cell products with other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have positioned ourselves to be in full control of our research and development and clinical manufacturing needs by establishing a fully validated, FDA registered, manufacturing facility. We believe that this has key advantages that distinguish us from our competitors, particularly because we are less reliant on contract manufacturing organizations, which are expensive and often have long lead times, shortages of skilled labor and a backlog of customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Company-Sponsored Clinical Development of Multi-TAA Specific T Cell Therapies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MT-401 for the Treatment of Post-Transplant AML</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are pursuing post-transplant AML as the lead indication for our first company-sponsored multiTAA-specific T cell program in the ARTEMIS study. We submitted an investigational new drug, or IND, application to the FDA, to conduct a Phase 2 clinical trial of multiTAA-specific T cell therapy, which we refer to as MT-401 (zedenoleucel), in post-allogeneic HSCT patients with AML in both the adjuvant and active disease setting. The dose administered in this multicenter trial is currently 200 million cells every two weeks for three doses. In the adjuvant setting, patients will be randomized to either multiTAA-specific T cell therapy or standard of care (observation) at approximately 90 days post-transplant, while the active disease patients will receive MT-401 following relapse post-transplant as part of a single-arm group.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In April 2020, the Orphan Product Development Office of the United States Food and Drug Administration, or the FDA, granted orphan drug designation to MT-401 (zedenoleucel), a multiTAA-specific T cell therapy that targets four TAAs, for the treatment of AML.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The same multiTAA-specific T cell therapy has been well tolerated in an ongoing Phase 1 clinical trial in AML and myelodysplastic syndrome, or MDS, conducted by our strategic partner Baylor College of Medicine, or BCM.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As reported in a 2021 publication by Lulla et al., 11 of the 17 patients in the adjuvant disease setting dosed with the multiTAA-specific T cell therapy after receiving an allogeneic hematopoietic stem cell transplant, or HSCT, never relapsed [median leukemia-free survival, or LFS, not reached at a median follow-up of 1.9 years], with 11 of 15 patients (two patients were each treated during two different remissions) remaining alive (estimated two-year overall survival of 77%) at a median follow-up of </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.9 years post-infusion, which compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT [median LFS of nine to 15 months and two-year survival probability of 42%].</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additionally, eight patients were treated for active disease that was resistant to salvage therapy post-HSCT with a median of five prior lines of therapy (range: four to 10).</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One of the eight patients crossed over from the adjuvant group, while two patients enrolled twice, but all three patients had active AML that failed another line of salvage therapy after their first multiTAA-specific T cell infusion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two of the eight patients achieved objective responses, with one complete response and one partial response, with six patients continuing with stable disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have observed evidence of a patient&#8217;s natural immune system participating in cancer killing (epitope spreading) after infusion of our multiTAA-specific T cell therapy.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The ARTEMIS trial conducted by Marker has completed in June 2021 the safety lead-in portion, which tested the comparability of MT-401 or zedenoleucel, the multiTAA-specific T cell product manufactured using peptides from two different vendors and enrolled six patients with active disease: one measurable residual disease (MRD) positive patient and five frank relapse patients.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consistent with the results of the BCM Phase 1 trial, there were no dose-limiting toxicities, cytokine release syndrome or neurotoxicity observed in this stage of the trial, and one MRD+ patient became MRD- after infusion of MT-401. Correlative studies showed that the patient saw significant expansion of infused multiTAA-specific T cells in addition to extensive epitope spreading. There were no objective responses from the frank relapse patients. By November 2022, all six patients had completed dose-limiting toxicity (DLT) periods with no DLTs reported.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the fourth quarter of 2021, the manufacturing of MT-401 for the Phase 2 trial started at the Marker Cell Therapy cGMP manufacturing facility, named MCTF01. &#160;The Company transitioned to treating patients using MT-401 manufactured with Marker&#8217;s new T cell manufacturing process. Specifically, the new process involves an improved T cell manufacturing process for MT-401 that reduces production time to 9 days (compared to the original process of &gt;30 days). This new process enabled a &gt;90% reduction in the number of operator interventions during production and an improved final T cell product candidate compared to the original product candidate used in the ARTEMIS trial. These process improvements have yielded an MT-401 product candidate that has five times the measurable specificity and four times the potency in terms of tumor killing as compared to the prior manufacturing process. We have now treated 12 patients with MT-401 manufactured using our improved manufacturing process, with 16 patients treated with MT-401 manufactured using the original process, for a total of 28 patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">After completing the safety lead-in portion, we initiated the remainder of the Phase 2 trial in July 2021, in which we intend to enroll 210 patients at approximately 20 transplant centers. Group 1 will comprise of 150 adjuvant (disease-free) patients, with the primary endpoint of relapse-free survival of patients randomized to receive MT-401 versus a control group. Group 2 will comprise of 60 active disease patients in a single arm, with primary endpoints of complete remission and duration of complete remission.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, a total of 11 patients in the adjuvant arm of the ARTEMIS study have been randomized to treatment with MT-401 using a new manufacturing process or to standard-of-care. &#160;All patients are too early for evaluation, but the Data Monitoring Committee has reviewed the existing safety data and has not identified any concerns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A total of four MRD+ patients have been treated and are currently evaluable. Two MRD+ patients were treated with MT-401 manufactured using the original manufacturing process and showed elimination of detectable disease. Two additional MRD+ patients were treated with MT-401 manufactured used in the improved process.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The first MRD+ patient was treated at 100 x 106 cells per infusion and was able to remain in stable disease for six months, allowing the patient to bridge to a second allogeneic transplant. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The second MRD+ patient was dosed at 200 x 106 cells per infusion and the PCR value, which proved to be a valuable tool for detecting MRD, has decreased by 70% only four weeks after the last infusion. This patient&#8217;s disease status will continue to be closely monitored and evaluated. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A fifth MRD+ patient has been treated with MT-401 manufactured used in the improved process but is too early for evaluation. Additional MRD+ patients have been enrolled and are awaiting treatment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We anticipate reporting a data readout of the MRD+ patient subset in the second half of 2023.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, a total of 15 frank relapse patients have been treated. In addition to the 11 patients previously reported, who were treated with MT-401 manufactured using the original manufacturing process, four additional patients have been treated with MT-401 manufactured using the improved manufacturing process.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Of the four patients treated with the improved manufacturing process, one of these patients received a dose of 100 x 106 cells per infusion, while the other three patients were dosed at 200 x 106 cells per infusion. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">None of the frank relapse patients showed an objective response to therapy. &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have suspended further enrollment of frank relapse patients while re-evaluating additional modifications for this patient cohort, including potentially higher cell doses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, we announced that we had been awarded a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of minimal residual disease in post-transplant AML after allogeneic stem cell transplant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Off-the-shelf MT-401 (MT-401-OTS) for the Treatment of AML</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We intend to expand our AML program with the development of MT-401-OTS, a scalable, off-the-shelf product candidate with the potential to provide treatment to patients in under three days. We intend to dose patients using &#8220;banked&#8221; products based on human leukocyte antigen matching. We believe our off-the-shelf platform has high scalability, where one donor has the potential to provide more than 100 patient products. Our open IND for MT-401 for the treatment of AML includes clearance of the protocol that will test the safety and efficacy of the off the shelf product in patients with AML/MDS who cannot access their HSCT donor. We are in the process of developing our patient cell bank inventory and expect to dose the first patient in 2023. &#160;We expect to expand our off-the-shelf platform into clinical trials for other hematological malignancies and solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MT-601 for the Treatment of Pancreatic Cancer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We reported interim data for an ongoing Phase 1/2 clinical trial (TACTOPS) of the multiTAA-specific T cell therapy targeting five TAAs for the treatment of pancreatic adenocarcinoma being conducted by BCM. In this trial, we have observed a clinical benefit with 4 of 13 patients (31%) showing objective responses in front-line unresectable or metastatic pancreatic cancer which correlated with the post-infusion detection of tumor-reactive T cells in patient peripheral blood and within tumor biopsy samples in patients in the tumor-resection arm of the trial. These T cells exhibited activity against both targeted antigens and non-targeted TAAs, indicating induction of antigen spreading. To date, we have not observed any cytokine release syndrome or neurotoxicity in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recently began developing multiTAA-specific T cells in pancreatic cancer with product manufactured with two additional antigens when compared to MT-401, to which we refer as MT-601, starting at a similar dose level used in the TACTOPS study. MT-601 is a multiTAA-specific T cell product targeting six tumor-associated antigens which are highly expressed in pancreatic cancer. In January 2022, the FDA granted orphan drug designation to MT-601 for the treatment of patients with pancreatic cancer. The FDA cleared the Company&#8217;s IND application for MT-601 in November 2022 to initiate the PANACEA study, a Phase 1 multicenter clinical trial in locally advanced, unresectable or metastatic pancreatic cancer to assess the safety and efficacy of MT-601 in combination with front-line chemotherapy. We expect to initiate the PANACEA study by the fourth quarter of 2023 and to enroll a total of approximately 40 patients. The PANACEA trial will include a dose escalation portion followed by a dose expansion portion, with a dose of 200 - 400 million cells every four weeks for up to six doses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:261.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MT-601 for the Treatment of Lymphoma</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also pursuing the development of MT-601 for the treatment of lymphoma. &#160;In August 2022, the FDA cleared the Company&#8217;s IND application for MT-601 for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment. &#160;The Phase 1 clinical trial, named APOLLO study, was initiated in the first quarter of 2023, and we anticipate reporting a clinical readout in the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Additional Clinical Development of multiTAA-Specific T Cell Therapies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are also evaluating the multiTAA-specific T cell therapies in a Phase 2 clinical trial for the treatment of breast cancer and in Phase 1 clinical trials for the treatment of ALL, lymphoma, multiple myeloma, or MM, and sarcoma, all of which are being conducted by BCM. As of June 2021, the multiTAA-specific T cell therapies were generally well tolerated by all of the patients enrolled in clinical trials in hematological and solid tumor indications with no incidents of cytokine release syndrome or neurotoxicity, which are frequently associated with CAR-T therapies. Our ongoing clinical trials may be also affected by the COVID-19 pandemic and the emergence of any new variant strains of COVID-19. &#160;Based on our observations in clinical trials in AML, pancreatic cancer, lymphoma, ALL and MM, we believe that the multiTAA-specific T cell therapies have the potential to mediate a meaningful anti-tumor effect, as well as significant in vivo expansion of T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our clinical-stage pipeline, including clinical trials being conducted by BCM and other partners, is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="mrkr-20221231x10k003.jpg" alt="Graphic" style="display:inline-block;height:260.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:503.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_99"></a><a id="_cp_text_2_108"></a><a id="_cp_text_1_109"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our multiTAA-specific T cells are designed to enhance the capacity of non-engineered T cells to find and kill cancer by increasing the diversity and quantity of naturally occurring cancer killing T cells within the patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our goal is to be the leader in the development and commercialization of transformative immunotherapies for the treatment of hematological malignancies and solid tumors. We are developing a portfolio of highly differentiated T cell therapies utilizing the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">multiTAA-specific T cell platform that we believe has the potential to significantly disrupt the current cell therapy landscape, while substantially improving survival and quality of life for patients with cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The key elements of our strategy include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;font-weight:bold;">Expedite clinical development, regulatory approval, and commercialization of our lead product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the results of the Phase 1 clinical trials of the multiTAA-specific T cell therapies conducted at BCM, we plan to advance our lead product candidates into Phase 2 clinical trials and facilitate the initiation of company-sponsored clinical trials. We are pursuing post-transplant AML as the lead indication for the multiTAA-specific T cell program. &#160;We completed the safety lead-in portion of our Phase 2 trial of MT-401 in post-transplant AML in June 2021 and initiated the remainder of the Phase 2 trial in July 2021. &#160;We initiated a Phase 1 trial of MT-601 in non-Hodgkin lymphoma in the first quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to initiate future additional clinical trials in other tumor types based on emerging data. &#160;Our current Good Manufacturing Practices, or cGMP, manufacturing facility in Houston, Texas is fully operational to support our clinical manufacturing. &#160;Before our new facility was operational, clinical product manufacturing was conducted at BCM&#8217;s GMP cell manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;font-weight:bold;">Continue to collaborate with our partners and increase our internal research and development activities to improve and develop adoptive cell therapy technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are party to a strategic alliance with BCM, pursuant to which we will sponsor selected research at BCM in support of our technology. In conjunction with this strategic alliance, BCM will conduct selected Phase 1 and Phase 2 clinical trials of our product candidates. If data from these early clinical trials are positive, we will consider the therapeutic and commercial potential for such therapies to be advanced as new product candidates for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we plan to use our company laboratories to enable the process development required to support the Phase 2 clinical trials of our product candidates. We have invested, and plan to continue to invest in our own research and development and chemistry, manufacturing and controls, or CMC, capabilities to enhance our ability to conduct process development to optimize our manufacturing process, product quality and commercial scalability. &#160;For instance, we optimized the multiTAA-specific T cell manufacturing process by closing the system and reducing the total manufacturing time from the original 36 days (BCM) to nine days. The improved manufacturing process has been implemented to supply all of the clinical products used in our current company-sponsored Phase 1 and Phase 2 trials. The improved manufacturing process enables products with increased antigen specificity and diversity, both of which have a strong linear correlation to anti-tumor activity and four-fold increase in potency in vitro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;font-weight:bold;">Invest in our platform to maximize the beneficial outcomes for cancer patients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to explore new product opportunities by increasing and/or customizing the antigens we target to expand the indications in which the multiTAA-specific T cell products will be efficacious, including solid tumors or other hematologic malignancies. Additionally, our research and development efforts may include the exploration of different doses and/or frequency of dosing and the relationship of these factors with potential therapeutic benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;font-weight:bold;">Leverage our relationships with our founding institutions, scientific founders and other scientific advisors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our world-renowned scientific founders and scientific advisors have made seminal contributions to major discoveries in the field of immuno-oncology, and have significant experience in oncology, immunology and cell therapy. We intend to significantly leverage the knowledge, experience and advice of our scientific founders and advisors, as well as the institutional expertise of BCM and our other major institutional partners, to advance our therapies through the clinic and into commercialization.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background and History of Cancer Immunotherapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite advances in options for treatment, cancer continues to be one of the main causes of death in developed countries. Historically, cancer therapy has been constrained to surgery, radiation, and chemotherapy. More recently, advances in the understanding of the immune system&#8217;s role in cancer surveillance have led to immunotherapy becoming an important treatment approach. Cancer immunotherapy began with treatments that nonspecifically activated the immune system and had limited efficacy and/or significant toxicity. In contrast, newer immunotherapy treatments activate specific, potent immune cells, leading to improved safety and efficacy. Within the immunotherapy category, treatments have included vaccines, cytokine therapies, antibody therapies, and adoptive cell therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 1996, Dr. Dana Leach, Dr. Matthew Krummel and Dr. James Allison reported that monoclonal antibodies, or mAbs, blocking CTLA-4 could treat tumors in animal models. Subsequently, mAbs that targeted CTLA-4 and PD-1 became known as immune checkpoint inhibitors, or ICIs. Immune checkpoints are a means by which cancer cells inhibit or turn down the body&#8217;s immune response to cancer. By interfering with these cloaking mechanisms, ICIs have shown an ability to activate T cells, shrink tumors, and improve patient survival. Recent clinical data from checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab have confirmed both the validity of this approach and the importance of T cells as promising tools for the treatment of cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Despite these many advances, there persists a significant unmet need in cancer therapeutics. We believe that the use of human cells as a therapeutic modality to re-engage the immune system will be the next significant advancement in the treatment of cancer. These cellular therapies may avoid the long-term side effects associated with current treatments and have the potential to be effective regardless of the type of previous treatments patients have experienced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">T Cell Therapy Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The field of adoptive cell transfer is currently comprised primarily of CAR and TCR engineered T cells and has emerged from principles of basic immunology to become a paradigm-shifting clinical immunotherapy. T cell therapy has evolved as one of the most promising branches of immunotherapy. T cell immunotherapy involves the infusion of T cells into a patient. Immune cells used for immunotherapy treatments can either be collected from the patient (autologous) or harvested from a donor (allogeneic). The cells are retrieved and either genetically modified to express tumor-specific CARs or TCRs or stimulated with specific antigens. The cells are then cultured to proliferate, and the proliferated cells are infused into the patient. Upon infusion, the cells can target and eliminate cancerous cells. Unlike chemotherapy, which is unable to distinguish between healthy and malignant cells, T cells produced for immunotherapy can selectively attack cancer cells that express the target antigen(s). This leads to a more effective treatment platform with fewer side effects. Some of these infused T cells may remain in the body for long periods, providing immunological memory, thus leading to longer and more durable responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">TCRs and CARs have distinct signaling properties and antigen sensitivities. TCRs recognize peptide fragments from proteins expressed either inside the cell or on the cell surface, which are presented to T cells via major histocompatibility complex molecules. CARs are programmed to recognize a specific cell surface protein. Because CARs are specific for a single antigen, or more precisely a single epitope within the single antigen, they are very narrowly focused and have limitations. When a CAR-T cell product is applied to a specific antigen of a heterogeneous disease, CAR-T cells may leave behind tumor cells that do not express the target antigen, which can lead to tumor relapse due to immune escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our approach is to avoid genetic engineering by relying upon the native T cell receptor, which has evolved over millions of years to provide T cells with an exquisite capacity to recognize and kill cancer cells. Use of the native T cell receptor is the bedrock of our versatile immunotherapy, which is intended to provide a cost-effective and non-toxic strategy to target multiple tumor antigens and lead to durable responses. The process entails expanding tumor-specific T cells from patients (autologous), or a patient&#8217;s hematopoietic stem cell donor (allogeneic). This is achieved by&#160;<i style="font-style:italic;">in vitro</i>&#160;manipulation consisting of co-culturing a patient&#8217;s or donor&#8217;s antigen presenting cells with patient (or donor) peripheral blood mononuclear cells, or PBMCs, respectively. As a source of antigen, we use overlapping peptide libraries spanning each of several immunogenic target antigens that are typically associated with certain types of cancer. These peptides are at least 15 amino acids in length, overlapping by approximately 11 amino acids and span the entire length of each of the target antigens. This typical footprint of peptides allows us to induce both CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;(helper) and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;(cytotoxic) T cells. Following manufacture, these cells are frozen and stored for later infusion. Once infused, the natural characteristics of T cells take over and the T cells multiply in quantity, forming an army of T cells that kill the targeted cancer cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:167.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have observed evidence of &#8220;epitope spreading&#8221; in our clinical trials, suggesting that the multiTAA-specific T cell therapy is inducing an enhanced response by the patient&#8217;s own T cells (specific for an expanded set of tumor-associated antigens beyond those targeted by the infused product). Correlative analyses show expansion of endogenous T cells, other than those present in the infused product, in the months following infusion. This phenomenon, also known as &#8220;antigen spreading,&#8221; is potentially important in generating a deep and durable response for a patient because it enables the killing of tumors that do not express any of the antigens initially targeted by our therapy and could be due to the lack of lymphodepletion that allows recruitment of the endogenous immune system for anti-tumor activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The MultiTAA-Specific T Cell Therapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In collaboration with BCM, we are advancing three multiTAA-specific T cell therapies through clinical development:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Autologous multiTAA-specific T cell therapies</i> target the NY-ESO-1, PRAME, MAGE-A4, Survivin and SSX2 antigens. We recently reported updated clinical data from BCM&#8217;s Phase 1/2 clinical trial of the autologous multiTAA therapy for the treatment of patients with pancreatic cancer, and we are currently evaluating these therapies for the treatment of patients with lymphoma, pancreatic and other selected solid tumors in Phase 1 trials.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Allogeneic multiTAA-specific T cell therapies </i>target the WT1, NY-ESO-1, PRAME, and Survivin antigens. The stem cell transplant donor is used as the source of the cells manufactured for our allogeneic therapies. We are pursuing post-transplant AML as the lead indication for the multiTAA-specific T cell program using our allogeneic therapies.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Off-the-shelf multiTAA-specific T cell therapies</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> - We plan to enroll patients that will be matched to the pre-manufactured inventory of MT-401-OTS products based on their human leukocyte antigen, or HLA. Because the MT-401-OTS product inventory is pre-manufactured, the T cell product is delivered to the patient in a significantly shorter amount of time than a patient-specific T cell product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the blood source and the antigens for stimulation differ between the autologous, allogeneic and off-the-shelf therapies, the manufacturing process for each product is identical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cancers are heterogeneous in their expression of antigens. Tumors generally consist of individual cancer cells expressing different antigens, and each of those antigens can be present at a different level that can change over time. Therapies targeting only a single antigen are vulnerable to evolutionary escape mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20221231x10k004.jpg" alt="Graphic" style="display:inline-block;height:167.22pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:236.97pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While single-antigen specific therapy can eliminate all the tumor cells expressing the targeted antigen, the residual tumor cells that do not express that antigen may survive and expand. In addition, tumor cells may also downregulate or mutate the targeted antigen, thus becoming invisible to the T cell therapy. Both phenomena create a transformed tumor that is impervious to that therapy. This process is referred to as antigen-negative tumor escape.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:177.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our solution to the problem of tumor heterogeneity is the development of T cell products that simultaneously attack multiple tumor-expressed antigens and thereby enable more complete initial tumor targeting, thus minimizing the subsequent opportunity for the cancer to engage escape mechanisms. Of note, data suggest that this strategy may be responsible for recruitment and activation of unique cancer-killing cells from the patient&#8217;s own immune repertoire to participate in cancer eradication, further minimizing the possibility for tumor cell escape.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mrkr-20221231x10k005.jpg" alt="Graphic" style="display:inline-block;height:176.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:244.46pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe our proprietary multiTAA-specific T cell platform may have meaningful advantages over current CAR and TCR-engineered cell therapy approaches. Compared to current gene-modified T cell therapies, the multiTAA-specific T cell product candidates are characterized by the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Clinical benefits observed in early-stage clinical trials in multiple cancer indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on our observations in clinical trials in AML, pancreatic cancer, lymphoma, ALL and MM, we believe that the multiTAA-specific T cell therapies have the potential to mediate a meaningful anti-tumor effect, as well as significant&#160;in vivo&#160;expansion of T cells. For example, in BCM&#8217;s Phase 1 clinical trial in lymphoma, there were complete responses, or CRs, in six of the fifteen evaluable patients with active disease. Significantly, no patient with a CR has subsequently relapsed with disease, whereas typically 30% or more of patients with CR in reported CAR-T studies relapse within one year. In patient results to date in this trial, observed therapeutic responses appear to be highly durable, with some patients being relapse-free beyond five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Non-gene modified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unlike CAR and TCR-based approaches, the &#160;multiTAA-specific T cell therapy does not require genetic modification of T cells, a costly and complex process that significantly complicates the manufacturing of a patient product. We believe our multiTAA-specific T cell therapy can be manufactured at a fraction of the cost of a gene-modified T cell product, with substantially reduced complexity of manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;No need for lymphodepletion before infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unlike CAR-T therapies, which require lymphodepletion of a patient&#8217;s existing T cells so that they will not compete with the infused therapy, the multiTAA-specific T cell therapies work with the natural capabilities of T cells to target cancer and do not require lymphodepletion prior to infusion.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Low incidence rate of adverse events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of January 2022, the multiTAA-specific T cell therapy was generally well tolerated by all of the patients enrolled in clinical trials in hematological and solid tumor indications with no incidences of cytokine release syndrome or neurotoxicity. This appears to compare favorably with published CD19 CAR-T studies that have been associated with substantial tolerability concerns, including one Phase 1 trial in which 95% of patients had Grade 3 or higher adverse events during treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Appears to drive endogenous immune responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In our clinical trials, we have observed evidence of &#8220;epitope spreading&#8221; in the treated patients, meaning that the multiTAA-specific T cell therapy is potentially inducing an enhanced response by the patient&#8217;s own T cells (specific for an expanded set of tumor-associated antigens beyond those targeted by the infused product). Correlative analyses show expansion of endogenous T cells, other than those present in the infused product, in the months following infusion. This phenomenon, also known as &#8220;antigen spreading,&#8221; is potentially important in generating a deep and durable response for a patient, because it enables the killing of tumors that do not express any of the antigens initially targeted by our therapy and could be due to the lack of lymphodepletion that allows recruitment of the endogenous immune system for anti-tumor activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Symbol';font-weight:bold;">&#183;</b>&#160;&#160;&#160;&#160;Capable of addressing a broad repertoire of cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While CAR-T and TCR therapies generally target a single epitope, our manufacturing process selects for T cells that are specific for multiple peptides derived from several targeted antigens. Deep gene sequencing of our products shows that a typical patient dose usually consists of approximately 4,000 unique T cell clonotypes, some of which target up to five different tumor-associated antigens. The five antigen targets can be recognized by a very wide range of T cells, which we believe facilitates robust killing of targeted cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Development of Our multiTAA-Specific T Cell Therapies by BCM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following clinical trials are being conducted by BCM pursuant to our strategic alliance. If data from these early clinical trials are positive, we will consider the therapeutic and commercial potential for such therapies to be advanced as new product candidates for us. In each trial, correlative studies showed significant expansion of multiTAA-specific T cells, as well as significant evidence of epitope spreading with expansion of endogenous T cells specific for tumor-associated antigens that were not targeted by the multiTAA-specific T cell therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acute Myeloid Leukemia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are pursuing &#160;the development of MT-401 for the treatment of post-transplant AML as the lead indication for the multiTAA-specific T cell program. Currently, available treatments for post-transplant AML patients are limited and include donor lymphocyte infusion, which has an approximately 15% overall response rate but a 30% to 50% risk of severe and debilitating graft-versus-host disease. The five-year mortality rate for patients who receive an allogeneic HSCT exceeds 50%, and patients who relapse after a transplant have a survival expectation of approximately 4.5 months.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:252.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">BCM recently completed a Phase 1 AML/MDS clinical trial of the multiTAA-specific T cell therapy for the treatment of patients with post-transplant AML. In this trial, we treated patients in remission and with active disease post-transplant. As reported in a 2021 publication by Lulla et al. and illustrated below, 11 of the 17 patients in the adjuvant disease setting dosed with the multiTAA-specific T cell therapy after receiving an allogeneic HSCT never relapsed [median LFS not reached at a median follow-up of 1.9 years], with 11 of 15 patients (two patients were each treated during two different remissions) remaining alive (estimated two-year overall survival of 77%) at a median follow-up of 1.9 years post-infusion which compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT [median LFS of nine to 15 months and two-year survival probability of 42%].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="mrkr-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:251.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:501.68pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, eight patients were treated for active disease that was resistant to salvage therapy post-HSCT with a median of five prior lines of therapy (range: four to ten). &#160;One of the eight patients crossed over from the adjuvant group while two patients enrolled twice, but all three patients had active AML that failed another line of salvage therapy after their first multiTAA-specific T cell infusion. &#160;As shown below, two of the eight patients achieved objective responses with one complete response and one partial response, with six patients continuing with stable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="mrkr-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:272.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:503.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this trial, the multiTAA-specific T cell therapy was well tolerated, with no drug-related serious adverse events and no instances of greater than Grade 2 graft-versus-host disease. The maximum grade treatment-related adverse event was seen in one patient in the adjuvant disease group who had a possibly drug-related Grade 3 elevation of liver enzymes but was treated with prednisone with complete resolution. After discontinuing treatment and receiving decitabine, the patient relapsed and later re-enrolled in the trial in the active disease group and entered CR for 13 months and survived for 2.5 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pancreatic Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are developing MT-601 for the treatment of advanced unresectable pancreatic cancer. In May 2020, we reported interim data from an ongoing Phase 1/2 clinical trial of the multiTAA-specific T cell therapy for the treatment of pancreatic adenocarcinoma being conducted by BCM. In this trial, BCM plans to enroll approximately 45 patients with advanced or borderline resectable pancreatic adenocarcinoma in three arms: Arm A, which includes patients with unresectable/metastatic disease who are responding to standard first-line chemotherapy; Arm B, which includes patients with progressive disease or therapy intolerance; and Arm C, which includes patients with surgically resectable disease. A total of 31 patients were administered the multiTAA-specific T cell therapy: 13 patients in Arm A, 10 patients in Arm B and eight patients in Arm C.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overall, we have observed a clinical benefit correlated with the detection of tumor-reactive T cells in patient peripheral blood (Arms A, B and C) and within tumor biopsy samples (Arm C) post-infusion. T cells exhibited activity against both targeted antigens as well as non-targeted TAAs, including MAGE-A2B and AFP, indicating induction of antigen/epitope spreading. No cytokine release syndrome or neurotoxicity has been observed in any arm of the trial to date.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arm A</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Arm A is designed to evaluate the safety and potential efficacy of using multiTAA-specific T cell therapy as part of first-line treatment for patients with pancreatic cancer. These patients in the chemo-responsive arm have completed or will complete at least three months of standard-of-care chemotherapy (gemcitabine/nab-paclitaxel or FOLFIRINOX), which is the period during which a response to chemotherapy would typically occur, before receiving up to six administrations of multiTAA-specific T cell therapy in conjunction with chemotherapy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For 12 of the 13 patients, sufficient cells for all six planned doses were generated; two doses were available for the remaining patient.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Out of the 13 evaluable patients (best overall response):</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four patients experienced objective responses after administration of multiTAA cells;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one patient experienced a radiographic complete response occurring at month nine after starting chemotherapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three patients experienced partial responses per RECIST occurring at six-nine months after starting chemotherapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six patients experienced stable disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one patient experienced a mixed response (some lesions increased in size and others decreased for a net zero change in size of tumor lesions);</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients had durable cancer control with nine of the 13 patients exceeding historical control of overall survival;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Five patients enrolled in the study were not administered multiTAA-specific T cells, either because of disease progression (four patients) which made them ineligible for treatment, or because insufficient starting material from the patient was available for manufacturing (one patient);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evidence of epitope-spreading was observed in all responders, suggesting that the multiTAA T cell therapy triggered the recruitment of a broader endogenous immune system response for improved anti-tumor activity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No infusion-related reactions, cytokine release syndrome or neurotoxicity was observed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In patients responding to therapy, significant expansion of the infused multiTAA-specific T cell therapy was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In patients responding to therapy, significant expansion of the infused multiTAA-specific T cell therapy was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:172.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arm B</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Arm B is designed to evaluate the use of multiTAA-specific T cell therapy as a second-line therapy for patients who have failed first-line chemotherapy. The patients in this chemo-refractory arm are either ineligible for chemotherapy or have progressed on chemotherapy and have received or are receiving up to six doses of multiTAA-specific T cell therapy as a monotherapy. The following graphic depicts the best clinical assessment of the 10 evaluable patients in Arm B:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:172.47pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:199.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Among the patients who saw clinical disease stabilization, significant expansion of the infused multiTAA-specific T cell therapy was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor-specific antigens.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:225.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arm C</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Arm C is designed to assess T cell infiltration and expansion. These patients with borderline surgically resectable disease received or will receive a dose of multiTAA-specific T cell therapy following chemotherapy, radiotherapy or combination and prior to surgical resection and up to five additional doses of T cells after surgery. In the patients evaluable in Arm C, multiTAA-specific T cells were measurable in meaningful numbers as detected by correlative analysis of resected tumor, and significant expansion of the infused multiTAA-specific T cells was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens. As illustrated below with respect to the six patients treated in Arm C, three of the patients in Arm C remain in the trial, while three patients had recurrence of disease:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="mrkr-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:225.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:467.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lymphoma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is currently evaluating the multiTAA-specific T cell therapy in a Phase 1 clinical trial for the treatment of patients with lymphoma. A total of 32 patients received two protocol-specified infusions of multiTAA-specific T cells, 14 with Hodgkin lymphoma, or HL, and 18 with aggressive non-Hodgkin lymphoma, or NHL, [diffuse large B-cell lymphoma, or DLBCL, (n=12), mantle cell lymphoma, or MCL, (n=2), T-cell lymphoma (n=3) and composite lymphoma (HL and DLBCL, n=1)].</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As reported in a recent publication by Vasileiou et al., BCM had treated 15 patients with active disease, which we refer to as the active lymphoma group, all of whom had completed a follow-up period beyond three months post-infusion. These patients were heavily pre-treated and, on average, had failed a median of five prior lines of therapy (range four to eight) for the HL patients and a median of three prior lines of therapy (range three to four) for the NHL patients. As illustrated below, in the active lymphoma group, six patients entered CR and nine patients had experienced stable disease. None of the patients in CR had relapsed, and the range for the duration of CR in these patients were between two and over five years after being infused with the multiTAA-specific T cell therapy with the exception of one CR patient who died of an unrelated pneumonia. Responses in all six patients who entered CR were associated with an expansion of infused T cells, as well as induction of broad-based antigen spreading across many tumor-associated antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="mrkr-20221231x10k010.jpg" alt="Graphic" style="display:inline-block;height:280.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:503.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:279.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We also treated 17 patients, including one patient who was treated a second time after a relapse, in remission, which we refer to as the adjuvant lymphoma group. Like the active lymphoma group, these patients were heavily pre-treated with seven patients with HL treated with a median of 4 prior lines of therapy (range three to five) and 10 patients with NHL with a median of three prior lines of therapy (range one to five). As illustrated below, in the adjuvant lymphoma group, all 17 patients had entered CR, with 14 patients in continued complete remission, or CCR, without relapsing. The duration of response ranged from approximately nine months to over five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="mrkr-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:278.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:503.93pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In both treatment groups, the multiTAA-specific T cell therapy was well tolerated, with no drug-related serious adverse events, suggesting that the multiTAA-specific T cell therapy might serve as a standard-of-care maintenance therapy for lymphoma patients in remission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, data from this trial show &#8220;epitope spreading,&#8221; or expansion of patients&#8217; endogenous T cells (specific for an expanded set of tumor-associated antigens beyond those targeted by the infused therapy) in the months following infusion. Significantly, we have observed this effect even though some patients in this trial received doses that had not yet been antigen-escalated to the full antigen dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acute Lymphoblastic Leukemia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is currently evaluating the multiTAA-specific T cell therapy in a Phase 1 clinical trial for the treatment of patients with ALL. Leukemic relapse is one of the primary causes of treatment failure in HSCT recipients. Like post-transplant AML patients, post-transplant ALL patients have limited treatment options, with donor lymphocyte infusions similarly associated with the risk of life-threatening graft-versus-host disease. While CAR-T therapies have shown potent anti-leukemia activity in post-transplant ALL patients, CD19-CAR-T cell therapies target a single antigen, carrying the inherent risk of immune escape, and are most effective in malignancies of B-cell lineage. In contrast, the multiTAA-specific T cell therapy targets multiple antigens expressed in both B- and T-cell ALL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this trial, as reported in February 2019 we had treated 18 patients. Of the seven evaluable patients:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All evaluable patients were up to 28 months in CCR;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One patient experienced relapse displayed mixed donor/recipient chimerism after transplant, but remained in CCR for 6 months; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients who remained in CCR had been durable for between four to 28 months, with a median of 16 months.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Multiple Myeloma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM is currently evaluating the multiTAA-specific T cell therapy in a Phase 1b/2a clinical trial for the treatment of patients with MM. In this trial, we are treating both active and adjuvant post-autologous stem cell transplant MM patients both within 90 days and more than 90 days post-transplant. We have not seen a meaningful difference in response rates or durability between the two arms and intend to standardize future trials based upon a protocol wherein patients will receive multiTAA-specific T cell therapy immediately post-transplant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As reported in a 2021 publication by Lulla et al., of the 12 patients that had been treated in the active MM group with a median of 3.5 prior lines:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">One patient had a CR;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Two patients achieved partial responses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Nine patients had stable disease following initial multiTAA-specific T cell infusion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Of the nine patients that had been treated in the adjuvant MM group, all nine patients had remained in CCR, with a median follow-up of 21 months. Only two patients had relapsed at months seven and 13 after infusion while the remaining patients remain in CCR at a median follow-up of 27.5 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Process Development and Manufacturing of The MultiTAA-Specific T Cell Therapies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the manufacturing process, blood is drawn from either the individual patient (in the case of the autologous T cells) or from the allogeneic stem cell transplant donor (in the case of the allogeneic T cells). Although the T cells that are selected and expanded by our process exist in a patient&#8217;s circulating blood, these T cells are often present at very low frequencies. Researchers at BCM believe that these T cells are adversely affected by the suppressive tumor microenvironment. It is a well-accepted concept that cancers not only evade immune detection but often actively suppress the function of the human immune system. Our manufacturing and culturing process is intended to (1)&#160;identify the T cells specific for the antigens that we intend to target, (2) restore these T cells to functionality with respect to their anti-tumor capability and (3) expand the population of those T cells specific for our targets to achieve the required patient dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After blood is drawn, PBMCs are isolated and used to manufacture a patient-specific product. These cells are placed inside a G-Rex manufacturing device and combined with an experimentally optimized mix of GMP-grade cytokines that is used to restore and enhance the functional capability of the cultured T cells. In addition, libraries of overlapping peptides, which we refer to as peptide pools, spanning the target antigens are combined with antigen presenting cells and added to the cell culture. Each peptide within a peptide pool represents a small segment of a target antigen, which a T cell might recognize. Each library represents the entire protein sequence of a target antigen, with each peptide overlapping significantly with the peptides adjacent to it within the antigen&#8217;s protein sequence. This overlapping structure allows us to isolate, activate and expand any T cell that is specific for any segment of the antigens that we target in the unique genetic background of every patient.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The G-Rex is a cell culture device manufactured by Wilson Wolf Manufacturing Corporation, or Wilson Wolf, used by many cell therapy developers, both in commercial and academic settings. The device allows a user to introduce cells, medium and other reagents into a cell culture chamber, which has a gas-permeable membrane at its bottom. The cells settle on this gas-permeable membrane through which oxygen and carbon dioxide are exchanged (i.e.&#160;the cells can breathe at the base of the device), while nutrients required for cell expansion are obtained from the medium above the cells. This system allows for the highly robust growth of cells in culture, by providing them with superior access to oxygen and nutrients. Cells manufactured in the device grow efficiently without need for agitation by a technician, scientist or automated system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inside the G-Rex, PBMCs are co-cultured with antigen-presenting cells that have been exposed to the stimulating peptide pools. This results in the selective expansion of T cells that specifically recognize the target antigens. At the end of the manufacturing process, the resulting product is a mix of helper (CD4+) and cytotoxic (CD8+) T cells that recognize the targeted antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once cell manufacturing is complete, the product is tested for identity, sterility, phenotype and functionality before it is released for infusion into a patient. Sampling of product indicates that, on average, approximately 4,000 different T cell clonotypes are present in a typical 5-antigen-specific patient product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon release of the final patient product, the cells are frozen and transported to the site where the cells&#160;will be administered. The standard dose for patients with lymphoma, AML or myeloma ranges from five to 20 million cells per meter squared (corresponding to typical doses of 10&#8201;to 40 million cells per adult patient). These cell doses represent a significantly smaller dose of cells, when compared to CAR-T or TCR therapies. As a result, our therapy requires only a very small infusion volume that can be administered to patients within minutes at an outpatient center. Due to the low incidence of adverse events with our therapies, patients do not need to be hospitalized and monitored overnight. Instead, the patients are evaluated for any immediate infusion-related reactions and can then usually be discharged within two hours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have established an in-house cGMP manufacturing facility, and we began manufacturing MT-401 for our Phase 2 trial in AML in the fourth quarter of 2021. Our facility allows for production of multiTAA-specific T cell products according to FDA guidelines and is designed to be scalable using modular processes. We believe that our in-house manufacturing facility confers key advantages that distinguish us from our competitors, in particular that we are less reliant on contract manufacturing organizations, which are expensive and often have long lead times, shortages of skilled labor and a backlog of customers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We completed the construction and qualification of our cGMP manufacturing facility in Houston, Texas in January 2021, and we began manufacturing MT-401 for our Phase 2 trial in AML in the fourth quarter of 2021. Our facility allows for production of multiTAA-specific T cell products according to FDA guidelines and is designed to be scalable using modular processes. Prior to that time, we relied on BCM to manufacture our multiTAA-specific T cell therapies, and we continue to rely on BCM to manufacture the raw materials, our active pharmaceutical ingredients, or APIs, and finished solid dose products for our peptide vaccines for clinical uses. We anticipate using our manufacturing facility to produce clinical supply of MT-601 and commercial supply of any approved product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our supply chain for manufacturing raw materials, API, peptide vaccines and multiTAA-specific T cell therapies ready for distribution and commercialization is a multi-step process. Establishing and managing the supply chain requires a significant financial commitment and the creation and maintenance of numerous third-party contractual relationships.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our drug discovery, development and ultimate commercialization activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. We face significant competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals which are competitive with our drug candidates. Our product candidates may compete with product candidates from a number of companies, which are developing various types of similar in vivo T-cell immunotherapies and therapeutic cancer vaccines to treat cancer, including: Advaxis Inc., Bavarian Nordic, BN Immunotherapeutics, Celldex, Immunocellular, Merck/Immune Design, SELLAS Life Sciences Group, Inc. (formerly) Galena BioPharma, NuGenerex Immuno-Oncology (formerly) Antigen Express and Transgene S.A. In addition, other adoptive T-cell therapies, monoclonal antibodies and checkpoint inhibitors also provide competition in the oncology space. In these areas, competitors include Adaptimmune, AstraZeneca plc, Bluebird Bio, Cellectis, Immatics, Iovance, Juno Therapeutics/Celgene/Bristol Myers Squibb, Kite Pharma/Gilead, Kuur Therapeutics, Medimmune, LLC, Merck &amp; Co, NexImmune, Novartis, Repertoire Immune Medicines, Roche Pharmaceuticals and Tessa Therapeutics. We believe that our non-engineered T cells therapy and our in vivo T-cell therapy approaches will be synergistic and may improve therapies being developed by these competitors. Many companies and institutions, either alone or together with their collaborative partners, have substantially greater financial, technical and human resources, and significantly greater experience than we do in the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drug discovery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">undertaking preclinical testing and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining FDA and other regulatory approvals of products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, marketing, distributing and selling products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA and other regulatory approval or commercializing products that compete with our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any drug candidate that we successfully develop may compete with existing therapies that have long histories of safe and effective use. Competition may also arise from:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other drug development technologies and methods of preventing or reducing the incidence of disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new small molecules; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other classes of therapeutic agents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face, and will continue to face, intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies, for establishing relationships with academic and research institutions and for licenses to drug candidates or proprietary technology. These competitors, either alone or with their collaborative partners, may succeed in developing products that are more effective than ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete successfully will depend, in part, on our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop proprietary products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and maintain products that reach the market first, are technologically superior to and/or are of lower cost than other products in the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract and retain scientific, product development and sales and marketing personnel;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain patent or other proprietary protection for our products and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain required regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture, market, distribute and sell any products that we develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In a number of countries, including in particular, developing countries, government officials and other groups have suggested that pharmaceutical companies should make drugs available at a low cost. In some cases, governmental authorities have indicated that where pharmaceutical companies do not do so, their patents might not be enforceable to prevent generic competition. Some major pharmaceutical companies have greatly reduced prices for their drugs in certain developing countries. If certain countries do not permit enforcement of any of our patents, sales of our products in those countries, and in other countries could be reduced by generic competition or by parallel importation of our product. Alternatively, governments in those countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products in those countries, thereby reducing our product sales, or we could respond to governmental concerns by reducing prices for our products. In all these situations, our results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BCM Exclusive License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 16, 2018, we entered into an exclusive license agreement, or the BCM License Agreement, with BCM, under which we received a worldwide, exclusive license to BCM&#8217;s rights in and to certain intellectual property rights, including European patent EP 2470644 (estimated expiration date August 24, 2030), to develop and commercialize multiTAA-specific T cell product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exclusive License to BCM&#8217;s Subject Technology:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">1. &#8220;Generation of CTL Lines with Specificity Against Multiple Tumor Antigens or Multiple Viruses&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2. &#8220;Pepmixes to Generate Multiviral CTLs with Broad Specificity&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">3. &#8220;Immunogenic Antigen Identification from a Pathogen and Correlation to Clinical Efficacy&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">4. &#8220;T cell performance assay as a prognostic factor for clinical outcome&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In partial consideration for the exclusive rights granted under the BCM License Agreement, Marker Cell Therapy, Inc., an entity that is now our wholly owned subsidiary, issued shares of its common stock to BCM valued at approximately $5.0 million at the time of issuance. Such initial equity issuance was exchanged into merger consideration of 149,081 shares of our common stock and warrants to acquire 54,064 shares of our common stock in connection with the merger we completed in October 2018, each as adjusted to reflect the reverse stock split that we effected in January 2023. Additional consideration includes a royalty paid on net sales by us to BCM according to the royalty schedule in the BCM License Agreement. The royalty fee schedule is based on aggregate net sales in four different ranges: (1) less than $500 million, (2) $500 million to $1.0 billion, (3) $1.0 billion and over, and (4) $2.0 billion and over. The corresponding royalty percentages range from 0.65% to 5.0%&#8201;-&#8201;increasing in proportion to the aggregate net sales. The royalty fee may be reduced in the event that we must pay additional royalties with respect to third-party owned patent rights or technology necessary for the use, manufacture or sale of a licensed product. We also agreed to pay BCM up to an aggregate of $64.85 million in milestone payments upon the occurrence of nine particular milestones relating to completion of the first dosing in clinical trials for a first and second distinct product, receipt of approval from the FDA and the achievement of certain net sales goals. We are also responsible for sublicensing fees. In addition, under the BCM License Agreement, we are responsible for reimbursing BCM for patent-related expenses. BCM is responsible for filing, prosecuting and maintaining all patent applications and patents included in the licensed patent rights, and we have agreed to reimburse BCM for all such related legal costs incurred after the date of the BCM License Agreement, except such legal costs shall be reduced on a pro-rata basis on a patent or patent application basis should BCM license such patent or patent application in additional fields of use to any third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM License Agreement).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have agreed to indemnify BCM and certain persons affiliated with BCM against claims and liabilities directly or indirectly related to or arising out of the design, process, manufacture or use by any third party of the licensed products, even though such claims and liabilities result in whole or in part from the negligence of the BCM indemnified parties or are based upon doctrines of strict liability or product liability, but not claims or liabilities arising from the gross negligence or intentional misconduct of any such BCM indemnified parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unless terminated sooner, the license will expire on a licensed product-by-product basis and country-by-country basis, on the later of&#8201;(1)&#160;the date of expiration of the last valid claim of patent rights to expire that covers the sale of such licensed product in such country, or (2)&#160;the first date following the tenth anniversary of the first commercial sale of first licensed product by us in such country. After such expiration, but not termination, the licenses granted to us shall survive and become a perpetual, paid-in-full license in such country with respect to such licensed product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have the right in our sole discretion to terminate the BCM License Agreement upon 60 days&#8217; written notice to BCM. BCM has the right to terminate the agreement upon material default or failure of us of our overall obligation to perform any of the terms, covenants or provisions of the license agreement, including failure to make timely payment, taken as a whole, and which default or failure remains uncured thirty days after written notice from BCM of such material default or failure to correct such default or failure. Notwithstanding the foregoing, if a material default or failure is not susceptible to cure within the 30-day cure period, BCM&#8217;s right to terminate shall be suspended if, and for so long as, (1)&#160;we have provided BCM with a written plan that is reasonably calculated to effect a cure, (2)&#160;such plan is reasonably acceptable to BCM, in its sole but reasonable discretion, and (3)&#160;we commit to and do carry out such plan; provided, however, that, unless mutually agreed to by the parties in such plan, such suspension of BCM&#8217;s right to terminate shall not extend beyond 60&#160;days after the original cure period. In addition, either party&#8217;s right to terminate the license agreement shall be tolled for so long as dispute resolution procedures are being pursued by the allegedly breaching party in good faith, and if it is finally and conclusively determined that the allegedly breaching party is in material breach, then the breaching party shall have the right to cure within 30 days after such determination. BCM also has the right to terminate the agreement if we shall (1)&#160;become involved in insolvency, dissolution, bankruptcy or receivership proceedings affecting the operation of our business, (2)&#160;make an assignment of all or substantially all of our assets for the benefit of creditors, or (3)&#160;if a receiver or trustee is appointed for us and we, after the expiration of 30 days following any of the enumerated events, are unable to secure a dismissal, stay or other suspension of such proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of termination of the BCM License Agreement, but not expiration, all rights to the subject technology and patent rights thereunder shall revert to BCM, except to the extent necessary to exercise any surviving right or license thereunder. We may sell any licensed products actually in our possession at the effective date of termination, provided that we continue to pay to BCM royalties on all such sales in accordance with the license agreement, otherwise comply with the terms of the license agreement and sell all such licensed products within six months after the effective date of the termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In furtherance of the BCM License Agreement and as contemplated by the terms thereof, we entered into a Sponsored Research Agreement, or the SRA, with BCM, which provides for the conduct of research for us by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have entered into additional agreements with BCM with respect to a strategic alliance to advance pre-clinical research, early-stage clinical trials, and Phase 2 clinical trials with respect to our product candidates, as well as continued access to our clinical data, and product manufacturing and support, including personnel and space at the institution for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, improvements, and know-how related to the business; to defend and enforce proprietary rights, including any patents that we may own in the future; to preserve the confidentiality of our trade secrets and other intellectual property; to obtain and maintain licenses to use intellectual property owned by third parties; and to operate without infringing valid and enforceable patents and other proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities&#8201;&#8212;&#8201;for example, the rights obtained under exclusive license arrangements such as those pursuant to our BCM License Agreement. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed in the future, nor can we be sure that any of our existing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">patents or any patents that may be granted in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To achieve this objective, a strategic focus for us has been identifying and licensing key patents and patent applications that serve to enhance our intellectual property and technology position. Currently, all of our multiTAA-specific T cell intellectual property rights are licensed from BCM. Our intellectual property portfolio currently includes patent applications having: (1) claims directed to methods of generating multi-antigen specific T cell products; and (2) claims directed to therapeutic uses of such multi-antigen specific T cell products. We believe our patent portfolio, together with our efforts to develop and patent next-generation technologies, provides us with a substantial intellectual property position. However, the area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents and other proprietary rights are vital to our business operations. We protect our technology through various United States and foreign patent filings and maintain trade secrets that we own. Our policy is to seek appropriate patent protection both in the United States and abroad for our proprietary technologies and product candidates. An enforceable patent with appropriate claim coverage can provide an advantage over competitors who may seek to employ similar approaches to develop therapeutics, and so the future commercial success of products, and therefore our future success, will be in part dependent on our intellectual property strategy. We reassess the value of each patent at the time maintenance fees are due, and in cases where maintaining the patent is judged to be of no significant strategic value, we decline to pay the maintenance fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that our patents, and any patents that may be issued, assigned, or licensed to us in the future, will afford protection against competitors with similar technology. In addition, no assurances can be given that any patents issued, assigned, or licensed to us will not be infringed upon or designed around by others or that others will not obtain patents that we would need to license or design around. If existing or future patents held by third parties and containing broad claims over technology used by us were upheld by a court or other authority of competent jurisdiction, the holders of such patents could require us to obtain licenses to use such technology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent coverage may also vary from country to country based on the scope of available patent protection. Moreover, in the United States, patent term may be adjusted to account for delays by the United States Patent and Trademark Office, or USPTO, during prosecution. &#160;There are also opportunities to obtain an extension of term for patents covering a product in certain jurisdictions, which adds further complexity to the determination of patent life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have a number of issued and pending patents covering composition of matter of our PolyStart technology and methods of using our PolyStart technology, including: U.S. 9,364,523 (estimated expiration date March 17, 2035); and U.S. 10,030,252 (estimated expiration date March 17, 2035); as well as pending U.S. patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of the issued United States patents is that they provide us with patent protection for the claims covered by the patents. While the expiration of a product patent normally results in a loss of market exclusivity for the covered product or product candidate, commercial benefits may continue to be derived from , for example: (1)&#160;later- expiring patents on processes and intermediates related to improved methods of manufacture of the active ingredient of such product; (2) patents relating to the use of such product; (3)&#160;patents relating to novel compositions and formulations; and (4) in the United States and certain other countries, other types of market exclusivity that may be available under relevant law. The effect of patent expiration on our product candidates also depends upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our pending patent applications cover a range of technologies, including specific embodiments and applications for treatment of various medical indications, improved application methods and adjunctive utilization with other therapeutic modalities. The coverage claimed in a patent application can be significantly reduced before the patent is issued. Accordingly, we do not know whether any of the patent applications we own, will acquire, license, or will license will issue as patents, or, if any patents are issued, whether they will provide significant proprietary protection or will be challenged, circumvented or invalidated. Because unissued U.S. patent applications are maintained in secrecy for a period of eighteen months and U.S. patent applications filed prior to November 29, 2000 are not disclosed until such patents are issued, and since publication of discoveries/inventions in the scientific or patent literature often lags behind actual discovery/invention, we cannot be certain of the priority of inventions covered by pending patent applications and whether potentially relevant earlier patent filings exist. Moreover, we may have to participate in opposition proceedings in a foreign patent office, or for United States patent applications filed before March 16, 2013, in interference proceedings declared by the USPTO, to determine priority of invention, or in United States inter partes review or post-grant review procedures, any of which could result in substantial cost to us, even if the eventual outcome is favorable to us. There can be no assurance that the patents, if issued, would be held valid by a court or other authority of competent jurisdiction. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties, or require us to cease using such technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We have patents and patent applications in other countries, as well as in the European Patent Office, that we believe provide equivalent or comparable protection for our product candidates in jurisdictions internationally that we consider to be key markets. Patent applications related to our PolyStart technology are pending in Brazil and Canada. &#160;Because of differences in patent laws and laws concerning proprietary rights, the extent of protection provided by U.S. patents or proprietary rights owned by us may differ from that of their foreign counterparts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trade Secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of immuno-oncology. However, trade secrets can be difficult to protect. We also plan to rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity and patent term extensions when available, as well as contractual agreements with our academic and commercial partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We require each of our employees, consultants and advisors to execute a confidentiality agreement upon the commencement of any employment, consulting or advisory relationship with us. Each agreement provides that all confidential information developed or made known to the individual during the course of the relationship will be kept confidential and not be disclosed to third parties except in specified circumstances. In the case of employees, the agreements provide that all inventions conceived by an employee shall be our exclusive property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have pending with the USPTO applications for registration of the trademarks POLYSTART and &#8220;Marker Therapeutics.&#8221; We currently have the trademark &#8220;TapImmune&#8221; registered with the USPTO. We also have rights to use other names essential to our business. Federally registered trademarks have a perpetual life if they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We regard our trademarks and other proprietary rights as valuable assets and believe they have significant value to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our patents, the protection of discoveries in connection with our development activities, our proprietary products, technologies, processes and know-how and all our intellectual property are important to our business. There can be no assurance that any of our patents, licenses or other intellectual property rights will afford us any protection from competition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a biologics license application, or BLA, after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so- called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once a BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast-track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast-track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast-track product has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast-track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast-track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast-track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The regenerative medicine advanced therapy, or RMAT, designation is intended to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars and Reference Product Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program; federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent; the Health Insurance Portability and Accountability Act, or HIPAA, which created additional federal criminal statutes which prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters, and which, as amended by Health Information Technology for Economic and Clinical Health Act, or HITECH, also imposes certain requirements on HIPAA covered entities and their business associates and covered subcontractors relating to the privacy, security and transmission of individually identifiable health information; the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the federal government, information related to payments or other transfers of value made to physicians (as defined by the Physician Payments Sunshine Act), other covered physicians and teaching hospitals, as well as ownership and investment interests held by health care professionals and their immediate family members; and U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. In addition, certain states require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and certain states and local jurisdictions require the registration of pharmaceutical sales representatives. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which the Company receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a personalized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions of particular importance to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act was enacted, which, among other things, removed penalties for not complying with ACA&#8217;s individual mandate to carry health insurance. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is also unclear how such challenges, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2%, which due to subsequent legislative amendments, including the Infrastructure Investment and Jobs Act, will stay in effect per fiscal year through 2031, except for a temporary suspension from May 1, 2020 through March 32, 2021 due to COVID-19 relief legislation, unless additional Congressional action is taken, and reduced payments to several types of Medicare providers. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Congress is also considering additional health reform measures as part of other reform initiatives. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump Administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA concurrently released a final rule and guidance in September 2020 providing pathways for states to build and submit importation </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. &#160;However, it is unclear whether these or similar policy initiatives will be implemented in the future. &#160;At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product Liability and Insurance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. We have not experienced any product liability claims to date. We currently carry products and clinical trial liability insurance policies. There can be no assurance that liability claims will not exceed such insurance coverage limits, which could have a materially adverse effect on our business, financial condition or results of operations or that such insurance will continue to be available on commercially reasonable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had 67 full-time employees. There were 54 in research, development, quality, CMC and clinical and 13 were in finance, legal, human resources or administrative support. None of our employees is subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Consultants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have consulting agreements with a number of leading academic scientists, clinicians and regulatory experts. They serve as important contacts for us throughout the broader scientific and clinical communities. They are distinguished individuals with expertise in numerous fields, including cellular biology, molecular biology, oncology, clinical, manufacturing and regulatory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We retain each consultant according to the terms of a consulting agreement. Under such agreements, we pay them a consulting fee and reimburse them for out-of-pocket expenses incurred in performing their services for us. In addition, some consultants hold options to purchase our common stock, subject to the vesting requirements contained in separate award agreements. Our consultants may be employed by other entities and therefore may have commitments to their employer or may have other consulting or advisory agreements that may limit their availability to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards. We strive to create a diverse environment, and our commitment to diversity, equity and inclusion begins with our leadership team of diverse backgrounds and experiences. Approximately 90% of our executive officers are women or self-identify as a member of an underrepresented minority group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We were incorporated under the laws of the State of Nevada in 1991 under the name &#8220;TapImmune, Inc.&#8221; and reincorporated in Delaware in October 2018 under the name &#8220;Marker Therapeutics, Inc.&#8221; On October 17, 2018, we completed a business combination with a Delaware corporation that was then known as &#8220;Marker Therapeutics, Inc.,&#8221; or Private Marker, in accordance with the terms of the Agreement and Plan of Merger and Reorganization dated as of May 15, 2018, or the Merger Agreement, by and among us, Private Marker and Timberwolf Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of TapImmune, or Merger Sub, pursuant to which, among other matters, Merger Sub merged with and into Private Marker, with Private Marker continuing as a wholly owned subsidiary of TapImmune and the surviving corporation of the merger. In connection with the merger, we changed our name from &#8220;TapImmune, Inc.&#8221; to &#8220;Marker Therapeutics, Inc.&#8221; and Private Marker changed its name to &#8220;Marker Cell Therapy, Inc.&#8221; and became our wholly owned subsidiary. Our principal executive offices are located at 4551 Kennedy Commerce Drive, Houston, Texas 77032, and our telephone number is (713) 400-6400. Our common stock is listed for trading on the Nasdaq Capital Market under the symbol &#8220;MRKR&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our website is located at <i style="font-style:italic;">www.markertherapeutics.com</i>. We make available free of charge on our website our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission. Our website and the information contained therein or connected thereto are not intended to be incorporated into this Annual Report on Form&#160;10-K.</p><a id="_f2ae80cc_df91_4844_8fea_a6a8dcf01271"></a><a id="ITEM1ARISKFACTORS_686864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1A. RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below before making an investment decision in our securities. These risk factors are effective as of the date of this Form 10-K and shall be deemed to be modified or superseded to the extent that a statement contained in our future filings modifies or replaces such statement. All of these risks may impair our business operations. The forward-looking statements in this Form 10-K involve risks and uncertainties and actual results may differ materially from the results we discuss in the forward-looking statements. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected. In that case, the trading price of our stock could decline, and you may lose all or part of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Associated with Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our business is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in this &#8220;Risk Factors&#8221; section and include, among others:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a development stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All of our product candidates are in clinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our product candidates, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business and operations could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Establishing and maintaining our own cGMP manufacturing facility is subject to many risks. Although we established our own cGMP manufacturing facility, in the future we may be dependent on third-party vendors to design, build, maintain and support our manufacturing and cell processing facilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our strategic relationship with BCM is dependent, in part, upon our ongoing relationship with key medical and scientific personnel and advisors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our stock may be volatile.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Financial Position and Capital Needs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a development stage company with a history of operating losses, and we expect losses to continue for the indefinite future. These factors raise substantial doubt regarding our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immunotherapy company with a history of losses, and we may always operate at a loss. We expect that we will continue to operate at a loss throughout our development stage, and as a result, we may exhaust our financial resources and be unable to complete the development of our product candidates. We anticipate that our ongoing operational costs will increase significantly, and our deficit will continue to grow, as we continue conducting our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no approved products or product candidates pending approval. As a result, we have not derived any revenue from the sales of products and have not yet demonstrated ability to obtain regulatory approval, formulate and manufacture commercial-scale products, or conduct sales and marketing activities necessary for successful product commercialization. We have no sources of significant revenue to provide incoming cash flows to sustain our future operations. Our ability to pursue our planned business activities depends upon our successful efforts to raise additional financing, which may be adversely impacted by potential worsening global economic conditions, including decades-high inflation and concerns of a recession in the United States or other major markets, and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide, including from the COVID-19 pandemic. Weakness and volatility in the capital markets and the economy in general could also increase our costs of borrowing. Such additional financing may not be available on favorable terms, or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future due to the substantial investment in research and development. We expect that our cash, cash equivalents and restricted cash as of December 31, 2022 will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2023. We expect to spend substantial additional sums on the continued administration and research and development of licensed and proprietary product candidates and technologies with no certainty that our approach and associated technologies will become commercially viable or profitable as a result of these expenditures. If we fail to raise a significant amount of capital, we may need to significantly curtail operations, allocate limited financial resources among our product candidates, or cease operations in the near future. If any of our product candidates fail in clinical trials or do not gain regulatory approval, we may never generate revenue. Even if we generate revenue in the future, we may not be able to become profitable or sustain profitability in subsequent periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These and other factors raise substantial doubt regarding our ability to continue as a going concern, which may create negative reactions to the price of our common stock. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. Further, the perception that we may be unable to continue as a going concern may impede our ability to pursue strategic opportunities or operate our business due to concerns regarding our ability to discharge our contractual obligations. In addition, if there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the FDIC, as receiver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although a statement by the U.S. Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day following the date of closure, uncertainty and liquidity concerns in the broader financial services industry remain. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. The U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments. However, widespread demands for customer withdrawals or other needs of financial institutions for immediate liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions in a timely fashion or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Development of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">All of our product candidates are in clinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our product candidates, or successfully develop any other product candidates, or experience significant delays in doing so, our business will be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts and all of our product candidates are still in clinical development. Each of our programs and product candidates will require additional preclinical and/or clinical development, regulatory approval, obtaining manufacturing supply, capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. We do not have any products that are approved for commercial sale, and we may never be able to develop or commercialize marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from our product candidates, which we do not expect will occur for several years, if ever, will depend heavily on the successful development, regulatory approval and eventual commercialization of our product candidates. The success of our multiTAA product candidates or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable, and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effective investigational new drug applications, or INDs, from the FDA or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials, including under the FDA&#8217;s current Good Clinical Practices, or GCPs, and current Good Laboratory Practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful development of, or making arrangements with third-party manufacturers for, our commercial manufacturing processes for any of our product candidates that receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of timely marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of products, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the benefits and use of our products, including method of administration, if approved, by patients, the medical community and third-party payors, for their approved indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events experienced by our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, perceived advantages, cost, safety and efficacy of alternative therapies for any product candidate, and any indications for such product candidate, that we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to produce any product candidates we develop on a commercial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidates and otherwise protecting our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining compliance with regulatory requirements, including the FDA&#8217;s current Good Manufacturing Practices, or cGMPs, and complying effectively with other procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining third-party coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety, tolerability and efficacy profile of the products following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any immunotherapies that we may develop are not likely to be commercially available for at least three years. Any delay in obtaining FDA and/or other necessary regulatory approvals in the United States and in countries outside the United States for any investigational new drug and failure to receive such approvals would have an adverse effect on the investigational new drug&#8217;s potential commercial success and on our business, prospects, financial condition and results of operations. The time required to obtain approval by the FDA and non-U.S. regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not previously submitted a biologics license application, or BLA, to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of cell therapies for cancer. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained, and the FDA or non-U.S. regulatory authorities may disagree with the design or implementation of our clinical trials or study endpoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of financial resources to commence and complete the planned trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining approval by an independent institutional review board, or IRB, at each clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">having patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding new clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a subject by subject basis for use in clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, the performance of our CROs may also be interrupted by health epidemics or other disruptions, such as the ongoing COVID-19 pandemic, including due to travel or quarantine policies or prioritization of resources toward such health epidemic or disruption. We could also encounter delays if physicians face unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRB for the institutions in which such trials are being conducted, the Data and Safety Monitoring Board or Committee for such trial, or by the FDA or other regulatory authorities due to a number of factors. Those factors could include failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our product candidates are in clinical development and their risk of failure is high. The clinical trials and manufacturing of our product candidates are, and the manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidates are based on new technologies and manufactured on a patient-by-patient basis for our multiTAA-specific T cell product candidates we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, the initial estimates of the clinical cost of development may prove to be inadequate, particularly if clinical trial timing or outcome is different than predicted or regulatory agencies require further testing before approval. For example, we previously experienced temporary delays in enrollment due to the COVID-19 pandemic and in satisfying certain FDA requirements for our Phase 2 trial of MT-401 for the treatment of post-transplant AML, and any further delay to our planned timelines for our trial may impact our cost estimates for this trial. &#160;In addition, costs to treat patients with relapsed/refractory cancer and to treat potential side effects that may result from our product candidates can be significant. Some clinical trial sites may not bill, or obtain coverage from, Medicare, Medicaid, or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and we may be required by those trial sites to pay such costs. Accordingly, our clinical trial costs may be significantly higher per patient than those of more conventional therapeutic technologies or drug products. In addition, our proposed personalized product candidates involve several complex manufacturing and processing steps, the costs of which will be borne by us. Depending on the number of patients we ultimately enroll in our trials, and the number of trials we may need to conduct, our overall clinical trial costs may be higher than for more conventional treatments. Further, delays and interruptions to ongoing trials related to the COVID-19 pandemic has increased the duration and costs of such trials. &#160;We outsource some of the management of our clinical trials to third parties. Agreements with clinical investigators and medical institutions for clinical testing and with other third parties for data management services, place substantial responsibilities on these parties that, if unmet, could result in delays in, or termination of, our clinical trials. If any of our clinical trial sites fail to comply with FDA-approved good clinical practices, we may be unable to use the data gathered at those sites. If these clinical investigators, medical institutions or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approval for, or successfully commercialize, agents. We cannot be certain that we will successfully recruit enough patients to complete our clinical trials nor that we will reach our primary endpoints. Delays in recruitment, lack of clinical benefit or unacceptable side effects would delay our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We, or our regulators, may suspend or terminate our clinical trials for a variety of reasons. For example, in the fourth quarter of 2019 the FDA placed a clinical hold on our IND of MT-401 for the treatment of patients with post-transplant AML and requested certain </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">information regarding quality and technical specifications for two reagents supplied by third party vendors that are used in our manufacturing process but not present in the final product infused to patients. In January 2021, the FDA lifted the clinical hold, permitting us to initiate a Phase 2 clinical trial for the treatment of post-transplant AML, with a safety lead-in portion. We completed the safety lead-in portion of the trial in June 2021, and we initiated the remainder of the Phase 2 trial in July 2021 and have completed enrollment of approximately 20 patients. We may voluntarily suspend or terminate our clinical trials at any time if we believe they present an unacceptable risk to the patients enrolled in our clinical trials or do not demonstrate clinical benefit. For example, in November 2019 we elected to suspend our Phase 2 clinical trial of TPIV200 for the treatment of platinum-sensitive advanced ovarian cancer based on an unblinded review of interim results conducted by an independent Data and Safety Monitoring Board, or DSMB. Although the DSMB did not express any safety concerns with respect to TPIV200, we elected to suspend the trial because it did not meet the threshold for probability of clinical benefit based upon our pre-specified criteria. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the patients enrolled in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our clinical trial operations are subject to regulatory inspections at any time. If regulatory inspectors conclude that we or our clinical trial sites are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observations or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deem our responses to be inadequate, or are dissatisfied with the corrective actions we or our clinical trial sites have implemented, our clinical trials may be temporarily or permanently discontinued, and we may be fined, we or our investigators may be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve our marketing applications or allow us to manufacture or market our products, and we may be criminally prosecuted. The lengthy approval process, as well as the unpredictability of future clinical trial results, may result in us failing to obtain regulatory approval for our product candidates, which would materially harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure can occur at any time during the clinical trial process. The results of preclinical testing and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. Our clinical trials to date have been conducted on a small number of patients in a single academic clinical site for a limited number of indications. We will have to conduct larger, well-controlled trials in our proposed indications at multiple sites to verify the results obtained to date and to support any regulatory submissions for further clinical development of our product candidates. Our assumptions related to our product candidates, such as with respect to lack of toxicity and manufacturing cost estimates, are based on early limited clinical trials and current manufacturing processes at Baylor College of Medicine, or BCM, and may prove to be incorrect. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control, including with respect to challenges related to enrollment, manufacturing and our reliance on third parties to conduct, supervise or monitor some or all aspects of our clinical trials. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may experience difficulties in patient enrollment in our future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">who remain in the study until its conclusion. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Accordingly, we cannot guarantee that our clinical trials will progress as planned or as scheduled. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business and operations could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 virus, which was declared by the World Health Organization as a global pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Remote work policies, quarantines, shelter-in-place and similar government orders, shutdowns or other restrictions on the conduct of business operations related to the COVID-19 pandemic or other health epidemics may negatively impact productivity. For instance, the COVID-19 pandemic disrupted our ongoing research and development activities and delayed certain of our clinical programs and timelines. In addition, although our employees are accustomed to working remotely, changes in internal controls due to remote work arrangements may result in control deficiencies in the preparation of our financial reports, which could be material. Such orders may also impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Health epidemics may also affect the conduct of our clinical trials. Although we are enrolling patients and initiating clinical sites in our Phase 2 trial of MT-401 (zedenoleucel) for post-transplant AML, we previously experienced temporary delays in enrollment due to the COVID-19 pandemic and in satisfying certain FDA requirements to move forward with the trial, which together resulted in a delay in our overall timelines for this trial. Our ongoing and future clinical trials may be also affected by the COVID-19 pandemic. Patient enrollment and clinical site initiation, while ongoing, may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or other health emergencies, if they arise. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, we may be unable to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, which would adversely impact clinical trial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The global COVID-19 pandemic continues to evolve. The extent to which the COVID-19 pandemic impacts our business and operations, including our clinical development and regulatory efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the continued geographic spread of the disease, the duration and effect of any future business disruptions in the United States and other countries to contain and treat patients with the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our preclinical studies and clinical trials may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified during the development of our product candidates, which could prevent or delay regulatory approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of some of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and effective for use in each target indication, and failures can occur at any stage of testing. Preclinical studies and clinical trials often fail to demonstrate safety or efficacy of the product candidate studied for the target indication. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA, EMA or foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from personalized cell therapy, as with our multiTAA-specific T cell therapy products, are not normally encountered in the general patient population and by medical personnel. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the labels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or other requirements subject to a REMS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to achieve or maintain third-party payor coverage and adequate reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation and physician or patient acceptance of our products may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or foreign regulatory agency in a timely manner or at all. Moreover, any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not obtain or maintain the benefits associated with orphan drug designation, including market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Generally, a product that has orphan drug designation and subsequently receives the first FDA approval for the disease for which it has such designation is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA has granted orphan drug designation for MT-401 for the treatment of AML after receiving an allogeneic stem cell transplant and for MT-601 for the treatment of patients with pancreatic cancer. We may seek orphan drug designation for other indications or product candidates. Even if we were to obtain orphan drug designation for a product candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA or European Commission (on the basis of the opinion of the European Medicines Agency, or the EMA), later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any product candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Establishing and maintaining our own cGMP manufacturing facility is subject to many risks. Although we established our own cGMP manufacturing facility, in the future we may be dependent on third-party vendors to design, build, maintain and support our manufacturing and cell processing facilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In July 2021, we opened an in-house cGMP manufacturing facility in Houston, Texas, which is now fully operational and is manufacturing MT-401 for the Phase 2 clinical trial for the treatment of post-transplant AML. We also intend to manufacture clinical supply of our other product candidates in our manufacturing facility, such as MT-601. Establishing and maintaining our own manufacturing facility is subject to many risks. We have limited prior experience in establishing a manufacturing facility and, although our facility is fully operational, we may encounter challenges given the complexity of manufacturing cell therapies. We will also compete for the small number of individuals with expertise in cell therapy manufacturing. Even with an operational facility, our manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures, transportation difficulties and numerous other factors that could prevent us from fully realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our clinical development and/or commercialization plans. In addition, the manufacturing process for any product candidates that we may develop is subject to the FDA and foreign regulatory authority approval process, and we may need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements on an ongoing basis. If we or our contract manufacturing organizations, or CMOs, are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize any approved products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Further, we may be required to establish multiple manufacturing facilities to expand our commercial footprint for any approved products, which may lead to regulatory delays or prove costly. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our clinical development and/or commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we expect our in-house cGMP manufacturing facility to be our primary source of multiTAA-specific T cell therapy-based product candidates and for commercial manufacturing of any products, if approved, we intend to evaluate potential third- party manufacturing capabilities in order to provide potential multiple sources of clinical and commercial supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">BCM or other third-party manufacturers, if any, may not be able to meet our needs concerning timing, quantity, or quality. If we are unable to contract for a sufficient supply of needed materials on acceptable terms, or if we should encounter delays or difficulties in our relationships with manufacturers, our clinical trials may be delayed, thereby delaying the submission of product candidates for regulatory approval or the market introduction and subsequent sales of any approved products. Any such delay may lower our revenues and potential profitability. If any third party breaches or terminates its agreement with us or fails to conduct its activities in a timely manner, the commercialization of our product candidates could be slowed down or blocked completely. It is possible that third parties relied upon by us will change their strategic focus, pursue alternative technologies, or develop alternative product candidates, either on their own or in collaboration with others, as a means for developing treatments for the diseases targeted by our collaborative programs, or for other reasons. The effectiveness of these third parties in marketing their own products may also affect our revenues and earnings. Also, if we enter into additional third-party agreements in the future, we may not be able to negotiate such agreements successfully and, even if established, these relationships may not be scientifically or commercially successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our manufacturing process is reliant upon specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. For some of this equipment and materials, we rely or may rely on sole-source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend on a limited number of vendors for supply of certain materials and equipment used in the manufacture of our multiTAA-specific T cell therapy-based product candidates. For example, we purchase equipment and reagents critical for the manufacture of our product candidates from Wilson Wolf (a company controlled by our director John Wilson), Almac and other suppliers. Some of our suppliers may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also may not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may not be able to obtain key materials and equipment to support clinical or commercial manufacturing. Further, the FDA may determine that our manufacturing process, or the materials required for the manufacture of our product candidates, are not acceptable, which would require us to find alternative suppliers or processes, which may not be available on favorable terms, if at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For some of this equipment and materials, we may rely, and may now and/or in the future rely, on sole-source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial, or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As we continue to develop and scale our manufacturing process, we may need to obtain rights to and supplies of specific materials and equipment to be used as part of that process. For example, our multiTAA-specific T cell manufacturing process is based, in part, upon the G-Rex&#174; cell culture device manufactured by Wilson Wolf, which is used by many cell therapy developers, both in commercial and academic settings. Although we do hold the license to patents from BCM that could be used to prevent third parties from developing similar and competing processes, we do not own any exclusive rights to the G-Rex&#174;. We may not be able to obtain rights to such materials and equipment on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development or scaling up of our manufacturing capabilities. If we, or any of our third-party suppliers encounter such </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">difficulties, our ability to supply our product candidates for clinical trials, or our product candidates for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates are biologics, and the process of manufacturing our product candidates is complex, highly regulated and subject to multiple risks. For example, the manufacture of our multiTAA-specific T cell therapy-based product candidates involves complex processes, including drawing blood from patients/donors, manufacturing the clinical product, and ultimately infusing the product into a patient. As a result of the complexities, the cost to manufacture biologics is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. Our manufacturing processes will be susceptible to product loss or failure due to any of the following: logistical issues associated with the collection of blood cells, or starting material, from the patient or a donor, shipping such material to the manufacturing site, shipping the final product back to the patient, and infusing the patient with the product; manufacturing issues associated with the variability in patients&#8217; or donor&#8217;s starting cells; interruptions in the manufacturing process; contamination; equipment failure; improper installation or operation of equipment, vendor or operator error; inconsistency in cell growth; and variability in product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If for any reason we lose a patient&#8217;s or a donor&#8217;s cells, or later-developed product at any point in the process, the manufacturing process for that patient will need to be restarted and the resulting delay may adversely affect that patient&#8217;s outcome and/or the results of clinical trials. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because our multiTAA-specific T cell therapy-based product candidates are manufactured for each particular patient, we will be required to maintain a chain of identity with respect to the patient&#8217;s/donor&#8217;s blood cells as it moves from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our product candidates from the market. Further, as product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in order to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we currently manufacture our clinical supply at our manufacturing facilities, we are working to develop our own commercially viable processes, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale up, process reproducibility, stability issues, lot consistency, and timely availability of raw materials. As a result of these challenges, we may experience delays in our clinical development and/or commercialization plans. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No assurance can be given that we will be able to develop a new, FDA-compliant, more efficient, lower cost manufacturing process upon which our business plan to commercialize multiTAA-based product candidates is dependent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In cooperation with our current contract manufacturers and suppliers, we developed and have implemented a new nine-day multiTAA-specific T cell manufacturing process for our current Phase 2 AML trial as well as future clinical trials using a patient-specific manufacturing approach. The new manufacturing process marks additional manufacturing improvements compared to the processes used in the BCM Phase 1 and 2 trials (36-day manufacturing time) and the current AML trial reflecting the improved manufacturing process (9-day manufacturing time). The new nine-day manufacturing process enables increased antigen specificity and diversity, which has exhibited a strong linear correlation to anti-tumor activity in vitro. The new process produces a patient product that is four times more potent, with the potential to greatly improve tumor killing. This new, scaled-up, pharmaceutical manufacturing process is new and subject to uncertainties. We cannot guarantee that we will be able to more efficiently and cost effectively, and in a more automated manner produce, measure and control the physical and/or chemical attributes of our product candidates in a cGMP facility. We also have never manufactured our adoptive T cell therapy product candidate on a commercial scale. As a result, we cannot give any assurance that we will be able to establish a manufacturing process that can produce our product candidates at a cost or in quantities necessary to make them commercially viable. Moreover, we and our third-party manufacturers will have to continually adhere to current cGMP regulations enforced by the FDA through its facilities inspection program. If these facilities (including our new in-house facility) cannot </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pass a pre-approval plant inspection, the FDA premarket approval of our product candidates will not be granted. In complying with cGMP and foreign regulatory requirements, we and any of our third-party manufacturers will be obligated to expend time, money and effort in production, record-keeping and quality control to assure that our product candidates meet applicable specifications and other requirements. If we or any of our third-party manufacturers fail to comply with these requirements, we may be subject to regulatory action. No assurance can be given that we or our partners will be able to establish and operate such a production facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may have difficulty demonstrating that the product candidates produced from our new processes are identical to the existing products. The FDA may require additional clinical testing before permitting a larger clinical trial with the new processes, and such drug product may not be as efficacious in the new clinical trials. Cellular products are not considered to be well characterized products because there are hundreds of markers present on T cells, and even small changes in manufacturing processes could alter the cell subtypes. It is unclear at this time which of those markers are critical for success of T cells to combat cancer, so our ability to predict the outcomes with newer manufacturing processes is limited. The changes that we may make to the existing manufacturing process may require additional testing, which may increase costs and timelines associated with these developments. In addition to developing a multi-antigen T cell-based therapy on existing adoptive T cell therapy technology, we are currently evaluating the desirability of conducting clinical trials of our product candidates in combination with other existing drugs. These combination therapies will require additional testing, and clinical trials will require additional FDA regulatory approval and will increase our future cost of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to our Reliance on Third Parties, Including BCM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our strategic relationship with BCM is dependent, in part, upon our ongoing relationship with key medical and scientific personnel and advisors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our multiTAA-specific T cell therapy has been developed through our collaboration with the Center for Cell and Gene Therapy at BCM, founded by Malcolm K. Brenner, M.D., Ph.D., a recognized pioneer in immuno-oncology. Our strategic relationship with BCM is dependent, in part, on our relationship with certain key employees and advisors, some of whom serve on our Scientific Advisory board, and in particular Dr. Vera, our founder, Chief Operating Officer and Chief Scientific Officer. If Dr. Vera discontinues his employment with us, our relationship with BCM may deteriorate, and our business could be harmed. We may also be dependent on BCM facilities and personnel to conduct research and development and manufacturing activities in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we have an exclusive license agreement with BCM under which we received a worldwide, exclusive license to BCM&#8217;s rights in and to three patent families to develop and commercialize the multiTAA-specific T cell product candidates, we will need to enter into additional agreements with BCM with respect to (i) a strategic alliance to advance preclinical research, early stage clinical trials, and Phase 2 clinical trials with respect to our product candidates, as well as continued access to our clinical data, and (ii) support, including personnel and space at the institution for the foreseeable future. Any delays in entering into new strategic agreements with BCM related to our product candidates could delay the development, manufacture, and clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An important element of our intellectual property portfolio is to license additional rights and technologies from BCM. Our inability to license the rights and technologies that we have identified, or newly developed multiTAA-specific T cell technology that we may in the future identify, could have a material adverse impact on our ability to complete the development of our product candidates or to develop additional product candidates. No assurance can be given that we will be successful in licensing any additional rights or technologies from BCM and others. Failure to obtain additional rights and licenses may detrimentally affect our planned development of additional product candidates and could increase the cost, and extend the timelines associated with our development of such other product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to establish or maintain the third-party relationships, including strategic collaborations, that are necessary to develop, commercialize and/or market some or all of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to depend on collaborators, partners, licensees, clinical research organizations and other third parties to support our discovery efforts, to formulate product candidates to manufacture our product candidates and to conduct clinical trials for some or all of our product candidates. We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, vendors and other third parties on favorable terms, if at all. Our ability to successfully negotiate such agreements will depend on, among other things, potential partners&#8217; evaluation of the superiority of our technology over competing technologies and the quality of the preclinical and clinical data that it has generated, and the perceived risks specific to developing our product candidates. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates. Management of any third-party relationships will require significant time and effort from our management team, coordination of our research and development programs with the research and development priorities of our collaborators and effective allocation of our resources to multiple projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we continue to enter into research and development collaborations at the early phases of drug development, our success will in part depend on the performance of our corporate collaborators. We will not directly control the amount or timing of resources devoted by our corporate collaborators to activities related to our immunotherapies. Our corporate collaborators may not commit sufficient resources to their research and development programs or the commercialization, marketing or distribution of their immunotherapies. If any corporate collaborator fails to commit sufficient resources, our preclinical or clinical development programs related to this collaboration could be delayed or terminated. Also, our collaborators may pursue existing or other development-stage products or alternative technologies in preference to those being developed in collaboration with us. Finally, if we fail to make required milestones or royalty payments to our collaborators or to observe other obligations in our agreements with them, our collaborators may have the right to terminate those agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our strategy includes eventual substantial reliance upon strategic collaborations for marketing and commercialization of our product candidates, and we may rely even more on strategic collaborations for research, development, marketing and commercialization of our other immunotherapies. If we are unsuccessful in securing such strategic collaborations, we may be unable to commercialize any approved products as we have not yet licensed, marketed or sold any of our immunotherapies or entered into successful collaborations for these services in order to ultimately commercialize our immunotherapies. Establishing strategic collaborations is difficult and time-consuming. Our discussions with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment of our financial, clinical, regulatory or intellectual property position. If we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of our immunotherapies or the generation of sales revenue. To the extent that we enter into co-promotion or other collaborative arrangements, our product revenues are likely to be lower than if we directly marketed and sold any products that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or in asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to develop our business. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Commercialization of our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for our product candidates, they may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of our product candidates, if we receive approval, depends on a number of factors, including the:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy and safety of our product candidates as demonstrated in clinical trials and post-marketing experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical indications for which our product candidates may be approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by physicians and patients of our product candidates as safe and effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential and perceived advantages of our product candidates over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety of our product candidates seen in a broader patient group, including our use outside the approved indications should physicians choose to prescribe for such uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling, or product insert requirements of the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of market introduction of our product candidates as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost in relation to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing and the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of any sales and marketing efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors and the medical community, we may not be able to generate significant revenues, which would compromise our ability to become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The market for any products that we successfully develop will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it will cost to commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. Our goal is to reduce the cost of manufacturing our therapies. However, unless we are able to reduce those costs to an acceptable amount, we may never be able to develop a commercially viable product. If we do not successfully develop and commercialize products based upon our approach or find suitable and economical sources for materials used in the production of our products, we will not become profitable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we are successful in getting market approval, commercial success of any of our product candidates will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations, which may be affected by existing and future health care reform measures designed to reduce the cost of health care. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other health care payors were not to provide adequate coverage and reimbursement levels for any of our products if approved, market acceptance and commercial success would be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our multiTAA-specific T cell therapy may be provided to patients in combination with other agents provided by third parties. The cost of such combination therapy may increase the overall cost of multiTAA-specific T cell therapy and may result in issues regarding the allocation of reimbursements between our therapy and the other agents, all of which may adversely affect our ability to obtain reimbursement coverage for the combination therapy from third-party medical insurers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a personalized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success is highly dependent upon our key personnel, and our ability to attract, retain, and motivate additional qualified personnel. We will also be required to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any approved products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, scientific, and medical personnel and consultants, including Peter Hoang, our President and Chief Executive Officer, Juan Vera, M.D., our Chief Operating Officer and Chief Scientific Officer, and Mythili Koneru, M.D., Ph.D. our Chief Medical Officer as well as others. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm to our business. We have a priority to quickly train additional qualified scientific and medical personnel to ensure the ability to maintain business continuity. Any delays in training such personnel could delay the development, manufacture, and clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to attract and retain highly skilled personnel is critical to our operations and expansion. We face competition for these types of personnel from other biotechnology companies and more established organizations, many of which have significantly larger operations and greater financial, technical, human and other resources than us. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive terms, or at all. If we are not successful in attracting and retaining these personnel, or integrating them into our operations, our business, prospects, financial condition and results of operations will be materially adversely affected. In such circumstances, we may be unable to conduct certain research and development programs, unable to adequately manage our clinical trials and development of our product candidates, and unable to adequately address our management needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not currently have an organization for the sale, marketing and distribution of any approved products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products approved by the FDA or comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. As a result, our actual or proposed immunotherapies could become obsolete before we recoup any portion of our related research and development and commercialization expenses. Competition in the biopharmaceutical industry is based significantly on scientific and technological factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize technological developments and the ability to obtain governmental approval for testing, manufacturing and marketing. We compete with specialized biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations. Many biopharmaceutical companies have focused their development efforts in the human therapeutics area, including cancer. Many major pharmaceutical companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies. These companies, as well as academic institutions, governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capital to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Potential competitors in the market for treating hematological malignancies are companies such as Amgen, GlaxoSmithKline, Juno Therapeutics/Celgene/Bristol-Myers Squibb, Kite Pharma/Gilead, Merck, Novartis, Pfizer, and Roche/Genentech, which already have products on the market or in development. Other companies, such as Adaptimmune, Bluebird Bio and Cellectis, which are focused on genetically engineered T cell technologies to treat cancer, may also be competitors. Furthermore, companies such as Iovance, Immatics, NexImmune, Repertoire Immune Medicines, Tessa Therapeutics and WindMIL Therapeutics are developing non-genetically modified T cell therapies such as tumor infiltrating lymphocytes and marrow infiltrating lymphocytes therapies that may compete with our product candidates. All these companies, and most of our other current and potential competitors have substantially greater research and development capabilities and financial, scientific, regulatory, manufacturing, marketing, sales, human resources, and experience than </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">we do. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the United States and internationally. Universities and public and private research institutions in the U.S. and around the world are also potential competitors. While these universities and public and private research institutions primarily have educational objectives, they may develop proprietary technologies that lead to other FDA approved therapies or that secure patent protection that we may need for the development of our technologies and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is a therapy to treat patients with AML after receiving an allogeneic stem cell transplant. Currently, there are numerous companies that are developing various alternate treatments for AML. Accordingly, we face significant competition in the AML treatment space from multiple companies. Even if we obtain regulatory approval for our lead product candidate, the availability and price of competitors&#8217; products could limit the demand and the price we will be able to charge for our therapy. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from other methods of treatment to our product, or if physicians switch to other new therapies, drugs or biologic products or choose to reserve our product candidates for use in limited circumstances. We are aware of certain investigational new drugs under development or approved products by competitors that are used for the prevention, diagnosis, or treatment of certain diseases we have targeted for drug development. Various companies are developing biopharmaceutical products that have the potential to directly compete with our immunotherapies even though their approach may be different. The competition comes from both biotechnology firms and from major pharmaceutical companies. Many of these companies have substantially greater financial, marketing, and human resources than us. We also experience competition in the development of our immunotherapies from universities, other research institutions and others in acquiring technology from such universities and institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, certain of our immunotherapies may be subject to competition from investigational new drugs and/or products developed using other technologies, some of which have completed numerous clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA often approves new oncology therapies initially only for use in patients with relapsed or refractory metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy. There is no guarantee, however, that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive second or third-line therapy, and who have the potential to benefit from treatment with our product candidates, are based on our research and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research by third parties, and may prove to be incorrect. We do not have verifiable internal marketing data regarding the potential size of the commercial market for our product candidates, nor have we obtained independent marketing surveys to verify the potential size of the commercial markets for our current product candidates or any future product candidates. &#160;Further, new studies may change the estimated incidence or prevalence of these cancers. The number of treatable patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates and may also be limited by the cost of our treatments and the reimbursement of those treatment costs by third-party payors. For instance, we expect our lead product candidate to initially target a small patient population that suffers from AML. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, and we may spend large amounts of money trying to obtain approval for product candidates that have an uncertain commercial market.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">New regulatory pathways for biosimilar competition could reduce the duration of market exclusivity for our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, there is an abbreviated path in the United States for regulatory approval of products that are demonstrated to be &#8220;biosimilar&#8221; or &#8220;interchangeable&#8221; with an FDA-approved biological product. The ACA provides a regulatory mechanism that allows for FDA approval of biologic drugs that are similar to (but not generic copies of) innovative drugs on the basis of less extensive data than is required by a full BLA. Under this regulation, an application for approval of a biosimilar may be filed four years after approval of the innovator product. However, qualified innovative biological products will receive 12 years of regulatory exclusivity, meaning that the FDA may not approve a biosimilar version until 12 years after the innovative biological product was first approved by the FDA. However, the term of regulatory exclusivity may not remain at 12 years in the United States and could be shortened. A number of jurisdictions outside of the United States have also established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier versions of biological products. For example, the European Union has had an established regulatory pathway for biosimilars since 2005.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to this risk, and uncertainties regarding patent protection, if one of our late-stage product candidates or other clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues from product sales of that product and thus our financial results and condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent to the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection laws. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could inhibit or prevent the commercialization of products we develop, alone or with collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no insurance coverage. While we obtained clinical trial insurance for our Phase 2 clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The multiple roles of certain of Dr. Vera, our Chief Scientific Officer and Chief Operating Officer, could limit his time and availability to us, and create, or appear to create, conflicts of interest.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dr. Vera is a co-founder and director of Allovir Inc., or Allovir. Allovir has technology which is being developed under a license agreement with BCM by the same research group at BCM. Allovir is a clinical-stage biopharmaceutical company that is investigating and developing virus-specific T cell therapy technology for the prevention and/or treatment of viral infections. Accordingly, Dr. Vera may have other commitments that would, at times, limit his availability to us. Other research being conducted by Dr. Vera may, at times, receive higher priority than research on our programs, which may, in turn, delay the development or commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, Dr. Vera has certain fiduciary or other obligations to us and certain fiduciary or other obligations to Allovir and BCM. Such multiple obligations may in the future result in a conflict of interest with respect to presenting other potential business opportunities to us or to Allovir. A conflict of interest also may arise concerning the timing and scope of the parties&#8217; planned and ongoing clinical trials, investigational new drug application filings and the parties&#8217; opportunities for marketing their respective product candidates, as well as our intellectual property rights with those of Allovir. In addition, he may be faced with decisions that could have different implications for us than for Allovir.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect our proprietary rights, we may not be able to compete effectively or operate profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our commercial success is dependent in part on our ability to obtain, maintain, and enforce the patents and other proprietary rights that we have licensed and may develop, and on our ability to avoid infringing the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims are directed to the technology. There can be no assurance that our patent applications or those of our licensor will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with relevant employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of the premises and physical and electronic security of the information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, trade secrets may otherwise become known or be independently discovered by competitors. To the extent that the consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we have patents and patent applications in other countries, we cannot be certain that the claims in other pending U.S. or European patent applications, international patent applications, and patent applications in certain other foreign territories directed to methods of generating multi-antigen specific T cell product candidates, or our other product candidates, will be considered patentable by the USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued licensed European patent will not be found invalid or unenforceable if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Most of our intellectual property rights are currently licensed from BCM, so that the preparation and prosecution of these patents and patent applications was not performed by us or under our control. Furthermore, patent law relating to the scope of claims in the biotechnology field in which we operate is still evolving and, consequently, patent positions in our industry may not be as strong as in other more well-established fields. The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications may not result in any patents being issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors, many of whom have substantially greater resources than us, and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensor in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensor have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and it is uncertain how much protection, if any, will be given to the patents we have licensed from a licensor if either the licensor or we attempt to enforce the patents and/or if they are challenged in court or in other proceedings, such as oppositions, invalidations, or like proceedings, which may be brought in foreign jurisdictions to challenge the validity of a patent. A third party may challenge our patents, if issued, or the patent rights that we license from others in the courts or patent offices in the United States and abroad. It is possible that a competitor may successfully challenge our patents or that a challenge will result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products and product candidates. Moreover, the cost of litigation to defend the validity of patents and to prevent or remedy infringement can be substantial. If the outcome of litigation is adverse to us, third parties may be able to use our patented invention without payment to us. Moreover, it is possible that competitors may infringe our patents or successfully avoid them through design innovation. To stop violation of our patent rights, we may need to file a lawsuit. These lawsuits are expensive and would consume time and other resources, even if we were successful in stopping or remedying the violation of our patent rights. In addition, there is a risk that a court would decide that our patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of our patents was upheld, a court would refuse to stop the other party on the ground that its activities are not covered by, that is, do not infringe, our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Should third parties file patent applications, or be issued patents claiming technology also used or claimed by our licensor(s) or by us in any future patent application, we may be required to participate in interference proceedings in the USPTO to determine priority of invention for those patents or patent applications that are subject to the first-to-invent law in the United States, or may be required to participate in derivation proceedings in the USPTO for those patents or patent applications that are subject to the &#8220;first-inventor-to-file&#8221; law in the United States. We may be required to participate in such interference or derivation proceedings involving our issued patents and pending applications. We may be required to cease using the technology or to license rights from prevailing third parties as a result of an unfavorable outcome in an interference proceeding or derivation proceeding. A prevailing party in that case may not offer us a license on commercially acceptable terms or on any terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we, our licensing partners, or any potential future collaborator initiates legal proceedings against a third party to enforce a patent directed to one of our product candidates, the defendant could counterclaim that the patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, non-obviousness or enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they are no longer directed to our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensor invalid or could prevent a patent from issuing from one or more of our pending patent applications. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. Furthermore, even if our patents are unchallenged, they may not adequately protect our intellectual property, provide exclusivity for our product candidates, prevent others from designing around our claims or provide us with a competitive advantage. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection could have a material adverse impact on our business development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The use of our technologies could potentially conflict with the rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential competitors or other entities may have or acquire patent or proprietary rights that they could enforce against our licensor. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations,&#160;<i style="font-style:italic;">inter partes&#160;</i>review proceedings and post-grant review, or PGR, proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Such potential third-party patents or patent applications could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position by requiring us to alter our product candidates, pay licensing fees or cease activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that later issue as patents that our product candidates may infringe. If our product candidates conflict with patent rights of others, third parties could bring legal actions against us or our collaborators, licensees, suppliers or customers, claiming damages and seeking to enjoin manufacturing and marketing of the affected product candidates. If these legal actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture or market the affected product candidates. We may not prevail in any legal action and a required license under the patent may not be available on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO and may become involved in post-grant proceedings including post grant review, derivation, reexamination,&#160;<i style="font-style:italic;">inter-partes&#160;</i>review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. In addition, recent U.S. Supreme Court rulings on several patent cases have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. While we do not believe that any of the patents owned or licensed by us will be found invalid based on these decisions, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing its inventions in all countries outside the United States, or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system will likely be introduced by the end of 2023, which would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. We have received confidential and proprietary information from third parties. We employ individuals or engage consultants who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to comply with any obligations under our existing license agreements or any future license agreements, or disputes arise with respect to those agreements, it could have a negative impact on our business and our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a party to license agreements with BCM that impose, and we may enter into additional licensing arrangements with third parties that may impose, diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. Our rights to use the licensed intellectual property are subject to the continuation of and our compliance with the terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and duration of our payment obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our rights upon termination of such agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and duration of exclusivity obligations of each party to the agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future licensing agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under our license agreement with BCM for our multiTAA-specific T cell therapy technologies, we are currently required to pay both substantial milestone payments and royalties to BCM based on our revenues from sales of any approved products utilizing the licensed technologies, and these payments could adversely affect the overall profitability for us of any products that we may seek to commercialize. In order to maintain our license rights under the BCM license agreement, we will need to meet certain specified milestones, subject to certain cure provisions, in the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, upon a liquidity event (as defined in our BCM license agreement with BCM) of the licensee under the BCM license agreement (which, the licensee shall be the Company), BCM will receive a liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM license agreement) received by such licensee or its stockholders in the liquidity event, thereby diluting the amount of proceeds available to the licensee or its stockholders in a liquidity event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be subject to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide sufficient rights to exclude others from commercializing products similar or identical to our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our technologies are in-licensed from third parties, and the protection of those technologies is not entirely within our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have a world-wide exclusive license from BCM of the rights in and to three patent families to develop and commercialize multiTAA-specific T cell product candidates in the field of oncology. As a result of these in-licenses, we could lose the right to develop each of the technologies if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the owner (s) of the patent rights underlying the technologies that we license do not properly maintain or enforce the patents and intellectual property underlying those properties,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BCM seeks to terminate our license in contravention of the license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we fail to make all payments due and owing under any of the licenses; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we fail to obtain on commercially reasonable terms, if at all, in-licenses from BCM or others for other rights that are necessary to develop the technology that we have already in-licensed.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any of the above occurs, we could lose the right to use the in-licensed intellectual property, which would adversely affect our ability to commercialize our technologies, products or services. The loss of any current or future licenses from BCM, or the exclusivity rights provided by such license agreements, could materially harm our financial condition and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely upon patents and licensed technologies to protect our technology. We may be unable to protect our intellectual property rights, and we may be liable for infringing the intellectual property rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to compete effectively depends on our ability to maintain the proprietary nature of our technologies and the proprietary technology of others with whom we have entered into collaboration and licensing agreements. We own or hold licenses to a number of issued patents and U.S. pending patent applications, as well as foreign patents and foreign counterparts. Our success depends in part on our ability to obtain patent protection both in the United States and abroad for our product candidates, as well as the methods for treating patients in the product indications using these product candidates. Such patent protection is costly to obtain and maintain, and sufficient funds might not be available. Our ability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Even if our product candidates, as well as methods for treating patients for prescribed indications using these product candidates are covered by valid and enforceable patents and have claims with sufficient scope, disclosure and support in the specification, the patents will provide protection only for a limited amount of time. Accordingly, rights under any issued patents may not provide us with sufficient protection for our product candidates or provide sufficient protection to afford us a commercial advantage against competitive products or processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we cannot guarantee that any patents will be issued from any pending or future patent applications owned by or licensed to us. Even if patents have been issued or will be issued, we cannot guarantee that the claims of these patents are or will be valid or enforceable or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. Furthermore, different countries have different procedures for obtaining patents, and patents issued in different countries offer different degrees of protection against use of the patented invention by others. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The patent positions of biotechnology and pharmaceutical companies, including our patent positions, involve complex legal and factual questions, and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated, or circumvented. Our patents can be challenged by our competitors who can argue that our patents are invalid and/or unenforceable, or that the patent claims should be limited or narrowly construed. Patents also will not protect our product candidates if competitors devise ways of making or using these product candidates without infringing our patents. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our technologies, methods of treatment, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">product candidates, and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets and we have the funds to enforce our rights, if necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expiration of our owned or licensed patents before completing the research and development of our product candidates and receiving all required approvals in order to sell and distribute the products on a commercial scale can adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensor, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may face legal claims involving stockholders, consumers, competitors, entities from whom we license technology, entities with whom we collaborate, persons claiming that we are infringing on their intellectual property and others. The biotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have employed intellectual property litigation to gain a competitive advantage. Competitors may infringe our intellectual property rights or those of our licensor. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that one or more of the patents which we own or in-license is not valid or is unenforceable, and/or is not infringed. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In addition, litigation may be necessary to enforce our issued patents, to protect our trade secrets and know-how, or to determine the enforceability, scope, and validity of the proprietary rights of others. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patent and/or pending patent applications will be due to the USPTO and foreign patent agencies in several stages over the lifetime of our patents and/or applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensor. Should third parties file patent applications or be issued patents claiming technology also used or claimed by us, we may be required to participate in interference or derivation proceedings in the USPTO to determine priority of invention. We may be required to participate in interference or derivation proceedings involving our issued patents and pending applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The costs of litigation or any proceeding relating to our intellectual property or contractual rights could be substantial even if resolved in our favor. Some of our competitors or financial funding sources have far greater resources than we do and may be better able to afford the costs of complex legal procedures. Also, in a lawsuit for infringement or contractual breaches, even if frivolous, we will require considerable time commitments on the part of management, our attorneys and consultants. Defending these types of proceedings or legal actions involve considerable expense and could negatively affect our financial results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain licenses needed for the development of our product candidates, or if we breach any of the agreements under which we license rights to patents or other intellectual property from third parties, we could lose license rights that are important to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to maintain and/or obtain licenses needed for the development of our product candidates in the future, we may have to develop alternatives to avoid infringing on the patents of others, potentially causing increased costs and delays in product development and introduction or precluding the development, manufacture, or sale of planned product candidates. Some of our licenses provide for limited periods of exclusivity that require minimum license fees and payments and/or may be extended only with the consent of the licensor. We might not meet these minimum license fees in the future, or these third parties might not grant extensions on any or all such licenses. This same restriction may be contained in licenses obtained in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the patents underlying the licenses might not be valid and enforceable. To the extent any product candidates developed by us are based on licensed technology, royalty payments on the licenses will reduce our gross profit from such product sales and may render the sales of such product candidates uneconomical. In addition, the loss of any current or future licenses or the exclusivity rights provided therein could materially harm our business financial condition and our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays. Even if we receive regulatory approval of our product candidates, we will be subject to ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our current and future product candidates, cell processing and manufacturing activities, are subject to comprehensive regulation by the FDA in the United States and by comparable authorities in other countries. The process of obtaining FDA and other required regulatory approvals, including foreign approvals, is expensive and often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved. In addition, regulatory agencies may lack experience with our technologies and product candidates, which may lengthen the regulatory review process, increase our development costs and delay or prevent their commercialization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No adoptive T cell therapy using multiTAA-specific T cells has been approved for marketing in the U.S. by the FDA. Consequently, there is no precedent for the successful commercialization of products based on our technologies. In addition, we have had only limited experience in filing and pursuing applications necessary to gain regulatory approvals, which may impede our ability to obtain timely FDA approvals, if at all. We have not yet sought FDA approval for any adoptive T cell therapy product. We will not be able to commercialize any of our potential product candidates until we obtain FDA approval, and so any delay in obtaining, or inability to obtain, FDA approval would harm our proposed business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be fined, forced to remove a product from the market and experience other adverse consequences including delay, which could materially harm our business development. Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our products. We may also be required to undertake post-marketing trials. Prescription drugs may be promoted only for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatment but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. In addition, if we or others identify side effects after any of our adoptive T cell therapy products are on the market, or if manufacturing problems occur, regulatory approval may be withdrawn, and reformulation of our products may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of any approved product candidates will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals)(such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug takeback&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, any sales of our product once commercialized outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recently enacted and future legislation in the United States and other countries may affect the prices we may obtain for our product candidates and increase the difficulty and cost to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States and many other countries, rising healthcare costs have been a concern for governments, patients and the health insurance sector, which has resulted in a number of changes to laws and regulations, and may result in further legislative and regulatory action regarding the healthcare and health insurance systems that could affect our ability to profitably sell any product candidates for which we have obtained marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For example, the ACA was enacted in the United States in March 2010, with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare, and includes measures to change health care delivery, increase the number of individuals with insurance, ensure access to certain basic health care services, and contain the rising cost of care. There have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. For example, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &quot;donut hole&quot; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is also unclear how such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, other federal health reform measures have been proposed and adopted in the United States. For example, as a result of the Budget Control Act of 2011 and subsequent legislative amendments thereto, including the Infrastructure Investment and Jobs Act, providers are subject to Medicare payment reductions of 2% per fiscal year until 2031, unless additional Congressional action is taken. Under current legislation the actual reduction in Medicare Payments will vary from 1% in 2022 to up to 3% in the fiscal year of this sequester. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and also introduced a quality payment program, or the Quality Payment Program, under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. This Quality Payment Program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. It is still unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement under the Medicare program. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, for example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In addition, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The combination of healthcare cost containment measures, increased health insurance costs, reduction of the number of people with health insurance coverage, as well as future legislation and regulations focused on reducing healthcare costs by reducing the cost of, or reimbursement and access to, pharmaceutical products, may limit or delay our ability to commercialize our products, generate revenue or attain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described above, the ACA and potential regulations thereunder easing the entry of competing follow-on biologics into the marketplace, other new legislation or implementation of existing statutory provisions on importation of lower-cost competing drugs from other jurisdictions, and legislation on comparative effectiveness research are examples of previously enacted and possible future changes in laws that could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect that additional state and federal healthcare reform measures will continue to be adopted in the future. While it is not possible to predict whether and when any such changes will occur, changes in the laws, regulations, and policies governing the development and approval of our product candidates and the commercialization, importation, and reimbursement of our product candidates could adversely affect our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to stringent and changing laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we may collect, receive, store, process, generate, use, transmit, disclose, make accessible, protect, secure, dispose of, share (collectively, processing) personal data and other sensitive data, including proprietary and confidential business data, intellectual property, trade secrets, data regarding clinical trial subjects, and sensitive third-party data. We may rely on third parties (such as service providers) for our data processing-related activities. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws. For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Additionally, the California Consumer Privacy Act of 2018, or CCPA, applies to personal data of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, California Privacy Rights Act of 2020, or CPRA, expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal data and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts and increase legal risk and compliance costs for us and the third parties upon whom we rely. Outside the United States, an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under the EU GDPR, companies may face temporary or definitive bans on data processing and other corrective actions, fines of up to 20 million euros or 4% of annual global revenue, whichever is greater, or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the CCPA, require our customers to impose specific contractual restrictions on their service providers. We publish privacy policies, marketing materials and other statements, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences. Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our stock may be volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The listing of our common stock on Nasdaq does not assure that a meaningful, consistent and liquid trading market currently exists or will exist in the future. The trading price of our common stock may fluctuate substantially. The price of our common stock that will prevail in the market may be higher or lower than the price at which our shares of common stock, depending on many factors, some of which are beyond our control and may not be related to our company or our operating performance. These fluctuations could cause you to lose part or all of your investment in our common stock. Those factors that could cause fluctuations include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price and volume of fluctuations in the overall stock market from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in stock market prices and trading volumes of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the thinly traded nature of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in our net loss or fluctuations in our operating results or in the expectations of securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of our preclinical studies and clinical trials or delays in anticipated timing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of new equity securities pursuant to a future offering, including issuances of preferred stock , or sales of large blocks of our stock and sales by insiders and our institutional investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new collaboration agreements with strategic partners or developments by our existing collaboration partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of acquisitions, mergers or business combinations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive developments, including announcements by competitors of new products or services or significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic conditions and trends, including changes in interest rates, and other national and global conditions, including the ongoing COVID-19 pandemic and related global economic uncertainty;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">major catastrophic events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">events affecting BCM or any future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new product candidates or technologies, commercial relationships or other events , including the results of clinical trials, or variations in our quarterly operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and other countries , including changes in the structure of healthcare payment systems, or other positive and negative events relating to healthcare and the overall pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of our common stock to maintain listing requirements on Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome of any litigation to which we are a party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting principles; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussion of our company or our stock price by the financial and scientific press and in online investor communities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The stock market in general, and the Nasdaq Capital Market, or Nasdaq, and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors, including potentially worsening economic conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Due to the potential volatility of our stock price, we may therefore be the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We completed a reverse stock split of our shares of common stock, which may reduce and may limit the market trading liquidity of the shares due to the reduced number of shares outstanding and may potentially have an anti-takeover effect.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We completed a reverse stock split, or the Reverse Stock Split, of our common stock by a ratio of one-for-ten (1:10) effective January 26, 2023. The liquidity of our common stock may be adversely affected by the Reverse Stock Split as a result of the reduced number of shares outstanding following the Reverse Stock Split. In addition, the Reverse Stock Split may increase the number of stockholders who own odd lots of our common stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty affecting such sales. Reducing the number of outstanding shares of our common stock through the Reverse Stock Split is intended, absent other factors, to increase the per share market price of our common stock. However, other factors, such as our financial results, market conditions and the market perception of our business may adversely affect the market price of our common stock. As a result, there can be no assurance that the Reverse Stock Split will result in the intended benefits, that the market price of our common stock will remain higher following the Reverse Stock Split or that the market price of our common stock will not decrease in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of additional equity securities may adversely affect the market price of our common stock and your rights may be reduced. Our stockholders may experience dilution in the future and it may adversely affect the market price of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur drug development and sale, general and administrative costs. Until such time, if ever, as we can generate substantial product revenue, we expect to fund our cash requirements through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. We do not currently have a committed external source of funds. To the extent that we sell equity securities or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. The sale or the proposed sale of substantial amounts of our common stock or other equity securities in the public markets may adversely affect the market price of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had 8.4 million shares of our common stock issued and outstanding (as adjusted for the Reverse Stock Split). Those outstanding shares represent a minority of our authorized shares, meaning that the ownership position of the current stockholders could be diluted significantly were we to issue a large number of additional shares. In addition, as of December 31, 2022, there were outstanding warrants to purchase up to approximately 1.8 million shares of our common stock at a weighted average exercise price of&#8201;$44.51 per share, and outstanding options for an aggregate of approximately 0.9 million shares of common stock at a weighted average exercise price of&#8201;$42.90 per share (each as adjusted for the Reverse Stock Split). We have registered the resale of the shares issuable upon exercise of our outstanding warrants, and as a result the shares issued upon exercise will be tradable by the exercising party. Upon such registration, the holders may sell these shares in the public markets from time to time, without limitations on the timing, amount, or method of sale. If our stock price rises, the holders may exercise their warrants and options and sell a large number of shares. This could cause the market price of our common stock to decline and cause existing stockholders to experience significant further dilution.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Further, in December 2022 we entered into a purchase agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock from time to time over the 24-month term of the purchase agreement. The purchase price for the shares that we may sell to Lincoln Park under the Purchase Agreement will fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our common stock to fall. We generally have the right to control the timing and amount of any future sales of our shares to Lincoln Park. Additional sales of our common stock, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none of those shares at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not intend to pay cash dividends.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the foreseeable future. Any future determination as to the payment of cash dividends on our common stock will be at our board of directors&#8217; discretion and depends on our financial condition, operating results, capital requirements and other factors that our board of directors considers to be relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, or are perceived to have been compromised, we could experience adverse consequences, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we and the third parties upon which we rely, may collect, receive, store, use, transmit, disclose, transfer, disclose, make accessible, protect, secure, dispose of, transmit, share, or otherwise process proprietary, confidential, and sensitive data, including personal data (such as health-related data regarding clinical trial subjects), intellectual property, and trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cyberattacks, malicious internet-based activity, and online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. We and the third parties upon which we rely may be subject to a variety of threats, including, but not limited to, malicious code (such as viruses and worms), social engineering attacks (including through phishing attacks), malware (including as a result of advanced persistent threat intrusions), denial of service attacks (such as credential stuffing), credential harvesting, software bugs, server malfunctions, software or hardware failures, unauthorized access, natural disasters, fire, terrorism, successful breaches, personnel misconduct or error, or human or technological error, war and telecommunication and electrical failures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In particular, severe ransomware attacks are becoming increasingly prevalent and severe, and can lead to significant interruptions in our operations, loss of sensitive data, reputational harm, and diversion of funds. Extortion payments may alleviate some of the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Additionally, the COVID-19 pandemic poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on third parties (such as service providers and technologies) to process sensitive information in a variety of contexts, including without limitation third-party providers of cloud-based infrastructure, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties&#8217; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place. &#160;If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. &#160;While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. Any of the previously identified or similar threats could cause a security incident or other incident during which our information technology systems or data could be compromised, which could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our data; it could also disrupt our ability (and that of third parties upon which we rely) to operate our business, including conducting our clinical trials. For example, if a compromise were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. &#160;Similarly, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may expend significant resources or modify our business activities (including our clinical trial activities) in an effort to protect against the compromise of our information technology systems and data. Further, certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and data. While we have implemented security measures designed to prevent our information technology systems and data from being compromised, there can be no assurance that these measures will be effective. We may be unable to detect vulnerabilities in our information technology systems because the threats against these systems change frequently, are often sophisticated, and may not be detected until after a compromise has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any identified vulnerabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, including: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class actions); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Additionally, applicable data privacy and security obligations may require us to notify relevant stakeholders; such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. &#160;Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from claims related to our data privacy and security obligations. We have cybersecurity insurance for a breach event covering expenses for notification, credit monitoring, investigation, crisis management, public relations and legal advice. We also maintain property and casualty insurance that may cover restoration of data, certain physical damage or third-party injuries caused by potential cybersecurity incidents. However, damage and claims arising from such incidents may not be covered or may exceed the amount of any insurance available. Additionally, we cannot be sure that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are required, pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. We are also required to disclose significant changes made in our internal control procedures on a quarterly basis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To comply with Section 404, we have engaged in the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. Our compliance with Section 404 requires that we incur substantial professional fees and expend significant management efforts, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the evaluation and testing process of our internal controls, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to limitation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our federal NOLs generated in tax years beginning before January 1, 2018, are permitted to be carried forward for only 20 years under applicable U.S. tax law. Our federal NOLs generated in tax years beginning after December 31, 2017, &#160;may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, or, the Code, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage over a rolling three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Catastrophic events may disrupt our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters and cGMP manufacturing facility are located in Houston, Texas. In the event of a major hurricane or other serious weather event or catastrophic event such as fire, power loss, cyberattack, war, terrorist attack or epidemic or pandemic, such as the COVID-19 pandemic, that impacts our corporate headquarters or other facilities, or the facilities of any third parties on which we may rely, we may be unable to continue our operations and may experience delays in our manufacturing process and shipment of clinical supply to trial sites or interruptions in our clinical trials and research activities, all of which could delay our development plans and materially harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in recent years the COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve recently raised interest rates multiple times in response to concerns about inflation and is expected to continue to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">raise rates. Higher interest rates, coupled with reduced government spending and volatility in financial markets, including with respect to foreign exchange, may increase economic uncertainty. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services]. In addition, the current military conflict between Russia and Ukraine could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely, although we have not experienced any such disruption to date. Related sanctions, export controls or other actions have been or may in the future be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with whom we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in tax laws or regulations could materially adversely affect our company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-style:normal;font-weight:normal;">New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us, which could adversely affect our business and financial condition. For instance, the United States recently passed the Inflation Reduction Act, which provides for a minimum tax equal to 15% of the adjusted financial statement income of certain large corporations, as well as a 1% excise tax on certain share buybacks by public corporations that would be imposed on such corporations. In addition, it is uncertain if and to what extent various states will conform to federal tax legislation. The impact of such changes or future legislation could increase our U.S. tax expense and could have a material adverse impact on our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_728ffc48_c6f3_40ef_a5b6_dbdefbac8df2"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_521175"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 1B. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_1ac688ec_41ef_465c_8e43_8829f27495a1"></a><a id="ITEM2PROPERTIES_338462"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 2. PROPERTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not own any real estate or other properties. We lease a manufacturing facility and office space at 4551 Kennedy Commerce Drive, Houston, Texas 77032 on a ten-year agreement from rent commencement date, set to expire in November 2030, which is also our principal business office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In April 2020, we entered into a lease for a research facility in Houston, Texas. The lease term is 71 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7ebdc3e8_a6af_456e_82d6_8d952a95fb57"></a><a id="ITEM3LEGALPROCEEDINGS_282506"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 3. LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Other than as described below, we are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An arbitration proceeding was brought against the Company before the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) by a broker seeking to be paid compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The broker&#8217;s claims were based on a placement agent agreement for a private placement it brokered in 2017, under which it alleged it was entitled to compensation for the 2018 transactions. The FINRA panel found in favor of the broker and awarded the broker $2.4 million for compensation, interest and attorney fees. As of December 31, 2021, the Company recorded an accrual of $2.4 million in accrued liabilities on its consolidated balance sheet and a $2.4 million charge to other expenses. On September 17, 2021, the broker filed a petition to confirm the FINRA arbitration award in the Supreme Court of New York for the County of New York. The Company removed the case to the United States District Court for the Southern District of New York on September 27, 2021. On October 22, 2021, the Company filed a motion in federal court to vacate the award. On March 9, 2022, the Company was notified that its motion to vacate the award was denied and the broker was awarded an additional $0.1 million in interest. Post judgment interest accrued at 1.02% until the judgment was paid. The Company paid the broker the $2.5 million judgment, which amount included accrued interest, on March 24, 2022. &#160;On January 3, 2023, the broker was awarded an additional $0.1 million in post-judgment interest, which was recorded to other expenses for the year ended December 31, 2022 and subsequently paid on January 9, 2023.</p><a id="_cc9ecbcc_5d32_4b91_b223_ef1be8d33248"></a><a id="ITEM4MINESAFETYDISCLOSURE_456568"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 4. MINE SAFETY DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not Applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bdfa71ce_8518_4fdb_be55_6522939713d9"></a><a id="PARTII_862782"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART II</b></p><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is listed for trading on the Nasdaq Capital Market under the symbol &#8220;MRKR&#8221;. As of March 1, 2023, we had 174 stockholders of record whom are holding shares. The price of our common stock on March 1, 2023 was $2.05 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No dividends have been declared or paid on our common stock. We have incurred recurring losses and do not currently intend to pay any cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not record any issuances of unregistered securities during the fourth quarter of 2022.</p><a id="_8364ad0a_2780_473c_b887_6703788e1e4a"></a><a id="ITEM6RESERVED"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ITEM 6. [RESERVED]</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_975b535d_3266_4142_856d_b763b845fde8"></a><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following discussion of our financial condition, changes in financial condition, plan of operations and results of operations should be read in conjunction with (i) our audited consolidated financial statements as of December 31, 2022 and December 31, 2021 and (ii) the section entitled &#8220;Business&#8221;, included in this annual report. The discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. &#160;We developed our lead product candidates from our multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens, or TAAs. MultiTAA-specific T cells are able to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. &#160;When infused into a cancer patient, the multiTAA-specific T cells are designed to kill cancer cells expressing the TAA targets and potentially recruit the patient&#8217;s immune system to participate in the cancer killing process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We licensed the underlying technology for multiTAA-specific T cell therapy from BCM in March 2018. BCM had utilized the therapy in seven exploratory clinical trials. In these studies, BCM treated over 150 patients suffering from a variety of cancers including lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia, pancreatic cancer, breast cancer and various sarcomas. In those studies, BCM saw evidence of clinical benefit, expansion of infused cells, epitope spreading, and decreased toxicity compared to other cellular therapies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are advancing three product candidates as part of our multiTAA-specific T cell program for: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">autologous treatment of lymphoma, and selected solid tumors </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allogeneic T cells for the treatment of acute myeloid leukemia, or AML</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">off-the-shelf products in various indications</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our current clinical development programs are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MT-401 for the treatment of post-transplant AML, currently in a Phase 2 clinical trial </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MT-401-OTS for the treatment of AML, for which we expect to dose the first patient in a Phase 2 clinical trial in 2023</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MT-601 for the treatment of pancreatic cancer, for which we have a cleared IND from the FDA to initiate a Phase 1 trial in the fourth quarter of 2023</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MT-601 for the treatment of lymphoma, for which we have a cleared IND from the FDA and initiated a Phase 1 trial in the first quarter of 2023</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that the simplicity of our manufacturing process allows additional modifications to expand multiTAA-specific T cell recognition of cancer targets. For example, we are currently analyzing the potential for a 12-antigen multiTAA-specific T cell therapy and assessing the potential for combination therapies for our multiTAA-specific T cell products.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have positioned ourselves to be in full control of our research and development and clinical manufacturing needs by establishing a fully validated, FDA registered, manufacturing facility. We believe that this has key advantages that distinguish us from our competitors, particularly because we are less reliant on contract manufacturing organizations, which are expensive and often have long lead times, shortages of skilled labor and a backlog of customers. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 24, 2022, we held our annual meeting of stockholders at which our stockholders approved a proposal to effect an amendment to our certificate of incorporation, as amended, to implement a reverse stock split at a ratio within a range between and including one-for three (1:3) and one-for-twelve (1:12) and a corresponding reduction in the total number of authorized shares of our common stock. On January 24, 2023, our board of directors approved the filing of a certificate of amendment to our amended and restated certificate of incorporation (the &#8220;Amendment&#8221;) with the Secretary of State of the State of Delaware to affect the one-for-ten (1:10) &#160;Reverse Stock Split of our outstanding common stock and a reduction in the total number of authorized shares of our common stock from 300,000,000 to 30,000,000 (the &#8220;Shares Reduction&#8221;). The Amendment became effective at 5:00 p.m. Eastern Time on January 26, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amendment, at the effective time of the Amendment, every ten (10) shares of our issued and outstanding common stock was automatically combined into one (1) issued and outstanding share of common stock and the authorized shares of our common stock was reduce from 300,000,000 to 30,000,000, without any change in par value per share. The Reverse Stock Split affected all shares of our common stock outstanding immediately prior to the effective time of the Amendment. No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share received a cash payment in lieu thereof. As a result of the Reverse Stock Split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and warrants issued by us and outstanding immediately prior to the effective time of the Amendment, which resulted in a proportionate decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options and warrants and a proportionate increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under our equity compensation plans immediately prior to the effective time of the Amendment were reduced proportionately. All share and per share amounts of common stock presented in this Annual Report on Form 10-K have been retroactively adjusted to reflect the one-for-10 (1:10) Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, our research and development expenses have related primarily to the development of our clinical platform and the identification and development of our product candidates. Clinical and research and development expenses consist of expenses incurred in performing research and development activities, cost of our clinical trials, including compensation, share-based compensation expense and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical costs are expensed as incurred. Costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per patient clinical trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that participate in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of sites included in the clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll eligible patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses that patients receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the drop-out or discontinuation rates of patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential additional safety monitoring or other studies requested by regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety profile of the product candidates; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to successfully manufacture patient doses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the potential for success of each product candidate will depend on numerous factors, including clinical trial outcomes, acceptance by regulatory authorities, competition, manufacturing capability and commercial viability. We determine which programs to pursue and how much to fund each program in response to ongoing scientific assessments, competitive developments, clinical trial results, as well as an assessment of each product candidate&#8217;s commercial potential. We anticipate our research and development costs will continue to increase over the next several years due to increased spending on the clinical development and manufacturing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in executive, finance, accounting, business development, legal and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, insurance costs and professional fees for consultancy, accounting, audit and investor relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, and the potential commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not recognize any income tax expense for the years ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists of interest income and arbitration settlement expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations For the Years Ended December 31, 2022 and 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the results of our operations (rounded to the thousand except for per share amounts) for the years ended December 31, 2022 and 2021, together with the changes to those items:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,514,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,242,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,272,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 183</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Related party service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,014,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,242,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,772,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 626</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,139,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,795,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,656,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,820,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,925,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (105,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,959,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40,720,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,761,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29,946,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39,478,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,532,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Arbitration settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (233,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,407,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,174,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (90)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 248,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 242,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,033</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (29,931,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (41,879,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 11,948,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (29)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3.58)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5.47)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.89</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,351,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,651,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 700,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><a id="_Hlk528651708"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">We did not generate any revenue during the years ended December 31, 2022 and 2021, respectively, from the sales or licensing of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas, or CPRIT, to support our Phase 2 clinical trial of MT-401. &#160;During the years ended December 31, 2022 and 2021, respectively, we recognized $3.4 million and $1.2 million of revenue associated with the CPRIT grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 12pt 0pt;">On September 13, 2022, we received notice from the FDA that we had been awarded a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support our Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. During the year ended December 31, 2022, we recognized $0.1 million of revenue associated with the FDA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">In April 2022, we entered into a binding services agreement, or the Service Agreement, with Wilson Wolf. Pursuant to the Services Agreement, Wilson Wolf made a cash payment to us in the amount of $8.0 million, as consideration for certain training and research services.  During the year ended December 31, 2022, we recognized $5.5 million of revenue associated with the Services agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Operating expenses incurred during the fiscal year ended December 31, 2022 were $39.0 million compared to $40.7 million in the prior year. Significant changes and expenditures in operating expenses are outlined as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Research and Development Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses decreased by 6% to $26.1 million for the year ended December 31, 2022, compared to $27.8 million for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease of $1.7 million in 2022 was primarily attributable to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $1.7 million in sponsored research and consulting expenses from BCM agreements,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $1.4 million in process development expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.6 million in technology licensing fees due to termination of Mayo license agreements, described below,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.3 million in consulting expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.2 million in stock-based compensation expenses, offset by</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $1.5 million in headcount-related expenses as we increased the number of research and development personnel,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $0.7 million in depreciation expense due to increased capital investments, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $0.3 million in vaccine-based clinical trial expenses related to the termination of the Mayo license agreements, described below. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Included in research and development expenses are expenses related to agreements with BCM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2018 and February 2020, we entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for us by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy. &#160;During the years ended December 31, 2022 and 2021, we incurred $0 and $0.03 million of expenses related to these agreements, respectively.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, we entered in a Clinical Supply Agreement with BCM, which provided for BCM to provide to us multi tumor antigen specific products. &#160;During the years ended December 31, 2022 and 2021, we incurred $0.7 million and $1.2 million related to this agreement, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, we entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to us manpower costs of projects for manufacturing, quality control testing and validation run activities. &#160;During the years ended December 31, 2022 and 2021, we incurred $0.4 million and $1.1 million related to this agreement, respectively. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, we entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to us investigator-initiated research studies. &#160;During the years ended December 31, 2022 and 2021, we incurred $0 and $0.5 million related to this agreement, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2022, we and Mayo Foundation for Medical Education and Research, or Mayo, mutually agreed to terminate the (i) Patent and Know-How License Agreement dated March 25, 2012, the (ii) License and Assignment Agreement dated July 21, 2015, and the (iii) License and Assignment Agreement effective May 4, 2016, which we collectively refer to as the License Agreements, in accordance with and subject to the terms of those agreements, pursuant to which Mayo granted the Company license grants to patent rights, know-how and materials in each of the License Agreements (as defined therein) that were directed to our peptide-based immunotherapeutic vaccine programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the terms of the termination, the License Agreements are of no further force or effect. All license grants under the License Agreements are terminated and all rights therein revert to Mayo. We also will assign Mayo all of the INDs covered under the License Agreements, including any interest in any clinical trials relating to any IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses decreased by 1% to $12.8 million for the year ended December 31, 2022 from $12.9 million during the prior period. The decrease in general and administrative expenses of $0.1 million mainly comprised the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $0.6 million in severance expense related to headcount reductions,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $0.5 million in advisory and professional fees, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase of $0.1 million in other general and administrative expenses, offset by </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.1 million in other headcount-related expenses,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.5 million in stock-based compensation,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.4 million in rent and utility expenses, in part due to the termination of our office lease at 3200 Southwest Freeway, Suite 2500 in Houston, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decrease of $0.3 million in recruiting expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2022, we implemented changes to our organizational structure as part of an operational cost reduction plan to conserve our available capital by reducing headcount in our general and administrative function by approximately 23.5%, including the separation of the Company&#8217;s Chief Financial Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income /(Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration settlement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An arbitration proceeding was brought against us before the Financial Industry Regulatory Authority, Inc., or FINRA by a broker seeking to be paid compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement, each brokered by another broker. &#160;The broker&#8217;s claims were based on a placement agent agreement for a private placement it brokered in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2017, under which it alleged it was entitled to compensation for the 2018 transactions. The FINRA panel found in favor of the broker and awarded the broker $2.4 million for compensation, interest and attorney fees. &#160;As of December 31, 2021, we recorded an accrual of $2.4 million in accrued liabilities on our consolidated balance sheet and a $2.4 million charge to other expenses. On September 17, 2021, the broker filed a petition to confirm the FINRA arbitration award in the Supreme Court of New York for the County of New York. &#160;We removed the case to the United States District Court for the Southern District of New York on September 27, 2021. &#160;On October 22, 2021, we filed a motion in federal court to vacate the award. &#160;On March 9, 2022, we were notified that our motion to vacate the award was denied and the broker was awarded an additional $0.1 million in interest. &#160;Post judgment interest accrued at 1.02% until the judgment was paid. &#160;We paid the $2.5 million judgment on March 24, 2022. &#160;On January 4, 2023, we were notified that the broker was awarded an additional $0.1 million in attorneys&#8217; fees, which we recorded to other expenses during fiscal year ending December 31, 2022. We paid the $0.1 million on January 9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Interest income was $0.2 million and $6,000 for the years ended December 31, 2022 and 2021, respectively, and was attributable to interest income relating to funds that are held in U.S. Treasury notes and U.S. government agency-backed securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease in our net loss during the year ended December 31, 2022 compared to the year ended December 31, 2021 was due to higher grant income and related party service revenue, cost reductions in our research and development activities and moderate stabilization of our clinical trial activities. We anticipate that we will continue to incur net losses in the future as we continue to invest in research and development activities, including clinical development of our multiTAA T cell product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not generated any revenues from the sales or licensing of our product candidates since inception and only have limited revenue associated with grants. We have financed our operations primarily through public and private offerings of our stock and debt including warrants and the exercise thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth our cash, cash equivalents and restricted cash and working capital as of December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,782,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43,497,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,837,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,081,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes our cash flows for the years ended December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26,972,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,280,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,945,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,131,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 202,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52,556,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31,715,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,145,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net cash used in operating activities during the year ended December 31, 2022 was $27.0 million. The use of cash primarily related to our net loss of $29.9 million and a $5.8 million decrease from changes in assets and liabilities. This was in addition to $5.3 million of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stock-based compensation, $2.8 million of depreciation expense, $0.9 million of right-of-use asset amortization and lease liability accretion and a $0.3 million gain on lease termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-line:none;">Net cash used in operating activities during the year ended December 31, 2021 was $27.3 million. The use of cash primarily related to our net loss of $41.9 million and a $5.5 million increase from changes in assets and liabilities. This was in addition to $6.0 million of stock-based compensation, $2.1 million of depreciation expense and $1.0 million of right-of-use asset amortization and lease liability accretion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-line:none;">Net cash used in investing activities was $4.9 million and $3.1 million for the purchase of property and equipment and construction in progress for the years ended December 31, 2022 and 2021, respectively. This included the purchase of $1.5 million and $1.6 million of property and equipment as well as $3.5 million and $1.6 million for the purchase of construction in progress for the years ended December 31, 2022 and 2021 respectively. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-line:none;">Purchases of property and equipment for the year ended December 31, 2022 were predominantly comprised of laboratory equipment along with $0.1 million of computers, software and equipment and $0.1 million of furniture and fixtures. $3.5 million of purchases in construction in progress related to a second modular cleanroom and the continued buildout of our manufacturing facility. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-line:none;">Purchases of property and equipment for the year ended December 31, 2021 were comprised of $1.0 million in laboratory equipment, $0.2 million of computers, software and equipment and $0.3 million of furniture and fixtures and $0.1 million of leasehold improvements. $1.6 million of purchases in construction in progress related to a second modular cleanroom and the continued buildout of our manufacturing facility.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $0.2 million and $52.6 million during the years ended December 31, 2022 and 2021, respectively. primarily due to the net proceeds received from sales from the ATM Agreement (as defined below) in 2022 and the underwritten public offering in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenues from the commercial sale of approved drug products, and we do not expect to generate substantial revenue for at least the next several years. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be compromised. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate significant revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of and seek marketing approval for our product candidates. In addition, if we obtain approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 16, 2021, the Company issued an aggregate of 3,228,286 shares of its common stock, for net proceeds of $52.6 million, pursuant to an underwritten public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the CPRIT to support the Company&#39;s Phase 2 clinical trial of MT-401. &#160;The CPRIT award is intended to support the adjuvant arm of the Company&#39;s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group. &#160;Through the date of this filing, the Company has received $4.8 million of funds from the CPRIT grant. The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 21, 2022, the Company entered into a binding Services Agreement, dated April 12, 2022 (see Note 9), with Wilson Wolf. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf, therefore Wilson Wolf is a related party. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society. Pursuant to the Services Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million. For the year ending December 31, 2022, the Company recognized $5.5 million of revenue pursuant to the Services Agreement and at December 31, 2022, the Company recorded $2.5 million of related party deferred revenue on its consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had working capital of $8.8 million, compared to working capital of $33.1 million as of December 31, 2021. Operating expenses incurred during the fiscal year ended December 31, 2022 were $39.0 million compared to $40.7 million in the prior year. &#160;Based on our revised clinical and research and development plans and our revised timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of December 31, 2022 will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2023. &#160;We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Furthermore, our operating plan may change, and we may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future funding requirements will depend on many factors, as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate or continue clinical trials of our product candidates;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the research and development of our product candidates and seek to discover additional product candidates; seek regulatory approvals for our product candidates if they successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue development of our manufacturing capabilities and our manufacturing facility;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluate strategic transactions we may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates and, if a product candidate is approved, our commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because all of our product candidates are in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability. Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We plan to continue to fund our operations and capital funding needs through equity and/or debt financing. We may also consider new collaborations or selectively partner our technology. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our existing stockholders&#8217; common stock. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. We may also be required to pay damages or have liabilities associated with litigation or other legal proceedings involving our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, based on our current assessment, we do not expect any material impact on our long-term liquidity due to the COVID-19 pandemic. However, we will continue to assess the effect of the pandemic on our operations. Further, the COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction due to these factors could materially affect our business and the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">ATM Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, we entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which we can offer and sell, from time to time at our sole discretion through the Sales Agents, shares of our common stock having an aggregate offering price of up to $75.0 million. Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021; however, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and we have provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2022, we sold 60,651 shares of our common stock under the ATM Agreement for net proceeds of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over a 24-month term, at a variable price with certain market-based terms as defined in the agreement. The purchase agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. &#160;During the year ended December 31, 2022, we did not sell any shares of our stock under the Purchase Agreement. &#160;In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have no sources of revenue to provide incoming cash flows to sustain our future operations. As outlined above, our ability to pursue our planned business activities is dependent upon our successful efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors raise substantial doubt regarding our ability to continue as a going concern within one year after the date that the financial statements are issued. Our consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</p><a id="_Hlk94098009"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Critical Accounting Policies and Estimates</span>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic and the COVID-19 control responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Property and equipment - Construction in Progress</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. &#160;The facility&#8217;s construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. &#160;All costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third and fourth quarters of 2021, and in connection with the Company&#8217;s manufacturing facility in Houston, Texas, the Company incurred $2.2 million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. &#160;Such costs were recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2021. Upon completion and installation of the modular cleanroom in 2022, all costs associated with the buildout, including $1.9 million of costs incurred during the first quarter of 2022, were recorded as manufacturing equipment and amortized over the estimated useful life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment Testing of Long-Lived Assets and Right-Of-Use Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management reviews long-lived assets (including property and equipment) and right-of-use assets for assets under operating leases for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Recoverability of assets is determined by first grouping the long-lived assets at the lowest level for which there are identifiable cash flows, and then comparing the carrying value of each asset group to its forecasted undiscounted cash flows. If the evaluation of the forecasted cash flows indicates that the carrying value of the assets is not recoverable, an impairment charge is recognized for the amount in excess of the carrying amount over its fair value. The Company performed a test for recoverability related to its manufacturing facility in Houston, Texas at December 31, 2022 and concluded that the carrying value of its long-lived assets was recoverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Expected Term</i>&#160;&#8212; The expected life of stock options was estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Expected Volatility</i>&#160;&#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#160;&#8212; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i style="font-style:italic;">Expected Dividend</i>&#160;&#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. &#160;The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. &#160;Forfeitures are accounted for as incurred. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Grant Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), we determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">In August 2021, we received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support our Phase 2 clinical trial of MT-401. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">The Company determined that the CPRIT Contract is not in the scope of ASC 808 or ASC 606. In accordance with ASC 730-20-25-8, the financial risk associated with the research and development has been transferred to CPRIT, because repayment of the grant depends solely on the results of research and development having future economic benefit. The Company accounts for this arrangement as a contract to perform research and development for others and applies ASC 606 by analogy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">The Company recognizes grant income when amounts eligible for reimbursement are determinable and have been incurred, the applicable conditions under the grant arrangements have been met, and collectability of amounts due is reasonably assured or already received. The classification of costs incurred related to grants is based on the nature of the activities performed by the Company. Grant Income is recognized when the related costs are incurred. &#160;Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. &#160;During the fourth quarter of 2021, the Company received $2.4 million advancement of funds in relation to the CPRIT grant. &#160; The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. &#160;At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. &#160;In January 2023, the Company received $2.4 million from CPRIT. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Tax Loss and Credit Carryforwards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we have approximately $135.2 million of federal and $38.5 million of state net operating loss carryforwards that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.6 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $93.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $16.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. &#160;Any change in ownership greater than 50% under Section 382 of the Internal Revenue Code places significant annual limitations on the use of such net operating loss carryforwards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2022 and 2021, we recorded a 100% valuation allowance against our deferred tax assets of approximately $41.4 million and $36.4 million, respectively, as our management believes it is uncertain that they will be fully realized. If we determine in the future that we will be able to realize all or a portion of our net operating loss carryforwards, an adjustment to valuation allowance against our deferred tax assets would increase net income in the period in which we make such a determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inflation affects the cost of raw materials, goods and services that we use. In recent years, inflation has been modest. However, fluctuations in energy costs and commodity prices can affect the cost of all raw materials and components. The competitive environment somewhat limits our ability to recover higher costs resulting from inflation by raising prices. Although we cannot precisely determine the effects of inflation on our business, it is management&#8217;s belief that the effects on future revenues and operating results will not be significant. We do not believe that inflation has had a material impact on our results of operations for the periods presented, except with respect to payroll-related costs and other costs arising from or related to government-imposed regulations.</p><a id="_c931cfc3_e0d7_4c73_a0cb_ffb259f0e7f3"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><a id="_05f9031c_0217_4e87_bd75_a57253381983"></a><a id="ITEM8FINANCIALSTATEMENTS_684464"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 8. FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Financial Statements are incorporated herein by reference to pages F-1 to F-25 at the end of this report and the supplementary data is not applicable.</p><a id="_ff95d768_ab9d_4c48_b786_7cf22be0fd67"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have had no changes in, or disagreements with our principal independent accountants.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8e7c012b_86ab_4075_9c18_99765087b8b7"></a><a id="ITEM9ACONTROLSANDPROCEDURES_136839"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9A. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2022 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Our management, with participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2022 to provide reasonable assurance that the information required to be disclosed by us in this Annual Report was (a) reported within the time periods specified by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer and Chief Accounting Officer, to allow timely decisions regarding any required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control Over Financial Reporting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the framework in Internal Control&#8212;Integrated Framework 2013 issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cybersecurity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We utilize information technology for internal and external communications with vendors, clinical sites, banks, investors and shareholders. Loss, disruption or compromise of these systems could significantly impact operations and results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are not aware of any material cybersecurity violation or occurrence. We believe our efforts toward prevention of such violation or occurrence, including system design and controls, processes and procedures, training and monitoring of system access, limit, but may not prevent unauthorized access to our systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than temporary disruption to operations that may be caused by a cybersecurity breach, we consider cash transactions to be the primary risk for potential loss. We and our financial institution take steps to minimize the risk by requiring multiple levels of authorization and other controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inherent Limitations on Effectiveness of Internal Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive Officer and Chief Accounting Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</p><a id="_8fd4cbba_8140_43ff_8863_f9b76386cd7f"></a><a id="ITEM9BOTHERINFORMATION_833436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 9B. OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="ITEM9CDISCLOSUREREGARDINGFOREIGNJURISDIC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM 9C. </b><b style="font-weight:bold;text-transform:uppercase;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ed1ffb9d_66fd_4df7_8c1a_20cf1037017c"></a><a id="PARTIII_534190"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART III</b></p><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item and not set forth below will be set forth in the sections headed &#8220;Election of Directors,&#8221; &#8220;Executive Officers&#8221; and &#8220;Delinquent Section 16(a) Reports&#8221; in our definitive proxy statement for our 2022 Annual Meeting of Stockholders, or our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2022 and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial and accounting officer or controller, or persons performing similar functions, known as the Code of Ethics and Business Conduct. The Code of Ethics and Business Conduct is available on our website at www.markertherapeutics.com under the Corporate Governance section of our Investors page. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K.</p><a id="_bd0f7222_3744_4c6c_a1b6_3cae11c4de18"></a><a id="ITEM11EXECUTIVECOMPENSATION_899018"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 11. EXECUTIVE COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Executive Compensation&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_d265bbd9_c7b0_4b49_92aa_0583a89037ef"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by Item 201(d) of Regulation S-K will be set forth in the section headed &#8220;Executive Compensation&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_42e9ddbb_1cf3_413c_abca_6a04faa1882b"></a><a id="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Transactions with Related Persons and Indemnification&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our Proxy Statement and is incorporated herein by reference.</p><a id="_1656e245_dac0_42fd_a8d3_7a3d58c4709b"></a><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information required by this item will be set forth in the section headed &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3ba3b86b_b16b_4af0_83cf_5174a676791a"></a><a id="PARTIV_855523"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PART IV</b></p><a id="ITEM15EXHIBITSFINANCIALSTATEMENTSCHEDULE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The documents filed as part of this report are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.25pt;text-align:justify;text-indent:-30.25pt;margin:0pt 0pt 12pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The financial statements and accompanying report of independent registered public accounting firm are set forth immediately following the signature page of this report on pages F-1 through F-25.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.25pt;text-align:justify;text-indent:-30.25pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All financial statement schedules are omitted because they are inapplicable, not required or the information is included elsewhere in the financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:30.25pt;text-align:justify;text-indent:-30.25pt;margin:0pt 0pt 12pt 0pt;">3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">EXHIBIT INDEX</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:21.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312522162322/d480537dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Incorporation of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/27/22</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465923007019/tm234466d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Incorporation of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/26/23</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex3-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.0</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054210/tv504949_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-A/A</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.24</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418028370/tv494002_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Marker Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/15/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.25</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920032463/tm205467d1_ex4-25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Common Stock of Marker Therapeutics, Inc.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.25</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/12/20</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000054/exhibit10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restructuring Agreement dated May 28, 2015</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/3/15</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000057/exhibit10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Restructuring Agreement, dated as of June 2, 2015</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/5/15</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418033374/tv496182_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Securities Purchase Agreement (including registration rights)</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/8/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418028370/tv494002_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/15/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement between Baylor College of Medicine and Marker Therapeutics, Inc. dated March 16, 2018***</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsored Research Contract between Baylor College of Medicine and Marker Therapeutics, Inc. dated November 16, 2018***</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488410000008/forddef14-c.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2009 Stock Incentive Plan*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DEF14-C</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">B</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/29/10</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417046574/v474594_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2014 Omnibus Stock Ownership Plan, as amended through August 29, 2017*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9/5/17</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054209/tv504951_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to 2014 Omnibus Stock Ownership Plan, as amended *</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/17/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054989/tv505356_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Award Agreement &#8211;Employee*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/23/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418056172/tv505663_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Award Agreement &#8211; Non-Employee Director*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-228056</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/30/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054989/tv505356_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Award Agreement &#8211; Consultant*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/23/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000168/exhibit10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Award Agreement &#8211; Consultant*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/16/15</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417049357/v475675_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between TapImmune Inc. and Peter Hoang dated as of September 22, 2017*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9/25/17</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516690727/d230909dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement by and between TapImmune Inc. and Michael J. Loiacono dated as of August 25, 2016*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/25/16</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418062867/tv508378_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Employment Agreement between Marker Therapeutics, Inc. and Michael J. Loiacono dated as of November 27, 2018*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/3/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418062867/tv508378_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Marker Therapeutics, Inc. and Anthony Kim dated as of November 27, 2018*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/3/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418054989/tv505356_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement between Dr. Juan Vera and Marker Therapeutics, Inc. dated October 19, 2018*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/23/18</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-39.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director and Officer Indemnification Agreement*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.39</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/tv514406_ex10-40.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Employment Agreement between Marker Therapeutics, Inc. and Peter Hoang, dated March 14, 2019*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.40</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/15/19</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420419025316/tv520511_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Marker Therapeutics, Inc. and Mythili Koneru, dated February 6, 2019.*</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/10/19</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920072918/tm2022347d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Marker Therapeutics, Inc. 2020 Equity Incentive Plan</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-239136</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/12/20</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920123055/mrkr-20200930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice and Stock Option Agreement under the Marker Therapeutics, Inc. 2020 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/9/20</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465920123055/mrkr-20200930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Marker Therapeutics, Inc. 2020 Equity Incentive Plan.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/9/20</p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488414000086/exhibit4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Purchase Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/14/14</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series A</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series C</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series D</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.29</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000006/exhibit4-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series E</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/12/15</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.30</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000030/exhibit4-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series A-1</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/10/15</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000142488415000030/exhibit4-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant Common Stock Purchase Warrants-Series E-1</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/10/15</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.32</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended Series A Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex43.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended Series C Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex44.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended Series D Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.35</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex45.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended Series E Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.36</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex46.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended Series A-1 Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.37</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex47.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended Series D-1 Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.38</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex49.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series F Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.39</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex410.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series F-1 Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.40</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of August 2016 Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.41</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex411.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of 2016 Private Placement Agent Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.11</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.42</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417033502/v469341_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of June 2017 Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/22/17</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.43</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417033502/v469341_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of 2017 Private Placement Agent Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/22/17</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.44</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424dex103.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant Amendment Agreement August 2016 Private Placement</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-27239</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/11/16</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.45</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420417033502/v469341_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant Exercise Agreement</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/22/17</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.46</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418033374/tv496182_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/8/18</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.47</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000114420418033374/tv496182_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Private Placement Warrant</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37393</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6/8/18</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;no.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">herewith</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:normal;width:5.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.48</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465922049970/tm2213489d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Services Agreement, between Wilson Wolf Manufacturing </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Corporation and Marker Therapeutics, Inc., effective April 12, </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2022</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4/26/22</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1049</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/tm2232522d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase Agreement, by and between Marker Therapeutics, Inc.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">and Lincoln Park Capital Fund, LLC,  dated December 12, 2022</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37939</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/13/22</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.50</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1094038/000110465922126446/tm2232522d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, by and between Marker </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Therapeutics, Inc. and Lincoln Park Capital Fund, LLC dated </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">December 12, 2022</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-37393</p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/13/22</p></td><td style="vertical-align:top;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Marcum LLP, an independent public accounting firm.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24.1</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_412578"><span style="font-style:normal;font-weight:normal;">Powers of Attorney (included on signature page)</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14a</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14a</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002#</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mrkr-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002#</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*&#160;&#160;&#160;&#160;&#160;Executive management contract or compensatory plan or arrangement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">**&#160;&#160;&#160;Confidential treatment has been granted as to certain portions of this exhibit pursuant to Rule 406 of the Securities Act of 1933, as amended, or Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">***&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for conditional treatment and this exhibit has been submitted separately with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">#&#160;&#160;&#160;&#160;&#160;These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><a id="_6608fbee_7159_41b0_8bfc_033b630fac9c"></a><a id="ITEM16FORM10KSUMMARY_680075"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM 16. FORM 10-K SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_ee595136_fbd4_43c7_b3c9_776eba06cfaf"></a><a id="SIGNATURES_412578"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 and 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dated: March 22, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marker Therapeutics, Inc.</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter Hoang</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter Hoang</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (Principal Executive Officer)&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael J. Loiacono</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael J. Loiacono</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Accounting Officer (Principal Financial and Accounting Officer)&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of the undersigned officers and directors of Marker Therapeutics, Inc., hereby constitutes and appoints Peter Hoang and Michael J. Loiacono, their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on March 22, 2023 on behalf of the registrant and in the capacities indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Peter Hoang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director (Principal Executive Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Peter Hoang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ N. David Eansor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">N. David Eansor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ David Laskow-Pooley</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Laskow-Pooley</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ John Wilson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">John Wilson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Juan Vera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Juan Vera</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Katharine Knobil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Katharine Knobil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steve Elms</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steve Elms</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Michael J. Loiacono</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Accounting Officer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael J. Loiacono</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3c5a33ae_aa63_42bd_befa_4cceba4b05b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS, INC.</p><a id="CONSOLIDATEDFINANCIALSTATEMENTS_582912"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DECEMBER 31, 2022 AND DECEMBER 31, 2021</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><b style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></a><b style="font-weight:bold;"> (PCAOB ID Number </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:AuditorFirmId" id="Narr_DfhcCkZ4i0qNShXrRcqsAA"><b style="font-weight:bold;">688</b></ix:nonNumeric><b style="font-weight:bold;">) </b></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_711572"><b style="font-style:normal;font-weight:bold;">Consolidated Balance Sheets</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_85122"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Operations</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity </b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_67365"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Cash Flows</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:91.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><b style="font-style:normal;font-weight:bold;">Notes to the Consolidated Financial Statements</b></a></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">F-8</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_85daedde_dbb2_4d11_ab4d_e26d42f7f34d"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To the Shareholders and Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Marker Therapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). &#160;In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Explanatory Paragraph &#8211; Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Critical Audit Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Asset Impairment - Determination of Impairment Indicators on Long Lived Assets and Right-of-Use Assets - Refer to Note 3 to the Consolidated Financial Statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical Audit Matter Description</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property, plant and equipment and right-of-use assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. As of December 31, 2022, the carrying value of the Company&#8217;s property plant and equipment was $12.3 million, and right-of-use assets $5.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have identified the determination of impairment indicators for property, plant and equipment and right-of-use assets as a critical audit matter due to the significant judgments management makes when determining whether events or changes in circumstances have occurred indicating that the carrying amounts of an asset group may not be recoverable. Auditing management&#8217;s judgments required a high degree of auditor judgment when performing audit procedures to evaluate whether management appropriately identified impairment indicators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">How the Critical Audit Matter Was Addressed in the Audit</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audit procedures related to the evaluation of indicators of impairment included the following, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the reasonableness of management&#8217;s impairment indicator analysis by performing the following procedures:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We inquired of management whether there are change of plans and circumstances affecting the use of property, plant and equipment or assets under lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We inspected minutes of the board of directors to understand if there were factors that would represent potential impairment indicators for property, plant and equipment and right-of-use assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the assumptions and the mathematical accuracy of the undiscounted cash flows used by management, for the asset recovery test.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 7pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:AuditorName" id="Narr_pMHsajIvDEOyDCD_trUwhw">Marcum LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 7pt 0pt;">Marcum LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 7pt 0pt;">We have served as the Company&#8217;s auditor since 2014<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="dei:AuditorLocation" id="Narr_CRzsbd-bJU-hSRSnlWxpCg">Houston, TX</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 22, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_1d4ca832_7130_4ee2_87f3_28214ef9480c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARKER THERAPEUTICS,&#160;INC.</b></p><a id="CONSOLIDATEDBALANCESHEETS_711572"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_85c3d5ca_44ab_45ce_957c_3ef7769313c5"></a><a id="Tc_IyzbKpDGW0idrpz7Ptkrdw_1_2"></a><a id="Tc_hMeMdqAlkk-nBqZCeAxwaA_1_5"></a><a id="Tc_MG8dGbvsukWueDOVqJdPEQ_2_2"></a><a id="Tc_o9SeKpCHW02XyTJGZVcurQ_2_5"></a><a id="Tc_VvGNpRvAgkaNMJhqMlR92A_3_0"></a><a id="Tc_OPWWvoNRD0-24QSJ9NNzYQ_4_0"></a><a id="Tc_Y3C__yFXG0-QA2_WEZs1ow_5_0"></a><a id="Tc_EIr0dQmXs0u7MK_wR-7KBQ_5_2"></a><a id="Tc_3oHiKfugUUqhY__zzYzgFA_5_5"></a><a id="Tc_HjRyj1BDz0iY-gydrEmISw_6_0"></a><a id="Tc_Iwfn_BouGUihnP86EKMvEg_7_0"></a><a id="Tc_coppvENF2kOprYbdYOPmWg_8_0"></a><a id="Tc_a15-q1vhlU-juOnmFDdu-w_9_0"></a><a id="Tc_5TVZNYMJtEqrxiYGkpsT9g_10_0"></a><a id="Tc_gH4RgWaROEK0FLZUMvDsAQ_11_0"></a><a id="Tc_gNqs3NAEn0C1gC_dk1t3dA_12_0"></a><a id="Tc_d0faW6cW6kaOWXBmukIW5A_13_0"></a><a id="Tc_GQPcFH14FkmsYx8t_BP5WA_14_0"></a><a id="Tc_BBMx7lLFfkSjTqF66qlzww_16_0"></a><a id="Tc_AqAtTX1JKUa3UJo84wAiEg_16_2"></a><a id="Tc_VWeg9W9LqkGml1uCuoICLg_16_5"></a><a id="Tc_8qm6KjDBxUG6PY77CKAkMQ_18_0"></a><a id="Tc_kCMqcQrm-Um4y-koOaYvkQ_19_0"></a><a id="Tc_7gwEhxjHk0S6JrgldkmFyQ_20_0"></a><a id="Tc_GHeqvk70H0eFeNp3kN51WQ_20_2"></a><a id="Tc_uUUFI8WnU0aWN3vw575jzQ_20_5"></a><a id="Tc_We_b_y0LcUGJSTUruBkr9w_21_0"></a><a id="Tc_QoXNlUApB0i-HYWga9LLaw_21_6"></a><a id="Tc_j_pMlUwZKUq-d83VKyFSYw_22_0"></a><a id="Tc_95PDVwDlKE6BOn9pUIEq3g_23_0"></a><a id="Tc_RmVIA8rcFEO4K9Bq4Pm-lw_24_0"></a><a id="Tc_jUDj7smE30av-e4Qmfv72w_25_0"></a><a id="Tc_n2K3-y49sEKKFzSZaRmCPA_26_0"></a><a id="Tc_TTxJw_27LEOp4WM5iA_Djg_27_0"></a><a id="Tc_sKoWaBTD1ky3o1k6Ls9TwQ_29_0"></a><a id="Tc_4c7svLNnskGmgYh0CER9lQ_31_0"></a><a id="Tc_HBCyqsws7U2eLt6JDpclRw_32_0"></a><a id="_d5312ad3_9199_4c37_ab4a_7dfa905e4c9a"></a><a id="_d5312ad3_9199_4c37_ab4a_7dfa905e4c9a_2"></a><a id="_d5312ad3_9199_4c37_ab4a_7dfa905e4c9a_3"></a><a id="Tc_0oT184Vr20SWUJtP8ScSAA_33_0"></a><a id="Tc_WUu7dVmmwU6sahHeBSbz-A_34_0"></a><a id="Tc_WLy8kjhY2kC2evnYuKgwEg_35_0"></a><a id="Tc_E3XPknTW_ky5UJmd5BVU9g_36_0"></a><a id="Tc_AAc7em1twkOrO9VcTFFW6w_38_0"></a><a id="Tc_mHxaDhxm00qGy9jKl02eNg_38_2"></a><a id="Tc_h5zHuIEgrUq30yZagUA3RQ_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_Muo4fAhIIECS2TIM6SWaZw_5_3">11,782,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_pz772NGRr0W3sesdBa6J7Q_5_6">42,351,145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="0" id="Tc_gDe5-rQhnEKuK9CAxFq3Tg_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="0" id="Tc_pzb0G7k4x0W8mpJzXypy0Q_6_6">1,146,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_ie2Ehx1yd0WicgJtuVGrxg_7_3">2,435,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_H6rWiu-c6UyoSwLuu1GRZA_7_6">2,484,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_n_X0lclcNUq8Q0c8_kU45g_8_3">2,402,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_ioPT2dau6Uyz9FSA8CiYWQ_8_6">237</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_VTKL9f8wB0yF--uQDDCAXg_9_3">16,619,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_f1sJQeYD10-iK1e5TRvQ3g_9_6">45,982,202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress" scale="0" id="Tc_khEipJzznEm550-LQFNKXA_11_3">12,323,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress" scale="0" id="Tc_qBGu9kBHLUeVKH2LtJk_3g_11_6">10,096,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:zerodash" name="us-gaap:ConstructionInProgressGross" scale="0" id="Tc_-_xXJeNnL0y6LNJXpytmNw_12_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="0" id="Tc_0py7sJ_s7kaqYjAXaMskHA_12_6">2,225,610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_ZAGJkQfXmUKoWdjuBCAxUg_13_3">5,479,786</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_C_slZ33gfUqQ9w_OAA2aGA_13_6">9,830,461</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_iguD7bVD-EyF8ao5brcOaQ_14_3">17,802,929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="0" id="Tc_ZXdt9JrWnE-DvMZ5ZH8PYQ_14_6">22,152,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_cegzebWwvkKFv8m9gL23Nw_16_3">34,422,184</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_HOAX_wx-vkCzGuTol2R24w_16_6">68,135,134</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#39; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_k36F5gZbqk6w4vniKXYdog_20_3">4,704,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_E5r-sqRHlECKpTU2Dve0HA_20_6">11,134,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Related party deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_FD94l1PVqkmGX-tgudq27A_21_3">2,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Tc_YJ4gtrorYESul_yqx1hikw_22_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Tc_7gKNJVuQLkOoCKr53sCaDA_22_6">1,146,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_ob4lQfISQke4tuWKVi_nLg_23_3">577,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_EQ1POS5o3kqJPEK7sfn3yA_23_6">620,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_qgoxj7sInEOBZio5v5Ioag_24_3">7,781,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_1MUu4aqCNUeNgCA207D1Gg_24_6">12,901,589</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_aI8TBdZy5E61QwSJz2kGNQ_26_3">7,039,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_tPIb5d6meECKXL8xpTeIGA_26_6">11,247,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Total non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_MmfhN6gIRkG0YTSQe8hlaQ_27_3">7,039,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" id="Tc_yooViQFtokW4BYRRoYS2nw_27_6">11,247,950</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_s4uj75vdxEeAtaiU-fKMFA_29_3">14,821,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_WTC2bssiAEmvZ9HdVT1XuA_29_6">24,149,539</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#39; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_HNXp5zOnHkKyMXjLaOY0Xw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_549m4dAvC0ymHTg0ECuJmA">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_7r1lT7CNf0utfuHKmrDUfg"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_lcWa4MmUXkaQN9aeZDEddA">5</ix:nonFraction></ix:nonFraction> million shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_7A8OUjaHfUmb9vDlCr0SrQ"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="6" id="Narr_d08DHlr_9Eukzt5xF_Rg7g">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bxX6QbSpekC8G-HwtQb90Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_eDcSIFJbBkiEl4pe1p3BoA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_1Xi6CF7P80m8QzEfsW3Ubg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_j3WMo856RU6xlQ-LzWdkeA">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_X95nlV6oXEaU29nsx24Mbg">30</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_sxUBqjww1Em6aMirCJuvzw">15</ix:nonFraction> million shares <span style="-sec-ix-hidden:Hidden_XJzDz4-ELkOS8norAoOL8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorized</span></span>, <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="Narr_F0PowPMPmEaYcK_lXnPp6w">8.4</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="Narr_ke0SM_S9RESOT0Rc07aXbw">8.3</ix:nonFraction> million shares <span style="-sec-ix-hidden:Hidden_J5UYgV3izECAEBRrpVGnhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding as of December&#160;31,&#160;2022 and 2021, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_n9HuMUEey0yGpu6tq1g1Iw_33_3">8,406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_FPyKCV9XnEG9fPC21nWWnw_33_6">8,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_LCLKlC3m00i7IIhdJqILlQ_34_3">447,641,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_YA25AEJPLEWjd6a10Obipw_34_6">442,095,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_M4MAZ5rX8EuqSjhQMvYoKQ_35_3">428,049,049</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_bePUK9vfFU2CyMSDI1Pelg_35_6">398,118,355</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_dhT5v_lNLUCjT56L8G_IMw_36_3">19,601,037</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_zCaOax7fYk2Zy67-mZzrzw_36_6">43,985,595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#39; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_Tc4-PYTGPke6uYfR2eRBlA_38_3">34,422,184</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_wQ1-PASEF0Sq3oEcXlzcig_38_6">68,135,134</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5628bf63_0a22_4e2b_a63e_af10aa8fd7d1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_85122"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_53f51e77_fa60_4752_a10e_bb1f0acdfeb6"></a><a id="_46f8db94_14a3_4e2e_b350_f7c72443ecca"></a><a id="Tc_2QES2LgmqEi-jMPMlqMzNA_1_2"></a><a id="Tc_FwHcwkBE-0WqzJD4-dBPWQ_2_2"></a><a id="Tc_sz-IcLCTZUu_XZi3sUrXAQ_3_2"></a><a id="Tc_mIvWlTgoUUuGbu_AISGYuA_3_5"></a><a id="Tc_kMfY3y45wUa8ZmEm0g4sJQ_4_0"></a><a id="Tc_tKMIAqsou0KjFUIcbRxdWA_5_0"></a><a id="Tc_a-0yysveBkCtFTkHfJrwVw_5_2"></a><a id="Tc_NOAa3zq74kaA5UpVgjUUWQ_5_5"></a><a id="Tc_jiXbMALA10-N2xzCcT0isA_6_0"></a><a id="Tc_Ik_XclcBb0m1f9obLuzKwA_6_6"></a><a id="Tc_D5PI63wxJEOgNW80xYeufA_7_0"></a><a id="Tc_4I6xRkRBqU221s3S8KoSlw_8_0"></a><a id="Tc_GkrVEC-VZUCulaVtttreZw_9_0"></a><a id="Tc_nd5syOMbg0iW1EtiIOmzAw_10_0"></a><a id="Tc_T1U3GT4_3kiMn3EJsjsCYg_11_0"></a><a id="Tc_pPQu5jVVN0yy7Wgx38OfgA_12_0"></a><a id="Tc_M3A8l5T2V0SKjoVKz7lpdQ_13_0"></a><a id="Tc_NmBOS-P5rk248gNK9Mi04Q_14_0"></a><a id="Tc_J0Xx3xtlqU6NkIwiE1uKFw_15_0"></a><a id="Tc_I7QHDT2KoU6Bgspe5eIwYQ_16_0"></a><a id="Tc_YSdVXJJGskCcnBg9-V5uaA_16_2"></a><a id="Tc_0J7SdaH4-0WEvCTeD6Lzag_16_5"></a><a id="Tc_4Cpk6Dxs7EeSZCGjvkKH9w_18_0"></a><a id="Tc_qHk3CT-7kU6XmwmDLHVZ1g_18_2"></a><a id="Tc_3B82rlvYuEivbMTUgyQsfA_18_5"></a><a id="Tc_uj-f6pHrCkOx04mYUjvp7A_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_lhALYDffbEuklraKG2XQmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_3EhUJbAz-0ynY8zSFpHHZA_5_3">3,513,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_Z55ugQPT_kKUAhzu1ioV8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_sJxrWZsgGEyQ1yo2QaC3nw_5_6">1,241,710</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Related party service revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ServiceMember_sVgjmKoubkywnwtNRRNxpg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_y0RUkuKg90asEqVdAx7djg_6_3">5,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_0MIl70u_tEexrTmVrtN7Tw_7_3">9,013,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_955Rctag_0mHCC9R-lI5hA_7_6">1,241,710</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_EuHTj7yIy0yVl5N-fA5idQ_9_3">26,139,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_KN7l8s-GiEe_zHg4kpKiNA_9_6">27,794,879</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_LSD9XTMC0UeFs6h2fxmqSA_10_3">12,820,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_f8PRN4bOQEq1TVW28idDqg_10_6">12,924,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_xMhvxMEDUEO8wo6ZQsuguA_11_3">38,959,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_pGJtHV0nkEqwHH5u1WrX5w_11_6">40,719,705</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_7sRgXkQgIEiY-DGQ6POmjQ_12_3">29,945,783</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_GxfmTmGJk0G4hskYlsdnzw_12_6">39,477,995</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other income (expenses):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Arbitration settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:GainLossRelatedToArbitrationSettlement" sign="-" scale="0" id="Tc_ONYkP2O8JEScZovhPJMH6g_14_3">232,974</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:GainLossRelatedToArbitrationSettlement" sign="-" scale="0" id="Tc_r4EHnIC530eWA2C-h3RR6g_14_6">2,406,576</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_79P2CyClYEOE9MRDdcemPQ_15_3">248,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_DNgnVajGdESELgmBVx1C9A_15_6">5,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_qhGaNOu3hUC5R2pa_IEsBw_16_3">29,930,694</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_VbHrqOjASU69u6VIhUQ2QQ_16_6">41,878,871</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc__i6RQ9lDokSRMSIeQ9T7Sw_18_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc__i6RQ9lDokSRMSIeQ9T7Sw_18_3_2">3.58</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_jpTbFpUnDk6Xqg0ytWcKFg_18_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_jpTbFpUnDk6Xqg0ytWcKFg_18_6_2">5.47</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_d7SlRN9xHUmMwzo1jqp3fw_19_3"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_d7SlRN9xHUmMwzo1jqp3fw_19_3_2">8,351,003</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_L6gUbFUN5U-TBEO_0rQ8oQ_19_6"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_L6gUbFUN5U-TBEO_0rQ8oQ_19_6_2">7,650,567</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6aaf9653_f1f3_4dc5_8f92_b6d65e92f804"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_133b3394_3b56_4c08_abef_35b282544f78"></a><a id="Tc_nGReJO5Tq0KPbcvqfePYBg_1_13"></a><a id="Tc_wrdRefa_MkmgJfpJfle8Sw_2_2"></a><a id="Tc_K1gInKvxVEWElsbdKfDFCg_2_7"></a><a id="Tc_SPxsXO7tH0CLHgcHxU1NDg_2_10"></a><a id="Tc_9Gk_cm2E4kqsEP72a6_urw_2_13"></a><a id="Tc_aYnYLXWxi0yQtm51kVTDfQ_3_2"></a><a id="Tc_G4gMjYmA1U6iYn10u3ypQg_3_4"></a><a id="Tc_aQBgNRb4LEaGo1D1BlyUeg_3_7"></a><a id="Tc_GaP0SrZ1f0a4AKEFNOYq-g_3_10"></a><a id="Tc_mFX7tHVHHEeAhRSBzC88fQ_3_13"></a><a id="Tc_r0blYR5VZk6R08IR255aFw_4_0"></a><a id="Tc_Li5i554KtkOQsRBs3YOAhw_4_4"></a><a id="Tc_KaFhXBn80UicCyP753n8fg_4_7"></a><a id="Tc_wjFIwXxSrEK10BKX94tYKg_4_10"></a><a id="Tc_Mzk_nNlyCUiY2v_XooOl6g_4_13"></a><a id="Tc_5eRxlWVUOU23i93ysTRJ1Q_5_0"></a><a id="Tc_hjw7cbWRGkCcgkTzMMiTCA_5_11"></a><a id="Tc_8YSTGeP7Bky411u9zR5P8A_6_0"></a><a id="Tc_-Aqv1P7nwUS0vXRYx6NKyA_6_5"></a><a id="Tc_L8VObUlzzEKlTUuZRzq3eA_6_11"></a><a id="Tc_tuYk7ei0mkmmGh9Merh_mg_7_0"></a><a id="Tc_ThYfdaxQhEmSLY7N5UL4Sg_7_11"></a><a id="Tc_vLKkmf2qKUuyq3O4Q03Rng_8_0"></a><a id="Tc_c8vbO_mmm0qEWfbXlZES_w_8_2"></a><a id="Tc_UeHvLck2OE6PyudNF_rXyA_8_5"></a><a id="Tc_Xbe46YlkC0uj0mI9ccx2cQ_8_8"></a><a id="Tc_9c6d7c6o6EiiIHBpkbgzCQ_9_0"></a><a id="Tc_GctBqPg7bEmBrsHMYtLDdA_10_0"></a><a id="Tc_RlRi6b0YNkSCz7EgEUvErg_10_11"></a><a id="Tc_kbmiORbUsE6apFhyf7_mLA_11_0"></a><a id="Tc_qn-oTkYKCEWj7U56gqlDQA_11_11"></a><a id="Tc_EeFm9rZJA0Ge19cjFKVVYA_12_0"></a><a id="Tc_Q7ZGwc24g0yn7qe85bVERg_12_2"></a><a id="Tc_1Aqlv_7EBUix2zLEfTOFLg_12_5"></a><a id="Tc_EQQ0DWwyq0q4rAxUaMwFvg_12_8"></a><a id="Tc_0dqCdoS8JEyvliWy2LkoGQ_13_0"></a><a id="Tc_AY_wQTip_0G2EVmfkKiXsQ_13_4"></a><a id="Tc_BrO1W67-l0e9rzyJX2XK5g_13_7"></a><a id="Tc_a38RHFQlfEOr9ukPeF-tyg_13_10"></a><a id="Tc_vYxTacj1ckW1tFEaCkhzJA_13_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional&#160;Paid-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#39;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Par&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in&#160;Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_UP9bcCKRckO6PJ8oR6R1uw_4_2">5,073,107</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_L5Oq6udTLEmFXZQ8t7936A_4_5">5,073</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GInYc9c9Y0moOPtffvDIDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_vFod39OTHk-N7c6pNmCIkA_4_8">383,578,984</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1uzjGStWO06DZSlcFGbVsQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_8A9we4_Vk02VHIO0lSN5lA_4_11">356,239,484</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gybZ2MTXbkS0l1bdg3VT7w_4_14">27,344,573</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common stock for cash (net of offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="Narr_1QaTEkpr70OvfxhPLVzyXw">3.9</ix:nonFraction> million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_KQnLALai-Ua4xxcOa5zQRA_5_2">3,228,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_SW4_pm7l7kmV_uzeW_p1KA_5_5">3,228</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_lDlY4YnEcUaLNoDRsejVcg_5_8">52,549,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_10HLp0gIZEa49Eqmbpi7iA_5_14">52,552,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock options exercised for cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_hXGUFF0r00Wa_OL48gW92Q_6_2">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_c-gbtV8bJEi2mov7QfnccQ_6_8">3,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_BFGCRw33UEqqNi48k3h-0w_6_14">3,087</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"> Stock-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_w2EE5AvVZUKTFMHl7rVDZg_7_2">6,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_nMaadIwQHketZUm9yvSBxQ_7_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_GMTTQvn_g0yPiH3nKnzeEQ_7_8">5,964,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_cghhNscaFECSk_qw0YodXw_7_14">5,964,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"> Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JKGI8Nx-2kSnc6KA5Cd6jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_6CP7eb5l3Ua3gtn2usjxPQ_8_11">41,878,871</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_2746Qgj98UC-kVFfmmgfYQ_8_14">41,878,871</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_npaXz9T0mUaUNEGeD_jgZQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_TvhH98vDyE-Ljf0142tntw_9_2">8,307,868</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_npaXz9T0mUaUNEGeD_jgZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Tb5Pa5A73UCF2fSTaZjehA_9_5">8,308</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FBFeOkr3ykuSOy5dBngOrw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_KLcylN5MSEC3euojKJtekw_9_8">442,095,642</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egIQ7QghbkGRIjamiNWiUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_K0TdCeJkaECHMKeJ_z1Xkw_9_11">398,118,355</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_MGIbDphM1EOu0SxCRzqyrA_9_14">43,985,595</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of common shares for cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_EO9qZ0nJIEWmZp7xoYVFkQ_10_2">60,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_NpLMVJ3fo0-7VEUoHDoVAg_10_5">61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F6wReus0oEaCdo351uy7TQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_lnlfQBUNf0-tQVL-oMK6jA_10_8">202,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_mfxrzIJQ_0acxNe6KQgLVQ_10_14">202,130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_bmKrV_jpz0iqyX9pufhMQg_11_2">37,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_hXhGojwxNEiJ8CTPgzqIsA_11_5">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F6wReus0oEaCdo351uy7TQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_4qIgBAwn90eLriwS_AisMQ_11_8">5,343,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_-W9ob6WgGk2EUtbFAVnOVw_11_14">5,344,006</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"> Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6tRxU7Rie0-8urQAVoZMJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_zBKNwq7sMkCCauOnKuCAqA_12_11">29,930,694</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_RHX4marRw0-qkGTw3q8NIg_12_14">29,930,694</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8cq4aMH20Sb7VO8y3pJew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_sVOT8J58bk6UMis3FwAD2w_13_2">8,405,771</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8cq4aMH20Sb7VO8y3pJew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_R7iDenIBJEGk7dnJKkip6Q_13_5">8,406</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GdnjYANna0qQFgzGMImcPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_cc2_NaqzZUabGkqYsbmHOg_13_8">447,641,680</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmkYNaQrdkaCT93Kx5jgTQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_F7ZdSgzgV06LQ8oSWhFRCQ_13_11">428,049,049</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_UNt27J9cRUGfgEpUkC_Mzw_13_14">19,601,037</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_12c5014e_4a11_45ca_8487_8d6c0532c77e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_67365"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0a2f81dd_7746_4e72_8b1e_c682bb5dcfcd"></a><a id="Tc_3v3agtOSeUq2sh2QS_c74w_1_2"></a><a id="Tc_uosi9NxxE0SjfBE0Yezmcw_2_2"></a><a id="Tc_HRwxW8-3FUq3m9PSEs68vw_3_2"></a><a id="Tc_ZJO7ptpOMEym_qKk-3Kq9g_3_5"></a><a id="Tc_zSvvT9Kc1UyMVR0eHjQCXA_4_0"></a><a id="Tc_kQRKB__ew0igy5tqIVJrEA_5_0"></a><a id="Tc_b3_YpZAcF0uTrrlul4K6Ag_5_2"></a><a id="Tc_oCxdP-8ick6rlDe_nuSvQw_5_5"></a><a id="Tc_HhQxhMg4lkOPIWU6-MNFbg_6_0"></a><a id="Tc_LEO4JGmGOkCi03AsI_T3YQ_7_0"></a><a id="Tc_G9uSr0jR0EarsFPVjxrgAw_8_0"></a><a id="Tc_h_D_laELkUKcCokcrA-70Q_9_0"></a><a id="Tc_rkR5uFDvCE2UJ1YqIkyy8g_10_0"></a><a id="Tc_rzdi4XCsVU-MULWgCJBvtA_10_6"></a><a id="Tc_CQlqUq2ufU6P9StCyBwpog_11_0"></a><a id="Tc_aG-UBURpI0uf2GPfCDi9aw_11_6"></a><a id="Tc_tI_pVJ8a-kCPcaVK0VD0Ng_12_0"></a><a id="Tc_iyDF7YNAt0u9B5Sjb7h8fw_13_0"></a><a id="Tc_ggqHcvt6FUmJFSMAX4SB_Q_14_0"></a><a id="Tc_raCa-0Q5kUq9YEUT9-EIUA_15_0"></a><a id="Tc_3H0lhCY5bkqcDJOUX8U1dw_16_0"></a><a id="Tc_d5mPmNS3X0yidIjdyyaNWg_16_6"></a><a id="Tc_hjD3ey0Bik6_UzCqAPFOwg_17_0"></a><a id="Tc_r42CA_zi-0i72430-8MP_Q_18_0"></a><a id="Tc_OE0cHTjWR062Az9JLTzu2w_19_0"></a><a id="Tc_UguJTAtaK0q1YRl5NLVxxA_20_0"></a><a id="Tc_zMsXQv6otkeLuvZLcDOK9Q_21_0"></a><a id="Tc_3wvZD67DGEqGwYW8EkHr6g_22_0"></a><a id="Tc_HBTD8Va-iU6bDMBEfdvmig_23_0"></a><a id="Tc_RhAIgfBgq0-elye0im4azA_24_0"></a><a id="Tc_SUn83SX5pUmoPeXOIL3Dhg_25_0"></a><a id="Tc_Z4lFkHxuA0ymqLADqT62gw_26_0"></a><a id="Tc_bTCDZzduNkil4zhuBnUkng_26_3"></a><a id="Tc__NB71a9N6UWw9GUxPIbV5Q_27_0"></a><a id="Tc_yVv1q-s-Y0GrWYSLEs60lw_28_0"></a><a id="Tc_qUztDpnuW0i71vt7j-tfLw_30_0"></a><a id="Tc_yfwSb1yUW0OqIgxaBa-_GQ_31_0"></a><a id="Tc_2P2f97qaV0Sf2zmiNCS6EQ_31_2"></a><a id="Tc_nIngOxOUI0yhD3j_AWRr-g_31_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_rgJh_kKMxEaDAsiAPqhgHg_5_3">29,930,694</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_AdSdIAPjQE2oluwve11kmw_5_6">41,878,871</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Reconciliation of net loss to net cash used in operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_KMdR4S4nnUy8nfMSja1BBw_7_3">2,789,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_vvR73w37FUuzzUSoZe0LlA_7_6">2,148,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_uPvFfNSna0Wc6F4z98Phgw_8_3">5,344,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_PY6EBVHTK0OSNG75ApL6pA_8_6">5,964,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Amortization on right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_kytWNTduPEmYZ2Cja0fxhA_9_3">891,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_MZtJiHIQgE6SYxMMC7Vz-Q_9_6">1,013,655</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Loss on disposal of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" sign="-" scale="0" id="Tc_iXuURBcui0qNjKMC1nSRGw_10_3">25,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Gain on lease termination</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:GainLossOnTerminationOfLeases" scale="0" id="Tc_v6sUMIiF4ESOI4oCNfiWmA_11_3">278,681</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Changes in operating assets and liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_QLLmSsGTgEeUgKBzVD4YSw_13_3">49,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_XR0JqMO8_UO2Wz-IUJ1wQg_13_6">426,710</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" id="Tc_v-dA5RowUE-qFbtoEScCfg_14_3">2,401,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" sign="-" scale="0" id="Tc_7aoanspHsUeUgHwqIP7uwQ_14_6">1,000,322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_f5I-d_mHgUagS7JhzjF3oA_15_3">4,300,939</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_vkp4HsL10EuLHDozRaGLtg_15_6">4,141,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Related party deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="0" id="Tc_K-vNBW-Rj0Of27JlEESvkg_16_3">2,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="0" id="Tc_Tf3FFk-sv0WB5S7FWPf_qg_17_3">1,146,186</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="0" id="Tc_vDLYgE3BDEKQ2VyI3tG9Ow_17_6">1,146,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc_JlmvyHRkH0ixD8Ic5CY87A_18_3">513,891</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc_h2uoUVlUqUSqMW-gcodehg_18_6">388,792</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_Q_gGHWjrnUeVik_tJtxbIw_19_3">26,972,153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_lmDl9xaN10WyWLCHHhlMkg_19_6">27,279,765</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" scale="0" id="Tc_spaTzjB4U02Lcyo0rTbGWQ_21_3">1,456,006</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" scale="0" id="Tc_0EV5cskT9UC1gTXAK9dZGA_21_6">1,572,161</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Purchase of construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:PaymentsForConstructionInProgress" scale="0" id="Tc_x45qB9MEz0qHgIsnh_W0HQ_22_3">3,489,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:PaymentsForConstructionInProgress" scale="0" id="Tc_pNDUq_7LVUOqNINS-Add0w_22_6">1,558,970</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_J2sxfX1OBkSWnIB03nwcqQ_23_3">4,945,136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_DReSYn4SrEW5mo7jzpToHg_23_6">3,131,131</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Proceeds from issuance of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_QZlGm6vhQUKcGqzUfK-6kg_25_3">202,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_6sUnj_o_aUGU1z2ch21ZkQ_25_6">52,552,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_QXluQXJ0Pkm9iRkbZM_0TQ_26_6">3,087</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_rsf6DLTzlUSVP3cth0HGDw_27_3">202,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_DCYjHRJMcke9kIBC-VzDNw_27_6">52,555,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_L7ttRYROlkq1zTb-dO589w_28_3">31,715,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_jKhj1J3peEWPZPtrWO5pSQ_28_6">22,144,949</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash, cash equivalents and restricted cash at beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_0LCsgk4TdkGmE3lnEBGKHQ_30_3">43,497,331</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_2NXcbYdiSUmPqYz517jXwA_30_6">21,352,382</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash, cash equivalents and restricted cash at end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_v4940jblpEu6m4eVZxOUVg_31_3">11,782,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_C-DWSigp_UKDyw2DC9eH_w_31_6">43,497,331</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8c1e4292_077e_47a5_8031_913151b48145"></a><a id="Tc_GAyIJXnrq0aLcc8PfKX4qw_1_2"></a><a id="Tc_4ITV2rMQGk-paNiPGF2qMw_2_2"></a><a id="Tc_hKj-kRg9R0eOyiOqqD89iA_3_2"></a><a id="Tc_USJmtZqpvkmRJ5VLZAVq3A_3_5"></a><a id="Tc_4o4_yM2pIUaaONxwfvyXdw_4_0"></a><a id="Tc_b0hTZq-6rEW4xuyrZKZvpg_5_0"></a><a id="Tc__V9gMyk0EU2lihxvAbThlw_5_2"></a><a id="Tc__jm9BtUef0aMszPYAmw7Sg_5_5"></a><a id="Tc_qaIvRcMunkiv_tnXKMwTkQ_6_0"></a><a id="Tc_F_ALRyL3mEeIt9ejUpl2nA_6_2"></a><a id="Tc_rjrvPkuRPkezA1mrMZ3L7w_6_5"></a><a id="Tc__U-hz4mleEKXuRXV1CN8MQ_7_0"></a><a id="Tc_sz_TUpb2bUOik1tfY5hIog_7_2"></a><a id="Tc_ifeGLjh2LkmGZtgmE01oXQ_7_5"></a><a id="Tc_UX5CoT-CJke85Wa64V0llw_7_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Years Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental schedule of non-cash financing and investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Reclassifications between construction in progress and fixed assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:ReclassificationsBetweenConstructionInProgressAndFixedAssets" scale="0" id="Tc_Thg7qtVf80-0sGbnS6womg_5_3">4,089,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:ReclassificationsBetweenConstructionInProgressAndFixedAssets" scale="0" id="Tc_nh7JJOX2VE2HUyMxo2ySGg_5_6">6,789,098</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capital expenditures included in accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" id="Tc_iPlBVByt90mMOV9sXfLIhg_6_3">57,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" id="Tc_sNbDQwz8aUenTPhCba9gSQ_6_6">2,160,765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes to right-of-use assets and lease liability due to close out of operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease" scale="0" id="Tc_DlyPFQE1R0WXvu2W_y9fIQ_7_3">3,459,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_27e578be_293f_4b22_8391_27170f18801b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MARKER THERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FOR THE FISCAL YEARS DECEMBER&#160;31, 2022 AND 2021</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:NatureOfOperations" id="Tb_4T5M1tzjCEayxr7VJLXF0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s multiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 26, 2023, the Company effected a one-for-ten (<ix:nonNumeric contextRef="Duration_1_26_2023_To_1_26_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oBMB2ozYCUm78jnnAf9ERw" name="us-gaap:StockholdersEquityReverseStockSplit" id="Narr_AoljI3aQwkitl6lLNyq-GQ">1-for-10</ix:nonNumeric>) reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;) and a corresponding reduction in the total number of authorized shares of its common stock from <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_XPzhwj-erUqIBzQu-ulhQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_zjftec4MZk6fVKN3ECRMng">300,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6ka_iEmMjE2aQAOD6iwO8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_r2roha5t-02BcAE5rNC0Gg">30,000,000</ix:nonFraction>. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_26_2023_To_1_26_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oBMB2ozYCUm78jnnAf9ERw" decimals="INF" format="ixt:numdotdecimal" name="mrkr:StockIssuedDuringPeriodValueReverseStockSplits" scale="0" id="Narr_sxz13EUnh0mj6hS3h6exQA">394.80</ix:nonFraction>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock" id="Tb_If7zR55fVkqay0LafHbZww" continuedAt="Tb_If7zR55fVkqay0LafHbZww_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2022, the Company had cash and cash equivalents of approximately </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="Narr_za1K5f3hWUSAzJCpWmc2rA">11.8</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 16, 2021, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_adx4CFnqxU6SYkOKLmDceQ">3,228,286</ix:nonFraction> shares of its common stock, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Pr0mByl5DkuhLF8EijC7jw">52.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC (the &#8220;Sales Agents&#8221;), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_w84Uaz3YUEqYjRHmFPZttg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesSubscriptions" scale="6" id="Narr_zjmh9NvLgEy-sdWoNTLJew">75.0</ix:nonFraction> million. Any shares of its common stock sold will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021; however, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_rJJmBdCj7EOIPmbz9BOYyA" decimals="3" format="ixt:numdotdecimal" name="mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" scale="-2" id="Narr_k0xvi144xUCWUTP9RxnGUA">3.0</ix:nonFraction>% of the gross sales price per share sold under the ATM Agreement, and the Company has provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2022, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_lYIjNL0t2E6NNbd5622y6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_OMgfhKOxckWXpFwb886a5Q">60,651</ix:nonFraction> shares of its common stock under the ATM Agreement for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_lYIjNL0t2E6NNbd5622y6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="6" id="Narr_cZwc-amSXkmF-e0Rd8WY8w">0.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="Narr_iewYsd6wm0K0YLTqDI6Kiw">13.1</ix:nonFraction> million from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) to support the Company&#8217;s Phase 2 clinical trial of MT-401. The CPRIT award is intended to support the adjuvant arm of the Company&#8217;s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group. Through </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_If7zR55fVkqay0LafHbZww_cont1" continuedAt="Tb_If7zR55fVkqay0LafHbZww_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the date of this filing, the Company has received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromCpritGrant" scale="6" id="Narr_96wVo77OWESvGNrfvqMcbA">4.8</ix:nonFraction> million of funds from the CPRIT grant. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromGrantRelatedToCprit" scale="6" id="Narr_mvgJ5tx5vkSEXbUgBkEPkw">3.4</ix:nonFraction> million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 21, 2022, the Company entered into a binding services agreement (the &#8220;Services Agreement&#8221;), dated April 12, 2022 (see Note 9), with Wilson Wolf Manufacturing Corporation (&#8220;Wilson Wolf&#8221;). Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf, therefore Wilson Wolf is a related party. Pursuant to the Services Agreement, Wilson Wolf made a cash payment to the Company in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_4_21_2021_To_4_21_2021_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_ZclhqIbMvU-O8EfMWIhhgw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_JBQ93hcCd0OBNk9JIDfEOg">8.0</ix:nonFraction> million. For the year ending December 31, 2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_73WDhaJFhk26kf_aw8N7qA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_qVkxuA7bRUuCIbd6E6g6Dg">5.5</ix:nonFraction> million of revenue pursuant to this agreement and at December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_elmgfz9S-0W_ZDXK3WDiaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="6" id="Narr_jvK2hKLrE02S2gdgz9-tRg">2.5</ix:nonFraction> million of related party deferred revenue on its consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had awarded the Company a $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_9_13_2022_To_9_13_2022_w0iIOXYe5U2sofHNZfyE-w" decimals="-5" format="ixt:numdotdecimal" name="mrkr:GrantReceived" scale="6" id="Narr_iXwzi2c1CUqMvektrDAohA">2.0</ix:nonFraction> million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromOrphanProductsGrantProgram" scale="6" id="Narr_ysRKcykIA0mS9Gy7cqQLxA">0.1</ix:nonFraction> million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OrphanProductsGrantProgram" scale="6" id="Narr_e3Wm0xdNgkmKtMhyCB01cQ">0.1</ix:nonFraction> million of grant income receivable. On March 13, 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_Wh3beEigoUy-Yo58AVbUmA">0.1</ix:nonFraction> million of funds from the FDA grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_12_12_2022_To_12_12_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kp85NnJBBUmUhXIRR_MpQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="Narr_yRdoLLSyJUmg_ROIoE9hGQ">25,000,000</ix:nonFraction> of shares of its common stock, or the Purchase Shares, from time to time over a 24-month term. &#160;For the year ended December 31, 2022, the Company did not sell any shares of its common stock under the Purchase Agreement. In January 2023, Lincoln Park was issued <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HZfAycR2kk-ZXkhm82bVPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="Narr_K0HORXOPlkO5wXCERj2rgA">180,410</ix:nonFraction> shares of stock as a commitment fee at a value of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_sdKnf_W3b06nZ9jMBEsNJA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:CommitmentFee" scale="6" id="Narr_nWSkzyLONka1z1s353JMNA">0.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical trials. Further, the Company&#8217;s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from sales of its product candidates, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Based on the Company&#8217;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of December 31, 2022 will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2023, as such these factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. In an effort to further preserve the Company&#8217;s working capital, the Company&#8217;s employees took a portion of their 2022 earned bonus in the form of equity in lieu of cash.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiates or continues clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_If7zR55fVkqay0LafHbZww_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, based on the Company&#8217;s current assessment, the Company does not expect any material impact on its long-term liquidity due to the COVID-19 pandemic. However, the Company will continue to assess the effect of the pandemic on its operations, including its clinical programs. Further, the COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#8217;s business and the value of its common stock.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_KBJ7F-iRBUO-1NOxC8RyMw" continuedAt="Tb_KBJ7F-iRBUO-1NOxC8RyMw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_-tM5d5mogUW4ewbebF6AoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;). Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_T3J4S7plQEaeqJjm6jKPBA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:UseOfEstimates" id="Tb_qIMXAJwRK0CoRC1HuU3p6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#8217;s estimates and assumptions include measurement of fair value and projections used in impairment testing, valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_BwcK-1tmK0e5N7e-Gz7wrA" continuedAt="Tb_BwcK-1tmK0e5N7e-Gz7wrA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents, Restricted Cash and Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash, cash equivalents and restricted cash at December&#160;31, 2022 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_OIoveDCmG0CEbCCCoiTU6g">250,000</ix:nonFraction>. As of December&#160;31, 2022, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="Narr_aCMS5WCJZEO9u9uCrQJxzA">1.8</ix:nonFraction> million in cash was uninsured based upon the FDIC insurance coverage limits.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_V5f3mzu9I02_XdYoIEBUxw_1_2"></a><a id="Tc_N80tBIy31UyOdQkqVz7wAg_1_5"></a><a id="Tc_6fb9PKcSsUmliptGCjwi1w_2_2"></a><a id="Tc_58G86PEeOkGCqHVSyYkEQg_2_5"></a><a id="Tc_ZGQzLuAh7k6uPb-Ud5mZpQ_4_0"></a><a id="Tc_TDZ99OF5UkyhqB-3-e8cvQ_4_2"></a><a id="Tc_X1rDvz4enUq8d2oZTamm9Q_4_5"></a><a id="Tc_vYF45H8qLkmPVCDoYAxdZg_5_0"></a><a id="Tc_o9NoCcrMTEq9nvFtNrNj-g_5_2"></a><a id="Tc_zVDy77Yw_0mpwoqxdtkLzA_5_3"></a><a id="Tc_oIUjMLPXmEOWY7kxVNtyzw_5_5"></a><a id="Tc_5gyjSilz-U6qidp_m1mUJA_6_0"></a><a id="Tc__N_CD09eGEea46wk7O8obg_6_2"></a><a id="Tc_9Rxi5Lz8z0yIdD6ouqMwkw_6_5"></a><ix:continuation id="Tb_KBJ7F-iRBUO-1NOxC8RyMw_cont1" continuedAt="Tb_KBJ7F-iRBUO-1NOxC8RyMw_cont2"><ix:continuation id="Tb_BwcK-1tmK0e5N7e-Gz7wrA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" id="Tb_2f-JwdkCQkKFHb4FHCUSAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_3f5XT_IrVUuBGA5OhQOB_A_4_3">11,782,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_vKGhIk4ZBEaZsWba6lFe-A_4_6">42,351,145</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="0" id="Tc_BLzETWsGMky_8bBXN1kpyA_5_6">1,146,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash shown in statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_My68kHpY9UmZhiNWfjapbA_6_3">11,782,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_-LM_LL39vUyRT7gF3ORcJw_6_6">43,497,331</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash received from grants in advance of incurring qualifying costs are recorded as restricted cash until they are earned and recorded to grant income.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:RetainexistingpolicyPolicyTextBlock" id="Tb_61rQuslGjUWTcQ5ZgvUzGQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock" id="Tb_fSTHtuXVjEuRwGCvNqzNag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment - Construction in Progress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility&#8217;s construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third and fourth quarters of 2021, and in connection with the Company&#8217;s manufacturing facility in Houston, Texas, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_McFGqwTRbE2KSZ_az8T4DQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="Narr_Omzcuefpvkmi3iDpwJLpDQ">2.2</ix:nonFraction> million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. &#160;Such costs were recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2021. The Company incurred another $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_de53l1GX8kGkNWjZK3KpnA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="Narr_EcxpT3nhHEqtGe_y4wLx-w">1.9</ix:nonFraction> million in related costs in 2022. Upon completion and installation of the second modular cleanroom in 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and are being amortized over the estimated useful life.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_RhacUHDsyE-Wo0TCoadpFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment Testing of Long-Lived Assets and Right-Of-Use Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management reviews long-lived assets (including property and equipment) and right-of-use assets for assets under operating leases for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Recoverability of assets is determined by first grouping the long-lived assets at the lowest level for which there are identifiable cash flows, and then comparing the carrying value of each asset group to its forecasted undiscounted cash flows. If the evaluation of the forecasted cash flows indicates that the carrying value of the assets is not recoverable, an impairment charge is recognized for the amount in excess of the carrying amount over its fair value. The Company performed a test for recoverability related to its manufacturing facility in Houston, Texas at December 31, 2022 and concluded that the carrying value of its long-lived assets was recoverable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_m1mIR_JMBEuLQhmDncQZfg" continuedAt="Tb_m1mIR_JMBEuLQhmDncQZfg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents and Patent Application Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KBJ7F-iRBUO-1NOxC8RyMw_cont2" continuedAt="Tb_KBJ7F-iRBUO-1NOxC8RyMw_cont3"><ix:continuation id="Tb_m1mIR_JMBEuLQhmDncQZfg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" id="Tb_nReB4zIj9EKn5cp0kSY6kw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i>&#160;&#8212; The expected life of stock options was estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i>&#160;&#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#160;&#8212; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i>&#160;&#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_tXBvZMwyukGa7lv9fmhdRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_zIzUPXyvRUyX02lwhiutmA" continuedAt="Tb_zIzUPXyvRUyX02lwhiutmA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KBJ7F-iRBUO-1NOxC8RyMw_cont3"><ix:continuation id="Tb_zIzUPXyvRUyX02lwhiutmA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2022 and 2021, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2022 and 2021.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:GrantIncomePolicyPolicyTextBlock" id="Tb_yJvLk0wTCU2HALpN7fFCig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:ReceiptOfProductDevelopmentResearchAward" scale="6" id="Narr_BhcjPKfbJEy8faYGaV6MSw">13.1</ix:nonFraction> million from CPRIT to support its Phase 2 clinical trial of MT-401. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 730-20-25-8, to the extent the financial risk associated with the research and development has been transferred to CPRIT, because repayment of the grant depends solely on the results of research and development having future economic benefit, the Company accounts for this obligation as a contract to perform research and development for others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. During the fourth quarter of 2021, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_10_1_2021_To_12_31_2021_JT2ojtlpfUiPgirbtHOffA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromCpritGrant" scale="6" id="Narr_qUCOCHwjHkOdffnOcucoqQ">2.4</ix:nonFraction> million advancement of funds in relation to the CPRIT grant. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromGrantRelatedToCprit" scale="6" id="Narr_sNtoYsh6TE2LDI7r1dbgKw">3.4</ix:nonFraction> million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. At December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:GrantIncomeReceivable" scale="6" id="Narr_mIAFSVmGWECPm0EZad_GQw">2.3</ix:nonFraction> million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. In January 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_1_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_us-gaap_SubsequentEventMember_Yue1bky0HUK0DiPiPA1ZmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_n2OEN6pBxkS1R5aNYYqPJw">2.4</ix:nonFraction> million from CPRIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_9_13_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_UoBREzfn7kO2CeAdFJzHPQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:AmountOfAwardGrantFromOrphanProductGrantProgram" scale="6" id="Narr_3HqC_MGcQE2XidEU4K5DVA">2.0</ix:nonFraction> million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromOrphanProductsGrantProgram" scale="6" id="Narr_YLDDX2yeLUe07sOnnOZXqA">0.1</ix:nonFraction> million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OrphanProductsGrantProgram" scale="6" id="Narr_cPYTm5HWXUy8AOV6ep5vCg">0.1</ix:nonFraction> million of grant income receivable. On March 13, 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_6jVBjGjUrUudS6bZlk_C7w">0.1</ix:nonFraction> million of funds from the FDA grant.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_hLDoAUpVtUmRPaP8J1FjEw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_-WPQSkzrC0qmR8aOmtsYFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aae58ab4_2eb7_4103_ae48_0e324c647bbe"></a><a id="_e42134e0_4d91_4ecd_af85_d93b96c7c4bd"></a><a id="Tc_mRBWbI7eS0KrdNtFxmrUIw_1_2"></a><a id="Tc_lWG6akUdCE6rmLhc4QGL1A_2_2"></a><a id="Tc_HRFeKXMI0ky9aaNwO99FYA_3_2"></a><a id="Tc_DBGuBTg6uUWrQCWYIby3DA_3_5"></a><a id="Tc_To5xWlz6NU-j5VGxXHVkpg_4_0"></a><a id="Tc_y63PjypAaEOEg52aeFh06w_5_0"></a><a id="Tc_Rf_j2bo-gkaSzBFeTUDizg_5_2"></a><a id="Tc_ZN_aV-GjUUm7BXzeA0QzLg_5_5"></a><a id="Tc_NKLnoGWaM0qPE7NNimZz9A_7_0"></a><a id="Tc_rYsJkVCf3EmjioLqHRqvYw_8_0"></a><a id="Tc_5rag1IDFVEu4azigjHnjxg_10_0"></a><a id="Tc_G8ereKaPh028r-y4Veh29A_11_0"></a><a id="Tc_-t144NApVk-WZ5FhZfHWqg_11_2"></a><a id="Tc_7rze6zS44EO_eQGQ0qhyLQ_11_5"></a><a id="Tc_5MCKIyyB3kGi1B0YBLQu0w_1_2"></a><a id="Tc_6CzDZ6Mpmkane7pEO9460g_2_2"></a><a id="Tc_pFzpdY-nnEWmwP4I_qxJgw_3_2"></a><a id="Tc_U9-mi1tWG0Ct3Zbu3faXaQ_3_4"></a><a id="Tc_zPaZfjkj0keRQOAz9tNmCA_4_0"></a><a id="Tc_-pZAYNdeVEi1vFrf-cOF0A_5_0"></a><a id="Tc_oEAO_9g800WlczM-btp4Ig_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_NlI_rrXrCkWSdi8cy_jNIA" name="us-gaap:MinorityInterestDisclosureTextBlock" id="Tb_MSY84QZV5EqtfcfdD6Z9rw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of net loss per share for the&#160;years ended December&#160;31, 2022 and 2021, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_Gd2_3o4EA06XXDBsTHii4A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_bfAkQcf5jk2uRggyVohDdQ_5_3">29,930,694</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_oKmvOXj3g0-JaJWhfFPjEQ_5_6">41,878,871</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average common shares outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_d7Ks34oFsEiIE4QJcxgLfg_8_3"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_d7Ks34oFsEiIE4QJcxgLfg_8_3_2">8,351,003</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_f-yG7u6IW0yho1AVJSPgfw_8_6"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_f-yG7u6IW0yho1AVJSPgfw_8_6_2">7,650,567</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ODP8WAUjKk-wDiNMAoKvNg_11_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ODP8WAUjKk-wDiNMAoKvNg_11_3_2">3.58</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_sn2jKTNEQU-hBrQOHGH9nA_11_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_sn2jKTNEQU-hBrQOHGH9nA_11_6_2">5.47</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:NetLossPerShareTableTextBlock" id="Tb_jPgVjEk62E-PVocTBTC02g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bQJrMgrRIEih2ZZ5LZh_Nw" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_G_5lS-7g7UamAq0mM0SR1w_4_2">886,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RBkehlwI7UK7Hw7PXAvVhw" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_fyNFe5Afdk6iBONoeDLqbQ_4_4">768,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OtJ-a1ZIt0GTo1DBVaijBA" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_zqfzNu85R0ayB6CBhrzLRQ_5_2">1,848,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DbSC03W-N0uqTlyKBJ9KHw" decimals="0" format="ixt:numdotdecimal" name="mrkr:CommonStockWarrantsEquityTreatment" scale="0" id="Tc_Kyz_p51w60eZGPZLSAB_gg_5_4">1,983,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_9Gr2_70yEEiU7Nmz36IHoQ_6_2">2,734,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Tc6PFRGjfEawXNl4_TfVfA_6_4">2,751,600</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_uhranP8CXkGY9xcYxJ7fCA" continuedAt="Tb_uhranP8CXkGY9xcYxJ7fCA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. &#160;The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_EA2qnlAMxUapgXjRK0-39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="6" id="Narr_c31lzAkADEenFiaoSJMxjA">3.4</ix:nonFraction> million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. &#160;At December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_EA2qnlAMxUapgXjRK0-39A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_eyiDqC77akec4-jQdlOUPQ">2.3</ix:nonFraction> million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. &#160;The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_1_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_us-gaap_SubsequentEventMember_Yue1bky0HUK0DiPiPA1ZmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="Narr_vJR-jBcUbEWJiKDYd9wNBQ">2.4</ix:nonFraction> million of funds from CPRIT in January 2023. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromOrphanProductsGrantProgram" scale="6" id="Narr_uKca2-qpDkmMDXTB7Zftug">0.1</ix:nonFraction> million of grant income related to the FDA grant as revenue for the year ended December 31, 2022. &#160;Additionally, at December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OrphanProductsGrantProgram" scale="6" id="Narr_eRoRrR9V_ECJjIbzxS8png">0.1</ix:nonFraction> million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. &#160;The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7NoYkmU3T0yNAjX5qvt6FA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_dUKTwPy4pU-3Zn3PMk7U5w">0.1</ix:nonFraction> million of funds from the FDA in January 2023.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uhranP8CXkGY9xcYxJ7fCA_cont1"></ix:continuation><a id="Tc_K2JweZoErk6jxo4x0bOD_A_1_4"></a><a id="Tc_1NKr8ozgIkCeb8s0OX5odA_1_7"></a><a id="Tc_J2pXb1d2WEuhuoxyeGvyUg_2_2"></a><a id="Tc_NtM4PyMGuEqTVOY8yxXf3g_2_4"></a><a id="Tc_PZ1K9-DhCkC6rTkF28LqKA_2_7"></a><a id="Tc_QRSRmLxrOU6G41SpaY_VfQ_3_0"></a><a id="Tc_IqSc9vDiRUmG81K_Cg8DfQ_3_4"></a><a id="Tc_2ONmy2VeKkiyjrYMve3qYw_3_7"></a><a id="Tc_Je2gptBH_0Ch0SZjj1kncw_4_0"></a><a id="Tc_zm76KwmWhk-zvpTV4nluvQ_4_2"></a><a id="Tc_PN21WxrDwUOKxtBMdr9CJw_5_0"></a><a id="Tc_spfJvezxZUqSCFn7jG2yGw_6_0"></a><a id="Tc_B2AEyTfaLUeiQrsCn_HxKg_6_2"></a><a id="Tc_7h5B6Ys1U0uikXdvgaHJdA_7_0"></a><a id="Tc_0T32reaHYUeLl6Ud2wo0OQ_8_0"></a><a id="Tc_0zejFBWiO0CbporZx9cgZg_9_0"></a><a id="Tc_yVwnIs8PjEOt69hERKwm9w_10_0"></a><a id="Tc_UcpH9REjAUuHh3SWMpou7w_10_4"></a><a id="Tc_jUNzNgJprUmuAFZwkzHwrA_10_7"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_59rskAXKoU-88lslqXSGJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;6:&#160;&#160;&#160;&#160;PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment consist of the following as of December&#160;31, 2022 and 2021, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_pCSuOI9k1E6DkhgOVOULQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab and manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NXup2CJ02USDTLUpDls9hQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_DQoXgrsxSkWyJZjN0mRTMw_3_2">5 Years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mMYtiCFfIEK_bdrpJ5dMRw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_h72kvHWnZkapZymwzho81w_3_5">11,824,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kiI02v_yr0miZEzODZfWew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_XOt4yHoAU0mT0iaL60eIFA_3_8">7,851,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_sQrTMozyWEyU4ra-AUAZ2g" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_K1eTHRN70kuQ_jgvi6sRJw">3</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_McT4zbJriU6hB34bDlJjeg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_HrnwrlMAek-k5tLs3uzfAA">5</ix:nonNumeric> Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_qtmbiBYUXEGhAeHMenyf7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_46mnqiZ9uU2QCCuOFo0ZFg_4_5">899,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_zKhfppn7GEWXbnJMKir-Sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_sAFIms-rGEKz4iHYJXN-ww_4_8">1,020,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_eEnb8GgPoU6evepNcjl2rA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_COGC_ScHaUS0LXUpu1GCJw_5_2">5 Years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_iRDTtaZteEiLcISmCUciWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_n2n8UYbdmEmu0XzseeM8KA_5_5">924,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_VtFCZtpzqUS4hInYPoLNNg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_pAqF7ilxvEiguk3QsSTn_g_5_8">793,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or estimated useful life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TLp-qtPIB02goeZcg_RReg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_uJjrTr6RyUaiD9NsB3pXWQ_6_5">3,950,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nqoFwEJHwUmDvKu-C4t_AA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_EKjOEhviSkWClWVsLuEb2Q_6_8">3,173,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Total   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_6fKAYWiPjki8uExYlWogVw_7_5">17,597,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_S2RodgUUaUybrTBRnCcbfQ_7_8">12,837,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_-3mcQrrNGUCA_ASeyBubXw_8_5">5,274,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_sejtpVHQrE6RAqUFC7LjWQ_8_8">2,740,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:zerodash" name="mrkr:ConstructionInProgress" scale="0" id="Tc_DcbXqshSOk2CSIbKyQQSEA_9_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="mrkr:ConstructionInProgress" scale="0" id="Tc_KU7altJc4kKszc1cXoTJSA_9_8">2,226,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fixed assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_aa968u4Rq0KYb1MNIrfUPA_10_5">12,323,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_31hNP2VdikOzPrnfgTqlEQ_10_8">12,323,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the years ended December 31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_pcCn28iij0iHebIp-Rp1xA">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_xjCffoZE_Eqsjlx7CaQXxQ">2.1</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. The Company incurred costs pursuant to an agreement with a vendor to design, engineer, build and eventually install modular cleanrooms in the manufacturing facility. $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_yhp5Hv7lwkaZQV2FAXpIpA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="Narr_DNX92NxhHEuRKEEpLNborQ">6.8</ix:nonFraction> million was recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2020. &#160;The completion of the facility&#8217;s construction occurred during December 2020 and the Company received its certificate of occupancy in January 2021, and as such was placed into service in January 2021. &#160;During January 2021, all costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the year ended December 31, 2021, and in connection with the opening of the Company&#8217;s manufacturing facility in Houston, Texas, the Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_McFGqwTRbE2KSZ_az8T4DQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="Narr_m5SnTAQDDUabmkSwj_0PpA">2.2</ix:nonFraction><span style="white-space:pre-wrap;"> million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. Such costs were recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2021.  The Company incurred another </span>$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RecapitalizationCosts" scale="6" id="Narr_6JMY_sNmHUOzogwEx8rU2g">1.9</ix:nonFraction> million in related costs in 2022. Upon completion and installation of the second modular cleanroom during the year ended December 31, 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and amortized over the estimated useful life.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_oQ3UdMDSvEKASfAZR2p5Eg" continuedAt="Tb_oQ3UdMDSvEKASfAZR2p5Eg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 7: LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company leases manufacturing, research and administrative facilities under operating leases. The Company evaluates its contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all of the Company&#8217;s leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term. The lease terms may include options to extend when it is reasonably certain that the Company will exercise that option. The Company did not consider that option in calculating right-of-use assets and lease liability as the Company is not reasonably certain it will extend the contract beyond the current terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Topic ASC 842 requires the Company to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. Right-of-use assets are recorded in non-current assets on the Company&#8217;s consolidated balance sheets. Current and non-current lease liabilities are recorded within current liabilities and non-current liabilities, respectively, on its consolidated balance sheets. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 15, 2022, the Company and its landlord agreed to terminate the Company&#8217;s office lease at 3200 Southwest Freeway, Suite 2500, Houston, Texas. &#160;As such the Company reduced its operating lease liabilities by $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw" decimals="-5" format="ixt:numdotdecimal" name="mrkr:DecreaseInOperatingLeaseLiabilitiesForLeaseTermination" scale="6" id="Narr_6X00vPFojUmXWiPZArevdg">3.7</ix:nonFraction> million and reduced its right-of-use </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_84cac522_4b46_44f0_a8b0_c5413c79a13c"></a><a id="Tc_Osxs6yMiF0aTlv7TkuM8rQ_2_2"></a><a id="Tc_II4Ah25Wz0eJAlMlF9dyqQ_3_3"></a><a id="Tc_PaXGeR7g6ECnO4HNk7lH6A_4_2"></a><a id="Tc_rh_knFKk7k2JB1DJl2O4Aw_4_5"></a><a id="Tc_oNpRGIT3skiYMRJCipBssA_5_0"></a><a id="Tc_u_iEvdFvA0mIBBfbQ7FOIA_6_0"></a><a id="Tc_2SPrrJlUdEWWZFC4LTr60w_6_2"></a><a id="Tc_UzkGpIzhZkK-HD2aT0S75Q_7_0"></a><a id="Tc_KPPodn_h-EunsSNlhaQXcA_7_6"></a><a id="Tc_HgBdAAmCok2XtylULjPDSw_8_0"></a><a id="Tc_3Z6tAHDm20G4HMqMDqfBiA_9_0"></a><a id="Tc_TyKV4rdZLEi830jrnH0nRQ_9_2"></a><a id="Tc_5v9u1FY8Bk2d0wlgjYAI8w_9_5"></a><a id="_13f7beca_db14_4604_984c_464e3251c7f2"></a><a id="Tc_VnuDUv1_zE6VdBG6R5_LdQ_1_2"></a><a id="Tc_OKlXVWM7qUOj_N2VNMp8sg_2_2"></a><a id="Tc_hdyxyaz9_Uq91LIBQC_ApA_3_2"></a><a id="Tc_bUuFHEIQCEqAXKY9NS65nw_3_5"></a><a id="Tc_smmFKS5ackWE8aSf7q8ltQ_4_0"></a><a id="Tc_54Uh7cKoZEOiLqmQWJAoWA_5_0"></a><a id="Tc__Vb1sFuA4k-mmymImxXd_A_5_2"></a><a id="Tc_px9r3SAkm0-QupfIVbuGUg_5_5"></a><a id="Tc_brk5EcXOMEOQR7APItps7w_1_0"></a><a id="Tc_OfxFUk3-4kyw8U6-avHGhA_2_0"></a><a id="Tc_8xFQWOCu-kSLPPTKVJx26A_3_0"></a><a id="Tc_KJlECrsoPE6ykZhal4bi0w_4_0"></a><a id="Tc_CSH7J6ZV00KoHpp8evovmQ_5_0"></a><a id="Tc_T9o1lyho90KIPGpVRwDN1A_6_0"></a><a id="Tc_pkpDTbqkzEOxdov9U0A14A_7_0"></a><a id="Tc_XET_h6w3YEulvHLXVqTvZg_8_0"></a><a id="Tc_Ym0s5EcHHkOawTOJ7vaeYw_9_0"></a><a id="Tc_pHixsWlum0K-wYg-nJ7hTA_9_2"></a><ix:continuation id="Tb_oQ3UdMDSvEKASfAZR2p5Eg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">assets by $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw" decimals="-5" format="ixt:numdotdecimal" name="mrkr:DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination" scale="6" id="Narr_WES-ZHIsrUaEjoV4GVz1-A">3.5</ix:nonFraction> million. &#160;A gain on lease termination was recorded in general and administrative expenses during the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had total operating lease liabilities of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_FsCUnVBQ7kCLmkxkShP6Qg">7.6</ix:nonFraction> million and right-of-use assets of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_R3uaOue70kKoqx-neNH4IA">5.5</ix:nonFraction> million, which were included in the consolidated balance sheet. &#160;As of December 31, 2021, the Company had total operating lease liabilities of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_G0fHUGPwd0-v8P3F2TFETw">11.9</ix:nonFraction> million and right-of-use assets of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_Nc2BwqzdekOxW6_OsIfdPg">9.8</ix:nonFraction> million, which were included in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. &#160;Certain of the Company&#8217;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. &#160;Variable expenses generally represent the Company&#8217;s share of the landlord&#8217;s operating expenses. &#160;The Company does not act as a lessor or have any leases classified as financing leases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company&#8217;s operating leases:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" id="Tb_z96kKyR--U6zNNbd430vVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense summary:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc__3A1alEmPka25fytDU_rGw_6_3">1,483,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_ycISG-JbN025-HWeIMMV5g_6_6">1,702,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Tc_o7pIoETYP0yuPrHCxxjKdQ_7_3">48,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="0" id="Tc_Nzy032NkXUaOGfcwOTH_JQ_8_3">648,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="0" id="Tc_hbGlhGz3WEiXIujXtQ8AAQ_8_6">606,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="Tc_Lb50_-tLrESw0Tjrsh2AYA_9_3">2,179,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="Tc_x6U5ZkabnkCXLjdpErMQYg_9_6">2,308,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_b1kJDvNqmUOfzYnOX7BmYw_5_3">1,106,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_JgcUTQbPzUCTHOToBlvmPg_5_6">1,077,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The weighted-average remaining lease term as of December 31, 2022 and December 31, 2021 was approximately <ix:nonNumeric contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_SHnLbYiO7EW4ykTO2XBoHw">7.5</ix:nonNumeric> years and <ix:nonNumeric contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_SbWd8Q4U5kG4_BfQn6wVKg">8.4</ix:nonNumeric> years, respectively. The weighted-average discount rate used to determine the operating lease liability as of December 31, 2022 and December 31, 2021 was approximately <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_aPqRJxoOU0WlQL1t_gMaYw">5.5</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_xZI8pGiedUuaO-zoxOf6FA">5.7</ix:nonFraction>%, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of the Company&#8217;s operating leases, excluding short-term leases, are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_Pv-zabLa-kitKHPidkDnig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_zzc_enpKnkCi0GQgN3EQzA_1_3">983,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_1c6HqTlS002O5FdZqDlo8g_2_3">1,254,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="Tc_OecLkEOqZUikHXvS8mBO9w_3_3">1,290,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="Tc_bNp20kX_7UCJ4vww9u1bVA_4_3">1,177,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December 31, 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="Tc_MUK08kLIlUOed8Wc5NVJtw_5_3">1,163,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="Tc_mf1QknWmEUm5AN6iF3kUgQ_6_3">3,590,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_telgvYB5PkaakJLOo4fODA_7_3">9,457,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_dn9KiZ-7zkaEe8m-mvAaVg_8_3">1,840,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_UG0NSdiBJUi5DxZXRV4_8g_9_3">7,617,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_GEA1USJMnUG32c6LynL1WQ_1_2"></a><a id="Tc_91pByo6mG0CP7RTpk7YCog_1_5"></a><a id="Tc_la-_C-R9gUumy62tcwPECw_2_2"></a><a id="Tc_kRzjQGI_FUW7D2uQ7gTVvQ_2_5"></a><a id="Tc_SD7Kn2if50CAuBarIGxV-g_3_0"></a><a id="Tc_gqQD7rdXEE-gEWyZJH6HhQ_3_2"></a><a id="Tc_IURCw6MVEUCvuXx6QbPrZA_3_5"></a><a id="Tc_68aRRrXlH0Wqy_JVjZF7kA_4_0"></a><a id="Tc_9Co_vSJ-mEaOq2wht6YrXg_5_0"></a><a id="Tc_54meEXUyMkSUlvK-oLG3aQ_6_0"></a><a id="Tc_9sglG0Zi_UqyYDTuHh6YjQ_7_0"></a><a id="Tc_KvZ7ziqZQk27ghSBOc_TFw_7_3"></a><a id="Tc_2wI4_iBDI0a8IhCPeQMvEQ_8_0"></a><a id="Tc_-_cqt2T2mEmsapEVmLMqYg_9_0"></a><a id="Tc_7SzPqj0tqEmPyGHFg519CQ_10_0"></a><a id="Tc_3yDcE32qnESuM2Iu1QD3eA_10_2"></a><a id="Tc_bmm93KG6mESEr63NtQ03Eg_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_saTJ1doSBECFk3uMIPZ42A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8: &#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued liabilities consist of the following as of December&#160;31, 2022 and 2021, respectively:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="Tb_X_eo7x0YtECvaCWmoRonWw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_RrvCCq8FKkaG8kp6Vz1iKg_3_3">1,612,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_Lvj4pGD0X06DescuQl0mgQ_3_6">5,144,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_oYG4_Z_veE-McXSOvfyBag_4_3">1,779,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_aOHpFCeL30Oxe28boD3UiQ_4_6">2,055,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Process development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:AccruedProcessDevelopmentExpensesCurrent" scale="0" id="Tc_E_GNGFqnyEqdr33a5UpytA_5_3">342,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="mrkr:AccruedProcessDevelopmentExpensesCurrent" scale="0" id="Tc_UpCY2fjMuUy6LUDWGY1SvA_5_6">385,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_nG6YlEZwnkGv-aUww8u7dw_6_3">558,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_f0f-UXoh-0iQwXPGuKShdA_6_6">644,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="mrkr:AccruedTechnologyLicenseFees" scale="0" id="Tc_dE_wKqzr9UaVRMzKMzC8FQ_7_6">250,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Arbitration settlement fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:ArbitrationSettlementLiabilitiesCurrent" scale="0" id="Tc_jyQ4H7vVw0iVFqsiWBk1fg_8_3">114,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="mrkr:ArbitrationSettlementLiabilitiesCurrent" scale="0" id="Tc_kdQtHZbYs0q_AzlwwvHOeA_8_6">2,407,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_TIhem8Y84ke2Skg5SNZ41w_9_3">300,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_4NOPPuFuOEiCoqjnZaTZNA_9_6">250,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_FuIPzOWfjEuw7JcSqUHBnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 4,705,000</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b9x6r4ODwECU40jh-cbSzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 11,135,000</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2022, the Company implemented changes to the Company&#8217;s organizational structure as part of an operational cost reduction plan to conserve the Company&#8217;s available capital. &#160;In connection with these changes, the Company reduced headcount in its general and administrative function by approximately <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_QveB1kU3tkucob1EUaCgcw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_Xm80aktwgk6GMT2oy8v3vw">23.5</ix:nonFraction>%, including the separation of the Company&#8217;s Chief Financial Officer. &#160;For the year ended December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_sD7iYvHxZkqwyKox7Z0qJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="Narr_GHf5e5TaQEutbEzff-b_Lg">0.3</ix:nonFraction> million of accrued compensation and benefits for severance expenses related to the operational cost reduction plan.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:RelatedPartyLiabilityDisclosureTextBlock" id="Tb_kvmrjyVzrkGsup2W9Cc3LA" continuedAt="Tb_kvmrjyVzrkGsup2W9Cc3LA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 9:&#160;&#160;&#160;&#160;RELATED PARTY DEFERRED REVENUE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On April 21, 2022, the Company entered into the Services Agreement, dated April 12, 2022, with Wilson Wolf. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the &#8220;Wilson Wolf Mission&#8221;). Pursuant to the Services Agreement, Wilson Wolf made a cash payment to the Company in the amount of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="Narr_AodkKj2lwUG7itscgcVPRw">8.0</ix:nonFraction></span><span style="font-weight:normal;"> million, as consideration for certain training and research services allocated as follows:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" scale="6" id="Narr_YoUpaVTqR0Kf8hYWtYOlIw">2.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for non-exclusive training of Wilson Wolf to make, use, and sell the Company&#8217;s cell culture non-proprietary media formulation that has been cleared in an FDA investigational new drug application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" scale="6" id="Narr_RQYnvYUN4kuoWMy9M8FbfQ">1.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for non-exclusive training of Wilson Wolf to replicate the Company&#8217;s quality management system inclusive of all underlying documents related thereto, none of which shall include unique information specific to the manufacture of the Company&#8217;s multiTAA product candidates such as direct peptide stimulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" scale="6" id="Narr_2oDNCZol7Eqebkb_Cmv-Gg">2.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for non-exclusive training of Wilson Wolf to be able to replicate the Company&#8217;s cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process which Wilson Wolf shall use as it sees fit in pursuit of the Wilson Wolf Mission; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" scale="6" id="Narr_7bsZIHesg0y95zIj3_laaQ">3.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for the Company to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes using G-Rex and to conduct CAR T and TCR G-Rex Optimization Work under the direction of Wilson Wolf (the &#8220;Work Direction&#8221;), whereunder all intellectual property provided by Wilson Wolf or created or derived by the Company will be solely owned by Wilson Wolf, and whereby the Company will make good faith efforts to complete the conduct of such work as soon as practicable within </span><ix:nonNumeric contextRef="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA" format="ixt-sec:durwordsen" name="mrkr:PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" id="Narr_IgTiSwH5oUGeKRoWuDM09w"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18 months</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the date of the agreement. Wilson Wolf has agreed to pay the Company an additional </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" scale="6" id="Narr_-_Jg3-I7OEGGy-VzrcxazA">1.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million if the Work Direction is completed within one year from the onset of the Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Services Agreement, in the event that the Company becomes insolvent, goes out of business, or an event other than force majeure occurs that cannot allow the Agreement to be fulfilled, Wilson Wolf will have right of first offer and right of first refusal for the Company&#8217;s manufacturing facility provided it is able and willing to meet whatever financial obligations are required to do so and provided further that such clause will not apply in the event of a merger, reorganization or consolidation of the Company with a third party that results in the outstanding voting securities of the Company immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at least fifty percent (<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA" decimals="2" format="ixt:numdotdecimal" name="mrkr:ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" scale="-2" id="Narr_y2MK1lfwLEyhnXODZeayJQ">50</ix:nonFraction>%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of the surviving entity immediately after such merger, reorganization or </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_kvmrjyVzrkGsup2W9Cc3LA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">consolidation, or the sale or other transfer of all or substantially all of the Company&#8217;s business or assets. The Company agrees to assist as needed to the extent permitted under any applicable law (including bankruptcy or insolvency statutes). Further, prior to the Company undertaking any financing that would encumber any of the Company&#8217;s assets necessary for the Company&#8217;s performance under this Services Agreement, Wilson Wolf shall have the first right to provide such financing on equal terms to what the Company can obtain elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recognizes related party revenue over time in accordance with Accounting Standard Codification, or ASC, 606 Revenue from Contracts with Customers, as each of the training or and research services are provided to Wilson Wolf. Revenue is recognized, using an output method based on progress toward satisfaction of the performance obligations. &#160;Additionally, in accordance the spirit of the standard expressed in ASC 606-50-1, the timing of the revenue recognition is expected to be approximately 12 months. For the year ending December 31, 2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_73WDhaJFhk26kf_aw8N7qA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr__tLPhLK7MUG07WPL5mJR-A">5.5</ix:nonFraction> million of revenue pursuant to the Services Agreement and at December 31, 2022, the Company recorded an $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_elmgfz9S-0W_ZDXK3WDiaw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="6" id="Narr_lGYnV_V6IkOrVKmxfdPi-w">2.5</ix:nonFraction> million related party deferred revenue on its consolidated balance sheet.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_JefRFPJJV02WL_WbGSZqZA" continuedAt="Tb_JefRFPJJV02WL_WbGSZqZA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10:&#160;&#160;&#160;&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increase in Authorized Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended June 30, 2022, the Company&#8217;s board of directors and stockholders approved a Certificate of Amendment (the &#8220;Amendment&#8221;) to the Company&#8217;s Certificate of Incorporation to increase the authorized shares of common stock of the Company from <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_MinimumMember_PZ0RPJnwKk65BP6T537-EQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DmJElRXukUq9G95Yj26vqA">15,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_MaximumMember_dikyAbnEbkGQJoXUA7yMkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_uYFDbrNZyEOeX1Gvij1o-Q">30,000,000</ix:nonFraction> shares. The Company filed the Amendment with the Secretary of State of Delaware on May 25, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_XPzhwj-erUqIBzQu-ulhQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_OKfa6hh_K0mAeYTgr7DO1A">300,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6ka_iEmMjE2aQAOD6iwO8w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_yykCW6wuM0m85j9PJwEY5g">30,000,000</ix:nonFraction>. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2023, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_4dlY8sZRkEmvuKN9syh0Lg"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_XT5pyDnUa0OEkcQxRbxGrQ">5,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_4c2tYDJ28Eahi3odtR6KlA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_UfC8hCwhCEWHETjYruP9gQ">0.001</ix:nonFraction></ix:nonFraction> par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4IrbszxQxkuMDMEM_xtEWQ">30,000,000</ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_tSE8T9TMTEukQjxbOYmP7Q">0.001</ix:nonFraction> par value per share, for issuance. Significant 2022 and 2021 common stock transactions were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2022 Common Stock Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Restricted Stock Units to Executives</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, upon the recommendation of the compensation committee of the Company&#8217;s board of directors, &#160;and pursuant to the Company&#8217;s 2020 Equity Incentive Plan, the Company&#8217;s board of directors approved the issuance of a total of <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rYx1qhT1B0-34GBZN7r13Q">37,252</ix:nonFraction> shares of common stock, valued at a total of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_vldb4ZC_nUu16SCvfhK35Q">180,200</ix:nonFraction>, subject to restricted stock units, which were immediately vested upon grant, to certain executives as performance bonuses for performance during the year ended December 31, 2021.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JefRFPJJV02WL_WbGSZqZA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Stock Pursuant to ATM Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_VP3-b6HOUk2DKLQ51VCCBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_b47EUxOqQkG5JLgxl6BWwg">60,651</ix:nonFraction> shares of its common stock under the ATM Agreement for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_VP3-b6HOUk2DKLQ51VCCBQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_crxhsI3OpUy7qvZz_mpL0A">202,100</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_DRQziVPupkyucYZQUxu7CQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_xwrHYjKoYUqSJUse6K5S9A">25,000,000</ix:nonFraction> of shares of our common stock, or the Purchase Shares, from time to time over a 24-month term , at a variable price with certain market-based terms as defined in the agreement. The purchase agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement is indexed to the Company&#8217;s own stock under ASC Subtopic 815-40, Contracts in Entity&#39;s Own Equity, and classified as equity. &#160;During the year ended December 31, 2022, we did not sell any shares of our stock under the Purchase Agreement. &#160;In January 2023, Lincoln Park was issued <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_j-Tt7k3AAEelDRzuTV__kA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_lq8vjkWfs0OqfuYMC-WdLA">180,410</ix:nonFraction> shares of stock as a commitment fee at a value of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_j-Tt7k3AAEelDRzuTV__kA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_IfBfi75br02XwAoC4DRryQ">0.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2021 Common Stock Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the year ended December 31, 2021, certain outstanding options were exercised for </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_EhfaszvU3UinGypAqqyo6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_dIHkZMN7YkOBb_4RVXZZog">146</ix:nonFraction></span><span style="font-weight:normal;"> shares of common stock providing aggregate proceeds to the Company of approximately </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_jSWMIRhbp0WIJO4zq_1XRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_A7IQdFXv90eonu_bN0b2Rw">3,100</ix:nonFraction></span><span style="font-weight:normal;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Board Compensation </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_5W-EffSPAk-sIjPcaw3pDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_53-0NA49zUijJRenB69lbw">6,329</ix:nonFraction><b style="font-weight:bold;"> </b>shares of common stock to its non-employee directors. The fair value of the common stock of approximately <b style="font-weight:bold;"> </b>$<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_meicGgKvzUadt_zzSUx2eg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_jzD5K48aOEikeB-zXVKnxg">0.2</ix:nonFraction><b style="font-weight:bold;"> </b>million was recognized as a component of stock-based compensation expense in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwritten Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 11, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp; Co., as representative of the several underwriters, to issue and sell <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA" decimals="INF" format="ixt:numdotdecimal" name="mrkr:NumberOfSharesAuthorizedToIssueAndSell" scale="0" id="Narr_KU8joAt520OfZog5_q93hw">2,857,200</ix:nonFraction> shares of common stock of the Company in an underwritten public offering. &#160;The offering price to the public was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_S5Q4yNrC5UKGn_ImsQmXDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_ClN1gpLBSEOo1Rqqzu-SWQ">17.50</ix:nonFraction> per share. &#160;In addition, the Company granted the underwriters an option to purchase, for a period of <ix:nonNumeric contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA" format="ixt-sec:durwordsen" name="mrkr:UnderwritingOptionPeriod" id="Narr_X1XX7klzGkmk52wOjCa19Q">30 days</ix:nonNumeric>, up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA" decimals="INF" format="ixt:numdotdecimal" name="mrkr:NumberOfAdditionalSharesAuthorizedToIssueAndSell" scale="0" id="Narr_jhTWdGDFHUSNRtGYtMbfsQ">428,580</ix:nonFraction> shares of common stock, which such option was partially exercised with respect to <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA" decimals="INF" format="ixt:numdotdecimal" name="mrkr:StockIssuedDuringPeriodAdditionalSharesNewIssues" scale="0" id="Narr_jArzvHw94kmnPhD_hU9zMA">371,086</ix:nonFraction> shares. &#160;An aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-R-FXgqsHkmEZgBWQWcxEw">3,228,286</ix:nonFraction> shares of the Company&#8217;s common stock was issued for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Nc7XqqoKC0OUzqdiSmZqWA">52.6</ix:nonFraction> million after offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_11_2021_To_3_11_2021_ipD27hsbDkSP-aqaxEKH-A" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OfferingCost" scale="6" id="Narr_34pKU8fc10aGPYeE_GCAnA">3.9</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_N9qkY86tJku7FBh_TZcqZQ_1_7"></a><a id="Tc_fPfN3ITlLES2RmxLReNgxg_2_2"></a><a id="Tc_AFqw129C706z2iOKkgaLgw_2_4"></a><a id="Tc_FWG_Gzg9h0ysjIVi8dof7g_2_7"></a><a id="Tc_DjF2k7Wz8USZILidcJRSmA_2_9"></a><a id="Tc_tdLdNu9hBkOvq1dzIQFpGw_3_2"></a><a id="Tc_i-XsnlxZqkmTyorzWfglOQ_3_4"></a><a id="Tc_k8_p3XwAjEm0EQr4jO8csw_3_7"></a><a id="Tc_hZnddtV7y0-l8oAXJjotYA_3_9"></a><a id="Tc_vmYu2bEC-E6e2yeyn-djzg_4_0"></a><a id="Tc_CPOGUAqXo0i2vXM4wLHQvQ_4_4"></a><a id="Tc_LwKg4hbP70OjJWCUmb-UYw_4_9"></a><a id="Tc_4Sn08VUiSUyvVzaKFrnK_A_4_10"></a><a id="Tc_LyfWtqfeU02rT6I5X3q6oA_5_0"></a><a id="Tc_3P6TyP90WUa6KcyGjn1G-w_5_7"></a><a id="Tc_d4fLnk1eAEiy6sbkwWnHqA_5_10"></a><a id="Tc_iirVnTV-IUew5zPq2n77KQ_6_0"></a><a id="Tc_IQwZE83e606Ktpy8hl_osQ_6_9"></a><a id="Tc_FEZodWBYT0OrQoSVOm1jDw_6_10"></a><a id="Tc_EWgGcIoxR061pjmdIXJngg_7_0"></a><a id="Tc_CIFpp7h3lk-veFUAy29qmQ_7_7"></a><a id="Tc_AJ9NACnDhkK64YGx30shng_7_10"></a><a id="Tc__ssWDfe9602VrKFujtWbOg_8_0"></a><a id="Tc_IRmkVay2hkqpKy3YnSot9Q_8_4"></a><a id="Tc_HlTZtQHGMEO10LmZ6KIhwQ_8_9"></a><a id="Tc_OMhfWE5c502MtCA0zirtag_8_10"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:WarrantsDisclosureTextBlock" id="Tb_Az_DSC2ltEmqAoq9W4Et9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11:&#160;&#160;&#160;&#160;WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share Purchase Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s share purchase warrants as of December&#160;31, 2022 and 2021, respectively, and changes during the period is presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_RYoECPvlqUm2SecYEAk3nw" name="mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock" id="Tb_egDTOiqGBk2nu_4nn2xLLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Nr80ab6FKUKMRQpsEEvBPw_4_2">2,083,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" scale="0" id="Tc_ryHFRZjkvEmdWt2z-i1tUA_4_5">47.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg" format="ixt-sec:duryear" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" id="Tc_yLUUEbXgMkq_IJiYrwo3Lw_4_7"> 2.60</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantExpiredOrCancelled" scale="0" id="Tc_vlLi9F3b7Ueddg7opqTutw_5_2">100,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" scale="0" id="Tc_u1eSuB1zZkKY7l650rBTDQ_5_5">55.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_9_HdjffZXUmwiiw623gwhQ_6_2">1,983,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9c2ncfX-nUKDgJq2YVeuBg_6_5">44.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" format="ixt-sec:duryear" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" id="Tc_4zpv9RWCcES2hS5SnKOpfQ_6_7"> 1.70</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:NumberOfWarrantExpiredOrCancelled" scale="0" id="Tc_hBQNx-viUkCu8dwbkH9-jw_7_2">135,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" scale="0" id="Tc_N_jF_zx0p0KXnBrEPDveoA_7_5">39.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Ky5TVjkGd0-fVEokayX0ow_8_2">1,848,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_CXSILqCoakO_SCt47IwHdg_8_5">44.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:duryear" name="mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" id="Tc_RCTeCg9z60-k75yOVG06mA_8_7"> 0.79</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_U_pp5lBWRkm0F30Cjit4zw" continuedAt="Tb_U_pp5lBWRkm0F30Cjit4zw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;12:&#160;&#160;&#160;&#160;STOCK OPTION PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Options to Purchase Shares of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 19, 2020, the Board adopted the 2020 Equity Incentive Plan (&quot;2020 Plan&quot;) which replaced the 2014 Omnibus Stock Option Plan. The 2020 Plan was further amended effective May 2022 to increase the number of shares of common stock authorized for issuance under the plan by <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_WhoS9ltZXk6NBcS9AfdoJA" decimals="INF" format="ixt:numdotdecimal" name="mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" scale="0" id="Narr_C7OvFxnuiUeXWAuk5OTQfQ">850,000</ix:nonFraction> shares. The 2020 Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Plan may be at prices and for terms as determined by the Company&#8217;s board of directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#8217;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the Nasdaq Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Options granted under the 2020 Plan have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_s5BTwwK2kU2hdKZtXLGr8Q">ten years</ix:nonNumeric> from the date of grant and generally vest over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Obs6ffYSPEG9OQl0NaVGFw">four years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2022 Equity Incentive Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 17, 2022, pursuant to the Company&#8217;s 2020 Equity Incentive Plan, the compensation committee of the Company&#8217;s board of directors approved a total of <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_J2wzhp4PQ0yD55El3XelKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_VBDMu2PnoE-HNovjlGHaGg">125,000</ix:nonFraction> options to purchase the Company&#8217;s common stock as equity-based incentive awards to the Company&#8217;s executive officers. &#160;Each option award was granted with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_yIinahL4sEGqxYXSIhjnhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_awS_0HJ98USTlVlLFhqf5g">4.60</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on February 17, 2022, with the option award vesting in 48 equal monthly installments over a <ix:nonNumeric contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_J2wzhp4PQ0yD55El3XelKg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_PxCwhWY6W0GyEewx5XR-Mg">four-year</ix:nonNumeric> period, subject to such executive officer&#8217;s continued service on the applicable vesting date. &#160;Additionally, on February 17, 2022, the compensation committee of the Company&#8217;s board of directors approved a total of <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_dWyn4xZK_0WCrGrgTFwZwg">39,500</ix:nonFraction> options to purchase the Company&#8217;s common stock to non-executive employees of the Company as equity-based incentive awards. &#160;Each option award was granted with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_pVnVS7CZdEWMB5iww4KJeQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_0Z0DZvIy7EOuLc0sTXsuwA">4.60</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on February 17, 2022, with the option award vesting in <ix:nonFraction unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw" contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g" decimals="INF" format="ixt:numdotdecimal" name="mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards" scale="0" id="Narr_fCusP2-vLEi4iE-tXUoetg">48</ix:nonFraction> equal monthly installments over a <ix:nonNumeric contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_GYPWt3QyH0yquT6kaWu1dg">four-year</ix:nonNumeric> period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The above awards were in addition to <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_3_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_kUuUrHRKk0G10jpx1s-bkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_pQQX4zpv7kODvWSe47i_fA">17,500</ix:nonFraction> stock option awards issued during the three months ended March 31, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_3_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_kUuUrHRKk0G10jpx1s-bkQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_R_iFXfO21Uup7tgX63gcUw">10.00</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on January 3, 2022, with <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_4_1_2021_To_4_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_pGIzcYnvJEiT9dhMXsElQg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_J-XRiU9SUkaB26rIyaNIUA">25</ix:nonFraction>% of the option award vesting in one year and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_JbX3ZgrhrUCG3fxE5SiYMg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_MJ6qOzFmsE-VhrVPkOAKLg">75</ix:nonFraction>% vesting in <ix:nonFraction unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw" contextRef="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_UIJSoFc-BEakDbs6zOJBIQ" decimals="INF" format="ixt:numdotdecimal" name="mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards" scale="0" id="Narr_Sr6W7oMyvk2OsfgIO4_xRQ">36</ix:nonFraction> equal monthly installments thereafter over a <ix:nonNumeric contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_JbX3ZgrhrUCG3fxE5SiYMg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_xLtPdlgOYkSYi0BCN_qnsw">three-year</ix:nonNumeric> period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A-AeQilLX0WzYGhiZT07Jg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_8aO_TarmA0mxn0Lrwmcz9Q">21,000</ix:nonFraction> stock option awards were issued during the three months ended June 30, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAwards2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_F-6NSFyNk0uhy-tFDHx2jg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_Zma4prJaY02DNiQ5HM1hLg">4.30</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on April 1, 2022, with <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_GhcbliHPX0GLe0R12grctQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_S6NOHXNsXUSNQFW6EdOo0A">25</ix:nonFraction>% of the option award vesting in <ix:nonNumeric contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_uGqtaqdy20eQ6t52skgzRA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_fl205L8hNkS_x7jEWWPYuQ">one year</ix:nonNumeric> and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mhcEIpDJQkmXGgO5cKQZuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_c7BCzwOzH0iNt-E3_W6aCw">75</ix:nonFraction>% vesting in <ix:nonFraction unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw" contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_uGqtaqdy20eQ6t52skgzRA" decimals="INF" format="ixt:numdotdecimal" name="mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards" scale="0" id="Narr_3znym03xz0el5qqJyfFshQ">36</ix:nonFraction> equal monthly installments thereafter over a <ix:nonNumeric contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mhcEIpDJQkmXGgO5cKQZuA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OzY-oCBA6Ue4-2xrCUPwJA">three-year</ix:nonNumeric> period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_U85KQ1vJe0u5uT4iGCYd1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_znDXCWgDOUe7tOW-Hxx8hg">10,000</ix:nonFraction> stock option awards were issued during the three months ended September 30, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_U85KQ1vJe0u5uT4iGCYd1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_Okz6HFSxrUyriP9w46XNzA">3.50</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on July 1, 2022, with <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ltpSYmw2Ck-js4TXpUSbpQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_DYzItTPYZU2f8sC4g7DujA">25</ix:nonFraction>% of the option award vesting in <ix:nonNumeric contextRef="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4Mlx9tG1EEGFYz6EXdp5Vg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_rbVGxoOwzEqZ4G2zYLoXWg">one year</ix:nonNumeric> and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_AxyTiy7MlUuwc7GAnr3jLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_ZbBdbGResUWdj3lIhzTvwQ">75</ix:nonFraction>% vesting in <ix:nonFraction unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw" contextRef="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_YqaWefj0tk20njxWAVYeyg" decimals="INF" format="ixt:numdotdecimal" name="mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards" scale="0" id="Narr_po3bZ-SsbEWC1Hx_OVqTow">36</ix:nonFraction> equal monthly installments thereafter over a <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_AxyTiy7MlUuwc7GAnr3jLA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_H3AiRWViAkOLRpD_YT_fRQ">three-year</ix:nonNumeric> period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ZEI3kl26Pk2zgb9tiZo19w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr__9PChTPrNkOA6xd1WeZhgA">7,000</ix:nonFraction> stock option awards were issued during the three months ended December 31, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3OQQVZE1uEm384QeLqzj-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_j8NQQY8ZwEOfmxGz-s_Mow">3.73</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on October 3, 2022, with <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_CgqUPlC4VU6qTAV9KfQcqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_L2Y_dqDekkesLxQOXjR4mA">25</ix:nonFraction>% of the option award vesting in <ix:nonNumeric contextRef="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_JUDa3cw9BUK0ZTYPzI9s9g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_biWOuLGwZ0GamUTjaxGsFQ">one year</ix:nonNumeric> and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OcBdsIpxMk6PRtghWozW-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_21nCZZj6CEyhwLEFyOc2pw">75</ix:nonFraction>% vesting in <ix:nonFraction unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw" contextRef="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_y6evzTYbj0ikSh5RHLTXHw" decimals="INF" format="ixt:numdotdecimal" name="mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards" scale="0" id="Narr_dJXvwxwzVEiKr1iIuSJzUw">36</ix:nonFraction> equal monthly installments thereafter over a <ix:nonNumeric contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OcBdsIpxMk6PRtghWozW-g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_dPW1kXGprE-MevAHTKnpVw">three-year</ix:nonNumeric> period, subject to such employee&#8217;s continued service on the applicable vesting date.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_wpKxUGEPWUyoT4xQ77wHzA_1_10"></a><a id="Tc_bffv-1lMwEyI9bcVz2ATVA_2_10"></a><a id="Tc_wo1rGNl7lUi_e4W51Jl66Q_3_4"></a><a id="Tc_dlzg37z04kus4UArMcq9ZA_3_10"></a><a id="Tc_vtDuURjbIUa6Doir95PBVw_4_2"></a><a id="Tc_r3OUY-lrkEiUlQ3Rna_4_Q_4_4"></a><a id="Tc_-Mk33gCdWEmh06JJ7-nfHg_4_7"></a><a id="Tc_m0Y53B67PE-n8H8EMKp1DA_4_10"></a><a id="Tc_jQ9UaUSbr0eweAeNT3J0ug_5_0"></a><a id="Tc_8VQpsu-8UUyHc9lHR3uGCQ_5_4"></a><a id="Tc_FSG3QQudaU-KBV1WAHahLg_5_7"></a><a id="Tc_TRwcgvEDMUiDoT0UCygmuQ_5_8"></a><a id="Tc_1MpIOAn0Hkq7pSojEEm1lg_6_0"></a><a id="Tc_gpmgZu7kGEy9tP-D0ebpbw_6_8"></a><a id="Tc_WmTM-tWAvkqCwfSOOFXwgA_7_0"></a><a id="Tc_xVOHPIzRRE-GWd7eKjRjSw_7_8"></a><a id="Tc_XxODSTTpEUivRaTr7E0yzQ_7_10"></a><a id="Tc_FmwekhTj2UOxAF9P_yUAmw_8_0"></a><a id="Tc_NTwczNWSpkKhkjNDTEtLrA_8_8"></a><a id="Tc_z1Na1CfY20GrguwXE-eV6g_8_10"></a><a id="Tc_MljD0Dm75UG3_J9c0E-akQ_9_0"></a><a id="Tc_1FaCu_Fi90qZdl-LmHTHOw_9_8"></a><a id="Tc_AEh8q1uSIkmsXR0lWAbezA_10_0"></a><a id="Tc_doncI7EoPEGlpanlFjzLcQ_10_8"></a><a id="Tc_8n1SKgEOY0q4_Dr7zmlXBg_11_0"></a><a id="Tc_97yePdchQkGlabAkawjyWQ_11_8"></a><a id="Tc_W77AOfM1EEWRypfQrNVhfQ_11_10"></a><a id="Tc_3HYb2eLt5EKYldchOTNZhg_12_0"></a><a id="Tc_A2uTHtkzSEeLDV1IVIn2BQ_12_4"></a><a id="Tc_CQ82Z0Mghk6Ve9DSIgtvYA_12_7"></a><a id="Tc_t9j8Ek5ackGbV4EHOiwjVQ_12_8"></a><a id="Tc_2X5FCiOKDEK9klNA74bOdg_13_0"></a><a id="Tc_KLVZ3iJ3BU6TV-Ta4Eaupw_13_4"></a><a id="Tc_vR_Tqzbo60mBwrRS0uiKqg_13_7"></a><a id="Tc_sFQ-p1YJakGHNyG5Ii0hvg_13_8"></a><a id="Tc_HwFTzovsxUa71beXcOknWw_1_2"></a><a id="Tc_nbI0xF0TO0-BvnTJm0Is_w_2_2"></a><a id="Tc_iA0Sq3zOJEqxgwT0MtLAIQ_3_2"></a><a id="Tc_XfMYlR7e0Umo93x45_X0Bw_3_5"></a><a id="Tc_JSnepkrawUuPzUpBLmydFg_4_0"></a><a id="Tc_7nrQ7h6Tc0WvFo-mtvsnpQ_4_2"></a><a id="Tc_yTcj4FoQLUamo_zYFLdH9w_4_5"></a><a id="Tc_AzPm0U-aNUey33SeWTLw8A_5_0"></a><a id="Tc_03JRz76s4Ua37TQtQxeJKA_6_0"></a><a id="Tc_1Bb_OMxrokSbHrnVgNtSCA_6_4"></a><a id="Tc_bfWA606YaUCZTS_KoZfAQw_6_7"></a><a id="Tc_i8AVQyiv6UyYCW_RM6RHfg_7_0"></a><a id="Tc_Mc2aD-askUW2kU1iVRaFwg_7_4"></a><a id="Tc_-Lih-m9d90apbaTGhuQ-vA_7_7"></a><a id="Tc_s2vG0I6bZUuaT8R0dfT6rQ_8_0"></a><a id="Tc_WKksXtQGWUiXObIxgZnvEQ_8_4"></a><a id="Tc_vYCH76W-ikaEfzWdQNQvdA_8_7"></a><a id="Tc_0asltOWv5UGfAaQKNuF4tw_1_2"></a><a id="Tc_3hWkOE-820ek4AJLo_Cmig_2_2"></a><a id="Tc_2Hgg2AdyD0uoIcMF_UJgvQ_3_2"></a><a id="Tc_x1TDfinoaEiPgnd5ceKIQA_3_5"></a><a id="Tc_PeGAfC_-6UGhSHojnAu_tg_4_0"></a><a id="Tc_n-DrQWYdA0uVeN5FFkt3Qw_5_0"></a><a id="Tc_lBEbuYDJBkSyHNlFOiZXPA_5_2"></a><a id="Tc_wkNYFPpTeEy2-BuDV4HMwQ_5_5"></a><a id="Tc_sPNZFMCciUekhXKBxpwFTQ_6_0"></a><a id="Tc_mGs_XG7xgU-CcwJ93FTvLg_7_0"></a><a id="Tc_je3MvHOQHUOAUMmfSQ_RSw_7_2"></a><a id="Tc_CmYh2mBiTUytLgjdg5KdMw_7_5"></a><ix:continuation id="Tb_U_pp5lBWRkm0F30Cjit4zw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, pursuant to the Company&#8217;s Non-Employee Director Compensation Policy, which had previously been approved by the Company&#8217;s board of directors, <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_OptionIndexedToIssuersEquityTypeAxis_mrkr_NonEmployeeStockOptionMember_gbP12LhguU6WycZv51CdaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_wmA43AUzAUezWHScjqrwMg">40,000</ix:nonFraction> stock option awards were issued during the year ended December 31, 2022 to independent members of the board of directors of the Company. &#160;Each option award was granted on May 24, 2022 with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_5_24_2022_To_5_24_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ubwm1qD4wE-HsJvlsJGJpQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_3irMql8MTkqFfXZrRews4g">3.377</ix:nonFraction> per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on May 24, 2022. &#160;Each option award will vest in <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_pGizx4L2jkuyni6fqTR9Hw">one year</ix:nonNumeric> subject to the director&#8217;s continuance of service through May 24, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, approximately <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_xLzOljk2o0KBWMLiKybJag" decimals="INF" format="ixt:numdotdecimal" name="mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" scale="0" id="Narr_RW8olUvSI0ahQB6YUCcztg">989,000</ix:nonFraction> shares of common stock are available to be issued under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s stock option activity is as follows for stock options:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_Tuvr34cA5ESb8TwOQc56hg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_qSFLuT4F50KirWdEnXUJFg_5_2">600,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_NDqiKTqFzkaHL2BrIpJ1JA_5_5">62.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_KcBeu-qijkO3TDgQskZ0Ag_5_10"> 8.3</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_pjoPOFVZ4kaleh1aYYhTrg_6_2">191,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_trE13r9x6Uml1bBE7OkBVg_6_5">28.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" format="ixt-sec:duryear" name="mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" id="Tc_Yykw1u5zSk-HcjXIKHuKTA_6_10"> 8.9</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_htmDFFO5sUaIHYoiT1EARA_7_2">146</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_eNqBR5hKZESfQKB-K7QIOg_7_5">21.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_LGt_4Llzjkied7fouUitDQ_8_2">22,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_3P476xPPRk63wmwA0eJWvQ_8_5">35.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_PUIVgJw50USJgvR21QLDYQ_9_2">768,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_kRbRBf_vCkaSYwShzztMEw_9_5">54.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_RYrho01bzEuhZBla_3GcQg_9_10"> 7.7</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_vXQ9h1Vxy0us_CQr60e6NQ_10_2">260,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9rLDiPshYUKSFp8vU9HFSQ_10_5">4.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:duryear" name="mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" id="Tc_olzjh_ml7UKB3mLFuQkm9Q_10_10"> 7.8</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_X0IKIL87aki-xejikF0r1A_11_2">142,450</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_F5P7tW5Kl0-dxXke_fLglA_11_5">36.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_tmOXODVhr0mI6-62YJL2sQ_12_2">886,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_5dw1v1mVgkmsg-bBlXo62Q_12_5">42.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_nTbCRRGurE2zXs_m13VRfQ_12_10"> 7.3</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_4FRbV667JUqE8yu0x7hpug_13_2">560,929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_M2HGGhe6AEez_uAOVRBFGw_13_5">59.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_FNNr2XOdxUikibaStALbOw_13_10"> 6.6</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2022 and 2021, respectively, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_V3awPmMKvE2Fnc3BDMIsQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_r2qUQxJW3EGLSjSt8YsLtA_4_3">4.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_gW89KH4-2UqTBX5YjVhZlw_4_6">29.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_6GVzQm_y8kyXKHZvk3wuaQ_5_3"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_LAhlytXp3EGG-6MjH6UW3w_5_6"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_8HYW8S1iVEayhXfqH9ONxQ_6_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_3W8bXC1IaEusJdKfKXcqEQ_6_6">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Cqi4gfFNAEeAqHlsHX79NA_7_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_uqwZ10hDC0qIBvEUYzrjtQ_7_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_mAYnNXAqhES-CJluVGMhuQ_8_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_mMKGddrNqkifdOdQGcmQ2w_8_6">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:StockBasedCompensationExpensesTableTextBlock" id="Tb_iUftVFiOrkenxUpmCMzfNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NGUNmIMxGkq1Z8jXaWqHoA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_0dNL2I2C9UCupNZGu6QzXQ_5_3">2,691,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_93kl4ltjMUiFOgjh_0uOaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_7sFEduXEtkCbX7_i8QSQPg_5_6">2,856,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_I0jHwwB580SqyJF3TUAQmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_Ero6_SQYZk6osZj7HbS7Ag_6_3">2,653,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbjncsNOXUKlnyjr3E54gw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_ZKTbFUQAJEimAgpFZikByA_6_6">3,108,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_u9AzQlJDGkyHBApsisTK8A_7_3">5,344,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_b-RFG0x1UE6u215S9iMQ2A_7_6">5,964,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At December&#160;31, 2022, the total stock-based compensation cost related to unvested awards not yet recognized was $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_rGiitZPzK0S7mVwkiRnSUw">3.5</ix:nonFraction> million. The expected weighted average period compensation costs to be recognized was <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_PsHUUuTAI0ilqV4ii3nqQw">1.8</ix:nonNumeric>&#160;years. Future option grants will impact the compensation expense recognized.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_4ApQ2KOHWEquq3qdBkICjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">NOTE 13: GRANT INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg" decimals="-5" format="ixt:numdotdecimal" name="mrkr:ReceiptOfProductDevelopmentResearchAward" scale="6" id="Narr_Sj7uaTRSUU2r00IJ-ZmaMg">13.1</ix:nonFraction> million from CPRIT to support the Company&#8217;s Phase 2 clinical trial of MT-401. The CPRIT award is intended to support the adjuvant arm of the Company&#8217;s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded <span style="-sec-ix-hidden:Hidden_VRXEGsrXjkaiFVGne_HW4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.4</span></span> million and $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_Z55ugQPT_kKUAhzu1ioV8A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="Narr_GfGkyIfJUE61y2F-qaThWQ">1.2</ix:nonFraction> million of grant income related to the CPRIT grant as revenue for the years ended December 31, 2022 and 2021, respectively. &#160;At December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:GrantIncomeReceivable" scale="6" id="Narr_Qpu6PQ5C4U20dmBViswShw">2.3</ix:nonFraction> million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. &#160;In January 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2023_To_1_31_2023_d7Z-oISLakWWyRl9aSgT8Q" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_0RO4AHaPX0S0Gul2cqAtzw">2.4</ix:nonFraction> million from CPRIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_9_13_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_UoBREzfn7kO2CeAdFJzHPQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="Narr_dG-lFlFoYUmsD9kMYn1Bkw">2.0</ix:nonFraction> million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. &#160;The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:RevenueFromOrphanProductsGrantProgram" scale="6" id="Narr_NZtpv8wwFkyPK5CZ6bkRmQ">0.1</ix:nonFraction> million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:OrphanProductsGrantProgram" scale="6" id="Narr_4WKJOouRJU2PLbGMpZCndQ">0.1</ix:nonFraction> million of grant income receivable. On March 13, 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA" decimals="-5" format="ixt:numdotdecimal" name="mrkr:FundsReceivedFromGrant" scale="6" id="Narr_IFzO5iLAAUWKS40tDnKgbQ">0.1</ix:nonFraction> million of funds from the FDA grant.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="Tb_KTiGIZoWKUyhsbGBMWSBVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be party to ordinary, routine litigation incidental to their business. Other than below, the Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#8217;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#8217;s interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An arbitration proceeding was brought against the Company before the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) by a broker seeking to be paid compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The broker&#8217;s claims were based on a placement agent agreement for a private placement it brokered in 2017, under which it alleged it was entitled to compensation for the 2018 transactions. The FINRA panel found in favor of the broker and awarded the broker $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:CompensationInterestAndAttorneyFees" scale="6" id="Narr_7VKdWJX5yUWfqgpRuhSObQ">2.4</ix:nonFraction> million for compensation, interest and attorney fees. As of December 31, 2021, the Company recorded an accrual of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="6" id="Narr_tcXtbo9uGkSsnWM9R7oDkQ">2.4</ix:nonFraction> million in accrued liabilities on its consolidated balance sheet and a $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherExpenses" scale="6" id="Narr_YCdXUI-mUk25YYUl54zl9A">2.4</ix:nonFraction> million charge to other expenses. On September 17, 2021, the broker filed a petition to confirm the FINRA arbitration award in the Supreme Court of New York for the County of New York. The Company removed the case to the United States District Court for the Southern District of New York on September 27, 2021. On October 22, 2021, the Company filed a motion in federal court to vacate the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 9, 2022, the Company was notified that its motion to vacate the award was denied and the broker was awarded an additional $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_9_2022_To_3_9_2022_mHWNE8BszkWyzvOf2FXUaw" decimals="-5" format="ixt:numdotdecimal" name="mrkr:LegalProceedingsBrokerAwardedAdditionalInterestAmount" scale="6" id="Narr_kHtR5sECzUm3Yyh62idz1A">0.1</ix:nonFraction> million in interest. Post judgment interest accrued at <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_3_9_2022_To_3_9_2022_mHWNE8BszkWyzvOf2FXUaw" decimals="4" format="ixt:numdotdecimal" name="mrkr:PercentageOfAccrualOfPostJudgmentInterest" scale="-2" id="Narr_9PCmwysoek6TxHBIiaV1iQ">1.02</ix:nonFraction>% until the judgment was paid. &#160;On March 24, 2022, the Company paid the broker $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_24_2022_To_3_24_2022_IbGXbqvguEioxE6sArNnqQ" decimals="-5" format="ixt:numdotdecimal" name="mrkr:BrokerWasAwardedAccruedInterest" scale="6" id="Narr_XedqbhCyEk6fgx5gSLiZEg">2.5</ix:nonFraction> million, which amount included accrued interest. On January 4, 2023, the Company was notified that the broker was awarded an additional $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_4_2023_To_1_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uUaeHZ6WLE2MqQaG64NZzw" decimals="-5" format="ixt:numdotdecimal" name="mrkr:AdditionalAttorneyFeesAwarded" scale="6" id="Narr_mLYjkSNbqk-PtMSYZ7Yg9Q">0.1</ix:nonFraction> million in attorneys&#8217; fees, which the Company recorded to other expenses during fiscal year ending December 31, 2022. &#160;The Company paid the $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tgbt7OSC3EulA327h83DEg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="Narr_k9cHjDWco0ay05dINlzZLA">0.1</ix:nonFraction> million on January 9, 2023.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_yXX4d9zdhk2Lny8PtLfXqA"></a><a id="Tc_gGLLW7IjHk-RVcJUnZTtmQ_1_2"></a><a id="Tc_R-65Zr_kt0y1qoOFDbsmxA_2_2"></a><a id="Tc_e_Puv7Cx_ESc2YYlxhCDSQ_3_2"></a><a id="Tc_iLEZnhhVmEe16GUDt7L_kw_3_5"></a><a id="Tc_Ofi8StoGb0aOGL8VfUNWnw_4_0"></a><a id="Tc_qpAlBlMl3U6h8fTf3bw-Xg_4_2"></a><a id="Tc_dn_uRv88i06M35iJvatqYA_4_5"></a><a id="Tc_bzLj00JW-E-papmE5dzRog_5_0"></a><a id="Tc_0sgwjbX4GkW0Mq0xRGHedw_6_0"></a><a id="Tc_U7S8aA0P_EenVrLn398A0Q_7_0"></a><a id="Tc_birWI4YW6kiZ5kD1SRTZUQ_7_2"></a><a id="Tc_FjbiOCt2Eky8c8LvTKMmsQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_sr6KH0nLYkKURj-H8NOxCg" continuedAt="Tb_sr6KH0nLYkKURj-H8NOxCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;15:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth related party transaction expenses recorded for the years ended December 31, 2022 and 2021, respectively.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_GkU9aKqiKEu8Zelg-vYtcA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_BMzNUjdDhUG_b5P76LRATw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_CGxQOTIfp0itzuoogcD3QQ_4_3">1,142,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_awMWjIqo90CWdC9K0cfcDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_z0oUFz8asEKPdXockykE2g_4_6">2,851,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bio-Techne Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_92UkqyWHCkqZKAb3ohfj-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_JwhoY43LdUWoPKre99hsxw_5_3">101,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_FG_G8klQXUmj79kiu1yNMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_OPfm5aHVjUuaOxcY2iKGgQ_5_6">306,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_8-nrYuOdiEO8hicagC8Wcg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_2d0ofgc71UCFyfvJWcuCCA_6_3">265,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_I0FgPzQc2EedkO5jGv2oEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_waQ19361TUufIFTPxvJvBw_6_6">280,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_g36FCfhvP0WjdlrSD9cBTw_7_3">1,508,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_JKHuH73Qak-zClHM2CBdig_7_6">3,437,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">$8,600 of related party transactions are included in accounts payable and accrued liabilities as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160; 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Bio-Techne Corporation</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Bio-Techne Corporation and two of its brands for the purchases of reagents, primarily cytokines. Mr. David Eansor is a member of the Company&#8217;s board of directors and was serving as the President of the Protein Sciences Segment of Bio-Techne Corporation. Mr. Eansor resigned from Bio-Techne Corporation on March 1, 2022, and as such, two months of transactions in 2022 are included in the table above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Wilson Wolf</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Wilson Wolf for the purchases of cell culture devices called G-Rexes. &#160;Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sr6KH0nLYkKURj-H8NOxCg_cont1"></ix:continuation><a id="Tc_4Gy-8HwIgU24arHzOSZ9kg_1_2"></a><a id="Tc_zslQ4KyrgkyZXYadX1uM9w_2_2"></a><a id="Tc_T9VlV8Z6k0iX7LsLfNB1Lw_3_2"></a><a id="Tc_9VhtWboedki6089fvbayCA_3_4"></a><a id="Tc_EV3opGh7r0Cq8_7LZJ6uPg_4_0"></a><a id="Tc_7bwafjDPvkqdaubI4iu4dA_5_0"></a><a id="Tc_3PC22zIojUq6p2YjjQhTHQ_6_0"></a><a id="Tc_wgKYQVwwQU2sTrpMUMCwlw_7_0"></a><a id="Tc_I7Ux3hoggUqsOd4ptw_WXA_7_2"></a><a id="Tc_tE30BM4u5UOPzp0OAA0DLw_8_0"></a><a id="Tc_wJXdt8Th2UCV19zl3ee3Jg_8_2"></a><a id="Tc_Gls8nrveD0m-TnqxbmKHPw_9_0"></a><a id="Tc_mmQzF3tZYUWwQUG6eALpFQ_9_4"></a><a id="Tc_OknU71qgPEexgqHc6oGANQ_10_0"></a><a id="Tc_4Izgar_Jpkut7CH82iR8ug_11_0"></a><a id="Tc_ox1iZyMXO0CgJe7e7eMHSA_11_2"></a><a id="Tc_vTm86SmMXkq4R48YnB1wVw_12_0"></a><a id="Tc_pExbMRDptEGLqmms_xm7iA_14_0"></a><a id="Tc_zC637ObHqEmBu-Y50ApHgg_15_0"></a><a id="Tc_UlCoDhqxTEuNvELLwLKUxA_17_0"></a><a id="Tc_iwrJ18xEe0GIhb2NshCikQ_18_0"></a><a id="Tc_IZf9gtBhskO-Q-YvYPMv2g_19_0"></a><a id="Tc_Nk1PQni3ME-PUWK5s9PiMA_20_0"></a><a id="Tc_5ac5TUKWxE6e1Q4jkwJTWg_22_0"></a><a id="Tc_7qDoJjONxEuLn4uIVvoVDQ_22_2"></a><a id="Tc_ohDpQ8ySYk-tmL_NnpfIWw_22_4"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_1eP1X43JYkawUMU9gFmpfw" continuedAt="Tb_1eP1X43JYkawUMU9gFmpfw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;16:&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has no income tax expense due to operating losses incurred for the&#160;years ended December&#160;31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December&#160;31, 2022 and 2021 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_DOi5uykLEESKu9zHUkh_yg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_zVAeMMbzR02wkmW1tVvBdw_5_2">30,072,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_E_AhqYK2p0uakb4QNiCpcw_5_4">29,087,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:Deferredtaxstockbasedcompensation" scale="0" id="Tc_gJoUK7cs_kSD0v9ulMCFfg_6_2">5,642,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="mrkr:Deferredtaxstockbasedcompensation" scale="0" id="Tc_rZNnHoUNR0OzBFlLoADNqQ_6_4">5,599,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" id="Tc_fVts4xzA7kWUMNnoghbKfg_7_4">510,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="mrkr:Deferredtaxassetslicenseagreement" scale="0" id="Tc_fKEp_kx72kitSUIWUEiXSw_8_4">127,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_fKRZK4OsF0K0djKqCBviqw_9_2">4,818,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_sIUmRe-nNkWDd6rkSu-MuA_10_2">733,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_Gd5G5sqSs06kpm7PgjM5gw_10_4">733,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Charitable Contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="0" id="Tc_b2kKwRsuz0WRLdGCr4PMtQ_11_4">8,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating Lease Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxAssetsOperatingLeaseLiability" scale="0" id="Tc_vD4bJhKkSkaEYys6kPbz1Q_12_2">1,611,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxAssetsOperatingLeaseLiability" scale="0" id="Tc_ZtNugsbFnkObAcy2TVn3qQ_12_4">2,514,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_oJR6XOiCPkCXV14SxrPggA_13_2">42,876,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_CQQXoEtcQ0eV6uShmRVYbg_13_4">38,578,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_JFxteyQcOkiqboMoFXHdIw_14_2">41,413,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_YGtMvzq8D0GuZKVOJXRyCQ_14_4">36,401,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_vu9EHr72QUCaz03anJabJQ_15_2">1,463,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_XsXufGOM-0OJNdx_kp5PCA_15_4">2,177,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxLiabilitiesFixedAssets" scale="0" id="Tc_l7WhHQiBhEWVdsleNH9NuQ_18_2">304,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxLiabilitiesFixedAssets" scale="0" id="Tc_SWyXUiyU_UWSPHrHpsDDzA_18_4">94,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxLiabilitiesRightOfUseAssets" scale="0" id="Tc_m4BhfXKNLE6K-b6wYuQs4Q_19_2">1,159,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="mrkr:DeferredTaxLiabilitiesRightOfUseAssets" scale="0" id="Tc_JJlFjjgZnEeLy4xXhoMJ_g_19_4">2,083,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_PC1Q8cfig0ydsuiuSGDUNA_20_2">1,463,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_gVOpdSUpyk2-zFmVNM9kAQ_20_4">2,177,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not, that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2022 and 2021. The Company has research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Narr_X8mcpnUFXEy4lNr6GTi1fw">733,000</ix:nonFraction> available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company has approximately $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_wFYWw1ClrUiD5vQsZLf__Q">135.2</ix:nonFraction> million of federal and $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_ozF178gOzECqvGfPuzLyfg">38.5</ix:nonFraction> million of state Net Operating Losses (&#8220;NOL&#8221;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="Narr_N_fIbzu1XEuU7Ow-I6Tnsg">41.6</ix:nonFraction> million, if not utilized, will expire between <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:Taxcreditcarryforwardexpirationyearrangestart" id="Narr_fRDd2dDpGUuKVgzWkkGLHQ">2029</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:Taxcreditcarryforwardexpirationyearrangeend" id="Narr_BAmdtg0x60qVcup3P18C3Q">2037</ix:nonNumeric>. The federal net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_G1H72RYOhku1flLkvnmwxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_xepOYQ0ziUWFRpWQCW1OGw">93.6</ix:nonFraction> million generated in 2018 and thereafter are subject to an <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_E_6jM-m13kOR5Fzj9eeTUw" decimals="2" format="ixt:numdotdecimal" name="mrkr:OperatingLossCarryforwardsLimitationPercentage" scale="-2" id="Narr_ncKJrrp4rkOUT3bS13RGqw">80</ix:nonFraction>% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_UwJZYpPUWka8KcHH3ef7ng">21.9</ix:nonFraction> million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_l66B3TClFEmlIWsk1ybpMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_BW1ONTvZmkeQ963dIb3a3w">16.6</ix:nonFraction> million generated in 2018 and thereafter are subject to an <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_75w7V3-2uEiEHBbWok-lEQ" decimals="2" format="ixt:numdotdecimal" name="mrkr:OperatingLossCarryforwardsLimitationPercentage" scale="-2" id="Narr_-ykRHMZHUkmiDFV8SFMu9g">80</ix:nonFraction>% limitation on taxable income, do not expire and will carry forward indefinitely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#8217;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_3Mk2bXSkc0CvfJZpplaLPA_1_2"></a><a id="Tc_7mQZuS8-9USwCWexJGxPSQ_2_2"></a><a id="Tc_svDXJoFzpk-zX6VQDjNtmg_2_6"></a><a id="Tc_yxZKdRVGYUOmv9bwkf44aA_3_4"></a><a id="Tc_xjRFvw9qpUCZ2PhHuPhuMw_3_8"></a><a id="Tc_F4aLfuZTHU2Ew7Lwm1F8EQ_4_2"></a><a id="Tc__mxRIWWQR0ivo5e0tNyCwQ_4_4"></a><a id="Tc_ag2xar_qWEmQ5glzaLY66w_4_6"></a><a id="Tc_Eklhe-ZCx0Sfbunwir4ibg_4_8"></a><a id="Tc_BO9B5VOIq0yJfxsWU5MyXQ_5_0"></a><a id="Tc_TiZ4oPY9b0Cdr0RMPuNXSA_5_5"></a><a id="Tc_K1Z1IA4X4k-eG07FxH_q8w_5_9"></a><a id="Tc_UcE3jiswdUmIFvKGLCUgpg_6_0"></a><a id="Tc_NG0LE2vGSU-6Ret03FeAoQ_6_5"></a><a id="Tc_N68SMn1-6UyDVDmSltK-PA_6_9"></a><a id="Tc_-JDshRVFh0mgn2njtL0vtw_7_0"></a><a id="Tc_mqyIOvZyaEWLiLsPcJBxhw_7_5"></a><a id="Tc_nImsLE9vU02JaPUwAcULQQ_7_9"></a><a id="Tc_riUi-EG96kWMll0EVv7zGg_8_0"></a><a id="Tc_BDE6MEdwhUCKuCBnqba9RQ_9_0"></a><a id="Tc_yO-LQVN7REqMcEdNnzdufA_9_5"></a><a id="Tc_NaFTeTzX70mK-8wWxI16bQ_9_9"></a><a id="Tc_vdLr3deb00KhO9VoGWUpSA_10_0"></a><a id="Tc_NtSL7tOqmU63qF1WYl-qgw_10_5"></a><a id="Tc_WVdMlql2y0OU8t0ryYVazg_10_9"></a><a id="Tc_G1jUoReC-UaUCCCHDnJbKQ_11_0"></a><a id="Tc_94WarpRRDUG5UHqQC62neA_11_5"></a><a id="Tc_bPG2NsjEtUOWMEj__pp2Dg_11_9"></a><a id="Tc_1QANFgIXMkS1V46FWXCqXw_12_0"></a><a id="Tc_bM3rIIj5Hkid9Vkpk4Eisg_12_2"></a><a id="Tc_H6nTgCrJ8k6chW01LvzQ0w_12_5"></a><a id="Tc_jSdILhUo6k-djUcmu4BmTQ_12_6"></a><a id="Tc_Z41krRJC1Uu1O6W9UBQ78w_12_9"></a><ix:continuation id="Tb_1eP1X43JYkawUMU9gFmpfw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s income tax returns for 2018 to 2021 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;years ended December&#160;31, 2022 and 2021, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" id="Tb_a24k_4JGHESFBWBNJARvMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_9T3b8FvooEWNGxN8sHdsuw_5_2">6,285,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_x4COmPTQYUOqrihW8HVu7A_5_4">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_H2_eGqmNcEKsdLlKLRPYFw_5_6">8,795,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_XIQCgtRcW0uLFbE7nONjmg_5_8">21.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="0" id="Tc_9ND1eF7AcE6-lD8qsiYi1A_6_2">44,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_xbymfHUw6Uexa6N6yfz7bw_6_4">0.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="0" id="Tc_bx-xWJzuoU2TumC0iJ5b0g_6_6">48,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_NiGXiEbL20e3_LP9VLGB0g_6_8">0.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="Tc_W65284MRKU6AFpmLsir1Ew_7_2">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_oxAwDM5nGEC8Hf2woOJ-Zg_7_4">0.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" sign="-" scale="0" id="Tc_sSnQElU_2kKzAIh0iGbF0Q_7_6">291,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_UFWiuo6wuU2TCOVLZ6Ht-A_7_8">0.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent Differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="mrkr:Permanentdifferencesotherpermanentdifferences" sign="-" scale="0" id="Tc_252dlflHrEKFjjKHMpPiqw_9_2">288,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="4" format="ixt:numdotdecimal" name="mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" sign="-" scale="-2" id="Tc_--dOUs4CmkCWwENv_pguuA_9_4">0.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="mrkr:Permanentdifferencesotherpermanentdifferences" sign="-" scale="0" id="Tc_B3yP809bk0isPj9vxDW0zQ_9_6">262,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="4" format="ixt:numdotdecimal" name="mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" sign="-" scale="-2" id="Tc_ccBGHfDCJkSFigYILWUvLQ_9_8">0.63</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="0" id="Tc_Z28SDEHVFk2aiGD3Vb3bHQ_10_2">5,012,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_rYQx3A8T1k-QpEOXRNCzpw_10_4">16.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="0" id="Tc_nrru4mLkxkOobhe2abUT7g_10_6">8,769,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_vr8z5yWlWUqxmKbdwPZ2BQ_10_8">20.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" id="Tc_HdzLMmD2i02c1Ev0inLhxQ_11_2">1,019,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_FPQdUZorikGULFxrSGaroA_11_4">3.40</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="0" id="Tc_O5bgBxOj1kajXeGkajbUrg_11_6">103,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-<ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_T-kkpEiHuUmFp0Hd4zbDvA_11_8">0.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_3f5VdKBO5E6pugyY9XhRuQ_12_4">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw" contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_Dy9FpzwxhEyoxVsEnMEnww_12_8">0.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2022, and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_ShOaj_8Yv0miXyaQVTieoQ"><ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_Kd2qQpk4r0SqKamcx5RziQ">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. <ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_LUqwjGKDhke7W59GQEAO2g"><ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_5YABJ71os0qSj-QV0ox7Cw">No</ix:nonFraction></ix:nonFraction> amounts were accrued for the payment of interest and penalties at December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.</p></ix:continuation><a id="endoffinancial"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_vBCDOLlWQEi5QjGlcRh3IA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE 17:</b></span><b style="font-weight:bold;">SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc., notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 14, 2023, the Company signed an agreement with AlloVir, Inc. in which Marker will collaborate with AlloVir to optimize certain aspects of AlloVir&#8217;s manufacturing process. Under the terms of this agreement, Marker will conduct a number of process improvement studies and provide AlloVir with the results of its findings. For its work with AlloVir, the Company will receive total compensation in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw" contextRef="Duration_3_14_2023_To_3_14_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_AllovirIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1XuOmQ5XPUeNbdcsl4Y23g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Narr_ysDqnwB_ekCCstdwWW1Qaw">400,000</ix:nonFraction>, estimated to be fully earned by the end of the third quarter in 2023.<br /><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>mrkr-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 11:51:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUBSIDIARIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marker Cell Therapy, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GeneMax Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GeneMax Pharmaceuticals Canada, Inc.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>mrkr-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 11:51:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>We consent to the incorporation by reference in the Registration Statement of Marker Therapeutics, Inc. on Form S-3, File No. 333-215258, No. 333-220538, No. 333-228059, No. 333-232122 and No. 333-258687 and on Form S-1 File No. 333-268979 and on Form S-8 File No. 333-223900, No. 333-228056, 333-239136 and 333-266797 of our report dated March 22, 2023, which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Marker Therapeutics, Inc. as of December 31, 2022 and 2021 and for the two years in the period ended December 31, 2022, which report is included in this Annual Report on Form 10-K of Marker Therapeutics, Inc. for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Marcum LLP</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marcum LLP</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Houston, TX</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 22, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>mrkr-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 11:51:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Peter L. Hoang, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Date:</font></font>March 22, 2023</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">/s/ Peter L. Hoang</i></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.01%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.98%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Peter L Hoang</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>mrkr-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 11:51:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Michael J. Loiacono, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>I have reviewed this Annual Report on Form 10-K of Marker Therapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">c.</font></font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">d.</font></font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the Audit Committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a.</font></font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">b.</font></font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Date:</font></font>March 22, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:51.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">/s/ Michael J. Loiacono</i></p></td><td style="vertical-align:bottom;width:48.77%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Michael J. Loiacono</b></p></td><td style="vertical-align:bottom;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Accounting Officer</p></td><td style="vertical-align:bottom;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>mrkr-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 11:51:31 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">18 U.S.C. Section 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10.55pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6.15pt 0pt;">In connection with the Annual Report of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter L. Hoang, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 22, 2023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">/s/ Peter L. Hoang</i></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Peter L. Hoang</b></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.2%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>mrkr-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/22/2023 11:51:32 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">18 U.S.C. Section 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.2pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10.55pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6.15pt 0pt;">In connection with the Annual Report of Marker Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael J. Loiacono, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.15pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:14.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Date:  March 22, 2023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">/s/ Michael J. Loiacono</i></p></td><td style="vertical-align:bottom;width:48.79%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Michael J. Loiacono</b></p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:51.2%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Accounting Officer</p></td><td style="vertical-align:bottom;width:48.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>mrkr-20221231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !@ 60# 2(  A$! Q$!_\0
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M@H**CGE$$$DI&0BEB!["OD;4/^"D/@_3M0NK1_#&KL]O*\3,'3!*L1G]*]7
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MC111H.BJK$ ?D*[+_@FQ\-/MNM^(?'5U%F*S0:;9L1UD8!I&'T7:/^!URO\
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MY8:.#JT9<FB2UZ;:FG\ _A/#\%?A9HWA5)4N;FV5I+NYC7:)IW8L[8].<#V
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)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>mrkr-20221231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $3 >0# 2(  A$! Q$!_\0
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MZT?;?]C]:^1H/B3XZ>RT^!K2\&D-\3WT\^(1JZEW@&I2)]E\C&_R\ 1[<XP
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M:/MO^Q^M?-$_[4^N/_9BV?AC39Y]>NH(])BDOG0PQ/>"T(O/D/ERAF#A5R"
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MZ[8,Q&X9 V$X! '4GOTJ_HNH:WH/B*\\0^'+G3-<-Q L%[8R!H6N A)5@X)
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MRQ/<C%<&)I*I*+ET.RC3I2@Y5%=G!2^(;#2)]3\/WD\FK1WY^U17NEQ!@@(
M(=<X4@@'@G((Z5P/C'Q]I/PYU?2M5DN/MLJ2)(D<]G*H^0DE2A 5]WR\[LJ1
MD5[%^T+JVE^%O#VB:PJ0B\%S+!!I=BBK+>^8 6*(HY8,JDGTS7SEJ/AN\\6W
M OO%(^U&=5-M:6K%H+5,Y* CJ_&&)]Z\FGA84*_M;M)[^;^X]JIB'.DJ<$M-
MO)'TWX4^.>E^-_#4&NRV.HV6IW"JD]E;Q^9$LI.V-#(V I88/H ?6LCQ=XO.
MK^.##=:3!!,=/%LZ:E,/*MLDD2"0*1M/W>Q)%><W"W&@>&KIAJT]G'*D)9'"
M_*T7^J4-C("G'Y5WOP2^*OAK7KN?0]/U>YU[QGJ,K37SJK?9TAAR 5DP%$>,
M8'4EN:[/XZ?+L9\RH1O'X_EYCM#UEOA_;7-QO.MFP@.Z+3F,@DXP&=L81>_S
M<\<9IF@V4GCF?4M4U:6[MKR6<>?9V\OEQ(0B[4!P&X7 .<<UZ9X^UZVM/!NO
MV<\\*ZB8-HL_.5I1G'(4')89R!UXKRF&]O4OY_[%U"ZURPDV2RWQ3+O,1MVE
M@!N&U1TZ=*K+,)2P^)=1KFFU:_XV[(BE0IU(WJQNNSM^1V/@.QM_ OQ7T#4+
M.,RQ:LS:3.D[F1H]P+J\9;)7E,,!U!]J^G*^?_@QH-UXW\4VOB:ZCV:/HF^.
MU8_\O5X1M=U_V$&5SW8GTKZ KW:S3G[IYF*]G[5JDK(N+_QZ?\!JG5Q?^/3_
M (#5.LF<8445PWQ9^)'_  KW1(/LD<5SK=^YBLH)SB-<#+RR8YV(.3CJ2!WR
M,YSC3BY2V1M1HSQ%14J:NV=S3HSB12>F17S%H7QX\1K<12MX@M-9W'YK:[T]
M;>W89Q\LL?S+[%MP]C7O7@7QM8^/M!&I62R0,DC07%K-CS+>9?O(V.#Z@C@@
M@US4,52Q&D'J>CC<JQ6 2E66G=?\&Q\>Z?XCM?"VGWOAKQ&C6=[I]].RIN$;
MH3(W8CY@00<CUI3XEO\ PN%\17^B70\,:NBZ?;L2$FE906+I&V"5PQRW2OM>
M]T?3]2ECEO+"UNY8_N/<0)(R_0D$BO+/VG?A[=^._ $=UIT+76J:-,;R*!.6
MEC*[954=VVX('^SCO7-5R^E5C-2UYNGXGG8:H\/656+U/!/!^LZ+;7J74DVH
M*B F)9;&0<=B2H(/'I7>_!+XO6GA+7M1TK7+$Z?8:_J;W-MJAD^2.1@J)',I
M'R;@HPW3)P:^?[;Q//-:VUO#*R)#E6"9#9ST8=01R,5UF4U'P_-_:4>()$8.
M'Z[.Q^OI7DX>E]2K.LKMO37MY:(^BKS^MTE2>B6OS/<_CC/=^ /B?I7C-[:6
MXT.\TW^RKR6-<K;NDA="Y'0-O;!Z97WKRNW^(MJOB\SZ>\^LS7%SOBM['$L\
MV3\J!5SCT],5Z[\._C[H&G?#[0].\6RZHFKQV2QW(N-*GD\T#@%B$(8E0":J
M^)/C1X;%E_9GPYL(+?Q%JF^ 7K:8;);6/&7E)**9&'\*C//)X%>A6RNABZ[K
M7UDK.W4^?ISD[0CJ<)9_:OB3=7&LZJ;G2)87DTX:;;2@>2(Y"&#/@[B6SDCC
MTINH:+:^"-6T7Q58Q--<:3>1.;>ZE:6.1&8(V V<. V0PYR*O7>F3^'?"]K9
M:1YA6#"LPYD8<EF/J2>3]:L^"=#O?BGXFL=(GA9=)TFXCO-8G;@,RG=#;C_:
M) 9O0#WKZ:GAZ.$H*C3C9):'M5:&'HTW*<%S6WMJWZGU(<9XSCMD8-6K+H_U
M%5B2Q)/4\U9LNC_45RK<^=*\G^L;ZFFTZ3_6-]33:0!7)_%CQ=-X$^&WB+7K
M9!)<V5J6A##(WL0BDCN 6!Q[5UE<E\6?"-QX]^&WB'0+1E2[O;8K"6. 9%8.
MH)[9*@9]Z /G71]%\,^#[#3=,DT>#4)6@26:[NHU=F+#)(W X&<\# %0K/#H
M6CZUJNEVD5G)<:@T64C"^5&I"KP.!CG\3FL_PUJFH^+M;7P_JUJ=,ETYS:S3
M*JFX$D8YB5P2-HQRW7M6MXHDN_ VJ):V.-2MM5$MQ(NINSE)!M#$-_$#D$J1
MQZ\U\%BZ527[MZRO=IO=?E_PQZ64UH4<2W4W::3[,JSZXVL>$-2CNU%Y,"D<
M#R?\]G.%((Z$'#<>E9MU)X>T:^BLM4DFU?4@H\V6XS+@D=2#\JY] *JZCXBO
MH_L"RI8):0W*7!L[.(QO)M[C+')'7'?%5M7\.Z3XIU634[77H;0R[?.AF 5E
M(&. 2"#@=*^XX8HJCAZKC;GE+:^R2[>MS'/:KJUH7ORI;^=SJK#04O=6L-+M
M+^.UT2_A=Q'+%YZ*Z ,OEAC\N03P./EKI_"?A?PC<%K=&EU:926S>$^6Y']V
M,87'U!/O6#X<M9'OM,NK"Q^W:'I8>+S'G6$S2LNW]WOP'V@G/('S<9Q6UH/@
MW5;;4M]A#)I<+ JMU>R12R1*?^>:H6#-V!8@#/0U\1Q-*@L?55":BK*_*TES
M==M>URL)5KRH1C4;?KV.,\::1'9>(]:TO3HX;+18Q'/,P0?N9&7<R1*.!G@Y
M[$UEZ;X?T#5;"2#[+YP9=K_:&+R8]<YX_#%7K?4M-BN=7@DO6E1KV?\ >7KY
MDD7=@,6/WOK4%K>6%C<Q6.BV\VK:M>/Y5O96V7DE8<XST '4D] *^YP$'3PE
M*,W=J*U?H?!8OVE3$U%3BT[Z6_,^D/V>_$EUXC^&=HE_+)<7NEW$VERSR\M+
MY1PK'_@!3\J])KA_@YX&O? '@P6.IW$=QJ=U<R7UUY(_=QR28_=KZA0H&>_-
M=Q5O?0^LAS<JYM^H4444%EJ]Z)]356K5[T3ZFJM-[@%9^L^(=+\.P)-JNI6F
MF1.=J/=SK$&/H-Q&3["M%1N8#U.*^'_B#\4Y->\6-KLL0N);@DV*3*&6SLPQ
M$:H#QO?!=CZG'0"N#%XJ.$AS-7N>[E&53S6LZ<79+<^U-+U>PUVS6[TV^MM0
MM6.!/:RK*F?3*DC/M5NOB'PI\4KK1[J;6-+V6NIVP\^:-%\M+J%"-T4JK\K
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M2Z*\BTC]I?PSJNHZE!*?[(MM-UR]T6ZN=4$D /V>!IFECW1@."$/RYR ,\Y
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M$BK>C?M#>%M2T6ZU>^O?L%C'-!!$ABGDN6>2UCN"K0"/S%*K)DX4C: Q(!X
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M;V\MT)!.7<@F93YTN%<8&\]<#'M/V>/^X*/L\?\ <%.S \%\>?LYQZR=<N=
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MSC) XXH \/\ &_[?4%I=?#'Q;;:?K?A_P-J-]JEI?07]E%YFK/#;D1);MN/
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M?@_87OQ+M-9&O6^A1ZO+J2V,:PZJLEX;5#;K&>/WC(G(4=3VKTCP3^VCX?\
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M?'W>:U]?_:M\#V&H:19:1<7/B.YOM9@TEX].M)I#$LA<?:!M0[XPR;<KP3D
MY!KHU^"FDKH5OI7V^]-O!XG;Q2&.S<TYN6N/*/'^KW,1ZX[YKE-'_94T'P[#
M#%I.KSZ:EEJ%O?Z:UMIUFDEJ879E1Y!$&N!\[+F4L0#D<\T: =)J'[1OPXTJ
M[U:VNO$\$<NEN$N<0R,-WG+"1&0I\S;+(B-LSM+#.*N2?'7P1;7-S!<ZRUDU
MM T\TEY:30QIM02/&79 OG*A#-%G>!U6N5'[+/AN+4-3EMKZ6SM+R^345@M[
M&U26*47B7C_Z0(_-=6EC^Z[$ ,0.@Q+XU_9ZM]:7Q%<:;J+,U\UY?V>C:@BM
M8PZE<0-!)<LP7S#E';"DE5+%@,T: 7[G]I[X;V/VE;W6[G39K:7R;BWO]+NK
M>: [ Y+QO&&551E9F(PJNI) 85;7]HOX>&[O(&\0B);7[2)+J:UF2V9H&Q,B
M3% CNO\ =5B2"" 017FG@[]DICX0TFS\2W=A;ZUI4LJVEY;VD&IR-;RI$)5G
M>YAVRRL85/F^6K*  /?KM>_97\)^)M"@T?4;N^GL(=0U'4A"1'M:6[8LP(VX
MVQL05&,': V1FC0#='[17P_?2;;48M;EN8)VE4QVUA<33P>5CS6FB5"\*IN7
M<S@ ;AD\U=O_ (Y^!-,L)KZY\101V45W/8O<>6YC\Z&W-Q( P7! B&X,.#P
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MY89!(->8JKC5A55^7\#TXI5*,E;5_>92>/=4&EI<W7V.?3C.;:VUU]RL(P<
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M+:1IA<,\,;&4$'>2HYR..?;BOHK-/4B<.5A)_K&^IIM.D_UC?4TVH,@HHHH
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MI:7/ERV$<31P_90N%^08 "DC"AB3@9![:OAG0;/_ (2#4I;ZPFBN_,$UG#J
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M8?\ "OM*E))7/YSRG/ZF+Q"HSN[^2T]+?D[NW737Z)HHHKD/O@HHHH ****
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MOXP^')M;TJ*>$.RVWG1S"-2S"*10&< <G:54X';-?.L_A34K;8"(7A/'VP2
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M[IYDCML4]RHR?6CXY>/?'VB:WJW_  BUY)IUEI/@]_$*P'2EN6O+M9MHMV+
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M<@X/<$ @]01110!4\*>!M!\"V#V.@:7!I5L[^8Z6X(+MC&6/5C@ <GH*VO+
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3[^M%%%D ?9X_[OZT44460'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>mrkr-20221231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %< J # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**XOXR
M?$7_ (5-\-=;\6?8?[2_LU$?[+YOE^9ND5/O8.,;L].U;4:,\15C1IJ\I-)>
MKT1G5J1HPE4F[)*[]$=I17B?P6_:<T[XL_"_Q'XPGTPZ*-!,INK1I_,(1(A(
M&#;1U&1TZ@UF_LT_M4K^T/JNNV0\.G0_[,ACFWF[\[S-[$8^XN.E>K4R;'TH
MUYSIV5%I3U6E]NNORN<$,RPE25*,9W=2_+H];;]-/G8]^HIGFH4W[UV?WL\5
MY?\ $KXWCX??$OP%X3&D_;QXIG:$78GV"WPR#.W:=WW\]1TKSL-AJN+J>SHJ
M[LW\DFWOY([*U>GAX<]1V5TOO=E^+/4Z*X+PW\9-%\6?$SQ'X)TZ.>2_T"%)
M+RX<!8][' C7G)(').,5Q\_QJ^(*>"3J\/PCU*75AJC67]DF\ ?R!'N%QNV=
M"WRXQU'6NJ&68J<N1Q2?N_%*,=)*Z>K6C6OEI?<PEC:$5S7;6NR;^%V>R?4]
MMHKY0\/_ +9'CCQ5K6L:3I7P:O[W4=(D\F_MXM2!:W?)&&_==<JWY5WG[07[
M4%O\!?#_ (;N;K0FU#5]8!<Z9]I\MH%5 7+-M;.&8+TYY]*[I\/YC"O##<B<
MY[)2BWM?6S=E;6[LGT.6.;X.5*5?F?+'=N,EUMU6NNFA[G16'X'\767CWP?H
M_B+3SFSU.U2YC!.2NX9*GW!R#[BO%OC'^V'H_P (?BOIG@V?26OXY! VH:@M
MP$%D)&QRNT[L+ASR."*\_"Y;B\97EAJ%-N<;W7:V^_\ 5SKKXW#X:DJ]6=HN
MUGZ['T+12*P=0RD,I&01T->:_'3XWV/P3T+3[B33;G6]7U6Y%GINEVIP]Q*<
M<9P<#D#H3E@,5S8?#5<75C0HQO*6R-ZU:GAZ;JU7:*/2Z*^</#O[5NN:9XZT
M3PS\2/A[=^"'UR40Z?>_:A/$SDA0K8 QRR@X.1N&1CFOHQIHTW;G5=HRV3C
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MVAYE^TQXID^(GQ4^&?A6QTO4=?\ !&IZ7_:J:+ILXL6U#<)"H)?;@*J*<'!
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M*C7DXQJQ<4TKVO*+VNNB[GNXW#XB<*$J24I0DFTW:_NM;V?<A_;6\::QX(^
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MJU*?-*G&GKI\44KWLVKWWLWKU/9RK#^TP$Z52-E-STUV;>U[.UMM$?FCXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-3#2IQE.Z:C+ETZ[ZKRT/6A74Y1C9IM7_KS.KHHHKC.@**** "BBB@ HHHH
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M$_X0W1_^?0_]_G_^*H_X0W1_^?0_]_G_ /BJ -NBL3_A#='_ .?0_P#?Y_\
MXJC_ (0W1_\ GT/_ '^?_P"*H VZ*Q/^$-T?_GT/_?Y__BJ/^$-T?_GT/_?Y
M_P#XJ@#;HK$_X0W1_P#GT/\ W^?_ .*H_P"$-T?_ )]#_P!_G_\ BJ -NBL3
M_A#='_Y]#_W^?_XJC_A#='_Y]#_W^?\ ^*H VZ*Q/^$-T?\ Y]#_ -_G_P#B
MJ/\ A#='_P"?0_\ ?Y__ (J@"V_A_3I->CUMK.(ZM';M:)=D?O%A9@Q3/H6
M/X50OO 7A[4QKHN]'M+@:ZB)J8DCS]K"+L0/Z[5X'I4G_"&Z/_SZ'_O\_P#\
M51_PANC_ //H?^_S_P#Q5:QK5(N\9-?/L[_GKZF;IPEHXK^M/RT.:N/@%\/+
MKQ%%KTWA/3Y-8BDCE2]96,@>/&QLYZC:OY5J6OPH\'6/B>\\1V_AK38=<O%=
M9[]+=1*X88?GL6'4CD]ZT?\ A#='_P"?0_\ ?Y__ (JC_A#='_Y]#_W^?_XJ
MMWC<3)6E5D]+;O;MOMY&2PU!.Z@M[[+?OZG*Z1^SO\-M >X;3_!VF6IN$$<N
MR,_.H=7 //9D4_4"N@?X;>%Y%ME;0K-A;:DVL0YCYCO&8LTX/9BS$D^]6O\
MA#='_P"?0_\ ?Y__ (JC_A#='_Y]#_W^?_XJB>,Q-1WG5DWYMA'#4(*T8)?)
M&+JWP6\"Z]I&GZ7J/A73+RPT]WDM8)H PA9V+/M[@,Q)(Z&M1OA]X;:VUFW.
MBV?D:Q$D%_$(AMN(TC\M$8>BI\H Z"IO^$-T?_GT/_?Y_P#XJC_A#='_ .?0
M_P#?Y_\ XJI>*Q#5G4?WOO?\]?74I4**=U!?<NUORT]#GK;X$> +/Q/#XB@\
M*V$>N12B9+Y5/F!QT;.>M=Y6)_PANC_\^A_[_/\ _%4?\(;H_P#SZ'_O\_\
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MDF1C[L2<UDW_ ,+?"6IZ-I^DW6@V<^G:?;/9VELR?)#"ZA'C7V*@ CT%7_\
MA#='_P"?0_\ ?Y__ (JC_A#='_Y]#_W^?_XJMXUZT9<T9M/U?H9.E3DN5Q5O
M0K:[\./"_B>5Y-6T&QU!WLCIS&XA#9MRP;R\?W=P!'H1D8K#N?@#\.[OPY:Z
M#+X0TQM'MIFN(K018596&"_!R6( &3Z"NE_X0W1_^?0_]_G_ /BJ/^$-T?\
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M@Y["NQUC]G#2+_QSX-\766KW^E:WX;M8K)9K8)B\A0;0LH(YRI8''9O85/\
MK+@X4ZE)U')RYW?WW'6G&,>92;<E=-:MVW6@GD>)E.$^1)+ET]U/2;;LTDD[
M-/1:^IZ7XD-J/#NJ&^222R^RR^>D.=[1[#N"XYSC.,5\\_LX:F-1\8V:7\]Q
M=SVNE7%GI"^?:2+:6<<D!*.8(T+L5> AVR,JX'();Z-U=[J+2;U[)5:\6!S
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M)ZS_ -_(O_B*K']O[P+_ - 77O\ OW#_ /'*0_\ !0#P*/\ F":]_P!^X?\
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MGF5H(6"_@)<UI_9?$B_Y=S_ :P_"W\L/Q-/_ (8 \ _]!76_^_L7_P ;I/\
MAW]X!_Z"NM_]_8O_ (W7NGPZ^)OAKXK^'DUKPQJ<>I61.U]H*O$^,[70\J?K
M^%=37@5,PS&A-TZDY1DMT]&CVJ?#^35(J=.A%I[-?\.?,)_X)^^ /^@KK?\
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M6=OW?S;6.W!)49/ H [+Q-_;)T*['A_[$-890MNVH[_(1B1EG"?,0!DX&,X
MR,YKP+PM\1_B-J_P\^%NHP/-K,VKP2)JTUIIV9'D+[%EW8\N)%&YBI*G &"V
M"#]#:18OI>DV5G)<RWCV\"0M<SG,DI50"['N3C)]S5'P?X2TWP)X:L-!T>)H
M--L4,<$;N7*KDGDGD\DT <%_PL+5_A_\#/#FM:E8WWB7Q Z:?8RVUP%L[B>Z
MFDC@.\,,(0[Y.1VSWK"UK]I*[T"VN[2_\.V&G>(+'46T^]MK[6TBM4/D)/&T
M<HC+R^8DBX58L@AMV  3W7QE^'<OQ2\$_P!@170LP^H65U)+O=&$<-S'*X1D
M^97*H0K#H2#6.?V=/"NZSN$N=:BU>WGGN'UF/4Y5O;@S*B2B67.65DBB7 QM
M$:[<8H \R\.?M*ZQXLUQM1GM)-,\)W$^@R6 MY8S<(MU#))*DX9#E?D.=I!^
M48QFK&F_MIV>K:<+NR\*S7XO([>;38K2\W-(LUS% J7!:-5@D_?*X7+@@,-V
M5KT71OV;O!&@3:>UE9WD<-C'9QQ6S7LCPG[*7\AF4D[F42,N3U4X.:=I_P"S
MKX1T]$AWZO=64#0_8K*ZU2:2"P2*=)TC@0MA5#QIZG:H7.WB@#E;/XW^+-9^
M)?A'P\N@6FE9UC4-*UZW:^$VTPV<=Q&\,@0;@5F5CD*<@K[UTWQJ^*P^%=YI
M%Z\-Y=PK8:I?26=L\:).+:W$NURRDY_NE2.>N16Y/\'?#DWB2'7DCN[?58M6
M;6A/!=.F9VMTMW! .#&T:*"G0XSUJWX[^%_A_P")"0KKMM)<"*VNK1/+F:/$
M=Q'Y<H^4]UX![=J ,KX;_$W4/&.OZYH>L^'O^$>U73(+6\\I+Q;I)(+@2>6=
MP5<.#$X9<$#C!(->4^/?B/XS^'.O:[=VGB8>*[K2].U+5-;TE+.-=/TFW6%V
ML4#@;Q,S",%6<EU\QL* IKWO3/!NEZ/XCU'7+6%TU&_MK>TGD,A(:.#?Y8 /
M QYC\]\UQGA_]GCPQX<O]4GM[S79[35);J:_TR[U6:6SNGN PE,D3'#9#'KT
MP,=!0!Q/]M>,=#U?5?"VI?$)8;9-$L?$-UXFO[2W22RA:65+N./"B,!O+!1G
M4[,MG=@5FMXQ\7M\,(O$.K^-=1T'1UN;R/1Y(M+B.LZZ&8#3QY+(1N?#G8J*
MS@H3L&ZN[N_V8/!NH:!=:3=3:W<I<36LC74VK3-<!+8DV\(D)SY4;,6"=">3
MD\U-J?[.6@:Q+HUQ=Z]XLEO]'\_['?G7KC[1'YV/,^?.>B@#N!D#@F@#N_!,
M^M7/@[0Y?$<,5OX@DLH6U"*#[B7!0>8%]@V:VZJZ7IZZ5IMK9+//<K;Q+$)K
MJ4RRO@8W.YY9CW)ZU:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,GQ/J<6FZ1,'U"+2Y[D-;VUS-R%F93LX[X(SCVKYY_9>\076L>,=2MCKL%U
M#:P3F2%/$3:HUYODB*S*I_U:JPF.YL$^<%VX7CWOX@Z6NL>"M8MFO=4T]3;.
MYN-%E\J\7:-V(FP<,<8Z=Z\"_9L\37VJ>/VL]3GOKIH]*9K1[SQ2=4;RR+9]
MQB6&-5W++'^\.<E75>C4 >P_&O4M,T[P)=OJE]IMC"&1P^IZI+IZ?*0QQ+#F
M0$ 9PHYZ=*YOX4)<#X=:++/<75Q'/K336YNC=,5A:1BBJ]SB5T ^ZS 9'08Q
M79^/_A7X<^)44']M6DAN[:.:*UO[69X+FV65=L@CD0@@,  1T..16-XB2;X8
M_#;S[S4[G7TT3?=I-=JBRO%%&[K&Q15!("A=V,GJ>: .&_:3_;B^%O[+LT6G
M^*-3GU#Q'.@DBT#2(Q/=E3]UG!(6,'MN()[ U\YG_@LAX3))C^$WC9X_X6*1
M#(_.OBGX/QS_ !!N=8^*'B>0:OXL\17\]Q)>3C<8ANQA,_=YX&.BA0.!7T'X
M \$GQHFJR/<7ZK8K$WEV$"S2-O?9G#.@"CJ3FNZ&'3CS2=C\RQ_&4J./E@<)
M0YW%M-N5M5O;3H>I?\/D/"W_ $23QK_WS%_C1_P^0\+?]$D\:_\ ?,7^->?M
M\%?$,T;7-I>V%SIWVJ2W2]^T[(RJ^9^\)(P%(B?H21QGJ*H2?"C7H[RUM'N]
M.2YO+A;>UB:] -P&VXE3/6/YA\W7KQP<=$<'2?VSA?&68+5X+_R9_P"1Z?\
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M8[<^E1O\?](&FRS)H/B&74K>[DL[O2%LE%S:.D:RDREG$:J4=&5M^&W +DY
M /3Z*\%T7]IZV\5>))(+&UDL?#[3Z/\ 8M7NK9G6\CO8W<K@.#&P"\,P(&UL
MCI6D/VL_ XLFNWCU9()8XI[ BSWMJ4,D\<"R6ZJQ9AOECX8*V'!QCF@#VBBO
M'K?]H:/5?&WA+0=/\-ZJIU34;W3-26]A6*;398+=9@'7<00RR(V5)&TY'/%=
M'\3OBG8_#*]TR;4[CRM.>TO[VXCCM&FE>.VA$C;&# *0.<$'=T&* .^HKC/
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M*JA2/]W\B[40;5P/E%?IK_PR)\!/^B4^"/\ P46__P 31_PR)\!/^B4^"/\
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M]BC[9!_SWC_[[% $U%0_;(/^>\?_ 'V*/MD'_/>/_OL4 345#]L@_P">\?\
MWV*/MD'_ #WC_P"^Q0!-14/VR#_GO'_WV*/MD'_/>/\ [[% $U%0_;(/^>\?
M_?8I\<T<N=CJ^.NTYH ?1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $-U9P7L82XA2= <[9%##/XU4_X1W2_P#H'6O_
M 'Y7_"O-_CGXN\4>$)]$F\-ZK;VC3.5N+2\T.\U".5 \99@ULK-&P7< &X;>
M<8*YK=^$GC+5/&>EWUQJDEK))#.$C-KI=Y8C;MSRMT S<]UXH E\=^*? WPT
MTU;WQ')I^G1/GRT:$-)*1U"H 2?P%>6-^UO\' 2!%,P]1IHYKY"_:'\<:AXY
M^+7B&YO97,5M=R6=O"QXBBC8JH [=,GW)/>FZ1\&[S7/!>D:K;LZ7M]>(A67
M'E);.QC23CYL[T)/&,,N.37IPP]-13J,_&,5QCF5?%U*674X\L+[IMM)VONO
MN/KW_AKGX.?\\9__  6BC_AKKX.?\\9__!:/\:^.]"^%$6NW]DT&N1S:3/-*
MOVM+61',<:PLY",,YQ, .V5ZXJIXT^%LGA/0CJRZK:W,+2 QVV0LWDNSB.0K
MG/(3)&!C(Y/..J.&PS=FW_7R.1\59^H.IR0LO+_[;S/LX_M=_!P?\L9__!:*
M0_M>_!L?\L9__!:/\:^6=4^!NG6)U"?^UIX=/%A;26EQ.JX-RQC$Z/@?<CW$
M\<X9/6LRU^ M^J*^HZI:63K,L,EJ[!9=X"O)&,G[P1U(X.2P'%=$,)@I;M_U
M\CH?$G$*ER\D/N_^VZ].Y]<?\-?_  :_YXS_ /@M'^--/[87P9'_ "QN/_!8
M/\:^1G^!LTNI7UG:ZE#<7-N=KVS*T;0F16>WW.5VON5?FV]#Q67=?#;3;?Q;
MX6TB+5);ZVU6)FFNHXC%AEFEC(17&0!Y7?KS7=#+LOEUE]__  !/B?/8_%&&
M]MO.W\W??MU/LP_MB?!D?\L;C_P6#_&FG]L?X,#_ )97'_@L'^-?$WA'X577
MB[PS+K*:E964?GM;017#@-,Z*K.!SQ@.N, Y/''6M4_ RY'AG5=1:_C::RF9
M=JJ<%%FFA.%^\Q,D2\CA5)+=*[5E.5WM*4NV_P#P"J?$^>U$I*$;-7VZ?^!'
MV&?VRO@L/^65Q_X*Q33^V;\%1_RRN?\ P5C_ !KY$E_9WN8=2>RF\2Z9&ZNM
ML2JM)BX+LGED)D@94_,>W;M46G_L^3ZO/810:W:QPW:J\5]+&RQN)/)\D%3C
M83YN,$D\' /2NN.3Y,]7.7W_ /VITKB'/KV=.'W?_;'U\?VT/@H/^65S_P""
ML?XTT_MI_!,?\LKG_P %8_QKX!TWP#KNN27B:=I[7GV24PS&-T 5@3_>(]#7
MKOP@_9MTCXD^#=#UF\U6\LI9=8FMM3CC*;8K) J^8F5/S^:\:\Y'S]*[JN09
M)AX<]64K>33Z7[#PO$>=8N7)3A'YIKJEW\SZ@/[:WP2'_+*Z_P#!6/\ &D_X
M;8^"(_Y977_@K'^-?'6K_##PT/!EW+I-GX@O/$Z>()?#L$1N8#!),@+^9M\L
M-@J,;=W7G..*WM"_93N8_!FE:WXF35;"XGO)FNK.W@'[JSCM9I@ Y!7SI&@V
MCDA=RY!)Q6CR'(81YJDIK6UKJ[]%;8ZXYYG<Y<L8P>E]G9?.^Y]2G]MOX(C_
M )977_@K'^-(?VW/@@/^6=U_X*A_C7QOXH^">C:;IOC"33-2U&\U339=+:QT
MZ6!0?)O51D$K]&D'F;<* ,J2>N!;T#]GZP>#P_H_B#^V]/\ %?B&&^FMGACC
M-EIYM]^%N <LQ.S+%678K*>:Z?\ 5WA_DYW*?WZ_#S7MR[*.M_U''/,Y<^3E
MA]VF_+;?>Y]>']M[X'C_ )9W7_@J'^-26_[;7P-FF5&,\"L<>9)I1*CZXR?T
MKY#\-_"WX;>(-!\*ZA-+XFTP:K:WUS/+-<PO!#]E*HP9E@)C1W8?O&!"#J#G
M(\L^)_@Y? ?CK5=#C$X@MF1H#<M&[M$Z*Z,6C)5@0P(8<$8.!TKJH<*9'B:C
MHQ]HI*^[71V?3HR:W$&:T*:JRY&G;9/JKKKV/V"\(ZCX/\>Z'#K'AYM,U;39
M<A;BV16&1U4C&5([@X(K9_X1W2_^@=:_]^5_PK\WO^"?'C[4M!^-">'(YI&T
MG6[>59K?.4$D:,Z28[$;2OT:OT%^*M_XATOP!K5WX7EL;;5X+:26.XU%&>.%
M54LSA%^^P X4D GJ<5^9\091_8N->&4N:+2:?6SOOYII_F?=9/F7]J855VK-
M.S7FNWWFY_PCNE_] ZU_[\K_ (4?\([I?_0.M?\ ORO^%?/VK^,_B9K7A/PP
MVCMJ%U'K/@U+F6[TZP4R0WSVK/YQD*[,[M@5%(.6^ZP/R^H>,OB'J7@[3?!E
MM8:-)X@U?Q!=)I\27,PL_+?[/),TLN5.T 1-N 7(SP#TKYL]L['_ (1W2_\
MH'6O_?E?\*/^$=TO_H'6O_?E?\*\+\5_M:Q^%_#JZE-X>MX;BU2].HV%WJR)
M,DMK*T4T-NJHS3-E"P8A$P5RP)P,JV_:3U+1;O6-6\4PRPZ/I^JZP+:+39(V
M\RTMK*.95E5DR7^<8VL/F;DX% 'T3_PCNE_] ZU_[\K_ (4?\([I?_0.M?\
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MLWJ< '#"- <?W1Z59O\ 3OBK?:AJMV-(\26[:G/]HN8X+*=49NV!MXP !]
M<U]D-^V9X47_ )A&J_\ ?,?_ ,73&_;1\)K_ ,PC5O\ OF/_ .+KHCAL>O\
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M5KF<ZA&)V0W$1E,$*K@\8D*9QCC.:YIO@#X\/3PW>?\ ?%1-\ OB$H 7P]J
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M0INFE4;5MG'JTNJ[R7XVV/+J5L3%75ON9YH?^"A7[5L9!;2? K <E?LK\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '*^.OAOI7CX:?-=S7VG:EISM)8ZII=RUO=6Q9=KA7'56'#*P*G
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M/\9/%K_\T0\?_P#@MF_^-5"_Q<\6M_S1+Q^/^X;-_P#&J_9GR]?_ .>^G?\
M?F3_ .*H\O7_ /GOIW_?F3_XJK7$.8+::^Y?Y&$L=7EN_P $?C _Q5\7-_S1
M+Q]_X+)O_C50/\3/%S=/@GX]'_<,F_\ C5?M-Y>O_P#/?3O^_,G_ ,51Y>O_
M //?3O\ OS)_\56JXES);37W+_(Y95ISW/Q3?XB^,'Q_Q97QZ"._]ES?_&J@
M;Q[XP(P/@MX\ ]/[+F_^-5^V?EZ__P ]]._[\R?_ !5'EZ__ ,]]._[\R?\
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M 'YD_P#BJ -BBL?R]?\ ^>^G?]^9/_BJ/+U__GOIW_?F3_XJ@#8HK'\O7_\
MGOIW_?F3_P"*H\O7_P#GOIW_ 'YD_P#BJ -BBL?R]?\ ^>^G?]^9/_BJ/+U_
M_GOIW_?F3_XJ@#8HK'\O7_\ GOIW_?F3_P"*H\O7_P#GOIW_ 'YD_P#BJ -B
MBL?R]?\ ^>^G?]^9/_BJ/+U__GOIW_?F3_XJ@#8HK'\O7_\ GOIW_?F3_P"*
MH\O7_P#GOIW_ 'YD_P#BJ -BBL?R]?\ ^>^G?]^9/_BJ/+U__GOIW_?F3_XJ
M@#8HK'\O7_\ GOIW_?F3_P"*H\O7_P#GOIW_ 'YD_P#BJ -BBL?R]?\ ^>^G
M?]^9/_BJ/+U__GOIW_?F3_XJ@#8HK'\O7_\ GOIW_?F3_P"*H\O7_P#GOIW_
M 'YD_P#BJ -BBL?R]?\ ^>^G?]^9/_BJ/+U__GOIW_?F3_XJ@#8HK'\O7_\
MGOIW_?F3_P"*H\O7_P#GOIW_ 'YD_P#BJ -BBL?R]?\ ^>^G?]^9/_BJ/+U_
M_GOIW_?F3_XJ@#8HK'\O7_\ GOIW_?F3_P"*H\O7_P#GOIW_ 'YD_P#BJ -B
MBL?R]?\ ^>^G?]^9/_BJ/+U__GOIW_?F3_XJ@#8HK'\O7_\ GOIW_?F3_P"*
MH\O7_P#GOIW_ 'YD_P#BJ -BBL?R]?\ ^>^G?]^9/_BJ/+U__GOIW_?F3_XJ
M@#8HK'\O7_\ GOIW_?F3_P"*H\O7_P#GOIW_ 'YD_P#BJ -BBL?R]?\ ^>^G
M?]^9/_BJN:>M^N_[:]N_3;]G1E^N<DT 7**** "BBB@ HHHH **** "BBB@
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M[O\ $Y*5;+ZE5*,[RZ7_ .&/;Z***_+#WPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#\[?B??W&K^/O$%U<.9)6O91D^@<@#\
M  /PKJ$\'^'QHUIJA@@+#13&]LTI^>],!F68C.<;0>.F0!7)^.5SXRUS_K]F
M_P#0S7/F,9Z5^M*#E3@HRM9=/0_7989SIP47:R_0Z#Q!:66JMI4<::-H&_3H
M;J258Y$$DCY##C=TP#CC%=8O@CP]'=6"Z=;6&MQ/;6RS-]I+YB,\J7%V>5VM
MM5".RCMWKR]H_2H7B!ZC-;.G*22C-JW]>OXG'5P;:24K&W-I6ASVGA,[#9V]
MQ>307UV9MSR1K*@\P\80;6. !Q[UKS>!SJ5W)'?^&H]+:$3M:V>E7 2YU%59
M JJ'+@@!BWF_Q8(P>HXAX0<U7>W'H*Z^672??OU^?R_*QYU7"/HST&;X6>%X
MY#:C4KV>XW*@N8YH1$2YN-IVX)POD#//._C'&;.M?"SPW%>:I*Z76GVRF25;
M/SXC(8T5V#Q-@X23;M&<GY3R:\O> $=!5:2V _A%:1I56[^U?]?,\BK@Y=SU
M32O@SX:!6^N;B[N+9;F&1(6G0(\+20J878+@/B4\@YPN=H'-9$OPBT6[EC+2
M7=JKA!+*DL0BT]@D1$<P(RSR%V52,<KT/('G,EJ/[HJM);*>H%=4*-=._MG]
MW_!_KTT/(JX-FCXZT/3/"FJV%QI*/=VDD,DWV;4RLWS)-+$0^S:"K>6&QQ][
MOUKLM2\)>&/$%WK]DVG6NCR0WT5M8W&F$1K&/L4L[&4,6WJ70 XP>G/&#YG)
M;XZ"JLEN/2O1]G*45:HTUU^::Z]+6\SQ*N%MT/1O$?P@\,:(KE-1O[IO*C2+
M=(D22N\\42SAV4#RB)&; !'R_?/.+VL_L_\ A^S262*XU=X0BK(YDB461W7"
MM-+N4$QCR4.,*2'X.""?(9+5?[HIADGBL)K)9&6TFD2:2'^%W4$*Q]P&;\S6
MBH8BR4:[OZ>GF>-5P\=;P/4KWX(^%F6*X;5+X^??+"PT^-6C0&4(8 ","0K\
MX^8GD84]:X"\TF7X:?&"RCTN=XI+&[MKBWD$V]TSM<!CM0@CNI52.A%<W+:J
M<Y4&I]"M@-=T_ _Y;I_Z%7HT*52G?VM5S335FCP<10B_AC9G[+J<@'UI::GW
M%^E.K^8#] "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /SM\<K_P 5CK?_ %^S?^AFL$K7H'QF\'7OA+Q]JT=S$XAN)WN()2/E
M=&8D$'\<?4&N$(K]8HU%.G&4=4TC]PHN-2C"<7=-(KE*8R9JR5IA6NE2"4"H
MT=1-'5PI3&2M5(Y)TKE!XLU \7M6BT=0O'71&9Y]2A<S)(:KR0>U:KPU \7M
M75&H>55PYD2055D@SVK9D@JM)!79"H>-6PMS&D@]JJR05M20>U5I(*ZX53PZ
M^$,22WJ;0X,:Y8<?\MT_G5N2#VKJ?A/X U'X@>/M'TK3H&D+W"M+( =L48(+
MN3V ']!W%=$L1&G3E.;LDKL\&MA/(_5%/N+]*=2 8 %+7\T'IA1110 4444
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MX]Z[:.WW\UNQYU3'8B/=_,_0T_L__#T]?"UE^;__ !5-/[/?P[/7PI9?F_\
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M>.6)?*SR'FDE).?>0CZ 5I)\2-1MM0N[Q+.V\VXNUO"#NPKBV>W '/3:Y/U
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MNKB*!8KES&-FUID8LH88R.H&0#Z)HKR#5OC3J_P^&G/XYT>PTZTDEO;:YO\
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M_"7P]C\+WELFK";2$T:_N'#1_:H%>639M#?*H:>7 !R V"3BO4** //;_P"
M?@C5-8GU*YTF226:]_M-H/MDZVXN]NTW B#A!(R\%@,GOU-7;_X,>#-3T^"R
MN=#BEMH-+CT:%?,<&.T1T>-%(;(*O&C!A\P*@@UVM% 'DGBK]GW2]9\/Z5X9
HL%MK?PXVL1:QK7VY9+N\OY(G21")G?.YFC56=MQV#:,5ZW110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>mrkr-20221231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #? 3P# 2(  A$! Q$!_\0
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M8]=M(V W@?\ +>(9V[O[Z_*#U"@YKZ.\(^--#\>:1_:GA_4H-5L/->$SVYR
MZG#*<\@BOI,/BZ.*CS4I7_/[CY?%8&O@Y6JQT[]/O-JBBBNPX HHHH ****
M"BBB@ HHHH XC5O@KX)U[3?&=AJ'A^WNK/QDRR:]%([XOF6)(E+?-\I"1H!M
MQ]T'KS6A%\,_#$'B32=>BT:"/5=)TQ]&LIT+ 06;E"T*IG;M)BCZC(V\5TPZ
M4M 'EG@W]F+X:^ /%-MX@T3PY]FOK(RG3XI+R>:UTTRY\TVEN[F*WW9(/EJO
M!(Z$BMH_!+P0?!B^$SX?@_X1X:E_:XL?,DV_:_M7VOS<[MV?/^?&<9XQCBNY
MK+\3^&=,\9>']0T/6;5;[2K^%K>YMF9E$D;<%<J01^!H X#QG^S%\-?B!XIN
M?$&N>'?M5]>&(ZA%'>3PVVI>5CROM=NCB*XV8 'F*W  Z#%>DWVF6>IZ;/I]
MY:PW5A<1-!-:S1AXI(V&UD93P5()!!XQ7QW\(/V8OAE)^TY\8=.?PNCV/AJ3
M0+C2(&O+@I9R26SRNR R?Q.JL<YY%>^_&[XJ:QX$G\(^'O"VF6>J>,/%VI/I
MVFIJ<S16=N(X7GFGF*@L52.,_(O+,RC(Y( *W@_]E7X9>!?$FGZWI6@3?:]+
M);2X;W4KJ[MM,)4J3:P2RM' <$C**, X&!Q7!_!7]CKPKX!T?2K_ ,9V5OJ7
MB6QUV^U>)TU*Y;3_ +1+>RRVT_V9G$1G2.2-0YCR"."< TSX@?M-^,/@KX$G
M;X@^'M"TCQ1-K]OH&EZK]O>+0KWSHC*+QG8&6*.)5D$B$%MR *2&!'D_C']H
MM_CA\.]0T.]N?#^JZEX9\<>$6?6/"L\DNFWL-QJ4+(T?F?,CJT;HZ$MC"D'#
M< 'TWXK_ &;/AG\0/%U_K^IZ+Y^IW)C35([34+BW@U Q@>6+R"*18YRHQCS5
M;C Z<5/X[_9I^'/Q)\0R:UKWA\W%[<0QVUZMO>3VT.HPIGRXKN*)U2X1<\+*
M& ''3BOG^S^*]_\ !>]_:4\2:;ID6HW ^(-A9F6[,@M+%)K"PC:[N3&K.((@
MV]RH)P.W4>]_ #XC>)/B/H>IW6O#PQJ-M;SHEAXA\'ZD+O3M3C9 S%5)+PO&
MV49')YP02#P ;FJ_!+P/K:>+$O/#MM*GBJQ@TS645G1;NVA1TBB(5@%"K(X&
MW'6M-_AOX9E\1?V[+H]O-JG]DG0C-+EPUB7#F J3M*E@"<C/OBNEHH \S^'O
M[-_P]^%NNIK'AW0GM[^&!K2S>ZOKBZ73[=B"T-JLSLMO&2!E8PH. .@ 'IE%
M% !1110 444C,$4LQ"J!DDG@"@!:*Y>?XH>#[:]^R2^)])2X!VE#>1\'T)S@
M&ND@GBNH4EAD2:)QE7C8,K#U!%-IK<B,X3TB[GG'[2$VCQ_!/Q9%K=X+*UN+
M-HHGP2S3GF%% Y)+A1BOSI1G=%++L? +CJ,XY -?J#XY\!Z)\1_#\FB^(+/[
M=I[NDNP2-&RNIRK*RD$$>QKX2_:(^#,?PA\<6L&GRBZTG5_.GTVTC+RW5NJ!
M?,C9>695W A^>.O3)^9S>A4G:JEHM/,_;_#W-<)04\!4DU4FW)7MRZ+H][VN
MW?2R/!/'L3/:VTN2%CD*8/1LC.?TQ7&5ZK<6]OJ$/DS(+B&0;P3ROMS65-X1
MTMI(G:(PC=M\M'.U_3-?+G[F<OX:BWS7+# 8JEN&(R%\UPA)'? )XKU^*%;:
M!(D!*1($4'DX P/QKE$TV"TN=/MX;=4MWNEDE5%X 4$@D^F_9U]:ZWY5;'0M
MS]:Y,0]D?G/$E1RQ,*?9?F_^ BM?WT.GPB61PFX@8()+>P'K6>/%=ENSLF7U
M.P9_G6?XL=C?Q(22%CW#/N>WY5B5YLIM.R/F8TTU=GH,<L=S&&C;<CKD.OH?
M0^M?;7[(_B9-<^$L-BS6"7.DW,EFT%E&L3K&#F-Y4'\;CG=_%UZYKX%\(&0F
MZ52?*^4X[;O_ -5>G_"CXU#X6P>)-3T:/[9K]\(;"VBN86^RI$C,\D[L"-YR
MQ15!Z@DG!KZ+)L3["NY2^%IW_K^MSR<PRJOFE/V&&BY335ORU?1>?D?H>E_;
M27DEHEQ$UW$BR/ '!=%.<,5Z@'!P?8U/7YC:I\2O%.J^+=7\3-KEU8ZSJL:P
MW<^FN;;?$H 2,;3D* ..<\DYY-6=+^,/CW1+&6RL?&>LP6LBE=C7/G,H/7:T
M@9E_X"17U"SFE?6+&_#?'<B<:\+V5T[[VUU2>SV[^1^F%%?,'P7_ &P;+4_[
M+\/^-8O[.OBBVXUWS1]FG<# ,N<&)FQR>5W'J,@5]*:;J]CK,+3:?>V]]"K;
M#);2K(H/ID$\U[%'$4\1'FINY^<9EE.,RFLZ.+IN+Z/HUW3V+=%%%=!Y 444
M4 %%%% "#I2T@Z4M !1110!PGA'X5Q>$_BGX_P#&B:E)<R^+1IX>S:(*MM]E
MA:(;6SEMV[)R!C%5/C)\))OB9'X<U'2=<?PQXK\-:@=2T?5EMEN4CD:)XI(Y
M821YD4D<CJRAE/0A@17HU% '@NM?LV:_XQ\+[O$OQ(OK_P <6^N0>(=,UR"P
M2.STJYAC\I(H+)F8>04:171G+/YC$L#C%O4_@)XH\<^#_P"RO&WCV'5;P:YI
MFLQ/I>B1V5M;BSN(YQ"D?F.Y\PQ_,SR,1GY0 ,'V+6M9L?#ND7FJ:G=Q6.G6
M<33W%S.VU(HU&68GT %&C:U8>(=-M]0TR\AO[&X0/%<6[AT<'N"*!75^6^IY
M!>?LZZC:R^/+_P .>/-1\-ZWXE\26_B2*[MK97CMY(K:&#[/-$6Q<0.L7S*2
MN=W!!4&M'X%_ RY^%.K^,O$&KZW:ZSXB\5W-O<7YTO3%TVPC,,9C3RK<.Y#$
M$EW9V9CC/"@5ZW10,**** "BBB@ HHHH *^.?CU\;)/$VH7UK'?-:>%K.0PJ
MD3$?;&!P7;'W@2#M7I@9/7CZ[U=97TF]6'/G&!PF.N[:<?K7Y>_$>27_ (E4
M9SY/ELV.V_@'\0/YUVX:"DVWT/D>(<34HTHTX.RE>_RMI^)JP_$?2FE\IK>X
MAAZ>84!'XJ#FO6OA;\5;[X=ZA!=V<[76@S$-<V*MF-T/5XQT5QUXZXP?;Y=K
MT?P";B7PO<(K;=LKK"S' ' )YP<<DUZ$HJ2LSX7#8FI2J*<'9H_3.SNX=0M(
M+JWD6:WG19(Y%Z,I&01]0:\ ^.7[2\?PT\=0:1I_AZUU>^L8EDNKJZD\LQ+(
M WEQD*2"5 ))XY'![9:^"OB5K'P#T>+1/$2:+=BQAE6Z;598"D0PWWA 2HV#
M\J^6?!D&JW_B#6?''B*\C\4G2XD9]/U6^EE-W(S+%!.PV#S(E)7*$@\*",&O
M-I4HMMRU2/O\PS&M"$(4O<E)7OY6N_N_(T_BIX<TJT^)$DUA=75AH6IK;:L;
M01I&]HEUB:2/D$?*KG''&>^*M_$;PIHGPK\<WFCFTD\0Z?;I%<1W.H7;PM=Q
M/&&W1M 44+R0&PW3GTKB?%?BW7?$OBNYO[W_ $VZNG$ES=2+M5N ,#& JJH
M '0 "NV\+?%;6_"VGPV"1:9K>FP'?:6NN62WD=HW7="204YYP#C/:DLKPL;2
M]DF_\RI<?9]64Z3QU2$6U9KHHJR5E;1JU[/5K6]VSUSXL_LMV.KZ?X1U+X;:
M)]GN9H?/O-)FU4H[QM&"CD2L<X)PV",G;P>:\"&]998Y(WAEB=HY8I>'BD4X
M9&'8@C!%?4?P"O['XY>/9/&6NVDEIXO\.Q10K/I\S):W,3B0*6C;)5A\^0&P
M<@XXKPW]H[QOHGCSX@:CK/A.2YBG$:6LAFL8X8)GA=PSD[B\A;(0$JI '4X
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M@TF^G=-D<OE/N\IBHW?P@L!_DUT=KX?T/XI)#/X*FTG1=6$IM[OP[>:N I;
M*RVLDG+H<D%"25(XR*[CX2^#_!_AGXXZ3X;UV_O]4\36,X.VP1#IZ77E^8J$
M_P"L8*ISN("EATQ7;4G:+5FG8^3P^7U%B*<Y).#:U>SOTU_*QU7P%^+VB:/\
M1I?"GA7PS%9>&;X3O'>22O)?W,D4;.LDC,2-K*C )_#D<\D5\SZWKK^*M;U+
M6Y;>&TDU.YDO&MX%VQQF1MVT#VSR>YR>]?;6N? KPY\*=#\7^+_"=E<IK\.E
M7;64<DYDCM6,;$F)3R#Z9)XX'6OA.!8XX(MC;DV*JN3G([?G7;EJA)SG'R1^
MR\-X>M0HS5=J]]+;)=N@LTZ10O,["-4!^:0X ^M9)\5Z<2"QD9E_B$1Q[XJ#
MQG*R6<$>3MDDY&./E!/]1^5<G7OJ-S[&QWLM]_:&F-+I[[Y&.%..5.>>O0XS
MC/?%)82J%%ND3PM!A&BD8;E7'#<9SGU^OI7,>%WF768UAZ.K"0=L8X)^AQ71
M307&NW=L]@)+=8V='OFB&W'0A<G+<@]L9%?#<582C/#^WJ5.64=DWH^]EW].
MVQ]GPUFSRZLZ<H)PEN[:KM\O+SO<C\1Z2^KZ<\4) FWJXWG@X[>W6N.E\)ZI
M'*B"W$F[C<C@J/J>U=Y&UQ'*\$D%Q<7$!8,T4>%9>S\D#D=AGO3LWLP!@TZX
M"ALGS=L1/MACG\:_(>>/<_8?[0PG*INJE>W5=3%\-Z"VCPW;WDD?S@*P!(50
M.<D\>M?=G[*WP$7P[I>C^/;_ %#4[;6;^W9QIL;B*W%N^?+65,9<XVOR>">!
MQS\R?![7=+\*?$G2-2\7Z"+_ $*$.)LA+A(&8#9,4ZL4/4 ' )(R0*_17P_X
MT\/>*]PT37--U<H@D9;&[CF*J>A(4D@'WKZ/**-*HW5;3:V7;S/R#CG/ZDJ<
M<!A/@DKRDMGTY?+N_D;5%%5(]7L)M2ETY+VW?4(D$DEHLJF5%/1BF<@'UQ7U
MA^&W2+=%%% PHHHH 0=*6D'2EH *@OI'ALKB2(;I4C9E'J0.*GHH _,_QQK%
MQ:>'Q*DC?:+N0*\V?F^8%F.?4\_G7EV !C'%?47[0?P>F\-:K>P-&R:)?3&>
MPO%7Y(G))\IO0@D@#NN,<@X^;]>\.ZCX;LKB[O+?_1H%W-*C@J>P [Y)[8KW
M824E='XOC*%6A5<)K5'5?#C4Y)XKVPF8O!&@D3=SM!X(^G_UZ_2+X;O+)\/O
M#33Y\TZ;;EB>O^K6O@3]DOX=ZC\6;NZ+6$MMIL5PJ7^I?\LC&.6BCSU<YVGT
MR3VK[]UCQOX9\'K';ZEK6GZ84 58)9U5@,<?+G.*X<2U)J*/LN'J4J5.5>H[
M1>BN=#7G?@'X^>#?B5XLUKPYHFH--JNER2H\;QD+.D;!'EB89#('.W/'(.!C
MFJ?Q-\80^+/ASJUCX.\2VL>J7]N\4=_9LL[6D?\ RTEV@Y!"DA>^]D Y-<[^
MRE\ V^"W@ZXFU6&$>)]48&Y\IMZV\"9$-NK=PHRS'N[L>>*Y%%*+;W/IY5JL
MJ\(4E>&[?Y)>9[E11169WA1110 4444 %%%% !1110!XW^T3\>;[X)VVC"Q\
M/C5I=3:55N;B<Q00E #M. 2S$$D#CA6YXKX7\6>-]>\=:C+?>(=7NM3F:1Y1
M'-*WDPELY$<9.U  <# Z=^M>_P#[=>NWC^+O#.C//C3(;)[\0#H9F=H]Y^B@
M@?[S5\RX)8# *D<U]_E&&IPP\:O*N9]?G_6Q\OF%:;JNG?1#)(XO)PR*8U^;
M;M!'Y5TOP]^(6M_"[7'UGPU<0VEY-$(I?/MEE25,[@K X(Y[J0>3S7G5[XRB
MM;N2.&%KA5."Q;: 1P<<5+IGBZ&^F\F6/[.Y'R%GR&/IG'%>[.DJD7&:NF>5
M&HX2O%V9]MW?[7$GC_X>OI'AVTGTKXAW<&WRWB!M8P,&61)G(11LW%3)C#$
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M\JD@'V.*9XIF:+32@/$K!"/U/\JY&OR:4^5V1]#"',KG?V]W;WD*RQ.)(RV
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M7WQ^R;:31^'_ !%<M_Q[RWR)'_O+$N[^8_*L<3%<MST^'L34^L>S6SO?_/\
M0]WHKQS]J3XTCX-_#B62RN(XO$FK%K33/,Z1-MS)<-_LQ)EC[[1WK0_9HU+Q
MEK?PCTC4O&T_GZC=KYMJ9(@D_P!E('E-/C@R,!O. /O =0:\_E?+S'W2Q,'7
M^KK5I7?9>OF>IT445!UA1110 4444 %%%% 'P3^V5IEY8_&Z:ZN9Q+;WVFV\
MEJN_)B1"R,N.WSAF]]WM7A<QS"XP-W10QQENWZXKZO\ VC/V7=9O-0\0^.M$
MU*ZU^ZN;A;B71G@#2I%M"L(GW9;9@$)CID#)QGY+-_!#)'%).-[)OWN-HQR>
M3T!X/'L:_1LOQ%%X:"4UI9=M>WZ>9\GBZ%5UI-1>MWWT6[_K8\T(8,0WWL\_
M7O0D9F=8U^\Y"C/J:ZF7PK97\DTMGJ"MN); *NJGK@D'-6--\'Q6LD,\\WGL
MI#[5X08Y!]3^E>XIQ:NF>0Z<HNTD:NH!AITL89G'"3, 2P4D!R!_NY--UG5X
M=+TC>FRYW@)&JG"D$'!X[8%."+K5PN4\VQC&?G4A97)[>H !]LGVK+\<V^W3
M[4Q@1PPR;=@& <CC'TP?SK\0XPQU'%8J-&D[^SO?:UWV\^_W=#^N?"_)\5EN
M75,5B(J*K--)IJ5E=*]^CU<?6_5&1_PFFJ9^]#[#R^GZUT6D>+(=0B7SB8[E
M1AH40L9#ZJ!SCU':N ;[IYQQU/:O0O"NF6D&EVMY#:>1<S0C>\A+,?7D]CU_
M*OS\_:3VGX,_M%:]\(_!'B32++3(KJ>_F-SI37!"1V4C#:YE7JP.U&VCONSU
MKS*/6KN)"DFGF>7DEHID",Q.23D#;R>PI&<)DMA5 R6)P!2'?YBXV^7@YSUS
MVQ6E6I*M",)NZCL?.SX>RZ=:IB'"TYN[:;U_3_@D]U+'XATB7[*P>;"DPL<-
M&P/((['J*YR?2[RVV^9;2#=P,#//X5K36GF2QS1L(;E#E9U'S#V]QZ@\4:5X
MD=7NH;N83W(<[8X+=O,51P2ZC(&>W/(KS7@YU9<M).3[)7?W'R6997/+8NJI
M)P\]_P"O,=X?T>YMKXS3H(@J$;206.?ITJ]J]_KV@)#J6F7-UI$2AXX+^U=T
MGE((655<$80;@K=<Y/I535M<^U6Z6]LE[;32RHN_R64LFX;\-_#\N>3CVK6T
MS4KR'2(O#D4FGIIDMT&MSJA<16,LA >82A@T2MP9.H.,D9YK[?A[AZK4F\1B
M(N*@]G=.]KWZ:(_,N(:F)KX*=' S4:DNKLU;JMGNM-C<T/Q3\0/%WA*[LQ=^
M(=3T?&+NTC,US J@Y ;(;;T!QGTKSB7PW=WUU+-)<1?.Q(;DDCM_^JOM#XE?
M##XD^&]'T@?#R[^S^&[6SCW:=X<N6BE:=AF6;+',P8X()8G'8\FMS0OV8['Q
M]INE>)?&\-[I_BFXA#ZI8V4R10W$@X#N%4[790I?81R3T-?=*O&*OT\C^<:F
M38BK/V-VY1ZR^%^CU^[YZ;'SU^S3X^F\'6'Q!/A>,:KJMIH0G0I"9#"RSA2Y
M&.@$C-M[^77N/[&/B'Q!XAN?%\^I:C>ZK8LT#BXNYFE'V@[]^TG@?+LR!P/E
MXKC/V'/AUXK\%?%+Q]-KF@+HME+;^7&J.K*&%W-A%()+*,.,MSA17V9!;0VJ
M;(8DA3).V-0HSW/%<U:HKR26]M3WLIP554Z-64VE#F]VUMV_ZV):***XCZT0
M=*6D'2EH *^ _CYHEUIWB/QK9%7,INY+A1CEXW82@^_RM^AK[\KS#XR_!>'X
MD117]C-'8Z];)Y:2R ^7/'G/ER8Y&"20PZ9/!!KHH5%"6IX6<8*>,P]J?Q+7
MU/S-!R,BND^'\<C>)$D4XCBB=I6[!<8Y_''Y5[!KO[+?B--1*-X7U%)'.2VG
MR1R0M]#G _2MK5/A5!\ _ =SXJ\46MNC+(L.G:"91)+J5XW^J29QP(P<LR@G
MY5;H.#Z;JQZ,_.Z>6XGF;G!I+=M-)'I#? V_\1?!OPWJ%A#L\0V\<LYMI,*9
MX99#((\GHP!!&?4@]<CY:\4_#*:QU2= W]ES[COLK^-HFC;N!GG'X?C7V7^Q
M_P")/'7C#X9-K/C+4$U&VN9R-*N&A$<TT(R&E;'&QGSL& 0BC.<U[9>Z;9ZB
MJB[M8+H+R!-&'Q^8KA5>5-M/4^RJ9-1Q]&G5IMQ=ENM[*U]S\R=!\)#0[I)W
M87^H;"T,: K$@Z;RQZ^G\A7OWA;X]ZWX)T.STC1M)TJ&QMUY^T"2265R<N[,
M&49))/3CIVKS_P")7C@ZEJVL^(;D$I),RP0C@+&#MBC'H  /U->.S^.-:FG,
M@O/)&<B.-!M'MR.?QKN<542YD?'1Q#P,VJ$OG;H?7VB^//#O[0?BJVT3QWHD
M5JJNOV>&=B]O-@@K$K<%7D==[ ]5CC7)W$'ZD50BA5 50, #H*_-'PAXI?Q#
M#)#-^YO8 &WQ\ C/##T(./TK]"_AQK\WBCP'H.JW.#<W5I&\I'0OC#'\2#7G
MUZ?)9K8^WR7'O%\T:GQ;W[KS]/U.DHHHKD/J0HHHH **** "BBB@#YL_:$_:
M-U;PGK.L^"]&TDVEY]F0'6KB7&P2KG=#'M^8@9 8L &!X..?D"QT#3;"W,45
MJC(S!B9_WC,1T)+9)/6O3_CYKU[KWQF\5-?3B;[%=#3[95.5CA1%8*/?<[D^
MY/I7GES<):0233<1QC.1R?\ ]=?FV9XRM6K3IN;Y$]NFG];GZGEF#I4*$)QB
MN9I7?75=_P!-B*YTZQN)$,]I!(W12T0/3WQ5"W\,V\-W'$;V>TTN1BCI#;K,
M\ )Y9%)7<!S\F1['L:@\7,.!;%@.[2<GZ\5K:7K$>IH"@V2+]^,GE?0CU%<N
M S3$Y=553"U'%_@_)K9G9C<OH8ZG[/%04E^7FGT-SQUX2T#35LM4\'7]WJ?A
MJ>X_LZ!+V&6.[2[CA#2($89D0@[@RYVDE3C KBKN"UU&%8)U$T4OS*,^GH17
MT7\'/VB]$^%'A"XTK7K:_P!9U*VN))]"M$MD*6\31J'59V/R NSY'4!N 1Q7
MSSXAE_X2CQ%J.M7<45O<WEQ)<^18@Q16Y<EF6/!R!DGJ>:^\P'#U7.::Q5&2
MC&5[]KVV6_7?LON-UXB4\CB\#CJ<JDH62:>K5^MTM5'9_::L][G-:WX2TZ*R
MEE"R0-M*I$KY#L>%'//)Q74H"H"E0, #CI6#JME%#:CRI)UEW!H85E8B60'(
M!4DYZ<_G6]EB1_#CKQG\*\?-\IJ9/5C2J34KJ^GZKH?I/#'$M#B?#3Q.'I2@
MHNSYK6O:^C6C\]FNVJ,7Q-K#:1IX6/$D\C; 9!D 8SGT-<?_ ,))JG_/]+^G
M^%;_ (]A9X+6;)"HY3:>AR,Y'Y8KCJ\$^P.[\,^)#JG[BY.VXB0MO&-L@]3Z
M$4SQ++=:;>1SP7 C6Y^1@H <%1Q@_P!W';UK,\#0![ZZGVEVBB 5>@))_P#K
M5/XODB.JV^V999%3RWA&2T>3G=Z '\^!7T7#\G',Z5G;772_3;Y[7Z'S?$<8
MSRNLI*^FFMNJU^6]NI#;^(-0MYE?[2\H!YCDQM8>AXKK[&[CU?3RZLRB4,I4
MD;D[$?A7G]=OX=C6UT2W8_*KJ9GD)QC)_P *_=))(_ &?H_^S;X[D^('PETJ
M\FLDL9K(MIKI%GRW,.$#IGH" ..QR.<5C?%']HRV\)ZC/I&@6L6J:E 2D]Q,
MQ%O _P#=XY=AW ( Z9SQ7/?"[QU?Z!^S!<E?#M]X=U'0K0649N[=H4N9&P%N
M8]P!()?<<C[V1SUKY?\ %^OOX=TU/(^:ZF8JC2?-CNS'U/\ 4U\1[&,JL]-+
MGY%Q!F,\%-TJ.C=W?>R\CUGPS\>/&VA:O=7LG]EW$<V<PFV*@@SS28R&R/\
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M0="%M%8^#AG6)<_?ES+LTK,_3#3M/MM(T^VL;*!+:SMHEAAAC&%C11A5 [
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3*.O=A11161Z(4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mrkr-20221231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #L 48# 2(  A$! Q$!_\0
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M(U_2M?:^73-0M-0:PN7LKL6LRR?9YU +1/@G:X#*2IY&1ZT:#X@TKQ3IPO\
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M:* $P/048'H*6B@!,#T%&!Z"EHH :0,=**5NE%  .E+2#I2T %%%% !1110
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MUN+QYI ^S73QR-*EW;^4C^0^Z212@4AE*C(*Y/U%10!XAX!^ VJ>%OB;X/\
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MX@>!KKQ3;> -7M++0OA_X=FL+JX+P*+?[:WGR;)8IPA02A9-[/ZM7H_PFE^
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M4=>[$;I10W2BLCTP'2EI!TI: "N8\=_$'3/ &G)<7Q::XFR+>TAQYDI'7KP
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MH \O^,/P&TWXQZGH=U?:E/I:Z<LR2&RAC\^<.!M7S&!VJK G&#G)Z=:^2C\
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MNUC=XXP43:,F1VX"KZGG^5?3&I?LM75S=$IJFGW,6?EDNK0^8![X)!_2N_\
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MIX[B[E.HRQ$-'&8Q'"A'?8,Y/U)^E>@445,ZDZCO-W*C%15D%%%%9E!1110
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C3HB@8 JU117(?2))*R"BBB@84444 %%%% "-THH;I10!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>mrkr-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %0 IT# 2(  A$! Q$!_\0
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M?$?Q=\$^$->M]$UOQ7I&E:M<%1'9W=XD<AW?=X)XSVS7S_\ "O\ :*\8^/O
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M^.OAZW^(7[:_A;2%*SVFJ^%+F$,I&UE>VNPISZ9*FO&OAAJU_P#%U]#\.:E
M[V_PY\):R\BODAY=KK&<>HW1#_@%?>.E?LX^%-)\<>%?%D<VJ3ZQX;TQ=)LI
M)[K<K0*CH/,&WYFPYYXZ"H_!W[,_@KP+K?C'5=*BO4NO%4<L5_YEQN5$D9F<
M1#'R#+'UZ#TKJI<1X.AAE1BFW"$8Q=MI7FI/?K"7WG/4R?$5:SJ.R4I-R5]U
M:+2^4HGP=K7/_!/_ ,-_]C9)_P"@25^EWA*XB'A71@94S]BA_B'_ #S%>4S_
M +'W@&Y^%%E\/';5O^$?M+\ZC&1>?OO-((.7V\CYCQBN2_X=W_"K&//\1_\
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M1_K?AO\ GU+\/\P_M*G_ "L^L**^3_\ A97BG_H.7?\ WW1_PLKQ3_T'+O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9M?%,#^-YM"DTU[:Z
M^SM<Q7+%#YL:LJL< Y RV!GKM;ICGYH^--@_@[]K3P3J^L:E>>*].U'0];-M
MHU^L2V^G8:RSY)10QW=]Y;VKZ;@\-Z3!XO;4/M,LNJ>4\D=K+<EUA5]JNZ1D
M_*&*J">G''>OF7XT3WWB7]K7P1IOB?35\*Z%9Z'K?]G:Q]L2Y_M %K+<?*4
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MSU/3_P#A67A;_H!VG_?%'_"LO"W_ $ [3_OBH?\ A:WA/_H-0?\ ?+?X4?\
M"UO"?_0:@_[Y;_"O;YLH[T__ "4\J^&_N_@3?\*R\+?] .T_[XH_X5EX6_Z
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M5:E%17DK%QC&.D58****V*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_"5ZY_T%[_\ [_O_ (U^-<V6_P L_P#P*/\ \B?,7H=G]Z_R-O\ X5%XM_Z
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M_P#&C_7"C_SY?WH/[3C_ "GV!17Q_P#\)7KG_07O_P#O^_\ C7T/\&;RXO\
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M)_Z!=G_X#I_A1_PCFD_] NS_ / =/\*T:*/8TOY5]P<L>QG?\(YI/_0+L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKH:_8:-3VM*-2UKI/[STXRYHJ7<****V*"BBB@ HHHH **** "BBB@ HHHH
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M:!+N%H3*H!*9&,@&M.N:^(VB7/B+P5JUA9M.MW)"?)%O,8F9QR!N!'!/4=Z
M*^G^ ([#Q8^L?;7D@$DMQ%:&,#9-*B)(V[J00G [;CUXQ\W_ !GU)?B3^UKX
M*\.6UEJ.D7&C:'K>^]U>S:VM+K<UE@V\K<2@=\=*^E+/0KRW^(ESJI:=K*?2
MXX#OF+1K*LA.%3.%X.20.:^>/VI(9+W]HCX616Z-<2+H6NDQQ#<P&ZRYP*\K
M-7%8&LYJZL]-KG/B+>RE=7T-S_A3%_\ ]!C2O_ @4?\ "F+_ /Z#&E?^! KB
M?[#U#_H'W7_?EO\ "C^P]0_Z!]U_WY;_  K\<]IA/^@=_P#@;_\ D3YCFI_R
M/[_^ =M_PIB__P"@QI7_ ($"C_A3%_\ ]!C2O_ @5Q/]AZA_T#[K_ORW^%']
MAZA_T#[K_ORW^%'M,)_T#O\ \#?_ ,B'-3_D?W_\ [;_ (4Q?_\ 08TK_P "
M!7(>#OV9M;\.>-/'^L7&NZ+);>(;^UN[5([GYHUBM(X6#9XR60D8SQ4']AZA
M_P! ^Z_[\M_A7'^#/ GBC2?&OQ!O]1L[M].U6_M)],4[GVQ):1QR#;_!^\5C
MCOUK>G5PJA->P:NOYGK[RT^'Y_(N,J=G[GX^:\CV;_A3%_\ ]!C2O_ @4?\
M"F+_ /Z#&E?^! KB?[#U#_H'W7_?EO\ "C^P]0_Z!]U_WY;_  K#VF$_Z!W_
M .!O_P"1(YJ?\C^__@';?\*8O_\ H,:5_P"! H_X4Q?_ /08TK_P(%<3_8>H
M?] ^Z_[\M_A1_8>H?] ^Z_[\M_A1[3"?] [_ / W_P#(AS4_Y']__ .V_P"%
M,7__ $&-*_\  @4?\*8O_P#H,:5_X$"N)_L/4/\ H'W7_?EO\*/[#U#_ *!]
MU_WY;_"CVF$_Z!W_ .!O_P"1#FI_R/[_ /@';?\ "F+_ /Z#&E?^! H_X4Q?
M_P#08TK_ ,"!7$_V'J'_ $#[K_ORW^%']AZA_P! ^Z_[\M_A1[3"?] [_P#
MW_\ (AS4_P"1_?\ \ [;_A3%_P#]!C2O_ @58M_@3K-XI:"_T^=0<$QR[@#^
M%<#_ &'J'_0/NO\ ORW^%>[?L^VD]GX>U-9X9(&-T"!(I4D;!ZUZN5X;!YAB
M5AY47%.^O-V^1T8>%*M44'%KY_\  .,_X9^\0?\ /S9_]]'_  H_X9^\0?\
M/S9_]]'_  KZ'HK[3_5;+NTOO/5_L^CYGEGPI^&&I^"-=N[R]E@DBEM_* B)
M)SN!_I7J=%%?0X+!4L!15"C?E\_,[*5*-&/)'8****[C8**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNJ7)TFXU"T;1EG5&B6$6<8E\H?PKYH?([MDUW_\ PD/P^_Z%F\_\"C_C7!>
M?&.CW?Q#^)T&M^'KY]!M-2LX] 1B8PL#6,338?CS!YYD.3G&<=JVA6Q7+.V.
M6W\T]-5M[OR]&RE*I9_O?Q?^1V?_  N?Q;_T$E_[\I_A1_PN?Q;_ -!)?^_*
M?X5:_P"$A^'W_0LWG_@4?\:/^$A^'W_0LWG_ (%'_&L?:XK_ *#E_P"!5/\
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M445]F>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDU^1^Y_T!/[YGSGN_P#/K\SJO^%3Z3_T.6F_]]#_ !H_X5/I/_0Y:;_WT/\
M&N5_X5_XF_Z 5_\ ]^31_P (!XE'_,"OO^_)H]S_ * G]\P]W_GU^9U7_"I]
M)_Z'+3?^^A_C7 ^ -$_X2GXB?$_0;_Q)IMMI_AG4K.TTZX"[?M$<MC%.Y))P
MQ#R,N1TVXK3_ .$ \2_] *^_[\FN-\&-XC\6>-_B!X?'AZ>-O"U_:V6Z)&9Y
M/.M([C+CL1YF!CMBM8*#C)_4GHN\^Z_K3\BE:S_=?F>N_P#"I])_Z'+3?^^A
M_C1_PJ?2?^ARTW_OH?XURG_" >)?^@%??]^31_P@'B7_ * 5]_WY-9>Y_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOLK^77:^ER\1G>$PU2%.3=Y/ML?JA16=X=UZT\4:'8ZM8F4V=Y$LT7GPM#(
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M1\,?^#!/\: /8:*\>_X;!^"7_14?#'_@P3_&C_AL'X)?]%1\,?\ @P3_ !H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD0KC8A7:_&W;R":/A+\$X/A/::K9V^K37]K>6EE:1B6((\0@MQ"6R#@ECEL
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?X^>)O">HG3-=T<ZY<RR7UX\L%_"FRWBFFB2.W1TB:9AY&64!F^<'G(4>O\
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MD.1AMK8QQG%@_:JT]KZTL;CPY?6U[<Z9'J,=LUQ"9#YN/*&-WW'+HN_H&;!
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M2))(-V9"#!%A"2N4!VYYIFB?!7X3>)]-,VG:7*EK:?\ $D6Y6[NH#+%"K0M
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M@* *QO\ AF&%;2&-M7M[\VLJM:QZCIXGA6**XMI;>)T+_,$2W9,C!/FL>.A
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MC/-,MOA'XK2RTZQN?$.BSZ;#K4VKW=FNE3*ER6G\^-,_:,@1OEAU#$)D<$$
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2(44C)QP2><8SSUSTZ58H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mrkr-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %L J # 2(  A$! Q$!_\0
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M<*!ZDU!8ZI9:FKM9W<%VJ'#&"57"_7!KB/V@E!^!GCT$ C^Q+L8_[9-7Q/\
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M(VX'8<=@?I+P1\;/B#\1/B/IUC9?#'4O#?@];<MJ>H^)HFM9TEP?EA4$AQG
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M>O>^E[W?S.ZMEU+$*E";]V'1:7=K+:UK>5CXJ\ ?"+QM^S[^U9I]RT^M^.=
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M7]_R\;MOOBO4_P!JGP)XE\1^$_@=#I6@:EJ4VG7EN][':6KR-; 1Q F0 ?*
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M:[1R+)*:J*ISO2W1=(\N^]O+:Y\__L,^%]8\(?L_Z=INNZ5>:-J"7MR[6M_
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M1:+XQ\2_M>^-/&&K^"M7\+Z9JWA]X;5M0A.T?\>ZHKN,J)"$+% 21R.U<O\
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MTZO-\%ME%/3S26CZK[K!1117RA[P4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45\Z>#OVV] \4_%SP_\ #N^^'GQ$
M\(:QKTMU%IUUXFT);*UN#;Q-+*4<RDL J]E/WESC-?1= !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/[H!]4T5\JM^V%:6&O:GXFN6N4\,3>'=(-CH-V8+:6/5;C4+VU>&25R%0AX
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M,;L].U=/_P -SQ?]"7+_ .#(?_&Z\N_X*5_\EB_9T_Z^->_])8*\BH ^KO\
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M:2]I=Z+<PQPZB-+NM-BOXI(@X86US^]C93N4@E@<!@<' ]:H **** "BBB@
MHHHH **** "BBB@ HHHH **** /C7]KKPYHWQ,_:N_9?\/WET9K*XN/$?G?8
MIU$B[;"-UYYQRH[>M>I?\,8^ /\ GMK7_@8/_B*\%\=?L_\ PS_9[_;:_9NU
M'P7X>L_"K:S<^(FU.X%S(5F*:?E-QD<A<&1\8Q][Z5]N?\);H?\ T&=/_P#
MJ/\ QH \=_X8Q\ ?\]M:_P# P?\ Q%'_  QCX _Y[:U_X&#_ .(KV+_A+=#_
M .@SI_\ X%1_XT?\);H?_09T_P#\"H_\: /'?^&,? '_ #VUK_P,'_Q%=5X!
M_9X\+?#CQ%%K6DR:BUY'$\2BYN Z;6&#QM'I7<?\);H?_09T_P#\"H_\:/\
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M$+\]-)O336S6OS/7K97B*&!I9C.WLZC:6NMTVGI\C>HHHKU3R HHHH ****
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MNO#WP$^#%]';>-)/%6G:EX:N;_1;K7+V:"U\N[MVN-UHTAB58U#G&W"[>.E
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MI/IUI';-=W<IEDE*J 26/)YZ9[8H ^,/^"BNKWVA?'+]F^^TV\GT^]BN-?\
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M / AO\:S/LD__/"7_O@T?9)_^>$O_?!H_M#-/^?U3_P*7^8>PP_\D?N1I_\
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MP:/[0S3_ )_5/_ I?YA[##_R1^Y&G_PF.O?]!F__ / AO\:/^$QU[_H,W_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKYR_;)^(SZ)I?A7P/8>.%^'NK>*;J>3_ (2#[2+=K.WM83*Q
M#GIOF^SQ>ZR,* /HVBOD[XF_&?Q?\2?V*K?XC^!M>M?#4[Z0UYJUW%&9+F*6
M+"36]N<A4)E61#(V2JC*C)!'U?&<QK]!0!\"^-?V?_A[^SC^VO\ LXZIX;CN
M=)76;GQ$VH7&J:O/<1DII^4P9Y&"<R-TQG('85]N_P#"P/"__0R:1_X'1?\
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M\"4_QKX\V+_='Y4;%_NC\J/]<*O_ #Y7WO\ R#^TY?RGV'_PE&C?]!>P_P#
ME/\ &C_A*-&_Z"]A_P"!*?XU\>;%_NC\J-B_W1^5'^N%7_GROO?^0?VG+^4^
MP_\ A*-&_P"@O8?^!*?XT?\ "4:-_P!!>P_\"4_QKX\V+_='Y4;%_NC\J/\
M7"K_ ,^5][_R#^TY?RGV'_PE&C?]!>P_\"4_QH_X2C1O^@O8?^!*?XU\>;%_
MNC\J-B_W1^5'^N%7_GROO?\ D']IR_E/L/\ X2C1O^@O8?\ @2G^-'_"4:-_
MT%[#_P "4_QKX\V+_='Y4;%_NC\J/]<*O_/E?>_\@_M.7\I]A_\ "4:-_P!!
M>P_\"4_QH_X2C1O^@O8?^!*?XU\>;%_NC\J-B_W1^5'^N%7_ )\K[W_D']IR
M_E/L/_A*-&_Z"]A_X$I_C1_PE&C?]!>P_P# E/\ &OCS8O\ ='Y4;%_NC\J/
M]<*O_/E?>_\ (/[3E_*?8?\ PE&C?]!>P_\  E/\:/\ A*-&_P"@O8?^!*?X
MU\>;%_NC\J-B_P!T?E1_KA5_Y\K[W_D']IR_E/L0>*-&/_,6L?\ P)3_ !JG
MHWQ \+^([\V.D^)-(U2]"EC;6=_%-( .IVJQ.!7R3&B^8ORCJ.U?/G_!.A0/
MVJ[O  QIE[C_ +[2O7RSB*ICZRI2II;=>_R/N^'<NCG>"Q^*G+E>'C&22UO?
MFW[;'ZL4445]P>&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<J/AMH[?$J;QS-Y]SK3Z6FCQK,X:""W$IE;RTQPS
ML1N;)R$0=JZJB@#S&X_9Y\+3^"O'OA02:A#HGC*]N+^_MXK@#R)9POG?9_E_
M=AF7>1S\SN>]>FJ-J@#H.*6B@#X;_P""@7A?4_&G[0'[-6C:/;BZU&YN/$'E
M0EU3=MLX6/+$ < FL7_AECXF_P#0O1_^!T'_ ,75GQ1_PN3_ (;C_9O_ .%J
M_P#"$_8OM7B+^QO^$1^U^9C^S_WGVCS^,X\O&SONSVK[UH ^ ?\ AECXF_\
M0O1_^!T'_P 72']ECXG8/_%/1_\ @=!_\77W_10!\KZ;\$?&=OIMI%)I*K)'
M"B,/M41P0H!_BJS_ ,*7\8?] I?_  )C_P#BJ^GZ*^,GPI@IR<G.6OFO_D3R
MWEU)N]W_ %\CY@_X4OXP_P"@4O\ X$Q__%4?\*7\8?\ 0*7_ ,"8_P#XJOI^
MBH_U2P/\\_O7_P B+^SJ/=_U\CY@_P"%+^,/^@4O_@3'_P#%4?\ "E_&'_0*
M7_P)C_\ BJ^GZ*/]4L#_ #S^]?\ R(?V=1[O^OD?,'_"E_&'_0*7_P "8_\
MXJC_ (4OXP_Z!2_^!,?_ ,57T_11_JE@?YY_>O\ Y$/[.H]W_7R/F#_A2_C#
M_H%+_P"!,?\ \51_PI?QA_T"E_\  F/_ .*KZ?HH_P!4L#_//[U_\B']G4>[
M_KY'S!_PI?QA_P! I?\ P)C_ /BJ/^%+^,/^@4O_ ($Q_P#Q5?3]%'^J6!_G
MG]Z_^1#^SJ/=_P!?(^8/^%+^,/\ H%+_ .!,?_Q5'_"E_&'_ $"E_P# F/\
M^*KZ?HH_U2P/\\_O7_R(?V=1[O\ KY'S!_PI?QA_T"E_\"8__BJ/^%+^,/\
MH%+_ .!,?_Q5?3]%'^J6!_GG]Z_^1#^SJ/=_U\CY@_X4OXP_Z!2_^!,?_P 5
M1_PI?QA_T"E_\"8__BJ^GZ*/]4L#_//[U_\ (A_9U'N_Z^1\P?\ "E_&'_0*
M7_P)C_\ BJ/^%+^,/^@4O_@3'_\ %5]/T4?ZI8'^>?WK_P"1#^SJ/=_U\CY@
M_P"%+^,/^@4O_@3'_P#%4?\ "E_&'_0*7_P)C_\ BJ^GZ*/]4L#_ #S^]?\
MR(?V=1[O^OD?,'_"E_&'_0*7_P "8_\ XJC_ (4OXP_Z!2_^!,?_ ,57T_11
M_JE@?YY_>O\ Y$/[.H]W_7R/F#_A2_C#_H%+_P"!,?\ \51_PI?QA_T"E_\
M F/_ .*KZ?HH_P!4L#_//[U_\B']G4>[_KY'S!_PI?QA_P! I?\ P)C_ /BJ
M/^%+^,/^@4O_ ($Q_P#Q5?3]%'^J6!_GG]Z_^1#^SJ/=_P!?(^8/^%+^,/\
MH%+_ .!,?_Q5'_"E_&'_ $"E_P# F/\ ^*KZ?HH_U2P/\\_O7_R(?V=1[O\
MKY'S!_PI?QA_T"E_\"8__BJ/^%+^,/\ H%+_ .!,?_Q5?3]%'^J6!_GG]Z_^
M1#^SJ/=_U\CY@_X4OXP_Z!2_^!,?_P 51_PI?QA_T"E_\"8__BJ^GZ*/]4L#
M_//[U_\ (A_9U'N_Z^1\P?\ "E_&'_0*7_P)C_\ BJ/^%+^,/^@4O_@3'_\
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M6!_GG]Z_^1#^SJ/=_P!?(^8/^%+^,/\ H%+_ .!,?_Q5'_"E_&'_ $"E_P#
MF/\ ^*KZ?HH_U2P/\\_O7_R(?V=1[O\ KY'S!_PI?QA_T"E_\"8__BJ/^%+^
M,/\ H%+_ .!,?_Q5?3]%'^J6!_GG]Z_^1#^SJ/=_U\CYA3X,>, ZDZ4N ?\
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M !T9OJ: /D;]O;QAJ'@']HC]FC7M*\G[?:7'B'R_M";T^:RB0Y&1V8]ZK?\
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MX9YT?_/1?SH\Z/\ YZ+^= 'N?_#8WQ"_Z@__ (!M_P#'*7_AL7XA?]0?_P
MV_\ CE>%^='_ ,]%_.E$T>?OK^=)[#6Y]Q?LY?&;Q%\4=6UNWUO['Y=G!%)%
M]EA,9RS,#G+'/05[M7R=^Q6RMXA\4X(/^BP=#_MO7UC7R7"F)K8O*:=;$2<I
M-RU>_P 3/L^,<+0P6<U:&'@HQ2CHM%K%,****^N/BPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7]D__H<_!G_@%_\ :J/^&Q?V3_\ H<_!G_@%_P#:J^A/^%?>%O\ H6](_P#
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M ,/!/V=O^BKZ%^<O_P 11_P\$_9V_P"BKZ%^<O\ \17LO_"OO"W_ $+>D?\
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M]G;_ **OH7YR_P#Q%>R_\*^\+?\ 0MZ1_P" $7_Q-'_"OO"W_0MZ1_X 1?\
MQ- 'C7_#P3]G;_HJ^A?G+_\ $4?\/!/V=O\ HJ^A?G+_ /$5[+_PK[PM_P!"
MWI'_ ( 1?_$T?\*^\+?]"WI'_@!%_P#$T >-?\/!/V=O^BKZ%^<O_P 11_P\
M$_9V_P"BKZ%^<O\ \17LO_"OO"W_ $+>D?\ @!%_\31_PK[PM_T+>D?^ $7_
M ,30!XU_P\$_9V_Z*OH7YR__ !%'_#P3]G?_ **OH7YR_P#Q%>R_\*^\+?\
M0MZ1_P" $7_Q->+^-_V=7UK]J7X9^-+#P_HB^$M$TG5+34HS#&K-+.J"$B/;
M\^"IY[4 /_X>"?L[?]%7T+\Y?_B*/^'@G[.W_15]"_.7_P"(KV7_ (5]X6_Z
M%O2/_ "+_P")H_X5]X6_Z%O2/_ "+_XF@#QK_AX)^SM_T5?0OSE_^(H_X>"?
ML[?]%7T+\Y?_ (BO9?\ A7WA;_H6](_\ (O_ (FC_A7WA;_H6](_\ (O_B:
M/&O^'@G[.W_15]"_.7_XBC_AX)^SM_T5?0OSE_\ B*]E_P"%?>%O^A;TC_P
MB_\ B:/^%?>%O^A;TC_P B_^)H \:_X>"?L[?]%7T+\Y?_B*/^'@G[.W_15]
M"_.7_P"(KV7_ (5]X6_Z%O2/_ "+_P")H_X5]X6_Z%O2/_ "+_XF@#QK_AX)
M^SM_T5?0OSE_^(H_X>"?L[?]%7T+\Y?_ (BO9?\ A7WA;_H6](_\ (O_ (FC
M_A7WA;_H6](_\ (O_B: /&O^'@G[.W_15]"_.7_XBC_AX)^SM_T5?0OSE_\
MB*]E_P"%?>%O^A;TC_P B_\ B:/^%?>%O^A;TC_P B_^)H \:_X>"?L[?]%7
MT+\Y?_B*/^'@G[.W_15]"_.7_P"(KV7_ (5]X6_Z%O2/_ "+_P")H_X5]X6_
MZ%O2/_ "+_XF@#QK_AX)^SM_T5?0OSE_^(H_X>"?L[?]%7T+\Y?_ (BO9?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/#<UA_PCWA37M.U":6>.86US/J:21+N#$OOC#,& Y'7!.*^T:* /B76/A?\
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MG=DHK-G&..M>ST44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mrkr-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #F 0H# 2(  A$! Q$!_\0
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M]#!JO_@;)_\ %5B44 ;?_"<^)/\ H8-5_P# V3_XJC_A.?$G_0P:K_X&R?\
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MS*G)U($:@?N_\MLG=^F*TK7]JCXKV0U\0^-M00ZZJK?-B,LY6W%J'0E<Q/Y
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MWMY;>YWJTS,S26]S=QDIGYGB 4*F:^D[>[TJQMH;:UN;*WM8$6*&%)T"QQJ
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M-9'V71K:+_D(VC0JX\WS<R@%58/YRY9?+%>L'_A*S_S.+_\ @HMO\*3'BO\
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M/JFG>'B@TVV"EKRX!QY*XS^ZZUY^*I3J)<I;?O+0]8HKSW_A+O&7_0-\._\
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MROV/5*5 "Z@YQGG'6N4_X6CX9_Y_KG_P6W7_ ,:I1\4O#0((O[D$=_[-NO\
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MCH&X?\2#2>O_ #X0_P#Q-?-?BBRMH?$VKQQVT,<:7DRJB1J%4!S@  <"OJM
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MR"H-7*OC5>V;RT_Z>/LG_.^NFE]A*47;_9OP\_0]M_X0>RSCS]8SZ?VQ>?\
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M;ZI/''-) [#5[\;9$8JZ\RCHP(STXXR*;IOPB\&:O9_:K*'4[BWWNGF+K%^
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M0&N <#BBWF'M:G\S^\]/O_A#X+TI('O4OK1+B9+>%I]<O4$DKG"(N9N68G
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6S.OV=0SLQ9C@18')/ HHIJ*6R __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mrkr-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $M G # 2(  A$! Q$!_\0
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MK_W_ !1]9H?S(/85OY6<']ON?^?B7_OLT?;[G_GXE_[[-=Y_PH?Q7_SRM?\
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MV!_K3O\ A5.N_P#/6+_ONCEP_P#,@O6[&Y_PF1_YZ?K1_P )D?\ GI^M8?\
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M[_A,S_?'Y"C_ (3,_P!\?D*\S_L/Q#_SX7/_ 'Z;_"C^P_$/_/A<_P#?IO\
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MB]@\.:A/=O:(DQ-Q87%JLT+EA'/ TT:">!BC[9HB\;8X8UX5^V_K-QX>\4?
M+4;39]HM_&I9-XR,_P!GW0Y'XUZ7\*_ /C32OB-XB\4^+!H]M-J%A;V4G]D:
MI=WR7\D3.1<"*Y0?8$ 9BMK"\B9F<L[L-[>3?M] MJ?P* !)_P"$S/ _Z\+J
MM:23J13[HSJ-J$FNQTG_  OOQ3ZV7_?C_P"O1_POOQ3ZV7_?C_Z]>>>1)_SS
M?_ODT>1)_P \W_[Y-?7?5:'\B/F_K%;^9GH?_"^_%/K9?]^/_KT?\+[\4^ME
M_P!^/_KUYYY$G_/-_P#ODT>1)_SS?_ODT?5:'\B#ZQ6_F9Z'_P +[\4^ME_W
MX_\ KT?\+[\4^ME_WX_^O7GGD2?\\W_[Y-'D2?\ /-_^^31]5H?R(/K%;^9G
MH?\ POOQ3ZV7_?C_ .O1_P +[\4^ME_WX_\ KUYYY$G_ #S?_ODT>1)_SS?_
M +Y-'U6A_(@^L5OYF>A_\+[\4^ME_P!^/_KTV/X\>*(U(!L\$D_ZCU.?7WKS
M[R)/^>;_ /?)H\B3_GFW_?)H^JT/Y$'UBM_,ST/_ (7WXI];+_OQ_P#7H_X7
MWXI];+_OQ_\ 7KSSR)/^>;_]\FCR)/\ GF__ 'R:/JM#^1!]8K?S,]#_ .%]
M^*?6R_[\?_7H_P"%]^*?6R_[\?\ UZ\\\B3_ )YO_P!\FCR)/^>;_P#?)H^J
MT/Y$'UBM_,ST/_A??BGULO\ OQ_]>C_A??BGULO^_'_UZ\\\B3_GF_\ WR:/
M(D_YYO\ ]\FCZK0_D0?6*W\S/0_^%]^*?6R_[\?_ %Z/^%]^*?6R_P"_'_UZ
M\\\B3_GF_P#WR:/(D_YYO_WR:/JM#^1!]8K?S,]!?X\>*)  39\$'_4>GXT[
M_A??BGULO^_'_P!>O//(D_YYM_WR:/(D_P">;_\ ?)H^JT/Y$'UBM_,ST/\
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M !1110 5!:?ZIO\ KH__ *$:GJ"T_P!4W_71_P#T(T 3T444 %%%% !1110
M4444 077W8_^NB_SJ>H+K[L?_71?YU/0 4444 %%%% !1110 4444 06_P#K
M;G_KH/\ T%:GJ"W_ -;<_P#70?\ H*U/0 4444 %%%% !1110 5!>_\ 'L_X
M?SJ>H+W_ (]G_#^= $]%%% !1110 4444 %%%% !4"?\?DO_ %S3^;5/4"?\
M?DO_ %S3^;4 3T444 %%%% !1110 4444 177_'M-_N'^5/C^XOT%,NO^/:;
M_</\J?']Q?H* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%^,
MOC9\._ASK$&D^+/'OACPQJL\*W$5CK.L6]I/)&S,JNJ2.K%2R, 0,$J1V-=;
M!>V]U+<Q0SQ326T@BG2-PQB<JKA6 ^Z=KHV#V8'H17BOB[X*^(/''QP\6ZL/
M%.O>$_"^H^%=(TASHHTYUU)X[G56GBE%S;S2($CN8L-'Y>?/;YF*_)H_!'X9
MS_#CX@_%QAI6H66D:OK-C>Z5<SZF;FVFMDTNTMRD<33.T3QRP3*VY$RAA +*
MBK& >J6^L6%UJ5WIT%[;3:A9K&]S:1RJTL"ON\LN@.5#;6P2.=IQT-?/G[5T
MZVWQ._9RE;[J^.6)_P#!==UI?L^_!CQO\+OB=X[U3Q/K>D>(K?7;.QEDUBRT
MA[&>_O%ENC(T@:[G.422- ,*NSRD0*L6VN7_ &V+@VGB[]G^4=5\;$\?]@^Z
MJHKFDD3)V39]'_\ "1VW^31_PD=M_DUXK_PE$OHU'_"42^C5ZGU,X/K1[5_P
MD=M_DT?\)';?Y->*_P#"42^C4?\ "42^C4?4P^M'M7_"1VW^31_PD=M_DUXK
M_P )1+Z-1_PE$OHU'U,/K1[5_P )';?Y-'_"1VW^37BO_"42^C4?\)1+Z-1]
M3#ZT>U?\)';?Y-,AU^VB0KG.69NOJ2?ZUXQ_PE$OHU'_  E$OHU'U,/K1[5_
MPD=M_DT?\)';?Y->*_\ "42^C4?\)1+Z-1]3#ZT>U?\ "1VW^31_PD=M_DUX
MK_PE$OHU'_"42^C4?4P^M'M7_"1VW^31_P )';?Y->*_\)1+Z-1_PE$OHU'U
M,/K1[5_PD=M_DT?\)';?Y->*_P#"42^C4?\ "42^C4?4P^M'L\NOVTH49QA@
MW7T-/_X2.V_R:\5_X2B7T:C_ (2B7T:CZF'UH]J_X2.V_P FC_A([;_)KQ7_
M (2B7T:C_A*)?1J/J8?6CVK_ (2.V_R:/^$CMO\ )KQ7_A*)?1J/^$HE]&H^
MIA]:/:O^$CMO\FC_ (2.V_R:\5_X2B7T:C_A*)?1J/J8?6CVK_A([;_)H_X2
M.V_R:\5_X2B7T:C_ (2B7T:CZF'UH]GCU^V1Y6SG>V[KTX _I3_^$CMO\FO%
M?^$HE]&H_P"$HE]&H^IA]:/:O^$CMO\ )H_X2.V_R:\5_P"$HE]&H_X2B7T:
MCZF'UH]J_P"$CMO\FC_A([;_ ":\5_X2B7T:C_A*)?1J/J8?6CVK_A([;_)H
M_P"$CMO\FO%?^$HE]&H_X2B7T:CZF'UH]J_X2.V_R:S_ !!XOM].T+4+P1F4
MVT#S^7NQNVJ6QGMG&*\E_P"$HE]&K/\ $?B.6;P]JD9#8>UE7\T-1/"<L6S*
MKBW&G*4=TF>B_ GXT)\;?#NH:JFD-HXM+K[+Y37'G;OD5MV=JX^]C&.U>EU\
MR?L%_P#).O$/_86/_HF.OINO%H2<Z<92W.7A_%UL=E=#$XAWG):O1=7VT"BB
MBMSZ **** "BBB@ J!/^/R7_ *YI_-JGJ!/^/R7_ *YI_-J )Z*** "BBB@
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MW_[X%'_"*:/_ - ZW_[X%:U%'/+N')'L8ESX6TA53&G6XRZC[GO4O_"*:/\
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M%%% !1110!%=?\>TW^X?Y4^/[B_04RZ_X]IO]P_RI\?W%^@H =1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%?+7Q@_9UO/C1^T/XFNI])\)'2E
M\'Z/91:IXM\''6660W>K&46,YN(5@E17B9\"0_/ 2!@;N_\ @5H&K^&OB-\9
M;+4]2\1ZC:MKMC-IKZU;_N'MO[(LD\R"X$*B5C+'-&X#L5,"E@K.SR 'LU?,
M?[8^N0^&_'?[/6IW"220VWC<NRQ %B/[/NQQDCUJI^Q_\/V\"^*?$+6FGZN1
M?V$5QKNH^(O!\&AW8U5IY7>&.:.%3>1C?(2YFNE4A-D[AR:H?M]_\A+X%_\
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MO]XT?VW:_P!XUXO_ ,)>_J:/^$O?U-'U-A]91[1_;=K_ 'C1_;=K_>->+_\
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M1110 4444 %%%% !4%[_ ,>S_A_.IZ@O?^/9_P /YT 3T444 %%%% !1110
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MS_UT'_H*U/0 4444 %%%% !1110 5!>_\>S_ (?SJ>H+W_CV?\/YT 3T444
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M_0=E_P# 8?\ Q5<U_P -A:C_ -&]?&C_ ,$-E_\ )M'_  V%J/\ T;U\:/\
MP0V7_P FUV_7L1_-^1R_5*/\OYG2_P##-]M_T'9?_ 8?_%4?\,WVW_0=E_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mrkr-20221231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %V J # 2(  A$! Q$!_\0
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MNRL[^A]'T5^?%I^T1\;[/X&:/\5)_%FEW5A%JW]F/I#Z7&'O,L<O)( -O3:
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MZHKXFLOBW\=/$GPCU'XUV'B/1;/P_;R2W,/A-]/5@]K'(5;=-]_=P>_.,Y'
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M[+HKXN\.?M.?$S4?A%\1(]/AB\4^*O#=S"MGK=IILB1WEG(Q#7 @*C<R!2<
M=\D<'/5_LW?%3Q'XP\=):7OQAT'QG8O:L\VCS:0=.U**7'1$VKD*>I^;(SP.
MM<];A[%8>E5JU)1M#?XG?1/I'2Z:MS<O7LS6EF]"M.$()^]Z=VN^NJZ7/J:B
MBBOESW HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5\3^/==F^(5[<:GXNM$CN+ZUL4M[BVN%.1+$=S*%&2 FWICGO7(_\/!_"_\
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M[?!%_@'X.O\ PX-;.N6TVHRWT,SVWDR('"@JV&(8_+G/'4\5Y/\ \/!_"_\
MT*FM?]_(?_BJ/^'@_A?_ *%36O\ OY#_ /%5%:KFN(H_5ZBO'3I&^E[:VOI=
MVUZE4Y992J^VA*TM>LNN^FVMCOOCO^R_I_QBUS3?$NFZ]>^#O&&GIY4.LZ<,
MLR9)"N 5)QDX((/)'(JC\%_V4;?X9^+K[QAX@\4ZAXX\87$#6Z:GJ*D>0A&&
MV@LQR1QDMTR !DUQ_P#P\'\+_P#0J:U_W\A_^*H_X>#^%_\ H5-:_P"_D/\
M\55+$9Q'#?4TWR6M]F]NU][>5[";RMU_K#MS7OUW[VVOYVN6C^Q.Q^".H_#W
M_A,.;O7QK?\ :']G?=Q_RS\OS.?][/X5Z3IGP(.G?M /\3/[:\P-HBZ/_9GV
M;'39^\\S=_L]-O?K7EG_  \'\+_]"IK7_?R'_P"*H_X>#^%_^A4UK_OY#_\
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M@Z6]HMG@79,3H9 V_P"3[^=N&Z=:\Y_X>#^%_P#H5-:_[^0__%4?\/!_"_\
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M9HF4J?-16(D.&/)YR<G.!7$?\/!_"_\ T*FM?]_(?_BJ/^'@_A?_ *%36O\
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M]3T6-DT]1IT5D%+ @M(4),AY/7DGJ37+_P##P?PO_P!"IK7_ '\A_P#BJ/\
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MY#_\51_P\'\+_P#0J:U_W\A_^*H_L_%?R?D']HX3^?\ ,^K**^4_^'@_A?\
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MFH-TU=FM)0<TJCLCSUE*L5.,@D'!R*2I;NX-Y=SW#(D;32-(4B7:BEB3A1V
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M?H6(P%'%24ZE[['Y_P#_  P=\1?^?W0__ B3_P"(H_X8.^(O_/[H?_@1)_\
M$5]5>!_C)XB\87&B*W@:XM8+O5-4TW49TO%E73/LDTD2F0A<,9"@X!P,GDXR
M?6:Z?[5Q/E]QR_V/A?/[S\_/^&#OB+_S^Z'_ .!$G_Q%'_#!WQ%_Y_=#_P#
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M,>%UE6+J8'%Q<:E-V:O?7U/S\_X8.^(O_/[H?_@1)_\ $4?\,'?$7_G]T/\
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M4L<#JQ]5\8?LR_%[XE:_HNF#PG!X5\)::/L>FVTFH02I86Y;+.Y5RTCL<LQ
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M$DNY?T1>Y5>@)YP.:QO#O[17PW\6ZM#IFD>++*^OY@QBMT5PTF!DA<J,G X
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MZ]R_]69ITHJNK4U\V][7Z1OLNU^K/S-T*"YU;XS%_A3'>Z>J7CSZ8]S* ]M
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M^=Q+AG(?)ZYSGO6CXW_95^'7Q%U^76=?TR\OKZ150,=1G1(T485$17"HH]
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MU=\YRZNY#<\\YSWI/AW%N$HWBKN^[M'TTWZ=K=]+)\*XZ5.4;P7-*]KNT?\
M#I>[VZ*RZNUOA#XPZ9:ZCX.\.^*M;M8="\=ZL2]UIT" ?;[?'R7[QC'D.YX(
M_C^^ ,G,VL0KXU^"8\2>,46PUJQ=+/0M88?O];C4X>&1.KB(8Q/V^X<\8^Z]
M>_8^^&'BC7;O6-7TF]U'4;J7S9IY]3N&+M_WWT[ #@#@5:\6_LG_  V\<:C%
M>:OH]S.T$*6UO#'?S10V\2C"QQQJP5%'H!U)/4U<L@Q;E.5XZJUKO7^\]-^N
MG7KO?27"^-<JDKQ]Y6M=ZO\ FE[N_73KUWO\6? X'XD_#O7_  WXYB7_ (5_
MHL#W-OXEN& DT.X(RJ0L>9!(>#".N<C%<-\$;K4KGQ5/X6L]-3Q-X<U;*ZEI
MMR?)A,"9S=;SQ \8^82=NAR#@_HOK7[,?P]UWPEI/A>?29XM TPEX+&VO9H8
MVD/623:P\Q_]ILGDU5T[]E'X:Z1X8U+0+'1I[33]2=6O#%?3++.J_=C:3=N,
M>>=F<$\D5?\ 8&+O2]Y>ZM7?5_W=K6Z:WT\K(O\ U8QO-1]^+Y%J[N[_ +NU
MN5;:WTOI:T5^=&C7DW@?XM7=C\/[AO%=E-<MI]O#+:[H]7MV.#%)%_$K=.W0
M,,<8L?$FVL?A;\5XY_ VI26=Y:&.<Q6DWF_V;=G_ %ELDPXF"'Y=V,$<'.#G
M]#_"W[*/PV\%-?R:-HT]E<WMNUJ]TM],9HXV^\(W+9C)'!*X.,C-1>$OV1?A
M;X*\0V>M:;X=)O[-_,@:ZNY9T1NS;'8@D=02.#S6*X=Q?(H\T5[U]W[O^'2_
MX]%ZG.N%,=[-0YHKWKZ-^ZO[NE_O?1==3L/@YXA\2^*?AQHNI^+M)71=>GA#
M3VRGKZ.5_@+#!V'D9Q7:445^A4XN$%%N[75]3]4I0=.G&$I<S2M=[OS84445
MH:A1110 5Y;\:O&=_P"&=1\(V$>OQ>#M'U6ZGCO_ !'/'$RVNR$O'$&F!B0R
M," S@CY2H^9A7J51SP1743131I+&W5'4,#^!H ^4D^.7C1_B+:+!K-W>>&EU
M'1;(ZB=+MK;2GCN(5>:2<R'[3$TG/E8^3>\2DX:NI^//QN\6^!]%\>3^'K*>
M:?2;FWL;>2#3FO%M%^S)<RW4JKR0PE$2@X4,I)XS7T*T,; @QJ0<9!'7'2JJ
M:-8QZG<Z@MM&M[<Q)#-,!S(B$E0WKC<V/K0!X9\*/B]K7B_XJ>+]'U+7(TTO
M$PT^V:UCAGL76Y:%$D4_-&[#!"3;C)M+IM0[1<T3XA^*?#7P:U'QA<ZC_P )
MA+>ZO#;Z-'J,<5F5MI;R*TC:5H8P.2S3<+D!@O;->W_9H1(S^4F]B&9MHR2.
MA)]J?Y:[0NT;1VQQ0!\JW'[8?B/3=)DEU#POHUK= >:LK:G*+7:L=R6B+F($
M32/:.L2X^;S%!Y!!]Y^&_BF^\1OXAAO@6:POQ'$YC",(Y((IUC<#C?'YNP_[
MOKFNN>UAD&&AC89!P5!Y!R#^%0:7H]EHL4T=C;1VRS3/<2[!R\CG+.3W)/>@
M"Y1110 4444 %%%% !4%]--;V<\MO;FZG1"T< <)YC <+D\#/J:GHH \6\&_
M'37/$MI\+9[GP[:VD?BV2[BO98[TNMG)%',P2,;09,^2<L=H ['.![36+9^#
M-!T^'2H;72+."+2G>6Q2.%0+9G#!FC_NDAW!Q_>/K6U0 5YO\0OB-K'@GQSX
M3LULK*?P]JUVNGSSLS^=%/(K^5\P^1 SA$4-G>6(RN,GTBL'4? GAW5_$NG^
M(;W1K*ZUO3P1:W\L(:6'K]T^VYL>F3CJ: /"O$G[3GBG3O MGJ5KX7LEU^75
M[VPN-.\Y[I;>*'4EL$8% IDD9Y8SM& 2' /&:]U\#:CJVK>%;"\UN)(-2F4O
M+$EL]MM^8X!C=F93C&06/-1_\*Z\+_O?^)!I_P"]D$S_ .CK\SBX-R&/'7SR
M9<_WN>M=%0 4444 %<_\0/$%_P"%/ ^NZQI6F-K.I6-G+<6^GJVTSNJDA,^Y
M].?3FN@JMJ.G6NKV%S8WMO'=V=S&T4T$RADD1A@JP/4$&@#BO@M\1[CXF>$[
MJ_O+=(+VQU"XTV=H8)8(Y7B8#>L<P$B @CY7&0017?5F^'?#>E^$M(ATO1K&
M#3=/AR4M[==J@DDL?<DDDD\DFM*@ K"\;>&[CQ9X:O--L]8OM NY5S#J&GR;
M987'0^A'J#U%;M8?C3P]=^*O#=YI5GK-UH$MRNPWUDJF9%/7;N! )'&>H[5<
M':2=[$35XM6N?GS??'+XE_"KX@ZEI.M>,+SQ%#8R/:7<4=[F.5#U:.0#*.!R
M#U4C!'44[Q9\8?B7\.?%&F7%MX\U;5+"XABU*S@U)QO,+<K'<PX^5NQ'<88<
M$5]%>&?V%?"?AW64U*37-3U2:$,\,=['$\:R_P ,C+M^?:><'@GKFHS^PGX;
MO_$/]K:UXIUW6Y99_/NEN3$/M)SDAF500#TXQQP,5]/]<P5]4MM?=W_R/E/J
M6.M9-[Z>]M_F>+?$SXH>.+OPEI?Q#\.^--<T?1M8N'MI=%N+O#VURHRYMR1F
M6 ]F'W>AK-E^-GC_ ,<>"K[6[+QCJVCZKH$,:Z@B3^7:7L1.U)$.,+/ZQ_QC
M+#D$5]&^/OV--)^(>MB_U#Q9JT$,$8M[*PM88$M[* ?=BB39P!Z]2>346O\
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M<[6T][[7EK\-^_3SM;E+#]L7XD^-/"C7/AZZTV/Q%I5NTNHZ4]B&^U0+RUS
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MVE\FTBS]?GD;JSGDGVJ'Q)^PKXAGT&V\.:!XHTS3- B*RW'F6\AGO[C',LS
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M=;T>Z2]TR]B$T$Z=&4_R/4$=B*U*K:9IEIHVGV]C86T5G9VZ"*&"%0J1J!@
M =!5FOT6/-RKFW/U:'-RKGWZV[A1115%A1110 5QWC_XA2>#[O1=+T_1Y_$&
MO:S+*EGI\,J0@K$F^61Y'^5%48'<DLH YX[&N7\<?#S3?'B:>]W/>Z??Z=,T
M]EJ6F7!@N;=F4H^UQV925(((([9 ( /.I_VG;6T^(%OX8NO#ES9RM<6%I.+B
M_MENXIKM5* 6H<R2*A<!V7( #'D*:Z#XB_&^#P%;:_<Q:'=ZQ:Z"\":E-#-%
M$L)D02;1O(W,%:+"CJ95&1R0MO\ LZ^"+.:.YM]/F@U"&XM;J#45N'-U!);I
MY:%)22PW)N5QGYP[[L[C5KQ-\&--\5WGB#[7J>I6VGZV\<MY:6%RUN96$'V>
M0.RGYDDB6-2A'&P$$$T 5?"'QRL?%OC#Q9H2:1>6HT!&E-T621;A58JV%4EE
M)(W*#]Y2#QTJOX)_:$T'Q-\,9O'.I*-$TJ*:*%X1+]KGB:5HUB22.(%DE+2H
MOED9!(K0\-? CPMX0U:YO])%_9M*KQ10)>/Y5K$\IEEBA7^!))#O8 YSC!&*
MEL/@EX=L]"U+3)I-2U+^TK^VU*[O;^]>6ZGFMWB:#=(>2%\B(8[A><Y)(!D0
M_M1?#6?3I+U->G\I& 9&TR[$N"CNSB,Q;BB+%+O<#:GEN&((-=SX5\76WBL:
MDL$;PRV%TUK*CD'/RJ\<BD'!5XW1P?1O:N!U+]E[P+J4.QH-1@?;Y?G6]_(D
MGEGSQ)'NS]QUN958=P1Z"NY\'>#8?"(U5DF\^74+O[0Q";%C142**)1D\)'&
MBYSS@GO@ '14444 %%%% !1110 4R65((GEE=8XT!9G<X"@=23V%/J.XMXKN
M"2">))H9%*/'(H96!Z@@]10!SEM\3O"=[I_AZ^M_$.GS6?B&X^RZ1/'.&6_E
MVNVV(C[_ ,L;GCLI-=/7@-E^RS):/\,[E?%EW%<^#;P3&WB@C^R7$6^=V549
M2T;MYRJ65\%4 QT(]^H *P%\>:$_C"3PLE^)->B@6XDM$B=O+1@2I=PNU<A6
M(!()QP*WZ\;\8_ 6[\7?$N]UV+6E\.Z;?V3VU[-HJ/%J-V##Y(CE=G:%T7AU
M)BW JH!QG(!UI^-O@/;X<8>*M-9/$=P]KI#K-E;V59/+9(R."=_R^YZ5O^'/
M&&B^+QJG]BZE;ZD-,OI=,O?L[;O(NH\>9$WHR[AD>]?/,'['%]#X;TW3F\7I
M<76D3^;I=Y+8(#:[7NIH_D0JN5GGB?@#B''<8];^"GPI?X1Z'J]A)J*ZG)J.
MHG4I)Q$4)E:WA24G).2TD3OG_; [9(!Z'1110 55U35+31--NM0O[A+6RM8F
MFFGD.%1%&23] *M52UFWN[K2;N*PF@M[YXV$$MS$98T?'RED!&X9QD9'UH K
M^&/%.E>,M'CU31KU+ZQD=XQ(@*E71BKHRL 596!!4@$$<BM6N'^#_@&\^''A
M*73+Z]AN[B>_N;YEM498(/.D+F./>S.5!).68DEF/H!W% !6=XAEU2#1;R31
M;>VN]42,M;P7<ACBD8?PE@"1GIG%:-9^OZI+HNC7E]!87.J301ETLK, RS-V
M5<D#)]S51W1,MF?*EE^W/J6D^,FT/QAX-C\.K#*UO=R"Y>22U?LS)L&Y,X)P
M<XY&:/$G[;/B/P-XFBTW7O!%E]E8I,MW8:BTB75LQXF@8H X(Y'(YX.#7G7C
M#X._%WX]_%$ZKXB\,2^'+:X_=^>XC,=I;KDA<*VZ1\9QZD]ATJ^-_@O\2O%\
MNA^&=$\":CI?A31RUOIS:A+%YA+MF2XG?><;C\VU>%' &>OU"H8.\>91VU][
M1>CO_7Y_)O$8VTN5RWT]W5^JM_7Y>K^._P!M#7O",EI>V?A73=8\-ZDIDTW5
MX;Z14F4?>C<>7^[E7HR'D=>00:V?$?[76IGP):^,O"?AJUUW1$"Q:K#)=M'=
M:7.>TJ!#F,_PR#@^U>+^-?@C\0-&\+CP)X5\&ZG?:,ERMYJ.K2^4#J-VHP&B
M4O\ NXE!(7HS=6]*Z*Q^"WCKX+^!+FS\->&+S7O&GB.T\G4M0B*&TTZV/6!%
M9@))3W8@@=JAT,)RQ:M>_?=>>NG]:=#15\;S23O:W;9^6FO]:]3M/#_[9^J^
M,/"MU<Z)X5L[GQ+I^^:ZT62]8/-;#GS;<A/WA7^-,9 Y&1G$7@3]MN^\="\T
MR'PYI]GXE8!M,M;B^98+X_Q0^84^24_P@C#'C(.*\M^'?[//CGX>6,?C&?PA
M?:EXFMY2NCZ/'(@$$H'_ !\W+!Q\JY^6,'YCUP.M+PA^S-XWU#4M3\3>,?"V
MI3QV\OVD:3;-%'<:G<,VX("K;8H\\LW! X49Z6Z&"]ZUK=->O;?5?U?J0L1C
M_=O>_73IWVT?]6Z'JWA7]NJYU#Q'+HWB'PU:^&YFWP1W%S=2&."Y!P%N!L!1
M,\%@#MZXQ22_MQ:SX6\:#1/&'@>/2(H90EW);7C3/&A'$B#8!(O(8$'D=*\O
M;]GWXG?%KXA7^M^,?#]WHEK*#<7<D"1%S&@ 6&! WS.0 H+'W8TOB;X'?%+X
MJ>+-(LO^$+G\,:!90IIVG_;)8W6RM5R<RN&+2-U)]S@8%/V&"OK;;77;TUU_
MKYS]8Q_+I??3W=_733^OEZCXQ_;5\2>!M;@M[[P;IM[IMRJW%GJ5CJ+M#>VQ
M/$D3&/&<<%3RIX.*] UG]I:X/AZP\3>'=)M=:\,W@""Z^T,DMM-CYH9TVG8P
M/O@]J^</'?P8^(VJ:=I7@[PUX&U2'PII4S/!<7S0B:[N'P)+F0[SY:GLB\ #
MG)KT[3?@GXE^%/@:Y\+>'M%N]7U'5U236]7!7R6('$,"LW 7/+D9/\OE^(E2
MH9<ZF&DXU>G(N9OU6MO/L?6<-.MB,S5+%04J7VN=\J7H]+^7<][^$_Q>T[XG
MZ<^U%L=7@&9[$ON('9T/&Y?Y=Z[^O"/@+\#+CPO<1^(]?1H-4 *VUD'_ -0I
MX+/@X+$=N@^O3W>O#RFKBZV$C/&QM/\ %KNUT?E^6Q[V<4L'1QDX8&5X?@GU
M2?5>?Y[A1117LGB!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '):M\6/".A>)6T"_UZUM=65/,>W?=A/D:0*S8VJQ1&8*2&(&0"*?X
M(^*7A7XC6MS<>'=9@U&.V5'E 5HV1'&Y'*N =C $AL8.#@\&N"\>_ _6O%GQ
M NM:T_6-/T.SNX/)NIK."=+NZC\EH_(G E\F="2I#,F]0,*1@&E\(_!77[31
M]6'B'6=/FU:?PS%X6M)=*MY(8HH(TDQ*^]V+2%I">, !1C.2: ._T7XF^%_$
M6N+H^FZS;WFHO;+=K#'NYB(4@AL8SM96VYSM96Q@@UT*7<$DFQ9HV?D;0X)X
MZ\?B/SKQ?X;_  1UCPW\2!XQN-173X;NT!O-(A=V/G_9H(/*)#F(PI]GWH0@
M?+X)P,'A[7]B*&UM4%OKUMIVH&W,,NIV-B8[@LT=XDCAM^<M]JCSZB$ _P .
MT ^EXM=T^?4UTZ.\B>]:#[4L*MDM%NVEQZ@-@''3(SU%7Z\7^%WP9U7P)K^D
M/.UA'9V?]HWCQZ3%]GLXI+EH@+:WA+,4B41&0Y/+OQU./:* "BBB@ HHHH *
M*** "BBH+VSBU"SGM9@QAF0QN$<H2I&#AE((^H.: (9=;TZ"XMH);^UCGNB5
M@C>90TQ'4(,Y;'M5VOF#P?\  'Q1X/U'X72V6G6T%WH5N+&\O#>Q36L%H+J6
M62(0/$7+LC(%DC=2&QNX3YOI^@ IC2HC(K.JLYPH)P6.,X'KP"?PI]>4_%WX
M6W_C3QAX3US2H[7[9I<&IV[3WLTGEQK/92Q)\BGD&1DW$8;:.O% 'HI\1Z2N
MGB^.J60L26 N3<)Y9(SD;LXXP<_0U8T_4;35K1+JQNH;RV?.R:WD$B-@X.&'
M!YKY#LOV6/%FK>"X]"OM-L-)T^VOK6^M;:.YBDF23S[);AV(C\K<L-M.8\)@
MK,%<%MS'ZP\+>'+;PEH%GI-H[206R[1(\<:,^2221&JKDD]E% &K1110 4V1
MUB1G=@B*"69C@ >IIU<]\0O#Y\5^ _$.BB%[G^T=/GM##'=&V:0.A4J)0K>6
M2#C=M..N* -C3M3L]7M5N;&[@O;9B0LUO()$)!P<$$BK->>_ KPOKG@_P!%I
MFNQ0VTL5S,;6UC\DO!;%SY22M"B1O(!U95'4=2"3Z%0 57U"2YAL9Y+.!+FZ
M5"8H9)/+5VQPI;!QGUP:L5!?7:V%G/<O'+*L2%RD$9D=L#.%4<D^PIK<3V/E
M^Y_;HC\/>+SH7BGP'?: \$XAO'-ZLSVX_OA!&-X[\'D<C-2>,_VVY? VM)97
M_@22>VG03VFH6FJJ\%Y;D_+-$WE#<".W!!X.#7D/QH\.?$W]H3XFV]S#\/-3
MT2Q!%G9R7ED8=L6<^9<2D?CCL.!D]<KX@?#3QJGA_2_ GAWP3XBU+1=*N'G;
M5[K3I ]W<OP[1!A^Y@]%XS]YJ^HAA<*^7F23>ZYMOG?\/\CY.>+QBY^5MI/1
M\N_RM^/^9[YXU_;4B\+6VGZI9>#Y-;\.:DN;+5H-1"*S@?/#(AC)CE4]4)]P
M2#FJ/B;]N9-*\&6GBK2?!$VN:/\ +#J)34A'-IMP>B2IY3?(W\$@.&Y'!XKQ
MK7OA-XV^'_@2]\%:1X0UK7K_ %=HKG6=0BLI);.!DY2&VXPSC/S3#K]U>*H6
MWPL\>?"?P9=W%CX)US7?%OB.Q>T^QPV$DUGI]H_#&X !629L?+&<A.IYP*\?
M-:6&H8&=6E/EDOA:]YO_ +==]_EWT/M.$/;8_/L/A<3056E)^_&4G3C%=7SI
MJW+NM^UFSZM_9T_:M\-_M"0W=K!;G0O$%MEWTFXG$C/%VDC?"[QZC&1]"#7M
M]?G]^QI^Q]XBMO%MKXX\9V]_X;BTN;=8Z<^Z"YN)1_$XX*QCT_B^G7] :^8R
MRMB:^'4\3&S_ #7>W0^ZXYR[)<KSB>'R.KST[*ZO=1EUBI7?,ORVNV@HHHKU
MC\^"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *0D*"2< =2:6L/QSHQ\1^#-=TH6BWYO;*:W^RO<M;";>A7895!*9SC
M< <=<4 2OXOT&.RBO&UO3EM)7,<=P;N,1NPZJ&S@D>@K2N;J"SC,D\T<$8R=
MTC!1P"3R?0 GZ U\EZ?\#/&&G7FB7UW\/M$\1:9937ZIHE]-91SA)K6WC5KB
M1(A#*0T3@.%#[-N=Q%>DW'PZUK0-"^'6CWEBGC2+2-"N=-N8)W/D3WGDPB-I
M"RMA66.= [@XW@'[YH ]HAU"UN;);R*YAELV3S!<)(#&5Z[@PXQ[U8KYRD^!
M_B'6/V9/$/P]O]-MUO;J.[GT^%KP*D;23R20Q3M&%5V4%2Q"B,DX"X%=5\:/
MAYXT\:>)]+N/#^MWVF:9:VT8>*RU66SWR_;[5I"P3[W^BK=*,]V'&<$ 'L$T
MT=O&TDLBQ1KU=S@#\:?7RM:?##XI:7;R#Q-=W_B+3H='EMY$35Y;D3Q_99(D
MM3;;?WDYG,<OVD_-@8+<8/TKX6M;RQ\,Z1;:BYEU"&SACN'+;MTH0!SGOR#S
M0!J4444 %%%% !1110 445!>V[W=G/#'/):O(A19XL;XR1C<N01D>X- $]%?
M)GA30?B=IWB3X5-J=OKVHP6MM'#/]LFG9EE^UW'VJ6YE2555A;FW8><D@DP4
M4(<FOK.@ HHKYL^/.G_%:]^(S3:'IM]=>%4T*_MH!H^JF%C(\<1,DD>S_6AM
MZQX8\*<;6:@#Z3HKXQN?#WQ7N-*\*WFGVGBF&+PMJ37%O;-<2Q2:I!YMS/B6
M-Y"P1XXH(1%*6:,R@%F/->Y_LXZ7XLT[0O%<WC#^T%U#4-?FU&&*_E+^3#-;
MV\GE19)VQQNTB!1P"C4 >MT444 %%%9?B>35HO#FIOH,-M<:V+:0V45Y(8X6
MFVG8'8!B%SC) /% &I17EO[-MAXMTKX7):>-HKU->BU34MTFHWGVJ:6(WDS1
MN7V@;2C#:   H7  P!ZE0 5G^(-=M/#&C7>JWYE6RM4,LS0PO*RJ.IVH"QQU
MX%:%5]0OK;3+&>[O9XK6TA0R2S3,%1% R22> *:W$]M#S3PU^T_\-/%^L6^E
M:5XF2YO[C(AA:VFC,I SM4L@!8]EZD\#)JK#^UA\+)=373V\4+;W9F\@I<V=
MQ%L?.,.6C 7!ZYQCO7PE\6+SP]X_^,5VOPUTN9;>\G5+>&V/-Q<9YEB4<QJ3
MR/3!/'02?&W5M-U'4-&L7NH-;\:6L/V?7=7L2##=S9PD8 _ULB#Y6E&-Y['&
M3]-'+*+<?B5UMI=>NG]?E\K+-:T5+X79[ZV?IK_2_'[X\7?M)_#SP)KDVD:[
MKCZ?J$0#&)[&X(92,AE8(0RGL02*;K7[2_PY\/V.EWU[XA"6.J0^=9W4=I/)
M%,H." RH0&!ZJ?F'<"OC7XBS1>%/@CI/AGQ[,FH>.0RSZ-:JP%UHUF>=ES)W
M#?PQ'D<<C%8'@J1/#'PNUFX\8.LGA35U8:3HLAQ<75Z!A;JW/6)$Z-)T;[N&
M[9QRZDX*5WO;IKZ:?UWZFDLSK*;C9;7ZZ>3U_K32^A]TR_M+_#B+PO#XB_X2
M$/HTEP;4W4=I.XCE SLD 3*$CD;@,]LTNF?M+_#G6=$U35K'Q#]JL],"M>&.
MTG+PHQP'*;-VS/!8# [D5\&_!#SM%&J>(=7NH;7P"L7V768[I-\>J9&5M8DR
M-\Q/(8?ZO[Q([YGPKM]3N_'DNK>&+M/#VFZ<SW%UJ-^XDM[*S)P4G.,2AE^7
M9CYSP!6CRRBN;WGI_5MM_P"O(A9K7?+[JUZ=?7?;_@Z]3]!/#7[3'PX\7W<]
MIH_B$7MW# ]P;=+282.BC+;%* N0.=JY. >*@T']J;X8>)=8M-+L/%$3WMU)
MY4*36TT09^R[G0 $]!D]>*_/^YBA\:?%R7_A6=G<:;')=>?IZK-Y;6VWEIBV
M?W2 @MR3M'!)J?XMW^D>+_'EM!X;1-6U>2..WO[S38MD.IWV</+!$.5!/<8W
M'+8&:?\ 9=%RM=ZJ_33UT)_M:NHWLG9VZZ^FI]Z77[5WPNL-4ETZ[\2&SO8I
MC!+#<V%Q&8G!P0V8QMP>N:M>)OVG/AQX.UB;2]8\0-9WL05BC65PP96&5=6"
M$,I'(920:^$/C/J5FNGZ#I&K7<&L>/[",PZMJ=JX*+'@"*UD8?ZZ:,<&0=/N
M_-C-3^+9(_#?PCT[0/&$BW7BG>EQHMGD"YT>S;EEN'Z[9.J0GE?O<9Q4K+*+
M47=Z^GWK3;]/QIYI63DK+3U^YZ[_ *_A]Y^(?VA_ 'A;2=(U34->":9JT9EL
MKR*UFEAF ZC<B$!AW4X(]*K1_M+_  XG\,3>(8O$/G:1!.+:>>*TG8P.1E?,
M4)N0'LQ !/ .:^-_A>Z^#/A!KU]X^D5_ >L(RZ7H$W_'S?7@Z7%MGF(+WDZ'
MT-<?\#TO;#6+SQ ][!IG@^SC\K7+B]7S;:Y@;_EU\OCS9'_A4<@_-D8S4_V;
M1M+5Z/Y/RVWZ==?N+_M2M>.B]Y?->>^W7II]Y]\:+^TO\.?$=EJEUIOB'[8F
MFP_:+J..TG\U(LX+A-FYE'<J#COBD\,?M-?#;QEJJZ;I'B1;N_>-I([?[+,C
M2[1DJFY!N;'11DGL#7Y\^"+:^USXFR7W@.1_#MO:3O>17EY< QZ9:@\M/)T*
MA>"#G=G;SFE\6'3_ !U\5FB^'=A*#<S)]F2U_=>9..7GC7/[E"P+@$_(.X[:
M/*Z/,U=[7Z:>NADLVK\JERK>W77TU/OO3OVK?A9JFJP:=%XICCNYI1 JW%K/
M" Y.,,SH O/')%.UG]JCX9^'M7NM+U/Q"]AJ%K(8I[>?3[E6C8>O[O\ 7ICF
MO@[XU:KI6O\ B33;6SFAUSQ3' +;6M5TY<0:E=YP#&@^\P^ZT@QYC<X[F[\6
M+RWTSP?X?T#Q'<1:C\0;#B>XB<%K"SV_N[.X?GS95Z^L8^4D] EEE%N.^O33
M[]MO^!Z#>:UTI:1TZZV]-]_OZ^I]V^)OVF/ASX/U%++5O$'V::2%+B(BTGDC
MFB895T=4*NI]5)%6-6_:(\ :)X:TOQ#=:]_Q)-2)6VOHK6:6-F'5&*H=C?[+
M8/M7P;J#IX8^"Z:3XRD6XU&\9;KPUI;'%WIL9.7G=NJ0R#I$1\Q^8;>IW?@@
M3X1\">(-=\:2HGPSU&)K?^R;E=SZM=@?(;4$C:R'K*.!COCC.66T8PYKMZV]
M?33?^O,TCF=:4^6R5U?KIZZ[?UY'V;9?M+_#G4?#NH:Y:^(1<:;I\B1W<D=I
M.SP;ONLR;-P0GC?C;GC-+X>_:6^'/BPWRZ3X@^VS65NUU+!':3^:8E^\R(4R
M^!R0H) YQBOS^^#<.ICQ;/K>E7\.A:%IRL^J:AJ&);6*T8X,$HX$Q<?*(^K'
MIC&17TVW?Q9\6)9?AK!/HD*737=@TMP%.GPKR99).B(HR3G.!QSWT>5T4Y+F
M>G733R>G]?GFLVKM1?*M=+:Z^:U_K\OT#\.?M0_#+Q9K-MI6F>)XY[^Y)6&)
M[::/S&QG:"R ;CV&<D\#FJX_:P^%HU/^SY?$XM;L3?9WCN;*XB\M\X(<M& N
M#USC'>O@KXF76D^-OB4D/@NV-]>7'EPRRZ?'Y<>H7O\ RTG@B',:,W('U;C.
M!>^-NJZ?=W&B:=<W<&M^.+.$V^N:O9$&*XDZ)$<9\Z5!\K2C&X\<XS365T6X
MJ[U7E=?AM_7H/-JR4G:.C\[/TUW_ *]?N_Q%^U#\-O"6LW6DZOX@>QU"V;$D
M,EC<$C/(((CPRD<@C((Z4>*/VH?AIX-FLH]6\1?9UO;=;NUF2SGDBGB;HR.B
M%6]#@Y!!!P:^&?B#/'H/PST;P]XLF2]\;6[+)91AAY^D6)&?L]R_\1;.Y8SS
M&.XSBJIE@\+_  2OK3QH1<6VJC[1X9T9CB[@F)PUZK=8H" 05(_>GH.-U>#G
M-!8' 3Q5*:4H_P VTO2UG=]-_P!3FQ><XBC3G*/*FE?5/3R>N_16Z].WW?J'
M[4?PSTSPYINOS^(\Z/J#O%;WD5G/(AD7[T;;4.QQUVM@XY Q5G2OVD_AWKOA
M35/$>G>(/MNE:6RK>R0VD[26X/1VCV;PG^UC'7GBOSW^"Y_X1KPMKNM^*Y%'
MPYO(VM9]+G&7U>Z"GRUM1GY9(R0QF'"#@YSM,?[->F>(CX[E\0:+J,7A[P_I
M2&36=5U#Y[2.T/WH90<"0N. G4GD8QFOS6GQ!BIRIKD7O]+.Z\]_AZZVZZ]3
MPZ7%.-J3I)TX^_TL[K^]\5N7KK;1/7[3_0+PM^U+\,O&M_+8Z+XD%]?1P/<"
MV6SG6214&6$:E 7;'.U<L<' JMH/[6_PH\2:U::39>+(S?7<HAB2>UGA4N>B
MEG0*"3QR1SQ7YVZW#:>.OC5<?\*ITV[TRVFO/-TR(2['@V\F;=_RR0$%^3\@
MZGBI_C7J&D^+_'5E;^'Q'K6O-$EMJFHZ9%M@U6_SAI((AZG W#&\Y8 9K)\1
M8N,'+EB[.W6TO\.OZ=?D\'Q7C8PE/E@^65M%*TO\.M[_ "V:VT3_ $(O_P!K
MOX4Z3JT^F7_B9[&_@F,$T%SIUU&T3@X(;,?&/4U:\5?M3_#+P5K$FEZSXB:R
MO$19 IL;AU=&&5='6,JZD'(920:_/[XWW]K!H/AW1-<NHM9^(NG(8M3U*V<$
M0P  16DSC/G31]W_ (1A"6QD3>*&7PS\$[+0?&K"[\32.ESX?L,XNM'M6Y<S
MOU$<O!6 \C[WRYP;EQ!BTZD>6/NJ][/3^Z]=^FG7[UI/BC&QE4CRP]U7O9V7
M]U^]\732^NEMVOO[7OVI/AGX:L]+O-0\1^79:I!]HL[J.SGDBF3.#AU0C<IX
M93\RGJ!1/^U)\,X/"MMXD/B/S-%GN&M1=16<[B.4#.R0!"8R1R-P&1R,U\ ^
M"F7PK\']:E\:L)?"^L(QT/0W/^DSWHX%Y >L,:=&?H_W<'J(/@.LV@P:QXAU
MVXCM?AV8OLFKVUTN]-6.,I:PID;IL_,'!'E_>)'0N/$&*E.,>6*YE?9^[YO7
M;KT=OQJ/%&-E.$>2*YE?9WCYOWOAZ]';7M?]#O#W[27P[\6:'K&K:/K_ /:%
MKI$8FO5AM)S-%&?X_*V;V4=V ('>J?A7]JGX7^-=9BTG1O$ZW>HRJS16YM)X
MVE*C.U-R#<Q X4<GH :_//X$Z5XBU/XG_P!K>"[S_A'+33'>ZNM4OI UO86>
M3D7#' <%?EV_Q'TZB#XE2:-\0?C3<)\+]*N(H;NY46<-ME#+.#EI8E_Y9(3\
MP!/R@9XZ"5Q%BO8QJ\D=[6L_>\XZ_)W6]O10N*\;["%;V<;N5K6?O><=?D[K
M>V^R_0FQ_:]^$VH:M#IJ>+$AO)9A $N;.XA"N3C#,\8"\\'<1CO4FO?M:?"[
MPOK5WI&K>(I-/U*TD,4]O/IUR&1O^_?3N".".17Y]?'?5=+UO7='LX)X==\8
MP0"WUW6=.'^CZA=9PH11_K'4?*THQYC<X[F[\6[B'2? 'A[P[XIFCU/XB6)&
M9HF!DTVQV_)9W+\^;(#R%ZQCY2>P)<0XN/M$E'W>MG;TWW]+[/IJ*?%.-BJJ
M48>Y;6SL[_9^+XO1M:/IJ?H!XI_:E^&?@R^AM-7\1_9I)X$NH'6RGDBGB<95
MXY$0JZGU!/((ZBEU;]J/X9Z)HFDZQ=>(\:7JBLUI=Q6<\D;E3AD)5#M<=T;#
M#(XKX!F9?"WP+;2_&SBYN=0(NO"^D$XN]/#'Y[IFZQP2 8$1'SGY@%QN)\*2
M/"_P_P!>U/QBX;P#JD;PP:-+_KM3O5&$DM<_ZLQ$@M-T ^7YLX%_ZP8IS4>6
M*NKZI^[_ (M=OQU3M?0T7%&-=10Y(J\;ZI^[_BUV^YV:=K^Z_OY?VH_AG)X4
MD\2Q>(_.T:*X%K-<Q6<[^1(1E1(H3<@;L6 !P0#1HG[4?PS\1Z;JM]IGB/[9
M#I<0N+M(K.<RQQ9P9!'LW,H[E00O?%?GG\ H;[3-6U#Q%<WD.F^![2/R=>DO
MD\VWO(6_Y=!'D>;*_P#"HY4_-E<9K-^'=GJ6L_%*74? <K>&;.RFDO%OKZ<&
M+3+,$Y:XD(PRA3M*D'?G;@YK./$6+DJ<N1>]I:SOZK7;UMLU?MG#BO&R5*7L
MX^]I:SO_ (E[VWK;9J_5?I!X-_:?^&?C_78M&T/Q-'=ZG,K-%;O;31&7 R54
MN@#-CHHY/85G/^U_\)H=4.G7'BDVEXLWD/%=6%S%Y;YP0Y:,!<'J3C%?GCXH
M@L_B#\8V@^&.F7,9NKE!916H,9><8+31KG,*%@7"D_(.XQQU7[3NNZ)J>I:%
MIYN;?7/'UA;BW\0Z]IP"VUW,. @ _P!9(GW6D&,D=/1OB'%*E.=H^Z[7UM+R
M6N_7T[=6^*<:J-2IRP]QVO9VEY1UO?KU5NVE_N[Q/^U9\,?!FMW.D:SXB>QU
M"W(#Q/87)!!&0RL(R&4@@A@2"#P:E\2?M1_#/PE_9[:GXC\F'4+9;NSN([.>
M6*XB/\2.J%3@\$9R",$ U\ ^/Y$\/?"+1_#GC&1;[QK$Z2Z7 I N-&L3R8;E
M^^_(9(3S&.<C.VC067PK\$=3B\;,)]*UA3-X:T1CB[6YS@WT;'F&# (;(Q+T
M XW"WQ!BN>4.6*TOJG[OE+7Y:>6E]%;XHQOM)0Y8KW>;5/W?*7O;]--;M:7=
ME]^WW[4GPST_PU8>()?$>[1KZ1X8;R*SGD02KUC?:A*/CG:V"1R,BEL_VI/A
MGJ'AF^\06OB/[3I=A*D5W+%9SL\!;[K.@3<$)XWXVYXSFOS^^">[PYX?UW7?
M$\J)\.+F-K2\TZX&XZO. ?+BMER,2H2&\T?ZL=2<X.7\#;;58O%USK^G7\.@
M^'-.1CJ]_J(\VU%HYP;>1>!,T@^41CECR,8R)CQ#BY.G[D?>Z6=UY[_#UUML
M]>I,.*L;)TO<C[_2SNO[WQ6Y>NMMGKU/T5\.?M1_#/Q<FHG2/$?VZ2PMVNYX
M([.?S?*7[S(A3<^WJ0H) Y/%-\)?M4_"[QOK]IHND>*HIM1NVV0136\T(D;^
MZ&= N3V&>>@K\X=$M+CQ5\8)KCX9P7'A^"*Z>\L99[C;_9L"G)EEE/"HHR3G
M/!V_-WF^)TNE^._BJD/@.R>[N[DQ0L^GQ&)+^]_Y:3P0CF)&;D+GCKQT$+B/
M%J"GR1=G;2_O?X=?TZKT,UQ9C534^2+M*VB?O?X=;_>NJ]#]<**XOX.Z/XJT
M'X<Z+8^--2CU7Q%%"!<7$8Z?W59OXV P"W<C/N>TK]!IR<X*35K]'NC]2I3=
M2G&;BXMJ]GNO)A1116AJ%%%% !117E'QTL=0O+KPHTMGK6I>$([J8ZU9>'WE
M%U)F(BW8B$B5HUDY94.<["05!H ]7HKY'7PA\1V^(MIXB72]=M=#MM0T52]U
MJMS/J4%J(E\X"!'\B8,V$F)!90\C#<4%=5\:5UO6F\?6=L/$4VM036HT*'1&
MF(C3[(&CE98Y$P&G-PGF'<JLJ%P0H% 'T=17SG\.['QU%XU\:-J]OXCTZ6^M
M[F":ZWM<6OVN2XD-H]FK-MVQ6Q1690BY #?-DU0^&=C\4?#_ ,'/$,=O_:$&
MJMJVGP:6UY#+/<K 7M8[V<QW3,PSFXDPQ*@ABN5VD@'TW17R;=^)_P!H'2]&
MD5QJ=[(V&6Z@T6V:=90ETL40C VF-Y(K8R.1E!*2"H(V^Y_"6_U"]'B<7<CR
MVT6JE("TAD5',,37$:,>J).9E')QC':@#OZ*** "BBB@ HHHH ***@OEN'LY
MUM'CCNBA$3S*616QP6 ()&>V10!/17R7X>^+OQ'EU?X5"[U4ZC-K"00W=C#!
M!;F=C>S1W4\L3)O*+ J,GDL A4F3(9<_6E !117S=\=?BK\0=#^)+:#X>M[K
M1-)70K^:/5;BR22UGN4BBD$IF.[RQ&I= &7!=LME%H ^D:*^,)OCW\2Y-+\,
MZI:7-W'I6EZHYU,R6D-Q)JNG^;<R+EXTVEC:6I8/#@,SC'!%>Z_LY>,O$WCC
M0O%6H>)I79_[?F.G0O;K$;>QD@@G@BX W;5FP6/).<]* /6J*** "BBL[Q&0
MN@:BS7ESIZK;R,;NS"F:(!22R!E92PQQE2/:@#1HKA_@L-<E^'&DWOB#5;K5
MM0U!3?![U(EEAAE.^*%O+C1240J"=H)(-=Q0 5F^(GTB/1KIM=:R72=O^D'4
M2GD;<_Q[_EQG'6M*J]_96VI64]K>01W-I,A26&90R.I'((/!%-:,3U1QOAN7
MX:7&JI'H#^%)-29'"IIIMC,4Q\P 3G&,Y]JR[77/@U97\1MM0\"P7L4@$?E3
M62R)(#QC!R&!_'-? ?Q:L_#W@7XQ77_"M=3N&M[2X5[::VZV]QGF.%QRZ@\
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MW/VB_P##FD7MQM5/-N+&*1]H&%&2I. . *WJ*SFO:*T]5YB=*$E9Q7W&!=>
M/#%[;6MO<>&](N(+52EO%+8Q,L*DY(0%<*"><"I$\#^'(]*DTQ?#^EKILCB5
M[,648A9QT8IMP3P.<=JVZ*CV<-^5?<3[&GORK[C!LO 'AC3//^Q^'-(M?M$1
MAF\BQB3S(SU1L+RI]#Q3=/\ A[X6TB\BN['PUH]E=1',<]O811NAZ9#!0170
M44O94U;W5]P>QI*WNK3R.:7X9^#UF$P\*:()0V\2#3H=V[.<YV]<]ZDO_AYX
M5U2\FN[WPSH]W=3'=)//81.[GU9BN2?K70T4>RIVMRK[A>PI6MR+[D8-_P"
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M%9WB+Q!I_A30=1UK5;J.RTS3[=[JYN)3A8XT4LS$^P!H T:*X+X(_%2/XR^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 2 #NM2TRTUFQFLKZWCN[29=LD$J[D<>A'<59    & .PKQFR_:@T'Q%:!M
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MX']S>&.U>W X' Q4OC3]B;_A.]<6^U#QS<16\*B"TL+734C@L[<?=AB7>=H
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M=V;,'BC=65BJL2N_8[)YA4L%8@''%=]86,&EV%M9VL8BMK>-88HQT5% "C\
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M@ HHHH *S/$MGJ>H>']0MM%U"+2=6F@9+6^FM_M"6\A&%<Q[EWX/.,C-:=%
M'CVA_!KQ'IVH>&3>>(-'O=*TJ9KRXL?[+G!N[MI&9KII&NF)E^;@N' ;+ =
MOL-%% !7AGCW]F9O&'CW7/$EGXFET1]6MRLWD6[-,9/LZP!&?S K6^$1S%LW
M%UR'';W.B@#YTF_9$:^TJ**Y\5[;VVN/M-C);Z<%BT\@W$B1P(TC$)'-.DB!
MF)'DJ"3G(]-^#OPHB^$>AZIIT6HMJ?V^^_M"29XO+;S#;PQR$\G)9HF?/^WC
MMD]]10 4444 %4]7MKN\TNZAL+M;"]>-EANGB$HB?'RL4)&X ]LC/J*N44 <
M9\)_A])\-?"\NERWT5[)->W%\PM;<V]M 99"YCAC+.40$]"S$DL<\XKLZ**
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MG,>4##(!;"@5P<7[#^C16"01ZVEI<?9_(DOK/34BN&)2\1F#AL@M]L&>N1$
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M>T?_ 'T*\+_X8=^#O_0M7'_@UNO_ (Y1_P ,/?!W_H6KC_P:W7_QRE['*_\
MG_/_ ,%Q_P#E@^?%_P#/N/\ X$__ ) ]T^U0?\]H_P#OH4?:H/\ GM'_ -]"
MO#/^&(/@[_T+5Q_X-;K_ ..4O_#$/P>_Z%JX_P#!I=?_ !RCV.6?\_Y_^"X_
M_+!\^+_Y]Q_\"?\ \B>Y?:H/^>T?_?0H^U0?\]H_^^A7AO\ PQ#\'O\ H6KC
M_P &MU_\<H_X8B^#W_0M7'_@TNO_ (Y2]EEG_/Z?_@N/_P L'SXK^2/_ ($_
M_D3W+[5!_P ]H_\ OH4?:H/^>T?_ 'T*\._X8C^#_P#T+=Q_X-+K_P".4?\
M#$?P?_Z%NX_\&EU_\<H]EEG_ #^G_P""X_\ RP?/B?Y(_P#@3_\ D3W'[5!_
MSVC_ .^A1]J@_P">T?\ WT*\/_X8D^$ _P"9;N/_  :77_QRC_AB7X0?]"W<
M?^#2Z_\ CE'LLL_Y_3_\%Q_^6#YL1_(O_ G_ /(GN'VJ#_GM'_WT*/M4'_/:
M/_OH5X?_ ,,3?"#_ *%NX_\ !I=?_'*7_AB?X0_]"Y<?^#2Z_P#CE+V66_\
M/Z?_ (+C_P#+"N:O_*OO?_R)[?\ :H/^>T?_ 'T*/M4/_/:/_OH5XA_PQ/\
M"'_H7+C_ ,&EU_\ '*/^&)_A#_T+EQ_X-+K_ ..4>RRW_G]/_P %K_Y8/FK?
MRK[W_D>W_:H?^>T?_?0H^U0_\]H_^^A7B/\ PQ1\(O\ H7+C_P &EU_\<H_X
M8I^$7_0N7'_@TNO_ (Y2]EEO_/Z?_@M?_+!\U;^5??\ \ ]N^U0_\]H_^^A3
M4EMHRQ5XE+'+$$#)]Z\3_P"&*?A%_P!"Y<?^#2Z_^.4?\,5?"+_H7+C_ ,&E
MU_\ '*/99=_S^G_X+7_RP?-5[+[_ /@'MWVJ'_GM'_WT*K7MMINI>5]KBM;K
MRG\R/SE5]C?WAGH?>O&_^&*OA%_T+EQ_X-+K_P".4?\ #%?PB_Z%RX_\&EU_
M\<H]EEW_ #^G_P" +_Y8.]3LOO\ ^ >V_:H/^>T?_?0H^U0?\]H_^^A7B7_#
M%?PB_P"A<N/_  :77_QRE_X8L^$?_0N7'_@TNO\ XY2]EEW_ #^G_P" +_Y8
M.\^R^_\ X![9]J@_Y[1_]]"C[5#_ ,]H_P#OH5XG_P ,6?"/_H7+C_P:77_Q
MRC_ABSX1_P#0N7'_ (-+K_XY2]EE_P#S]G_X O\ Y8.\^WX_\ ]L^U0_\]H_
M^^A1]JA_Y[1_]]"O$_\ ABSX1_\ 0N7'_@SNO_CE'_#%GPC_ .A<N/\ P:77
M_P <H]EE_P#S]G_X O\ Y8.\NQ[4LMLC,RO$K-RQ! )^M.^U0_\ /:/_ +Z%
M>)_\,6?"/_H7+C_P9W7_ ,<H_P"&+/A&?^9<N/\ P9W7_P <H]EE_P#S]G_X
M O\ Y,-3VS[5!_SVC_[Z%1P-:6L2Q0F&*->B(0H'X"O%_P#ABWX1_P#0N7'_
M (,[K_XY1_PQ9\(Q_P RY<?^#.Z_^.4O9X#_ )^S_P# %_\ )C/;/M4/_/:/
M_OH4?:H?^>T?_?0KQ/\ X8M^$?\ T+EQ_P"#.Z_^.4?\,6_"/_H7+C_P9W7_
M ,<H]G@/^?L__ %_\F,]HW6GGB?,/G!=GF9&[;G.,^F>U2?:H?\ GM'_ -]"
MO$_^&+?A'_T+EQ_X,[K_ ..4?\,6?",_\RY<?^#.Z_\ CE+V> _Y^S_\ 7_R
M8]#VS[5#_P ]H_\ OH4TS6Q</OBW@8#9&<5XK_PQ;\(Q_P RY<?^#.Z_^.4?
M\,6?",?\RY<?^#.Z_P#CE'L\#_S]E_X O_DQVCW/;/M4/_/:/_OH4?:H?^>T
M?_?0KQ/_ (8L^$>?^1<N/_!G=?\ QRC_ (8L^$?_ $+EQ_X,[K_XY2]G@?\
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M6[C_ ,&EU_\ '*3_ (8A^#__ $+=Q_X-+K_XY2Y,+_/+_P !7_R0^7#?SO\
M\!7_ ,D>Y?:H/^>T?_?0H^UP?\]H_P#OH5X;_P ,0_![_H6[C_P:77_QRD_X
M8@^#W_0M7'_@TNO_ (Y1R87^>7_@*_\ D@Y,-_/+_P !7_R1[E]K@_Y[1_\
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M]O?I6-<^ ]-NK:WMW>X^S0VRVHA\P%71595W CD@.WYUF7/PITL616S>2*\
M_=W,Y\P@\<D<;NG0\9H Z:;Q!IL%Z;22]A2YV1R>46YVNQ5#]"015@:C:D B
MYA(*[L^8.F<9^F:YVY^'.DWUO9I<^=)+;0PPK,K[&(C5E'3L=Y)'3('I56_^
M$?A_4X%CN8YI"&W%PX!;G/.!C&3TQCVH ZM]2M44DW$7!(P'!.1SC [^U*NH
M6K@$7$77'+@'.,X^M<A=?"O3?/MFLG:TC216F7&XR*"#@?W22!SUQ2:C\'/#
M6J3^;/!,6VE3MDP#G.3TZ\]>O% '8?VA:_\ /S#Z_P"L'UJE+XITF&,/)J$"
M(89;@,6X,<9Q(WT!(KG6^#WAMDM5^SR+]FR8RKC()"C/3_9!_/UJ[??#71=3
MMK."Z2>5+5)$0^9MR';+9P #D]NE &S)XATV%;9GO85%R,PDM]_IC'N<C ZF
MII-7LH83-)=PQ1J"Q:1PN !DYSTP.:YRS^&&BV)0Q_:#Y<B21AY-P0JVX 9'
M3)/7U-5S\(?#SP7$4B7$PG8,[R2Y;( '7&>@ ^G% '61:I9S)O2YB*X+9+ <
M9QGGM[TESJMI:6EQ<R3KY-N"TK)\^P#KD#)KC=2^$&F:K=XN)I&T\Q[6MQ]Y
MWS]XMZ?[(&.:W+;P)H]HUVT=N5>YB,3MGD AP<>APY&?IZ4 :T6K6<T"S+<Q
MB-@&!=MIP1D9!Y''/-*^JV4;QH]W KR'"*9!EC@MQSZ G\*YB\^&&E3/J%Q&
M9#>787]Y.V]4*@!2!QTQTS5*T^"^@0V<D<WG3SS*HGG#!2Y"%3CC@'<>* .N
MN->T^V6X+W2'[/%Y\H3+E(_[Q SQP::OB'3WDM$%QE[J/SHAL;[F,[FX^4>[
M8K+T?X>Z3H5M=V]J)E@N;<VS(7&%0YSC Z_,?Z8JSJ'@ZRU*W:WDEN$@>S^P
MR1QR8$D6" &XZC<>1CK0!H6^LV-U/)#%=1O*A *@]STQZ].U1S^(=-MK&6\D
MNXQ;Q':[#D@[MF,#G.[C&.3619?#G1M.^P_9TEB^QRI+%A^C*"/3H<G(&,U+
M'X#TR(ZB4,R_;TV3#<""-[-T((SEB,G/&* -.37M/AE@BDND22?)1&R#P,G(
M_AP".N.M6I+VWB^_/$G ;YG X/0UQTGP@\/S6]W#,MS<?:MHDDEEW.<8QSCV
M YSQQ5Z[^&^C7U^+J=)9'6W6U5"^46-0, #'L#]>: -:\\2:98QW$DUY&JV[
M*DNW+%6;[HP,\GTJQ%JME-&KI=P,C+O!$@Y7U^E8-K\-]&M=-DL"DLUH\D,A
MCE?.?+(*@\<CCG.2?6FWGPTT6\N1-Y<D+!MX6(@*&W,P.,=BQXZ8QD'% '0P
M:I:7%M%<1W,30R@%'W !@>G\Z;<ZQ96=K-<RW42PPKOD8-NVCUP*YM?A=HZO
M"PDN_P!RK*BF0%5W !S@CJP4<]NV*-,^%>AZ/87EG:+/%#=P""0+( 2 Q(/3
M[V3UH Z*TUJPOK87$-U$T1)7);:00<$$'D$'L>:1M=T]9'0WD6]-NX!LGYCA
M?UXK!7X8:,-02];[3+.)#,QDER))2,&1AC[WZ<#BH[#X5Z)IJ1I%]I*(",-(
M.26)))QGJQ]J .@O_$&GZ:D33W( EW%/+4R9"_>/R@\#N>@J6/5[.5$99U(?
M&!SG&<9QU ]^E8VG_#_3-)TNRT^R>XM8+5)(E\N0 NCD%@W'.2![\5'<?#?1
M+J(H\4O.?G63#8..,]<<=* -_P#M.T+1*+F-FD.U K Y.TMV]E)_"LZ#QIHM
MS+;QQWZ%[@!HP58;@0Q!Y' (5CD^E5-*^'^F:1J[ZE$UQ)=NJJ6D<8PJLH
M  &&-5&^%'A]]%?2W@D>V9!'DD;PH# #('^T?K0!TS:O8K.L)O(!*P+!#*N2
M!C)QG_:'YBH]3UVQT=HUN[@1/("4C"EG?! .U0"3U'2N>?X6:&\"0[9EBC+%
M I4%,E6(!VYZH".XYQQ6KJ/A2VU.^M;R6YNENK52L$L<@!CS]XCC&6P <]A0
M!:T_Q!I^JW,MO:W(EEB&67:1D9P2"1A@#P2,X/!JM_PF6C[]GVO,GS?NQ$^\
M%<Y&W&<\$XZD D<"DT[PG:Z7=":">ZRJNB(TF517.Y@!CH6P?P':LU_AKILD
M*QM=7_ Y<3X9C\WS,<<G$CC)ZACG- &U'XETN6VN+A+V)H+<*99 >$# %<_4
M$?G5Q+VWD?8D\;N<G:K@GCKQ69<^$[*ZM+FV<RB.Y$2R[6QN$> !P. 0.<5G
M:'\--&\/7GVNT6?[3YCR^;))EMS*RGG'^T3]>: -6S\5:5?WT=G!>*]U('Q"
M596^4X8$$<$8/!K6KFM,\ :;I6IVFH1R74MU;(T:O++DL#G);CD_,3[GDYKI
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mrkr-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mrkr-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %T J # 2(  A$! Q$!_\0
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MUOQ.PHHHKS3M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%64LF0-Q!^7)QBOG"RT+X[_"7XR?$_6O!WP\L=>TSQ+JIN8[B_O8ES&I?85
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M1\K>+O@WXQU/Q!^SG<6^BM+;^%EB&LL)XA]EPD0.<M\WW6^[GI7FC_LQ>,/
M^N>)M'A^%UA\0]+U+49+JPU>X\0RV444+MDQSPK*N[ [XZ]V&!7WI15T.)<7
M0BH1BK6M]I?:<KWC)/1M];6W3(JY+AZKYFW?Y/HH[--:I??L?)_QB^#FKO9^
M$M.T_P""^B^*]'TS34@5M.UZ2ROK"7J8XIW()C#'()W9R>%KT+]E#P-X]\">
M!]1MO'-W+NGO6FT[3)[TWDFGVY'$33'.[Z9.,>Y%>W45Q5\YKU\)]3G%6O>_
MO-[WZR:5[ZM)-]3JI9=2I8CZQ%N^UM$NW1)ORNW;H%%%%> >J%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\4?MH?$_Q?X,
M^*6G66@^)-1TBS?2TE:"TFV(7\QQN(]< 5X'_P +]^)7_0\ZW_X%&O5?V]?^
M2P:7_P!@A/\ T8]?-M?<8*E3>'@W%;=CX''5:D<3-*3W[G>_\+]^)7_0\ZW_
M .!1H_X7[\2O^AYUO_P*-<%17;[&G_*ON1P^WJ_SO[V=[_POWXE?]#SK?_@4
M:/\ A?OQ*_Z'G6__  *-<%11[&G_ "K[D'MZO\[^]G>_\+]^)7_0\ZW_ .!1
MH_X7[\2O^AYUO_P*-<%11[&G_*ON0>WJ_P [^]G>_P#"_?B5_P!#SK?_ (%&
MC_A?OQ*_Z'G6_P#P*-<%11[&G_*ON0>WJ_SO[V=[_P +]^)7_0\ZW_X%&C_A
M?OQ*_P"AYUO_ ,"C7!44>QI_RK[D'MZO\[^]G>_\+]^)7_0\ZW_X%&C_ (7[
M\2O^AYUO_P "C7!44>QI_P J^Y![>K_._O9WO_"_?B5_T/.M_P#@4:3_ (7Y
M\2<Y_P"$YUO/_7R:X.BCV-/^5?<@]O5_G?WL[W_A?OQ*_P"AYUO_ ,"C1_PO
MWXE?]#SK?_@4:X*BCV-/^5?<@]O5_G?WL[W_ (7[\2O^AYUO_P "C1_POWXE
M?]#SK?\ X%&N"HH]C3_E7W(/;U?YW][.]_X7[\2O^AYUO_P*-'_"_?B5_P!#
MSK?_ (%&N"HH]C3_ )5]R#V]7^=_>SO?^%^_$K_H>=;_ / HT?\ "_?B5_T/
M.M_^!1K@J*/8T_Y5]R#V]7^=_>SO?^%^_$K_ *'G6_\ P*-'_"_?B5_T/.M_
M^!1K@J*/8T_Y5]R#V]7^=_>SO?\ A?OQ*_Z'G6__  *-'_"_?B5_T/.M_P#@
M4:X*BCV-/^5?<@]O5_G?WL[W_A?OQ*_Z'G6__ HT?\+]^)7_ $/.M_\ @4:X
M*BCV-/\ E7W(/;U?YW][.]_X7[\2O^AYUO\ \"C1_P +]^)7_0\ZW_X%&N"H
MH]C3_E7W(/;U?YW][.]_X7[\2O\ H>=;_P# HT?\+]^)7_0\ZW_X%&N"HH]C
M3_E7W(/;U?YW][.]_P"%^_$K_H>=;_\  HT?\+]^)7_0\ZW_ .!1K@J*/8T_
MY5]R#V]7^=_>SO?^%^_$K_H>=;_\"C1_POWXE?\ 0\ZW_P"!1K@J*/8T_P"5
M?<@]O5_G?WL[M_C_ /$E%+'QSK> ,G_2C7H%W-\?["/5))_$FL1Q:;ID>L7,
MAU)=JVKABK*?XC\K?*.1BO 94\R)TSC<",U]'77[7SSZ2UHGAG]X+8VJ22W*
ML"@A1(T<;?F57$CX_P!O';-<U:FXV]E33[Z(ZJ%52O[:HUVU?]=CBD^(_P ;
M);I;9-9\8-<M$)Q"(Y2YC)P'QMSMSQGIFMG3=:^/NK:0-2MM:\2O:M!/<(#<
M$22)"ZI)M3&XL&8#:!DX..AITO[2D*QZE%;Z%=K%?/<SL\U\&D26>[BN' 8*
M/W8\K:%Z_,234<G[1MN\=^1H-RD]S)J)4K>+M1+J]2Z_NYRNS9Z'.>*S<:G2
MDOP-5.FMZTOQ.>D^+GQ?AL)KZ3Q+XICL89##+<N9!%'(#@HS;<!L\8/.:H?\
M+]^)7_0\ZW_X%&NB\:_'JW\9>%_$.DR:'.IU*]FN[4RW*E++S)_-)7:BLQZ@
MJQ*D\X!KR"NBG3C)>_32?R.6K5E%KDJ-KU9WO_"_?B5_T/.M_P#@4:/^%^_$
MK_H>=;_\"C7!45K[&G_*ON1E[>K_ #O[V=[_ ,+]^)7_ $/.M_\ @4:/^%^_
M$K_H>=;_ / HUP5%'L:?\J^Y![>K_._O9WO_  OWXE?]#SK?_@4:/^%^_$K_
M *'G6_\ P*-<%11[&G_*ON0>WJ_SO[V=[_POWXE?]#SK?_@4:/\ A?OQ*_Z'
MG6__  *-<%11[&G_ "K[D'MZO\[^]G>_\+]^)7_0\ZW_ .!1H_X7[\2O^AYU
MO_P*-<%11[&G_*ON0>WJ_P [^]G>_P#"_?B5_P!#SK?_ (%&C_A?OQ*_Z'G6
M_P#P*-<%11[&G_*ON0>WJ_SO[V=[_P +]^)7_0\ZW_X%&C_A?OQ*_P"AYUO_
M ,"C7!44>QI_RK[D'MZO\[^]G>_\+]^)7_0\ZW_X%&C_ (7[\2O^AYUO_P "
MC7!44>QI_P J^Y![>K_._O9WO_"_?B5_T/.M_P#@4:/^%^_$K_H>=;_\"C7!
M44>QI_RK[D'MZO\ ._O9WO\ POWXE?\ 0\ZW_P"!1H_X7[\2O^AYUO\ \"C7
M!44>QI_RK[D'MZO\[^]G>_\ "_?B5_T/.M_^!1H_X7[\2O\ H>=;_P# HUP5
M%'L:?\J^Y![>K_._O9WO_"_?B5_T/.M_^!1H_P"%^_$K_H>=;_\  HUP5%'L
M:?\ *ON0>WJ_SO[V=[_POWXE?]#SK?\ X%&C_A?OQ*_Z'G6__ HUP5%'L:?\
MJ^Y![>K_ #O[V=[_ ,+]^)7_ $/.M_\ @4:/^%^_$K_H>=;_ / HUP5%'L:?
M\J^Y![>K_._O9WO_  OWXE?]#SK?_@4:/^%^_$K_ *'G6_\ P*-<%11[&G_*
MON0>WJ_SO[V=[_POWXE?]#SK?_@4:/\ A?OQ*_Z'G6__  *-<%11[&G_ "K[
MD'MZO\[^]G>_\+]^)7_0\ZW_ .!1H_X7[\2O^AYUO_P*-<%11[&G_*ON0>WJ
M_P [^]G?P_'SXDF>$'QSK9!D4$?:CZBOU)T]VDL+9F)9FB4DGN<"OQZ@_P"/
MB'_KHG_H0K]A-,_Y!MI_UR3^0KYW-X1AR<JMO^A]+DLYS]IS-O;]2S1117SA
M].%%%% 'P#^WK_R6#2_^P0G_ *,>OFVOI+]O7_DL&E_]@A/_ $8]?-AK[W _
M[M#T/SS'_P"]5/4-P)ZBEKWGQKXM^'EW9Z@-*.D'3WM;Y/L,&F&.ZDN'*?97
MCD,8V!"&)^8<9&#FO!1G SUKHIS=17:L<M6FJ;LI7%I.E+75?#&_T'2/%L6I
M^(U6?3[&":Y2S:'SA=3A"(HMI^4Y8@G=A<*03S6DGRINUS.*YI)7L<IUH) Z
MG%?1,/@KX4^(-.USQ0]SY6CM<23,(KAH)[3/V<B&. <,!YDX/^Z-N0*R1K'P
MNT2/5++1&@\^Z$CVE]J4#7,=K(J1A,,\;$*X,WWE?:V"0<"N58CFT47]QUO#
M<NLIJWJ>&=:6ND^(T^CW7C34I= E6?2W*&.1(1"K-Y:^9M0*H W[L?*N>N!G
M%<W75%W29R27*V@KO/!7PAOO&_ABZUN#4[.QMX9Y+?;=*X!=(O-^9Q\J CY0
M3U)Q6=X<^'-]XHT)M5M-1TV*);Z#33;W$LBR^?,2(EP$(PVUCG.!CG%7[[X>
M?$"QM;C07T/49;+3[T71BBA#QB<_(LJMC+9"\8[#H*QG-/W8R29O"FU[THMH
M?)\#/&4:!?[+#7*SR6\T(N(<0R*478TF_;O+2*H3.[)QBN7\0>%=4\*M9IJM
MK]CENX%N8HFD1I/+;[K,H)*9]& ->BVUW\9(KVZ\F'5Y+F6]D>X06\,G^E/M
M=BRX(5_W*L"0,%,C'-8&N>!?'_B QWNHZ5J6H7-O";9P\#&2&*   ,< 'A@1
M@L3U-1"I*_ORC\BYTXV]R,K^9PE%:&M>'M3\.30PZK83:?--$LT<<X 9D(R&
MQU&00>:SZZDT]4<C33LPHHK?\!2:#!XNTV;Q,T@T6&02S)'$9/-(Y5& (.PG
M[Q'.,TF[)L<5S-(Y_K2UO_$&XTJ\\=^(;C0WC?1IKZ:2S,4)A01%B5"H?N@
MX ]JP*$[I,)+E;044451(G2@'/2MSP/=:?9>,]"N-7\HZ5%>Q/=>?$98_*#?
M-N0<L,=JO_%"_P!&U3QI=W.@B :<T4(S;0^5&9!&HD(&%S\V>0J@G)VBHYGS
M<MOF:<JY.:_78Y6BBBK,PI.E+73_  QU/1M&^(.@WGB&TM[W1([I/M<=VC/&
ML>>7*+RVWKMY![@U,GRINURHKFDDW8Y?()ZTM>A^+M3\/2_#/1K.RN=,OM:^
MUO+,;>S-O-:0Y<+$6V#SBV0S.S'&$"C@FO/*4)<RO:Q4X\KLG<****LS"DR#
MWJ_H%U:V6NZ=<7UM%>645Q&\]O-NV2(&&X-M(.,>E>K?$CQ#\/\ 4_"&M1>'
MOLMMJ+ZO-+#%%8!3-$9R496* QH(L# 8<@@ISNK*4W&25KW-H4U*+DY)6/&Z
M***U,0HHJWHS(NL6#2306\8N(RTUU$984 899T'+*.ZCJ.*3&M2GN![BEKWC
MQOXI^&]SX9\16NGKIMSJ+0&*WN[>P,4M[*!"(IU C582"LQ9%P,%?OG)KP>L
MJ<W45VK&M6FJ;LI)^@4445L8A2;@>XI1]Y>@Y'WNGX^U>_W^O?"PW-^+B]TZ
M^O!H$]G;WUGH[10273JS>;Y01?+=6*QID'Y06+9QC&I4<+6BWZ&].FJE[R2]
M3P"BD7.T9ZXI:V, HHI&^Z>IX[4 &X>HI:^A/#?BGX<Z9;:+#J=QH&H/'IV+
MFY72&7$K/#F#9Y7.Q$?YR2SL[@,F0:^?)-ID?8,1[CM&,<9XXY[>]8TZCFW>
M+5C>I35-)J2=Q****V, I-P'<4M>U> ->\&PZ#X;M]:U;0[.XM9GEGD.AF>8
MPE&S#(QC*ERV,2'>/FSA=N#E4FX*Z5S:E!5'9NQXK15_Q#<V]YX@U2XM((+6
MTENI9(8+8DQ1H6)54) )4# &0/I5"M%JC)Z.P4444Q"9 [B@'->P?"GQ%X*T
MOPU#!XK.EW#B]\V"$Z<7N8F^8 RR;"&CR5/5L!<>6<YKS_Q]<Z=>>--8GTB:
M.XTV2;=!+% ($8;1G"!5"C.>BC/7 SBL8U'*;CR[=3>5-1@I\R=^A@4445L8
M!29Q2UZK\'M5^'6D:'K3>+P9]3G>$0Q2V;2JL2RQLPC8<!V&\,2!\HP#S6=2
M?)&Z5_0UIP]I+E;2]3RD'/3FEKL?BSJ6A:KXN\_0/L[6OV6%)YK.#R()9POS
MM''M7:.@Z#)!/>N.IQ?-%.UB9QY9-)W"BBK6E201:K8O<@&V2XC:8,NX; X+
M9'<8SQ5$HJ;ACJ*-PSC(S7OWBKQ9\/[O^TO['N-&MM9DDN_[+OYM.$EK:Q-)
M$4$BBW09*"15!CD*$G+G(Q#XE\:?#.X\/:A8:39V\5Y+87GELUBJP271=-K$
M^694S^\>+:X5<A6 %<JKR=O<9V/#Q5_?1X.6 /)% .:]>;Q!H?AOP<8;>/32
M]WX3B>Q>6QAN)CJ?VK$Q9F1BK!0X&[ VXQV-;U^GP+O)@S7%TTLJQ^9<H]Q&
M$8DJ^(U0+\J@-TY)[TW7:^R_D2L.G]M?,\#I:]::7X6Z-\0/!LVFB2_\/QMG
M5FU)I'5_D&&>,#((8G*KE3@8'K6OQ\-]-U/PI=:9/YX34[9]123S94-L AG\
MQ'4#A]X4)G<F,\U7MK_9?W$^QM?WE]_H>6@@]#F@'->Z:_J_PF\5V]Q<W)DM
M;B*RF2U@MHQ;2&8SRD%FBB5& 3RC'D?=W!^16G::%\'_ !EK)9=0MQ?7,OF)
M;0F>RACB2U<LK\!1\Z(<K@G) R36?UBRO*#^XT6&N[1FOO/GFDKV>VT[X+RW
M \^_NK>!;I<M$]Q)YT9C7*KD*4C63=\Y!<KCH:YOXE6WAF+PYHDGA]$C5[Z]
M$(#AY&M1Y6PR-@,2)#*%+ ';BM(UN9J/*UZHSE0Y8N7,G;LS@(/^/B'_ *Z)
M_P"A"OV$TSC3;3_KBG\A7X]P?\?$/_71/_0A7[":9_R#;3_KDG\A7A9SM3^?
MZ'T&1[U/E^I9HHHKYD^J"BBB@#XZ_:^^"'C?XC_$K3]3\.:$^IV,>FI \JS(
MF'#N2,,0>A%>&_\ #*'Q7_Z%*7_P)B_^*K]-Z0G ->Q2S.K1@J<4K+U_S/%K
M951K5'4E)W?I_D?F3_PRA\5_^A2E_P# F+_XJC_AE#XK_P#0I2_^!,7_ ,57
MV?X?^,'C._\ %>H:!-X3M+ZZLM6MH;E[*Y>,0:?/&S1W0#K^\4,CIN4@,4;
M&*]HK7^V*_\ *OQ_S,?[%H?S/\/\C\R/^&4/BO\ ]"E+_P"!,7_Q5'_#*'Q7
M_P"A2E_\"8O_ (JOTWJ&]F>WLYY8E1Y$C9E61]BD@9 +8.![XXH_MBO_ "K\
M?\P_L6A_,_P_R/S-/[)OQ5+!CX0D+#H?M$.?_0J7_AE#XK_]"E+_ .!,7_Q5
M?3FJ_M1>*O#$RPZQX<LE.G:G)8:O-!'<E0?,MA$B+M/E%X[GS5>4A&5!@Y;
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M@CFO]>9-PM15I[/S[/MKIV+_ +0P;=.T)6J?"[K?L]--=+[?+;2_X90^*_\
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M8JI<=5(\Z=!7CJ]>G=?U?]*EF6%ASITY<T-6N9;::K3S6F^OK:Y_PRC\5_\
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MQ<X^SE>*O\2UCO=>[VL[.S^>A-_PRA\5_P#H4I?_  )B_P#BJ/\ AE'XK_\
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MBH]WHEGX7\::+J6I>&9M<4W8\/27LGFV;H1B>'+$_9W/*;L$8(Y !K\WJ8O
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M,515D[K??[]?F?+^O?L'Z%XO\52:[XA\9:[JUS/*KSJRPQJZ#&(UVK\B@#:
MN,#I6S\3?V-M'^)EU8I/XGU/2M%TR$6^FZ+80Q+:V:8YV@C)8GDL<DU]#T4_
M[*P5I1]G\6^^OKJ/^Q,O<91]DO>U>KU]7<^;]8_8C\/7W@S3_"MCXDU72-$M
MR)[F&VCB+7]S_P ]IV*Y8@<*OW5'0<DT:=^Q'X>T/P/>>'=)\2:KISZBY_M+
M4HDB-S=P_P ,!8K\D8/)5<;CUSC%?2%%/^RL%?F]FKVMUV[;Z#_L7+[\WLE>
MUNNW9:Z?+]3YN\%_L0^'? -GJ;Z1XCU2'6[N/R(M8:.(SV<1X<0C;A&8<;_O
M 9QC-5O _P"PAX4\$:X=837-0U/48D8V;WT,4D=O.?NS;-N'9>H#9&>2#BOI
MJBDLIP2Y;4E[NV^@EDF71Y;45[NV^GGOOY[[=CY?T_\ 8'\*-XO37M>\2:UX
MFD:X-S<P7YCQ=OG/[Q@-Q!/4 \]*N_$?]BC3/BCXEDUC6O&>LE@HBMK2"&%(
M+2$?=BB3;A5 _P 37TG12_LG!<KA[-6;N]]7YZB_L/+N1T_9*S=WJ]7YZZG/
M> O 6B?#3PO9^'_#]DMEIUJN HY:1OXG=OXF/4DUT-%%>K"$8148JR1[4(1I
MQ4(*R6R"BBBJ+"BOG35OC7K^FZMXRO%U_3Y-2TJ[U"QL? ?V$O<W*P6[213;
ME_>_/M$F['E[&VCYL&L/Q%\9/$UE9^&['P_X[_X3J?4=17[5=^%M%MY[J*,Z
M?=7!AC5W$+'= K!<^8JD@ALJ: /=HO@[X(@DUN1/"NEAM:1HM0_T92+A&;<R
MD= "QW'&,MR>1FIM+^%7@_1;$V=EX;TZ"V-K/9-&(%(>"9@TT;9^\'95+9SG
M STKR:^^-OB1/@GX.UQ)[ :]JND7M_<7<""6%'MK*6<IMS@.6159<_*0X[4?
M!CXS:]=:#XWN_&%W/C0M/MM17^V;2&SN@CVYED?R[<R!K?@;) "Q(E7!*4 >
MS0^"-)M=7TS4;: VLVGV+:;$D1PAMCMQ&P[@%%(].?6K.C>%='\.B$:9IEK8
M"&V2SC%O$$V0H24C&.B@LQ ]S7Q[<_MA>._$'B?PO>:39Z)I?AU+DV^K6;3F
MXENL7\<&89 F!N1QM&0=S\YP ?5OA#^TWJOQ8\0Z!I<?A:TTS[?%=7=Q,^K)
M-Y5O%':NH41!LR'[6@9'*;=I/<"@#UIOACX2:9)F\.:8TJ.9%8VRDAC*\Q/3
M_GI+(_\ O.Q[U6T#X2^%?"E[ID^C:3!I<6G>>UM:VJA(4DE"J\NT#E]J[ 2>
M%) KQSP+^T!KVIS_ !->ZO+;5'TJSN+W2;&.TV.K1RW*+ P#;MQ\A?W;XD.&
M8?*PQ?\  WQWUZ?X2QZM*EOXEU]_$-MH*-+-%!;&2X:$*PFM_,1T3SN2@R,%
M"-RDD ^A**^5[+]M+4)M)M[FY\)Z?9SRQ1WRK+K!$4ENUM'.(8W,/S73>852
M+&&VD[AT'O7PX\27OB&RUJ._>.:XTS5KG3_/B7:)41@4) Z,%8*1ZJ: .NHH
MHH **** "BBB@ HHHH AM[."T,I@@CA,KF23RT"[W/5CCJ?>IJ\6\'I\1]6O
MKJ^L/%?]H:''XA:V\O7+*!96L808YC&T$:#<\H;;N'"HO.2:]IH ***HZY=+
M8Z+J%RUY'IZPV\DAO)5W)  I/F,,C(7&2,]J )I["UN8A%-;12QAQ($= 0&!
MR&P>^><U(EM%$^Y(D1L;=RJ <9SC\^:^;?#WQ4\67N@>&M6TWQE8^(M O?&,
M&GM>R6UN]Y+8/$N4D$&(X6+AW&5#B-HP0&)->=>)/VCOBGIUEXZ%O>*ESJ5D
ME[X8;^S4<::%A:[E#_+B0?92C#?D[@1VH ^VZ*BM9#+;1.>K(&/XBI: "BBB
M@"I!I%C:WDMW#96\-W*"))XXE61\G)RP&3S5;Q/Y?_"/Z@)M6;0HFA96U)71
M#;@\;PS@J"/4BO+O"OQ/\2ZY^TGXB\*7NF7^F^&K/1A-9+<6&U)Y5N-C7 GY
MW*X.%0=DR>3@>O7MC;ZE9S6EW!'<VLZ&.6&90R.I&""#P0:F2O%I$S3E%I'R
MSX2_9&^#DOC*VU!?&,_BW4?.:X-E=ZI;7 N9.6+.J*&?GYB,X..<C-0^(?V7
M?A%XI\67&L>(/B7=ZIJ4TX:X2XUBS7=@X\K"H"J@#:%7&!P,5\K?'[2/#/PR
M^-=R/AKK$OEV<HF5K4G_ $"Y#',44@/S!3CZ9V\XKH/VC-'T^Y\*^&/$VOV=
MOX=^)^JIOU/1K1!MN8<?)>2H/]1(_&4_BR3@8-?FLL5AHPJP>&C>F[O5V?3?
MOV3\[=3\@GC<)"%:F\)"]-W?O/E?3?J^R?2]M;I_3'Q)_9B^%7BOQ#_Q//']
MQI;6,:VUKI$>I6D$.GP@96*.-DRH[\\DG)))J7QK^S+\*-6T70=&N?'$VA:%
M96XEL=.M]3M8HIBWWKD[D)D=\<N2>F!@#%?).HQ#Q;\#QKGC15L]3L66T\.:
MNPS=:LBG#V\B]9(XQTF/W?N?-T"_#6)?&/PUUVP\8JL7@S1HGDL=?E&9].O&
M&4MX,\RB4_>AZ#[^5QRWCL-.;C]67OJ^[];2[+3TV>VU/,L)4J./U2/[R/-J
MWZVEV6F^VSVU7UK=?LR_"B#X<6F@6WCB;2= N;AI;B[M]3M5;5)EZ"60H0XC
MSPBX SG&>:N^!OV>OA9X"\)Z^/#_ (U>VEO@MK<^(TU*U:YMHV_Y8I)MVQ[\
M'D#<?7@8^,?@(;O7KK4?#&HV<6H>!)XS=:RUW)Y46F(HP+V.0@^7*O0 ?ZS[
MA!SQF_"^[U/3OB//HWA"V'BK3=1D>SFTZ]A\N#4K,,3F92<1@*-^_.8R,YXJ
M89EAKTZBPRU]U;W731=5KTUWZ[Q3S?"7I58X1+FO%:NZZ:+JM=UKOUW^R_A[
M^RI\'O"VMRZUI?C!M7OK&!YHY+G4;2=+)NUSM"8RA.07RH.#CI5?0OV2O@[J
M?C2WU*X\<77B[4I;@W,EI>:O;3_;'Y8[PBAFSU(!YQZ5\=:O-!\/OC+,/AGJ
M,VIQPW0AL62/SO.+8#6^,8G3)*9(PXYQS5KXSZ9I?@?QY8W'AZ1=$UU8DNM1
MTS3I=\6D7V<M%#*.N#@[1G83MR<5F\?A80=\+&T):ZZ>JZ/;[O*]LWF>"A3=
M\'&U.6JOIZI[-Z;=M=KV^N?$O[,/PD\=^*I=6UGXF76I:A<2*IB_M>S50H.%
MA153Y5 ^4*N,#I6O\7?V;?A?XXN].TK6_'<_AW3]%@6"R\/6NI6EO!:#'+>6
MZ%M[=2S$DU\>_&[2K1M#\.:]J]K#H?Q U1#-J>D6J!5EB(S'>2(,>1+)U,??
M[^%SBNJUNW'CK]G9?$OQ%5=/UNQ*VGAG6F&;S68Q]Z"1.KQIVF)X]^<]*QU#
MFJTUAU>W,]7JM_>?1^3ZZ=CZ;)>+*_#^-JXK*J2I5U&_.GK9J[3;3<6[V]=+
MZZ_;'PE\'?#/]G[PG;:3H>LZ;;0WH^TM?WU]#Y]]R0'+Y 8#H-HP/SKO7\=^
M&H[".^;Q%I2V4DAB2Y-[$(V<#)4-NP2!VK\Q_A)$/%W@G7-'\7(J> =+B>Y3
M6YO]9H]TP^1;?O(96 #0#AOO?*1FL_X"RW^JZU>^&9+&+5_!M\GG:W!>N(H+
M2%/^7P2G(ADC!R&'7[N&SBNNCG[BJ<*=%*,E9>37E;:_5>?5-%XCC?%YEB(X
MG$PYYUKN[;;YO/3X;[-=-E=-'ZD0^._#5Q97%Y%XATJ6TMBHGG2]B,<6XX7<
MV["Y/3/6EL?'7AK4WE6S\0Z5=M%&TTBP7L3E$7[S'#<*.YZ"ORG\"7=_H/Q3
MFTSP&C>*[*]G>Q2QN[?$6JVI)^6:,G 4J-VXD;<;LC%+XN-G\.?C [?#C4YI
MS;3(+9K?]]LF88>W1L?OT#$IG&''8YY?^LTU!5'25D[/7\N_]=S@7%\U355T
M59/E>O\ Z3T?_#=S]5+'Q_X7U.ZBM;/Q)I%W<RG;'#!?1.[GT #9/X4P_$?P
MD)3$?%&BB4-L*?VA#NW9QC&[KFORZ^..C:7X3\5:5=:8D7A_Q1) MUK&BZ<^
M8=)O,Y"Q2 _*3PQC&?+/RY..+WQCT^WO_!WAWQ)XAMXM'^(6IY>ZL8$ -]:X
M_=WTR#'DR.>,?\M!\^!WJ7$56/M$Z:O#STM]VC\GYK=6+GQ76A[6+HJ\-]79
MK[M'Y/7=;JS_ $[OO'OAC2[N6TO?$>DVEU$=LD$]]$CH?0J6R*DOO&OA[2X[
M:2\U[3+2.Z3S8'GO(T$J?WD);YA[BOS%UF)?%GP0CU_QHJV6M6C):>'=4(S<
MZQ"IP\,J=7CB'2<]/N?-VZ'X'@^//AIXAT+QW&H^'&D1//;^(;@XFT>[(RJ6
MQ/,F\]81P<YXSSK#B"<ZBIJFO>5UK_Z5V]=MGL;4^*:E2JJ2I+WH\T;O_P!*
MTTTZ[;/9W/T6/COPT-/%^?$.E"Q,GD_:?ML7E>9C.S=NQNQSCK1;^._#5W:W
M-S!XATJ:WM5#3S1WL3)""< N0V%!/'-?EE\#)]3N_%-UX;M-/B\0>&=24_VO
M8WS>3;K;)R;IG.1 \8^82=0>.<X-3P[=7/A3XMSV/PZED\46MQ<O8VUO<6V4
MU6W8X,4T1X9&'7..F[Y<<81XEFXPG[+1NV^M_+NO^&[7YX\7SE"%1T=).SUU
MOY::K;;T[7_5BQ\=^&M4F:&S\0Z5=RJC2&."]B=@JC+-@-T Y)IEG\0?"VH7
M,5M:^)='N;B9@D<,-_$[NQZ  -DD^@K\K_B)%I_PY^+0E\ :A)#<VKQRJMG)
MYPLKL_ZRWBE_Y;HK$J&QAAP<]3=^.NBZ=H.K:'?Q00^'_&5U;BZUO0]//[G3
M[C(*,I'^J=Q\YA&?+/&>P<N)*D8S;I*\'9ZZ/T=M_+_)CEQ;5A&HW15X.S][
M1]-';?RWMKT=OU!E^(WA."9X9?%&C1RHQ1XWU"(,K X((W<'/:I=0\>>&M)N
MWM;[Q%I5G=)C?!<7T2.N1D94MD9!S7YB_%:SBUGX=Z!XH\40QZ5X_OV $4:@
M/JUD%^6\GC&/*?(VA_\ EJ/FQQDNDB7Q?\#IM7\:*MI<:81:>&M:89NM2P?G
MLV7K+%&#D2G_ %?W<G.!;XBJ*4H*FM%S+7IY]G^OJF6^*ZJG*"I*Z7,M7MOK
MI[K_  OZIGZ<7?COPU8);O=>(=*MDN8_.@:6]B42IG&Y<M\P]QQ3SXU\/+I8
MU(Z]I@TXR>4+PWD?DE_[N_=C/MG-?F)\*HAXO\ Z[I7B]%C\"Z3$\\&NR_ZW
M2;MAE([?O+YI #0#@_?^4C)E_9CNM<U3Q3=>$X=+B\0>#M33?KNGWS;+6"!>
MMT7/$3H.0XY)&/3#I\13J2IKV6D]M7=/TMM?JNGFFATN*ZE2=*/L=*FVKNGM
MJK;7ZKI?JFC],[;QWX:O8;F:W\1:5/%;)YD\D5[$RQ+G&YB&^49XR:-/\=^&
MM6N1;V/B'2KRX*EA%;WL4CD 9)P&S@ $FORGM[AO!7QCN+?X9WDWB&W-VUG8
MA[;>-1B?@PR1=)$;E3D<CG [3_%:TTSX??$^&;P9=G3M0MUBN)[:PF\U-,ON
MLEO#,/\ 6JK<9]RN6QDY?ZRS4'-TE[KL]?R>S_I^F/\ K?4C!SE17NRL[2_]
M)=K/_AGMM^IMM\1/"EY<106_B?1IYY6"1QQW\3,[$X  #9)/I1<_$/PK97$M
MO<>)M'@GB8I)%+?Q*R,.H(+9!'I7Y@?'71K'3V\/ZK<VL.@>.M0A-SK6AV0
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M\LDX$<I^8\J,J,C26:4U[2G]6AHN;;1_XNTM>O70UGG-&+JTOJE/1*3TT?\
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M^.;3^PC"OB#RD.LKHI_T%-1W?.+0CG&<9Q\H;.WC%3_;$80<OJ\/<E;1:/\
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M(0&0HV1C.1F@#Z-HHHH **** &>:GF^7O7S,;MF><>N/2JNM:59:YI-W8:C
MMU87$9CG@<$AT(Y! Y(->4^%OACXMTG]I#Q#XVU/4-.U#0M1T<6%N8XI([B
M+<;XH,%V7:JEB6 &YF/%>QTFDU9B:4E9GS=X?\5?LS>$_$]M<:8_AG2M;M9C
M'%)]D>.2"3.T\LORD9(R<8]J/%UQ^S1I'BC4;?Q';^'8M<68O="\M)&D9V^;
M<25.[.<YY!!KYU_;PU/P#?\ Q$B7PZ@?Q3%E=9N+4C[.Q ^56]91W([<')Z<
M/XW']G_!G1K#QP1+XP!C?0(5XO+33SR1=D_\LVX,2'YAR>%(%?GE?-'1G5H>
MRIM0UO;3TWT;V]5;S7Y5B<YEAZE;#>QI25/6ZC[OH]=)/;KJK>:^S_'NI?LZ
M/JEK?^*4\.S7>H6D4]M<W%N[K-;XVH48*5V@#&!TQCBE\1:I^SK>>%_#VHZL
MOAV?051[/2Y6MG:",*<O&H"X1LG)!P3G/-?%_A@?V9\#]4_X3DA_#EYO;PO9
MM_Q^_;L@--;D_<M^TA/RL< #<,AGP,66QT/Q#?>)6C7X7NGE:K!<@G[5<;3Y
M*6@Z_:0>0PX49W?*<&%G#G-1]C#WU?5;><O+K?MKY.%GTIU(Q>'IKVBOK';K
M>6OP];]M;=']I)J?[.FH?#V1HT\.S>$M/O094CMG,,-Q(N%=U"Y!(& S#'8'
MM1X8U/\ 9TU'0?$-CH2>'9--$"W6J6UK;."\*-PSJ%W,JDY.,@=37PS\"XM9
M'C6[O-&F@LO#UO$YUJ?6!OLET\G#)<@</N'"J/F+8VX(R*NAPW.I_&<O\)TO
MK%5O'FTQKF0![> <L\S'@1A<[MV1MX;/.<XYU)QA/V$==+6U?IW72WROVRAQ
M#*4:=3ZM#WGRV4=7TO'75=+?*^NGWC\.]3_9TO\ Q#_9OA#_ (1I=8U&&2T6
M.VA,<DR,/G16('4#H#DUG:;XB_9C\&^)8I;4>&=*UJPG*JS6;I)!*#C^)/E(
M/<]*^(?BD='UKXI(G@*%YKJ1HD9M)1D@GO\ /[Q[-/O)&7Y4$Y[C P*[;]IR
MYT\:?X;L_$$UO??%FVA":_=Z<1Y(3'[N.<CA[@# 9EP.#G/%7_;$E3G)48?N
MWO;1^GGU\UZ:W_;THTJDE0IWIO1V]U^4=?BZ];J^UM?JSQ,?V9_"_B2X@URT
M\-VNL*XN)/M-H[,Y;YP^[:0X;.=V2#FM#X@ZW^SSJ%_8:SXM;P_>7&IVB36E
M[=0/()H!\J[&"D8&,;1T/4 U\6>(1_9OP,L++QR?,U]RDOA6W'_']:V9)+F<
MGI;M_P LT;YLY*X7J> Q_9WP=UN3QN=W@J[\S^Q+-_\ C[DU(#'FVF?N(O25
MC\A&!@MC#_M=N3IJC!)KFU6W^+]'YK36Q7]NR<W26'II./-K';_'K]S\UIK8
M^S]:U/\ 9TO/!FA7VH)X=G\,P/+9Z<YMG:"%P=SH %^1CG/(!/7D46>I_LZ:
MAX"OUM4\.S>%;"Z2>\BAMG\N*9QM221 N>>@8C Z9KXH^ :W-G#KM]K;PQ_#
M3RA%KZ7H)BN3C,<4"]3=9Y0KRO))VYSF?!J'6I/B)<7?A.6/3]*MED>_N-9(
M>SBTXG#K>8^5U*X!7&6;&WG%3'.92]G+V$??TM;73KOK'[MFNER(<02G[*7U
M:'OZ6Y==-+[ZQ^[9KI<^Z_"&J?LZZAIVO:;X=3P[);S6AFU*VM+9PTMO&=QR
MNW<RJ>2!GU(XJ/X?ZW^S@WB6&V\)MX:BUN\C>VB^S0-'(ZLI#(K%1R1D<')Z
M#K7PF(O[7^->?A'#J%J#>^9I&7VRQ <ER3]R,?,?G/"?>)YJ7XQR:+J_Q&@3
MPBB7.J.L4=])HZ%;6YU'/SO9H/F"%L8QP3DJ "*G^VI1AS^QA[KMHM_\+_K=
M,C_6&4(>T^KTWR2MHM_\#_X'5/K8^U]'U[]E_1/$-J]DOA>QU>VN (F>T='B
MF#8&=RX4@]STJYXVA_9N\,>*;NV\467AZUUQG%Q.+VTD:20O\V\MM(;.<YR<
MU\7_ !]GM2FAV^M2PWGQ*@B*>(+JR(,1X'EI,1P]RHXD=>.@.6!-=9XQ TK]
MG/3-/^)9\[Q6Q63PG;CC4;2S/WC<L>D!_@1AN],=M?[5?[RG[&'NJ][:>CUT
METZZZ>:W_MI_O:7U>G[BYK\NGI+7273KJK>:^NO'WQF^#?AZQT?6M;TZSU/3
M=4@ L=6AT874,BIQY8D"'!7'W#@CTJE+\??@GJ?@:+7_ .S[;4-!T^8V;*NA
M^8;!F^8;H]F8U<YPV I((SFOB7X8^,I?!GP_U^#Q-##J?@G5XWCM]$NF(>YO
M ,+/;GK'Y9QND''\/)Z1_ B"X\-75WXTU._72O!=JK6FHB:,2KJX8<V,<3<2
MLXZGH@^8D$"DL\K5)QY81]Y:Z:KS>MFNO33Y-J/$E>K4ARTXVFM5RZQ\V[V<
M>NMG;Y-_;V@?'WX*>*?#>KKI>G6][8:6!?7.F1Z'EPOW3.L.SY@H^\P!*@\\
M4WP1^T%\$/%UY=Z)H%E:&YNX&9K!=%$1O0GS>4JE )'[A.IQQS7PA\-=,O\
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M'FD" L>@R>]6*\E^,_@74?$/B+0=8A\*V'CO3K.SO+230=1G2)$FF\LI<CS
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MP4GY1SP.!?\ CQJ>FZOJ^BV2SP:YXVMX/L^O:QIP'V>^N,X15 _UDBCY6E&
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ML]ZKX.T'Q7IG_"22ZVVM>'(-(COM4E>2XM)(X9(Q&C?\^^Z1Y OW@SOR01@
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M<0"0.<9R>W-<YH/P4\-^&?B?J?CO35O+?5]2M7MKF$W<CV[EY1(T@C9B%8D
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MDVC]7BVTFU9A1113*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^-KS]NGQEX$^(!\/^/?!=CI<=M-Y5Y]D:0RHIZ21[FPZ]&X^\.A%)XT_;?\
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M;20A^V]5()'K@YJIIO@OP_HVLWFKZ?H6F6.K7F[[3?VUG''//N(9M\B@,V2
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MC3[SPY/=Z+H?C>5]^D7ES;,+*\;_ )]I 7_=NW\+YP3QCUJZ'^Q_\0OAWX0
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M\'*X-2P_&_X@?%;P/J&JZ1XPU?1?$_AJR$VIV\5P8[._M5.WSU/W8YQD!DR
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M1-)Q::OY'YB_&:QU#]G'XUR6_A3QE/J LR+B$-<-*]L&SFWG!^5CMX([JPR
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MPG:3AAP36Q\>-&F^%GBCP]KGAK6=3T&;5($U1/#US>.;W1I,@A'Y(VD\KGG
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MVJ66C:1#Y-EI>GW0AMHO5]NTY=N[$DFJ;?L<_#]?!*^%;9M7LM*:?[3="VO
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M6G]D5_\ GY3_ /!M/_Y(CZ_2_EG_ . 3_P#D3Z HKY__ .%H_'[_ *(GIO\
MX5,'_P 32_\ "T?C]_T1/3?_  J8/_B:/[(K_P#/RG_X-I__ "0_K]+^6?\
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M (FE_9=;^>'_ (,A_P#)#]M'L_N?^1[O17A'_"S/CM_T1K3O_"G@_P#B:/\
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M0_\ Q-'_  LOXZ?]$<T[_P *:'_XFE_9U7^:'_@</_DAV/=:*\)_X67\=/\
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MHKP#_A:/Q^_Z(IIG_A4P?_$TG_"T?C]_T1/3/_"I@_\ B:/JL_YH_P#@4?\
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MST&2<&G:OXAUO1K.*\ET\2J+65Y(8AE1('38A.<Y*[P.V<4 96A?&"'7DO\
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M31@7!^S%E5<QX[8_KZ]: .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>mrkr-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 11:51:44 AM-->
<!--Modified on: 3/22/2023 11:51:44 AM-->
<xsd:schema xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:us-types="http://fasb.org/us-types/2022" targetNamespace="http://www.tapimmune.com/20221231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:mrkr="http://www.tapimmune.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentDetails">
        <link:definition>40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2" id="DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2">
        <link:definition>40702 - Disclosure - LEASES - Maturities of Operating Leases (Details) Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" id="DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails">
        <link:definition>40702 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" id="DisclosureLeasesMaturitiesOfOperatingLeasesDetails">
        <link:definition>40703 - Disclosure - LEASES - Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails">
        <link:definition>41601 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails">
        <link:definition>41603 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantsTables" id="DisclosureWarrantsTables">
        <link:definition>31103 - Disclosure - WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" id="DisclosureStockOptionPlansTables">
        <link:definition>31203 - Disclosure - STOCK OPTION PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" id="DisclosureNatureOfOperationsDetails">
        <link:definition>40101 - Disclosure - NATURE OF OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" id="DisclosureFinancialConditionGoingConcernAndManagementPlansDetails">
        <link:definition>40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails" id="DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails">
        <link:definition>40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERSE - Computation of loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails">
        <link:definition>40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" id="DisclosureOtherReceivableDetails">
        <link:definition>40501 - Disclosure - OTHER RECEIVABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40701 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails" id="DisclosureRelatedPartyDeferredRevenueDetails">
        <link:definition>40901 - Disclosure - RELATED PARTY DEFERRED REVENUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails" id="DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails">
        <link:definition>41001 - Disclosure - STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>41002 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails" id="DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails">
        <link:definition>41003 - Disclosure - STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails" id="DisclosureStockholdersEquityStockPurchaseAgreementDetails">
        <link:definition>41004 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" id="DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails">
        <link:definition>41101 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>41102 - Disclosure - WARRANTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" id="DisclosureStockOptionPlansStockOptionActivityDetails">
        <link:definition>41201 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" id="DisclosureStockOptionPlansWeightedAverageAssumptionsDetails">
        <link:definition>41202 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" id="DisclosureStockOptionPlansStockBasedCompensationExpensesDetails">
        <link:definition>41203 - Disclosure - STOCK OPTION PLANS - Stock-based compensation expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" id="DisclosureStockOptionPlansAdditionalInformationDetails">
        <link:definition>41204 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" id="DisclosureGrantIncomeDetails">
        <link:definition>41301 - Disclosure - GRANT INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails" id="DisclosureLegalProceedingsDetails">
        <link:definition>41401 - Disclosure - LEGAL PROCEEDINGS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" id="DisclosureIncomeTaxesAdditionalInformationSDetails">
        <link:definition>41602 - Disclosure - INCOME TAXES - Additional Information's (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41701 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" id="DisclosureFinancialConditionGoingConcernAndManagementPlans">
        <link:definition>10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" id="DisclosureNetLossPerShareApplicableToCommonShareholders">
        <link:definition>10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" id="DisclosureOtherReceivable">
        <link:definition>10501 - Disclosure - OTHER RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10601 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10701 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities" id="DisclosureAccountsPayableAndAccruedLiabilities">
        <link:definition>10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenue" id="DisclosureRelatedPartyDeferredRevenue">
        <link:definition>10901 - Disclosure - RELATED PARTY DEFERRED REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11001 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>11101 - Disclosure - WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlans" id="DisclosureStockOptionPlans">
        <link:definition>11201 - Disclosure - STOCK OPTION PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" id="DisclosureGrantIncome">
        <link:definition>11301 - Disclosure - GRANT INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedings" id="DisclosureLegalProceedings">
        <link:definition>11401 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11501 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11601 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11701 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" id="DisclosureNetLossPerShareApplicableToCommonShareholdersTables">
        <link:definition>30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30603 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30703 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" id="DisclosureAccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>30803 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31603 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mrkr-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element name="RelatedPartyDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_RelatedPartyDisclosureAbstract" substitutionGroup="xbrli:item" />
  <xsd:element name="ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element id="mrkr_StockBasedCompensationExpensesTableTextBlock" name="StockBasedCompensationExpensesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantsEquityTreatment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_CommonStockWarrantsEquityTreatment" substitutionGroup="xbrli:item" />
  <xsd:element name="OperatingLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_OperatingLeaseExpenseAbstract" substitutionGroup="xbrli:item" />
  <xsd:element id="mrkr_OtherLeaseInformationAbstract" name="OtherLeaseInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_AccountsPayableAndAccruedLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element id="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" name="AccountsPayableAndAccruedLiabilitiesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedTechnologyLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="mrkr_AccruedTechnologyLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="mrkr_NumberOfWarrantExpiredOrCancelled" name="NumberOfWarrantExpiredOrCancelled" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
  <xsd:element name="ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" substitutionGroup="xbrli:item" />
  <xsd:element name="ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
  <xsd:element name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" substitutionGroup="xbrli:item" />
  <xsd:element name="CommonStockCapitalSharesReservedForFutureIssuanceTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="ExerciseOfStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_ExerciseOfStockWarrantsMember" substitutionGroup="xbrli:item" />
  <xsd:element name="CommonStockCapitalSharesReservedForFutureIssuanceLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="mrkr_BoardCompensationMember" name="BoardCompensationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_WarrantsDisclosureAbstract" name="WarrantsDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" name="SharePurchaseWarrantsTableTextBlockTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_NonEmployeeStockOptionMember" name="NonEmployeeStockOptionMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_ClassOfWarrantOrRightExerciseAxis" name="ClassOfWarrantOrRightExerciseAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_ClassOfWarrantOrRightExerciseDomain" name="ClassOfWarrantOrRightExerciseDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_Deferredtaxstockbasedcompensation" name="Deferredtaxstockbasedcompensation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mrkr_Deferredtaxassetslicenseagreement" name="Deferredtaxassetslicenseagreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mrkr_Permanentdifferencesotherpermanentdifferences" name="Permanentdifferencesotherpermanentdifferences" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_IncomeTaxLineItems" name="IncomeTaxLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_Taxcreditcarryforwardexpirationyearrangestart" name="Taxcreditcarryforwardexpirationyearrangestart" nillable="true" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_Taxcreditcarryforwardexpirationyearrangeend" name="Taxcreditcarryforwardexpirationyearrangeend" nillable="true" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_OperatingLossCarryforwardsLimitationPercentage" name="OperatingLossCarryforwardsLimitationPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mrkr_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mrkr_PurchasesFromBioTechneCorporationMember" name="PurchasesFromBioTechneCorporationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" name="PropertyPlantAndEquipmentOtherThanConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" name="PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" name="ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" name="LiquidityFinancialConditionAndGoingConcernAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" name="LiquidityFinancialConditionAndGoingConcernTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" name="SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_ManufacturingFacilityInHoustonTexasMember" name="ManufacturingFacilityInHoustonTexasMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets" name="ReclassificationsBetweenConstructionInProgressAndFixedAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="mrkr_NumberOfSharesAuthorizedToIssueAndSell" name="NumberOfSharesAuthorizedToIssueAndSell" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_UnderwritingOptionPeriod" name="UnderwritingOptionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" name="NumberOfAdditionalSharesAuthorizedToIssueAndSell" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" name="StockIssuedDuringPeriodAdditionalSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="mrkr_EquityIncentivePlan2020Member" name="EquityIncentivePlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_EquityIncentiveAwards2021Member" name="EquityIncentiveAwards2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_NonExecutiveEmployeesMember" name="NonExecutiveEmployeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="mrkr_ConstructionInProgress" name="ConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="mrkr_PaymentsForConstructionInProgress" name="PaymentsForConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="mrkr_AccruedProcessDevelopmentExpensesCurrent" name="AccruedProcessDevelopmentExpensesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element name="GainLossRelatedToArbitrationSettlement" id="mrkr_GainLossRelatedToArbitrationSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ControlledEquityOfferingSalesAgreementMember" id="mrkr_ControlledEquityOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" id="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" id="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ArbitrationSettlementLiabilitiesCurrent" id="mrkr_ArbitrationSettlementLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FundsReceivedFromCpritGrant" id="mrkr_FundsReceivedFromCpritGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FundsReceivedFromGrant" id="mrkr_FundsReceivedFromGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReceiptOfProductDevelopmentResearchAward" id="mrkr_ReceiptOfProductDevelopmentResearchAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CompensationInterestAndAttorneyFees" id="mrkr_CompensationInterestAndAttorneyFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WilsonWolfManufacturingCorporationMember" id="mrkr_WilsonWolfManufacturingCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" id="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LegalProceedingsBrokerAwardedAdditionalInterestAmount" id="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueFromGrantRelatedToCprit" id="mrkr_RevenueFromGrantRelatedToCprit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfAccrualOfPostJudgmentInterest" id="mrkr_PercentageOfAccrualOfPostJudgmentInterest" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BindingServicesAgreementMember" id="mrkr_BindingServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" id="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" id="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" id="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" id="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" id="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" id="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquityIncentivePlan2022Member" id="mrkr_EquityIncentivePlan2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease" id="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyLiabilityDisclosureTextBlock" id="mrkr_RelatedPartyLiabilityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" id="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrantIncomeReceivable" id="mrkr_GrantIncomeReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DecreaseInOperatingLeaseLiabilitiesForLeaseTermination" id="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination" id="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OperationalCostReductionPlanMember" id="mrkr_OperationalCostReductionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockBasedCompensationTable" id="mrkr_StockBasedCompensationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockBasedCompensationLineItems" id="mrkr_StockBasedCompensationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantIncomeTable" id="mrkr_GrantIncomeTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantIncomeLineItems" id="mrkr_GrantIncomeLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GainLossOnTerminationOfLeases" id="mrkr_GainLossOnTerminationOfLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfEqualMonthlyInstallmentsForVestingOfAwards" id="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="mrkr_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="mrkr_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RetainexistingpolicyPolicyTextBlock" id="mrkr_RetainexistingpolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" id="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueReverseStockSplits" id="mrkr_StockIssuedDuringPeriodValueReverseStockSplits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrantReceived" id="mrkr_GrantReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CancerPreventionAndResearchInstituteOfTexasMember" id="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" id="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" id="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AmountOfAwardGrantFromOrphanProductGrantProgram" id="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LincolnParkMember" id="mrkr_LincolnParkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtmAgreementMember" id="mrkr_AtmAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BrokerWasAwardedAccruedInterest" id="mrkr_BrokerWasAwardedAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdditionalAttorneyFeesAwarded" id="mrkr_AdditionalAttorneyFeesAwarded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock" id="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrantIncomePolicyPolicyTextBlock" id="mrkr_GrantIncomePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FinancialConditionGoingConcernAndManagementPlansTable" id="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancialConditionGoingConcernAndManagementPlansLineItems" id="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetLossPerShareTableTextBlock" id="mrkr_NetLossPerShareTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommitmentFee" id="mrkr_CommitmentFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OfferingCost" id="mrkr_OfferingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueFromOrphanProductsGrantProgram" id="mrkr_RevenueFromOrphanProductsGrantProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OrphanProductsGrantProgram" id="mrkr_OrphanProductsGrantProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockPurchaseAgreementMember" id="mrkr_StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AllovirIncMember" id="mrkr_AllovirIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>mrkr-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 11:51:44 AM-->
<!--Modified on: 3/22/2023 11:51:44 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2" roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeasesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" />
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638150826996901200" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638150826996901200" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826996901200" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638150826996901200" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826996901200" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638150826996901200" xlink:to="us-gaap_RestrictedCashCurrent_638150826996911194" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638150826996901200" xlink:to="us-gaap_PrepaidExpenseCurrent_638150826996911194" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638150826996901200" xlink:to="us-gaap_OtherReceivablesNetCurrent_638150826996911194" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_638150826996911194" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638150826996911194" xlink:to="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_638150826996911194" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638150826996911194" xlink:to="us-gaap_ConstructionInProgressGross_638150826996911194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638150826996911194" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638150826996911194" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638150826996911194" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638150826996911194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638150826996911194" xlink:to="us-gaap_LiabilitiesCurrent_638150826996911194" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638150826996911194" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638150826996921191" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638150826996911194" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638150826996921191" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638150826996911194" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638150826996921191" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638150826996911194" xlink:to="us-gaap_DeferredRevenueCurrent_638150826996921191" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638150826996911194" xlink:to="us-gaap_LiabilitiesNoncurrent_638150826996921191" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638150826996921191" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638150826996921191" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638150826996921191" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638150826996921191" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638150826996921191" xlink:to="us-gaap_PreferredStockValue_638150826996921191" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638150826996931194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638150826996921191" xlink:to="us-gaap_CommonStockValue_638150826996931194" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638150826996931194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638150826996921191" xlink:to="us-gaap_AdditionalPaidInCapital_638150826996931194" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638150826996931194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638150826996921191" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638150826996931194" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GainLossRelatedToArbitrationSettlement" xlink:label="mrkr_GainLossRelatedToArbitrationSettlement_638150826996931194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="mrkr_GainLossRelatedToArbitrationSettlement_638150826996931194" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638150826996931194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest_638150826996931194" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638150826996931194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638150826996931194" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638150826996931194" xlink:to="us-gaap_OperatingExpenses_638150826996941192" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638150826996941192" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638150826996941192" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638150826996941192" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638150826996941192" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638150826996931194" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150826996941192" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_ProfitLoss_638150826996941192" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638150826996941192" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_ShareBasedCompensation_638150826996941192" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638150826996941192" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638150826996941192" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638150826996951193" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638150826996951193" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638150826996951193" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638150826996951193" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638150826996951193" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638150826996951193" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638150826996951193" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GainLossOnTerminationOfLeases" xlink:label="mrkr_GainLossOnTerminationOfLeases_638150826996951193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826996941192" xlink:to="mrkr_GainLossOnTerminationOfLeases_638150826996951193" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638150826996961195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638150826996961195" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_638150826996961195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638150826996961195" xlink:to="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_638150826996961195" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PaymentsForConstructionInProgress" xlink:label="mrkr_PaymentsForConstructionInProgress_638150826996961195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638150826996961195" xlink:to="mrkr_PaymentsForConstructionInProgress_638150826996961195" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638150826996961195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638150826996961195" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638150826996961195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638150826996961195" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638150826996961195" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638150826996961195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638150826996961195" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638150826996961195" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826996961195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826996961195" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638150826996971194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent_638150826996971194" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ConstructionInProgress" xlink:label="mrkr_ConstructionInProgress_638150826996971194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="mrkr_ConstructionInProgress_638150826996971194" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638150826996971194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638150826996971194" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638150826996971194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638150826996971194" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2" xlink:type="extended" xlink:title="40702 - Disclosure - LEASES - Maturities of Operating Leases (Details) Calc2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638150826996971194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638150826996971194" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638150826996971194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638150826996971194" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638150826996981193" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_638150826996981193" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638150826996981193" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40703 - Disclosure - LEASES - Maturities of Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638150826996981193" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638150826996981193" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638150826996981193" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638150826996981193" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638150826996981193" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638150826996981193" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638150826996981193" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638150826996991194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccountsPayableCurrent_638150826996991194" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638150826996991194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638150826996991194" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedProcessDevelopmentExpensesCurrent" xlink:label="mrkr_AccruedProcessDevelopmentExpensesCurrent_638150826996991194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:to="mrkr_AccruedProcessDevelopmentExpensesCurrent_638150826996991194" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638150826996991194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638150826996991194" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedTechnologyLicenseFees" xlink:label="mrkr_AccruedTechnologyLicenseFees_638150826996991194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:to="mrkr_AccruedTechnologyLicenseFees_638150826996991194" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ArbitrationSettlementLiabilitiesCurrent" xlink:label="mrkr_ArbitrationSettlementLiabilitiesCurrent_638150826996991194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:to="mrkr_ArbitrationSettlementLiabilitiesCurrent_638150826996991194" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638150826996991194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638150826996991194" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638150826997001194" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638150826997001194" xlink:to="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_638150826997001194" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638150826997001194" xlink:to="mrkr_DeferredTaxLiabilitiesFixedAssets_638150826997001194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638150826997001194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638150826997001194" xlink:to="us-gaap_DeferredTaxAssetsGross_638150826997001194" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638150826997001194" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxstockbasedcompensation" xlink:label="mrkr_Deferredtaxstockbasedcompensation_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="mrkr_Deferredtaxstockbasedcompensation_638150826997001194" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638150826997001194" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxassetslicenseagreement" xlink:label="mrkr_Deferredtaxassetslicenseagreement_638150826997001194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="mrkr_Deferredtaxassetslicenseagreement_638150826997001194" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638150826997011194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638150826997011194" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638150826997011194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638150826997011194" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_638150826997011194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="mrkr_DeferredTaxAssetsOperatingLeaseLiability_638150826997011194" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638150826997011194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638150826997001194" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638150826997011194" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638150826997011194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638150826997001194" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638150826997011194" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41603 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638150826997011194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638150826997011194" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638150826997011194" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638150826997011194" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638150826997021195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638150826997021195" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Permanentdifferencesotherpermanentdifferences" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_638150826997021195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="mrkr_Permanentdifferencesotherpermanentdifferences_638150826997021195" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638150826997021195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638150826997021195" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638150826997021195" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638150826997021195" order="6" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>mrkr-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 11:51:44 AM-->
<!--Modified on: 3/22/2023 11:51:44 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureWarrantsTables" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNatureOfOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureRelatedPartyDeferredRevenueDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityStockPurchaseAgreementDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureGrantIncomeDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLegalProceedingsDetails" roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationSDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="mrkr-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityTypeAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:title="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_1" xlink:title="us-gaap_ProjectMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1" xlink:to="us-gaap_ProjectMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1 To us-gaap_ProjectMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightExerciseAxis" xlink:label="mrkr_ClassOfWarrantOrRightExerciseAxis_1" xlink:title="mrkr_ClassOfWarrantOrRightExerciseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightExerciseDomain" xlink:label="mrkr_ClassOfWarrantOrRightExerciseDomain_1" xlink:title="mrkr_ClassOfWarrantOrRightExerciseDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="mrkr_ClassOfWarrantOrRightExerciseAxis_1" xlink:to="mrkr_ClassOfWarrantOrRightExerciseDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:mrkr_ClassOfWarrantOrRightExerciseAxis_1 To mrkr_ClassOfWarrantOrRightExerciseDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1" xlink:title="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="us-gaap_HedgingRelationshipDomain_1" xlink:title="us-gaap_HedgingRelationshipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1" xlink:to="us-gaap_HedgingRelationshipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_1 To us-gaap_HedgingRelationshipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_1" xlink:title="us-gaap_RestructuringPlanAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_1" xlink:title="us-gaap_RestructuringPlanDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringPlanAxis_1" xlink:to="us-gaap_RestructuringPlanDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringPlanAxis_1 To us-gaap_RestructuringPlanDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GainLossRelatedToArbitrationSettlement" xlink:label="mrkr_GainLossRelatedToArbitrationSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="mrkr_GainLossRelatedToArbitrationSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="31103 - Disclosure - WARRANTS (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="mrkr_StockIssuedDuringPeriodValueReverseStockSplits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrkr_StockIssuedDuringPeriodValueReverseStockSplits" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" xlink:type="extended" xlink:title="40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BindingServicesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_LincolnParkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FundsReceivedFromCpritGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromGrantRelatedToCprit" xlink:label="mrkr_RevenueFromGrantRelatedToCprit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_RevenueFromGrantRelatedToCprit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_GrantReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommitmentFee" xlink:label="mrkr_CommitmentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_CommitmentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_OrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SignificantAccountingPoliciesTable" xlink:label="mrkr_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_SignificantAccountingPoliciesTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProjectMember" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SignificantAccountingPoliciesLineItems" xlink:label="mrkr_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConstructionInProgressGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_FundsReceivedFromCpritGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeReceivable" xlink:label="mrkr_GrantIncomeReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_GrantIncomeReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_OrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_GrantReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" xlink:label="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockWarrantsEquityTreatment" xlink:label="mrkr_CommonStockWarrantsEquityTreatment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="mrkr_CommonStockWarrantsEquityTreatment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER RECEIVABLE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProjectMember" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_TenantImprovements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_OtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="mrkr_OrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ComputerEquipmentAndSoftwareMember" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mrkr_ComputerEquipmentAndSoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ConstructionInProgress" xlink:label="mrkr_ConstructionInProgress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="mrkr_ConstructionInProgress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProjectMember" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ConstructionInProgressGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="us-gaap_RestructuringPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperationalCostReductionPlanMember" xlink:label="mrkr_OperationalCostReductionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="mrkr_OperationalCostReductionPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedProcessDevelopmentExpensesCurrent" xlink:label="mrkr_AccruedProcessDevelopmentExpensesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccruedProcessDevelopmentExpensesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedTechnologyLicenseFees" xlink:label="mrkr_AccruedTechnologyLicenseFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccruedTechnologyLicenseFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ArbitrationSettlementLiabilitiesCurrent" xlink:label="mrkr_ArbitrationSettlementLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_ArbitrationSettlementLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails" xlink:type="extended" xlink:title="40901 - Disclosure - RELATED PARTY DEFERRED REVENUE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BindingServicesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" xlink:label="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" xlink:label="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" xlink:label="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" xlink:label="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_ExerciseOfStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BoardCompensationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RecapitalizationCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_ExerciseOfStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BoardCompensationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AtmAgreementMember" xlink:label="mrkr_AtmAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrkr_AtmAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrkr_EquityIncentivePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails" xlink:type="extended" xlink:title="41003 - Disclosure - STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mrkr_BoardCompensationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mrkr_ExerciseOfStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfSharesAuthorizedToIssueAndSell" xlink:label="mrkr_NumberOfSharesAuthorizedToIssueAndSell" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_NumberOfSharesAuthorizedToIssueAndSell" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_UnderwritingOptionPeriod" xlink:label="mrkr_UnderwritingOptionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_UnderwritingOptionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" xlink:label="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:label="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OfferingCost" xlink:label="mrkr_OfferingCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_OfferingCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails" xlink:type="extended" xlink:title="41004 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockPurchaseAgreementMember" xlink:label="mrkr_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mrkr_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_LincolnParkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41201 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrkr_EquityIncentivePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockBasedCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - STOCK OPTION PLANS - Stock-based compensation expenses (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockBasedCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" xlink:type="extended" xlink:title="41204 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentiveAwards2021Member" xlink:label="mrkr_EquityIncentiveAwards2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mrkr_EquityIncentiveAwards2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2022Member" xlink:label="mrkr_EquityIncentivePlan2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mrkr_EquityIncentivePlan2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mrkr_EquityIncentivePlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NonExecutiveEmployeesMember" xlink:label="mrkr_NonExecutiveEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mrkr_NonExecutiveEmployeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NonEmployeeStockOptionMember" xlink:label="mrkr_NonEmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="mrkr_NonEmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockBasedCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" xlink:label="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - GRANT INCOME (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeTable" xlink:label="mrkr_GrantIncomeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="mrkr_GrantIncomeTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="mrkr_GrantIncomeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeLineItems" xlink:label="mrkr_GrantIncomeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_GrantIncomeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_FundsReceivedFromGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_OrphanProductsGrantProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeReceivable" xlink:label="mrkr_GrantIncomeReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_GrantIncomeReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="us-gaap_GrantsReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - LEGAL PROCEEDINGS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CompensationInterestAndAttorneyFees" xlink:label="mrkr_CompensationInterestAndAttorneyFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="mrkr_CompensationInterestAndAttorneyFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" xlink:label="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PercentageOfAccrualOfPostJudgmentInterest" xlink:label="mrkr_PercentageOfAccrualOfPostJudgmentInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="mrkr_PercentageOfAccrualOfPostJudgmentInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BrokerWasAwardedAccruedInterest" xlink:label="mrkr_BrokerWasAwardedAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="mrkr_BrokerWasAwardedAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AdditionalAttorneyFeesAwarded" xlink:label="mrkr_AdditionalAttorneyFeesAwarded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="mrkr_AdditionalAttorneyFeesAwarded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PurchasesFromBioTechneCorporationMember" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_PurchasesFromBioTechneCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxstockbasedcompensation" xlink:label="mrkr_Deferredtaxstockbasedcompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="mrkr_Deferredtaxstockbasedcompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxassetslicenseagreement" xlink:label="mrkr_Deferredtaxassetslicenseagreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="mrkr_Deferredtaxassetslicenseagreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="mrkr_DeferredTaxAssetsOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="mrkr_DeferredTaxLiabilitiesFixedAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" xlink:type="extended" xlink:title="41602 - Disclosure - INCOME TAXES - Additional Information's (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_IncomeTaxLineItems" xlink:label="mrkr_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangestart" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangeend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AllovirIncMember" xlink:label="mrkr_AllovirIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mrkr_AllovirIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>mrkr-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 11:51:44 AM-->
<!--Modified on: 3/22/2023 11:51:44 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:to="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" xml:lang="en-US">Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Excludes construction in progress.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" xml:lang="en-US">Property, Plant and Equipment Other Than Construction in Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Construction in Progress, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Related party deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 30 million and 15 million shares authorized, 8.4 million and 8.3 million shares issued and outstanding as of December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Related party service revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">LIQUIDITY, GOING CONCERN AND FINANCIAL CONDITION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses):</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GainLossRelatedToArbitrationSettlement" xlink:label="mrkr_GainLossRelatedToArbitrationSettlement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GainLossRelatedToArbitrationSettlement" xlink:to="mrkr_GainLossRelatedToArbitrationSettlement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GainLossRelatedToArbitrationSettlement_lbl" xml:lang="en-US">The amount of gain (loss) pertaining to the arbitration that was charged against earnings in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GainLossRelatedToArbitrationSettlement_lbl" xml:lang="en-US">Gain (Loss) Related to Arbitration Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GainLossRelatedToArbitrationSettlement_lbl" xml:lang="en-US">Arbitration settlement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid- in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Beginning Balance, Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common shares for cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Aggregate proceeds from shares issued under the purchase agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares for cash (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised for cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised for cash (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Aggregate shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Reconciliation of net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization on right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GainLossOnTerminationOfLeases" xlink:label="mrkr_GainLossOnTerminationOfLeases" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GainLossOnTerminationOfLeases" xlink:to="mrkr_GainLossOnTerminationOfLeases_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GainLossOnTerminationOfLeases_lbl" xml:lang="en-US">Amount of gain (loss) on termination of lease before expiration of leases term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GainLossOnTerminationOfLeases_lbl" xml:lang="en-US">Gain Loss On Termination Of Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_GainLossOnTerminationOfLeases_lbl" xml:lang="en-US">Gain on lease termination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Related party deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:to="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" xml:lang="en-US">The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; excluding cash outflows to pay for construction of self-constructed assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment Excluding Construction In Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PaymentsForConstructionInProgress" xlink:label="mrkr_PaymentsForConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PaymentsForConstructionInProgress" xlink:to="mrkr_PaymentsForConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PaymentsForConstructionInProgress_lbl" xml:lang="en-US">The cash outflow for acquisition of Construction in Progress.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PaymentsForConstructionInProgress_lbl" xml:lang="en-US">Payments For Construction in Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_PaymentsForConstructionInProgress_lbl" xml:lang="en-US">Purchase of construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental schedule of non-cash financing and investing activities:</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets" xlink:label="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets" xlink:to="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets_lbl" xml:lang="en-US">Amount of reclassifications between construction in progress and fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets_lbl" xml:lang="en-US">Reclassifications Between Construction in Progress and Fixed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets_lbl" xml:lang="en-US">Reclassifications between construction in progress and fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital expenditures included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease" xlink:label="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease" xlink:to="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease_lbl" xml:lang="en-US">Amount of changes to right-of-use assets and lease liability due to close out of an operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease_lbl" xml:lang="en-US">Change To Right Of Use Assets And Lease Liability Due To Close Out Of An Operating Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease_lbl" xml:lang="en-US">Changes to right-of-use assets and lease liability due to close out of operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract_lbl" xml:lang="en-US">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity Financial Condition And Going Concern Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity Financial Condition And Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_lbl" xml:lang="en-US">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAbstract" xlink:label="us-gaap_DueToRelatedPartiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAbstract_lbl" xml:lang="en-US">RELATED PARTY DEFERRED REVENUE</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyLiabilityDisclosureTextBlock" xlink:label="mrkr_RelatedPartyLiabilityDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyLiabilityDisclosureTextBlock" xlink:to="mrkr_RelatedPartyLiabilityDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyLiabilityDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for related party liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyLiabilityDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Liability, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RelatedPartyLiabilityDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY DEFERRED REVENUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK OPTION PLANS.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_WarrantsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantsDisclosureAbstract_lbl" xml:lang="en-US">WARRANTS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WarrantsDisclosureTextBlock" xlink:label="mrkr_WarrantsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WarrantsDisclosureTextBlock" xlink:to="mrkr_WarrantsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for information about warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Warrants Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_WarrantsDisclosureTextBlock_lbl" xml:lang="en-US">WARRANTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK OPTION PLANS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK OPTION PLANS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">LEGAL PROCEEDINGS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US">LEGAL PROCEEDINGS</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="mrkr_RelatedPartyDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyDisclosureAbstract" xlink:to="mrkr_RelatedPartyDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyDisclosureAbstract_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Credit Risk</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RetainexistingpolicyPolicyTextBlock" xlink:label="mrkr_RetainexistingpolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RetainexistingpolicyPolicyTextBlock" xlink:to="mrkr_RetainexistingpolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RetainexistingpolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for the Retain existing  policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RetainexistingpolicyPolicyTextBlock_lbl" xml:lang="en-US">RetainExistingPolicy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RetainexistingpolicyPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock" xlink:to="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for property and equipment, construction in progress.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock_lbl" xml:lang="en-US">Property And Equipment Construction In Progress, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment - Construction in Progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment Testing of Long-Lived Assets and Right-Of-Use Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patents and Patent Application Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Director [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomePolicyPolicyTextBlock" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomePolicyPolicyTextBlock" xlink:to="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Grant Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Grant Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:label="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:to="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of the components of cash and cash equivalents, restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents, Restricted Cash [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of net loss per share</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NetLossPerShareTableTextBlock" xlink:label="mrkr_NetLossPerShareTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NetLossPerShareTableTextBlock" xlink:to="mrkr_NetLossPerShareTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NetLossPerShareTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of net loss per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NetLossPerShareTableTextBlock_lbl" xml:lang="en-US">Net Loss Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NetLossPerShareTableTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of lease cost and other information related to operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule Of Lease Cost And Other Information Related to Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of quantitative information about operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Common stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:to="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of share purchase warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Share Purchase Warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Summary of the company's stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule or Description of Weighted Average Discount Rate [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule or description of weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of stock based compensation expenses recorded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US">Stock based Compensation Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">RELATED PARTY LIABILITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of related party transaction expenses recorded during the respective periods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" xlink:to="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of expected tax expense benefit based on federal statutory rate is reconciled with actual tax provision benefit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" xml:lang="en-US">Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rate is Reconciled With Actual Tax Provision Benefit [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_lbl" xml:lang="en-US">Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US">Disclosure of information about organization, consolidation and presentation of financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent event</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US">NATURE OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="mrkr_StockIssuedDuringPeriodValueReverseStockSplits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="mrkr_StockIssuedDuringPeriodValueReverseStockSplits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">The amount of stock issued during period, value, reverse stock splits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Stock Issued During Period, Value, Reverse Stock Splits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Reverse stock split value</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xml:lang="en-US">Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_lbl" xml:lang="en-US">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Represents the information pertaining to controlled equity offering sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Controlled Equity Offering Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BindingServicesAgreementMember" xlink:to="mrkr_BindingServicesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BindingServicesAgreementMember_lbl" xml:lang="en-US">This member stands for binding services agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BindingServicesAgreementMember_lbl" xml:lang="en-US">Binding Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_BindingServicesAgreementMember_lbl" xml:lang="en-US">Binding Services Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US">Represents the information pertaining to Cantor Fitzgerald &amp; Co and RBC Capital Markets, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US">Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_lbl" xml:lang="en-US">Sales Agents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_WilsonWolfManufacturingCorporationMember" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US">Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US">Wilson Wolf Manufacturing Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_lbl" xml:lang="en-US">Wilson Wolf Manufacturing Corporation</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LincolnParkMember" xlink:to="mrkr_LincolnParkMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LincolnParkMember_lbl" xml:lang="en-US">The information pertaining to Lincoln Park.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LincolnParkMember_lbl" xml:lang="en-US">Lincoln Park [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LincolnParkMember_lbl" xml:lang="en-US">Lincoln Park</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_lbl" xml:lang="en-US">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US">Common Stock, Value, Subscriptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US">Represents the percent of calculation of compensation rate by using gross sales price per share sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US">Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_lbl" xml:lang="en-US">Commission rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued during period for services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Amount of notice received</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FundsReceivedFromCpritGrant" xlink:to="mrkr_FundsReceivedFromCpritGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US">Funds Received From Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US">Funds received from CPRIT grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FundsReceivedFromCpritGrant_lbl" xml:lang="en-US">Funds received from CPRIT grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromGrantRelatedToCprit" xlink:label="mrkr_RevenueFromGrantRelatedToCprit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RevenueFromGrantRelatedToCprit" xlink:to="mrkr_RevenueFromGrantRelatedToCprit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_lbl" xml:lang="en-US">Revenue From Grant Related to CPRIT.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_lbl" xml:lang="en-US">Revenue From Grant Related to CPRIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_lbl" xml:lang="en-US">Revenue from CPRIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantReceived" xlink:to="mrkr_GrantReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US">Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US">Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantReceived_lbl" xml:lang="en-US">Grant income received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock issued during period other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock issued during period other (in shares)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommitmentFee" xlink:label="mrkr_CommitmentFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommitmentFee" xlink:to="mrkr_CommitmentFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommitmentFee_lbl" xml:lang="en-US">Represents the amount of commitment fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommitmentFee_lbl" xml:lang="en-US">Commitment Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommitmentFee_lbl" xml:lang="en-US">Commitment fee</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RevenueFromOrphanProductsGrantProgram" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" xml:lang="en-US">Amount of revenue recognized for grant from FDA's Orphan Products Grant program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" xml:lang="en-US">Revenue From Orphan Products Grant Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_lbl" xml:lang="en-US">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OrphanProductsGrantProgram" xlink:to="mrkr_OrphanProductsGrantProgram_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OrphanProductsGrantProgram_lbl" xml:lang="en-US">Amount of receivable from FDA's Orphan Products Grant program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OrphanProductsGrantProgram_lbl" xml:lang="en-US">Orphan Products Grant Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OrphanProductsGrantProgram_lbl" xml:lang="en-US">Grant income receivable</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_FundsReceivedFromGrant" xlink:to="mrkr_FundsReceivedFromGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US">Funds received from CPRIT grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US">Funds Received From Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_FundsReceivedFromGrant_lbl" xml:lang="en-US">Funds received from CPRIT grant</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SignificantAccountingPoliciesTable" xlink:label="mrkr_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SignificantAccountingPoliciesTable" xlink:to="mrkr_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Schedule reflecting a significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US">Project [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProjectMember_lbl" xml:lang="en-US">Project [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" xml:lang="en-US">Manufacturing facility in Houston, Texas</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_lbl" xml:lang="en-US">Manufacturing facility in Houston, Texas</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SignificantAccountingPoliciesLineItems" xlink:label="mrkr_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SignificantAccountingPoliciesLineItems" xlink:to="mrkr_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Line items reflecting a significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, uninsured amount</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" xml:lang="en-US">Receipt of product development research award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" xml:lang="en-US">Receipt Of Product Development Research Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_lbl" xml:lang="en-US">Receipt of product development research award</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeReceivable" xlink:label="mrkr_GrantIncomeReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomeReceivable" xlink:to="mrkr_GrantIncomeReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomeReceivable_lbl" xml:lang="en-US">Amount of grant income receivable by the company, as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomeReceivable_lbl" xml:lang="en-US">Grant Income Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantIncomeReceivable_lbl" xml:lang="en-US">Grant income receivable</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" xlink:label="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" xlink:to="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram_lbl" xml:lang="en-US">The amount of Award grant from orphan product grant program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram_lbl" xml:lang="en-US">Amount Of Award Grant From Orphan Product Grant Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram_lbl" xml:lang="en-US">Amount of award grant from orphan product grant program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Common stock options</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockWarrantsEquityTreatment" xlink:label="mrkr_CommonStockWarrantsEquityTreatment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockWarrantsEquityTreatment" xlink:to="mrkr_CommonStockWarrantsEquityTreatment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_lbl" xml:lang="en-US">Common stock warrants - equity treatment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_lbl" xml:lang="en-US">Common Stock Warrants Equity Treatment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_lbl" xml:lang="en-US">Common stock purchase warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_lbl" xml:lang="en-US">Schedule of Receivables with Imputed Interest [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" xml:lang="en-US">The information pertaining to cancer Ppevention And Research Institute Of Texas.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" xml:lang="en-US">Cancer Prevention And Research Institute Of Texas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_lbl" xml:lang="en-US">Cancer Prevention And Research Institute Of Texas</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems" xlink:to="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xml:lang="en-US">Receivables with Imputed Interest [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_lbl" xml:lang="en-US">OTHER RECEIVABLE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Reimbursements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab and manufacturing equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab and manufacturing equipment</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ComputerEquipmentAndSoftwareMember" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ComputerEquipmentAndSoftwareMember" xlink:to="mrkr_ComputerEquipmentAndSoftwareMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Computers, equipment and software</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Computers, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ConstructionInProgress" xlink:label="mrkr_ConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ConstructionInProgress" xlink:to="mrkr_ConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ConstructionInProgress_lbl" xml:lang="en-US">Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ConstructionInProgress_lbl" xml:lang="en-US">Construction in Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ConstructionInProgress_lbl" xml:lang="en-US">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total fixed assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination" xlink:label="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination" xlink:to="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination_lbl" xml:lang="en-US">Amount of reduction in operating lease liabilities for termination of lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination_lbl" xml:lang="en-US">Decrease In Operating Lease Liabilities For Lease Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination_lbl" xml:lang="en-US">Reduction in operating lease liabilities for lease termination</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination" xlink:label="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination" xlink:to="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination_lbl" xml:lang="en-US">Amount of reduction in operating lease right of use assets for termination of lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination_lbl" xml:lang="en-US">Decrease In Operating Lease Right Of Use Assets For Lease Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination_lbl" xml:lang="en-US">Reduction in right-of-use assets for lease termination</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease, liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December 31, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperatingLeaseExpenseAbstract" xlink:label="mrkr_OperatingLeaseExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OperatingLeaseExpenseAbstract" xlink:to="mrkr_OperatingLeaseExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OperatingLeaseExpenseAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OperatingLeaseExpenseAbstract_lbl" xml:lang="en-US">Operating Lease Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OperatingLeaseExpenseAbstract_lbl" xml:lang="en-US">Operating lease expense summary:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OtherLeaseInformationAbstract" xlink:label="mrkr_OtherLeaseInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OtherLeaseInformationAbstract" xlink:to="mrkr_OtherLeaseInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OtherLeaseInformationAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OtherLeaseInformationAbstract_lbl" xml:lang="en-US">Other Lease Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OtherLeaseInformationAbstract_lbl" xml:lang="en-US">Other information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows - operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">weighted-average discount rate used to determine the operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Year ending December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Year ending December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Year ending December 31, 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Year ending December 31, 2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Year ending December 31, 2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less present value discount</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xml:lang="en-US">This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_lbl" xml:lang="en-US">Accounts Payable And Accrued Liabilities [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xml:lang="en-US">Restructuring Plan [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xml:lang="en-US">Restructuring Plan [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperationalCostReductionPlanMember" xlink:label="mrkr_OperationalCostReductionPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OperationalCostReductionPlanMember" xlink:to="mrkr_OperationalCostReductionPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OperationalCostReductionPlanMember_lbl" xml:lang="en-US">This member stands for operational cost reduction plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OperationalCostReductionPlanMember_lbl" xml:lang="en-US">Operational Cost Reduction Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OperationalCostReductionPlanMember_lbl" xml:lang="en-US">Operational Cost Reduction Plan</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US">Accounts Payable And Accrued Liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedProcessDevelopmentExpensesCurrent" xlink:label="mrkr_AccruedProcessDevelopmentExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccruedProcessDevelopmentExpensesCurrent" xlink:to="mrkr_AccruedProcessDevelopmentExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccruedProcessDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for Process development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccruedProcessDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued Process Development Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AccruedProcessDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Process development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedTechnologyLicenseFees" xlink:label="mrkr_AccruedTechnologyLicenseFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AccruedTechnologyLicenseFees" xlink:to="mrkr_AccruedTechnologyLicenseFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AccruedTechnologyLicenseFees_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of Consulting agreements payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AccruedTechnologyLicenseFees_lbl" xml:lang="en-US">Accrued Technology License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AccruedTechnologyLicenseFees_lbl" xml:lang="en-US">Technology license fees</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ArbitrationSettlementLiabilitiesCurrent" xlink:label="mrkr_ArbitrationSettlementLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ArbitrationSettlementLiabilitiesCurrent" xlink:to="mrkr_ArbitrationSettlementLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ArbitrationSettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for arbitration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ArbitrationSettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Arbitration Settlement Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ArbitrationSettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Arbitration settlement fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Reduction in headcount of general and administrative function (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Cash payment from related party</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation_lbl" xml:lang="en-US">The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to make, use, and sell Marker's cell culture non-proprietary media formulation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation_lbl" xml:lang="en-US">Related Party Advance Received For Non Exclusive Training To Make Use And Sell Marker&amp;rsquo;s Cell Culture Non Proprietary Media Formulation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation_lbl" xml:lang="en-US">Advance received for non-exclusive training of Wilson Wolf to make, use, and sell Marker's cell culture non-proprietary media formulation</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments_lbl" xml:lang="en-US">The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to replicate Marker's quality management system inclusive of all underlying documents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments_lbl" xml:lang="en-US">Related Party Advance Received For Non Exclusive Training To Replicate Marker&amp;rsquo;s Quality Management System Inclusive Of All Underlying Documents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments_lbl" xml:lang="en-US">Advance received for non-exclusive training of Wilson Wolf to replicate Marker's quality management system inclusive of all underlying documents</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess_lbl" xml:lang="en-US">The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to be able to replicate Marker's cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess_lbl" xml:lang="en-US">Related Party Advance Received For Non Exclusive Training To Replicate Marker&amp;rsquo;s cGMP Compliant Linearly Scalable G-Rex Based T-Cell Manufacturing Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess_lbl" xml:lang="en-US">Advance received for non-exclusive training of Wilson Wolf to replicate Marker's cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" xlink:label="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" xlink:to="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses_lbl" xml:lang="en-US">The amount of advance received under the hired to invent doctrine for Marker to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes using G-Rex and to conduct CAR T and TCR G-Rex Optimization Work under the direction of Wilson Wolf (the "Work Direction").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses_lbl" xml:lang="en-US">Related Party Advance Received Under The Hired To Invent Doctrine For Marker To Train Wilson Wolf On Its Expertise In The Optimization Of T-Cell Therapy Manufacturing Processes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses_lbl" xml:lang="en-US">Advance received under the hired to invent doctrine for Marker to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" xlink:label="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" xlink:to="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate_lbl" xml:lang="en-US">The period for completion of optimization work under the direction of Wilson Wolf which Marker will make good faith efforts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate_lbl" xml:lang="en-US">Period For Completion Of Optimization Work Under Direction Of Wilson Wolf Which Marker Will Make Good Faith Efforts From The Agreement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate_lbl" xml:lang="en-US">Period for completion of optimization work under the direction of Wilson Wolf which Marker will make good faith efforts from the agreement date</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" xlink:label="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" xlink:to="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement_lbl" xml:lang="en-US">The additional amount agreed to received from Wilson Wolf if the Work Direction is completed within one year from the onset of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement_lbl" xml:lang="en-US">Additional Amount Agreed To Pay If The Work Direction Is Completed Within One Year From The Onset Of The Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement_lbl" xml:lang="en-US">Additional amount agreed to received from Wilson Wolf if the Work Direction is completed within one year from the onset of the agreement</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" xlink:label="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" xlink:to="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered_lbl" xml:lang="en-US">Percentage of threshold minimum combined voting power of the surviving entity or parent corporation of the surviving entity immediately after merger, reorganization or consolidation, or the sale or other transfer of all or substantially all of entity's business or assets considered, in the event if the agreement cannot be fulfilled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered_lbl" xml:lang="en-US">Threshold Minimum Combined Voting Power Of Surviving Entity Or Parent Corporation Of Surviving Entity Considered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered_lbl" xml:lang="en-US">Threshold minimum combined voting power of the surviving entity or parent corporation of the surviving entity considered (in percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ExerciseOfStockWarrantsMember" xlink:to="mrkr_ExerciseOfStockWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ExerciseOfStockWarrantsMember_lbl" xml:lang="en-US">This member stands for exercise of Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ExerciseOfStockWarrantsMember_lbl" xml:lang="en-US">Exercise of Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ExerciseOfStockWarrantsMember_lbl" xml:lang="en-US">Exercise of Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BoardCompensationMember" xlink:to="mrkr_BoardCompensationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BoardCompensationMember_lbl" xml:lang="en-US">This member stands for board compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BoardCompensationMember_lbl" xml:lang="en-US">Board Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_BoardCompensationMember_lbl" xml:lang="en-US">Board Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Issuance of shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecapitalizationCosts" xlink:to="us-gaap_RecapitalizationCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecapitalizationCosts_lbl" xml:lang="en-US">Recapitalization Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RecapitalizationCosts_lbl" xml:lang="en-US">Related costs</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" xml:lang="en-US">Schedule of common stock capital shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AtmAgreementMember" xlink:label="mrkr_AtmAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AtmAgreementMember" xlink:to="mrkr_AtmAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AtmAgreementMember_lbl" xml:lang="en-US">The member stands for  ATM agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AtmAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AtmAgreementMember_lbl" xml:lang="en-US">ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EquityIncentivePlan2020Member" xlink:to="mrkr_EquityIncentivePlan2020Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">Represents member information pertaining to 2020 equity incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">Equity Incentive Plan 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_EquityIncentivePlan2020Member_lbl" xml:lang="en-US">2020 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" xml:lang="en-US">Common Stock Capital Shares Reserved For Future Issuance [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Underwritten Public Offering</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfSharesAuthorizedToIssueAndSell" xlink:label="mrkr_NumberOfSharesAuthorizedToIssueAndSell" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfSharesAuthorizedToIssueAndSell" xlink:to="mrkr_NumberOfSharesAuthorizedToIssueAndSell_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfSharesAuthorizedToIssueAndSell_lbl" xml:lang="en-US">Represents the number of shares authorized to issue and sell.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfSharesAuthorizedToIssueAndSell_lbl" xml:lang="en-US">Number Of Shares Authorized To Issue And Sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NumberOfSharesAuthorizedToIssueAndSell_lbl" xml:lang="en-US">Number of shares authorized to issue and sell</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_UnderwritingOptionPeriod" xlink:label="mrkr_UnderwritingOptionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_UnderwritingOptionPeriod" xlink:to="mrkr_UnderwritingOptionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_UnderwritingOptionPeriod_lbl" xml:lang="en-US">Represents the underwriting option period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_UnderwritingOptionPeriod_lbl" xml:lang="en-US">Underwriting Option Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_UnderwritingOptionPeriod_lbl" xml:lang="en-US">Option period</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" xlink:label="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" xlink:to="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell_lbl" xml:lang="en-US">Represents the number of additional shares authorized to issue and sell.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell_lbl" xml:lang="en-US">Number Of Additional Shares Authorized To Issue And Sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell_lbl" xml:lang="en-US">Number of additional shares authorized to issue and sell</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:label="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:to="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" xml:lang="en-US">Number of additional new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Additional Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues_lbl" xml:lang="en-US">Number of additional shares issued</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OfferingCost" xlink:label="mrkr_OfferingCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OfferingCost" xlink:to="mrkr_OfferingCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OfferingCost_lbl" xml:lang="en-US">Represents the amount of offering cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OfferingCost_lbl" xml:lang="en-US">Offering Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_OfferingCost_lbl" xml:lang="en-US">Offering cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockPurchaseAgreementMember" xlink:label="mrkr_StockPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockPurchaseAgreementMember" xlink:to="mrkr_StockPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockPurchaseAgreementMember_lbl" xml:lang="en-US">This Member represents stock purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfWarrantExpiredOrCancelled" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfWarrantExpiredOrCancelled" xlink:to="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" xml:lang="en-US">Number of warrants expired or cancelled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" xml:lang="en-US">Number of Warrants, Expired or cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_lbl" xml:lang="en-US">Number of Warrants, Expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" xml:lang="en-US">Class of warrant or rights outstanding exercised weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised for cash</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Class of warrant or right outstanding issued weighted average remaining life.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationTable" xlink:to="mrkr_StockBasedCompensationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationTable_lbl" xml:lang="en-US">This table lists the stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationTable_lbl" xml:lang="en-US">Stock-Based Compensation [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_StockBasedCompensationLineItems" xlink:to="mrkr_StockBasedCompensationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_StockBasedCompensationLineItems_lbl" xml:lang="en-US">Line items represent stock-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_StockBasedCompensationLineItems_lbl" xml:lang="en-US">Stock-Based Compensation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_StockBasedCompensationLineItems_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, grants in period, gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled / Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share Outstanding, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Cancelled / Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options granted in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Options vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock price volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate of interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentiveAwards2021Member" xlink:label="mrkr_EquityIncentiveAwards2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EquityIncentiveAwards2021Member" xlink:to="mrkr_EquityIncentiveAwards2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EquityIncentiveAwards2021Member_lbl" xml:lang="en-US">Represents member information pertaining to Equity Incentive Awards 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EquityIncentiveAwards2021Member_lbl" xml:lang="en-US">2021 Equity Incentive Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_EquityIncentiveAwards2021Member_lbl" xml:lang="en-US">2021 Equity Incentive Awards</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2022Member" xlink:label="mrkr_EquityIncentivePlan2022Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EquityIncentivePlan2022Member" xlink:to="mrkr_EquityIncentivePlan2022Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EquityIncentivePlan2022Member_lbl" xml:lang="en-US">Represents member information pertaining to 2022 equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EquityIncentivePlan2022Member_lbl" xml:lang="en-US">2022 Equity Incentive Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_EquityIncentivePlan2022Member_lbl" xml:lang="en-US">2022 Equity Incentive Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive officer</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NonExecutiveEmployeesMember" xlink:label="mrkr_NonExecutiveEmployeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NonExecutiveEmployeesMember" xlink:to="mrkr_NonExecutiveEmployeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NonExecutiveEmployeesMember_lbl" xml:lang="en-US">Represents the information pertaining to non-executive employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NonExecutiveEmployeesMember_lbl" xml:lang="en-US">Non-executive employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NonExecutiveEmployeesMember_lbl" xml:lang="en-US">Non-executive employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NonEmployeeStockOptionMember" xlink:label="mrkr_NonEmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NonEmployeeStockOptionMember" xlink:to="mrkr_NonEmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NonEmployeeStockOptionMember_lbl" xml:lang="en-US">Non Employee Stock Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NonEmployeeStockOptionMember_lbl" xml:lang="en-US">Non Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NonEmployeeStockOptionMember_lbl" xml:lang="en-US">Non Employee Stock Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Non-Employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche one</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Tranche two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" xlink:label="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" xlink:to="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards_lbl" xml:lang="en-US">Number of equal monthly installments for option award vesting over the vesting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards_lbl" xml:lang="en-US">Number of Equal Monthly Installments for Vesting of Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards_lbl" xml:lang="en-US">Number of equal monthly installments of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Award vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of options to purchase shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" xml:lang="en-US">Share based compensation arrangement number of share options available for issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Options Available for Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_lbl" xml:lang="en-US">Number of shares options available to be issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Compensation cost not yet recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Compensation cost not yet recognized, period for recognition</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeTable" xlink:label="mrkr_GrantIncomeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomeTable" xlink:to="mrkr_GrantIncomeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomeTable_lbl" xml:lang="en-US">This table lists the grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomeTable_lbl" xml:lang="en-US">Grant Income [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeLineItems" xlink:label="mrkr_GrantIncomeLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_GrantIncomeLineItems" xlink:to="mrkr_GrantIncomeLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_GrantIncomeLineItems_lbl" xml:lang="en-US">Line items represents grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_GrantIncomeLineItems_lbl" xml:lang="en-US">Grant Income [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_GrantIncomeLineItems_lbl" xml:lang="en-US">GRANT INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">FDA's orphan products grant program, grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CompensationInterestAndAttorneyFees" xlink:label="mrkr_CompensationInterestAndAttorneyFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_CompensationInterestAndAttorneyFees" xlink:to="mrkr_CompensationInterestAndAttorneyFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_CompensationInterestAndAttorneyFees_lbl" xml:lang="en-US">Compensation, interest and attorney fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_CompensationInterestAndAttorneyFees_lbl" xml:lang="en-US">Compensation, Interest And Attorney fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_CompensationInterestAndAttorneyFees_lbl" xml:lang="en-US">Compensation, interest and attorney fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other expenses</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" xlink:label="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" xlink:to="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount_lbl" xml:lang="en-US">Amount of legal proceedings broker awarded additional interest amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount_lbl" xml:lang="en-US">Legal Proceedings Broker Awarded Additional Interest Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount_lbl" xml:lang="en-US">Broker was awarded with additional in interest</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PercentageOfAccrualOfPostJudgmentInterest" xlink:label="mrkr_PercentageOfAccrualOfPostJudgmentInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PercentageOfAccrualOfPostJudgmentInterest" xlink:to="mrkr_PercentageOfAccrualOfPostJudgmentInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PercentageOfAccrualOfPostJudgmentInterest_lbl" xml:lang="en-US">The percentage of accrual of post judgment interest until judgment is paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PercentageOfAccrualOfPostJudgmentInterest_lbl" xml:lang="en-US">Percentage of Accrual of Post Judgment Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PercentageOfAccrualOfPostJudgmentInterest_lbl" xml:lang="en-US">Percentage of accrual of post judgment interest</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BrokerWasAwardedAccruedInterest" xlink:label="mrkr_BrokerWasAwardedAccruedInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_BrokerWasAwardedAccruedInterest" xlink:to="mrkr_BrokerWasAwardedAccruedInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_BrokerWasAwardedAccruedInterest_lbl" xml:lang="en-US">"Amount of legal proceedings broker
 awarded accrued interest amount."</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_BrokerWasAwardedAccruedInterest_lbl" xml:lang="en-US">Broker was awarded accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_BrokerWasAwardedAccruedInterest_lbl" xml:lang="en-US">Broker was awarded accrued interest</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AdditionalAttorneyFeesAwarded" xlink:label="mrkr_AdditionalAttorneyFeesAwarded" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AdditionalAttorneyFeesAwarded" xlink:to="mrkr_AdditionalAttorneyFeesAwarded_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AdditionalAttorneyFeesAwarded_lbl" xml:lang="en-US">"Amount of additional attorney fees awarded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AdditionalAttorneyFeesAwarded_lbl" xml:lang="en-US">Additional attorney fees awarded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AdditionalAttorneyFeesAwarded_lbl" xml:lang="en-US">Additional attorney fees awarded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Long-Term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Payment of commitment fee</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US">Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US">Baylor College of Medicine [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_lbl" xml:lang="en-US">Baylor College of Medicine</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PurchasesFromBioTechneCorporationMember" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_PurchasesFromBioTechneCorporationMember" xlink:to="mrkr_PurchasesFromBioTechneCorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_lbl" xml:lang="en-US">Represents information about the purchases from bio techne corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_lbl" xml:lang="en-US">Bio-Techne Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_lbl" xml:lang="en-US">Bio-Techne Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Total Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously reported</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US">Deferred Income Taxes and Other Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_lbl" xml:lang="en-US">Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net Operating Loss Carryforward</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxstockbasedcompensation" xlink:label="mrkr_Deferredtaxstockbasedcompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Deferredtaxstockbasedcompensation" xlink:to="mrkr_Deferredtaxstockbasedcompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Deferredtaxstockbasedcompensation_lbl" xml:lang="en-US">Deferred tax stock based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Deferredtaxstockbasedcompensation_lbl" xml:lang="en-US">Deferred tax stock based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Deferredtaxstockbasedcompensation_lbl" xml:lang="en-US">Stock Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxassetslicenseagreement" xlink:label="mrkr_Deferredtaxassetslicenseagreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Deferredtaxassetslicenseagreement" xlink:to="mrkr_Deferredtaxassetslicenseagreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Deferredtaxassetslicenseagreement_lbl" xml:lang="en-US">Amount of deferred tax assets license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Deferredtaxassetslicenseagreement_lbl" xml:lang="en-US">Deferred tax assets license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Deferredtaxassetslicenseagreement_lbl" xml:lang="en-US">License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized R&amp;E</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Charitable Contributions</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">The amount of Deferred tax assets, operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease Liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:to="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" xml:lang="en-US">The amount of deferred tax liability, Fixed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_lbl" xml:lang="en-US">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">The amount of deferred tax liability, Right-of-Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities Right of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Right-of-Use Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total Deferred Tax Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net Deferred Tax Assets/(Liabilities)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign tax authority</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and local jurisdiction</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_IncomeTaxLineItems" xlink:label="mrkr_IncomeTaxLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_IncomeTaxLineItems" xlink:to="mrkr_IncomeTaxLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Tax [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Tax [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_IncomeTaxLineItems_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" xml:lang="en-US">Tax credit carryforward expiration year range start.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" xml:lang="en-US">Tax credit carry forward expiration year range start</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_lbl" xml:lang="en-US">Tax credit carryforwards expiration period</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" xml:lang="en-US">Tax credit carryforward expiration year range end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" xml:lang="en-US">Tax credit carry forward expiration year range end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_lbl" xml:lang="en-US">Tax credit carryforwards expiration year end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xml:lang="en-US">The percentage of limitation for operating loss carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_lbl" xml:lang="en-US">Operating Loss Carryforwards Limitation Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Tax rate change</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory rate, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Tax rate change, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Permanent Differences</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Permanentdifferencesotherpermanentdifferences" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_Permanentdifferencesotherpermanentdifferences" xlink:to="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" xml:lang="en-US">Permanent differences other permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" xml:lang="en-US">Permanent differences other permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_lbl" xml:lang="en-US">Permanent differences- Other permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_lbl" xml:lang="en-US">Deferred true-up</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision/(benefit)</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xml:lang="en-US">Represents the effective tax rate reconciliation due to other permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Other Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xml:lang="en-US">Permanent differences- Other permanent differences, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Deferred true-up, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax provision (benefit), Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AllovirIncMember" xlink:label="mrkr_AllovirIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrkr_AllovirIncMember" xlink:to="mrkr_AllovirIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrkr_AllovirIncMember_lbl" xml:lang="en-US">Represents information pertaining to AlloVir, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrkr_AllovirIncMember_lbl" xml:lang="en-US">AlloVir, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrkr_AllovirIncMember_lbl" xml:lang="en-US">AlloVir, Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>mrkr-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2023 11:51:44 AM-->
<!--Modified on: 3/22/2023 11:51:44 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNatureOfOperations" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperations" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlans" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholders" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureOtherReceivable" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivable" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeases" roleURI="http://www.tapimmune.com/role/DisclosureLeases" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureAccountsPayableAndAccruedLiabilities" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureRelatedPartyDeferredRevenue" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenue" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureWarrants" roleURI="http://www.tapimmune.com/role/DisclosureWarrants" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlans" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlans" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureGrantIncome" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncome" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLegalProceedings" roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedings" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersTables" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeasesTables" roleURI="http://www.tapimmune.com/role/DisclosureLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesTables" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureWarrantsTables" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansTables" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNatureOfOperationsDetails" roleURI="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" roleURI="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureOtherReceivableDetails" roleURI="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosurePropertyAndEquipmentDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLeasesMaturitiesOfOperatingLeasesDetails" roleURI="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureRelatedPartyDeferredRevenueDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockholdersEquityStockPurchaseAgreementDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureWarrantsAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureStockOptionPlansAdditionalInformationDetails" roleURI="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureGrantIncomeDetails" roleURI="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureLegalProceedingsDetails" roleURI="http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationSDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" roleURI="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="mrkr-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638150826999541200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638150826999541200" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638150826999541200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638150826999541200" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638150826999541200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638150826999541200" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638150826999541200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638150826999541200" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638150826999541200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638150826999541200" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638150826999551199" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638150826999551199" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638150826999551199" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638150826999551199" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638150826999551199" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638150826999551199" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638150826999551199" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638150826999551199" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638150826999551199" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638150826999551199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638150826999551199" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638150826999561198" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638150826999561198" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638150826999561198" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638150826999561198" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638150826999561198" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638150826999561198" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638150826999561198" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638150826999561198" order="23" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638150826999561198" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638150826999561198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638150826999561198" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638150826999571195" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638150826999571195" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638150826999571195" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638150826999571195" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638150826999571195" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638150826999571195" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638150826999571195" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638150826999571195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638150826999571195" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638150826999581194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638150826999581194" order="34" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638150826999581194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638150826999581194" order="35" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638150826999581194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638150826999581194" order="36" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_32" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638150826999581194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="us-gaap_AssetsAbstract_638150826999581194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638150826999581194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638150826999581194" xlink:to="us-gaap_AssetsCurrentAbstract_638150826999581194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826999581194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638150826999581194" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826999581194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638150826999581194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638150826999581194" xlink:to="us-gaap_RestrictedCashCurrent_638150826999581194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638150826999581194" xlink:to="us-gaap_PrepaidExpenseCurrent_638150826999591193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638150826999581194" xlink:to="us-gaap_OtherReceivablesNetCurrent_638150826999591193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638150826999581194" xlink:to="us-gaap_AssetsCurrent_638150826999591193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638150826999581194" xlink:to="us-gaap_AssetsNoncurrentAbstract_638150826999591193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress" xlink:label="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638150826999591193" xlink:to="mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress_638150826999591193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638150826999591193" xlink:to="us-gaap_ConstructionInProgressGross_638150826999591193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638150826999591193" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638150826999591193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638150826999591193" xlink:to="us-gaap_AssetsNoncurrent_638150826999591193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638150826999581194" xlink:to="us-gaap_Assets_638150826999591193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638150826999591193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638150826999591193" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638150826999591193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638150826999591193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638150826999591193" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638150826999591193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638150826999591193" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638150826999601198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638150826999591193" xlink:to="us-gaap_DeferredRevenueCurrent_638150826999601198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638150826999591193" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638150826999601198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638150826999591193" xlink:to="us-gaap_LiabilitiesCurrent_638150826999601198" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638150826999591193" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638150826999601198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638150826999601198" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638150826999601198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638150826999601198" xlink:to="us-gaap_LiabilitiesNoncurrent_638150826999601198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638150826999591193" xlink:to="us-gaap_Liabilities_638150826999601198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638150826999591193" xlink:to="us-gaap_StockholdersEquityAbstract_638150826999601198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638150826999601198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638150826999601198" xlink:to="us-gaap_PreferredStockValue_638150826999601198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638150826999611197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638150826999601198" xlink:to="us-gaap_CommonStockValue_638150826999611197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638150826999611197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638150826999601198" xlink:to="us-gaap_AdditionalPaidInCapital_638150826999611197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638150826999611197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638150826999601198" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638150826999611197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638150826999611197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638150826999601198" xlink:to="us-gaap_StockholdersEquity_638150826999611197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638150826999611197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638150826999611197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_119" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638150826999611197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638150826999611197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockSharesAuthorized_638150826999621195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockSharesIssued_638150826999621195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_PreferredStockSharesOutstanding_638150826999621195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638150826999621195" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockSharesAuthorized_638150826999621195" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockSharesIssued_638150826999621195" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_119" xlink:to="us-gaap_CommonStockSharesOutstanding_638150826999621195" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_234" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_234" xlink:to="us-gaap_StatementTable_638150826999621195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150826999621195" xlink:to="srt_ProductOrServiceAxis_638150826999621195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638150826999621195" xlink:to="srt_ProductsAndServicesDomain_638150826999621195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638150826999621195" xlink:to="us-gaap_GrantMember_638150826999621195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_638150826999621195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638150826999621195" xlink:to="us-gaap_ServiceMember_638150826999621195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150826999621195" xlink:to="us-gaap_StatementLineItems_638150826999631198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_RevenuesAbstract_638150826999631198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638150826999631198" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150826999631198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_CostsAndExpensesAbstract_638150826999631198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638150826999631198" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638150826999631198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638150826999631198" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638150826999631198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638150826999631198" xlink:to="us-gaap_OperatingExpenses_638150826999631198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638150826999631198" xlink:to="us-gaap_OperatingIncomeLoss_638150826999631198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638150826999631198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GainLossRelatedToArbitrationSettlement" xlink:label="mrkr_GainLossRelatedToArbitrationSettlement_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638150826999631198" xlink:to="mrkr_GainLossRelatedToArbitrationSettlement_638150826999631198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638150826999631198" xlink:to="us-gaap_InvestmentIncomeInterest_638150826999631198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638150826999631198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_NetIncomeLoss_638150826999631198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_EarningsPerShareBasic_638150826999641198" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_EarningsPerShareDiluted_638150826999641198" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638150826999641198" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999631198" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638150826999641198" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_493" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_493" xlink:to="us-gaap_StatementTable_638150826999641198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150826999641198" xlink:to="us-gaap_StatementEquityComponentsAxis_638150826999641198" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638150826999641198" xlink:to="us-gaap_CommonStockMember_638150826999641198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638150826999641198" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638150826999641198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638150826999641198" xlink:to="us-gaap_RetainedEarningsMember_638150826999641198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638150826999641198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638150826999641198" xlink:to="us-gaap_EquityComponentDomain_638150826999641198" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150826999641198" xlink:to="us-gaap_StatementLineItems_638150826999651199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockholdersEquity_638150826999651199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_SharesIssued_638150826999651199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150826999651199" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150826999651199" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638150826999651199" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638150826999651199" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638150826999651199" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_638150826999651199" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638150826999651199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_NetIncomeLoss_638150826999651199" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6381508269996511991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_StockholdersEquity_6381508269996511991" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999651199" xlink:to="us-gaap_SharesIssued_638150826999661198" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638150826999661198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_655" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_ProfitLoss_638150826999661198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638150826999661198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_ShareBasedCompensation_638150826999661198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638150826999661198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638150826999661198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638150826999661198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GainLossOnTerminationOfLeases" xlink:label="mrkr_GainLossOnTerminationOfLeases_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="mrkr_GainLossOnTerminationOfLeases_638150826999671195" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638150826999671195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_638150826999671195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638150826999671195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_638150826999671195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638150826999671195" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638150826999671195" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638150826999671195" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638150826999661198" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638150826999671195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638150826999671195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress" xlink:label="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_638150826999671195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638150826999671195" xlink:to="mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress_638150826999671195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PaymentsForConstructionInProgress" xlink:label="mrkr_PaymentsForConstructionInProgress_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638150826999671195" xlink:to="mrkr_PaymentsForConstructionInProgress_638150826999681193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638150826999671195" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638150826999681193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638150826999681193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638150826999681193" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638150826999681193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638150826999681193" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638150826999681193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638150826999681193" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638150826999681193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638150826999681193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638150826999681193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638150826999681193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381508269996811931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381508269996811931" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638150826999691192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_655" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638150826999691192" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets" xlink:label="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets_638150826999691192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638150826999691192" xlink:to="mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets_638150826999691192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638150826999691192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638150826999691192" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638150826999691192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease" xlink:label="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease_638150826999691192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638150826999691192" xlink:to="mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease_638150826999691192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - NATURE OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_728" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638150826999691192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_728" xlink:to="us-gaap_NatureOfOperations_638150826999691192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans" xlink:type="extended" xlink:title="10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_638150826999701200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock_638150826999701200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_731" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638150826999701200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_731" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638150826999701200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders" xlink:type="extended" xlink:title="10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_734" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_638150826999701200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_734" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_638150826999701200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivable" xlink:type="extended" xlink:title="10501 - Disclosure - OTHER RECEIVABLE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638150826999701200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638150826999701200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10601 - Disclosure - PROPERTY AND EQUIPMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327057" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638150826999711194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327057" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638150826999711194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10701 - Disclosure - LEASES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416650" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638150826999711194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416650" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638150826999711194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:type="extended" xlink:title="10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638150826999711194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638150826999711194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenue" xlink:type="extended" xlink:title="10901 - Disclosure - RELATED PARTY DEFERRED REVENUE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAbstract" xlink:label="us-gaap_DueToRelatedPartiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyLiabilityDisclosureTextBlock" xlink:label="mrkr_RelatedPartyLiabilityDisclosureTextBlock_638150826999711194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueToRelatedPartiesCurrentAbstract" xlink:to="mrkr_RelatedPartyLiabilityDisclosureTextBlock_638150826999711194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11001 - Disclosure - STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_14" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638150826999721192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_14" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638150826999721192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="11101 - Disclosure - WARRANTS">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WarrantsDisclosureTextBlock" xlink:label="mrkr_WarrantsDisclosureTextBlock_638150826999721192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract_637040620889325859" xlink:to="mrkr_WarrantsDisclosureTextBlock_638150826999721192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlans" xlink:type="extended" xlink:title="11201 - Disclosure - STOCK OPTION PLANS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414378" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638150826999721192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_414378" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638150826999721192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncome" xlink:type="extended" xlink:title="11301 - Disclosure - GRANT INCOME">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638150826999721192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638150826999721192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLegalProceedings" xlink:type="extended" xlink:title="11401 - Disclosure - LEGAL PROCEEDINGS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_638150826999731194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract_637040620889325859" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_638150826999731194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11501 - Disclosure - RELATED PARTY TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="loc_mrkr_RelatedPartyDisclosureAbstract_327033" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638150826999731194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrkr_RelatedPartyDisclosureAbstract_327033" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638150826999731194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11601 - Disclosure - INCOME TAXES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638150826999731194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620889325859" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638150826999731194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11701 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638150826999731194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventsTextBlock_638150826999731194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638150826999741199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638150826999741199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638150826999741199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638150826999741199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638150826999741199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638150826999741199" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638150826999751230" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RetainexistingpolicyPolicyTextBlock" xlink:label="mrkr_RetainexistingpolicyPolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_RetainexistingpolicyPolicyTextBlock_638150826999751230" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock" xlink:label="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock_638150826999751230" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638150826999751230" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_638150826999751230" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_638150826999751230" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638150826999751230" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638150826999751230" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomePolicyPolicyTextBlock" xlink:label="mrkr_GrantIncomePolicyPolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mrkr_GrantIncomePolicyPolicyTextBlock_638150826999751230" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638150826999751230" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638150826999751230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638150826999751230" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock" xlink:label="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_638150826999761197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock_638150826999761197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables" xlink:type="extended" xlink:title="30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_81" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638150826999761197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_81" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638150826999761197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NetLossPerShareTableTextBlock" xlink:label="mrkr_NetLossPerShareTableTextBlock_638150826999761197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_81" xlink:to="mrkr_NetLossPerShareTableTextBlock_638150826999761197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30603 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327063" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638150826999761197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327063" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638150826999761197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - LEASES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416654" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_638150826999771197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416654" xlink:to="mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_638150826999771197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638150826999771197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416654" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638150826999771197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_85" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638150826999771197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_85" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_638150826999771197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsTables" xlink:type="extended" xlink:title="31103 - Disclosure - WARRANTS (Tables)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638150826999771197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract_637040620889325859" xlink:to="us-gaap_StatementTable_638150826999771197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638150826999771197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150826999771197" xlink:to="us-gaap_StatementEquityComponentsAxis_638150826999771197" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638150826999771197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638150826999771197" xlink:to="us-gaap_EquityComponentDomain_638150826999771197" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638150826999771197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638150826999771197" xlink:to="us-gaap_WarrantMember_638150826999771197" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638150826999781197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150826999771197" xlink:to="us-gaap_StatementLineItems_638150826999781197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock" xlink:label="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_638150826999781197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150826999781197" xlink:to="mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock_638150826999781197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansTables" xlink:type="extended" xlink:title="31203 - Disclosure - STOCK OPTION PLANS (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620889325859" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_638150826999781197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620889325859" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_638150826999781197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638150826999781197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620889325859" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638150826999781197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationExpensesTableTextBlock" xlink:label="mrkr_StockBasedCompensationExpensesTableTextBlock_638150826999781197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620889325859" xlink:to="mrkr_StockBasedCompensationExpensesTableTextBlock_638150826999781197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="mrkr_RelatedPartyDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638150826999781197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_RelatedPartyDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638150826999781197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31603 - Disclosure - INCOME TAXES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638150826999781197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638150826999781197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock" xlink:label="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock_638150826999791195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - NATURE OF OPERATIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638150826999791195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638150826999791195" xlink:to="srt_RangeAxis_638150826999791195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638150826999791195" xlink:to="srt_RangeMember_638150826999791195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638150826999791195" xlink:to="srt_MaximumMember_638150826999791195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638150826999791195" xlink:to="srt_MinimumMember_638150826999791195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638150826999791195" xlink:to="us-gaap_SubsequentEventTypeAxis_638150826999791195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150826999791195" xlink:to="us-gaap_SubsequentEventTypeDomain_638150826999791195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150826999791195" xlink:to="us-gaap_SubsequentEventMember_638150826999791195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638150826999791195" xlink:to="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638150826999791195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638150826999791195" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_638150826999791195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638150826999791195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638150826999791195" xlink:to="us-gaap_CommonStockSharesAuthorized_638150826999791195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="mrkr_StockIssuedDuringPeriodValueReverseStockSplits_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638150826999791195" xlink:to="mrkr_StockIssuedDuringPeriodValueReverseStockSplits_638150826999801195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails" xlink:type="extended" xlink:title="40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:label="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansTable" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_LiquidityFinancialConditionAndGoingConcernAbstract" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" xlink:to="us-gaap_TypeOfArrangementAxis_638150826999801195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638150826999801195" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150826999801195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150826999801195" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_638150826999801195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150826999801195" xlink:to="mrkr_BindingServicesAgreementMember_638150826999801195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" xlink:to="srt_CounterpartyNameAxis_638150826999801195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638150826999801195" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638150826999801195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember" xlink:label="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638150826999801195" xlink:to="mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_638150826999801195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150826999801195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" xlink:to="us-gaap_SubsequentEventTypeAxis_638150826999801195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150826999801195" xlink:to="us-gaap_SubsequentEventTypeDomain_638150826999811198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150826999811198" xlink:to="us-gaap_SubsequentEventMember_638150826999811198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150826999811198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150826999811198" xlink:to="us-gaap_RelatedPartyDomain_638150826999811198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150826999811198" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_638150826999811198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150826999811198" xlink:to="mrkr_LincolnParkMember_638150826999811198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" xlink:to="us-gaap_StatementEquityComponentsAxis_638150826999811198" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638150826999811198" xlink:to="us-gaap_EquityComponentDomain_638150826999811198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638150826999811198" xlink:to="us-gaap_CommonStockMember_638150826999811198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems" xlink:label="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansTable_638150826999801195" xlink:to="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638150826999811198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638150826999811198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150826999821191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638150826999821191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_CommonStockSharesSubscriptions_638150826999821191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150826999821191" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent" xlink:label="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent_638150826999821191" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638150826999821191" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_638150826999821191" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_FundsReceivedFromCpritGrant_638150826999821191" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromGrantRelatedToCprit" xlink:label="mrkr_RevenueFromGrantRelatedToCprit_638150826999821191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_RevenueFromGrantRelatedToCprit_638150826999821191" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638150826999831190" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_DeferredRevenueCurrent_638150826999831190" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_GrantReceived_638150826999831190" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_638150826999831190" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_638150826999831190" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommitmentFee" xlink:label="mrkr_CommitmentFee_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_CommitmentFee_638150826999831190" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram_638150826999831190" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram_638150826999831190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_OrphanProductsGrantProgram_638150826999831190" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems_638150826999811198" xlink:to="mrkr_FundsReceivedFromGrant_638150826999841190" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SignificantAccountingPoliciesTable" xlink:label="mrkr_SignificantAccountingPoliciesTable_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="mrkr_SignificantAccountingPoliciesTable_638150826999841190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesTable_638150826999841190" xlink:to="srt_ProductOrServiceAxis_638150826999841190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638150826999841190" xlink:to="srt_ProductsAndServicesDomain_638150826999841190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638150826999841190" xlink:to="us-gaap_GrantMember_638150826999841190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesTable_638150826999841190" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999841190" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999841190" xlink:to="us-gaap_ProjectMember_638150826999841190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_638150826999841190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638150826999841190" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember_638150826999841190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638150826999841190" xlink:to="us-gaap_SubsequentEventMember_638150826999851196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesTable_638150826999841190" xlink:to="us-gaap_SubsequentEventTypeAxis_638150826999851196" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150826999851196" xlink:to="us-gaap_SubsequentEventTypeDomain_638150826999851196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_6381508269998511961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150826999851196" xlink:to="us-gaap_SubsequentEventMember_6381508269998511961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SignificantAccountingPoliciesLineItems" xlink:label="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesTable_638150826999841190" xlink:to="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="us-gaap_CashFDICInsuredAmount_638150826999851196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="us-gaap_CashUninsuredAmount_638150826999851196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="us-gaap_ConstructionInProgressGross_638150826999851196" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward_638150826999851196" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromCpritGrant" xlink:label="mrkr_FundsReceivedFromCpritGrant_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_FundsReceivedFromCpritGrant_638150826999851196" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeReceivable" xlink:label="mrkr_GrantIncomeReceivable_638150826999851196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_GrantIncomeReceivable_638150826999851196" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_OrphanProductsGrantProgram_638150826999861194" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram_638150826999861194" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantReceived" xlink:label="mrkr_GrantReceived_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_GrantReceived_638150826999861194" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_FundsReceivedFromGrant_638150826999861194" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="us-gaap_OtherReceivablesNetCurrent_638150826999861194" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram" xlink:label="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_SignificantAccountingPoliciesLineItems_638150826999851196" xlink:to="mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram_638150826999861194" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638150826999861194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_RestrictedCashCurrent_638150826999861194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638150826999861194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638150826999861194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERSE - Computation of loss per Share (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract_636948102906705552" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToParentDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948102906705552" xlink:to="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638150826999871196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAttributableToParentDilutedAbstract_638150826999871196" xlink:to="us-gaap_NetIncomeLoss_638150826999871196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948102906705552" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638150826999871196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638150826999871196" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638150826999871196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638150826999871196" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638150826999871196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948102906705552" xlink:to="us-gaap_EarningsPerShareAbstract_638150826999871196" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638150826999871196" xlink:to="us-gaap_EarningsPerShareBasic_638150826999871196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638150826999871196" xlink:to="us-gaap_EarningsPerShareDiluted_638150826999871196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract_636948103393835552" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638150826999871196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_636948103393835552" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638150826999871196" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638150826999871196" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638150826999881196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638150826999881196" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638150826999881196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638150826999881196" xlink:to="us-gaap_EmployeeStockOptionMember_638150826999881196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638150826999881196" xlink:to="us-gaap_WarrantMember_638150826999881196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638150826999871196" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638150826999881196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockWarrantsEquityTreatment" xlink:label="mrkr_CommonStockWarrantsEquityTreatment_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638150826999881196" xlink:to="mrkr_CommonStockWarrantsEquityTreatment_638150826999881196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638150826999881196" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638150826999881196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureOtherReceivableDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER RECEIVABLE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfReceivablesWithImputedInterestTable" xlink:label="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638150826999881196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638150826999881196" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999881196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999881196" xlink:to="us-gaap_ProjectMember_638150826999881196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CancerPreventionAndResearchInstituteOfTexasMember" xlink:label="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_638150826999881196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638150826999881196" xlink:to="mrkr_CancerPreventionAndResearchInstituteOfTexasMember_638150826999881196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638150826999881196" xlink:to="us-gaap_SubsequentEventMember_638150826999891193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638150826999881196" xlink:to="us-gaap_SubsequentEventTypeAxis_638150826999891193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150826999891193" xlink:to="us-gaap_SubsequentEventTypeDomain_638150826999891193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_6381508269998911931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150826999891193" xlink:to="us-gaap_SubsequentEventMember_6381508269998911931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesWithImputedInterestLineItems" xlink:label="us-gaap_ReceivablesWithImputedInterestLineItems_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfReceivablesWithImputedInterestTable_638150826999881196" xlink:to="us-gaap_ReceivablesWithImputedInterestLineItems_638150826999891193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638150826999891193" xlink:to="us-gaap_TenantImprovements_638150826999891193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638150826999891193" xlink:to="us-gaap_OtherReceivablesNetCurrent_638150826999891193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638150826999891193" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram_638150826999891193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638150826999891193" xlink:to="mrkr_OrphanProductsGrantProgram_638150826999891193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_638150826999891193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesWithImputedInterestLineItems_638150826999891193" xlink:to="mrkr_FundsReceivedFromGrant_638150826999891193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327071" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_327071" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999901194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999901194" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638150826999901194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638150826999901194" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638150826999901194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638150826999901194" xlink:to="us-gaap_EquipmentMember_638150826999901194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ComputerEquipmentAndSoftwareMember" xlink:label="mrkr_ComputerEquipmentAndSoftwareMember_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638150826999901194" xlink:to="mrkr_ComputerEquipmentAndSoftwareMember_638150826999901194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638150826999901194" xlink:to="us-gaap_OfficeEquipmentMember_638150826999901194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638150826999901194" xlink:to="us-gaap_LeaseholdImprovementsMember_638150826999901194" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999901194" xlink:to="srt_RangeAxis_638150826999901194" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638150826999901194" xlink:to="srt_RangeMember_638150826999901194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638150826999901194" xlink:to="srt_MinimumMember_638150826999901194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638150826999901194" xlink:to="srt_MaximumMember_638150826999901194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999901194" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999901194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638150826999901194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999901194" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638150826999901194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999901194" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638150826999911193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ConstructionInProgress" xlink:label="mrkr_ConstructionInProgress_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999901194" xlink:to="mrkr_ConstructionInProgress_638150826999911193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999901194" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638150826999911193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999901194" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638150826999911193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_416638" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_416638" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999911193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999911193" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999911193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_638150826999911193" xlink:to="us-gaap_ProjectMember_638150826999911193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ManufacturingFacilityInHoustonTexasMember" xlink:label="mrkr_ManufacturingFacilityInHoustonTexasMember_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember_638150826999911193" xlink:to="mrkr_ManufacturingFacilityInHoustonTexasMember_638150826999911193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638150826999911193" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999911193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638150826999911193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999911193" xlink:to="us-gaap_Depreciation_638150826999911193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638150826999911193" xlink:to="us-gaap_ConstructionInProgressGross_638150826999921195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LEASES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416659" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination" xlink:label="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416659" xlink:to="mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination_638150826999921195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination" xlink:label="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416659" xlink:to="mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination_638150826999921195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416659" xlink:to="us-gaap_OperatingLeaseLiability_638150826999921195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416659" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638150826999921195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_636947436315711245" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperatingLeaseExpenseAbstract" xlink:label="mrkr_OperatingLeaseExpenseAbstract_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636947436315711245" xlink:to="mrkr_OperatingLeaseExpenseAbstract_638150826999921195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_638150826999921195" xlink:to="us-gaap_OperatingLeaseCost_638150826999921195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_638150826999921195" xlink:to="us-gaap_ShortTermLeaseCost_638150826999921195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_638150826999921195" xlink:to="us-gaap_VariableLeaseCost_638150826999921195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638150826999921195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OperatingLeaseExpenseAbstract_638150826999921195" xlink:to="us-gaap_LeaseCost_638150826999921195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OtherLeaseInformationAbstract" xlink:label="mrkr_OtherLeaseInformationAbstract_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_636947436315711245" xlink:to="mrkr_OtherLeaseInformationAbstract_638150826999931197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OtherLeaseInformationAbstract_638150826999931197" xlink:to="us-gaap_OperatingLeasePayments_638150826999931197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OtherLeaseInformationAbstract_638150826999931197" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638150826999931197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_OtherLeaseInformationAbstract_638150826999931197" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638150826999931197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40703 - Disclosure - LEASES - Maturities of Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_416700" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638150826999931197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638150826999931197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638150826999931197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638150826999931197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638150826999931197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638150826999931197" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638150826999931197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638150826999931197" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638150826999941194" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_416700" xlink:to="us-gaap_OperatingLeaseLiability_638150826999941194" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_184" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesTable" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_184" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638150826999941194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638150826999941194" xlink:to="us-gaap_RestructuringPlanAxis_638150826999941194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis_638150826999941194" xlink:to="us-gaap_RestructuringPlanDomain_638150826999941194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperationalCostReductionPlanMember" xlink:label="mrkr_OperationalCostReductionPlanMember_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain_638150826999941194" xlink:to="mrkr_OperationalCostReductionPlanMember_638150826999941194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccountsPayableAndAccruedLiabilitiesLineItems" xlink:label="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesTable_638150826999941194" xlink:to="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="us-gaap_AccountsPayableCurrent_638150826999941194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638150826999941194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedProcessDevelopmentExpensesCurrent" xlink:label="mrkr_AccruedProcessDevelopmentExpensesCurrent_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="mrkr_AccruedProcessDevelopmentExpensesCurrent_638150826999941194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638150826999941194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638150826999941194" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AccruedTechnologyLicenseFees" xlink:label="mrkr_AccruedTechnologyLicenseFees_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="mrkr_AccruedTechnologyLicenseFees_638150826999951193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ArbitrationSettlementLiabilitiesCurrent" xlink:label="mrkr_ArbitrationSettlementLiabilitiesCurrent_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="mrkr_ArbitrationSettlementLiabilitiesCurrent_638150826999951193" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638150826999951193" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_638150826999951193" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_AccountsPayableAndAccruedLiabilitiesLineItems_638150826999941194" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638150826999951193" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails" xlink:type="extended" xlink:title="40901 - Disclosure - RELATED PARTY DEFERRED REVENUE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAbstract" xlink:label="us-gaap_DueToRelatedPartiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueToRelatedPartiesCurrentAbstract_1" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150826999951193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150826999951193" xlink:to="srt_ProductOrServiceAxis_638150826999951193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638150826999951193" xlink:to="srt_ProductsAndServicesDomain_638150826999951193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638150826999951193" xlink:to="us-gaap_ServiceMember_638150826999951193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150826999951193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150826999951193" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150826999951193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150826999951193" xlink:to="us-gaap_RelatedPartyDomain_638150826999961195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150826999961195" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_638150826999961195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150826999951193" xlink:to="us-gaap_TypeOfArrangementAxis_638150826999961195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638150826999961195" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150826999961195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BindingServicesAgreementMember" xlink:label="mrkr_BindingServicesAgreementMember_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150826999961195" xlink:to="mrkr_BindingServicesAgreementMember_638150826999961195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150826999951193" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638150826999961195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation_638150826999961195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments_638150826999961195" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess" xlink:label="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess_638150826999961195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses" xlink:label="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses_638150826999961195" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate" xlink:label="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate_638150826999961195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate_638150826999961195" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement" xlink:label="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement_638150826999971194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement_638150826999971194" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered" xlink:label="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered_638150826999971194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered_638150826999971194" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150826999971194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150826999971194" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638150826999971194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150826999961195" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638150826999971194" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638150827000101218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638150827000101218" xlink:to="srt_RangeAxis_638150827000101218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638150827000101218" xlink:to="srt_RangeMember_638150827000101218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638150827000101218" xlink:to="srt_MinimumMember_638150827000101218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638150827000101218" xlink:to="srt_MaximumMember_638150827000101218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638150827000101218" xlink:to="us-gaap_SubsequentEventTypeAxis_638150827000101218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150827000101218" xlink:to="us-gaap_SubsequentEventTypeDomain_638150827000101218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150827000101218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150827000101218" xlink:to="us-gaap_SubsequentEventMember_638150827000101218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638150827000101218" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638150827000111212" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638150827000111212" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638150827000111212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638150827000111212" xlink:to="mrkr_ExerciseOfStockWarrantsMember_638150827000111212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638150827000101218" xlink:to="us-gaap_TypeOfArrangementAxis_638150827000111212" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638150827000111212" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000111212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000111212" xlink:to="mrkr_BoardCompensationMember_638150827000111212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ControlledEquityOfferingSalesAgreementMember" xlink:label="mrkr_ControlledEquityOfferingSalesAgreementMember_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000111212" xlink:to="mrkr_ControlledEquityOfferingSalesAgreementMember_638150827000111212" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638150827000101218" xlink:to="us-gaap_ClassOfStockLineItems_638150827000111212" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638150827000111212" xlink:to="us-gaap_CommonStockSharesAuthorized_638150827000111212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638150827000111212" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638150827000111212" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000111212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638150827000111212" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000111212" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638150827000111212" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638150827000121198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638150827000111212" xlink:to="us-gaap_RecapitalizationCosts_638150827000121198" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_637242165560737926" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637242165560737926" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638150827000121198" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638150827000121198" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638150827000121198" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638150827000121198" xlink:to="mrkr_ExerciseOfStockWarrantsMember_638150827000121198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" xlink:to="us-gaap_StatementEquityComponentsAxis_638150827000121198" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638150827000121198" xlink:to="us-gaap_EquityComponentDomain_638150827000121198" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638150827000121198" xlink:to="us-gaap_CommonStockMember_638150827000121198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638150827000121198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" xlink:to="us-gaap_TypeOfArrangementAxis_638150827000121198" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638150827000121198" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000131196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000131196" xlink:to="mrkr_BoardCompensationMember_638150827000131196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638150827000131196" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638150827000131196" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000131196" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AtmAgreementMember" xlink:label="mrkr_AtmAgreementMember_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000131196" xlink:to="mrkr_AtmAgreementMember_638150827000131196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" xlink:to="us-gaap_PlanNameAxis_638150827000131196" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638150827000131196" xlink:to="us-gaap_PlanNameDomain_638150827000131196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638150827000131196" xlink:to="mrkr_EquityIncentivePlan2020Member_638150827000131196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000121198" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638150827000131196" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000131196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000131196" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150827000141193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150827000141193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638150827000141193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638150827000141193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638150827000141193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638150827000141193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638150827000141193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638150827000141193" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638150827000141193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638150827000141193" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_638150827000141193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_638150827000141193" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638150827000141193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000131196" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638150827000141193" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails" xlink:type="extended" xlink:title="41003 - Disclosure - STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000151193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000151193" xlink:to="us-gaap_TypeOfArrangementAxis_638150827000151193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638150827000151193" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000151193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BoardCompensationMember" xlink:label="mrkr_BoardCompensationMember_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638150827000151193" xlink:to="mrkr_BoardCompensationMember_638150827000151193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000151193" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638150827000151193" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638150827000151193" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638150827000151193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ExerciseOfStockWarrantsMember" xlink:label="mrkr_ExerciseOfStockWarrantsMember_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638150827000151193" xlink:to="mrkr_ExerciseOfStockWarrantsMember_638150827000151193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000151193" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638150827000151193" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638150827000151193" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000151193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000151193" xlink:to="us-gaap_OverAllotmentOptionMember_638150827000151193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems" xlink:label="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable_638150827000151193" xlink:to="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfSharesAuthorizedToIssueAndSell" xlink:label="mrkr_NumberOfSharesAuthorizedToIssueAndSell_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="mrkr_NumberOfSharesAuthorizedToIssueAndSell_638150827000151193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638150827000151193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="us-gaap_SharePrice_638150827000151193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_UnderwritingOptionPeriod" xlink:label="mrkr_UnderwritingOptionPeriod_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="mrkr_UnderwritingOptionPeriod_638150827000161193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell" xlink:label="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell_638150827000161193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues" xlink:label="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues_638150827000161193" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000161193" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638150827000161193" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OfferingCost" xlink:label="mrkr_OfferingCost_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="mrkr_OfferingCost_638150827000161193" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638150827000161193" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638150827000161193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638150827000161193" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems_638150827000151193" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150827000171192" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails" xlink:type="extended" xlink:title="41004 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638150827000171192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638150827000171192" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638150827000171192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638150827000171192" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000171192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockPurchaseAgreementMember" xlink:label="mrkr_StockPurchaseAgreementMember_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638150827000171192" xlink:to="mrkr_StockPurchaseAgreementMember_638150827000171192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638150827000171192" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000171192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000171192" xlink:to="us-gaap_RelatedPartyDomain_638150827000171192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LincolnParkMember" xlink:label="mrkr_LincolnParkMember_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150827000171192" xlink:to="mrkr_LincolnParkMember_638150827000171192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638150827000171192" xlink:to="us-gaap_SubsequentEventTypeAxis_638150827000171192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150827000171192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150827000171192" xlink:to="us-gaap_SubsequentEventTypeDomain_638150827000171192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150827000171192" xlink:to="us-gaap_SubsequentEventMember_638150827000181195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638150827000171192" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638150827000181195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638150827000181195" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638150827000181195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638150827000181195" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638150827000181195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638150827000181195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfWarrantExpiredOrCancelled" xlink:label="mrkr_NumberOfWarrantExpiredOrCancelled_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_NumberOfWarrantExpiredOrCancelled_638150827000181195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6381508270001811951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6381508270001811951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_638150827000181195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash_638150827000181195" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_638150827000181195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice_638150827000181195" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_6381508270001811951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice_6381508270001811951" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife" xlink:label="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract" xlink:to="mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife_638150827000191193" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - WARRANTS - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WarrantsDisclosureAbstract" xlink:label="mrkr_WarrantsDisclosureAbstract_637040620891023944" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_WarrantsDisclosureAbstract_637040620891023944" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638150827000191193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="41201 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="mrkr_StockBasedCompensationTable_638150827000191193" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000191193" xlink:to="us-gaap_PlanNameAxis_638150827000191193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638150827000191193" xlink:to="us-gaap_PlanNameDomain_638150827000191193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638150827000191193" xlink:to="mrkr_EquityIncentivePlan2020Member_638150827000191193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000191193" xlink:to="mrkr_StockBasedCompensationLineItems_638150827000191193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638150827000191193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638150827000191193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638150827000191193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638150827000191193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638150827000201196" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638150827000201196" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638150827000201196" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638150827000201196" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638150827000201196" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638150827000201196" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381508270002011961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381508270002011961" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638150827000201196" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638150827000201196" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_638150827000201196" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638150827000201196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000191193" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638150827000201196" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="41202 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638150827000211191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638150827000211191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638150827000211191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638150827000211191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637040620891336472" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638150827000211191" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="41203 - Disclosure - STOCK OPTION PLANS - Stock-based compensation expenses (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mrkr_StockBasedCompensationTable_638150827000211191" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000211191" xlink:to="us-gaap_IncomeStatementLocationAxis_638150827000211191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638150827000211191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638150827000211191" xlink:to="us-gaap_IncomeStatementLocationDomain_638150827000211191" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638150827000211191" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638150827000221192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638150827000211191" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638150827000221192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000211191" xlink:to="mrkr_StockBasedCompensationLineItems_638150827000221192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000221192" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638150827000221192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails" xlink:type="extended" xlink:title="41204 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationTable" xlink:label="mrkr_StockBasedCompensationTable_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573" xlink:to="mrkr_StockBasedCompensationTable_638150827000221192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000221192" xlink:to="us-gaap_AwardTypeAxis_638150827000221192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638150827000221192" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638150827000221192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentiveAwards2021Member" xlink:label="mrkr_EquityIncentiveAwards2021Member_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638150827000221192" xlink:to="mrkr_EquityIncentiveAwards2021Member_638150827000221192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2022Member" xlink:label="mrkr_EquityIncentivePlan2022Member_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638150827000221192" xlink:to="mrkr_EquityIncentivePlan2022Member_638150827000221192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000221192" xlink:to="us-gaap_PlanNameAxis_638150827000221192" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638150827000221192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638150827000221192" xlink:to="us-gaap_PlanNameDomain_638150827000221192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EquityIncentivePlan2020Member" xlink:label="mrkr_EquityIncentivePlan2020Member_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638150827000221192" xlink:to="mrkr_EquityIncentivePlan2020Member_638150827000231194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000221192" xlink:to="srt_TitleOfIndividualAxis_638150827000231194" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638150827000231194" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638150827000231194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638150827000231194" xlink:to="srt_ExecutiveOfficerMember_638150827000231194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NonExecutiveEmployeesMember" xlink:label="mrkr_NonExecutiveEmployeesMember_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638150827000231194" xlink:to="mrkr_NonExecutiveEmployeesMember_638150827000231194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000221192" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638150827000231194" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_638150827000231194" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638150827000231194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NonEmployeeStockOptionMember" xlink:label="mrkr_NonEmployeeStockOptionMember_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_638150827000231194" xlink:to="mrkr_NonEmployeeStockOptionMember_638150827000231194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000221192" xlink:to="us-gaap_GranteeStatusAxis_638150827000231194" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638150827000231194" xlink:to="us-gaap_GranteeStatusDomain_638150827000231194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638150827000231194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638150827000231194" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638150827000231194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638150827000231194" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638150827000241193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000221192" xlink:to="us-gaap_VestingAxis_638150827000241193" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638150827000241193" xlink:to="us-gaap_VestingDomain_638150827000241193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638150827000241193" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638150827000241193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638150827000241193" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638150827000241193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_StockBasedCompensationLineItems" xlink:label="mrkr_StockBasedCompensationLineItems_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationTable_638150827000221192" xlink:to="mrkr_StockBasedCompensationLineItems_638150827000241193" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638150827000241193" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638150827000241193" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638150827000241193" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards" xlink:label="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards_638150827000241193" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards_638150827000241193" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638150827000251190" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638150827000251190" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638150827000251190" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued" xlink:label="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued_638150827000251190" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638150827000251190" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638150827000251190" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638150827000251190" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638150827000251190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638150827000251190" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_StockBasedCompensationLineItems_638150827000241193" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638150827000261190" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureGrantIncomeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - GRANT INCOME (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeTable" xlink:label="mrkr_GrantIncomeTable_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="mrkr_GrantIncomeTable_638150827000261190" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeTable_638150827000261190" xlink:to="srt_ProductOrServiceAxis_638150827000261190" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638150827000261190" xlink:to="srt_ProductsAndServicesDomain_638150827000261190" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638150827000261190" xlink:to="us-gaap_GrantMember_638150827000261190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeTable_638150827000261190" xlink:to="us-gaap_SubsequentEventTypeAxis_638150827000261190" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150827000261190" xlink:to="us-gaap_SubsequentEventTypeDomain_638150827000261190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150827000261190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150827000261190" xlink:to="us-gaap_SubsequentEventMember_638150827000261190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeLineItems" xlink:label="mrkr_GrantIncomeLineItems_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeTable_638150827000261190" xlink:to="mrkr_GrantIncomeLineItems_638150827000271197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ReceiptOfProductDevelopmentResearchAward" xlink:label="mrkr_ReceiptOfProductDevelopmentResearchAward_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638150827000271197" xlink:to="mrkr_ReceiptOfProductDevelopmentResearchAward_638150827000271197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_FundsReceivedFromGrant" xlink:label="mrkr_FundsReceivedFromGrant_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638150827000271197" xlink:to="mrkr_FundsReceivedFromGrant_638150827000271197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638150827000271197" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638150827000271197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RevenueFromOrphanProductsGrantProgram" xlink:label="mrkr_RevenueFromOrphanProductsGrantProgram_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638150827000271197" xlink:to="mrkr_RevenueFromOrphanProductsGrantProgram_638150827000271197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OrphanProductsGrantProgram" xlink:label="mrkr_OrphanProductsGrantProgram_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638150827000271197" xlink:to="mrkr_OrphanProductsGrantProgram_638150827000271197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_GrantIncomeReceivable" xlink:label="mrkr_GrantIncomeReceivable_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638150827000271197" xlink:to="mrkr_GrantIncomeReceivable_638150827000271197" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_GrantIncomeLineItems_638150827000271197" xlink:to="us-gaap_GrantsReceivable_638150827000271197" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - LEGAL PROCEEDINGS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_LossContingenciesTable_638150827000271197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150827000271197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638150827000271197" xlink:to="us-gaap_SubsequentEventTypeAxis_638150827000271197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150827000271197" xlink:to="us-gaap_SubsequentEventTypeDomain_638150827000281197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150827000281197" xlink:to="us-gaap_SubsequentEventMember_638150827000281197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638150827000271197" xlink:to="us-gaap_LossContingenciesLineItems_638150827000281197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_CompensationInterestAndAttorneyFees" xlink:label="mrkr_CompensationInterestAndAttorneyFees_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="mrkr_CompensationInterestAndAttorneyFees_638150827000281197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_638150827000281197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="us-gaap_OtherExpenses_638150827000281197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount" xlink:label="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount_638150827000281197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PercentageOfAccrualOfPostJudgmentInterest" xlink:label="mrkr_PercentageOfAccrualOfPostJudgmentInterest_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="mrkr_PercentageOfAccrualOfPostJudgmentInterest_638150827000281197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_BrokerWasAwardedAccruedInterest" xlink:label="mrkr_BrokerWasAwardedAccruedInterest_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="mrkr_BrokerWasAwardedAccruedInterest_638150827000281197" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AdditionalAttorneyFeesAwarded" xlink:label="mrkr_AdditionalAttorneyFeesAwarded_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="mrkr_AdditionalAttorneyFeesAwarded_638150827000281197" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_638150827000281197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638150827000281197" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_638150827000281197" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_RelatedPartyDisclosureAbstract" xlink:label="mrkr_RelatedPartyDisclosureAbstract_637040620891492737" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_RelatedPartyDisclosureAbstract_637040620891492737" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150827000291192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150827000291192" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000291192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000291192" xlink:to="us-gaap_RelatedPartyDomain_638150827000291192" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember" xlink:label="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150827000291192" xlink:to="mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_638150827000291192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_PurchasesFromBioTechneCorporationMember" xlink:label="mrkr_PurchasesFromBioTechneCorporationMember_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150827000291192" xlink:to="mrkr_PurchasesFromBioTechneCorporationMember_638150827000291192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_WilsonWolfManufacturingCorporationMember" xlink:label="mrkr_WilsonWolfManufacturingCorporationMember_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150827000291192" xlink:to="mrkr_WilsonWolfManufacturingCorporationMember_638150827000291192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638150827000291192" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638150827000291192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638150827000291192" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638150827000291192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_StatementTable_638150827000291192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_638150827000291192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150827000291192" xlink:to="srt_RestatementAxis_638150827000291192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_638150827000291192" xlink:to="srt_RestatementDomain_638150827000301222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_638150827000301222" xlink:to="srt_ScenarioPreviouslyReportedMember_638150827000301222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150827000291192" xlink:to="us-gaap_StatementLineItems_638150827000301222" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAbstract" xlink:label="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150827000301222" xlink:to="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638150827000301222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxstockbasedcompensation" xlink:label="mrkr_Deferredtaxstockbasedcompensation_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="mrkr_Deferredtaxstockbasedcompensation_638150827000301222" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638150827000301222" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Deferredtaxassetslicenseagreement" xlink:label="mrkr_Deferredtaxassetslicenseagreement_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="mrkr_Deferredtaxassetslicenseagreement_638150827000301222" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638150827000301222" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638150827000301222" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_638150827000301222" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="mrkr_DeferredTaxAssetsOperatingLeaseLiability_638150827000301222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="mrkr_DeferredTaxAssetsOperatingLeaseLiability_638150827000301222" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsGross_638150827000311192" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638150827000311192" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxesAbstract_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsNet_638150827000311192" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150827000301222" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638150827000311192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesFixedAssets" xlink:label="mrkr_DeferredTaxLiabilitiesFixedAssets_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638150827000311192" xlink:to="mrkr_DeferredTaxLiabilitiesFixedAssets_638150827000311192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638150827000311192" xlink:to="mrkr_DeferredTaxLiabilitiesRightOfUseAssets_638150827000311192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638150827000311192" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638150827000311192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638150827000311192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638150827000301222" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638150827000311192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails" xlink:type="extended" xlink:title="41602 - Disclosure - INCOME TAXES - Additional Information's (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_StatementTable_638150827000321194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150827000321194" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638150827000321194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638150827000321194" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638150827000321194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638150827000321194" xlink:to="us-gaap_ForeignCountryMember_638150827000321194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638150827000321194" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638150827000321194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_IncomeTaxLineItems" xlink:label="mrkr_IncomeTaxLineItems_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638150827000321194" xlink:to="mrkr_IncomeTaxLineItems_638150827000321194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_638150827000321194" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638150827000321194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_638150827000321194" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638150827000321194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_638150827000321194" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638150827000321194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangestart" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangestart_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_638150827000321194" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangestart_638150827000321194" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Taxcreditcarryforwardexpirationyearrangeend" xlink:label="mrkr_Taxcreditcarryforwardexpirationyearrangeend_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_638150827000321194" xlink:to="mrkr_Taxcreditcarryforwardexpirationyearrangeend_638150827000321194" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_638150827000321194" xlink:to="us-gaap_OperatingLossCarryforwards_638150827000321194" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_OperatingLossCarryforwardsLimitationPercentage" xlink:label="mrkr_OperatingLossCarryforwardsLimitationPercentage_638150827000321194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrkr_IncomeTaxLineItems_638150827000321194" xlink:to="mrkr_OperatingLossCarryforwardsLimitationPercentage_638150827000321194" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41603 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638150827000331191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638150827000331191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638150827000331191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638150827000331191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638150827000331191" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638150827000331191" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637040620891649186" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_Permanentdifferencesotherpermanentdifferences" xlink:label="mrkr_Permanentdifferencesotherpermanentdifferences_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="mrkr_Permanentdifferencesotherpermanentdifferences_638150827000331191" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638150827000331191" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems_638150827000331191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638150827000331191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638150827000331191" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_638150827000341194" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638150827000341194" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638150827000341194" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638150827000341194" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_UnrecognizedTaxBenefits_638150827000341194" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638150827000331191" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638150827000341194" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638150827000341194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638150827000341194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638150827000341194" xlink:to="us-gaap_SubsequentEventTypeAxis_638150827000341194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638150827000351192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638150827000341194" xlink:to="us-gaap_SubsequentEventTypeDomain_638150827000351192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638150827000351192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638150827000351192" xlink:to="us-gaap_SubsequentEventMember_638150827000351192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000351192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638150827000341194" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000351192" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638150827000351192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638150827000351192" xlink:to="us-gaap_RelatedPartyDomain_638150827000351192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mrkr-20221231.xsd#mrkr_AllovirIncMember" xlink:label="mrkr_AllovirIncMember_638150827000351192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638150827000351192" xlink:to="mrkr_AllovirIncMember_638150827000351192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638150827000351192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638150827000341194" xlink:to="us-gaap_SubsequentEventLineItems_638150827000351192" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638150827000351192" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638150827000351192" xlink:to="us-gaap_ShareBasedCompensation_638150827000351192" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896723248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MARKER THERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-4497941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4551 Kennedy Commerce Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-6400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRKR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,798,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001094038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston, TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896400048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,782,172<span></span>
</td>
<td class="nump">$ 42,351,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,146,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">2,435,079<span></span>
</td>
<td class="nump">2,484,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">2,402,004<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,619,255<span></span>
</td>
<td class="nump">45,982,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress', window );">Property, plant and equipment, net</a></td>
<td class="nump">12,323,143<span></span>
</td>
<td class="nump">10,096,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,225,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">5,479,786<span></span>
</td>
<td class="nump">9,830,461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">17,802,929<span></span>
</td>
<td class="nump">22,152,932<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">34,422,184<span></span>
</td>
<td class="nump">68,135,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">4,704,611<span></span>
</td>
<td class="nump">11,134,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party deferred revenue</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,146,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">577,198<span></span>
</td>
<td class="nump">620,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,781,809<span></span>
</td>
<td class="nump">12,901,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">7,039,338<span></span>
</td>
<td class="nump">11,247,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">7,039,338<span></span>
</td>
<td class="nump">11,247,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,821,147<span></span>
</td>
<td class="nump">24,149,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 30 million and 15 million shares authorized, 8.4 million and 8.3 million shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">8,406<span></span>
</td>
<td class="nump">8,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">447,641,680<span></span>
</td>
<td class="nump">442,095,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(428,049,049)<span></span>
</td>
<td class="num">(398,118,355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">19,601,037<span></span>
</td>
<td class="nump">43,985,595<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 34,422,184<span></span>
</td>
<td class="nump">$ 68,135,134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Excludes construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972903981904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">8,400,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">8,400,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896518208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 9,013,544<span></span>
</td>
<td class="nump">$ 1,241,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">26,139,323<span></span>
</td>
<td class="nump">27,794,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,820,004<span></span>
</td>
<td class="nump">12,924,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,959,327<span></span>
</td>
<td class="nump">40,719,705<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(29,945,783)<span></span>
</td>
<td class="num">(39,477,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GainLossRelatedToArbitrationSettlement', window );">Arbitration settlement</a></td>
<td class="num">(232,974)<span></span>
</td>
<td class="num">(2,406,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">248,063<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,930,694)<span></span>
</td>
<td class="num">$ (41,878,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (3.58)<span></span>
</td>
<td class="num">$ (5.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (3.58)<span></span>
</td>
<td class="num">$ (5.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">8,351,003<span></span>
</td>
<td class="nump">7,650,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">8,351,003<span></span>
</td>
<td class="nump">7,650,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,513,544<span></span>
</td>
<td class="nump">$ 1,241,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Related party service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GainLossRelatedToArbitrationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) pertaining to the arbitration that was charged against earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GainLossRelatedToArbitrationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896570080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid- in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 5,073<span></span>
</td>
<td class="nump">$ 383,578,984<span></span>
</td>
<td class="num">$ (356,239,484)<span></span>
</td>
<td class="nump">$ 27,344,573<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">5,073,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="nump">$ 3,228<span></span>
</td>
<td class="nump">52,549,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,552,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="nump">3,228,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised for cash (in shares)</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">5,964,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,964,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">6,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,878,871)<span></span>
</td>
<td class="num">(41,878,871)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 8,308<span></span>
</td>
<td class="nump">442,095,642<span></span>
</td>
<td class="num">(398,118,355)<span></span>
</td>
<td class="nump">43,985,595<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">8,307,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">202,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="nump">60,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">5,343,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,344,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">37,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,930,694)<span></span>
</td>
<td class="num">(29,930,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 8,406<span></span>
</td>
<td class="nump">$ 447,641,680<span></span>
</td>
<td class="num">$ (428,049,049)<span></span>
</td>
<td class="nump">$ 19,601,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="nump">8,405,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898188368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net of offering costs</a></td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972895081904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (29,930,694)<span></span>
</td>
<td class="num">$ (41,878,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,789,106<span></span>
</td>
<td class="nump">2,148,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,344,006<span></span>
</td>
<td class="nump">5,964,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization on right-of-use assets</a></td>
<td class="nump">891,343<span></span>
</td>
<td class="nump">1,013,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">25,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GainLossOnTerminationOfLeases', window );">Gain on lease termination</a></td>
<td class="num">(278,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">49,555<span></span>
</td>
<td class="num">(426,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Other receivables</a></td>
<td class="num">(2,401,767)<span></span>
</td>
<td class="nump">1,000,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,300,939)<span></span>
</td>
<td class="nump">4,141,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party deferred revenue</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,146,186)<span></span>
</td>
<td class="nump">1,146,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(513,891)<span></span>
</td>
<td class="num">(388,792)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(26,972,153)<span></span>
</td>
<td class="num">(27,279,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress', window );">Purchase of property and equipment</a></td>
<td class="num">(1,456,006)<span></span>
</td>
<td class="num">(1,572,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_PaymentsForConstructionInProgress', window );">Purchase of construction in progress</a></td>
<td class="num">(3,489,130)<span></span>
</td>
<td class="num">(1,558,970)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,945,136)<span></span>
</td>
<td class="num">(3,131,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">202,130<span></span>
</td>
<td class="nump">52,552,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">202,130<span></span>
</td>
<td class="nump">52,555,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(31,715,159)<span></span>
</td>
<td class="nump">22,144,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the period</a></td>
<td class="nump">43,497,331<span></span>
</td>
<td class="nump">21,352,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">11,782,172<span></span>
</td>
<td class="nump">43,497,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets', window );">Reclassifications between construction in progress and fixed assets</a></td>
<td class="nump">4,089,135<span></span>
</td>
<td class="nump">6,789,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable</a></td>
<td class="nump">57,607<span></span>
</td>
<td class="nump">$ 2,160,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease', window );">Changes to right-of-use assets and lease liability due to close out of operating leases</a></td>
<td class="nump">$ 3,459,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of changes to right-of-use assets and lease liability due to close out of an operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GainLossOnTerminationOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of leases term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GainLossOnTerminationOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PaymentsForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of Construction in Progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PaymentsForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; excluding cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassifications between construction in progress and fixed assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972901894880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;we&#8221;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#8217;s multiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $394.80.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898122720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock', window );">FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2022, the Company had cash and cash equivalents of approximately </span><span style="font-style:normal;font-weight:normal;">$11.8</span><span style="font-style:normal;font-weight:normal;"> million. The Company&#8217;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 16, 2021, the Company issued an aggregate of 3,228,286 shares of its common stock, for net proceeds of $52.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company entered into a Controlled Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and RBC Capital Markets, LLC (the &#8220;Sales Agents&#8221;), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021; however, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and the Company has provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2022, the Company sold 60,651 shares of its common stock under the ATM Agreement for net proceeds of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (&#8220;CPRIT&#8221;) to support the Company&#8217;s Phase 2 clinical trial of MT-401. The CPRIT award is intended to support the adjuvant arm of the Company&#8217;s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group. Through </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the date of this filing, the Company has received $4.8 million of funds from the CPRIT grant. The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 21, 2022, the Company entered into a binding services agreement (the &#8220;Services Agreement&#8221;), dated April 12, 2022 (see Note 9), with Wilson Wolf Manufacturing Corporation (&#8220;Wilson Wolf&#8221;). Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf, therefore Wilson Wolf is a related party. Pursuant to the Services Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million. For the year ending December 31, 2022, the Company recognized $5.5 million of revenue pursuant to this agreement and at December 31, 2022, the Company recorded $2.5 million of related party deferred revenue on its consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of its common stock, or the Purchase Shares, from time to time over a 24-month term. &#160;For the year ended December 31, 2022, the Company did not sell any shares of its common stock under the Purchase Agreement. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical trials. Further, the Company&#8217;s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from sales of its product candidates, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Based on the Company&#8217;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of December 31, 2022 will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2023, as such these factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. In an effort to further preserve the Company&#8217;s working capital, the Company&#8217;s employees took a portion of their 2022 earned bonus in the form of equity in lieu of cash.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#8217;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#8217;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#8217;s future funding requirements will depend on many factors, as it:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiates or continues clinical trials of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the research and development of its product candidates and seeks to discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains and enforces intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluates strategic transactions the Company may undertake; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to the foregoing, based on the Company&#8217;s current assessment, the Company does not expect any material impact on its long-term liquidity due to the COVID-19 pandemic. However, the Company will continue to assess the effect of the pandemic on its operations, including its clinical programs. Further, the COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#8217;s ability to access capital, which could in the future negatively affect the Company&#8217;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#8217;s business and the value of its common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity Financial Condition And Going Concern Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898047408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;). Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#8217;s estimates and assumptions include measurement of fair value and projections used in impairment testing, valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents, Restricted Cash and Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash, cash equivalents and restricted cash at December&#160;31, 2022 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of December&#160;31, 2022, approximately $1.8 million in cash was uninsured based upon the FDIC insurance coverage limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,782,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,351,145</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,146,186</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash shown in statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,782,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,497,331</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash received from grants in advance of incurring qualifying costs are recorded as restricted cash until they are earned and recorded to grant income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment - Construction in Progress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility&#8217;s construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third and fourth quarters of 2021, and in connection with the Company&#8217;s manufacturing facility in Houston, Texas, the Company incurred $2.2 million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. &#160;Such costs were recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2021. The Company incurred another $1.9 million in related costs in 2022. Upon completion and installation of the second modular cleanroom in 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and are being amortized over the estimated useful life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment Testing of Long-Lived Assets and Right-Of-Use Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management reviews long-lived assets (including property and equipment) and right-of-use assets for assets under operating leases for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Recoverability of assets is determined by first grouping the long-lived assets at the lowest level for which there are identifiable cash flows, and then comparing the carrying value of each asset group to its forecasted undiscounted cash flows. If the evaluation of the forecasted cash flows indicates that the carrying value of the assets is not recoverable, an impairment charge is recognized for the amount in excess of the carrying amount over its fair value. The Company performed a test for recoverability related to its manufacturing facility in Houston, Texas at December 31, 2022 and concluded that the carrying value of its long-lived assets was recoverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents and Patent Application Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i>&#160;&#8212; The expected life of stock options was estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i>&#160;&#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#160;&#8212; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i>&#160;&#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2022 and 2021, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support its Phase 2 clinical trial of MT-401. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 730-20-25-8, to the extent the financial risk associated with the research and development has been transferred to CPRIT, because repayment of the grant depends solely on the results of research and development having future economic benefit, the Company accounts for this obligation as a contract to perform research and development for others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. During the fourth quarter of 2021, the Company received $2.4 million advancement of funds in relation to the CPRIT grant. The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. In January 2023, the Company received $2.4 million from CPRIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898057600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth the computation of net loss per share for the&#160;years ended December&#160;31, 2022 and 2021, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,930,694)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41,878,871)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average common shares outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,351,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,650,567</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.47)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 886,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 768,600</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,848,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,983,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,734,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898844928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">OTHER RECEIVABLE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. &#160;The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. &#160;At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. &#160;The Company received $2.4 million of funds from CPRIT in January 2023. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022. &#160;Additionally, at December 31, 2022, the Company recorded $0.1 million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. &#160;The Company received $0.1 million of funds from the FDA in January 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898012368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;6:&#160;&#160;&#160;&#160;PROPERTY AND EQUIPMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment consist of the following as of December&#160;31, 2022 and 2021, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab and manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,824,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,851,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3-5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 899,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,020,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 924,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 793,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or estimated useful life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,950,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,173,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Total   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,597,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,837,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,274,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,740,000)</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,226,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fixed assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,323,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,323,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation expense for the years ended December 31, 2022 and 2021 was approximately $2.8 million and $2.1 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. The Company incurred costs pursuant to an agreement with a vendor to design, engineer, build and eventually install modular cleanrooms in the manufacturing facility. $6.8 million was recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2020. &#160;The completion of the facility&#8217;s construction occurred during December 2020 and the Company received its certificate of occupancy in January 2021, and as such was placed into service in January 2021. &#160;During January 2021, all costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the year ended December 31, 2021, and in connection with the opening of the Company&#8217;s manufacturing facility in Houston, Texas, the Company incurred $2.2<span style="white-space:pre-wrap;"> million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. Such costs were recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2021.  The Company incurred another </span>$1.9 million in related costs in 2022. Upon completion and installation of the second modular cleanroom during the year ended December 31, 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and amortized over the estimated useful life.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898092912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 7: LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company leases manufacturing, research and administrative facilities under operating leases. The Company evaluates its contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all of the Company&#8217;s leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term. The lease terms may include options to extend when it is reasonably certain that the Company will exercise that option. The Company did not consider that option in calculating right-of-use assets and lease liability as the Company is not reasonably certain it will extend the contract beyond the current terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Topic ASC 842 requires the Company to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. Right-of-use assets are recorded in non-current assets on the Company&#8217;s consolidated balance sheets. Current and non-current lease liabilities are recorded within current liabilities and non-current liabilities, respectively, on its consolidated balance sheets. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 15, 2022, the Company and its landlord agreed to terminate the Company&#8217;s office lease at 3200 Southwest Freeway, Suite 2500, Houston, Texas. &#160;As such the Company reduced its operating lease liabilities by $3.7 million and reduced its right-of-use </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">assets by $3.5 million. &#160;A gain on lease termination was recorded in general and administrative expenses during the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had total operating lease liabilities of approximately $7.6 million and right-of-use assets of approximately $5.5 million, which were included in the consolidated balance sheet. &#160;As of December 31, 2021, the Company had total operating lease liabilities of approximately $11.9 million and right-of-use assets of approximately $9.8 million, which were included in the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. &#160;Certain of the Company&#8217;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. &#160;Variable expenses generally represent the Company&#8217;s share of the landlord&#8217;s operating expenses. &#160;The Company does not act as a lessor or have any leases classified as financing leases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following summarizes quantitative information about the Company&#8217;s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense summary:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,483,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,702,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 606,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,179,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,308,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,106,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,077,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The weighted-average remaining lease term as of December 31, 2022 and December 31, 2021 was approximately 7.5 years and 8.4 years, respectively. The weighted-average discount rate used to determine the operating lease liability as of December 31, 2022 and December 31, 2021 was approximately 5.5% and 5.7%, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Maturities of the Company&#8217;s operating leases, excluding short-term leases, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 983,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,254,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,290,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,177,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December 31, 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,163,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,590,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,457,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,840,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,617,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972897970736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;8: &#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued liabilities consist of the following as of December&#160;31, 2022 and 2021, respectively:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,612,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,144,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,779,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,055,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Process development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 342,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Arbitration settlement fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 114,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,407,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_FuIPzOWfjEuw7JcSqUHBnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 4,705,000</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b9x6r4ODwECU40jh-cbSzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 11,135,000</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2022, the Company implemented changes to the Company&#8217;s organizational structure as part of an operational cost reduction plan to conserve the Company&#8217;s available capital. &#160;In connection with these changes, the Company reduced headcount in its general and administrative function by approximately 23.5%, including the separation of the Company&#8217;s Chief Financial Officer. &#160;For the year ended December 31, 2022, the Company recorded $0.3 million of accrued compensation and benefits for severance expenses related to the operational cost reduction plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898110800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY DEFERRED REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAbstract', window );"><strong>RELATED PARTY DEFERRED REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RelatedPartyLiabilityDisclosureTextBlock', window );">RELATED PARTY DEFERRED REVENUE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 9:&#160;&#160;&#160;&#160;RELATED PARTY DEFERRED REVENUE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On April 21, 2022, the Company entered into the Services Agreement, dated April 12, 2022, with Wilson Wolf. Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the &#8220;Wilson Wolf Mission&#8221;). Pursuant to the Services Agreement, Wilson Wolf made a cash payment to the Company in the amount of </span><span style="font-weight:normal;">$8.0</span><span style="font-weight:normal;"> million, as consideration for certain training and research services allocated as follows:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for non-exclusive training of Wilson Wolf to make, use, and sell the Company&#8217;s cell culture non-proprietary media formulation that has been cleared in an FDA investigational new drug application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for non-exclusive training of Wilson Wolf to replicate the Company&#8217;s quality management system inclusive of all underlying documents related thereto, none of which shall include unique information specific to the manufacture of the Company&#8217;s multiTAA product candidates such as direct peptide stimulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for non-exclusive training of Wilson Wolf to be able to replicate the Company&#8217;s cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process which Wilson Wolf shall use as it sees fit in pursuit of the Wilson Wolf Mission; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million for the Company to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes using G-Rex and to conduct CAR T and TCR G-Rex Optimization Work under the direction of Wilson Wolf (the &#8220;Work Direction&#8221;), whereunder all intellectual property provided by Wilson Wolf or created or derived by the Company will be solely owned by Wilson Wolf, and whereby the Company will make good faith efforts to complete the conduct of such work as soon as practicable within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18 months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the date of the agreement. Wilson Wolf has agreed to pay the Company an additional </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million if the Work Direction is completed within one year from the onset of the Agreement.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Services Agreement, in the event that the Company becomes insolvent, goes out of business, or an event other than force majeure occurs that cannot allow the Agreement to be fulfilled, Wilson Wolf will have right of first offer and right of first refusal for the Company&#8217;s manufacturing facility provided it is able and willing to meet whatever financial obligations are required to do so and provided further that such clause will not apply in the event of a merger, reorganization or consolidation of the Company with a third party that results in the outstanding voting securities of the Company immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at least fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of the surviving entity immediately after such merger, reorganization or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">consolidation, or the sale or other transfer of all or substantially all of the Company&#8217;s business or assets. The Company agrees to assist as needed to the extent permitted under any applicable law (including bankruptcy or insolvency statutes). Further, prior to the Company undertaking any financing that would encumber any of the Company&#8217;s assets necessary for the Company&#8217;s performance under this Services Agreement, Wilson Wolf shall have the first right to provide such financing on equal terms to what the Company can obtain elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recognizes related party revenue over time in accordance with Accounting Standard Codification, or ASC, 606 Revenue from Contracts with Customers, as each of the training or and research services are provided to Wilson Wolf. Revenue is recognized, using an output method based on progress toward satisfaction of the performance obligations. &#160;Additionally, in accordance the spirit of the standard expressed in ASC 606-50-1, the timing of the revenue recognition is expected to be approximately 12 months. For the year ending December 31, 2022, the Company recognized $5.5 million of revenue pursuant to the Services Agreement and at December 31, 2022, the Company recorded an $2.5 million related party deferred revenue on its consolidated balance sheet.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyLiabilityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyLiabilityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898064960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK OPTION PLANS.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;10:&#160;&#160;&#160;&#160;STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Increase in Authorized Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended June 30, 2022, the Company&#8217;s board of directors and stockholders approved a Certificate of Amendment (the &#8220;Amendment&#8221;) to the Company&#8217;s Certificate of Incorporation to increase the authorized shares of common stock of the Company from 15,000,000 shares to 30,000,000 shares. The Company filed the Amendment with the Secretary of State of Delaware on May 25, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2023, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#8217;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has authorized up to 30,000,000 shares of common stock, $0.001 par value per share, for issuance. Significant 2022 and 2021 common stock transactions were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2022 Common Stock Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Restricted Stock Units to Executives</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, upon the recommendation of the compensation committee of the Company&#8217;s board of directors, &#160;and pursuant to the Company&#8217;s 2020 Equity Incentive Plan, the Company&#8217;s board of directors approved the issuance of a total of 37,252 shares of common stock, valued at a total of approximately $180,200, subject to restricted stock units, which were immediately vested upon grant, to certain executives as performance bonuses for performance during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Stock Pursuant to ATM Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company issued and sold 60,651 shares of its common stock under the ATM Agreement for net proceeds of $202,100.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over a 24-month term , at a variable price with certain market-based terms as defined in the agreement. The purchase agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement is indexed to the Company&#8217;s own stock under ASC Subtopic 815-40, Contracts in Entity's Own Equity, and classified as equity. &#160;During the year ended December 31, 2022, we did not sell any shares of our stock under the Purchase Agreement. &#160;In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2021 Common Stock Transactions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Exercise of Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the year ended December 31, 2021, certain outstanding options were exercised for </span><span style="font-weight:normal;">146</span><span style="font-weight:normal;"> shares of common stock providing aggregate proceeds to the Company of approximately </span><span style="font-weight:normal;">$3,100</span><span style="font-weight:normal;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Board Compensation </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, the Company issued an aggregate of 6,329<b style="font-weight:bold;"> </b>shares of common stock to its non-employee directors. The fair value of the common stock of approximately <b style="font-weight:bold;"> </b>$0.2<b style="font-weight:bold;"> </b>million was recognized as a component of stock-based compensation expense in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwritten Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 11, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp; Co., as representative of the several underwriters, to issue and sell 2,857,200 shares of common stock of the Company in an underwritten public offering. &#160;The offering price to the public was $17.50 per share. &#160;In addition, the Company granted the underwriters an option to purchase, for a period of 30 days, up to an additional 428,580 shares of common stock, which such option was partially exercised with respect to 371,086 shares. &#160;An aggregate of 3,228,286 shares of the Company&#8217;s common stock was issued for net proceeds of $52.6 million after offering costs of $3.9 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898047408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_WarrantsDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_WarrantsDisclosureTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;11:&#160;&#160;&#160;&#160;WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share Purchase Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s share purchase warrants as of December&#160;31, 2022 and 2021, respectively, and changes during the period is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,083,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,983,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (135,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,848,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898092912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTION PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTION PLANS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;12:&#160;&#160;&#160;&#160;STOCK OPTION PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Options to Purchase Shares of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 19, 2020, the Board adopted the 2020 Equity Incentive Plan ("2020 Plan") which replaced the 2014 Omnibus Stock Option Plan. The 2020 Plan was further amended effective May 2022 to increase the number of shares of common stock authorized for issuance under the plan by 850,000 shares. The 2020 Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Plan may be at prices and for terms as determined by the Company&#8217;s board of directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#8217;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the Nasdaq Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Options granted under the 2020 Plan have a maximum term of ten years from the date of grant and generally vest over four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2022 Equity Incentive Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 17, 2022, pursuant to the Company&#8217;s 2020 Equity Incentive Plan, the compensation committee of the Company&#8217;s board of directors approved a total of 125,000 options to purchase the Company&#8217;s common stock as equity-based incentive awards to the Company&#8217;s executive officers. &#160;Each option award was granted with an exercise price of $4.60 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on February 17, 2022, with the option award vesting in 48 equal monthly installments over a four-year period, subject to such executive officer&#8217;s continued service on the applicable vesting date. &#160;Additionally, on February 17, 2022, the compensation committee of the Company&#8217;s board of directors approved a total of 39,500 options to purchase the Company&#8217;s common stock to non-executive employees of the Company as equity-based incentive awards. &#160;Each option award was granted with an exercise price of $4.60 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on February 17, 2022, with the option award vesting in 48 equal monthly installments over a four-year period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The above awards were in addition to 17,500 stock option awards issued during the three months ended March 31, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $10.00 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on January 3, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">21,000 stock option awards were issued during the three months ended June 30, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $4.30 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on April 1, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">10,000 stock option awards were issued during the three months ended September 30, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $3.50 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on July 1, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, 7,000 stock option awards were issued during the three months ended December 31, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $3.73 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on October 3, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#8217;s continued service on the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also, pursuant to the Company&#8217;s Non-Employee Director Compensation Policy, which had previously been approved by the Company&#8217;s board of directors, 40,000 stock option awards were issued during the year ended December 31, 2022 to independent members of the board of directors of the Company. &#160;Each option award was granted on May 24, 2022 with an exercise price of $3.377 per share, the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on May 24, 2022. &#160;Each option award will vest in one year subject to the director&#8217;s continuance of service through May 24, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, approximately 989,000 shares of common stock are available to be issued under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of the Company&#8217;s stock option activity is as follows for stock options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 600,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 768,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.7</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.8</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (142,450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 886,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.3</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 560,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#8217;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2022 and 2021, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth stock-based compensation expenses recorded during the respective periods:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,691,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,856,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,653,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,108,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,344,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,964,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At December&#160;31, 2022, the total stock-based compensation cost related to unvested awards not yet recognized was $3.5 million. The expected weighted average period compensation costs to be recognized was 1.8&#160;years. Future option grants will impact the compensation expense recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972897997920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">GRANT INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">NOTE 13: GRANT INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company&#8217;s Phase 2 clinical trial of MT-401. The CPRIT award is intended to support the adjuvant arm of the Company&#8217;s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded <span style="-sec-ix-hidden:Hidden_VRXEGsrXjkaiFVGne_HW4A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.4</span></span> million and $1.2 million of grant income related to the CPRIT grant as revenue for the years ended December 31, 2022 and 2021, respectively. &#160;At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. &#160;In January 2023, the Company received $2.4 million from CPRIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. &#160;The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898110800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>LEGAL PROCEEDINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may be party to ordinary, routine litigation incidental to their business. Other than below, the Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#8217;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#8217;s interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">An arbitration proceeding was brought against the Company before the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) by a broker seeking to be paid compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The broker&#8217;s claims were based on a placement agent agreement for a private placement it brokered in 2017, under which it alleged it was entitled to compensation for the 2018 transactions. The FINRA panel found in favor of the broker and awarded the broker $2.4 million for compensation, interest and attorney fees. As of December 31, 2021, the Company recorded an accrual of $2.4 million in accrued liabilities on its consolidated balance sheet and a $2.4 million charge to other expenses. On September 17, 2021, the broker filed a petition to confirm the FINRA arbitration award in the Supreme Court of New York for the County of New York. The Company removed the case to the United States District Court for the Southern District of New York on September 27, 2021. On October 22, 2021, the Company filed a motion in federal court to vacate the award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 9, 2022, the Company was notified that its motion to vacate the award was denied and the broker was awarded an additional $0.1 million in interest. Post judgment interest accrued at 1.02% until the judgment was paid. &#160;On March 24, 2022, the Company paid the broker $2.5 million, which amount included accrued interest. On January 4, 2023, the Company was notified that the broker was awarded an additional $0.1 million in attorneys&#8217; fees, which the Company recorded to other expenses during fiscal year ending December 31, 2022. &#160;The Company paid the $0.1 million on January 9, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972897997920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RelatedPartyDisclosureAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;15:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth related party transaction expenses recorded for the years ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,142,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,851,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bio-Techne Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 265,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,508,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,437,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">$8,600 of related party transactions are included in accounts payable and accrued liabilities as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements with The Baylor College of Medicine (&#8220;BCM&#8221;)</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160; 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#8217;s Center for Cell and Gene Therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Bio-Techne Corporation</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Bio-Techne Corporation and two of its brands for the purchases of reagents, primarily cytokines. Mr. David Eansor is a member of the Company&#8217;s board of directors and was serving as the President of the Protein Sciences Segment of Bio-Techne Corporation. Mr. Eansor resigned from Bio-Techne Corporation on March 1, 2022, and as such, two months of transactions in 2022 are included in the table above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchases from Wilson Wolf</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is currently utilizing Wilson Wolf for the purchases of cell culture devices called G-Rexes. &#160;Mr. John Wilson is a member of the Company&#8217;s board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898047408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;16:&#160;&#160;&#160;&#160;INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has no income tax expense due to operating losses incurred for the&#160;years ended December&#160;31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December&#160;31, 2022 and 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,072,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,087,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,642,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,599,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,818,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Charitable Contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating Lease Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,611,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,514,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,876,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,578,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(41,413,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,401,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,463,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,177,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (304,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,159,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,083,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,463,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,177,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not, that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2022 and 2021. The Company has research and development tax credit carryforwards of $733,000 available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company has approximately $135.2 million of federal and $38.5 million of state Net Operating Losses (&#8220;NOL&#8221;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.6 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $93.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $16.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#8217;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s income tax returns for 2018 to 2021 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the&#160;years ended December&#160;31, 2022 and 2021, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,285,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,795,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (48,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (291,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent Differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 288,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.63 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,012,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-16.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,769,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-20.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-3.40 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2022, and 2021, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898810672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE 17:</b></span><b style="font-weight:bold;">SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc., notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 14, 2023, the Company signed an agreement with AlloVir, Inc. in which Marker will collaborate with AlloVir to optimize certain aspects of AlloVir&#8217;s manufacturing process. Under the terms of this agreement, Marker will conduct a number of process improvement studies and provide AlloVir with the results of its findings. For its work with AlloVir, the Company will receive total compensation in the amount of $400,000, estimated to be fully earned by the end of the third quarter in 2023.<br/><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972895103728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;). Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#8211; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#8217;s estimates and assumptions include measurement of fair value and projections used in impairment testing, valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, Restricted Cash and Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents, Restricted Cash and Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash, cash equivalents and restricted cash at December&#160;31, 2022 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insured limits of $250,000. As of December&#160;31, 2022, approximately $1.8 million in cash was uninsured based upon the FDIC insurance coverage limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,782,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,351,145</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,146,186</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash shown in statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,782,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,497,331</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash received from grants in advance of incurring qualifying costs are recorded as restricted cash until they are earned and recorded to grant income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RetainexistingpolicyPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock', window );">Property and equipment - Construction in Progress</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment - Construction in Progress</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility&#8217;s construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third and fourth quarters of 2021, and in connection with the Company&#8217;s manufacturing facility in Houston, Texas, the Company incurred $2.2 million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. &#160;Such costs were recorded in fixed assets &#8211; construction in progress on the balance sheet as of December 31, 2021. The Company incurred another $1.9 million in related costs in 2022. Upon completion and installation of the second modular cleanroom in 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and are being amortized over the estimated useful life.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment Testing of Long-Lived Assets and Right-Of-Use Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment Testing of Long-Lived Assets and Right-Of-Use Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management reviews long-lived assets (including property and equipment) and right-of-use assets for assets under operating leases for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Recoverability of assets is determined by first grouping the long-lived assets at the lowest level for which there are identifiable cash flows, and then comparing the carrying value of each asset group to its forecasted undiscounted cash flows. If the evaluation of the forecasted cash flows indicates that the carrying value of the assets is not recoverable, an impairment charge is recognized for the amount in excess of the carrying amount over its fair value. The Company performed a test for recoverability related to its manufacturing facility in Houston, Texas at December 31, 2022 and concluded that the carrying value of its long-lived assets was recoverable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents and Patent Application Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents and Patent Application Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Term</i>&#160;&#8212; The expected life of stock options was estimated using the &#8220;simplified method,&#8221; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Volatility</i>&#160;&#8212; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#160;&#8212; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Expected Dividend</i>&#160;&#8212; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2022 and 2021, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#8217;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2022 and 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomePolicyPolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support its Phase 2 clinical trial of MT-401. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with ASC 730-20-25-8, to the extent the financial risk associated with the research and development has been transferred to CPRIT, because repayment of the grant depends solely on the results of research and development having future economic benefit, the Company accounts for this obligation as a contract to perform research and development for others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. During the fourth quarter of 2021, the Company received $2.4 million advancement of funds in relation to the CPRIT grant. The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. In January 2023, the Company received $2.4 million from CPRIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#8217;s Orphan Products Grant program to support the Company&#8217;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for property and equipment, construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RetainexistingpolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the Retain existing  policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RetainexistingpolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898810672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,782,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,351,145</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,146,186</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash shown in statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,782,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,497,331</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents, restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898029872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,930,694)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (41,878,871)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted average common shares outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,351,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,650,567</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.47)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NetLossPerShareTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 886,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 768,600</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock purchase warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,848,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,983,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Potentially dilutive securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,734,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,751,600</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NetLossPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net loss per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NetLossPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898851024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Lives</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab and manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,824,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,851,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3-5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 899,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,020,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5 Years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 924,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 793,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease term or estimated useful life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,950,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,173,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Total   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,597,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,837,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,274,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,740,000)</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,226,000</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fixed assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,323,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,323,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972895028976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of quantitative information about operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense summary:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,483,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,702,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 648,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 606,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,179,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,308,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,106,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,077,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 983,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,254,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,290,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,177,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December 31, 2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,163,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,590,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,457,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,840,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,617,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lease cost and other information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898844928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,612,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,144,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,779,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,055,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Process development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 342,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 644,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Technology license fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Arbitration settlement fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 114,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,407,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 250,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_FuIPzOWfjEuw7JcSqUHBnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 4,705,000</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_b9x6r4ODwECU40jh-cbSzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 11,135,000</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972898092912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock', window );">Schedule of share purchase warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,083,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (100,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,983,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (135,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,848,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896372528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTION PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of the company's stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Intrinsic Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (in years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 600,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 768,623</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.7</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.8</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Canceled/Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (142,450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 886,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.3</p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options vested and exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 560,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule or description of weighted average discount rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected stock price volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate of interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationExpensesTableTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Compensation expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,691,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,856,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,653,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,108,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,344,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,964,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of stock based compensation expenses recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896566704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RelatedPartyDisclosureAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transaction expenses recorded during the respective periods</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Baylor College of Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,142,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,851,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bio-Techne Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 306,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Wilson Wolf Manufacturing Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 265,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280,000</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,508,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,437,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896725280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Years Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net Operating Loss Carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,072,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,087,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,642,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,599,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued Expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 510,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;E</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,818,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 733,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Charitable Contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Operating Lease Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,611,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,514,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,876,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,578,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: Valuation Allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(41,413,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36,401,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,463,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,177,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Fixed Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (304,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (94,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-Use Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,159,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,083,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Deferred Tax Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,463,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,177,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Deferred Tax Assets/(Liabilities)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock', window );">Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pretax Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,285,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,795,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (48,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (291,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent Differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">- Other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 288,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.63 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,012,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-16.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,769,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-20.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,019,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-3.40 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-0.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax provision/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected tax expense benefit based on federal statutory rate is reconciled with actual tax provision benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892561792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 26, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockIssuedDuringPeriodValueReverseStockSplits', window );">Reverse stock split value</a></td>
<td class="nump">$ 394.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of stock issued during period, value, reverse stock splits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892400208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Sep. 13, 2022</div></th>
<th class="th"><div>Apr. 21, 2021</div></th>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,228,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,130<span></span>
</td>
<td class="nump">$ 52,552,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,130<span></span>
</td>
<td class="nump">52,552,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Amount of notice received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromCpritGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromGrantRelatedToCprit', window );">Revenue from CPRIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,146,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,146,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromOrphanProductsGrantProgram', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,651<span></span>
</td>
<td class="nump">3,228,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 3,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember', window );">Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommitmentFee', window );">Commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember', window );">Lincoln Park | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued during period other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued during period other (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember', window );">ATM Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during period for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember', window );">ATM Agreement | Sales Agents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent', window );">Commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember', window );">Binding Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember', window );">Binding Services Agreement | Wilson Wolf Manufacturing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems', window );"><strong>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of commitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percent of calculation of compensation rate by using gross sales price per share sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromCpritGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds Received From Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromCpritGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from CPRIT grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RevenueFromGrantRelatedToCprit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grant Related to CPRIT.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RevenueFromGrantRelatedToCprit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RevenueFromOrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for grant from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RevenueFromOrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972903974752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Sep. 13, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,225,610<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ReceiptOfProductDevelopmentResearchAward', window );">Receipt of product development research award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromCpritGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeReceivable', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromOrphanProductsGrantProgram', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantReceived', window );">Grant income received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">2,402,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember', window );">Manufacturing facility in Houston, Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram', window );">Amount of award grant from orphan product grant program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Award grant from orphan product grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromCpritGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds Received From Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromCpritGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from CPRIT grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant income receivable by the company, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ReceiptOfProductDevelopmentResearchAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of product development research award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ReceiptOfProductDevelopmentResearchAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RevenueFromOrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for grant from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RevenueFromOrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items reflecting a significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896774608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,782,172<span></span>
</td>
<td class="nump">$ 42,351,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,146,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in statements of cash flows</a></td>
<td class="nump">$ 11,782,172<span></span>
</td>
<td class="nump">$ 43,497,331<span></span>
</td>
<td class="nump">$ 21,352,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972895022656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERSE - Computation of loss per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,930,694)<span></span>
</td>
<td class="num">$ (41,878,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, Basic</a></td>
<td class="nump">8,351,003<span></span>
</td>
<td class="nump">7,650,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, Diluted</a></td>
<td class="nump">8,351,003<span></span>
</td>
<td class="nump">7,650,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (3.58)<span></span>
</td>
<td class="num">$ (5.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (3.58)<span></span>
</td>
<td class="num">$ (5.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972895592256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">2,734,000<span></span>
</td>
<td class="nump">2,751,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockWarrantsEquityTreatment', window );">Common stock purchase warrants</a></td>
<td class="nump">886,000<span></span>
</td>
<td class="nump">768,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockWarrantsEquityTreatment', window );">Common stock purchase warrants</a></td>
<td class="nump">1,848,000<span></span>
</td>
<td class="nump">1,983,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockWarrantsEquityTreatment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants - equity treatment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockWarrantsEquityTreatment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972993494128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,402,004<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromOrphanProductsGrantProgram', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasMember', window );">Cancer Prevention And Research Institute Of Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesWithImputedInterestLineItems', window );"><strong>OTHER RECEIVABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from CPRIT grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RevenueFromOrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for grant from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RevenueFromOrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesWithImputedInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesWithImputedInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_CancerPreventionAndResearchInstituteOfTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892164064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 17,597,000<span></span>
</td>
<td class="nump">$ 12,837,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(5,274,000)<span></span>
</td>
<td class="num">(2,740,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ConstructionInProgress', window );">Construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,226,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total fixed assets, net</a></td>
<td class="nump">12,323,000<span></span>
</td>
<td class="nump">12,323,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 11,824,000<span></span>
</td>
<td class="nump">7,851,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember', window );">Computers, equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 899,000<span></span>
</td>
<td class="nump">1,020,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember', window );">Computers, equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember', window );">Computers, equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 924,000<span></span>
</td>
<td class="nump">793,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 3,950,000<span></span>
</td>
<td class="nump">$ 3,173,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrkr_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972894682976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,225,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember', window );">Manufacturing facility in Houston, Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrkr_ManufacturingFacilityInHoustonTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896353872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination', window );">Reduction in operating lease liabilities for lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination', window );">Reduction in right-of-use assets for lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 7,617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">$ 5,479,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,830,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction in operating lease liabilities for termination of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction in operating lease right of use assets for termination of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896514736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Quantitative Information About Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OperatingLeaseExpenseAbstract', window );"><strong>Operating lease expense summary:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,483,000<span></span>
</td>
<td class="nump">$ 1,702,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">648,000<span></span>
</td>
<td class="nump">606,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">2,179,000<span></span>
</td>
<td class="nump">2,308,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OtherLeaseInformationAbstract', window );"><strong>Other information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows - operating leases</a></td>
<td class="nump">$ 1,106,000<span></span>
</td>
<td class="nump">$ 1,077,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">weighted-average discount rate used to determine the operating lease liability</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OperatingLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OperatingLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OtherLeaseInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OtherLeaseInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972902504896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2023</a></td>
<td class="nump">$ 983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2024</a></td>
<td class="nump">1,254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2025</a></td>
<td class="nump">1,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2026</a></td>
<td class="nump">1,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ending December 31, 2027</a></td>
<td class="nump">1,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">9,457,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(1,840,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December 31, 2022</a></td>
<td class="nump">$ 7,617,000<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892199312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,612,000<span></span>
</td>
<td class="nump">$ 5,144,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,779,000<span></span>
</td>
<td class="nump">2,055,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccruedProcessDevelopmentExpensesCurrent', window );">Process development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,000<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558,000<span></span>
</td>
<td class="nump">644,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccruedTechnologyLicenseFees', window );">Technology license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ArbitrationSettlementLiabilitiesCurrent', window );">Arbitration settlement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="nump">2,407,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,704,611<span></span>
</td>
<td class="nump">$ 11,134,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mrkr_OperationalCostReductionPlanMember', window );">Operational Cost Reduction Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems', window );"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in headcount of general and administrative function (as a percent)</a></td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccountsPayableAndAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccountsPayableAndAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccruedProcessDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for Process development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccruedProcessDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AccruedTechnologyLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Consulting agreements payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AccruedTechnologyLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ArbitrationSettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for arbitration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ArbitrationSettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mrkr_OperationalCostReductionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mrkr_OperationalCostReductionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972902449584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY DEFERRED REVENUE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY LIABILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,013,544<span></span>
</td>
<td class="nump">$ 1,241,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember', window );">Wilson Wolf Manufacturing Corporation | Binding Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY LIABILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Cash payment from related party</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation', window );">Advance received for non-exclusive training of Wilson Wolf to make, use, and sell Marker's cell culture non-proprietary media formulation</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments', window );">Advance received for non-exclusive training of Wilson Wolf to replicate Marker's quality management system inclusive of all underlying documents</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess', window );">Advance received for non-exclusive training of Wilson Wolf to replicate Marker's cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses', window );">Advance received under the hired to invent doctrine for Marker to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate', window );">Period for completion of optimization work under the direction of Wilson Wolf which Marker will make good faith efforts from the agreement date</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement', window );">Additional amount agreed to received from Wilson Wolf if the Work Direction is completed within one year from the onset of the agreement</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered', window );">Threshold minimum combined voting power of the surviving entity or parent corporation of the surviving entity considered (in percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Related party service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY LIABILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional amount agreed to received from Wilson Wolf if the Work Direction is completed within one year from the onset of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for completion of optimization work under the direction of Wilson Wolf which Marker will make good faith efforts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to make, use, and sell Marker's cell culture non-proprietary media formulation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to be able to replicate Marker's cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to replicate Marker's quality management system inclusive of all underlying documents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of advance received under the hired to invent doctrine for Marker to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes using G-Rex and to conduct CAR T and TCR G-Rex Optimization Work under the direction of Wilson Wolf (the "Work Direction").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of threshold minimum combined voting power of the surviving entity or parent corporation of the surviving entity immediately after merger, reorganization or consolidation, or the sale or other transfer of all or substantially all of entity's business or assets considered, in the event if the agreement cannot be fulfilled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_BindingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892263520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 26, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">3,228,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="nump">$ 202,130<span></span>
</td>
<td class="nump">$ 52,552,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember', window );">Board Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember', window );">Exercise of Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892495152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="nump">3,228,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,130<span></span>
</td>
<td class="nump">$ 52,552,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="nump">$ 202,130<span></span>
</td>
<td class="nump">$ 52,552,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtmAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember', window );">Board Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,651<span></span>
</td>
<td class="nump">3,228,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 3,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,252<span></span>
</td>
<td class="nump">6,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember', window );">Exercise of Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrkr_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972902525936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Mar. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">3,228,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,130<span></span>
</td>
<td class="nump">$ 52,552,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OfferingCost', window );">Offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate proceeds from shares issued under the purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,130<span></span>
</td>
<td class="nump">52,552,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NumberOfSharesAuthorizedToIssueAndSell', window );">Number of shares authorized to issue and sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,857,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_UnderwritingOptionPeriod', window );">Option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell', window );">Number of additional shares authorized to issue and sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,228,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember', window );">Exercise of Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember', window );">Board Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional shares authorized to issue and sell.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfSharesAuthorizedToIssueAndSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares authorized to issue and sell.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfSharesAuthorizedToIssueAndSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_UnderwritingOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the underwriting option period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_UnderwritingOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrkr_BoardCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892205632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate proceeds from shares issued under the purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,130<span></span>
</td>
<td class="nump">$ 52,552,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="nump">3,228,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate proceeds from shares issued under the purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Lincoln Park | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate proceeds from shares issued under the purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrkr_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrkr_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896426320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS - Summary of Share Purchase Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_WarrantsDisclosureAbstract', window );"><strong>WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Beginning balance</a></td>
<td class="nump">1,983,000<span></span>
</td>
<td class="nump">2,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NumberOfWarrantExpiredOrCancelled', window );">Number of Warrants, Expired or cancelled</a></td>
<td class="num">(135,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants, Ending balance</a></td>
<td class="nump">1,848,000<span></span>
</td>
<td class="nump">1,983,000<span></span>
</td>
<td class="nump">2,083,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 44.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash', window );">Weighted Average Exercise Price, Exercised for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired or cancelled</a></td>
<td class="nump">39.70<span></span>
</td>
<td class="nump">$ 55.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 44.51<span></span>
</td>
<td class="nump">$ 44.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">9 months 14 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights outstanding exercised weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right outstanding issued weighted average remaining life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfWarrantExpiredOrCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants expired or cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfWarrantExpiredOrCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896319872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS - Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">768,623<span></span>
</td>
<td class="nump">600,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">191,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled / Expired</a></td>
<td class="num">(142,450)<span></span>
</td>
<td class="num">(22,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">886,173<span></span>
</td>
<td class="nump">768,623<span></span>
</td>
<td class="nump">600,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options vested and exercisable</a></td>
<td class="nump">560,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Outstanding, Beginning Balance</a></td>
<td class="nump">$ 54.69<span></span>
</td>
<td class="nump">$ 62.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="nump">4.68<span></span>
</td>
<td class="nump">28.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Cancelled / Expired</a></td>
<td class="nump">36.78<span></span>
</td>
<td class="nump">35.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share Outstanding, Ending Balance</a></td>
<td class="nump">42.90<span></span>
</td>
<td class="nump">$ 54.69<span></span>
</td>
<td class="nump">$ 62.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and exercisable</a></td>
<td class="nump">$ 59.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Options granted</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Options vested and exercisable</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options granted in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972900947008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS - Weighted Average Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTION PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 29.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896454368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS - Stock-based compensation expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expenses</a></td>
<td class="nump">$ 5,344,000<span></span>
</td>
<td class="nump">$ 5,964,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expenses</a></td>
<td class="nump">2,691,000<span></span>
</td>
<td class="nump">2,856,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expenses</a></td>
<td class="nump">$ 2,653,000<span></span>
</td>
<td class="nump">$ 3,108,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972890114464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION PLANS - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2022 </div>
<div>installment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>installment</div>
</th>
<th class="th">
<div>May 24, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>installment</div>
</th>
<th class="th">
<div>Feb. 17, 2022 </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2022 </div>
<div>installment</div>
</th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">191,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.00<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 29.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="nump">$ 28.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued', window );">Number of shares options available to be issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAwards2021Member', window );">2021 Equity Incentive Awards | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards', window );">Number of equal monthly installments of award | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards', window );">Number of equal monthly installments of award | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of options to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | Employees | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | Non-Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | Non Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of options to purchase shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | Non-executive employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards', window );">Number of equal monthly installments of award | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | 2020 Equity Incentive Plan | Executive officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member', window );">2022 Equity Incentive Awards | 2020 Equity Incentive Plan | Non-executive employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_StockBasedCompensationLineItems', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards', window );">Number of equal monthly installments of award | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equal monthly installments for option award vesting over the vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement number of share options available for issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_StockBasedCompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_StockBasedCompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrkr_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAwards2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrkr_EquityIncentiveAwards2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrkr_EquityIncentivePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=mrkr_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=mrkr_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mrkr_NonExecutiveEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mrkr_NonExecutiveEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972896310512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANT INCOME (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 13, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_ReceiptOfProductDevelopmentResearchAward', window );">Receipt of product development research award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,013,544<span></span>
</td>
<td class="nump">$ 1,241,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_RevenueFromOrphanProductsGrantProgram', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OrphanProductsGrantProgram', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeReceivable', window );">Grant income receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_FundsReceivedFromGrant', window );">Funds received from CPRIT grant</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_GrantIncomeLineItems', window );"><strong>GRANT INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,513,544<span></span>
</td>
<td class="nump">$ 1,241,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">FDA's orphan products grant program, grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_FundsReceivedFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds received from CPRIT grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_FundsReceivedFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represents grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_GrantIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of grant income receivable by the company, as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_GrantIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_ReceiptOfProductDevelopmentResearchAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipt of product development research award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_ReceiptOfProductDevelopmentResearchAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_RevenueFromOrphanProductsGrantProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for grant from FDA's Orphan Products Grant program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_RevenueFromOrphanProductsGrantProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972902532208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2023</div></th>
<th class="th"><div>Jan. 04, 2023</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_CompensationInterestAndAttorneyFees', window );">Compensation, interest and attorney fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount', window );">Broker was awarded with additional in interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_PercentageOfAccrualOfPostJudgmentInterest', window );">Percentage of accrual of post judgment interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_BrokerWasAwardedAccruedInterest', window );">Broker was awarded accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_AdditionalAttorneyFeesAwarded', window );">Additional attorney fees awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Payment of commitment fee</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_AdditionalAttorneyFeesAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>"Amount of additional attorney fees awarded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_AdditionalAttorneyFeesAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_BrokerWasAwardedAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>"Amount of legal proceedings broker
 awarded accrued interest amount."</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_BrokerWasAwardedAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_CompensationInterestAndAttorneyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation, interest and attorney fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_CompensationInterestAndAttorneyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of legal proceedings broker awarded additional interest amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_PercentageOfAccrualOfPostJudgmentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of accrual of post judgment interest until judgment is paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_PercentageOfAccrualOfPostJudgmentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892384496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total Research and development</a></td>
<td class="nump">$ 1,508,000<span></span>
</td>
<td class="nump">$ 3,437,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember', window );">Baylor College of Medicine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total Research and development</a></td>
<td class="nump">1,142,000<span></span>
</td>
<td class="nump">2,851,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_PurchasesFromBioTechneCorporationMember', window );">Bio-Techne Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total Research and development</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">306,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember', window );">Wilson Wolf Manufacturing Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total Research and development</a></td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_PurchasesFromBioTechneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_PurchasesFromBioTechneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_WilsonWolfManufacturingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972902449648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforward</a></td>
<td class="nump">$ 30,072,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_Deferredtaxstockbasedcompensation', window );">Stock Compensation</a></td>
<td class="nump">5,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;E</a></td>
<td class="nump">4,818,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and Development</a></td>
<td class="nump">733,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating Lease Liability</a></td>
<td class="nump">1,611,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets</a></td>
<td class="nump">42,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation Allowance</a></td>
<td class="num">(41,413,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Assets</a></td>
<td class="nump">1,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DeferredTaxLiabilitiesFixedAssets', window );">Fixed Assets</a></td>
<td class="num">(304,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-Use Assets</a></td>
<td class="num">(1,159,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">$ (1,463,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,087,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_Deferredtaxstockbasedcompensation', window );">Stock Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,599,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_Deferredtaxassetslicenseagreement', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,514,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,578,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,401,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,177,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DeferredTaxLiabilitiesFixedAssets', window );">Fixed Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,083,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,177,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Deferred tax assets, operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liability, Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liability, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Deferredtaxassetslicenseagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Deferredtaxassetslicenseagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Deferredtaxstockbasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Deferredtaxstockbasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972892269344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information's (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_IncomeTaxLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Deferred Tax Assets, Tax Credit Carryforwards, Research</a></td>
<td class="nump">$ 733,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</a></td>
<td class="nump">135,200,000<span></span>
</td>
<td class="nump">$ 41,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="nump">$ 38,500,000<span></span>
</td>
<td class="nump">21,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_Taxcreditcarryforwardexpirationyearrangestart', window );">Tax credit carryforwards expiration period</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_Taxcreditcarryforwardexpirationyearrangeend', window );">Tax credit carryforwards expiration year end</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_IncomeTaxLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OperatingLossCarryforwardsLimitationPercentage', window );">Operating Loss Carryforwards Limitation Percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_IncomeTaxLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_OperatingLossCarryforwardsLimitationPercentage', window );">Operating Loss Carryforwards Limitation Percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_OperatingLossCarryforwardsLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of limitation for operating loss carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_OperatingLossCarryforwardsLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Taxcreditcarryforwardexpirationyearrangeend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year range end.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Taxcreditcarryforwardexpirationyearrangeend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Taxcreditcarryforwardexpirationyearrangestart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year range start.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Taxcreditcarryforwardexpirationyearrangestart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972891793488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="num">$ (6,285,000)<span></span>
</td>
<td class="num">$ (8,795,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(44,000)<span></span>
</td>
<td class="num">(48,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="num">$ (291,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit, Percent</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change, Percent</a></td>
<td class="num">(0.03%)<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Permanent Differences</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_Permanentdifferencesotherpermanentdifferences', window );">Permanent differences- Other permanent differences</a></td>
<td class="nump">$ 288,000<span></span>
</td>
<td class="nump">$ 262,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">5,012,000<span></span>
</td>
<td class="nump">8,769,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Deferred true-up</a></td>
<td class="nump">$ 1,019,000<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences', window );">Permanent differences- Other permanent differences, Percent</a></td>
<td class="num">(0.96%)<span></span>
</td>
<td class="num">(0.63%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Percent</a></td>
<td class="num">(16.75%)<span></span>
</td>
<td class="num">(20.94%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Deferred true-up, Percent</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(0.25%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision (benefit), Percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the effective tax rate reconciliation due to other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrkr_Permanentdifferencesotherpermanentdifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent differences other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrkr_Permanentdifferencesotherpermanentdifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrkr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139972900711616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,344,006<span></span>
</td>
<td class="nump">$ 5,964,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | AlloVir, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_AllovirIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrkr_AllovirIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>mrkr-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrkr="http://www.tapimmune.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrkr-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_12_12_2022_To_12_12_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kp85NnJBBUmUhXIRR_MpQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_DRQziVPupkyucYZQUxu7CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F6wReus0oEaCdo351uy7TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_21_2021_To_4_21_2021_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_ZclhqIbMvU-O8EfMWIhhgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-21</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HZfAycR2kk-ZXkhm82bVPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_j-Tt7k3AAEelDRzuTV__kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_lYIjNL0t2E6NNbd5622y6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmkYNaQrdkaCT93Kx5jgTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GdnjYANna0qQFgzGMImcPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egIQ7QghbkGRIjamiNWiUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FBFeOkr3ykuSOy5dBngOrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1uzjGStWO06DZSlcFGbVsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GInYc9c9Y0moOPtffvDIDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8cq4aMH20Sb7VO8y3pJew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_npaXz9T0mUaUNEGeD_jgZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_S5Q4yNrC5UKGn_ImsQmXDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-11</instant>
        </period>
    </context>
    <context id="Duration_5_24_2022_To_5_24_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ubwm1qD4wE-HsJvlsJGJpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ZEI3kl26Pk2zgb9tiZo19w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_OptionIndexedToIssuersEquityTypeAxis_mrkr_NonEmployeeStockOptionMember_gbP12LhguU6WycZv51CdaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">mrkr:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A-AeQilLX0WzYGhiZT07Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3OQQVZE1uEm384QeLqzj-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_U85KQ1vJe0u5uT4iGCYd1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAwards2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_F-6NSFyNk0uhy-tFDHx2jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentiveAwards2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_kUuUrHRKk0G10jpx1s-bkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_yIinahL4sEGqxYXSIhjnhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_pVnVS7CZdEWMB5iww4KJeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrkr:NonExecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_meicGgKvzUadt_zzSUx2eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ltpSYmw2Ck-js4TXpUSbpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_GhcbliHPX0GLe0R12grctQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_CgqUPlC4VU6qTAV9KfQcqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_pGIzcYnvJEiT9dhMXsElQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_JUDa3cw9BUK0ZTYPzI9s9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_AxyTiy7MlUuwc7GAnr3jLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4Mlx9tG1EEGFYz6EXdp5Vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mhcEIpDJQkmXGgO5cKQZuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_J2wzhp4PQ0yD55El3XelKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2022_To_1_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_JbX3ZgrhrUCG3fxE5SiYMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OcBdsIpxMk6PRtghWozW-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_14_2023_To_3_14_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_AllovirIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1XuOmQ5XPUeNbdcsl4Y23g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:AllovirIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ServiceMember_sVgjmKoubkywnwtNRRNxpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_lhALYDffbEuklraKG2XQmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_Z55ugQPT_kKUAhzu1ioV8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_QveB1kU3tkucob1EUaCgcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mrkr:OperationalCostReductionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_8-nrYuOdiEO8hicagC8Wcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_92UkqyWHCkqZKAb3ohfj-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_BMzNUjdDhUG_b5P76LRATw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_I0FgPzQc2EedkO5jGv2oEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_FG_G8klQXUmj79kiu1yNMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:PurchasesFromBioTechneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_awMWjIqo90CWdC9K0cfcDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_sQrTMozyWEyU4ra-AUAZ2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_McT4zbJriU6hB34bDlJjeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_eEnb8GgPoU6evepNcjl2rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NXup2CJ02USDTLUpDls9hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_iRDTtaZteEiLcISmCUciWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TLp-qtPIB02goeZcg_RReg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mMYtiCFfIEK_bdrpJ5dMRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_qtmbiBYUXEGhAeHMenyf7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_VtFCZtpzqUS4hInYPoLNNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nqoFwEJHwUmDvKu-C4t_AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kiI02v_yr0miZEzODZfWew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_zKhfppn7GEWXbnJMKir-Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrkr:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_jSWMIRhbp0WIJO4zq_1XRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:ExerciseOfStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_VP3-b6HOUk2DKLQ51VCCBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrkr:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_us-gaap_SubsequentEventMember_Yue1bky0HUK0DiPiPA1ZmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_EA2qnlAMxUapgXjRK0-39A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:CancerPreventionAndResearchInstituteOfTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_l66B3TClFEmlIWsk1ybpMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_G1H72RYOhku1flLkvnmwxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6tRxU7Rie0-8urQAVoZMJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JKGI8Nx-2kSnc6KA5Cd6jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_NlI_rrXrCkWSdi8cy_jNIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_9_2023_To_1_9_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tgbt7OSC3EulA327h83DEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_sD7iYvHxZkqwyKox7Z0qJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mrkr:OperationalCostReductionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_elmgfz9S-0W_ZDXK3WDiaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_73WDhaJFhk26kf_aw8N7qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_de53l1GX8kGkNWjZK3KpnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_McFGqwTRbE2KSZ_az8T4DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_yhp5Hv7lwkaZQV2FAXpIpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrkr:ManufacturingFacilityInHoustonTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_w84Uaz3YUEqYjRHmFPZttg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6ka_iEmMjE2aQAOD6iwO8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_XPzhwj-erUqIBzQu-ulhQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-26</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RangeAxis_srt_MinimumMember_PZ0RPJnwKk65BP6T537-EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_RangeAxis_srt_MaximumMember_dikyAbnEbkGQJoXUA7yMkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_EhfaszvU3UinGypAqqyo6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mrkr:ExerciseOfStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_5W-EffSPAk-sIjPcaw3pDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BoardCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NGUNmIMxGkq1Z8jXaWqHoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_I0jHwwB580SqyJF3TUAQmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_93kl4ltjMUiFOgjh_0uOaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbjncsNOXUKlnyjr3E54gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2023_To_1_26_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oBMB2ozYCUm78jnnAf9ERw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-26</startDate>
            <endDate>2023-01-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_RYoECPvlqUm2SecYEAk3nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_xLzOljk2o0KBWMLiKybJag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_WhoS9ltZXk6NBcS9AfdoJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-19</instant>
        </period>
    </context>
    <context id="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-21</startDate>
            <endDate>2022-04-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_75w7V3-2uEiEHBbWok-lEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_E_6jM-m13kOR5Fzj9eeTUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_11_2021_To_3_11_2021_ipD27hsbDkSP-aqaxEKH-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2021-03-11</startDate>
            <endDate>2021-03-11</endDate>
        </period>
    </context>
    <context id="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_y6evzTYbj0ikSh5RHLTXHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_YqaWefj0tk20njxWAVYeyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_uGqtaqdy20eQ6t52skgzRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrkr:NonExecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrkr:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_UIJSoFc-BEakDbs6zOJBIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mrkr:NonExecutiveEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrkr:EquityIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-11</startDate>
            <endDate>2021-03-11</endDate>
        </period>
    </context>
    <context id="Duration_3_9_2022_To_3_9_2022_mHWNE8BszkWyzvOf2FXUaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="Duration_9_13_2022_To_9_13_2022_w0iIOXYe5U2sofHNZfyE-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2022-09-13</startDate>
            <endDate>2022-09-13</endDate>
        </period>
    </context>
    <context id="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-13</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7NoYkmU3T0yNAjX5qvt6FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_d7Z-oISLakWWyRl9aSgT8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_JT2ojtlpfUiPgirbtHOffA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OtJ-a1ZIt0GTo1DBVaijBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bQJrMgrRIEih2ZZ5LZh_Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DbSC03W-N0uqTlyKBJ9KHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RBkehlwI7UK7Hw7PXAvVhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_rJJmBdCj7EOIPmbz9BOYyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrkr:CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_sdKnf_W3b06nZ9jMBEsNJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2022_To_3_24_2022_IbGXbqvguEioxE6sArNnqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="As_Of_9_13_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_UoBREzfn7kO2CeAdFJzHPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="Duration_1_4_2023_To_1_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uUaeHZ6WLE2MqQaG64NZzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-04</startDate>
            <endDate>2023-01-04</endDate>
        </period>
    </context>
    <context id="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrkr:WilsonWolfManufacturingCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrkr:BindingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-21</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_LiJpe6ByN0awpAG6BNal_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2023_76HOzdeFcEmvS3bm87KgOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001094038</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw">
        <measure>mrkr:installment</measure>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      id="Hidden_bxX6QbSpekC8G-HwtQb90Q"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      id="Hidden_eDcSIFJbBkiEl4pe1p3BoA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Hidden_FuIPzOWfjEuw7JcSqUHBnw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">4704611</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Hidden_b9x6r4ODwECU40jh-cbSzg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11134913</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_EF5PdThRwEmKAfFPFR4CbQ_2_1">0001094038</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_fw8kQSq4vkaOYAk0XfPjMA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_XbDIQYM06k-eAlvH8-NlXA_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_QXUcs95exkKn0GsePHHGng_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_XdWKaixp50qBJOya_RlCUA_6_1">false</dei:AmendmentFlag>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_BeV59xUVLEuI-GjO_48wvw_7_1">false</dei:IcfrAuditorAttestationFlag>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Hidden_XJzDz4-ELkOS8norAoOL8w"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Hidden_J5UYgV3izECAEBRrpVGnhg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_lhALYDffbEuklraKG2XQmQ"
      decimals="0"
      id="Hidden_VRXEGsrXjkaiFVGne_HW4A"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3513544</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-6"
      id="Hidden_hMFFrHQHMkq7-EVZp3BQdw"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-6"
      id="Hidden_1HJlOWutCU21PJuZ_5nO2w"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_aFuDoL2z9kaAPt2E7r0BQw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_ibzjZI3SIkuByPlvtYINuA_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_OM_fOHw7vkm04Zgcq55WIg">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_PrrRKs5ZbkShw_ZKMOGvrQ_6_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_igKbb5PLx0OeCsQAjV6ZJQ">001-37939</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_Yfq2b0KUGkm1J6huij49lw">MARKER THERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_mj3qO2Iu6UqzHtSKdgHZqA_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_h3KgBaB-pU-QenO3WPNJRA_0_2">45-4497941</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_oBs65FQ9oEi6S_lRh_fXCg">4551 Kennedy Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_qMXioG5j7EuidT6GazGKeQ">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_Nt1ltKW3IES4RPjqEh5IdQ">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_FriPNodcYUOdsr4XHAwXog_3_2">77032</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_XfLthzsVokqDn2TwWqHDLQ">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_-MPvI-fK70airuy1DCpYzA">400-6400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_DtfRfvt7g0mhsd86qiTfyw_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_7PYDcYKU80aDR8quPGhjPw_2_2">MRKR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_ed5SITrnJ0C_JFb3hB2UJQ">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_uxoL9U4ozEiSekr4-yxhPQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_Gd4KlgJ5yUutc3Ep7Mgndw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_0vHAcwq150a4NxkV2AiHeg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_G5NIjIrrKEqZD2vpOFDkFw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_JrH6cZRRE0iDJroZr1fXkQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_Rg3paNmquUe1tgULphdmLg_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_SWxieoZpb0a11kptj5gZ5g_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_Of-JJ9qKz02tarEA2JHaMQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_7B_Wj0M_GEuns2PoF-AJeA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_LiJpe6ByN0awpAG6BNal_g"
      decimals="0"
      id="Narr_pdVFRMThikW8dOUsd8eFhg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">22800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_17_2023_76HOzdeFcEmvS3bm87KgOQ"
      decimals="INF"
      id="Narr_8Qlztl1x8UajNF3WNNiDdw"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8798829</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_DfhcCkZ4i0qNShXrRcqsAA">688</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_pMHsajIvDEOyDCD_trUwhw">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_CRzsbd-bJU-hSRSnlWxpCg">Houston, TX</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_Muo4fAhIIECS2TIM6SWaZw_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11782172</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_pz772NGRr0W3sesdBa6J7Q_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">42351145</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_gDe5-rQhnEKuK9CAxFq3Tg_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_pzb0G7k4x0W8mpJzXypy0Q_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1146186</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_ie2Ehx1yd0WicgJtuVGrxg_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2435079</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_H6rWiu-c6UyoSwLuu1GRZA_7_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2484634</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_n_X0lclcNUq8Q0c8_kU45g_8_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2402004</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_ioPT2dau6Uyz9FSA8CiYWQ_8_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">237</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_VTKL9f8wB0yF--uQDDCAXg_9_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">16619255</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_f1sJQeYD10-iK1e5TRvQ3g_9_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">45982202</us-gaap:AssetsCurrent>
    <mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_khEipJzznEm550-LQFNKXA_11_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">12323143</mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress>
    <mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_qBGu9kBHLUeVKH2LtJk_3g_11_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">10096861</mrkr:PropertyPlantAndEquipmentOtherThanConstructionInProgress>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_-_xXJeNnL0y6LNJXpytmNw_12_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_0py7sJ_s7kaqYjAXaMskHA_12_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2225610</us-gaap:ConstructionInProgressGross>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_ZAGJkQfXmUKoWdjuBCAxUg_13_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5479786</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_C_slZ33gfUqQ9w_OAA2aGA_13_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">9830461</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_iguD7bVD-EyF8ao5brcOaQ_14_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">17802929</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_ZXdt9JrWnE-DvMZ5ZH8PYQ_14_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">22152932</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_cegzebWwvkKFv8m9gL23Nw_16_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">34422184</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_HOAX_wx-vkCzGuTol2R24w_16_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">68135134</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_k36F5gZbqk6w4vniKXYdog_20_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">4704611</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_E5r-sqRHlECKpTU2Dve0HA_20_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11134913</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_FD94l1PVqkmGX-tgudq27A_21_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2500000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_YJ4gtrorYESul_yqx1hikw_22_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_7gKNJVuQLkOoCKr53sCaDA_22_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1146186</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_ob4lQfISQke4tuWKVi_nLg_23_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">577198</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_EQ1POS5o3kqJPEK7sfn3yA_23_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">620490</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_qgoxj7sInEOBZio5v5Ioag_24_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">7781809</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_1MUu4aqCNUeNgCA207D1Gg_24_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">12901589</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_aI8TBdZy5E61QwSJz2kGNQ_26_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">7039338</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_tPIb5d6meECKXL8xpTeIGA_26_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11247950</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_MmfhN6gIRkG0YTSQe8hlaQ_27_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">7039338</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_yooViQFtokW4BYRRoYS2nw_27_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11247950</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_s4uj75vdxEeAtaiU-fKMFA_29_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">14821147</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_WTC2bssiAEmvZ9HdVT1XuA_29_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">24149539</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="INF"
      id="Narr_HNXp5zOnHkKyMXjLaOY0Xw"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="INF"
      id="Narr_549m4dAvC0ymHTg0ECuJmA"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-6"
      id="Narr_7r1lT7CNf0utfuHKmrDUfg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-6"
      id="Narr_lcWa4MmUXkaQN9aeZDEddA"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-6"
      id="Narr_7A8OUjaHfUmb9vDlCr0SrQ"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-6"
      id="Narr_d08DHlr_9Eukzt5xF_Rg7g"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="INF"
      id="Narr_1Xi6CF7P80m8QzEfsW3Ubg"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="INF"
      id="Narr_j3WMo856RU6xlQ-LzWdkeA"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-6"
      id="Narr_X95nlV6oXEaU29nsx24Mbg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-6"
      id="Narr_sxUBqjww1Em6aMirCJuvzw"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_F0PowPMPmEaYcK_lXnPp6w"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_ke0SM_S9RESOT0Rc07aXbw"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_n9HuMUEey0yGpu6tq1g1Iw_33_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">8406</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_FPyKCV9XnEG9fPC21nWWnw_33_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">8308</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_LCLKlC3m00i7IIhdJqILlQ_34_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">447641680</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_YA25AEJPLEWjd6a10Obipw_34_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">442095642</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_M4MAZ5rX8EuqSjhQMvYoKQ_35_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-428049049</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_bePUK9vfFU2CyMSDI1Pelg_35_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-398118355</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_dhT5v_lNLUCjT56L8G_IMw_36_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">19601037</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_zCaOax7fYk2Zy67-mZzrzw_36_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">43985595</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_Tc4-PYTGPke6uYfR2eRBlA_38_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">34422184</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_wQ1-PASEF0Sq3oEcXlzcig_38_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">68135134</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_lhALYDffbEuklraKG2XQmQ"
      decimals="0"
      id="Tc_3EhUJbAz-0ynY8zSFpHHZA_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3513544</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_Z55ugQPT_kKUAhzu1ioV8A"
      decimals="0"
      id="Tc_sJxrWZsgGEyQ1yo2QaC3nw_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1241710</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ServiceMember_sVgjmKoubkywnwtNRRNxpg"
      decimals="0"
      id="Tc_y0RUkuKg90asEqVdAx7djg_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_0MIl70u_tEexrTmVrtN7Tw_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">9013544</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_955Rctag_0mHCC9R-lI5hA_7_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1241710</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_EuHTj7yIy0yVl5N-fA5idQ_9_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">26139323</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_KN7l8s-GiEe_zHg4kpKiNA_9_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">27794879</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_LSD9XTMC0UeFs6h2fxmqSA_10_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">12820004</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_f8PRN4bOQEq1TVW28idDqg_10_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">12924826</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_xMhvxMEDUEO8wo6ZQsuguA_11_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">38959327</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_pGJtHV0nkEqwHH5u1WrX5w_11_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">40719705</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_7sRgXkQgIEiY-DGQ6POmjQ_12_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-29945783</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_GxfmTmGJk0G4hskYlsdnzw_12_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-39477995</us-gaap:OperatingIncomeLoss>
    <mrkr:GainLossRelatedToArbitrationSettlement
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_ONYkP2O8JEScZovhPJMH6g_14_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-232974</mrkr:GainLossRelatedToArbitrationSettlement>
    <mrkr:GainLossRelatedToArbitrationSettlement
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_r4EHnIC530eWA2C-h3RR6g_14_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-2406576</mrkr:GainLossRelatedToArbitrationSettlement>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_79P2CyClYEOE9MRDdcemPQ_15_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">248063</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_DNgnVajGdESELgmBVx1C9A_15_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5700</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_qhGaNOu3hUC5R2pa_IEsBw_16_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-29930694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_VbHrqOjASU69u6VIhUQ2QQ_16_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-41878871</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc__i6RQ9lDokSRMSIeQ9T7Sw_18_3"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-3.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc__i6RQ9lDokSRMSIeQ9T7Sw_18_3_2"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-3.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_jpTbFpUnDk6Xqg0ytWcKFg_18_6"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-5.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_jpTbFpUnDk6Xqg0ytWcKFg_18_6_2"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-5.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_d7SlRN9xHUmMwzo1jqp3fw_19_3"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8351003</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_d7SlRN9xHUmMwzo1jqp3fw_19_3_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8351003</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_L6gUbFUN5U-TBEO_0rQ8oQ_19_6"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">7650567</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_L6gUbFUN5U-TBEO_0rQ8oQ_19_6_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">7650567</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw"
      decimals="INF"
      id="Tc_UP9bcCKRckO6PJ8oR6R1uw_4_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">5073107</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw"
      decimals="0"
      id="Tc_L5Oq6udTLEmFXZQ8t7936A_4_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5073</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GInYc9c9Y0moOPtffvDIDg"
      decimals="0"
      id="Tc_vFod39OTHk-N7c6pNmCIkA_4_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">383578984</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1uzjGStWO06DZSlcFGbVsQ"
      decimals="0"
      id="Tc_8A9we4_Vk02VHIO0lSN5lA_4_11"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-356239484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ"
      decimals="0"
      id="Tc_gybZ2MTXbkS0l1bdg3VT7w_4_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">27344573</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_1QaTEkpr70OvfxhPLVzyXw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA"
      decimals="INF"
      id="Tc_KQnLALai-Ua4xxcOa5zQRA_5_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">3228286</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA"
      decimals="0"
      id="Tc_SW4_pm7l7kmV_uzeW_p1KA_5_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3228</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A"
      decimals="0"
      id="Tc_lDlY4YnEcUaLNoDRsejVcg_5_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">52549530</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_10HLp0gIZEa49Eqmbpi7iA_5_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">52552758</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA"
      decimals="INF"
      id="Tc_hXGUFF0r00Wa_OL48gW92Q_6_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">146</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A"
      decimals="0"
      id="Tc_c-gbtV8bJEi2mov7QfnccQ_6_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3087</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_BFGCRw33UEqqNi48k3h-0w_6_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3087</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA"
      decimals="INF"
      id="Tc_w2EE5AvVZUKTFMHl7rVDZg_7_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">6329</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wDRpfrEGPEiEanuGlDjxYA"
      decimals="0"
      id="Tc_nMaadIwQHketZUm9yvSBxQ_7_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">7</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TDrXVCxhZkqK7vEEgvKO5A"
      decimals="0"
      id="Tc_GMTTQvn_g0yPiH3nKnzeEQ_7_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5964041</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_cghhNscaFECSk_qw0YodXw_7_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5964048</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JKGI8Nx-2kSnc6KA5Cd6jw"
      decimals="0"
      id="Tc_6CP7eb5l3Ua3gtn2usjxPQ_8_11"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-41878871</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_2746Qgj98UC-kVFfmmgfYQ_8_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-41878871</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_npaXz9T0mUaUNEGeD_jgZQ"
      decimals="INF"
      id="Tc_TvhH98vDyE-Ljf0142tntw_9_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8307868</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_npaXz9T0mUaUNEGeD_jgZQ"
      decimals="0"
      id="Tc_Tb5Pa5A73UCF2fSTaZjehA_9_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">8308</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FBFeOkr3ykuSOy5dBngOrw"
      decimals="0"
      id="Tc_KLcylN5MSEC3euojKJtekw_9_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">442095642</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_egIQ7QghbkGRIjamiNWiUw"
      decimals="0"
      id="Tc_K0TdCeJkaECHMKeJ_z1Xkw_9_11"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-398118355</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_MGIbDphM1EOu0SxCRzqyrA_9_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">43985595</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw"
      decimals="INF"
      id="Tc_EO9qZ0nJIEWmZp7xoYVFkQ_10_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">60651</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw"
      decimals="0"
      id="Tc_NpLMVJ3fo0-7VEUoHDoVAg_10_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">61</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F6wReus0oEaCdo351uy7TQ"
      decimals="0"
      id="Tc_lnlfQBUNf0-tQVL-oMK6jA_10_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">202069</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_mfxrzIJQ_0acxNe6KQgLVQ_10_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">202130</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw"
      decimals="INF"
      id="Tc_bmKrV_jpz0iqyX9pufhMQg_11_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">37252</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L1b-4KSdHkmIer9YFj7icw"
      decimals="0"
      id="Tc_hXhGojwxNEiJ8CTPgzqIsA_11_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">37</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F6wReus0oEaCdo351uy7TQ"
      decimals="0"
      id="Tc_4qIgBAwn90eLriwS_AisMQ_11_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5343969</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_-W9ob6WgGk2EUtbFAVnOVw_11_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5344006</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6tRxU7Rie0-8urQAVoZMJA"
      decimals="0"
      id="Tc_zBKNwq7sMkCCauOnKuCAqA_12_11"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-29930694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_RHX4marRw0-qkGTw3q8NIg_12_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-29930694</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8cq4aMH20Sb7VO8y3pJew"
      decimals="INF"
      id="Tc_sVOT8J58bk6UMis3FwAD2w_13_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8405771</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a8cq4aMH20Sb7VO8y3pJew"
      decimals="0"
      id="Tc_R7iDenIBJEGk7dnJKkip6Q_13_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">8406</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GdnjYANna0qQFgzGMImcPA"
      decimals="0"
      id="Tc_cc2_NaqzZUabGkqYsbmHOg_13_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">447641680</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OmkYNaQrdkaCT93Kx5jgTQ"
      decimals="0"
      id="Tc_F7ZdSgzgV06LQ8oSWhFRCQ_13_11"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-428049049</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_UNt27J9cRUGfgEpUkC_Mzw_13_14"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">19601037</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_rgJh_kKMxEaDAsiAPqhgHg_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-29930694</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_AdSdIAPjQE2oluwve11kmw_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-41878871</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_KMdR4S4nnUy8nfMSja1BBw_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2789106</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_vvR73w37FUuzzUSoZe0LlA_7_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2148983</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_uPvFfNSna0Wc6F4z98Phgw_8_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5344006</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_PY6EBVHTK0OSNG75ApL6pA_8_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5964048</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_kytWNTduPEmYZ2Cja0fxhA_9_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">891343</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_MZtJiHIQgE6SYxMMC7Vz-Q_9_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1013655</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_iXuURBcui0qNjKMC1nSRGw_10_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-25995</us-gaap:GainLossOnDispositionOfAssets1>
    <mrkr:GainLossOnTerminationOfLeases
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_v6sUMIiF4ESOI4oCNfiWmA_11_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">278681</mrkr:GainLossOnTerminationOfLeases>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_QLLmSsGTgEeUgKBzVD4YSw_13_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-49555</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_XR0JqMO8_UO2Wz-IUJ1wQg_13_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">426710</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_v-dA5RowUE-qFbtoEScCfg_14_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2401767</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_7aoanspHsUeUgHwqIP7uwQ_14_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-1000322</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_f5I-d_mHgUagS7JhzjF3oA_15_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-4300939</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_vkp4HsL10EuLHDozRaGLtg_15_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">4141414</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_K-vNBW-Rj0Of27JlEESvkg_16_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2500000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_Tf3FFk-sv0WB5S7FWPf_qg_17_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-1146186</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_vDLYgE3BDEKQ2VyI3tG9Ow_17_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1146186</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_JlmvyHRkH0ixD8Ic5CY87A_18_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-513891</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_h2uoUVlUqUSqMW-gcodehg_18_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-388792</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_Q_gGHWjrnUeVik_tJtxbIw_19_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-26972153</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_lmDl9xaN10WyWLCHHhlMkg_19_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-27279765</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_spaTzjB4U02Lcyo0rTbGWQ_21_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1456006</mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress>
    <mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_0EV5cskT9UC1gTXAK9dZGA_21_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1572161</mrkr:PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress>
    <mrkr:PaymentsForConstructionInProgress
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_x45qB9MEz0qHgIsnh_W0HQ_22_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3489130</mrkr:PaymentsForConstructionInProgress>
    <mrkr:PaymentsForConstructionInProgress
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_pNDUq_7LVUOqNINS-Add0w_22_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1558970</mrkr:PaymentsForConstructionInProgress>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_J2sxfX1OBkSWnIB03nwcqQ_23_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-4945136</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_DReSYn4SrEW5mo7jzpToHg_23_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-3131131</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_QZlGm6vhQUKcGqzUfK-6kg_25_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">202130</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_6sUnj_o_aUGU1z2ch21ZkQ_25_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">52552758</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_QXluQXJ0Pkm9iRkbZM_0TQ_26_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3087</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_rsf6DLTzlUSVP3cth0HGDw_27_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">202130</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_DCYjHRJMcke9kIBC-VzDNw_27_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">52555845</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_L7ttRYROlkq1zTb-dO589w_28_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-31715159</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_jKhj1J3peEWPZPtrWO5pSQ_28_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">22144949</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_0LCsgk4TdkGmE3lnEBGKHQ_30_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">43497331</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ"
      decimals="0"
      id="Tc_2NXcbYdiSUmPqYz517jXwA_30_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">21352382</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_v4940jblpEu6m4eVZxOUVg_31_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11782172</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_C-DWSigp_UKDyw2DC9eH_w_31_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">43497331</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mrkr:ReclassificationsBetweenConstructionInProgressAndFixedAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_Thg7qtVf80-0sGbnS6womg_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">4089135</mrkr:ReclassificationsBetweenConstructionInProgressAndFixedAssets>
    <mrkr:ReclassificationsBetweenConstructionInProgressAndFixedAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_nh7JJOX2VE2HUyMxo2ySGg_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">6789098</mrkr:ReclassificationsBetweenConstructionInProgressAndFixedAssets>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_iPlBVByt90mMOV9sXfLIhg_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">57607</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_sNbDQwz8aUenTPhCba9gSQ_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2160765</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <mrkr:ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_DlyPFQE1R0WXvu2W_y9fIQ_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3459332</mrkr:ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_4T5M1tzjCEayxr7VJLXF0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;1:&#160;&#160;&#160;&#160;NATURE OF OPERATIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Marker Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d; or &#x201c;we&#x201d;), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company&#x2019;s multiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Reverse Stock Split &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the &#x201c;Reverse Stock Split&#x201d;) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $394.80.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="Duration_1_26_2023_To_1_26_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oBMB2ozYCUm78jnnAf9ERw"
      id="Narr_AoljI3aQwkitl6lLNyq-GQ">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_XPzhwj-erUqIBzQu-ulhQA"
      decimals="INF"
      id="Narr_zjftec4MZk6fVKN3ECRMng"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6ka_iEmMjE2aQAOD6iwO8w"
      decimals="INF"
      id="Narr_r2roha5t-02BcAE5rNC0Gg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">30000000</us-gaap:CommonStockSharesAuthorized>
    <mrkr:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="Duration_1_26_2023_To_1_26_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oBMB2ozYCUm78jnnAf9ERw"
      decimals="INF"
      id="Narr_sxz13EUnh0mj6hS3h6exQA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">394.80</mrkr:StockIssuedDuringPeriodValueReverseStockSplits>
    <mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_If7zR55fVkqay0LafHbZww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;2:&#160;&#160;&#160;&#160;FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;As of December 31, 2022, the Company had cash and cash equivalents of approximately &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$11.8&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million. The Company&#x2019;s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing; successfully progress its product candidates through preclinical and clinical development; obtain regulatory approval of one or more of its product candidates; maintain and enforce intellectual property rights; develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 16, 2021, the Company issued an aggregate of 3,228,286 shares of its common stock, for net proceeds of $52.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company entered into a Controlled Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and RBC Capital Markets, LLC (the &#x201c;Sales Agents&#x201d;), pursuant to which the Company can offer and sell, from time to time at its sole discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. Any shares of its common stock sold will be issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-258687), which the SEC declared effective on August 19, 2021; however, our use of the shelf registration statement on Form S-3 will be limited for so long as we are subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement and in accordance with the ATM agreement. The Sales Agents will be entitled to compensation under the Sales Agreement at a commission rate equal to 3.0% of the gross sales price per share sold under the ATM Agreement, and the Company has provided each of the Sales Agents with indemnification and contribution rights. During the year ended December 31, 2022, the Company sold 60,651 shares of its common stock under the ATM Agreement for net proceeds of $0.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (&#x201c;CPRIT&#x201d;) to support the Company&#x2019;s Phase 2 clinical trial of MT-401. The CPRIT award is intended to support the adjuvant arm of the Company&#x2019;s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group. Through &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the date of this filing, the Company has received $4.8 million of funds from the CPRIT grant. The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On April 21, 2022, the Company entered into a binding services agreement (the &#x201c;Services Agreement&#x201d;), dated April 12, 2022 (see Note 9), with Wilson Wolf Manufacturing Corporation (&#x201c;Wilson Wolf&#x201d;). Mr. John Wilson is a member of the Company&#x2019;s board of directors and is serving as the CEO of Wilson Wolf, therefore Wilson Wolf is a related party. Pursuant to the Services Agreement, Wilson Wolf made a cash payment to the Company in the amount of $8.0 million. For the year ending December 31, 2022, the Company recognized $5.5 million of revenue pursuant to this agreement and at December 31, 2022, the Company recorded $2.5 million of related party deferred revenue on its consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 13, 2022, the Company received notice from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) that it had awarded the Company a $2.0 million grant from the FDA&#x2019;s Orphan Products Grant program to support the Company&#x2019;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 12, 2022, the Company entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, the Company has the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of its common stock, or the Purchase Shares, from time to time over a 24-month term. &#160;For the year ended December 31, 2022, the Company did not sell any shares of its common stock under the Purchase Agreement. In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical trials. Further, the Company&#x2019;s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from sales of its product candidates, if approved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Based on the Company&#x2019;s clinical and research and development plans and its timing expectations related to the progress of its programs, the Company expects that its cash and cash equivalents as of December 31, 2022 will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2023, as such these factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern. In an effort to further preserve the Company&#x2019;s working capital, the Company&#x2019;s employees took a portion of their 2022 earned bonus in the form of equity in lieu of cash.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company has based this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it currently expects. Furthermore, the Company&#x2019;s operating plan may change, and it may need additional funds sooner than planned in order to meet operational needs and capital requirements for product development and commercialization. Because of the numerous risks and uncertainties associated with the development and commercialization of the Company&#x2019;s product candidates and the extent to which the Company may enter into additional collaborations with third parties to participate in their development and commercialization, the Company is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical trials. The Company&#x2019;s future funding requirements will depend on many factors, as it:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;initiates or continues clinical trials of its product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;continues the research and development of its product candidates and seeks to discover additional product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;seeks regulatory approvals for any product candidates that successfully complete clinical trials;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;maintains and enforces intellectual property rights;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;establishes sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any product candidates that may receive regulatory approval;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;evaluates strategic transactions the Company may undertake; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;enhances operational, financial and information management systems and hires additional personnel, including personnel to support development of product candidates and, if a product candidate is approved, commercialization efforts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These factors raise substantial doubt regarding the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the foregoing, based on the Company&#x2019;s current assessment, the Company does not expect any material impact on its long-term liquidity due to the COVID-19 pandemic. However, the Company will continue to assess the effect of the pandemic on its operations, including its clinical programs. Further, the COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company&#x2019;s ability to access capital, which could in the future negatively affect the Company&#x2019;s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company&#x2019;s business and the value of its common stock.&lt;/p&gt;</mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_za1K5f3hWUSAzJCpWmc2rA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q"
      decimals="INF"
      id="Narr_adx4CFnqxU6SYkOKLmDceQ"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">3228286</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q"
      decimals="-5"
      id="Narr_Pr0mByl5DkuhLF8EijC7jw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">52600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="As_Of_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_w84Uaz3YUEqYjRHmFPZttg"
      decimals="-5"
      id="Narr_zjmh9NvLgEy-sdWoNTLJew"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">75000000.0</us-gaap:CommonStockSharesSubscriptions>
    <mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_CounterpartyNameAxis_mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_rJJmBdCj7EOIPmbz9BOYyA"
      decimals="3"
      id="Narr_k0xvi144xUCWUTP9RxnGUA"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.030</mrkr:CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_lYIjNL0t2E6NNbd5622y6g"
      decimals="INF"
      id="Narr_OMgfhKOxckWXpFwb886a5Q"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">60651</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_mrkr_ControlledEquityOfferingSalesAgreementMember_lYIjNL0t2E6NNbd5622y6g"
      decimals="-5"
      id="Narr_cZwc-amSXkmF-e0Rd8WY8w"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">200000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg"
      decimals="-5"
      id="Narr_iewYsd6wm0K0YLTqDI6Kiw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">13100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <mrkr:FundsReceivedFromCpritGrant
      contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg"
      decimals="-5"
      id="Narr_96wVo77OWESvGNrfvqMcbA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">4800000</mrkr:FundsReceivedFromCpritGrant>
    <mrkr:RevenueFromGrantRelatedToCprit
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_mvgJ5tx5vkSEXbUgBkEPkw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3400000</mrkr:RevenueFromGrantRelatedToCprit>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_21_2021_To_4_21_2021_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_ZclhqIbMvU-O8EfMWIhhgw"
      decimals="-5"
      id="Narr_JBQ93hcCd0OBNk9JIDfEOg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">8000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_73WDhaJFhk26kf_aw8N7qA"
      decimals="-5"
      id="Narr_qVkxuA7bRUuCIbd6E6g6Dg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_elmgfz9S-0W_ZDXK3WDiaw"
      decimals="-5"
      id="Narr_jvK2hKLrE02S2gdgz9-tRg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2500000</us-gaap:DeferredRevenueCurrent>
    <mrkr:GrantReceived
      contextRef="Duration_9_13_2022_To_9_13_2022_w0iIOXYe5U2sofHNZfyE-w"
      decimals="-5"
      id="Narr_iXwzi2c1CUqMvektrDAohA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2000000.0</mrkr:GrantReceived>
    <mrkr:RevenueFromOrphanProductsGrantProgram
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_ysRKcykIA0mS9Gy7cqQLxA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:RevenueFromOrphanProductsGrantProgram>
    <mrkr:OrphanProductsGrantProgram
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_e3Wm0xdNgkmKtMhyCB01cQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:OrphanProductsGrantProgram>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA"
      decimals="-5"
      id="Narr_Wh3beEigoUy-Yo58AVbUmA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:FundsReceivedFromGrant>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="Duration_12_12_2022_To_12_12_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kp85NnJBBUmUhXIRR_MpQA"
      decimals="0"
      id="Narr_yRdoLLSyJUmg_ROIoE9hGQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">25000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HZfAycR2kk-ZXkhm82bVPA"
      decimals="INF"
      id="Narr_K0HORXOPlkO5wXCERj2rgA"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">180410</us-gaap:StockIssuedDuringPeriodSharesOther>
    <mrkr:CommitmentFee
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_sdKnf_W3b06nZ9jMBEsNJA"
      decimals="-5"
      id="Narr_nWSkzyLONka1z1s353JMNA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">500000</mrkr:CommitmentFee>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_KBJ7F-iRBUO-1NOxC8RyMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;3:&#160;&#160;&#160;&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#x2019;s estimates and assumptions include measurement of fair value and projections used in impairment testing, valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents, Restricted Cash and Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash, cash equivalents and restricted cash at December&#160;31, 2022 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of December&#160;31, 2022, approximately $1.8 million in cash was uninsured based upon the FDIC insurance coverage limits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,782,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,351,145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,146,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash shown in statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,782,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,497,331&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash received from grants in advance of incurring qualifying costs are recorded as restricted cash until they are earned and recorded to grant income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment - Construction in Progress&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility&#x2019;s construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the third and fourth quarters of 2021, and in connection with the Company&#x2019;s manufacturing facility in Houston, Texas, the Company incurred $2.2 million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. &#160;Such costs were recorded in fixed assets &#x2013; construction in progress on the balance sheet as of December 31, 2021. The Company incurred another $1.9 million in related costs in 2022. Upon completion and installation of the second modular cleanroom in 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and are being amortized over the estimated useful life.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment Testing of Long-Lived Assets and Right-Of-Use Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management reviews long-lived assets (including property and equipment) and right-of-use assets for assets under operating leases for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Recoverability of assets is determined by first grouping the long-lived assets at the lowest level for which there are identifiable cash flows, and then comparing the carrying value of each asset group to its forecasted undiscounted cash flows. If the evaluation of the forecasted cash flows indicates that the carrying value of the assets is not recoverable, an impairment charge is recognized for the amount in excess of the carrying amount over its fair value. The Company performed a test for recoverability related to its manufacturing facility in Houston, Texas at December 31, 2022 and concluded that the carrying value of its long-lived assets was recoverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patents and Patent Application Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#160;&#x2014; The expected life of stock options was estimated using the &#x201c;simplified method,&#x201d; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#160;&#x2014; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#160;&#x2014; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt;&#160;&#x2014; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2022 and 2021, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support its Phase 2 clinical trial of MT-401. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASC 730-20-25-8, to the extent the financial risk associated with the research and development has been transferred to CPRIT, because repayment of the grant depends solely on the results of research and development having future economic benefit, the Company accounts for this obligation as a contract to perform research and development for others.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. During the fourth quarter of 2021, the Company received $2.4 million advancement of funds in relation to the CPRIT grant. The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. In January 2023, the Company received $2.4 million from CPRIT.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#x2019;s Orphan Products Grant program to support the Company&#x2019;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New Accounting Standards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_-tM5d5mogUW4ewbebF6AoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the Securities Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these footnotes to applicable guidance is meant to refer to the authoritative U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_T3J4S7plQEaeqJjm6jKPBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Marker Cell Therapy,&#160;Inc. and GeneMax Pharmaceuticals&#160;Inc.&#160;&#x2013; a dormant subsidiary that wholly owns GeneMax Pharmaceuticals Canada,&#160;Inc. All significant intercompany balances and transactions are eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_qIMXAJwRK0CoRC1HuU3p6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management&#x2019;s estimates and assumptions include measurement of fair value and projections used in impairment testing, valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_BwcK-1tmK0e5N7e-Gz7wrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents, Restricted Cash and Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers highly liquid investments with a maturity of three&#160;months or less when purchased to be cash equivalents. Cash, cash equivalents and restricted cash at December&#160;31, 2022 consisted of cash and certificates of deposit in institutions in the United States. Balances at certain institutions have exceeded Federal Deposit Insurance Corporation insured limits and U.S. government agency securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash in accounts which are in excess of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insured limits of $250,000. As of December&#160;31, 2022, approximately $1.8 million in cash was uninsured based upon the FDIC insurance coverage limits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,782,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,351,145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,146,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash shown in statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,782,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,497,331&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash received from grants in advance of incurring qualifying costs are recorded as restricted cash until they are earned and recorded to grant income.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Narr_OIoveDCmG0CEbCCCoiTU6g"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_aCMS5WCJZEO9u9uCrQJxzA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1800000</us-gaap:CashUninsuredAmount>
    <mrkr:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_2f-JwdkCQkKFHb4FHCUSAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,782,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,351,145&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,146,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash shown in statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,782,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,497,331&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_3f5XT_IrVUuBGA5OhQOB_A_4_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11782172</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_vKGhIk4ZBEaZsWba6lFe-A_4_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">42351145</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_BLzETWsGMky_8bBXN1kpyA_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1146186</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_My68kHpY9UmZhiNWfjapbA_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11782172</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_-LM_LL39vUyRT7gF3ORcJw_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">43497331</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mrkr:RetainexistingpolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_61rQuslGjUWTcQ5ZgvUzGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leasehold improvements, furniture, equipment and software are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, which range from&#160;three&#160;to&#160;five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life or the remaining lease term.&lt;/p&gt;</mrkr:RetainexistingpolicyPolicyTextBlock>
    <mrkr:PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_fSTHtuXVjEuRwGCvNqzNag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment - Construction in Progress&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. In connection with the manufacturing facility, the Company has incurred costs pursuant to an agreement with a vendor to design, engineer, build and install modular cleanrooms in a manufacturing facility. The facility&#x2019;s construction was completed during December 2020, and a certificate of occupancy was delivered to the Company in January 2021, and as such was placed into service in January 2021. All costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the third and fourth quarters of 2021, and in connection with the Company&#x2019;s manufacturing facility in Houston, Texas, the Company incurred $2.2 million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. &#160;Such costs were recorded in fixed assets &#x2013; construction in progress on the balance sheet as of December 31, 2021. The Company incurred another $1.9 million in related costs in 2022. Upon completion and installation of the second modular cleanroom in 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and are being amortized over the estimated useful life.&lt;/p&gt;</mrkr:PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2021_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_McFGqwTRbE2KSZ_az8T4DQ"
      decimals="-5"
      id="Narr_Omzcuefpvkmi3iDpwJLpDQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2200000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_de53l1GX8kGkNWjZK3KpnA"
      decimals="-5"
      id="Narr_EcxpT3nhHEqtGe_y4wLx-w"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1900000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_RhacUHDsyE-Wo0TCoadpFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment Testing of Long-Lived Assets and Right-Of-Use Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management reviews long-lived assets (including property and equipment) and right-of-use assets for assets under operating leases for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Recoverability of assets is determined by first grouping the long-lived assets at the lowest level for which there are identifiable cash flows, and then comparing the carrying value of each asset group to its forecasted undiscounted cash flows. If the evaluation of the forecasted cash flows indicates that the carrying value of the assets is not recoverable, an impairment charge is recognized for the amount in excess of the carrying amount over its fair value. The Company performed a test for recoverability related to its manufacturing facility in Houston, Texas at December 31, 2022 and concluded that the carrying value of its long-lived assets was recoverable.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_m1mIR_JMBEuLQhmDncQZfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patents and Patent Application Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_nReB4zIj9EKn5cp0kSY6kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs stock-based compensation expense related to the issuance of common stock and stock options. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#160;&#x2014; The expected life of stock options was estimated using the &#x201c;simplified method,&#x201d; as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock options grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&lt;/i&gt;&#160;&#x2014; The Company computes stock price volatility over expected terms based on its historical common stock trading prices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#160;&#x2014; The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend&lt;/i&gt;&#160;&#x2014; The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company amortizes the fair value of the awards expected to vest on a straight-line basis over the requisite service period of the awards. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received as if the Company had paid cash for those services. Forfeitures are accounted for as incurred.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_tXBvZMwyukGa7lv9fmhdRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from its external service providers. The Company estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each project and total project spending. The Company adjusts its accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_zIzUPXyvRUyX02lwhiutmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax balances. Potential deferred tax assets and liabilities are measured using enacted tax rates expected to apply to the taxable income in the&#160;years in which those differences are expected to be recovered or settled. The effect on potential deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the date of allowances against deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50&#160;percent likely to be realized upon settlement. A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. As of December&#160;31, 2022 and 2021, no liability for unrecognized tax benefits was required to be reported. The guidance also discusses the classification of related interest and penalties on income taxes. The Company&#x2019;s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the&#160;years ended December&#160;31, 2022 and 2021.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <mrkr:GrantIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_yJvLk0wTCU2HALpN7fFCig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Grant Income represents funding under cost reimbursement programs from government agencies and non-profit foundations for qualified research and development activities performed by the Company. In applying the provisions of ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes the award upon achievement of certain milestones as credits to research and development expenses. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support its Phase 2 clinical trial of MT-401. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with ASC 730-20-25-8, to the extent the financial risk associated with the research and development has been transferred to CPRIT, because repayment of the grant depends solely on the results of research and development having future economic benefit, the Company accounts for this obligation as a contract to perform research and development for others.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. During the fourth quarter of 2021, the Company received $2.4 million advancement of funds in relation to the CPRIT grant. The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. In January 2023, the Company received $2.4 million from CPRIT.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#x2019;s Orphan Products Grant program to support the Company&#x2019;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.&lt;/p&gt;</mrkr:GrantIncomePolicyPolicyTextBlock>
    <mrkr:ReceiptOfProductDevelopmentResearchAward
      contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg"
      decimals="-5"
      id="Narr_BhcjPKfbJEy8faYGaV6MSw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">13100000</mrkr:ReceiptOfProductDevelopmentResearchAward>
    <mrkr:FundsReceivedFromCpritGrant
      contextRef="Duration_10_1_2021_To_12_31_2021_JT2ojtlpfUiPgirbtHOffA"
      decimals="-5"
      id="Narr_qUCOCHwjHkOdffnOcucoqQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2400000</mrkr:FundsReceivedFromCpritGrant>
    <mrkr:RevenueFromGrantRelatedToCprit
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_sNtoYsh6TE2LDI7r1dbgKw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3400000</mrkr:RevenueFromGrantRelatedToCprit>
    <mrkr:GrantIncomeReceivable
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_mIAFSVmGWECPm0EZad_GQw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2300000</mrkr:GrantIncomeReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_1_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_us-gaap_SubsequentEventMember_Yue1bky0HUK0DiPiPA1ZmA"
      decimals="-5"
      id="Narr_n2OEN6pBxkS1R5aNYYqPJw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2400000</us-gaap:OtherReceivablesNetCurrent>
    <mrkr:AmountOfAwardGrantFromOrphanProductGrantProgram
      contextRef="As_Of_9_13_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_UoBREzfn7kO2CeAdFJzHPQ"
      decimals="-5"
      id="Narr_3HqC_MGcQE2XidEU4K5DVA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2000000.0</mrkr:AmountOfAwardGrantFromOrphanProductGrantProgram>
    <mrkr:RevenueFromOrphanProductsGrantProgram
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_YLDDX2yeLUe07sOnnOZXqA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:RevenueFromOrphanProductsGrantProgram>
    <mrkr:OrphanProductsGrantProgram
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_cPYTm5HWXUy8AOV6ep5vCg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:OrphanProductsGrantProgram>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA"
      decimals="-5"
      id="Narr_6jVBjGjUrUudS6bZlk_C7w"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:FundsReceivedFromGrant>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_hLDoAUpVtUmRPaP8J1FjEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per share includes only the weighted average common shares outstanding, without consideration of potentially dilutive securities. Diluted loss per share includes the weighted average common shares outstanding and any potentially dilutive common stock equivalent shares in the calculation.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_-WPQSkzrC0qmR8aOmtsYFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New Accounting Standards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on its financial position or results of operations upon adoption.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_NlI_rrXrCkWSdi8cy_jNIA"
      id="Tb_MSY84QZV5EqtfcfdD6Z9rw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;4:&#160;&#160;&#160;&#160;NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth the computation of net loss per share for the&#160;years ended December&#160;31, 2022 and 2021, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,930,694)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,878,871)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Weighted average common shares outstanding &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,351,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,650,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.58)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.47)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 886,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 768,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,848,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,983,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,734,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,751,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_Gd2_3o4EA06XXDBsTHii4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,930,694)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,878,871)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Weighted average common shares outstanding &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,351,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,650,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.58)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.47)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_bfAkQcf5jk2uRggyVohDdQ_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-29930694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_oKmvOXj3g0-JaJWhfFPjEQ_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-41878871</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_d7Ks34oFsEiIE4QJcxgLfg_8_3"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8351003</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_d7Ks34oFsEiIE4QJcxgLfg_8_3_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">8351003</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_f-yG7u6IW0yho1AVJSPgfw_8_6"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">7650567</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_f-yG7u6IW0yho1AVJSPgfw_8_6_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">7650567</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_ODP8WAUjKk-wDiNMAoKvNg_11_3"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-3.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_ODP8WAUjKk-wDiNMAoKvNg_11_3_2"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-3.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_sn2jKTNEQU-hBrQOHGH9nA_11_6"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-5.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_sn2jKTNEQU-hBrQOHGH9nA_11_6_2"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">-5.47</us-gaap:EarningsPerShareBasic>
    <mrkr:NetLossPerShareTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_jPgVjEk62E-PVocTBTC02g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 886,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 768,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock purchase warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,848,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,983,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Potentially dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,734,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,751,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:NetLossPerShareTableTextBlock>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bQJrMgrRIEih2ZZ5LZh_Nw"
      decimals="0"
      id="Tc_G_5lS-7g7UamAq0mM0SR1w_4_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">886000</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_RBkehlwI7UK7Hw7PXAvVhw"
      decimals="0"
      id="Tc_fyNFe5Afdk6iBONoeDLqbQ_4_4"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">768600</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OtJ-a1ZIt0GTo1DBVaijBA"
      decimals="0"
      id="Tc_zqfzNu85R0ayB6CBhrzLRQ_5_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">1848000</mrkr:CommonStockWarrantsEquityTreatment>
    <mrkr:CommonStockWarrantsEquityTreatment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DbSC03W-N0uqTlyKBJ9KHw"
      decimals="0"
      id="Tc_Kyz_p51w60eZGPZLSAB_gg_5_4"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">1983000</mrkr:CommonStockWarrantsEquityTreatment>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_9Gr2_70yEEiU7Nmz36IHoQ_6_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">2734000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_Tc6PFRGjfEawXNl4_TfVfA_6_4"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">2751600</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_uhranP8CXkGY9xcYxJ7fCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5:&#160;&#160;&#160;&#160;&#160;OTHER RECEIVABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. &#160;The Company recorded $3.4 million of grant income related to the CPRIT grant as revenue for the year ended December 31, 2022. &#160;At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. &#160;The Company received $2.4 million of funds from CPRIT in January 2023. The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022. &#160;Additionally, at December 31, 2022, the Company recorded $0.1 million of grant income receivable, which represented grant income earned in advance of funds to be received from the FDA. &#160;The Company received $0.1 million of funds from the FDA in January 2023.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:TenantImprovements
      contextRef="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_EA2qnlAMxUapgXjRK0-39A"
      decimals="-5"
      id="Narr_c31lzAkADEenFiaoSJMxjA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3400000</us-gaap:TenantImprovements>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_EA2qnlAMxUapgXjRK0-39A"
      decimals="-5"
      id="Narr_eyiDqC77akec4-jQdlOUPQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2300000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_1_31_2023_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_us-gaap_SubsequentEventMember_Yue1bky0HUK0DiPiPA1ZmA"
      decimals="-5"
      id="Narr_vJR-jBcUbEWJiKDYd9wNBQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2400000</us-gaap:OtherReceivablesNetCurrent>
    <mrkr:RevenueFromOrphanProductsGrantProgram
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_uKca2-qpDkmMDXTB7Zftug"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:RevenueFromOrphanProductsGrantProgram>
    <mrkr:OrphanProductsGrantProgram
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_eRoRrR9V_ECJjIbzxS8png"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:OrphanProductsGrantProgram>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_7NoYkmU3T0yNAjX5qvt6FA"
      decimals="-5"
      id="Narr_dUKTwPy4pU-3Zn3PMk7U5w"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:FundsReceivedFromGrant>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_59rskAXKoU-88lslqXSGJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;6:&#160;&#160;&#160;&#160;PROPERTY AND EQUIPMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Property and equipment consist of the following as of December&#160;31, 2022 and 2021, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab and manufacturing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,824,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,851,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3-5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 899,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,020,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 924,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 793,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease term or estimated useful life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,950,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,173,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Total   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,597,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,837,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,274,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,740,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,226,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fixed assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,323,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,323,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense for the years ended December 31, 2022 and 2021 was approximately $2.8 million and $2.1 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Company entered into a lease for a manufacturing facility in Houston, Texas. The Company incurred costs pursuant to an agreement with a vendor to design, engineer, build and eventually install modular cleanrooms in the manufacturing facility. $6.8 million was recorded in fixed assets &#x2013; construction in progress on the balance sheet as of December 31, 2020. &#160;The completion of the facility&#x2019;s construction occurred during December 2020 and the Company received its certificate of occupancy in January 2021, and as such was placed into service in January 2021. &#160;During January 2021, all costs associated with the buildout were recorded as either manufacturing equipment and/or leasehold improvements and amortized over the estimated useful life of the asset and/or leasehold lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;During the year ended December 31, 2021, and in connection with the opening of the Company&#x2019;s manufacturing facility in Houston, Texas, the Company incurred $2.2&lt;span style="white-space:pre-wrap;"&gt; million of costs pursuant to an agreement with a vendor to build and eventually install a second modular cleanroom. Such costs were recorded in fixed assets &#x2013; construction in progress on the balance sheet as of December 31, 2021.  The Company incurred another &lt;/span&gt;$1.9 million in related costs in 2022. Upon completion and installation of the second modular cleanroom during the year ended December 31, 2022, all costs associated with the buildout were recorded as manufacturing equipment and leasehold improvements and amortized over the estimated useful life.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_pCSuOI9k1E6DkhgOVOULQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Lives&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab and manufacturing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,824,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,851,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3-5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 899,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,020,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5 Years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 924,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 793,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease term or estimated useful life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,950,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,173,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Total   &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,597,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,837,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,274,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,740,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,226,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total fixed assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,323,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,323,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_NXup2CJ02USDTLUpDls9hQ"
      id="Tc_DQoXgrsxSkWyJZjN0mRTMw_3_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_mMYtiCFfIEK_bdrpJ5dMRw"
      decimals="0"
      id="Tc_h72kvHWnZkapZymwzho81w_3_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11824000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_kiI02v_yr0miZEzODZfWew"
      decimals="0"
      id="Tc_XOt4yHoAU0mT0iaL60eIFA_3_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">7851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_sQrTMozyWEyU4ra-AUAZ2g"
      id="Narr_K1eTHRN70kuQ_jgvi6sRJw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_McT4zbJriU6hB34bDlJjeg"
      id="Narr_HrnwrlMAek-k5tLs3uzfAA">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_qtmbiBYUXEGhAeHMenyf7A"
      decimals="0"
      id="Tc_46mnqiZ9uU2QCCuOFo0ZFg_4_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">899000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mrkr_ComputerEquipmentAndSoftwareMember_zKhfppn7GEWXbnJMKir-Sw"
      decimals="0"
      id="Tc_sAFIms-rGEKz4iHYJXN-ww_4_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1020000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_eEnb8GgPoU6evepNcjl2rA"
      id="Tc_COGC_ScHaUS0LXUpu1GCJw_5_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_iRDTtaZteEiLcISmCUciWA"
      decimals="0"
      id="Tc_n2n8UYbdmEmu0XzseeM8KA_5_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">924000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_VtFCZtpzqUS4hInYPoLNNg"
      decimals="0"
      id="Tc_pAqF7ilxvEiguk3QsSTn_g_5_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">793000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TLp-qtPIB02goeZcg_RReg"
      decimals="0"
      id="Tc_uJjrTr6RyUaiD9NsB3pXWQ_6_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3950000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_nqoFwEJHwUmDvKu-C4t_AA"
      decimals="0"
      id="Tc_EKjOEhviSkWClWVsLuEb2Q_6_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3173000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_6fKAYWiPjki8uExYlWogVw_7_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">17597000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_S2RodgUUaUybrTBRnCcbfQ_7_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">12837000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_-3mcQrrNGUCA_ASeyBubXw_8_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5274000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_sejtpVHQrE6RAqUFC7LjWQ_8_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2740000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <mrkr:ConstructionInProgress
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_DcbXqshSOk2CSIbKyQQSEA_9_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</mrkr:ConstructionInProgress>
    <mrkr:ConstructionInProgress
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_KU7altJc4kKszc1cXoTJSA_9_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2226000</mrkr:ConstructionInProgress>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_aa968u4Rq0KYb1MNIrfUPA_10_5"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">12323000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_31hNP2VdikOzPrnfgTqlEQ_10_8"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">12323000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_pcCn28iij0iHebIp-Rp1xA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="-5"
      id="Narr_xjCffoZE_Eqsjlx7CaQXxQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2100000</us-gaap:Depreciation>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2020_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_yhp5Hv7lwkaZQV2FAXpIpA"
      decimals="-5"
      id="Narr_DNX92NxhHEuRKEEpLNborQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">6800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="As_Of_12_31_2021_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_ManufacturingFacilityInHoustonTexasMember_McFGqwTRbE2KSZ_az8T4DQ"
      decimals="-5"
      id="Narr_m5SnTAQDDUabmkSwj_0PpA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2200000</us-gaap:ConstructionInProgressGross>
    <us-gaap:RecapitalizationCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_6JMY_sNmHUOzogwEx8rU2g"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1900000</us-gaap:RecapitalizationCosts>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_oQ3UdMDSvEKASfAZR2p5Eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE 7: LEASES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases manufacturing, research and administrative facilities under operating leases. The Company evaluates its contracts to determine if an arrangement is a lease at inception and classify it as a finance or operating lease. Currently, all of the Company&#x2019;s leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term. The lease terms may include options to extend when it is reasonably certain that the Company will exercise that option. The Company did not consider that option in calculating right-of-use assets and lease liability as the Company is not reasonably certain it will extend the contract beyond the current terms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Topic ASC 842 requires the Company to recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. Right-of-use assets are recorded in non-current assets on the Company&#x2019;s consolidated balance sheets. Current and non-current lease liabilities are recorded within current liabilities and non-current liabilities, respectively, on its consolidated balance sheets. Costs associated with operating leases are recognized on a straight-line basis within operating expenses over the term of the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of September 15, 2022, the Company and its landlord agreed to terminate the Company&#x2019;s office lease at 3200 Southwest Freeway, Suite 2500, Houston, Texas. &#160;As such the Company reduced its operating lease liabilities by $3.7 million and reduced its right-of-use &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;assets by $3.5 million. &#160;A gain on lease termination was recorded in general and administrative expenses during the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had total operating lease liabilities of approximately $7.6 million and right-of-use assets of approximately $5.5 million, which were included in the consolidated balance sheet. &#160;As of December 31, 2021, the Company had total operating lease liabilities of approximately $11.9 million and right-of-use assets of approximately $9.8 million, which were included in the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Such leases do not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. &#160;Certain of the Company&#x2019;s leases include renewal options and escalation clauses; renewal options have not been included in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. &#160;Variable expenses generally represent the Company&#x2019;s share of the landlord&#x2019;s operating expenses. &#160;The Company does not act as a lessor or have any leases classified as financing leases. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following summarizes quantitative information about the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense summary:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,483,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,702,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 606,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,179,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,308,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,106,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,077,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average remaining lease term as of December 31, 2022 and December 31, 2021 was approximately 7.5 years and 8.4 years, respectively. The weighted-average discount rate used to determine the operating lease liability as of December 31, 2022 and December 31, 2021 was approximately 5.5% and 5.7%, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Maturities of the Company&#x2019;s operating leases, excluding short-term leases, are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 983,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,254,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,290,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,177,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,163,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,590,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,457,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,840,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,617,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <mrkr:DecreaseInOperatingLeaseLiabilitiesForLeaseTermination
      contextRef="As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw"
      decimals="-5"
      id="Narr_6X00vPFojUmXWiPZArevdg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3700000</mrkr:DecreaseInOperatingLeaseLiabilitiesForLeaseTermination>
    <mrkr:DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination
      contextRef="As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw"
      decimals="-5"
      id="Narr_WES-ZHIsrUaEjoV4GVz1-A"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3500000</mrkr:DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_FsCUnVBQ7kCLmkxkShP6Qg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">7600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_R3uaOue70kKoqx-neNH4IA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_G0fHUGPwd0-v8P3F2TFETw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">11900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_Nc2BwqzdekOxW6_OsIfdPg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">9800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_z96kKyR--U6zNNbd430vVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense summary:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,483,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,702,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 648,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 606,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,179,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,308,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating cash flows - operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,106,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,077,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc__3A1alEmPka25fytDU_rGw_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1483000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_ycISG-JbN025-HWeIMMV5g_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1702000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_o7pIoETYP0yuPrHCxxjKdQ_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">48000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_Nzy032NkXUaOGfcwOTH_JQ_8_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">648000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_hbGlhGz3WEiXIujXtQ8AAQ_8_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">606000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_Lb50_-tLrESw0Tjrsh2AYA_9_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2179000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_x6U5ZkabnkCXLjdpErMQYg_9_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2308000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_b1kJDvNqmUOfzYnOX7BmYw_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1106000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_JgcUTQbPzUCTHOToBlvmPg_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1077000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      id="Narr_SHnLbYiO7EW4ykTO2XBoHw">P7Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      id="Narr_SbWd8Q4U5kG4_BfQn6wVKg">P8Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="3"
      id="Narr_aPqRJxoOU0WlQL1t_gMaYw"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="3"
      id="Narr_xZI8pGiedUuaO-zoxOf6FA"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_Pv-zabLa-kitKHPidkDnig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 983,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,254,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,290,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,177,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,163,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,590,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,457,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,840,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,617,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_zzc_enpKnkCi0GQgN3EQzA_1_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">983000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_1c6HqTlS002O5FdZqDlo8g_2_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1254000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_OecLkEOqZUikHXvS8mBO9w_3_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_bNp20kX_7UCJ4vww9u1bVA_4_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1177000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_MUK08kLIlUOed8Wc5NVJtw_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_mf1QknWmEUm5AN6iF3kUgQ_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3590000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_telgvYB5PkaakJLOo4fODA_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">9457000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_dn9KiZ-7zkaEe8m-mvAaVg_8_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1840000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_UG0NSdiBJUi5DxZXRV4_8g_9_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">7617000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_saTJ1doSBECFk3uMIPZ42A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;8: &#160;&#160;&#160;&#160;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accounts payable and accrued liabilities consist of the following as of December&#160;31, 2022 and 2021, respectively:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,612,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,144,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,779,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,055,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Process development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 342,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 558,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 644,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Technology license fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Arbitration settlement fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,407,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_FuIPzOWfjEuw7JcSqUHBnw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 4,705,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_b9x6r4ODwECU40jh-cbSzg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 11,135,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In August 2022, the Company implemented changes to the Company&#x2019;s organizational structure as part of an operational cost reduction plan to conserve the Company&#x2019;s available capital. &#160;In connection with these changes, the Company reduced headcount in its general and administrative function by approximately 23.5%, including the separation of the Company&#x2019;s Chief Financial Officer. &#160;For the year ended December 31, 2022, the Company recorded $0.3 million of accrued compensation and benefits for severance expenses related to the operational cost reduction plan.&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_X_eo7x0YtECvaCWmoRonWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,612,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,144,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,779,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,055,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Process development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 342,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 558,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 644,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Technology license fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Arbitration settlement fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,407,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_FuIPzOWfjEuw7JcSqUHBnw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 4,705,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_b9x6r4ODwECU40jh-cbSzg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 11,135,000&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_RrvCCq8FKkaG8kp6Vz1iKg_3_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1612000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_Lvj4pGD0X06DescuQl0mgQ_3_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5144000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_oYG4_Z_veE-McXSOvfyBag_4_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1779000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_aOHpFCeL30Oxe28boD3UiQ_4_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2055000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrkr:AccruedProcessDevelopmentExpensesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_E_GNGFqnyEqdr33a5UpytA_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">342000</mrkr:AccruedProcessDevelopmentExpensesCurrent>
    <mrkr:AccruedProcessDevelopmentExpensesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_UpCY2fjMuUy6LUDWGY1SvA_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">385000</mrkr:AccruedProcessDevelopmentExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_nG6YlEZwnkGv-aUww8u7dw_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">558000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_f0f-UXoh-0iQwXPGuKShdA_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">644000</us-gaap:AccruedProfessionalFeesCurrent>
    <mrkr:AccruedTechnologyLicenseFees
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_dE_wKqzr9UaVRMzKMzC8FQ_7_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">250000</mrkr:AccruedTechnologyLicenseFees>
    <mrkr:ArbitrationSettlementLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_jyQ4H7vVw0iVFqsiWBk1fg_8_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">114000</mrkr:ArbitrationSettlementLiabilitiesCurrent>
    <mrkr:ArbitrationSettlementLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_kdQtHZbYs0q_AzlwwvHOeA_8_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2407000</mrkr:ArbitrationSettlementLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_TIhem8Y84ke2Skg5SNZ41w_9_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_4NOPPuFuOEiCoqjnZaTZNA_9_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">250000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_QveB1kU3tkucob1EUaCgcw"
      decimals="3"
      id="Narr_Xm80aktwgk6GMT2oy8v3vw"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.235</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RestructuringPlanAxis_mrkr_OperationalCostReductionPlanMember_sD7iYvHxZkqwyKox7Z0qJg"
      decimals="-5"
      id="Narr_GHf5e5TaQEutbEzff-b_Lg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrkr:RelatedPartyLiabilityDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_kvmrjyVzrkGsup2W9Cc3LA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE 9:&#160;&#160;&#160;&#160;RELATED PARTY DEFERRED REVENUE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;On April 21, 2022, the Company entered into the Services Agreement, dated April 12, 2022, with Wilson Wolf. Mr. John Wilson is a member of the Company&#x2019;s board of directors and is serving as the CEO of Wilson Wolf. Wilson Wolf is in the business of creating products and services intended to simplify and expedite the transition of cell therapies and gene-modified cell therapies to mainstream society (the &#x201c;Wilson Wolf Mission&#x201d;). Pursuant to the Services Agreement, Wilson Wolf made a cash payment to the Company in the amount of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$8.0&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million, as consideration for certain training and research services allocated as follows:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million for non-exclusive training of Wilson Wolf to make, use, and sell the Company&#x2019;s cell culture non-proprietary media formulation that has been cleared in an FDA investigational new drug application;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million for non-exclusive training of Wilson Wolf to replicate the Company&#x2019;s quality management system inclusive of all underlying documents related thereto, none of which shall include unique information specific to the manufacture of the Company&#x2019;s multiTAA product candidates such as direct peptide stimulation;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million for non-exclusive training of Wilson Wolf to be able to replicate the Company&#x2019;s cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process which Wilson Wolf shall use as it sees fit in pursuit of the Wilson Wolf Mission; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million for the Company to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes using G-Rex and to conduct CAR T and TCR G-Rex Optimization Work under the direction of Wilson Wolf (the &#x201c;Work Direction&#x201d;), whereunder all intellectual property provided by Wilson Wolf or created or derived by the Company will be solely owned by Wilson Wolf, and whereby the Company will make good faith efforts to complete the conduct of such work as soon as practicable within &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;18 months&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; from the date of the agreement. Wilson Wolf has agreed to pay the Company an additional &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million if the Work Direction is completed within one year from the onset of the Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Pursuant to the Services Agreement, in the event that the Company becomes insolvent, goes out of business, or an event other than force majeure occurs that cannot allow the Agreement to be fulfilled, Wilson Wolf will have right of first offer and right of first refusal for the Company&#x2019;s manufacturing facility provided it is able and willing to meet whatever financial obligations are required to do so and provided further that such clause will not apply in the event of a merger, reorganization or consolidation of the Company with a third party that results in the outstanding voting securities of the Company immediately prior thereto ceasing to represent, or being converted into or exchanged for voting securities that do not represent, at least fifty percent (50%) of the combined voting power of the voting securities of the surviving entity or the parent corporation of the surviving entity immediately after such merger, reorganization or &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;consolidation, or the sale or other transfer of all or substantially all of the Company&#x2019;s business or assets. The Company agrees to assist as needed to the extent permitted under any applicable law (including bankruptcy or insolvency statutes). Further, prior to the Company undertaking any financing that would encumber any of the Company&#x2019;s assets necessary for the Company&#x2019;s performance under this Services Agreement, Wilson Wolf shall have the first right to provide such financing on equal terms to what the Company can obtain elsewhere.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company recognizes related party revenue over time in accordance with Accounting Standard Codification, or ASC, 606 Revenue from Contracts with Customers, as each of the training or and research services are provided to Wilson Wolf. Revenue is recognized, using an output method based on progress toward satisfaction of the performance obligations. &#160;Additionally, in accordance the spirit of the standard expressed in ASC 606-50-1, the timing of the revenue recognition is expected to be approximately 12 months. For the year ending December 31, 2022, the Company recognized $5.5 million of revenue pursuant to the Services Agreement and at December 31, 2022, the Company recorded an $2.5 million related party deferred revenue on its consolidated balance sheet.&lt;/p&gt;</mrkr:RelatedPartyLiabilityDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA"
      decimals="-5"
      id="Narr_AodkKj2lwUG7itscgcVPRw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">8000000.0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation
      contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA"
      decimals="-5"
      id="Narr_YoUpaVTqR0Kf8hYWtYOlIw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2000000.0</mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation>
    <mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments
      contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA"
      decimals="-5"
      id="Narr_RQYnvYUN4kuoWMy9M8FbfQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1000000.0</mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments>
    <mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess
      contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA"
      decimals="-5"
      id="Narr_2oDNCZol7Eqebkb_Cmv-Gg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2000000.0</mrkr:RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess>
    <mrkr:RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses
      contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA"
      decimals="-5"
      id="Narr_7bsZIHesg0y95zIj3_laaQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3000000.0</mrkr:RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses>
    <mrkr:PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate
      contextRef="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA"
      id="Narr_IgTiSwH5oUGeKRoWuDM09w">P18M</mrkr:PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate>
    <mrkr:AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement
      contextRef="As_Of_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_Y7pK7_4md0GHmMKXJsNddA"
      decimals="-5"
      id="Narr_-_Jg3-I7OEGGy-VzrcxazA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1000000.0</mrkr:AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement>
    <mrkr:ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered
      contextRef="Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA"
      decimals="2"
      id="Narr_y2MK1lfwLEyhnXODZeayJQ"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.50</mrkr:ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_73WDhaJFhk26kf_aw8N7qA"
      decimals="-5"
      id="Narr__tLPhLK7MUG07WPL5mJR-A"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_elmgfz9S-0W_ZDXK3WDiaw"
      decimals="-5"
      id="Narr_lGYnV_V6IkOrVKmxfdPi-w"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2500000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_JefRFPJJV02WL_WbGSZqZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;10:&#160;&#160;&#160;&#160;STOCKHOLDERS&#x2019; EQUITY&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Increase in Authorized Shares&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the three months ended June 30, 2022, the Company&#x2019;s board of directors and stockholders approved a Certificate of Amendment (the &#x201c;Amendment&#x201d;) to the Company&#x2019;s Certificate of Incorporation to increase the authorized shares of common stock of the Company from 15,000,000 shares to 30,000,000 shares. The Company filed the Amendment with the Secretary of State of Delaware on May 25, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 26, 2023, the Company effected the Reverse Stock Split and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2023, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All historical share and per share amounts reflected in this report have been adjusted to reflect the Reverse Stock Split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has authorized up to 5,000,000 shares of preferred stock, $0.001 par value per share, for issuance. The preferred stock will have such rights, privileges and restrictions, including voting rights, dividend conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company&#x2019;s board of directors upon its issuance. To date, the Company has not issued any preferred shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has authorized up to 30,000,000 shares of common stock, $0.001 par value per share, for issuance. Significant 2022 and 2021 common stock transactions were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;2022 Common Stock Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Issuance of Restricted Stock Units to Executives&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2022, upon the recommendation of the compensation committee of the Company&#x2019;s board of directors, &#160;and pursuant to the Company&#x2019;s 2020 Equity Incentive Plan, the Company&#x2019;s board of directors approved the issuance of a total of 37,252 shares of common stock, valued at a total of approximately $180,200, subject to restricted stock units, which were immediately vested upon grant, to certain executives as performance bonuses for performance during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Issuance of Stock Pursuant to ATM Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2022, the Company issued and sold 60,651 shares of its common stock under the ATM Agreement for net proceeds of $202,100.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Purchase Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 12, 2022, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions of the agreement, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over a 24-month term , at a variable price with certain market-based terms as defined in the agreement. The purchase agreement does not exhibit any of the characteristics for liability classification under ASC Topic 480, Distinguishing Liabilities from Equity. Instead, the purchase agreement is indexed to the Company&#x2019;s own stock under ASC Subtopic 815-40, Contracts in Entity's Own Equity, and classified as equity. &#160;During the year ended December 31, 2022, we did not sell any shares of our stock under the Purchase Agreement. &#160;In January 2023, Lincoln Park was issued 180,410 shares of stock as a commitment fee at a value of $0.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;2021 Common Stock Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Exercise of Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;During the year ended December 31, 2021, certain outstanding options were exercised for &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;146&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; shares of common stock providing aggregate proceeds to the Company of approximately &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$3,100&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Board Compensation &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021, the Company issued an aggregate of 6,329&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;shares of common stock to its non-employee directors. The fair value of the common stock of approximately &lt;b style="font-weight:bold;"&gt; &lt;/b&gt;$0.2&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;million was recognized as a component of stock-based compensation expense in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Underwritten Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On March 11, 2021, the Company entered into an underwriting agreement with Piper Sandler &amp;amp; Co., as representative of the several underwriters, to issue and sell 2,857,200 shares of common stock of the Company in an underwritten public offering. &#160;The offering price to the public was $17.50 per share. &#160;In addition, the Company granted the underwriters an option to purchase, for a period of 30 days, up to an additional 428,580 shares of common stock, which such option was partially exercised with respect to 371,086 shares. &#160;An aggregate of 3,228,286 shares of the Company&#x2019;s common stock was issued for net proceeds of $52.6 million after offering costs of $3.9 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_MinimumMember_PZ0RPJnwKk65BP6T537-EQ"
      decimals="INF"
      id="Narr_DmJElRXukUq9G95Yj26vqA"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_srt_RangeAxis_srt_MaximumMember_dikyAbnEbkGQJoXUA7yMkg"
      decimals="INF"
      id="Narr_uYFDbrNZyEOeX1Gvij1o-Q"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_XPzhwj-erUqIBzQu-ulhQA"
      decimals="INF"
      id="Narr_OKfa6hh_K0mAeYTgr7DO1A"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_1_26_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6ka_iEmMjE2aQAOD6iwO8w"
      decimals="INF"
      id="Narr_yykCW6wuM0m85j9PJwEY5g"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="INF"
      id="Narr_4dlY8sZRkEmvuKN9syh0Lg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="INF"
      id="Narr_XT5pyDnUa0OEkcQxRbxGrQ"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="INF"
      id="Narr_4c2tYDJ28Eahi3odtR6KlA"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="INF"
      id="Narr_UfC8hCwhCEWHETjYruP9gQ"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="INF"
      id="Narr_4IrbszxQxkuMDMEM_xtEWQ"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="INF"
      id="Narr_tSE8T9TMTEukQjxbOYmP7Q"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw"
      decimals="INF"
      id="Narr_rYx1qhT1B0-34GBZN7r13Q"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">37252</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw"
      decimals="0"
      id="Narr_vldb4ZC_nUu16SCvfhK35Q"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">180200</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_VP3-b6HOUk2DKLQ51VCCBQ"
      decimals="INF"
      id="Narr_b47EUxOqQkG5JLgxl6BWwg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">60651</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_mrkr_AtmAgreementMember_VP3-b6HOUk2DKLQ51VCCBQ"
      decimals="0"
      id="Narr_crxhsI3OpUy7qvZz_mpL0A"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">202100</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_DRQziVPupkyucYZQUxu7CQ"
      decimals="0"
      id="Narr_xwrHYjKoYUqSJUse6K5S9A"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">25000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_j-Tt7k3AAEelDRzuTV__kA"
      decimals="INF"
      id="Narr_lq8vjkWfs0OqfuYMC-WdLA"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">180410</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_j-Tt7k3AAEelDRzuTV__kA"
      decimals="-5"
      id="Narr_IfBfi75br02XwAoC4DRryQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_EhfaszvU3UinGypAqqyo6Q"
      decimals="INF"
      id="Narr_dIHkZMN7YkOBb_4RVXZZog"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">146</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_mrkr_ExerciseOfStockWarrantsMember_jSWMIRhbp0WIJO4zq_1XRQ"
      decimals="0"
      id="Narr_A7IQdFXv90eonu_bN0b2Rw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3100</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_5W-EffSPAk-sIjPcaw3pDA"
      decimals="INF"
      id="Narr_53-0NA49zUijJRenB69lbw"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">6329</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_mrkr_BoardCompensationMember_meicGgKvzUadt_zzSUx2eg"
      decimals="-5"
      id="Narr_jzD5K48aOEikeB-zXVKnxg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <mrkr:NumberOfSharesAuthorizedToIssueAndSell
      contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA"
      decimals="INF"
      id="Narr_KU8joAt520OfZog5_q93hw"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">2857200</mrkr:NumberOfSharesAuthorizedToIssueAndSell>
    <us-gaap:SharePrice
      contextRef="As_Of_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_S5Q4yNrC5UKGn_ImsQmXDA"
      decimals="2"
      id="Narr_ClN1gpLBSEOo1Rqqzu-SWQ"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">17.50</us-gaap:SharePrice>
    <mrkr:UnderwritingOptionPeriod
      contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA"
      id="Narr_X1XX7klzGkmk52wOjCa19Q">P30D</mrkr:UnderwritingOptionPeriod>
    <mrkr:NumberOfAdditionalSharesAuthorizedToIssueAndSell
      contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA"
      decimals="INF"
      id="Narr_jhTWdGDFHUSNRtGYtMbfsQ"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">428580</mrkr:NumberOfAdditionalSharesAuthorizedToIssueAndSell>
    <mrkr:StockIssuedDuringPeriodAdditionalSharesNewIssues
      contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA"
      decimals="INF"
      id="Narr_jArzvHw94kmnPhD_hU9zMA"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">371086</mrkr:StockIssuedDuringPeriodAdditionalSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA"
      decimals="INF"
      id="Narr_-R-FXgqsHkmEZgBWQWcxEw"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">3228286</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_11_2021_To_3_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_9DUjbaW65kqEQvYRM5sTxA"
      decimals="-5"
      id="Narr_Nc7XqqoKC0OUzqdiSmZqWA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">52600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mrkr:OfferingCost
      contextRef="Duration_3_11_2021_To_3_11_2021_ipD27hsbDkSP-aqaxEKH-A"
      decimals="-5"
      id="Narr_34pKU8fc10aGPYeE_GCAnA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3900000</mrkr:OfferingCost>
    <mrkr:WarrantsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_Az_DSC2ltEmqAoq9W4Et9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;11:&#160;&#160;&#160;&#160;WARRANTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share Purchase Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of the Company&#x2019;s share purchase warrants as of December&#160;31, 2022 and 2021, respectively, and changes during the period is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&#160;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,083,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (100,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,983,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (135,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,848,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:WarrantsDisclosureTextBlock>
    <mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_RYoECPvlqUm2SecYEAk3nw"
      id="Tb_egDTOiqGBk2nu_4nn2xLLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&#160;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,083,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (100,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,983,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (135,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,848,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ"
      decimals="0"
      id="Tc_Nr80ab6FKUKMRQpsEEvBPw_4_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">2083000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash
      contextRef="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg"
      decimals="2"
      id="Tc_ryHFRZjkvEmdWt2z-i1tUA_4_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">47.00</mrkr:ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg"
      id="Tc_yLUUEbXgMkq_IJiYrwo3Lw_4_7">P2Y7M6D</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife>
    <mrkr:NumberOfWarrantExpiredOrCancelled
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_vlLi9F3b7Ueddg7opqTutw_5_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">100000</mrkr:NumberOfWarrantExpiredOrCancelled>
    <mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_u1eSuB1zZkKY7l650rBTDQ_5_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">55.00</mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="0"
      id="Tc_9_HdjffZXUmwiiw623gwhQ_6_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">1983000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="2"
      id="Tc_9c2ncfX-nUKDgJq2YVeuBg_6_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">44.20</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      id="Tc_4zpv9RWCcES2hS5SnKOpfQ_6_7">P1Y8M12D</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife>
    <mrkr:NumberOfWarrantExpiredOrCancelled
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_hBQNx-viUkCu8dwbkH9-jw_7_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">135000</mrkr:NumberOfWarrantExpiredOrCancelled>
    <mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_N_jF_zx0p0KXnBrEPDveoA_7_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">39.70</mrkr:ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_Ky5TVjkGd0-fVEokayX0ow_8_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">1848000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="2"
      id="Tc_CXSILqCoakO_SCt47IwHdg_8_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">44.51</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice>
    <mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_RCTeCg9z60-k75yOVG06mA_8_7">P0Y9M14D</mrkr:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_U_pp5lBWRkm0F30Cjit4zw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;12:&#160;&#160;&#160;&#160;STOCK OPTION PLANS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Options to Purchase Shares of Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 19, 2020, the Board adopted the 2020 Equity Incentive Plan ("2020 Plan") which replaced the 2014 Omnibus Stock Option Plan. The 2020 Plan was further amended effective May 2022 to increase the number of shares of common stock authorized for issuance under the plan by 850,000 shares. The 2020 Plan allows for grants of stock options, restricted shares, stock bonuses and other equity-based awards to employees and non-employee directors of the Company. Awards under the 2020 Plan may be at prices and for terms as determined by the Company&#x2019;s board of directors and may have vesting requirements as determined by the Board, provided that the exercise price for any stock option must be at least equal to the fair market value (as defined in the 2020 Plan) of a share of the stock on the grant date. Once granted, the exercise price of an option may not be reduced without the approval of the Company&#x2019;s stockholders, other than under certain limited circumstances such as a stock split or take any other action with respect to a stock option that would be treated as a repricing under the rules and regulations of the Nasdaq Stock Exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Options granted under the 2020 Plan have a maximum term of ten years from the date of grant and generally vest over four years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;2022 Equity Incentive Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 17, 2022, pursuant to the Company&#x2019;s 2020 Equity Incentive Plan, the compensation committee of the Company&#x2019;s board of directors approved a total of 125,000 options to purchase the Company&#x2019;s common stock as equity-based incentive awards to the Company&#x2019;s executive officers. &#160;Each option award was granted with an exercise price of $4.60 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on February 17, 2022, with the option award vesting in 48 equal monthly installments over a four-year period, subject to such executive officer&#x2019;s continued service on the applicable vesting date. &#160;Additionally, on February 17, 2022, the compensation committee of the Company&#x2019;s board of directors approved a total of 39,500 options to purchase the Company&#x2019;s common stock to non-executive employees of the Company as equity-based incentive awards. &#160;Each option award was granted with an exercise price of $4.60 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on February 17, 2022, with the option award vesting in 48 equal monthly installments over a four-year period, subject to such employee&#x2019;s continued service on the applicable vesting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The above awards were in addition to 17,500 stock option awards issued during the three months ended March 31, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $10.00 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on January 3, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#x2019;s continued service on the applicable vesting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;21,000 stock option awards were issued during the three months ended June 30, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $4.30 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on April 1, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#x2019;s continued service on the applicable vesting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;10,000 stock option awards were issued during the three months ended September 30, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $3.50 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on July 1, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#x2019;s continued service on the applicable vesting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, 7,000 stock option awards were issued during the three months ended December 31, 2022 to new employees upon their commencement of employment with the Company. Each option award was granted with an exercise price of $3.73 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on October 3, 2022, with 25% of the option award vesting in one year and the remaining 75% vesting in 36 equal monthly installments thereafter over a three-year period, subject to such employee&#x2019;s continued service on the applicable vesting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Also, pursuant to the Company&#x2019;s Non-Employee Director Compensation Policy, which had previously been approved by the Company&#x2019;s board of directors, 40,000 stock option awards were issued during the year ended December 31, 2022 to independent members of the board of directors of the Company. &#160;Each option award was granted on May 24, 2022 with an exercise price of $3.377 per share, the closing price of the Company&#x2019;s common stock on the Nasdaq Global Market on May 24, 2022. &#160;Each option award will vest in one year subject to the director&#x2019;s continuance of service through May 24, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, approximately 989,000 shares of common stock are available to be issued under the 2020 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of the Company&#x2019;s stock option activity is as follows for stock options:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 600,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,912)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 768,623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (142,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 886,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 560,929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Black-Scholes option pricing model is used to estimate the fair value of stock options granted under the Company&#x2019;s share-based compensation plans. The weighted average assumptions used in calculating the fair values of stock options that were granted during the&#160;years ended December&#160;31, 2022 and 2021, respectively, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth stock-based compensation expenses recorded during the respective periods:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,691,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,856,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,653,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,108,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,964,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At December&#160;31, 2022, the total stock-based compensation cost related to unvested awards not yet recognized was $3.5 million. The expected weighted average period compensation costs to be recognized was 1.8&#160;years. Future option grants will impact the compensation expense recognized.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued
      contextRef="As_Of_5_19_2020_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_WhoS9ltZXk6NBcS9AfdoJA"
      decimals="INF"
      id="Narr_C7OvFxnuiUeXWAuk5OTQfQ"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">850000</mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_s5BTwwK2kU2hdKZtXLGr8Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw"
      id="Narr_Obs6ffYSPEG9OQl0NaVGFw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_J2wzhp4PQ0yD55El3XelKg"
      decimals="INF"
      id="Narr_VBDMu2PnoE-HNovjlGHaGg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_yIinahL4sEGqxYXSIhjnhA"
      decimals="2"
      id="Narr_awS_0HJ98USTlVlLFhqf5g"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">4.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_J2wzhp4PQ0yD55El3XelKg"
      id="Narr_PxCwhWY6W0GyEewx5XR-Mg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g"
      decimals="INF"
      id="Narr_dWyn4xZK_0WCrGrgTFwZwg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">39500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_pVnVS7CZdEWMB5iww4KJeQ"
      decimals="2"
      id="Narr_0Z0DZvIy7EOuLc0sTXsuwA"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">4.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards
      contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g"
      decimals="INF"
      id="Narr_fCusP2-vLEi4iE-tXUoetg"
      unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw">48</mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_2_17_2022_To_2_17_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_nAKsp9oraUuoBi0fMJp11g"
      id="Narr_GYPWt3QyH0yquT6kaWu1dg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_3_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_kUuUrHRKk0G10jpx1s-bkQ"
      decimals="INF"
      id="Narr_pQQX4zpv7kODvWSe47i_fA"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">17500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_3_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_kUuUrHRKk0G10jpx1s-bkQ"
      decimals="2"
      id="Narr_R_iFXfO21Uup7tgX63gcUw"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">10.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2021_To_4_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_pGIzcYnvJEiT9dhMXsElQg"
      decimals="2"
      id="Narr_J-XRiU9SUkaB26rIyaNIUA"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_JbX3ZgrhrUCG3fxE5SiYMg"
      decimals="2"
      id="Narr_MJ6qOzFmsE-VhrVPkOAKLg"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards
      contextRef="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_mrkr_NonExecutiveEmployeesMember_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_UIJSoFc-BEakDbs6zOJBIQ"
      decimals="INF"
      id="Narr_Sr6W7oMyvk2OsfgIO4_xRQ"
      unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw">36</mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_3_2022_To_1_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_JbX3ZgrhrUCG3fxE5SiYMg"
      id="Narr_xLtPdlgOYkSYi0BCN_qnsw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_A-AeQilLX0WzYGhiZT07Jg"
      decimals="INF"
      id="Narr_8aO_TarmA0mxn0Lrwmcz9Q"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_6_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentiveAwards2021Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_F-6NSFyNk0uhy-tFDHx2jg"
      decimals="2"
      id="Narr_Zma4prJaY02DNiQ5HM1hLg"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">4.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_GhcbliHPX0GLe0R12grctQ"
      decimals="2"
      id="Narr_S6NOHXNsXUSNQFW6EdOo0A"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_uGqtaqdy20eQ6t52skgzRA"
      id="Narr_fl205L8hNkS_x7jEWWPYuQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mhcEIpDJQkmXGgO5cKQZuA"
      decimals="2"
      id="Narr_c7BCzwOzH0iNt-E3_W6aCw"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards
      contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_uGqtaqdy20eQ6t52skgzRA"
      decimals="INF"
      id="Narr_3znym03xz0el5qqJyfFshQ"
      unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw">36</mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_4_1_2022_To_4_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_mhcEIpDJQkmXGgO5cKQZuA"
      id="Narr_OzY-oCBA6Ue4-2xrCUPwJA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_U85KQ1vJe0u5uT4iGCYd1g"
      decimals="INF"
      id="Narr_znDXCWgDOUe7tOW-Hxx8hg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_U85KQ1vJe0u5uT4iGCYd1g"
      decimals="2"
      id="Narr_Okz6HFSxrUyriP9w46XNzA"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ltpSYmw2Ck-js4TXpUSbpQ"
      decimals="2"
      id="Narr_DYzItTPYZU2f8sC4g7DujA"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4Mlx9tG1EEGFYz6EXdp5Vg"
      id="Narr_rbVGxoOwzEqZ4G2zYLoXWg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_AxyTiy7MlUuwc7GAnr3jLA"
      decimals="2"
      id="Narr_ZbBdbGResUWdj3lIhzTvwQ"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards
      contextRef="Duration_7_1_2022_To_7_1_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_YqaWefj0tk20njxWAVYeyg"
      decimals="INF"
      id="Narr_po3bZ-SsbEWC1Hx_OVqTow"
      unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw">36</mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_AxyTiy7MlUuwc7GAnr3jLA"
      id="Narr_H3AiRWViAkOLRpD_YT_fRQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_ZEI3kl26Pk2zgb9tiZo19w"
      decimals="INF"
      id="Narr__9PChTPrNkOA6xd1WeZhgA"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3OQQVZE1uEm384QeLqzj-g"
      decimals="2"
      id="Narr_j8NQQY8ZwEOfmxGz-s_Mow"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_CgqUPlC4VU6qTAV9KfQcqw"
      decimals="2"
      id="Narr_L2Y_dqDekkesLxQOXjR4mA"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_JUDa3cw9BUK0ZTYPzI9s9g"
      id="Narr_biWOuLGwZ0GamUTjaxGsFQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OcBdsIpxMk6PRtghWozW-g"
      decimals="2"
      id="Narr_21nCZZj6CEyhwLEFyOc2pw"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards
      contextRef="Duration_10_3_2022_To_10_3_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_y6evzTYbj0ikSh5RHLTXHw"
      decimals="INF"
      id="Narr_dJXvwxwzVEiKr1iIuSJzUw"
      unitRef="Unit_Standard_installment_S0XA_gBc1US64U_DJTCszw">36</mrkr:NumberOfEqualMonthlyInstallmentsForVestingOfAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_OcBdsIpxMk6PRtghWozW-g"
      id="Narr_dPW1kXGprE-MevAHTKnpVw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_OptionIndexedToIssuersEquityTypeAxis_mrkr_NonEmployeeStockOptionMember_gbP12LhguU6WycZv51CdaQ"
      decimals="INF"
      id="Narr_wmA43AUzAUezWHScjqrwMg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_5_24_2022_To_5_24_2022_us-gaap_AwardTypeAxis_mrkr_EquityIncentivePlan2022Member_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ubwm1qD4wE-HsJvlsJGJpQ"
      decimals="3"
      id="Narr_3irMql8MTkqFfXZrRews4g"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">3.377</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_pGizx4L2jkuyni6fqTR9Hw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_xLzOljk2o0KBWMLiKybJag"
      decimals="INF"
      id="Narr_RW8olUvSI0ahQB6YUCcztg"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">989000</mrkr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_Tuvr34cA5ESb8TwOQc56hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total Intrinsic Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 600,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22,912)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 768,623&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Canceled/Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (142,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 886,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options vested and exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 560,929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ"
      decimals="INF"
      id="Tc_qSFLuT4F50KirWdEnXUJFg_5_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">600181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020__FyrqMoJgkm2Nk8dyxmMUQ"
      decimals="2"
      id="Tc_NDqiKTqFzkaHL2BrIpJ1JA_5_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">62.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_rbh7I3tPSkijbW8PJ1kqvg"
      id="Tc_KcBeu-qijkO3TDgQskZ0Ag_5_10">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="INF"
      id="Tc_pjoPOFVZ4kaleh1aYYhTrg_6_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">191500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_trE13r9x6Uml1bBE7OkBVg_6_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">28.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      id="Tc_Yykw1u5zSk-HcjXIKHuKTA_6_10">P8Y10M24D</mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="INF"
      id="Tc_htmDFFO5sUaIHYoiT1EARA_7_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">146</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_eNqBR5hKZESfQKB-K7QIOg_7_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">21.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="INF"
      id="Tc_LGt_4Llzjkied7fouUitDQ_8_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">22912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_3P476xPPRk63wmwA0eJWvQ_8_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">35.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="INF"
      id="Tc_PUIVgJw50USJgvR21QLDYQ_9_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">768623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="2"
      id="Tc_kRbRBf_vCkaSYwShzztMEw_9_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">54.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      id="Tc_RYrho01bzEuhZBla_3GcQg_9_10">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="INF"
      id="Tc_vXQ9h1Vxy0us_CQr60e6NQ_10_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_9rLDiPshYUKSFp8vU9HFSQ_10_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">4.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_olzjh_ml7UKB3mLFuQkm9Q_10_10">P7Y9M18D</mrkr:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="INF"
      id="Tc_X0IKIL87aki-xejikF0r1A_11_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">142450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_F5P7tW5Kl0-dxXke_fLglA_11_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">36.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="INF"
      id="Tc_tmOXODVhr0mI6-62YJL2sQ_12_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">886173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="2"
      id="Tc_5dw1v1mVgkmsg-bBlXo62Q_12_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">42.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_nTbCRRGurE2zXs_m13VRfQ_12_10">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="INF"
      id="Tc_4FRbV667JUqE8yu0x7hpug_13_2"
      unitRef="Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig">560929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="2"
      id="Tc_M2HGGhe6AEez_uAOVRBFGw_13_5"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">59.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_FNNr2XOdxUikibaStALbOw_13_10">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_V3awPmMKvE2Fnc3BDMIsQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate of interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="2"
      id="Tc_r2qUQxJW3EGLSjSt8YsLtA_4_3"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="2"
      id="Tc_gW89KH4-2UqTBX5YjVhZlw_4_6"
      unitRef="Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg">29.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tc_6GVzQm_y8kyXKHZvk3wuaQ_5_3">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      id="Tc_LAhlytXp3EGG-6MjH6UW3w_5_6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_8HYW8S1iVEayhXfqH9ONxQ_6_3"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_3W8bXC1IaEusJdKfKXcqEQ_6_6"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_Cqi4gfFNAEeAqHlsHX79NA_7_3"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_uqwZ10hDC0qIBvEUYzrjtQ_7_6"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="2"
      id="Tc_mAYnNXAqhES-CJluVGMhuQ_8_3"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="2"
      id="Tc_mMKGddrNqkifdOdQGcmQ2w_8_6"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <mrkr:StockBasedCompensationExpensesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_iUftVFiOrkenxUpmCMzfNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Compensation expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,691,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,856,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,653,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,108,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,964,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:StockBasedCompensationExpensesTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_NGUNmIMxGkq1Z8jXaWqHoA"
      decimals="0"
      id="Tc_0dNL2I2C9UCupNZGu6QzXQ_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_93kl4ltjMUiFOgjh_0uOaw"
      decimals="0"
      id="Tc_7sFEduXEtkCbX7_i8QSQPg_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2856000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_I0jHwwB580SqyJF3TUAQmw"
      decimals="0"
      id="Tc_Ero6_SQYZk6osZj7HbS7Ag_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_RbjncsNOXUKlnyjr3E54gw"
      decimals="0"
      id="Tc_ZKTbFUQAJEimAgpFZikByA_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_u9AzQlJDGkyHBApsisTK8A_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_b-RFG0x1UE6u215S9iMQ2A_7_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5964000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_rGiitZPzK0S7mVwkiRnSUw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_PsHUUuTAI0ilqV4ii3nqQw">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_4ApQ2KOHWEquq3qdBkICjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 13: GRANT INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In August 2021, the Company received notice of a Product Development Research award totaling approximately $13.1 million from CPRIT to support the Company&#x2019;s Phase 2 clinical trial of MT-401. The CPRIT award is intended to support the adjuvant arm of the Company&#x2019;s Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia following a hematopoietic stem cell transplant. The primary objectives of the adjuvant arm of the trial are to evaluate relapse-free survival after MT-401 treatment when compared with a randomized control group.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded &lt;span style="-sec-ix-hidden:Hidden_VRXEGsrXjkaiFVGne_HW4A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.4&lt;/span&gt;&lt;/span&gt; million and $1.2 million of grant income related to the CPRIT grant as revenue for the years ended December 31, 2022 and 2021, respectively. &#160;At December 31, 2022, the Company recorded $2.3 million of grant income receivable, which represented grant income earned in advance of the next tranche of funds to be received from CPRIT. &#160;In January 2023, the Company received $2.4 million from CPRIT.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 13, 2022, the Company received notice from the FDA that it had awarded the Company a $2.0 million grant from the FDA&#x2019;s Orphan Products Grant program to support the Company&#x2019;s Phase 2 clinical trial of MT-401 for the treatment of post-transplant AML. &#160;The Company recorded $0.1 million of grant income related to the FDA grant as revenue for the year ended December 31, 2022 and at December 31, 2022, the Company recorded $0.1 million of grant income receivable. On March 13, 2023, the Company received $0.1 million of funds from the FDA grant.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <mrkr:ReceiptOfProductDevelopmentResearchAward
      contextRef="Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg"
      decimals="-5"
      id="Narr_Sj7uaTRSUU2r00IJ-ZmaMg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">13100000</mrkr:ReceiptOfProductDevelopmentResearchAward>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_Z55ugQPT_kKUAhzu1ioV8A"
      decimals="-5"
      id="Narr_GfGkyIfJUE61y2F-qaThWQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <mrkr:GrantIncomeReceivable
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_Qpu6PQ5C4U20dmBViswShw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2300000</mrkr:GrantIncomeReceivable>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_1_1_2023_To_1_31_2023_d7Z-oISLakWWyRl9aSgT8Q"
      decimals="-5"
      id="Narr_0RO4AHaPX0S0Gul2cqAtzw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2400000</mrkr:FundsReceivedFromGrant>
    <us-gaap:GrantsReceivable
      contextRef="As_Of_9_13_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_UoBREzfn7kO2CeAdFJzHPQ"
      decimals="-5"
      id="Narr_dG-lFlFoYUmsD9kMYn1Bkw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2000000.0</us-gaap:GrantsReceivable>
    <mrkr:RevenueFromOrphanProductsGrantProgram
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_NZtpv8wwFkyPK5CZ6bkRmQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:RevenueFromOrphanProductsGrantProgram>
    <mrkr:OrphanProductsGrantProgram
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_4WKJOouRJU2PLbGMpZCndQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:OrphanProductsGrantProgram>
    <mrkr:FundsReceivedFromGrant
      contextRef="Duration_3_13_2023_To_3_13_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ppz0D3cJZki16-dpU4LhzA"
      decimals="-5"
      id="Narr_IFzO5iLAAUWKS40tDnKgbQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:FundsReceivedFromGrant>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_KTiGIZoWKUyhsbGBMWSBVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;14:&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company may be party to ordinary, routine litigation incidental to their business. Other than below, the Company knows of no material, active or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of the Company&#x2019;s directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to the Company&#x2019;s interest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;An arbitration proceeding was brought against the Company before the Financial Industry Regulatory Authority, Inc. (&#x201c;FINRA&#x201d;) by a broker seeking to be paid compensation for two financing transactions that occurred in 2018, a warrant conversion and a private placement brokered by another broker. The broker&#x2019;s claims were based on a placement agent agreement for a private placement it brokered in 2017, under which it alleged it was entitled to compensation for the 2018 transactions. The FINRA panel found in favor of the broker and awarded the broker $2.4 million for compensation, interest and attorney fees. As of December 31, 2021, the Company recorded an accrual of $2.4 million in accrued liabilities on its consolidated balance sheet and a $2.4 million charge to other expenses. On September 17, 2021, the broker filed a petition to confirm the FINRA arbitration award in the Supreme Court of New York for the County of New York. The Company removed the case to the United States District Court for the Southern District of New York on September 27, 2021. On October 22, 2021, the Company filed a motion in federal court to vacate the award.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On March 9, 2022, the Company was notified that its motion to vacate the award was denied and the broker was awarded an additional $0.1 million in interest. Post judgment interest accrued at 1.02% until the judgment was paid. &#160;On March 24, 2022, the Company paid the broker $2.5 million, which amount included accrued interest. On January 4, 2023, the Company was notified that the broker was awarded an additional $0.1 million in attorneys&#x2019; fees, which the Company recorded to other expenses during fiscal year ending December 31, 2022. &#160;The Company paid the $0.1 million on January 9, 2023.&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <mrkr:CompensationInterestAndAttorneyFees
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="-5"
      id="Narr_7VKdWJX5yUWfqgpRuhSObQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2400000</mrkr:CompensationInterestAndAttorneyFees>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_tcXtbo9uGkSsnWM9R7oDkQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2400000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="-5"
      id="Narr_YCdXUI-mUk25YYUl54zl9A"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2400000</us-gaap:OtherExpenses>
    <mrkr:LegalProceedingsBrokerAwardedAdditionalInterestAmount
      contextRef="Duration_3_9_2022_To_3_9_2022_mHWNE8BszkWyzvOf2FXUaw"
      decimals="-5"
      id="Narr_kHtR5sECzUm3Yyh62idz1A"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:LegalProceedingsBrokerAwardedAdditionalInterestAmount>
    <mrkr:PercentageOfAccrualOfPostJudgmentInterest
      contextRef="Duration_3_9_2022_To_3_9_2022_mHWNE8BszkWyzvOf2FXUaw"
      decimals="4"
      id="Narr_9PCmwysoek6TxHBIiaV1iQ"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.0102</mrkr:PercentageOfAccrualOfPostJudgmentInterest>
    <mrkr:BrokerWasAwardedAccruedInterest
      contextRef="Duration_3_24_2022_To_3_24_2022_IbGXbqvguEioxE6sArNnqQ"
      decimals="-5"
      id="Narr_XedqbhCyEk6fgx5gSLiZEg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2500000</mrkr:BrokerWasAwardedAccruedInterest>
    <mrkr:AdditionalAttorneyFeesAwarded
      contextRef="Duration_1_4_2023_To_1_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_uUaeHZ6WLE2MqQaG64NZzw"
      decimals="-5"
      id="Narr_mLYjkSNbqk-PtMSYZ7Yg9Q"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</mrkr:AdditionalAttorneyFeesAwarded>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tgbt7OSC3EulA327h83DEg"
      decimals="-5"
      id="Narr_k9cHjDWco0ay05dINlzZLA"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">100000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_sr6KH0nLYkKURj-H8NOxCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;15:&#160;&#160;&#160;&#160;RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table sets forth related party transaction expenses recorded for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,142,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,851,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Bio-Techne Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 306,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Wilson Wolf Manufacturing Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 265,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 280,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,508,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,437,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"&gt;$8,600 of related party transactions are included in accounts payable and accrued liabilities as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Agreements with The Baylor College of Medicine (&#x201c;BCM&#x201d;)&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160; 2018, January 2020 and February 2020, the Company entered in Sponsored Research Agreements with BCM, which provided for the conduct of research for the Company by credentialed personnel at BCM&#x2019;s Center for Cell and Gene Therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2019, May 2020 and July 2021, the Company entered into Clinical Supply Agreements with BCM, which provided for BCM to provide to the Company multi tumor antigen specific products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In October 2019, the Company entered in a Workforce Grant Agreement with BCM, which provided for BCM to provide to the Company manpower costs of projects for manufacturing, quality control testing and validation run activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Company entered in a Clinical Trial Agreement with BCM, which provided for BCM to provide to the Company investigator-initiated research studies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Purchases from Bio-Techne Corporation&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is currently utilizing Bio-Techne Corporation and two of its brands for the purchases of reagents, primarily cytokines. Mr. David Eansor is a member of the Company&#x2019;s board of directors and was serving as the President of the Protein Sciences Segment of Bio-Techne Corporation. Mr. Eansor resigned from Bio-Techne Corporation on March 1, 2022, and as such, two months of transactions in 2022 are included in the table above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Purchases from Wilson Wolf&lt;/i&gt;&lt;i style="font-style:italic;"&gt;.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is currently utilizing Wilson Wolf for the purchases of cell culture devices called G-Rexes. &#160;Mr. John Wilson is a member of the Company&#x2019;s board of directors and is serving as the CEO of Wilson Wolf Manufacturing Corporation.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_GkU9aKqiKEu8Zelg-vYtcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Baylor College of Medicine&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,142,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,851,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Bio-Techne Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 306,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Wilson Wolf Manufacturing Corporation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 265,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 280,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,508,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,437,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_BMzNUjdDhUG_b5P76LRATw"
      decimals="0"
      id="Tc_CGxQOTIfp0itzuoogcD3QQ_4_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1142000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember_awMWjIqo90CWdC9K0cfcDg"
      decimals="0"
      id="Tc_z0oUFz8asEKPdXockykE2g_4_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2851000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_92UkqyWHCkqZKAb3ohfj-Q"
      decimals="0"
      id="Tc_JwhoY43LdUWoPKre99hsxw_5_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">101000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_PurchasesFromBioTechneCorporationMember_FG_G8klQXUmj79kiu1yNMw"
      decimals="0"
      id="Tc_OPfm5aHVjUuaOxcY2iKGgQ_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">306000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_8-nrYuOdiEO8hicagC8Wcg"
      decimals="0"
      id="Tc_2d0ofgc71UCFyfvJWcuCCA_6_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">265000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_I0FgPzQc2EedkO5jGv2oEg"
      decimals="0"
      id="Tc_waQ19361TUufIFTPxvJvBw_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">280000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_g36FCfhvP0WjdlrSD9cBTw_7_3"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1508000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_JKHuH73Qak-zClHM2CBdig_7_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">3437000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_1eP1X43JYkawUMU9gFmpfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;16:&#160;&#160;&#160;&#160;INCOME TAXES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has no income tax expense due to operating losses incurred for the&#160;years ended December&#160;31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The effects of temporary differences that give rise to significant portions of the deferred tax assets as of December&#160;31, 2022 and 2021 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net Operating Loss Carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,072,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,087,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,642,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,599,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued Expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;E&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,818,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Charitable Contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating Lease Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,611,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,514,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,876,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,578,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(41,413,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,401,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,463,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,177,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (304,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (94,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,159,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,083,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,463,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,177,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Deferred Tax Assets/(Liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the history of losses, management believes that it is more likely than not, that future benefits of deferred tax assets will not be realized and has established a full valuation allowance for the years ended December 31, 2022 and 2021. The Company has research and development tax credit carryforwards of $733,000 available to offset future federal income taxes. The research and development tax credit carryforwards begin to expire in 2030.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The Company has approximately $135.2 million of federal and $38.5 million of state Net Operating Losses (&#x201c;NOL&#x201d;s) that may be available to offset future taxable income, if any. The federal net operating loss carryforwards of $41.6 million, if not utilized, will expire between 2029 and 2037. The federal net operating loss carryforwards of $93.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state net operating loss carryforwards of $21.9 million, if not utilized, will begin to expire in 2035. The state net operating loss carryforwards of $16.6 million generated in 2018 and thereafter are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In accordance with Section&#160;382 of the Internal Revenue code, the usage of the Company&#x2019;s net operating loss carryforwards may be limited in the event of a change in ownership. A full Section&#160;382 analysis has not been prepared and NOLs could be subject to limitation under Section&#160;382.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2022, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;amp;E expenses. The Company will &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;continue to monitor this issue for future developments, but it does not expect R&amp;amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The Company&#x2019;s income tax returns for 2018 to 2021 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the&#160;years ended December&#160;31, 2022 and 2021, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,285,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,795,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (48,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (291,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent Differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;- Other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 288,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 262,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.63 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,012,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-16.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,769,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-20.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred true-up&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,019,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-3.40 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. As of December 31, 2022, and 2021, there were no unrecognized tax benefits. The Company recognizes accrued interest and penalties as income tax expense. No amounts were accrued for the payment of interest and penalties at December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position in the next year.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_DOi5uykLEESKu9zHUkh_yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Years Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net Operating Loss Carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,072,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,087,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,642,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,599,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued Expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 510,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;E&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,818,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 733,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Charitable Contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating Lease Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,611,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,514,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,876,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,578,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Valuation Allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;(41,413,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (36,401,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,463,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,177,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (304,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (94,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,159,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,083,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Deferred Tax Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,463,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,177,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Deferred Tax Assets/(Liabilities)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_zVAeMMbzR02wkmW1tVvBdw_5_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">30072000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_E_AhqYK2p0uakb4QNiCpcw_5_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">29087000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <mrkr:Deferredtaxstockbasedcompensation
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_gJoUK7cs_kSD0v9ulMCFfg_6_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5642000</mrkr:Deferredtaxstockbasedcompensation>
    <mrkr:Deferredtaxstockbasedcompensation
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_rZNnHoUNR0OzBFlLoADNqQ_6_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">5599000</mrkr:Deferredtaxstockbasedcompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_fVts4xzA7kWUMNnoghbKfg_7_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">510000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <mrkr:Deferredtaxassetslicenseagreement
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_fKEp_kx72kitSUIWUEiXSw_8_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">127000</mrkr:Deferredtaxassetslicenseagreement>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_fKRZK4OsF0K0djKqCBviqw_9_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">4818000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_sIUmRe-nNkWDd6rkSu-MuA_10_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">733000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_Gd5G5sqSs06kpm7PgjM5gw_10_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">733000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_b2kKwRsuz0WRLdGCr4PMtQ_11_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">8000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <mrkr:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_vD4bJhKkSkaEYys6kPbz1Q_12_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1611000</mrkr:DeferredTaxAssetsOperatingLeaseLiability>
    <mrkr:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_ZtNugsbFnkObAcy2TVn3qQ_12_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2514000</mrkr:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_oJR6XOiCPkCXV14SxrPggA_13_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">42876000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_CQQXoEtcQ0eV6uShmRVYbg_13_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">38578000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_JFxteyQcOkiqboMoFXHdIw_14_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">41413000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_YGtMvzq8D0GuZKVOJXRyCQ_14_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">36401000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_vu9EHr72QUCaz03anJabJQ_15_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1463000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_XsXufGOM-0OJNdx_kp5PCA_15_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2177000</us-gaap:DeferredTaxAssetsNet>
    <mrkr:DeferredTaxLiabilitiesFixedAssets
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_l7WhHQiBhEWVdsleNH9NuQ_18_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">304000</mrkr:DeferredTaxLiabilitiesFixedAssets>
    <mrkr:DeferredTaxLiabilitiesFixedAssets
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_SWyXUiyU_UWSPHrHpsDDzA_18_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">94000</mrkr:DeferredTaxLiabilitiesFixedAssets>
    <mrkr:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_m4BhfXKNLE6K-b6wYuQs4Q_19_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1159000</mrkr:DeferredTaxLiabilitiesRightOfUseAssets>
    <mrkr:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_JJlFjjgZnEeLy4xXhoMJ_g_19_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2083000</mrkr:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Tc_PC1Q8cfig0ydsuiuSGDUNA_20_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1463000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_NIuHZ6u1EkiAyDVK6DI-3w"
      decimals="0"
      id="Tc_gVOpdSUpyk2-zFmVNM9kAQ_20_4"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">2177000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="0"
      id="Narr_X8mcpnUFXEy4lNr6GTi1fw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">733000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_wFYWw1ClrUiD5vQsZLf__Q"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">135200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_ozF178gOzECqvGfPuzLyfg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">38500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_N_fIbzu1XEuU7Ow-I6Tnsg"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">41600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <mrkr:Taxcreditcarryforwardexpirationyearrangestart
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_fRDd2dDpGUuKVgzWkkGLHQ">2029</mrkr:Taxcreditcarryforwardexpirationyearrangestart>
    <mrkr:Taxcreditcarryforwardexpirationyearrangeend
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Narr_BAmdtg0x60qVcup3P18C3Q">2037</mrkr:Taxcreditcarryforwardexpirationyearrangeend>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_G1H72RYOhku1flLkvnmwxw"
      decimals="-5"
      id="Narr_xepOYQ0ziUWFRpWQCW1OGw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">93600000</us-gaap:OperatingLossCarryforwards>
    <mrkr:OperatingLossCarryforwardsLimitationPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_E_6jM-m13kOR5Fzj9eeTUw"
      decimals="2"
      id="Narr_ncKJrrp4rkOUT3bS13RGqw"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.80</mrkr:OperatingLossCarryforwardsLimitationPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_UwJZYpPUWka8KcHH3ef7ng"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">21900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_l66B3TClFEmlIWsk1ybpMA"
      decimals="-5"
      id="Narr_BW1ONTvZmkeQ963dIb3a3w"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">16600000</us-gaap:OperatingLossCarryforwards>
    <mrkr:OperatingLossCarryforwardsLimitationPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_75w7V3-2uEiEHBbWok-lEQ"
      decimals="2"
      id="Narr_-ykRHMZHUkmiDFV8SFMu9g"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.80</mrkr:OperatingLossCarryforwardsLimitationPercentage>
    <mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_a24k_4JGHESFBWBNJARvMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Years&#160;Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pretax Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,285,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,795,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (48,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (291,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent Differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;- Other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 288,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 262,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.63 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,012,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-16.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,769,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-20.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred true-up&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,019,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-3.40 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 103,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;-0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax provision/(benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_9T3b8FvooEWNGxN8sHdsuw_5_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-6285000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="4"
      id="Tc_x4COmPTQYUOqrihW8HVu7A_5_4"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_H2_eGqmNcEKsdLlKLRPYFw_5_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-8795000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="4"
      id="Tc_XIQCgtRcW0uLFbE7nONjmg_5_8"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_9ND1eF7AcE6-lD8qsiYi1A_6_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-44000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="4"
      id="Tc_xbymfHUw6Uexa6N6yfz7bw_6_4"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.0015</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_bx-xWJzuoU2TumC0iJ5b0g_6_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-48000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="4"
      id="Tc_NiGXiEbL20e3_LP9VLGB0g_6_8"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.0011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_W65284MRKU6AFpmLsir1Ew_7_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">10000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="4"
      id="Tc_oxAwDM5nGEC8Hf2woOJ-Zg_7_4"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_sSnQElU_2kKzAIh0iGbF0Q_7_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-291000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="4"
      id="Tc_UFWiuo6wuU2TCOVLZ6Ht-A_7_8"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.0069</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <mrkr:Permanentdifferencesotherpermanentdifferences
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_252dlflHrEKFjjKHMpPiqw_9_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-288000</mrkr:Permanentdifferencesotherpermanentdifferences>
    <mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="4"
      id="Tc_--dOUs4CmkCWwENv_pguuA_9_4"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">-0.0096</mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <mrkr:Permanentdifferencesotherpermanentdifferences
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_B3yP809bk0isPj9vxDW0zQ_9_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-262000</mrkr:Permanentdifferencesotherpermanentdifferences>
    <mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="4"
      id="Tc_ccBGHfDCJkSFigYILWUvLQ_9_8"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">-0.0063</mrkr:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_Z28SDEHVFk2aiGD3Vb3bHQ_10_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-5012000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="4"
      id="Tc_rYQx3A8T1k-QpEOXRNCzpw_10_4"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">-0.1675</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_nrru4mLkxkOobhe2abUT7g_10_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">-8769000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="4"
      id="Tc_vr8z5yWlWUqxmKbdwPZ2BQ_10_8"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">-0.2094</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="0"
      id="Tc_HdzLMmD2i02c1Ev0inLhxQ_11_2"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">1019000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="4"
      id="Tc_FPQdUZorikGULFxrSGaroA_11_4"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">-0.0340</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="0"
      id="Tc_O5bgBxOj1kajXeGkajbUrg_11_6"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">103000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="4"
      id="Tc_T-kkpEiHuUmFp0Hd4zbDvA_11_8"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">-0.0025</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      decimals="4"
      id="Tc_3f5VdKBO5E6pugyY9XhRuQ_12_4"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_0tS8taog10OXPGTldiyg_Q"
      decimals="4"
      id="Tc_Dy9FpzwxhEyoxVsEnMEnww_12_8"
      unitRef="Unit_Standard_pure_gI1ILcikjEaNlHDJBkoemw">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_ShOaj_8Yv0miXyaQVTieoQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_Kd2qQpk4r0SqKamcx5RziQ"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA"
      decimals="-5"
      id="Narr_LUqwjGKDhke7W59GQEAO2g"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ"
      decimals="-5"
      id="Narr_5YABJ71os0qSj-QV0ox7Cw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ"
      id="Tb_vBCDOLlWQEi5QjGlcRh3IA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE 17:&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc., notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On March 14, 2023, the Company signed an agreement with AlloVir, Inc. in which Marker will collaborate with AlloVir to optimize certain aspects of AlloVir&#x2019;s manufacturing process. Under the terms of this agreement, Marker will conduct a number of process improvement studies and provide AlloVir with the results of its findings. For its work with AlloVir, the Company will receive total compensation in the amount of $400,000, estimated to be fully earned by the end of the third quarter in 2023.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_3_14_2023_To_3_14_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_AllovirIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1XuOmQ5XPUeNbdcsl4Y23g"
      decimals="0"
      id="Narr_ysDqnwB_ekCCstdwWW1Qaw"
      unitRef="Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw">400000</us-gaap:ShareBasedCompensation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M\ Y])R!3B7":C$4*Z;\ /N;2)!3L$QH$)Q%'D+1(M_.9!.T@($_QB)R?79S
M[3:%ZCK<[O\IU+%25 2]XP2V^VYU21/H>]A>&M06O.CCA\Y5^^L)^;U&?N\4
M>C3#_I89?ADH)M8DD=H</:\*YL;!V([>1MW63>AO#[G]@_M6@%J[KM*(N1&F
MNGK-:M.X=]5]_>M>=?V4JC43FG#(,+3=NK[TB*HZJ3*,+-WM?98&>\%-<WQ\
M0%D'W,^D-'O#$C3/6?0'4$L#!!0    (  ] =E8@A$+@( <  )X=   8
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M[4;M',B>*657@DNP_C?0^P-02P,$%     @ #T!V5KB]O5LE!0  U T  !D
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MW!T-.\S4;XAZXG09[NTS[? *",,%GEUD_ +\GVOM5A.OH'W(3?X&4$L#!!0
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M:\W3C4#56B8-XUX>X_A*(['WA0B%HH0;(]='2&2<Z-8RY:!@ZD29 7O(M(;
MY-AG/$F86C-;:??=-XLPF#\WA1NX%H5T*6(2?FK<*_I/>T; #*>/PA%FK]+8
MT4F^*AQ$\K2(U":5?X%GY3AA!:G@\@.6DG]$H9>W>,^/Y 2<_A'^K=;)7=Z[
MU3?%[D@.2K(88IR7G'?%HQ50[K 5*3D*#@7N&I7R57)DD= 6H O9\&[-(0 0
M.$D\"AU).H"VO<QF5&,9LU19BJ>1L5.RI(0R+.))E"7><9JP[4*M+S(*9N4V
M;T/AKB-YNZX)%*83.I2&-;F:SD)B*O**K<11%6L^\MY+4%_M9<3NE@]L,0DA
M]D,F$8'&D?!:&2TF?9B,1?*ZE$2(?*))GK"],M(G9,T"\._X^Y,H?E]%L*3]
MP9=6AW.@0IX:Y#PJ&D=#PC,7$N'K+CG2OF=!?SU)D[==;L_S40-UR<!4I1>%
MFW*2/#O;!4*!5HF,X0S*X\35F^L<IJPQ9U)=9-/F>D$X!0[2;BE7"NHZ75M2
MM>?0:2]<0Z:JIH2SGU)0&;+>&(7@V?SHD]INEZN++N&>\R2!*E4P\C)7O.(7
MCYAS2$)9L!2#1E$/V)VAA26 3.Q6( NFOEWU&SE(EI,],"!.X"?&-UI &83?
MHR7T[XR06J]E)"K,'&.T8DN,4MN#,):]A)0#A[^6F82$<#H:]=E/BH:$M,_>
MB4=,:Z2BR0#[=86TB+-(>*5:'FN$;'5DS\:#.>:,)"F0NL[;!0.>9UKP0 &V
MH0H'>Y7*9#()/'#32-Z-2*%-TM6CRGC$KJ$Y>X[H:$S0O,$P+?@0%!-#$9R3
MC69LMISB8''F.4= #M_OM7J4F/N0HNS9?#!KNJ7#%:=<T\HQ?<"X1%P.0HL"
MZ^,"H9[._*?,"OX=LX)@</D%=ET.%E]MUY*R-*_:6.6-PB$Z(XNH'< *0@Z"
M#\+K'(S[3.Z W9ZL@G- BM72S?H@ 9J2!,I$7P'H<1FH?*O>9!QSBA4T##SD
M+>G\6%%T9^B"&DS*+DT^$P:]TB<X)@\XSCP_H=MRY#39N!+4S-M^*GJM2IMC
M1!M0.QOQYS9=-U&48T$Y:0S8[USCG*16='EA)L>JE75ZQVP)< N5<[RK\.P$
M75LCB!)>66K[W(^+ 'A-T7,.JXVWS9DN#WMK8%VK!)=,6O5W3+0 PSYDB+2T
M'E5DZN^Q+MU70-9N'&YUE2M&6Z/Q\__]_\M\2O@32)A?O3[)TX".]B8AI,,3
M]FL+./*0%=?US_?!4X**_6<LZ$\6X_X(S:W-&_3GH["QL]PJ;2]<+^X6-UET
M2G+!#*OO,L>[I<R>$#,;S1KK[QS(5J:$_6!^V:"@M?'H::7^JS3H#'LMW.#7
M]7HX#7 5R(B;+5NCM@R[.)VYZH$-6OZBM=%\WO0A-#^XYQ(17Z#,-=\0L-(3
M4I4U+N*\NZ4[*#SIB&ZZ:#:J.?KOT?F(.!:#B?]JSI^#;H5B:2*54?NA<2TS
M?H"K+KP>0;N;[?&K-<?D\*TCG@[FW[;U?<WIEE^T],]!L#X2GEJ.P\9616&3
M0)Q0U>'G%\#=G_E@1N+;UHU+JLN\Z,]13VI0$$XGGZ2?=D!(>#EJY-LY_ED'
M?]#*UW/\\SK?S-N'=$+W7</#)\+'_6E+N2:@E*[J3Z9>B5?HB*V'AC(S"^KO
M@_YBXL3^<(*^]0FB/78\X)Y-*!C3KVI0N\\'M:5[%<8]Y#2-J_*>]V=!PUU=
MCV3#V@/E3NB->X:E"Q^L\&^5Y6KYTGOG'S@K<O],_)KKC4QI+EN#=3283WM^
M*BH^K-J[Y\Z5LE;MW,^MX+AM$P'VUTK9XH,.*-^_;_\&4$L#!!0    (  ]
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MVI+AAF.1!>R22B--9&46&I"7V0V$+>[ 6"!M7?\3-F![MT)$55@Q85U'RPM
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M8"Z7T&J*NDE'B!%BE[&-S?+K9+2/\Z@L6UM]X\->+;*Z1REH6HN<".;/P@S
MC*=J!J1FSD^W9P4:R 2;7/AI:FO4%[2VS*IF"U)HJYGB_B7'P5?><9Z=*56&
M$".1LD2QD(@7G9CW+:P4_38/+1/33=_8&Z9[I\4C+7PDRPG9D&UB@:ZF4$B$
M7#!8R(7.E:UBAX18]SLM!)3Y\_9CC1.E8M=KZ]G)6]QE_L!=ILLA=K1?][=B
M$C?!JLRRR4\J-YW_12MV_M'SS!&7F#16I;XQU((_8LC#8[W9[U,P?>^3QOL0
ME#M,N+"8[,I?&Y/*-,<&DH\Z1A;38!T,ES+E\F>M$(^1X(Z:[!TQ^B=I4>\_
MQRO -C27/9I2Y2JX+'U(=V-H!VY0P)FE0C5M53'OM,4=)FP6$@B6KR>C:;_0
M-D/SWJ"L_ZRS>6S9KM";2@2=Z6B2_("^]:H,QCIA-L<#;;3Q,-G?Y6*8>MO=
M]K9E,VS/GXJK@@_DL@[\&P(;IC#RJ]0UCG(1K>S]4R#_4VC:]G;-0 QMWK+<
MV=//NDQDM>5)GBN7PL*:)/;BH?SW.9%LEWX7J2U69N-Y+*&]T:Y;VKAW;ZX(
M_<]?!SPY$-AXA>Y6NP^0LWCOWHC'KQ=D<XY3$G>7'*J3T?NW V'C%T%\\681
M;N$S@W!5X;' 1Q19%L!^;HQO7]A ]UEV^A=02P,$%     @ #T!V5DV9^RMI
M!0  ZPT  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULK5=K;^(X%/TK
M%C,:[4H,A- 'VP<2I9V7MBT"=D?ST207\#:),[93RO[Z/=<)*7V 9G='JHH?
M]QZ?^[1SMM+FSBZ)G'A(D\R>-Y;.Y2?MMHV6E$K;TCEEV)EKDTJ'J5FT;6Y(
MQEXI3=IA$!RU4ZFR1O_,KXU,_TP7+E$9C8RP19I*L[Z@1*_.&YW&9F&L%DO'
M"^W^62X7-"'W1SXRF+5KE%BEE%FE,V%H?MX8=$XN#EC>"_RI:&6WQH(MF6E]
MQY//\7DC8$*44.080>+GGH:4) P$&M\KS$9])"MNCS?H'[SML&4F+0UU\E7%
M;GG>Z#5$3'-9)&ZL5Y^HLN>0\2*=6/]?K$K9\+@AHL(ZG5;*8)"JK/R5#Y4?
MMA1ZP0Z%L%((/>_R(,_R4CK9/S-Z)0Q+ XT'WE2O#7(JXZ!,G,&N@I[KCZ]^
M'TRO+L5H,)Y^$]/QX&8R&$X_W]Y,SMH.^"S5CBJLBQ(KW('5"<6USMS2BJLL
MIO@I0!O$:G;AAMU%N!?QDJ*6Z'::(@S"< ]>M[:VZ_&Z/\7:$NO@=2RNEA.;
MRXC.&R@'2^:>&OUW;SI'P>D>I@<UTX-]Z/^2Z7ZLF]OIE>@<GHC=H&*Z)#'7
M"6I490OAY"PA8<E9+!JW1/DETE$L<FG<6C@C,RO+LJ('] =+%B*1-@@[:P@'
MN#5)8P5Q*@@$DM(9F3J80F8Q#S"%\W+RQ9FL6^+=FUX8=$]_VN^'BLTWS\8G
MY@N9)^PVBYXE,Q07<IT !86?T(*$GHMKBE4$+]?";T6GV3D(FT$08!PV>X<=
M/[Y0^OV4HB5$A]KDVDCOM.<$.D$I_GR]&QSY]:\JL5#[JA.<+;-B#N<7AB.U
M#S4\.GP5->P%?GVJG4S$&+DK3;3T$8D)4= YNJY[8MMAT*MLZS8/NL=/8-_V
MFD>8PBT[L\0*:4BH+$H*]K_B;ASI(D-^Y7+MDXU/QZ(IL)\H.5.)<@II)2TC
MO\B?EA@L#!$3M6B92%'.X#V1^H7IAL'IQ?#:CSJGOXJ6^)R)&WU?0H=!I]<4
M7^!>W$Y\2.!)?:"9J5>:/I>&.LUEMD9N.S*E/9,<5FJ>U/Y\3A G-\5JJ;"5
M&WVOMFLETEE<1*YT8J6_V=N<-EN+" < 4,F$O4P&29%1(J03E5F=XU,KAIZ7
MU^?KSEOQD> #N,C(?.W-GE#N:KM_:R*MMFS^4B3KJCI?M]=I,42;41$2:%+D
M.<1_U%RL"ZA7:SS</B+%;:J$*U)(2EBZH$QP>U!S%;$.>\EZ VXCIQ_I[PB+
M1,V8.QP;D?B(?'2/-/\72YGE>H7#(VV=3U (_H4FYOLE;S^6:%-\+R22><U!
M=@8WO"/KN';9T_?8BLOR-47U2/&)[VT<% L\ ?9GGGR,Q-0@,WZ.A2J[9Y8+
MZ;1Y#WCD'%=VG9S6%;%G.2HPE7P!S(U.=S6\EB_/&MSB:6,,*")O"H=2_YO]
ML4.7W>16FKVLX. 9PAC;NCKR^GQ?.WA((@.;,$OAD:F 'ZV=OD,' -=KTQ*7
M$N:**\G5RD2D2,LR@/J6 ^IBFFEI8MZ,%6XX>,-Z0BOT);[S?1RMUQS!.8K+
M<P,U,MH1]X9(41:!X806:;7_NJTEQ8H<PRTRCM8>Q^+OV@>DZHO-LI&"7!$M
MF]YO:?DF8U+;'1G$RHOX66=FYN7]+V=HC2\BO'T7_5!8MQ5>C5K$32I"X1>@
M@AM(L:^0S]SD/KX?T\,F=E_T,MO _??0J1>1&U[=LM@/W;*MUQYW[:T'>$IF
MX3\S8 -?<>5;O%ZMOV0&Y0/^4;S\#$(T%PKA26@.U:!U?-@0IORT*"=.Y_XY
M/],.'P=^N,37&!D6P/Y<(^NJ"1]0?]_U_P%02P,$%     @ #T!V5A25?=B"
M"@  <!X  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULS5EM;]LX$OXK
MA+>[2 '%EOR>O@1(TRRNA[ZA:7?O/M(R'?,JB5Z2BN/[]??,4)(EUTG:'@ZX
M+XE%<=YGGAE2+[;&?G5KI;RXR[/"O>RMO=\\&PQ<NE:Y='VS407>K(S-I<>C
MO1FXC55RR41Y-AC&\7202UWTSE_PVD=[_L*4/M.%^FB%*_-<VMTKE9GMRU[2
MJQ<^Z9NUIX7!^8N-O%'7RG_9?+1X&C1<ECI7A=.F$%:M7O8NDF>OQK2?-_RA
MU=:U?@NR9&',5WIXLWS9BTDAE:G4$P>)?[?J4F49,8(:?U4\>XU((FS_KKG_
MSK;#EH5TZM)D?^JE7[_LS7MBJ5:RS/PGL_V;JNR9$+_49([_BFW8FXQZ(BV=
M-WE%# UR783_\J[R0XM@'M]#,*P(AJQW$,1:OI9>GK^P9BLL[08W^L&F,C64
MTP4%Y=I;O-6@\^=OWE]^>'<E/E_\X^KZQ<"#(ZT/THKZ5: >WD.=#,4[4_BU
M$U?%4BV[# 90I=%G6.OS:O@@Q]<J[8M1$HEA/!P^P&_4V#=B?J.?M"]0CX]3
M4T4\<QN9JI<]I+Q3]E;USG_[)9G&SQ_0;=SH-GZ(^Z.Z/4S]_L/G*Y%,GXDV
M&_%YK<2ER3>RV(FU=*(P0A>IR97P\DZH.Q2S4V)9XMD(E+:57A<W(C/.*4=;
M2VO54J#:A0>KG9+6"47!%0B-RA?*-N$1LEC2CZ3/8M5JA5)SPJR$5_G&6!2Y
M6&JL6E6DX.[7THL;%*&PVK$"3M\4>J5367@! JK30 ]V*"W%NI#B$NJ!M>2W
M]RLBI%6T:64RH(U[)G[[93Z,1\__Z_^_5_[X)_N#D_W>O1WU#E^RNJSJZ]J^
MS[#O(MCWO>J\!UI_:(+W%L$3E]+:'<*VE7:OVBB.XMDPBN-XK\!9%,]GG:5K
M;]*OG#5(#LE@6;^:1--QEWX23<[..BL7:6I+V'$5DJMK13+<:SU)X@[A6YUR
M-E[<6*4 ]/Y>RF38U?A2;K27F?XWQ'[Z3>:;YU?-NW$T3^:=W8?</J&2I4W7
MG#:OU2TZTZ8C?C8:=1@</E^NI87\14:U5GBK%V5(W?LD=O5I14ZAH< /<J$S
M[7=[>Z-IDG3#%DV2\3=6M?\C3O/9M+-E-(\FLZ[LM\JA+/Z061D"?4&%(E&>
MS8Z3<1*-$S;XZ7YQ-(W&<=)=_&P0@P?S&)RFHP,[DMGL03L>^]^15[M.J^\O
MGM_U':@/-#T9Q>,#D\\.%GA@.36KTR^4LP?D291,S@X8H'#FHT===LR$D\9Q
M'7:5ZY[^M.\(-X[$:W#24J++O9W%QY[9J%;/(:#F5D)HF>FO*M-K8Y8!^X]!
M^E9GF5B@):A0S^@EAHG5G:>:9,+P,F2LIJ;F ^]=)*2X;9)9-LF,3<I1A6J,
M1N#Y"G6V%.4&FXCW6F.P0G=",PF=+\),56 (91A80&F@0M6PM"=NN;&5/3M:
M+DB'*&Q8E;[$RX4JU$J'_G>OH:1YRUA&(&K3+65AT:K$UF-F_4Q;;D\#MHU\
MRQ;RD9XI%(:Q::N1L#%/:OB3MU)GC'HT.ZQ6,*LV?J66P+2L-6LH%\3_N,B%
MNM$%B<"THL$;#TBS^%MKY&9CS9W&:$Y1>9*,)OTA9N0L(Z=!\5HIDOQD-.]/
MVB_A<*^.-%*$_802>Q@_?__A+?]*GJ,H.-2YW%'X'G $K.(7P1&1T"N(WP7=
M:WT*;.^.7D></D[ZTUI?9D.I@S;#>1.%;*H<M%!^JQ1Y:7A6!7\T^PF19Z.]
M2'&#=,9V)!C[/YDS9R0?<G?ED6XT:KER\2_,?.0&E,0\_A4EDJ,S<MI2K1UX
M8VG8C$IO8LAVL"JB'EXTTGJE"TU1#5:$6'V7#<CZL\?<=CS!)C\L*YG^'_KK
M#9UT4V.7#!A;[=?BNCH!C^;#>KA^4T"E HGQ"159X#20FJ6*^%7I@(/UOJK<
M&/EGS]WC?JDJA,T*OF LOZ6*!T\I4H#G#?O<;.$QM]:;OK@(D-=6%'"<[1R0
M-YQB"#:1XCB%;:2M@!/U"?&FS)8DLN7;EE-+.,>V&??%%9]3Z!C"< H8"G#*
M:5&072%@A\"*O]B\D3MHS=&TZJ]2,\H;>*&>2*G>ZX-6ZT3%^$%4*09%#:78
M.RE^%302@$4'*8F!I=N/RHZ3:LQ]&NXQPK@0C'OSZ;(Q,)F-^^+/M<Y42]?0
M[7#*RC("3LY*1-%72(@F4J8<3ZP[M=?]*/N0)(UOD.DSGB0N2SJ?0?._FX7#
MF8# LEBB(-S>-U4[PR:9TVFO6H .]1#?R/[!T/3WIX_&XT@Q^+JH5.=*J,6T
M?%AEZ)=KD9>.FW.E&SB86ZI;,3DE+00%!),,,*46$;$MW^C>:&#@$P3X40%)
M1T+_F)J4.0MK)$4$*KL451@&D;]*N':EP6V?0'NZ5K9]&\YQ(DZLRD(Q^S!V
M-4SV_?EIOSG_LIKWS!U1&S'(%KHRY%+=%_."YS!*@J:%WI0Z8%48$!#>7!=U
MP6 X"(B'8Y8NPJW%@M%#!O39&*?9%H*8*CN"&55M?D?RT=!V&,3NM/&-#KD!
MWK)/8)1VK@Q@4@T!K3$'DR4.AV3'TBA7HSGA5"WQ,049&=@8XH(G5#6(W#I,
M66"Y%<;6>5Q0@((:'1,:!&_=!EF%;46H->Y88-[<HCA/-M/E+ZO4[EPE<B(T
MFN62G1\=Z0N<L]K1X\J:',BM(2:4,]_29,ZTN:H[B;A7/O!LB]<YU\Z.">HF
M3I96?F9NW>1\?"J.JM,%!:&:T.MKL9-JAG^ZSU,NW;ZX[C>C% T()9\>J-W3
MV< JI$8*S%T&E"$:E&!)L [N&%)O-5]B[_G_+^ZH?N3NZO$[JM9#\JB(C\JF
M58?_B2T7N2GQYB/RD<[#5-9'EK[T[P]"<T:>1L/Y))R1T11P9OE5G,RCV=G!
MVC4/>5P_5>[N3PM5C%KW(=4]0-Q/)L1O/&^>$SQ3\V,EJLFFN?L(EUVG<3\>
M$=GP+*GIIF=8@$/0(<DEKUMWI(]Y^E1\H)F2X+6B7AZA'L[GM?"S*60-I\/Z
M>4K*7#9#V+%3YOZJ+TXJ.HRZ,S(>OIR&V[_3(7B/L=3<)WA;JM-RT[K\B9-J
M[Z@_)K<G\:A68TC<WNRQJ"F2P;Y(#N\=XA"\(X^<1=>78@8Q=%&?6KT@ .+2
MO"E"A_!KO%F;+ R/4N1*.J ('T:E#[=X^R,V)FHX0U>Y%G:UN1&/-@<:F,F.
MJA\Y/'T%=H+;'FJX=X5U[F![$*Y!S+C614+87PGEXXOLR&@&"KJ<. V7$Z<T
M$YQ2FPG4#ELD]U.^_&BC[&)'W'BH*B'9\L" 6?SX'7O4!5"@[Y;^% 9SQ5Y%
MUJ\VH-M#FTV.#BA\8ZSI%*)@ [$&!,LLS#KNR#>+OGAOJ#$"%EP077.I(X:^
M6$?B/L;^NV]+ .L\Q!4>,S.Y4VZI"1D^SH>.7P_(5MW2UT>>5\)I!*++S/.<
MUO[ $?0#XK#F:("4'71[82G-,#3H$!CNEY0 3:";YG[GN<OUCWU]&K2^ N;*
MWO"W3CX@%3Y\$&Q6F\^I%^$KXGY[^!;[3EH,W$YD:@72&+7?$S9\WPP/WFSX
MF^+">&]R_KE6-)S2!KQ?&>/K!Q+0?&0^_P]02P,$%     @ #T!V5J\9/O-<
M P  9@<  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULI57;;MM&$/V5
M 1/D21 I2HD=1Q)@.2H:%([=R':?5^107'@OS.[0C/OUG5U2BI+&0H$^D-S+
MG#-G9CFS\\ZZ1U\C$GS3ROA%4A,U%VGJBQJU\&/;H.&=RCHMB*=NE_K&H2@C
M2*LTS[)WJ1;2),MY7+MUR[EM24F#MPY\J[5PSRM4MELDDV2_\$7N:@H+Z7+>
MB!UND.Z;6\>S],!22HW&2VO 8;5(+B<7JUFPCP8/$CM_-(80R=;:QS#Y5"Z2
M+ A"A04%!L&?)[Q"I0(1R_@Z<"8'EP%X/-ZS_Q9CYUBVPN.557_)DNI%<IY
MB95H%7VQW>\XQ/,V\!56^?B&KK>=L''1>K)Z +,"+4W_%=^&/!P!SK,7 /D
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M28!]IU66"OV=EEBP^IVF=8> 9Z.N>%$38/"NH^9E*#GUM%F ;8?4M:,$KOS
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MDAI053K8=8=.10IJA1,36_)PPO:R+"@L.1+[JB+\YQQ*5D\MSSH$[HIM+G7
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MS?WX4+TWDN/2)>7&:MSEZ&<GL^NOL^GU[4]R^N6"3+_=?9Y=3;_<DK>W;"[
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MR+J!UPLM*MLT-T)C"[;3'-\\D,8!]S,A]'%A C2OZ/0/4$L#!!0    (  ]
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MH07P_9QSM9OH#9K;V_@?4$L#!!0    (  ] =E8.)9&KT (  (H&   9
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MSO%6!](HX/Q4"+T:F 6:>^+P'U!+ P04    "  /0'967:49$/$#   H'P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6RUF6UOHT84A?_*B%;5KM08
M!K_$3FVD+,QJMU(VD;UI/T_L<8P"C'<8[+3JC^\,$/!L\:R1;O/!!LQYKCG7
M7,T)\R,7+_F.,8E>TR3+%\Y.ROV-Z^;K'4MI/N![EJE/MERD5*I=\>SF>\'H
MIA2EB>M[WL1-:9PYP;P\]B"".2]D$F?L0:"\2%,J_OK $GY<.-AY.[",GW=2
M'W"#^9X^LQ63C_L'H?;<AK*)4Y;E,<^08-N%<XMO")YI07G&'S$[YB?;2%_*
M$^<O>N?S9N%X^ANQA*VE1E#U=F A2Q)-4M_C6PUUFII:>+K]1O]87KRZF">:
MLY G?\8;N5LX4P=MV)86B5SRXR=67]!8\]8\R<M7=*S.':F*ZR*7/*W%:C^-
ML^J=OM9&G CPZ(S KP7^I8)A+1A>*AC5@M&E@G$M*"_=K:Z]-"ZBD@9SP8](
MZ+,536^4[I=JY5><Z1_*2@KU::QT,OAR^_5Q2=#]1W3_0):W7S_??UFA=Q&3
M-$[R]^@*/:XB].[G]W-7JFI:XZYK\H>*[)\A_TZS ?(GOR+?\X<=\M NC]AZ
M@(:XE/L=\N@'U0M5?>B=E9/+JV-3[BJ'&YO]QF:_Y U[V-QE:449=5/TT+C)
M]W3-%HZ:"CD3!^8$O_R$)]YO709#PB)(& &"&:T8-JT8VNA!R--432AU9ZU?
M$"WDCHOX;[;IZH85U+<;%6Q<PO3X/@1#K_J;NX=3IR&KDO]6Q>/OJAHNCAH7
M1U875\53SKX5+).('=1KEWU60E_[(&$1)(P P8PVC)LVC$'FRABR%9"P"!)&
M@&!&*R9-*R;6.V*I[@.1LWJPY/LD[KPI[!!\I=9^5]CKLMVJ[&L[)(P P0S;
MKQO;K_O:C@XT*5B7^15J>CJ#9Z/!U!S H;5@7Z,A800(9A@];8R>6HV^HZ]Q
M6J1=MEJ%?:<+)"R"A!$@F.'^K'%_!C+H9Y"M@(1%D# "!#-:@;TV,WE02T@[
MJ6]#0&E13?OQDI1 U37]/LFH^)+1@_Y!ERP[[;#>ED/2(E :@:*9;6DS+88)
MM1@TU8+2(E :@:*9#6F3+0:+MOA\'/WNY@_M17L;#AIOH6BFX6T(QO84?!=G
MY]9$=F7O'SUH_ 6E$2B:V8,V 6.8"(Q!,S H+0*E$2B:V9 V!V-[ANTSA2!C
M: A*BVJ:]5]GM=__1_[%;0#&]@1<#Z%+5T>0@30$I46@- )%,]O2QF4\A9E+
MH.D9E!:!T@@4S6Q(FZ"Q-17VFDNS"Y-1:*_9VV_0D Q%J_QV3QXRZF?(=U0\
MQUF.$K95>&]PK=P2U6/9:D?R??G<\8E+R=-R<\?HA@E]@OI\R[E\V]&/,IN'
MX\&_4$L#!!0    (  ] =E8HI+ZT  L  ("3   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;+W=?W/:.!X&\+>BX6YVNC.]@FT@))MDAF!)EMS03-.]
M_NV  $_!IK9)]F[VQ9\-#L9!47#GN>P?6R!\/P+B!__0-_;E4YS\2!=*9>2O
MU3)*KUJ++%M?M-OI9*%60?HI7JLH_\DL3E9!EM]-YNUTG:A@NBU:+=MVI]-O
MKX(P:EU?;A^[2ZXOXTVV#"-UEY!TLUH%R7]NU#)^NFI9K><'OH;S158\T+Z^
M7 =S=:^R/]=W27ZOO5>FX4I%:1A')%&SJ];0NO"[W:)@^XQ_A^HI/;A-BK?R
M$,<_BCMB>M7J%*](+=4D*X@@_^=1C=1R64CYZ_A9HJW]F$7AX>UGG6W??/YF
M'H)4C>+E]W":+:Y:@Q:9JEFP669?XR=/E6^H5WB3>)EN_T^>=L\]Z[?(9)-F
M\:HLSE_!*HQV_P9_E1_$08'5?:7 +@OL4PN<LL YM:!;%G1/+>B5!;U3"_IE
M0?]E0>^5@K.RX.S4@D%9,#BUX+PL.']9\.HOKO/\F^N<^K:M_2][M]#MEI+M
M(N8&67!]F<1/)"F>GWO%C>URNJW/EZPP*B)UGR7Y3\.\+KMF8CP<C\3P,QE]
M&;OBF_@R_DCX%S'FQ0,C^G5,AF.7W ['0TYOZ?@;N?L\'-^3#Z[*@G"9_D[^
M1?Z\=\F'?_Y^V<[R%U2P[4DY.-\-;K\RN$5NXRA;I(1&4S75U MSO?-6O7QC
M?-L M/-/<O]QVL\?YXUM%&^#Y!.QG(_$[MB.Y@6-S.6NFN3E]K;<UI2[YO)[
MM=Z/KBNGYO+A.G_QMK4MMS3E[)3WWG^UG)O+91!](H[UZD?GO?'B-_-]N6YT
M<<(G;RB7IY?K/GG_ET>O+8;./M7.UG.PJ=:\\)O=0%W]0,4*_R)=!Q-UU<K7
MZ*E*'E7K^K=_6/W.'[JE'XFY2(PB,8;$.!+SD)A 8A*)^2"LEKWN/GM=DWX]
M"M(%":(IF10WU,]-^!@L592ENG09J:;I0F(N$J-(C"$QCL0\)":0F-QA_2U6
M[&4]7EO6H%/\=]E^/$P.:-1:<GK[Y/2,R1EO5@\J(?&,I(L@YTF8IAOM=MV-
M$6J:&R3F(C&*Q-@.ZQTL XYM#^Q!O[X(<.2@'A(32$PB,1^$U6+3W\>F;XS-
M71)/E)JF9);$JVUF@FBBBAA-XM4JCDB^&SGY\9%$*M-%R8@WC1(2<Y$816*L
M?_1UVK/[FJ]3CAS50V("B<G^T5=+L2/CO%RYZ#ZV7L\^ZPWV3ZPEX&R?@#-C
M H1FF=^M069QLMT.TRWX1K/I@H_$7"1&D1A#8AR)>4A,(#%Y=EHXCI]F#L=@
M'XZ!,1S#5;R)LB(:49R%>4@2-5'AHWZ[RD@US002<Y$816(,B7$DY@V.M_H=
M2[.:$LA1)1+S05@M.>?[Y)P;D\,V4;Y5]1R7W>;5Z.ZK^$;F21!I-Z:,8-/\
M(#$7B5$DQI 81V+>^=%7<E>WTRS.CW)F=S7/D\@7YX.P6C*L3C5MU#%FXZMZ
M5-%&'81"%P<STC0/4,V%:A2J,:C&H9H'U014DZ56.\:A2Z*/&K:>GH-)5\N8
M'E?-5)+DZY1D%R-M=HQ$X^P@-1>J4:C&H!J':AY4$Z56/ZK;[5LOC^C)\HF'
ML3@*Q-M6?5FWJV7=-B[KO-A6(F&4[YB;]SW,3N,%'JFYI59;Q7<T7RP4.BR#
M:ARJ>5!-0#4)U7R45@]0-9=O&:<KRP"9UA30.7JHYD(U"M485.-0S8-J JK)
M4CM<G>B.*OBH4>NYJ>;A+?-$O&;%$SPL]0F"SL-#-1>J4:C&H!J':AY4$U!-
M6IKY>&V"_A_3\58U'V^9)^1_X0"866R<).C4/%2C4(U!-5YJ;QZ1\J##"J@F
MH9J/TNI1JN;H+?,D_6@W+7E?3,5K<P.=AH=J+E2C4(U!-0[5/*@FH)J$:CY*
MJX>KFOZW=I.C[]#N;$&[ J":"]4H5&-0C4,U#ZH)J":AFH_2ZCFL.@TL<ZM!
M@P9.L]0X9]!6 ZA&H1J#:ARJ>5!-0#59:H?'+/J=?L]ZN<-U_+273;+U;%2]
M!):YF>#7>M3,:..80#L*H!J%:@RJ<:CF034!U:1UW,K0/\K(\7.*C.@#8E<=
M!;:YH^!S<:1N&9&[(-'N(9G+FT8!JKE0C4(U!M4X5/.@FH!J$JKY**T>KJKA
MP+;>:P_)AO8E0#47JE&HQJ :AVH>5!-034(U'Z75<U@U0]CF9HCB,&"8K524
MD9G23D69@<;Q@G9!0#4*U1A4X_9QOT=/=_P<.JJ :A*J^2BM'IRJ"<(V-T$<
M;AV2O\E;A]/-6N,405LBH!J%:@RJ<:CF034!U214\U%:/6M5XX3=?;>-16AC
M!51SH1J%:@RJ<:CF034!U214\U%:/8=5^X5M;K_8KMW*8^ADNDG":$[6*@GC
M*8FSA4JT@8/V7]B:/H*>KN_5A8Y+H1J#:ARJ>5!-0#4)U7R45@]3U8!AFQLP
MW@H3^1 ^'Y'7G<GNQLPW#A:T00.J4:C&H!JWC\\T8 TZ7>MHOPS:>@'5)%3S
M45H]5E7KA6T^]<+]YB%5/S?% 8VB05W;$V@F&D<'VE,!U2A48U"-0S4/J@FH
M)J&:C]+J :MZ*NS!N^V,07LNH)H+U2A48U"-0S4/J@FH)J&:C]+J.:SZ-VSX
MR2#LXXER79?_R#QRXR1!VS*@&H-J_,3/UX..*J":A&H^2JN?=+AJX7#,+1S#
M;[=D.$^4VDYPO7V4WLPU72%!-1>J4:C&H!J':AY4$U!-0C4?I=7#5K5T.._6
MTN% 6SJ@F@O5*%1C4(U#-0^J":@FH9J/TNHYK%HZ''-+1X.F=[/4.&?0W@ZH
M1J$:@VH<JGE034 U66IO-;VC!JT'Z.!:%>;6#L.1^:(UOA@PG"CMZ?/-<N-
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M+%Y?M?+MW8<XR^+5]N9"!5.5%$_(?SZ+X^SY3C' 4YS\V+Z=Z_\!4$L#!!0
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M;&PRN^ZEE+GYE9[3V2KS]?G,0+%Z+&A;&TJC4)H#I;DH6ENK)BHWM&'HKXS
M]<3.@D'3\HK6TE4U'K:A;2F4YD!I+HK6%JR)PPU]'OXYW7*Q-ZQ2!DUZ1F>E
MH$DXE&9#:;2BM4?8TX-3/]5,HX'<BX\.CW#_1\QM-#FWH0^Z[[/'A'_+\GPI
M'S.I]SW0C!M*LZ T&TJC4)H#I;DH6EN[)@\W)NBKQ08T&(?2+"C-AM(HE.9
M:2Z*UK:PR=L-?>#^*^,P1?BL&.HL])T[^S4]ZG3)AG:E4)H#I;DH6MN<)D(W
M]!GZ-8NR-?/23.2[+3GE!W[Z([^TY\;YS6;1)_+ OS/UC@R:ID-I%I1F0VD4
M2G.@-!=%:^O8Q//&*?QP"@WJH30+2K.A- JE.5":BZ*U;^5L,GU3G^EWN<M!
MC^JJ'Y1F06DVE$8K6OM6!]6U1\6,QJDJ8E7,.#FXZMGVH<GB37T6?\RYI1[1
MV0-H' ^EV5 :A=(<*,U%T=K:-:&]::(/AB8TOH?2+"C-AM(HE.9 :2Z*UK:P
MR?A-?<9_5 2K9W3V#IKJF\>F^M"V%$ISH#0716LKU:3ZIC[5W[\:J;0)&NA#
M:1:49D-I%$ISH#0716LKUUP>,,?P8RGT:@&49D%I-I1&H30'2G-1M+:%S=4"
M4W_[_&7Q]$5^7W1QZW.9SI9Q;2QV6Q;5]TN7GQ0GGBQ4V@F]BF J;CQ7WJ@!
M;6M#:11*<Z T%T4KQ>OO/=\;<K$IGO5.2+%;*Y]9K=^MGR>_+)ZB/GC?,L[L
M\JGP!E,^I'[-Q,:/$A+PM40.3J;RER/*Y[[+%VF\*YXB?HS3- Z+R2UG*R[R
M&>3GZSA.7U[D#>JG[^<_ 5!+ P04    "  /0'96B"IL/K\"  !,"   &0
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MW72E*E946T5'T$P7+$]4R/)'-R-9H0)3 7)^0^6M4G;4!ZJ:U_\'4$L#!!0
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M&ZC[2\;DRXD.T&QK^?\!4$L#!!0    (  ] =E:(,T2AAP0  #09   9
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MJ2O5_<HL-VRPKVML=  ;(G#',KD6X#:+2-0'<!71EBUZ97N-C(@W)+P /OP
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MF.LR%^;,<\<?=1+1D0Z6YH4D7/6$MLJJ"A0LEEO,B5:M$?/4"6@+K3\"G06
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M+O1T-%_(8I'_@ZV)]51PF G)D@*L,D@(-5>T*WPX +C>"P!8 . IH/T"H%4
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M8JX#U/TE8W(_T1N43;#_#U!+ P04    "  /0'96L6\I;Z4"  !J"0  &0
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MU;D-9*"LO"4I&X(6^MY@186@F7Y4LP),&<CW:TK%>T,-4-U53?X!4$L#!!0
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M,^#_)F)05P:41FJ:]8(_"0[S,*C? D6S-6P=%\]MN5S&69SF::=0H!X+*(V
MTB@H+82BV8JVAHWGPR1=2+=C 4HCH#0*2@NA:+:\K;/CN:V='AZIF]1;84@:
M :514%I8TYPVKZU>:PMY;E^H3K?H7[3,[Q3_FO-,(_YH/CL%!'6)0&D$E$9!
M:2$4S1:Y]9.\*4P&!O640&D$E$9!:2$4S9:W-98\I[_1*P.#NDN@- )*HS7M
MV[^AA5#UVK_"M^X1=KM'E^SIM06O.[*O6J T DJCH+00BF8KVEI)V -)MQC4
M1 *E$5 :!:6%4#1;WM9$PDX7HT^Z=9-Z*PSJ(X'2*"@MK&G.Y&VKUWI$V.T1
MU>GVC0M>-ZRW@*#>$"B-@M)"*)HM<FLBX0E,!@9UE$!I!)1&06DA%,V6MW64
ML'L/4)\,#&HJ@=((*(WBCNU.H^X5+U3%E7S#O4VW*9?WY?9HA2*19[K:CMI<
M;;9@?RPW'A]<7WBGI-I(W6*J?=V73-['F4()7QODZ.C8=$!66Z6K$RVVY=;>
M.Z&U2,O##6<K+HL"YONU$/KYI*B@V; ^_P]02P,$%     @ #T!V5L#I[!52
M!0  324  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULM9IA<^(V$(;_
MBH9VVKN9-M@R&)(",PG*S67:S*4AZ4T_*K8 3VR+DT7(_?M*MF-C+-3XLLF'
M@(WVE?:QM.P*379</&9KQB1Z3N(TF_;64F[.^OTL6+.$9B=\PU+UR9*+A$IU
M*5;];",8#7.C).YCQ_'["8W2WFR2W[L1LPG?RCA*V8U V39)J/A^P6*^F_;<
MWLN-VVBUEOI&?S;9T!5;,'F_N1'JJE^IA%'"TBSB*1)L.>V=NV?$<[1!WN*?
MB.VRO?=(N_+ ^:.^N JG/4>/B,4LD%J"JI<G-F=QK)74.+Z5HKVJ3VVX__Y%
M_5/NO'+F@69LSN.O42C7T]ZXAT*VI-M8WO+=9U8Z--1Z 8^S_#_:%6U]OX>"
M;29Y4AJK$2116KS2YQ+$GH$[.&* 2P-\:'"L!Z\T\%[;PZ T&.1D"E=R#H1*
M.IL(OD-"MU9J^DT.,[=6[D>I?NX+*=2GD;*3L\7=E_F?G[_\12YO%[^BR[_O
MK^[^1;^C\S",]'.A,;I*B]FEG]('PB2-XNRC:G*_(.C#SQ\G?:F&H<7Z0=GE
MO.@2'^G2Q>B:IW*=H<LT9&%3H*_&7SF!7YRXP%;%:RI.D.O_AK"#7=. [.:$
M!2?(<W-S;# GKS=W+=YXU2/Q<CVOPR,QC.JB4!F8572\.,LV-&#3G@H(&1-/
MK#?[Y2?7=_XP$8(4(T!B#7J#BM[ ICZ[RK(M30.&^!(%/$G4K,W65/6#U#1&
M <W6Z$/T<L\T>R\*_6&NK\/FT\S#>(S'_J3_M(_,.HZNR(#$&LB&%;+A&Y&9
M,%DUNTZ_0LS?8ZX7D^<TD9-VLR$>#O%H.*X:-@CX%0'?2N!&\("Q4#DL>(+V
M><P+'@O)@T<3!=\P(M_1?P>SI=W0Z*%)S^;AJ/)P9/4P=P#QC0[C&6+/3 11
MQL)7+PJK>M>G#2E&1JWEZ@Y\,ZQQ!6MLA759XD$;$07,A,-JWQ4'I!@IQ,;[
M\\P]P68>IQ6/TS=-'A,AJV)70I!BY+2UQ#QG/#(3<ITZCW*LC-1J=M#EMVTD
MOZN4*6"ISF?134Q3$QV[6%<\H&H$2JT)<B\A=4'2GU(&"B&D&H%2:R+$-4+\
MSCF0O8/.<'$[I1KA(3[X[H/JM$FM3KM=:U[Z@VF07;0S*:\5G-RQBBR':0)4
MKTU4=8[MVI/L\[MK=+X2C"4JSAFI0";'<U U J769%<GV^X0)KZ!)MB@:@1*
MK8FPSM9=>[H.$-^L'72&Z[?BF^_X0_=PT0)UVJ165P"NO03X\2+'+MR9ULA8
M"K5C'%"O35QU#>#:BX +3D6HT6Q8FN7;7T8TH)4 J!J!4FL"K(L&]Q0FT(&6
M"J!J!$JMN:U9%Q787E3L+](RPNV%O&/+U2[:%2BH&BG5&J'2PZ?FZ@O710.V
M9M2S3S02Z(G&6_8J0*"E Z@:*=6:T;&QG]1$5!<%V%X4_%^0MYMWA@*I1J#4
MFNCJR@##[,ACT%H 5(U J341UA4#?N]M>7L'G>&V=_E-*9NAV>&/ 4T@=1F
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M831BPIR@/U]QKEYW3(+J193%OU!+ P04    "  /0'96SNQ=2<(#  #.%
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M<PK8)HHP?9^0,-D--:CM'[P$JS67#XS1(,4KLB#\[W1.Q9U11O&#B,0L2&)
MR7*HC>&#"VWID%G\$Y =.[H&4LIKDGR7-Y_]H6;*$9&0>%R&P.)K2Z8D#&4D
M,8Y_BZ!:F5,Z'E_OHW_*Q LQKYB1:1)^"WR^'FJ.!GRRQ)N0OR2[/TDAJ"?C
M>4G(LD^PRVUM2P/>AO$D*IS%"*(@SK_Q6P'BR 'U3CB@P@'5'4YEZ!0.G7,S
M= N';D8FEY)Q<#''HP%-=H!*:Q%-7F0P,V\A/XCEO"\X%;\&PH^/%E]GT[_
M;/[U\^P9S+^,GQ?@'BQXXGT'LS2;F;&<F8"_@U]=PG$0LM^$Q<_  &R-*6$#
M@XMAR&"&5Z2<Y"G1B900@:<DYFL&'F.?^-4 AAA_*0+M14R0,J)+/!UTX!U
M)D(M YJ>[PY;W-WSW4V%FDXY)9TL7D<U)?>3\>+1!=/9T_SQ>3&6T]-&.H_4
M;8\D:\8#2[%'AIHH"HS0+=%&O_P$+?/W-DJW#.;>*%B%8+<DV%5%'SUOHE="
M0;($BVR-@MF&,XYC/XA7=V!"5D$<BTLPP2&./=(&-D_0RQ+(VKD=V99CH<[
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MM.I5!KBT)2FB5;% O5YD;Y6T2@4=J*!;K90S7T)%PHKNCJ7;C6739M?3^PU
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MJOFH%J!:N-0:)Z<'IQMS>K3+&-422FMFK%9GK";-V#C/1D+<SY2'/'M6Q.K
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M0FG-+*R+?K2]13^R>;FTZ$=.=]ZQ1(M^4,U -1/5+%2S4<U!-1?5/%3S42U
MM1#5(E2+42VAM&:8UD4_&E?THZ%%/ZBFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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MP=IGP6JQ8G-86]);HE6E[[L<L[&;^)^:M0\^Y);3K:G9&CO5%KRO6;W4Y,;
M5FGOSY%'UT1DW6.Q6IPO1FE7_6Y]K,X=:?.\QV2'ECO,5B'A*(*E1!J7/;F1
M6'8.R":")FDK_4R%;,S382#/3L"4@;R^I%3L)NH&Q6G,_0-02P,$%     @
M#T!V5A3*;7H;!0  )!P  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL
MM9EK;^(X%(;_BI5=C6:DI8F=&W0 B8'.[DB=F:JTL_O5! -6DYBU#;3[Z]<.
M:0)*XA)$OT!NYW4>7]_C]'>,/XD5(1(\)W$J!M9*RO6U;8MH11(LKMB:I.K.
M@O$$2W7*E[98<X+G65 2V\AQ CO!-+6&_>S:'1_VV4;&-"5W'(A-DF#^\H7$
M;#>PH/5ZX9XN5U)?L(?]-5Z2*9&/ZSNNSNQ"94X3D@K*4L#)8F"-X/78=71
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M>?!ZN=40C5/9[FB><\SV?"[@*8=,DLD&GZ)F2Z,"X=8CU'EP*=8TA*&!"2^
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MCP#F=Q#'& )/(XY@#L #AL2Q?0_NO(^BU7LJ6O]_;_0;4$L#!!0    (  ]
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MR#1($X TCP@9)^KGAOH*,+@B04@C#=("(*UW@XR3P-4@;0#2?D?(?PT-<@Q
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  /0'96?UOBGNT    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  /
M0'96F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    (  ] =E9!C1>990<  ,$P   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  /
M0'96?57JQ!T&  #P&0  &               @(&G#P  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ #T!V5OO0;%;$ @  L D  !@
M         ("!^A4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   (  ] =E:7LJ7_O@0  $<4   8              " @?08  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  /0'96&+.)#Q<%  !^&P
M&               @('H'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ #T!V5I(2?SM" @  V@0  !@              ("!-2,  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  ] =E8@A$+@( <
M )X=   8              " @:TE  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  /0'96O4+49AL%  !]"P  &               @($#
M+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #T!V5F2I
M'((R#@  ;"<  !@              ("!5#(  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    (  ] =E8S.MN2\A,  -<Y   9
M  " @;Q   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M#T!V5@HJ+GHY!   :0L  !D              ("!Y50  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  /0'96E!QJS/L"   9"   &0
M            @(%560  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    (  ] =E:XO;U;)04  -0-   9              " @8=<  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ #T!V5O@AEZA_!P
M"Q<  !D              ("!XV$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  /0'96L-"MQQ8$   @"@  &0              @(&9
M:0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  ] =E9F
MI;57_0@  $\6   9              " @>9M  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ #T!V5MMR7"&K"   RQ8  !D
M     ("!&G<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ] =E9-F?LK:04  .L-   9              "
M@2>8  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ #T!V
M5A25?=B""@  <!X  !D              ("!QYT  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  /0'96KQD^\UP#  !F!P  &0
M        @(& J   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   (  ] =E8M?J<3UA0  #1!   9              " @1.L  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ #T!V5J4 --:) @  =P8
M !D              ("!(,$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  /0'96CA/^-D4#  #L"   &0              @('@PP
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  ] =E;EMN6^
M/ ,  /D'   9              " @5S'  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ #T!V5D[G4)QS P  U H  !D
M ("!S\H  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  /
M0'96I.>B9?D"  !1!P  &0              @(%YS@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  ] =E8(K&14Y (  %\'   9
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M970S-2YX;6Q02P$"% ,4    "  /0'96**2^M  +  " DP  &0
M    @('"Y0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M  ] =E9G,C%&C08  (D_   9              " @?GP  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ #T!V5H@J;#Z_ @  3 @  !D
M             ("!O?<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    "  /0'96@*EQ2#<#  !["@  &0              @(&S^@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  ] =E8T8IEA^@(
M /\*   9              " @2'^  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ #T!V5H+G:($6!   XAH  !D              ("!
M4@$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  /0'96
MB#-$H8<$   T&0  &0              @(&?!0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    (  ] =E;K=1#@]0(  ! +   9
M      " @5T* 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ #T!V5K%O*6^E @  :@D  !D              ("!B0T! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  /0'96D+?A=6D#  !J"P
M&0              @(%E$ $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    (  ] =E:\A_=X%@,  ,@+   9              " @044 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ #T!V5LR[52DG
M!   MQ(  !D              ("!4A<! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    "  /0'96\V/ ]?\%  #2'   &0
M@(&P&P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (  ]
M=E9QZ;_+>@4  +PN   9              " @>8A 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ #T!V5L#I[!52!0  324  !D
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M=#4T+GAM;%!+ 0(4 Q0    (  ] =E:\]'\Y\ (  ($(   9
M  " @2 _ 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M#T!V5L3%RXC] @  " L  !D              ("!1T(! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    "  /0'96(6IH0=H0  "/' $ &0
M            @(%[10$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    (  ] =E8U$KC5H@0  +$B   9              " @8Q6 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ #T!V5L$YI7E5!
MDQP  !D              ("!95L! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    "  /0'96GJ"X4CP#  "9#0  &0              @('Q
M7P$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (  ] =E84
MRFUZ&P4  "0<   9              " @61C 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ #T!V5O"TDOFZ P  IQ   !D
M     ("!MF@! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
M"  /0'96,4+(,8$$  !\$0  &0              @(&G; $ >&PO=V]R:W-H
M965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (  ] =E8'*EH1S0(  $,*   9
M              " @5]Q 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L!
M A0#%     @ #T!V5O2UR"LX P  [!,   T              ( !8W0! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  /0'96EXJ[',     3 @  "P
M        @ '&=P$ 7W)E;',O+G)E;'-02P$"% ,4    "  /0'96\81?9$D%
M   \*@  #P              @ &O> $ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ #T!V5M))O&T1 @  %R8  !H              ( !)7X! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #T!V5L"(;73I 0
M?B4  !,              ( !;H ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $@ 2 "O$P  B((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans</Role>
      <ShortName>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - OTHER RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivable</Role>
      <ShortName>OTHER RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - RELATED PARTY DEFERRED REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenue</Role>
      <ShortName>RELATED PARTY DEFERRED REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrants</Role>
      <ShortName>WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - STOCK OPTION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlans</Role>
      <ShortName>STOCK OPTION PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - GRANT INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncome</Role>
      <ShortName>GRANT INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLegalProceedings</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30303 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30603 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30703 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30803 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31103 - Disclosure - WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantsTables</Role>
      <ShortName>WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureWarrants</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31203 - Disclosure - STOCK OPTION PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansTables</Role>
      <ShortName>STOCK OPTION PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureStockOptionPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31603 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40101 - Disclosure - NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureNatureOfOperations</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails</Role>
      <ShortName>FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERSE - Computation of loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERSE - Computation of loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40501 - Disclosure - OTHER RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureOtherReceivableDetails</Role>
      <ShortName>OTHER RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureOtherReceivable</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40701 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureLeasesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40702 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails</Role>
      <ShortName>LEASES - Quantitative Information About Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40703 - Disclosure - LEASES - Maturities of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails</Role>
      <ShortName>LEASES - Maturities of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40901 - Disclosure - RELATED PARTY DEFERRED REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails</Role>
      <ShortName>RELATED PARTY DEFERRED REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenue</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41001 - Disclosure - STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41002 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41003 - Disclosure - STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41004 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41101 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails</Role>
      <ShortName>WARRANTS - Summary of Share Purchase Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41201 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails</Role>
      <ShortName>STOCK OPTION PLANS - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41202 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails</Role>
      <ShortName>STOCK OPTION PLANS - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41203 - Disclosure - STOCK OPTION PLANS - Stock-based compensation expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails</Role>
      <ShortName>STOCK OPTION PLANS - Stock-based compensation expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41204 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails</Role>
      <ShortName>STOCK OPTION PLANS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41301 - Disclosure - GRANT INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureGrantIncomeDetails</Role>
      <ShortName>GRANT INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureGrantIncome</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41401 - Disclosure - LEGAL PROCEEDINGS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails</Role>
      <ShortName>LEGAL PROCEEDINGS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureLegalProceedings</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41601 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41602 - Disclosure - INCOME TAXES - Additional Information's (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails</Role>
      <ShortName>INCOME TAXES - Additional Information's (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41603 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails</Role>
      <ShortName>INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrkr-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41701 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tapimmune.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrkr-20221231x10k.htm 112, 126</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 8 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrkr-20221231x10k.htm 131</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:IcfrAuditorAttestationFlag, us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockSharesOutstanding, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax -  mrkr-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="mrkr-20221231x10k.htm">mrkr-20221231x10k.htm</File>
    <File>mrkr-20221231.xsd</File>
    <File>mrkr-20221231_cal.xml</File>
    <File>mrkr-20221231_def.xml</File>
    <File>mrkr-20221231_lab.xml</File>
    <File>mrkr-20221231_pre.xml</File>
    <File>mrkr-20221231xex21d1.htm</File>
    <File>mrkr-20221231xex23d1.htm</File>
    <File>mrkr-20221231xex31d1.htm</File>
    <File>mrkr-20221231xex31d2.htm</File>
    <File>mrkr-20221231xex32d1.htm</File>
    <File>mrkr-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrkr-20221231x10k001.jpg</File>
    <File>mrkr-20221231x10k002.jpg</File>
    <File>mrkr-20221231x10k003.jpg</File>
    <File>mrkr-20221231x10k004.jpg</File>
    <File>mrkr-20221231x10k005.jpg</File>
    <File>mrkr-20221231x10k006.jpg</File>
    <File>mrkr-20221231x10k007.jpg</File>
    <File>mrkr-20221231x10k008.jpg</File>
    <File>mrkr-20221231x10k009.jpg</File>
    <File>mrkr-20221231x10k010.jpg</File>
    <File>mrkr-20221231x10k011.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="463">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrkr-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 463,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 135,
   "dts": {
    "calculationLink": {
     "local": [
      "mrkr-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrkr-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrkr-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrkr-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrkr-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrkr-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 479,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 15
   },
   "keyCustom": 73,
   "keyStandard": 236,
   "memberCustom": 21,
   "memberStandard": 24,
   "nsprefix": "mrkr",
   "nsuri": "http://www.tapimmune.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2023_To_12_31_2023_NlI_rrXrCkWSdi8cy_jNIA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2023_To_12_31_2023_NlI_rrXrCkWSdi8cy_jNIA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - OTHER RECEIVABLE",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivable",
     "shortName": "OTHER RECEIVABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.tapimmune.com/role/DisclosureLeases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:RelatedPartyLiabilityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - RELATED PARTY DEFERRED REVENUE",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenue",
     "shortName": "RELATED PARTY DEFERRED REVENUE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:RelatedPartyLiabilityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - STOCKHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - WARRANTS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.tapimmune.com/role/DisclosureWarrants",
     "shortName": "WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - STOCK OPTION PLANS",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlans",
     "shortName": "STOCK OPTION PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - GRANT INCOME",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncome",
     "shortName": "GRANT INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - LEGAL PROCEEDINGS",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.tapimmune.com/role/DisclosureLegalProceedings",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.tapimmune.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_RYoECPvlqUm2SecYEAk3nw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - WARRANTS (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantsTables",
     "shortName": "WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_RYoECPvlqUm2SecYEAk3nw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - STOCK OPTION PLANS (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables",
     "shortName": "STOCK OPTION PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31603 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - NATURE OF OPERATIONS (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
     "shortName": "NATURE OF OPERATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_26_2023_To_1_26_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oBMB2ozYCUm78jnnAf9ERw",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
     "shortName": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERSE - Computation of loss per Share (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERSE - Computation of loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:NetLossPerShareTableTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails",
     "shortName": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:NetLossPerShareTableTextBlock",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - OTHER RECEIVABLE (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
     "shortName": "OTHER RECEIVABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_mrkr_CancerPreventionAndResearchInstituteOfTexasMember_EA2qnlAMxUapgXjRK0-39A",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:TenantImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "PROPERTY AND EQUIPMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "mrkr:DecreaseInOperatingLeaseLiabilitiesForLeaseTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - LEASES (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_9_15_2022_5YncGszr_keCQuNpycEpqw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "mrkr:DecreaseInOperatingLeaseLiabilitiesForLeaseTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - LEASES - Quantitative Information About Operating Leases (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails",
     "shortName": "LEASES - Quantitative Information About Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - LEASES - Maturities of Operating Leases (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails",
     "shortName": "LEASES - Maturities of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - RELATED PARTY DEFERRED REVENUE (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
     "shortName": "RELATED PARTY DEFERRED REVENUE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "mrkr:RelatedPartyLiabilityDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_4_21_2022_To_4_21_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_WilsonWolfManufacturingCorporationMember_us-gaap_TypeOfArrangementAxis_mrkr_BindingServicesAgreementMember_p3AkCfuaPEe3Clp-91DJCA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Discretion of the Board of Directors and Common Stock Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RecapitalizationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_w83Z75SCO0eyEia6vDIBxw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_mrkr_EquityIncentivePlan2020Member_ZndJEwD3ZU-JpnCyiv4UJw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_3_16_2021_To_3_16_2021_hKNIFWpZH0iuhJaQKVYK3Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Underwritten Public Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_3_11_2021_To_3_11_2021_ipD27hsbDkSP-aqaxEKH-A",
      "decimals": "-5",
      "lang": null,
      "name": "mrkr:OfferingCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Stock Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_LincolnParkMember_us-gaap_SubsidiarySaleOfStockAxis_mrkr_StockPurchaseAgreementMember_DRQziVPupkyucYZQUxu7CQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - WARRANTS - Summary of Share Purchase Warrants (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails",
     "shortName": "WARRANTS - Summary of Share Purchase Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SharePurchaseWarrantsTableTextBlockTableTextBlock",
       "mrkr:WarrantsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "lang": null,
      "name": "mrkr:NumberOfWarrantExpiredOrCancelled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_tHUbSco0xUeove4pVpjtLA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - STOCK OPTION PLANS - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
     "shortName": "STOCK OPTION PLANS - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FmMvSpYhpE2affqGUFKLig",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_Ef8p4i7EMk-QkU6jpNwKzg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - STOCK OPTION PLANS - Weighted Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails",
     "shortName": "STOCK OPTION PLANS - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:StockBasedCompensationExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - STOCK OPTION PLANS - Stock-based compensation expenses (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails",
     "shortName": "STOCK OPTION PLANS - Stock-based compensation expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:StockBasedCompensationExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41204 - Disclosure - STOCK OPTION PLANS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
     "shortName": "STOCK OPTION PLANS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "mrkr:GrantIncomePolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_8_1_2021_To_8_31_2021_IHJPpiBv5k6NuYUC-q7-pg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "mrkr:ReceiptOfProductDevelopmentResearchAward",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - GRANT INCOME (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
     "shortName": "GRANT INCOME (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_9_13_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_UoBREzfn7kO2CeAdFJzHPQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "mrkr:CompensationInterestAndAttorneyFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - LEGAL PROCEEDINGS (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails",
     "shortName": "LEGAL PROCEEDINGS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "mrkr:CompensationInterestAndAttorneyFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails",
     "shortName": "INCOME TAXES - Summary of Effects of Temporary Differences that Give Rise to Significant Portions of the Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41602 - Disclosure - INCOME TAXES - Additional Information's (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
     "shortName": "INCOME TAXES - Additional Information's (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_XFc3fCjNnUyhCRZDbIDzzQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41603 - Disclosure - INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails",
     "shortName": "INCOME TAXES- Summary of Expected Tax Expense (Benefit) Based on the U.S. Federal Statutory Rate is Reconciled with the Actual Tax Provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "mrkr:SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_3_14_2023_To_3_14_2023_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_mrkr_AllovirIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1XuOmQ5XPUeNbdcsl4Y23g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_I-vymenjK0mVlqc2dBnDHw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - NATURE OF OPERATIONS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.tapimmune.com/role/DisclosureNatureOfOperations",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans",
     "shortName": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrkr-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_n8b2hGZVZEqMPvdTQ67wNQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrkr:LiquidityFinancialConditionAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Payable And Accrued Liabilities [Line Items]",
        "verboseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_AccountsPayableAndAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table lists the accounts payable and accrued liabilities. The line items identify information about the accounts payable and accrued liabilities.",
        "label": "Accounts Payable And Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesTable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_AccruedProcessDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for Process development expenses.",
        "label": "Accrued Process Development Expenses, Current",
        "terseLabel": "Process development expenses"
       }
      }
     },
     "localname": "AccruedProcessDevelopmentExpensesCurrent",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_AccruedTechnologyLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Consulting agreements payable.",
        "label": "Accrued Technology License Fees",
        "terseLabel": "Technology license fees"
       }
      }
     },
     "localname": "AccruedTechnologyLicenseFees",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional amount agreed to received from Wilson Wolf if the Work Direction is completed within one year from the onset of the agreement.",
        "label": "Additional Amount Agreed To Pay If The Work Direction Is Completed Within One Year From The Onset Of The Agreement",
        "terseLabel": "Additional amount agreed to received from Wilson Wolf if the Work Direction is completed within one year from the onset of the agreement"
       }
      }
     },
     "localname": "AdditionalAmountAgreedToPayIfWorkDirectionIsCompletedWithinOneYearFromOnsetOfAgreement",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_AdditionalAttorneyFeesAwarded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Amount of additional attorney fees awarded.",
        "label": "Additional attorney fees awarded",
        "terseLabel": "Additional attorney fees awarded"
       }
      }
     },
     "localname": "AdditionalAttorneyFeesAwarded",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_AllovirIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AlloVir, Inc.",
        "label": "AlloVir, Inc [Member]",
        "terseLabel": "AlloVir, Inc"
       }
      }
     },
     "localname": "AllovirIncMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_AmountOfAwardGrantFromOrphanProductGrantProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Award grant from orphan product grant program.",
        "label": "Amount Of Award Grant From Orphan Product Grant Program",
        "terseLabel": "Amount of award grant from orphan product grant program"
       }
      }
     },
     "localname": "AmountOfAwardGrantFromOrphanProductGrantProgram",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ArbitrationSettlementLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for arbitration.",
        "label": "Arbitration Settlement Liabilities, Current",
        "terseLabel": "Arbitration settlement fees"
       }
      }
     },
     "localname": "ArbitrationSettlementLiabilitiesCurrent",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_AtmAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for  ATM agreement.",
        "label": "ATM Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtmAgreementMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_BindingServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for binding services agreement.",
        "label": "Binding Services Agreement [Member]",
        "terseLabel": "Binding Services Agreement"
       }
      }
     },
     "localname": "BindingServicesAgreementMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_BoardCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for board compensation.",
        "label": "Board Compensation [Member]",
        "terseLabel": "Board Compensation"
       }
      }
     },
     "localname": "BoardCompensationMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_BrokerWasAwardedAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Amount of legal proceedings broker\n awarded accrued interest amount.\"",
        "label": "Broker was awarded accrued interest",
        "terseLabel": "Broker was awarded accrued interest"
       }
      }
     },
     "localname": "BrokerWasAwardedAccruedInterest",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_CancerPreventionAndResearchInstituteOfTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The information pertaining to cancer Ppevention And Research Institute Of Texas.",
        "label": "Cancer Prevention And Research Institute Of Texas [Member]",
        "terseLabel": "Cancer Prevention And Research Institute Of Texas"
       }
      }
     },
     "localname": "CancerPreventionAndResearchInstituteOfTexasMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cantor Fitzgerald &amp; Co and RBC Capital Markets, LLC.",
        "label": "Cantor Fitzgerald Co. And Rbc Capital Markets Llc [Member]",
        "terseLabel": "Sales Agents"
       }
      }
     },
     "localname": "CantorFitzgeraldCo.AndRbcCapitalMarketsLlcMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of changes to right-of-use assets and lease liability due to close out of an operating lease.",
        "label": "Change To Right Of Use Assets And Lease Liability Due To Close Out Of An Operating Lease",
        "terseLabel": "Changes to right-of-use assets and lease liability due to close out of operating leases"
       }
      }
     },
     "localname": "ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights outstanding exercised weighted average exercise price.",
        "label": "Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash",
        "verboseLabel": "Weighted Average Exercise Price, Exercised for cash"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights outstanding expired or Cancelled weighted average exercise price.",
        "label": "Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Expired or cancelled"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price.",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrkr_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right outstanding issued weighted average remaining life.",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life",
        "verboseLabel": "Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clinical Trial Agreement with Baylor College of Medicine.",
        "label": "Baylor College of Medicine [Member]",
        "terseLabel": "Baylor College of Medicine"
       }
      }
     },
     "localname": "ClinicalTrialAgreementWithBaylorCollegeOfMedicineMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_CommitmentFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of commitment fees.",
        "label": "Commitment Fee",
        "terseLabel": "Commitment fee"
       }
      }
     },
     "localname": "CommitmentFee",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_CommonStockCapitalSharesReservedForFutureIssuanceTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock capital shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance [Table]",
        "terseLabel": "Common Stock Capital Shares Reserved For Future Issuance [Table]"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceTable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percent of calculation of compensation rate by using gross sales price per share sold.",
        "label": "Common Stock, Shares, Commission Rate Calculation on Gross Sales Price per Share, Percent",
        "terseLabel": "Commission rate"
       }
      }
     },
     "localname": "CommonStockSharesCommissionRateCalculationOnGrossSalesPricePerSharePercent",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_CommonStockWarrantsEquityTreatment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants - equity treatment.",
        "label": "Common Stock Warrants Equity Treatment",
        "verboseLabel": "Common stock purchase warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsEquityTreatment",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_CompensationInterestAndAttorneyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation, interest and attorney fees.",
        "label": "Compensation, Interest And Attorney fees",
        "terseLabel": "Compensation, interest and attorney fees"
       }
      }
     },
     "localname": "CompensationInterestAndAttorneyFees",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computers, equipment and software",
        "terseLabel": "Computers, equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgress",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ControlledEquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to controlled equity offering sales agreement.",
        "label": "Controlled Equity Offering Sales Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "ControlledEquityOfferingSalesAgreementMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_DecreaseInOperatingLeaseLiabilitiesForLeaseTermination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction in operating lease liabilities for termination of lease.",
        "label": "Decrease In Operating Lease Liabilities For Lease Termination",
        "terseLabel": "Reduction in operating lease liabilities for lease termination"
       }
      }
     },
     "localname": "DecreaseInOperatingLeaseLiabilitiesForLeaseTermination",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction in operating lease right of use assets for termination of lease.",
        "label": "Decrease In Operating Lease Right Of Use Assets For Lease Termination",
        "terseLabel": "Reduction in right-of-use assets for lease termination"
       }
      }
     },
     "localname": "DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Deferred tax assets, operating lease liability.",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Operating Lease Liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_DeferredTaxLiabilitiesFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax liability, Fixed Assets",
        "label": "Deferred Tax Liabilities, Fixed Assets",
        "negatedLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax liability, Right-of-Use Assets",
        "label": "Deferred Tax Liabilities Right of Use Assets",
        "negatedLabel": "Right-of-Use Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_Deferredtaxassetslicenseagreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets license agreement.",
        "label": "Deferred tax assets license agreement",
        "verboseLabel": "License Agreement"
       }
      }
     },
     "localname": "Deferredtaxassetslicenseagreement",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_Deferredtaxstockbasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax stock based compensation.",
        "label": "Deferred tax stock based compensation",
        "verboseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "Deferredtaxstockbasedcompensation",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the effective tax rate reconciliation due to other permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Other Permanent Differences",
        "verboseLabel": "Permanent differences- Other permanent differences, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_EquityIncentiveAwards2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to Equity Incentive Awards 2021.",
        "label": "2021 Equity Incentive Awards",
        "terseLabel": "2021 Equity Incentive Awards"
       }
      }
     },
     "localname": "EquityIncentiveAwards2021Member",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to 2020 equity incentive plan.",
        "label": "Equity Incentive Plan 2020 [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_EquityIncentivePlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to 2022 equity Incentive Plan.",
        "label": "2022 Equity Incentive Awards",
        "terseLabel": "2022 Equity Incentive Awards"
       }
      }
     },
     "localname": "EquityIncentivePlan2022Member",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ExerciseOfStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of Stock Warrants.",
        "label": "Exercise of Stock Warrants [Member]",
        "terseLabel": "Exercise of Stock Warrants"
       }
      }
     },
     "localname": "ExerciseOfStockWarrantsMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_FinancialConditionGoingConcernAndManagementPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Line Items]",
        "terseLabel": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "localname": "FinancialConditionGoingConcernAndManagementPlansLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_FinancialConditionGoingConcernAndManagementPlansTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS [Table]"
       }
      }
     },
     "localname": "FinancialConditionGoingConcernAndManagementPlansTable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_FundsReceivedFromCpritGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds Received From Grant",
        "label": "Funds received from CPRIT grant",
        "terseLabel": "Funds received from CPRIT grant"
       }
      }
     },
     "localname": "FundsReceivedFromCpritGrant",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_FundsReceivedFromGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received from CPRIT grant",
        "label": "Funds Received From Grant",
        "terseLabel": "Funds received from CPRIT grant"
       }
      }
     },
     "localname": "FundsReceivedFromGrant",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_GainLossOnTerminationOfLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of leases term.",
        "label": "Gain Loss On Termination Of Leases",
        "negatedLabel": "Gain on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLeases",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_GainLossRelatedToArbitrationSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) pertaining to the arbitration that was charged against earnings in the period.",
        "label": "Gain (Loss) Related to Arbitration Settlement",
        "terseLabel": "Arbitration settlement"
       }
      }
     },
     "localname": "GainLossRelatedToArbitrationSettlement",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_GrantIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represents grant income.",
        "label": "Grant Income [Line Items]",
        "terseLabel": "GRANT INCOME"
       }
      }
     },
     "localname": "GrantIncomeLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_GrantIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant income.",
        "label": "Grant Income, Policy [Policy Text Block]",
        "terseLabel": "Grant Income"
       }
      }
     },
     "localname": "GrantIncomePolicyPolicyTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_GrantIncomeReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of grant income receivable by the company, as of the balance sheet date.",
        "label": "Grant Income Receivable",
        "terseLabel": "Grant income receivable"
       }
      }
     },
     "localname": "GrantIncomeReceivable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_GrantIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table lists the grant income.",
        "label": "Grant Income [Table]"
       }
      }
     },
     "localname": "GrantIncomeTable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_GrantReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of grant income transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Grant Received",
        "terseLabel": "Grant income received"
       }
      }
     },
     "localname": "GrantReceived",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_LegalProceedingsBrokerAwardedAdditionalInterestAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of legal proceedings broker awarded additional interest amount.",
        "label": "Legal Proceedings Broker Awarded Additional Interest Amount",
        "terseLabel": "Broker was awarded with additional in interest"
       }
      }
     },
     "localname": "LegalProceedingsBrokerAwardedAdditionalInterestAmount",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_LincolnParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The information pertaining to Lincoln Park.",
        "label": "Lincoln Park [Member]",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "localname": "LincolnParkMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "localname": "LiquidityFinancialConditionAndGoingConcernAbstract",
     "nsuri": "http://www.tapimmune.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mrkr_LiquidityFinancialConditionAndGoingConcernTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity Financial Condition And Going Concern Text Block",
        "label": "Liquidity Financial Condition And Going Concern [Text Block]",
        "terseLabel": "FINANCIAL CONDITION, GOING CONCERN AND MANAGEMENT PLANS"
       }
      }
     },
     "localname": "LiquidityFinancialConditionAndGoingConcernTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_ManufacturingFacilityInHoustonTexasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Manufacturing facility in Houston, Texas",
        "terseLabel": "Manufacturing facility in Houston, Texas"
       }
      }
     },
     "localname": "ManufacturingFacilityInHoustonTexasMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_NetLossPerShareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net loss per share.",
        "label": "Net Loss Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities"
       }
      }
     },
     "localname": "NetLossPerShareTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Employee Stock Option",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_NonExecutiveEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to non-executive employees.",
        "label": "Non-executive employees",
        "terseLabel": "Non-executive employees"
       }
      }
     },
     "localname": "NonExecutiveEmployeesMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_NumberOfAdditionalSharesAuthorizedToIssueAndSell": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of additional shares authorized to issue and sell.",
        "label": "Number Of Additional Shares Authorized To Issue And Sell",
        "terseLabel": "Number of additional shares authorized to issue and sell"
       }
      }
     },
     "localname": "NumberOfAdditionalSharesAuthorizedToIssueAndSell",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_NumberOfEqualMonthlyInstallmentsForVestingOfAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal monthly installments for option award vesting over the vesting period.",
        "label": "Number of Equal Monthly Installments for Vesting of Awards",
        "terseLabel": "Number of equal monthly installments of award"
       }
      }
     },
     "localname": "NumberOfEqualMonthlyInstallmentsForVestingOfAwards",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrkr_NumberOfSharesAuthorizedToIssueAndSell": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares authorized to issue and sell.",
        "label": "Number Of Shares Authorized To Issue And Sell",
        "terseLabel": "Number of shares authorized to issue and sell"
       }
      }
     },
     "localname": "NumberOfSharesAuthorizedToIssueAndSell",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_NumberOfWarrantExpiredOrCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants expired or cancelled.",
        "label": "Number of Warrants, Expired or cancelled",
        "negatedTerseLabel": "Number of Warrants, Expired or cancelled"
       }
      }
     },
     "localname": "NumberOfWarrantExpiredOrCancelled",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_OfferingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of offering cost.",
        "label": "Offering Cost",
        "terseLabel": "Offering cost"
       }
      }
     },
     "localname": "OfferingCost",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_OperatingLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease Expense [Abstract]",
        "terseLabel": "Operating lease expense summary:"
       }
      }
     },
     "localname": "OperatingLeaseExpenseAbstract",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_OperatingLossCarryforwardsLimitationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of limitation for operating loss carryforwards",
        "label": "Operating Loss Carryforwards Limitation Percentage"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationPercentage",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_OperationalCostReductionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for operational cost reduction plan.",
        "label": "Operational Cost Reduction Plan [Member]",
        "terseLabel": "Operational Cost Reduction Plan"
       }
      }
     },
     "localname": "OperationalCostReductionPlanMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Line Items]",
        "terseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about organization, consolidation and presentation of financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_OrphanProductsGrantProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable from FDA's Orphan Products Grant program.",
        "label": "Orphan Products Grant Program",
        "terseLabel": "Grant income receivable"
       }
      }
     },
     "localname": "OrphanProductsGrantProgram",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_OtherLeaseInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other Lease Information [Abstract]",
        "terseLabel": "Other information:"
       }
      }
     },
     "localname": "OtherLeaseInformationAbstract",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_PaymentsForConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of Construction in Progress.",
        "label": "Payments For Construction in Progress",
        "negatedLabel": "Purchase of construction in progress"
       }
      }
     },
     "localname": "PaymentsForConstructionInProgress",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; excluding cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment Excluding Construction In Progress",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_PercentageOfAccrualOfPostJudgmentInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of accrual of post judgment interest until judgment is paid.",
        "label": "Percentage of Accrual of Post Judgment Interest",
        "terseLabel": "Percentage of accrual of post judgment interest"
       }
      }
     },
     "localname": "PercentageOfAccrualOfPostJudgmentInterest",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for completion of optimization work under the direction of Wilson Wolf which Marker will make good faith efforts.",
        "label": "Period For Completion Of Optimization Work Under Direction Of Wilson Wolf Which Marker Will Make Good Faith Efforts From The Agreement Date",
        "terseLabel": "Period for completion of optimization work under the direction of Wilson Wolf which Marker will make good faith efforts from the agreement date"
       }
      }
     },
     "localname": "PeriodForCompletionOfOptimizationWorkUnderDirectionOfWilsonWolfWhichMarkerWillMakeGoodFaithEffortsFromAgreementDate",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_Permanentdifferencesotherpermanentdifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Permanent differences other permanent differences.",
        "label": "Permanent differences other permanent differences",
        "negatedLabel": "Permanent differences- Other permanent differences"
       }
      }
     },
     "localname": "Permanentdifferencesotherpermanentdifferences",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for property and equipment, construction in progress.",
        "label": "Property And Equipment Construction In Progress, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment - Construction in Progress"
       }
      }
     },
     "localname": "PropertyAndEquipmentConstructionInProgressPolicyPolicyTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_PropertyPlantAndEquipmentOtherThanConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Excludes construction in progress.",
        "label": "Property, Plant and Equipment Other Than Construction in Progress",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherThanConstructionInProgress",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_PurchasesFromBioTechneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about the purchases from bio techne corporation.",
        "label": "Bio-Techne Corporation [Member]",
        "terseLabel": "Bio-Techne Corporation"
       }
      }
     },
     "localname": "PurchasesFromBioTechneCorporationMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_ReceiptOfProductDevelopmentResearchAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipt of product development research award",
        "label": "Receipt Of Product Development Research Award",
        "terseLabel": "Receipt of product development research award"
       }
      }
     },
     "localname": "ReceiptOfProductDevelopmentResearchAward",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ReclassificationsBetweenConstructionInProgressAndFixedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reclassifications between construction in progress and fixed assets",
        "label": "Reclassifications Between Construction in Progress and Fixed Assets",
        "terseLabel": "Reclassifications between construction in progress and fixed assets"
       }
      }
     },
     "localname": "ReclassificationsBetweenConstructionInProgressAndFixedAssets",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to make, use, and sell Marker's cell culture non-proprietary media formulation.",
        "label": "Related Party Advance Received For Non Exclusive Training To Make Use And Sell Marker&amp;rsquo;s Cell Culture Non Proprietary Media Formulation",
        "terseLabel": "Advance received for non-exclusive training of Wilson Wolf to make, use, and sell Marker's cell culture non-proprietary media formulation"
       }
      }
     },
     "localname": "RelatedPartyAdvanceReceivedForNonExclusiveTrainingToMakeUseAndSellMarkersCellCultureNonProprietaryMediaFormulation",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to be able to replicate Marker's cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process.",
        "label": "Related Party Advance Received For Non Exclusive Training To Replicate Marker&amp;rsquo;s cGMP Compliant Linearly Scalable G-Rex Based T-Cell Manufacturing Process",
        "terseLabel": "Advance received for non-exclusive training of Wilson Wolf to replicate Marker's cGMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process"
       }
      }
     },
     "localname": "RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersCgmpCompliantLinearlyScalableGRexBasedTCellManufacturingProcess",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of advance received from Wilson Wolf Mission for giving non-exclusive training of Wilson Wolf to replicate Marker's quality management system inclusive of all underlying documents.",
        "label": "Related Party Advance Received For Non Exclusive Training To Replicate Marker&amp;rsquo;s Quality Management System Inclusive Of All Underlying Documents",
        "terseLabel": "Advance received for non-exclusive training of Wilson Wolf to replicate Marker's quality management system inclusive of all underlying documents"
       }
      }
     },
     "localname": "RelatedPartyAdvanceReceivedForNonExclusiveTrainingToReplicateMarkersQualityManagementSystemInclusiveOfAllUnderlyingDocuments",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of advance received under the hired to invent doctrine for Marker to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes using G-Rex and to conduct CAR T and TCR G-Rex Optimization Work under the direction of Wilson Wolf (the \"Work Direction\").",
        "label": "Related Party Advance Received Under The Hired To Invent Doctrine For Marker To Train Wilson Wolf On Its Expertise In The Optimization Of T-Cell Therapy Manufacturing Processes",
        "terseLabel": "Advance received under the hired to invent doctrine for Marker to train Wilson Wolf on its expertise in the optimization of T-cell therapy manufacturing processes"
       }
      }
     },
     "localname": "RelatedPartyAdvanceReceivedUnderHiredToInventDoctrineForMarkerToTrainWilsonWolfOnItsExpertiseInOptimizationOfTCellTherapyManufacturingProcesses",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_RelatedPartyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyDisclosureAbstract",
     "nsuri": "http://www.tapimmune.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mrkr_RelatedPartyLiabilityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party liability.",
        "label": "Related Party Liability, Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY DEFERRED REVENUE"
       }
      }
     },
     "localname": "RelatedPartyLiabilityDisclosureTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_RetainexistingpolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the Retain existing  policy.",
        "label": "RetainExistingPolicy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "RetainexistingpolicyPolicyTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_RevenueFromGrantRelatedToCprit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grant Related to CPRIT.",
        "label": "Revenue From Grant Related to CPRIT",
        "terseLabel": "Revenue from CPRIT"
       }
      }
     },
     "localname": "RevenueFromGrantRelatedToCprit",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_RevenueFromOrphanProductsGrantProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized for grant from FDA's Orphan Products Grant program.",
        "label": "Revenue From Orphan Products Grant Program",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "RevenueFromOrphanProductsGrantProgram",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents, restricted cash.",
        "label": "Schedule of Cash and Cash Equivalents, Restricted Cash [Table Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsRestrictedCashTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lease cost and other information related to operating leases.",
        "label": "Schedule Of Lease Cost And Other Information Related to Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of quantitative information about operating leases"
       }
      }
     },
     "localname": "ScheduleOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement number of share options available for issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Options Available for Issued",
        "terseLabel": "Number of shares options available to be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOptionsAvailableForIssued",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_SharePurchaseWarrantsTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share purchase warrants.",
        "label": "Share Purchase Warrants [Table Text Block]",
        "terseLabel": "Schedule of share purchase warrants"
       }
      }
     },
     "localname": "SharePurchaseWarrantsTableTextBlockTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options granted in period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items reflecting a significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a significant accounting policies.",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_StockBasedCompensationExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of stock based compensation expenses recorded.",
        "label": "Stock based Compensation Expenses [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expenses"
       }
      }
     },
     "localname": "StockBasedCompensationExpensesTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_StockBasedCompensationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent stock-based compensation.",
        "label": "Stock-Based Compensation [Line Items]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "StockBasedCompensationLineItems",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_StockBasedCompensationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table lists the stock-based compensation.",
        "label": "Stock-Based Compensation [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationTable",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrkr_StockIssuedDuringPeriodAdditionalSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional new stock issued during the period.",
        "label": "Stock Issued During Period Additional Shares New Issues",
        "terseLabel": "Number of additional shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAdditionalSharesNewIssues",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrkr_StockIssuedDuringPeriodValueReverseStockSplits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of stock issued during period, value, reverse stock splits",
        "label": "Stock Issued During Period, Value, Reverse Stock Splits",
        "terseLabel": "Reverse stock split value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrkr_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This Member represents stock purchase agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrkr_SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected tax expense benefit based on federal statutory rate is reconciled with actual tax provision benefit.",
        "label": "Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rate is Reconciled With Actual Tax Provision Benefit [Table Text Block]",
        "terseLabel": "Summary Of Expected Tax Expense Benefit Based On Federal Statutory Rates Reconciled With Actual Tax Provision Benefit"
       }
      }
     },
     "localname": "SummaryOfExpectedTaxExpenseBenefitBasedOnFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitTableTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_Taxcreditcarryforwardexpirationyearrangeend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year range end.",
        "label": "Tax credit carry forward expiration year range end",
        "verboseLabel": "Tax credit carryforwards expiration year end"
       }
      }
     },
     "localname": "Taxcreditcarryforwardexpirationyearrangeend",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mrkr_Taxcreditcarryforwardexpirationyearrangestart": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year range start.",
        "label": "Tax credit carry forward expiration year range start",
        "verboseLabel": "Tax credit carryforwards expiration period"
       }
      }
     },
     "localname": "Taxcreditcarryforwardexpirationyearrangestart",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "mrkr_ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of threshold minimum combined voting power of the surviving entity or parent corporation of the surviving entity immediately after merger, reorganization or consolidation, or the sale or other transfer of all or substantially all of entity's business or assets considered, in the event if the agreement cannot be fulfilled.",
        "label": "Threshold Minimum Combined Voting Power Of Surviving Entity Or Parent Corporation Of Surviving Entity Considered",
        "terseLabel": "Threshold minimum combined voting power of the surviving entity or parent corporation of the surviving entity considered (in percent)"
       }
      }
     },
     "localname": "ThresholdMinimumCombinedVotingPowerOfSurvivingEntityOrParentCorporationOfSurvivingEntityConsidered",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrkr_UnderwritingOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the underwriting option period.",
        "label": "Underwriting Option Period",
        "terseLabel": "Option period"
       }
      }
     },
     "localname": "UnderwritingOptionPeriod",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrkr_WarrantsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsDisclosureAbstract",
     "nsuri": "http://www.tapimmune.com/20221231",
     "xbrltype": "stringItemType"
    },
    "mrkr_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about warrants.",
        "label": "Warrants Disclosure [Text Block]",
        "verboseLabel": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrkr_WilsonWolfManufacturingCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Clinical Trial Agreement with Wilson Wolf Manufacturing Corporation.",
        "label": "Wilson Wolf Manufacturing Corporation [Member]",
        "terseLabel": "Wilson Wolf Manufacturing Corporation"
       }
      }
     },
     "localname": "WilsonWolfManufacturingCorporationMember",
     "nsuri": "http://www.tapimmune.com/20221231",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r224",
      "r227",
      "r412",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive officer",
        "terseLabel": "Executive officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r258",
      "r371",
      "r394",
      "r408",
      "r409",
      "r421",
      "r423",
      "r432",
      "r474",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r258",
      "r371",
      "r394",
      "r408",
      "r409",
      "r421",
      "r423",
      "r432",
      "r474",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r197",
      "r375",
      "r422",
      "r431",
      "r470",
      "r471",
      "r475",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r197",
      "r375",
      "r422",
      "r431",
      "r470",
      "r471",
      "r475",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r256",
      "r258",
      "r284",
      "r285",
      "r286",
      "r370",
      "r371",
      "r394",
      "r408",
      "r409",
      "r421",
      "r423",
      "r432",
      "r467",
      "r474",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r256",
      "r258",
      "r284",
      "r285",
      "r286",
      "r370",
      "r371",
      "r394",
      "r408",
      "r409",
      "r421",
      "r423",
      "r432",
      "r467",
      "r474",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r224",
      "r227",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r121",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r174",
      "r202",
      "r203",
      "r316",
      "r333",
      "r334",
      "r335",
      "r336",
      "r346",
      "r359",
      "r360",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r121",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r174",
      "r202",
      "r203",
      "r316",
      "r333",
      "r334",
      "r335",
      "r336",
      "r346",
      "r359",
      "r360",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r121",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r164",
      "r174",
      "r316",
      "r333",
      "r334",
      "r335",
      "r346",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r465",
      "r466",
      "r509",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r462",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r430"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r108",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r127"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r430"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r453",
      "r454",
      "r455",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid- in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r61",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Net of offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Total stock compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r105",
      "r111",
      "r128",
      "r145",
      "r188",
      "r191",
      "r195",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r326",
      "r330",
      "r337",
      "r430",
      "r472",
      "r473",
      "r517"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r123",
      "r133",
      "r145",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r326",
      "r330",
      "r337",
      "r430",
      "r472",
      "r473",
      "r517"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r145",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r326",
      "r330",
      "r337",
      "r472",
      "r473",
      "r517"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "verboseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r32",
      "r125",
      "r410"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash, Cash Equivalents, Restricted Cash and Credit Risk"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r27",
      "r32",
      "r37"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r27",
      "r93"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r27",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash, FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash financing and investing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash, uninsured amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Issuance of shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Number of Warrants, Ending balance",
        "periodStartLabel": "Number of Warrants, Beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureWarrantsSummaryOfSharePurchaseWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r453",
      "r454",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock par value (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r8",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r430"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value, 30 million and 15 million shares authorized, 8.4 million and 8.3 million shares issued and outstanding as of December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r5",
      "r6",
      "r106",
      "r110",
      "r308"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Taxes and Other Assets [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "auth_ref": [
      "r87",
      "r505"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "terseLabel": "Charitable Contributions"
       }
      }
     },
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r87",
      "r505"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized R&amp;E"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net Deferred Tax Assets/(Liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r87",
      "r505"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net Operating Loss Carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r87",
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r87",
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r86",
      "r87",
      "r505"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r87",
      "r505"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r30",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r30",
      "r186"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r261",
      "r289",
      "r290",
      "r292",
      "r296",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "STOCK OPTION PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTION PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r14",
      "r215",
      "r216",
      "r217",
      "r221",
      "r222",
      "r223",
      "r364",
      "r452"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party deferred revenue"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY DEFERRED REVENUE"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r140",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r166",
      "r168",
      "r170",
      "r171",
      "r172",
      "r174",
      "r335",
      "r336",
      "r389",
      "r392",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "verboseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r140",
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r168",
      "r170",
      "r171",
      "r172",
      "r174",
      "r335",
      "r336",
      "r389",
      "r392",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "verboseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Income tax provision (benefit), Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r146",
      "r302",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "U.S. federal statutory rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r503",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r319",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax rate change, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r503",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Deferred true-up, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r503",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes, net of federal benefit, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Lab and manufacturing equipment",
        "terseLabel": "Lab and manufacturing equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r61",
      "r120",
      "r137",
      "r138",
      "r139",
      "r150",
      "r151",
      "r152",
      "r154",
      "r161",
      "r164",
      "r175",
      "r201",
      "r242",
      "r293",
      "r294",
      "r295",
      "r315",
      "r316",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r360",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign tax authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "FDA's orphan products grant program, grant receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment Testing of Long-Lived Assets and Right-Of-Use Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r206",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r303",
      "r306",
      "r313",
      "r317",
      "r320",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r163",
      "r164",
      "r187",
      "r301",
      "r318",
      "r321",
      "r393"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax provision/(benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "verboseLabel": "Permanent Differences"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r299",
      "r300",
      "r306",
      "r307",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r298",
      "r302"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "verboseLabel": "Tax rate change"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "verboseLabel": "Deferred true-up"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "verboseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Related party deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r447",
      "r511"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r45",
      "r372",
      "r373",
      "r374",
      "r376",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "verboseLabel": "Patents and Patent Application Costs"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r25",
      "r185"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r356",
      "r429"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Year ending December 31, 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "Year ending December 31, 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r357"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r145",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r327",
      "r330",
      "r331",
      "r337",
      "r419",
      "r472",
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r107",
      "r113",
      "r430",
      "r451",
      "r464",
      "r510"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r124",
      "r145",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r327",
      "r330",
      "r331",
      "r337",
      "r430",
      "r472",
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r145",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r327",
      "r330",
      "r331",
      "r337",
      "r472",
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "verboseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "OTHER RECEIVABLE"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Payment of commitment fee"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r55",
      "r56",
      "r208",
      "r209",
      "r210",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r177",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r27",
      "r28",
      "r31"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r31",
      "r109",
      "r117",
      "r122",
      "r134",
      "r135",
      "r139",
      "r145",
      "r153",
      "r155",
      "r156",
      "r158",
      "r159",
      "r163",
      "r164",
      "r169",
      "r188",
      "r190",
      "r194",
      "r196",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r336",
      "r337",
      "r420",
      "r472"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expenses):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office furniture",
        "terseLabel": "Office furniture"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r188",
      "r190",
      "r194",
      "r196",
      "r420"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r350",
      "r429"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease, liability",
        "terseLabel": "Operating lease liabilities included in the Condensed Consolidated Balance Sheet at December 31, 2022",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesDetails",
      "http://www.tapimmune.com/role/DisclosureLeasesMaturitiesOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r349",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows - operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease, right-of-use asset",
        "terseLabel": "Operating lease, right-of-use asset",
        "verboseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization on right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r355",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "weighted-average discount rate used to determine the operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r354",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r57",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r24",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r430"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r132",
      "r204",
      "r205",
      "r411"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r80"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r122",
      "r134",
      "r135",
      "r141",
      "r145",
      "r153",
      "r163",
      "r164",
      "r188",
      "r190",
      "r194",
      "r196",
      "r200",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r325",
      "r328",
      "r329",
      "r336",
      "r337",
      "r390",
      "r420",
      "r427",
      "r428",
      "r446",
      "r472"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r52",
      "r405",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r48",
      "r126"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r50",
      "r114",
      "r391",
      "r430"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of property and equipment",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RecapitalizationCosts": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.",
        "label": "Recapitalization Costs",
        "terseLabel": "Related costs"
       }
      }
     },
     "localname": "RecapitalizationCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER RECEIVABLE"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesWithImputedInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Receivables with Imputed Interest [Line Items]",
        "terseLabel": "OTHER RECEIVABLE"
       }
      }
     },
     "localname": "ReceivablesWithImputedInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r257",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r100",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Cash payment from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Total Research and development"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "verboseLabel": "RELATED PARTY LIABILITY"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r257",
      "r363",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r361",
      "r362",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Amount of notice received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r81",
      "r119",
      "r525"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r443",
      "r449"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Reduction in headcount of general and administrative function (as a percent)"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r68",
      "r112",
      "r399",
      "r404",
      "r430"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r120",
      "r150",
      "r151",
      "r152",
      "r154",
      "r161",
      "r164",
      "r201",
      "r293",
      "r294",
      "r295",
      "r315",
      "r316",
      "r334",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GRANT INCOME"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r183",
      "r184",
      "r189",
      "r192",
      "r193",
      "r197",
      "r198",
      "r199",
      "r251",
      "r252",
      "r375"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "GRANT INCOME"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureGrantIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of computation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosurePropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfReceivablesWithImputedInterestTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table for the detailed disclosure of receivables or notes with discounts or premiums resulting from the determination of present value in cash or noncash transactions, including description of the receivable, the effective interest rate, the face amount, amortization period and method.",
        "label": "Schedule of Receivables with Imputed Interest [Table]"
       }
      }
     },
     "localname": "ScheduleOfReceivablesWithImputedInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transaction expenses recorded during the respective periods"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r74",
      "r75",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of the company's stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule or Description of Weighted Average Discount Rate [Table Text Block]",
        "terseLabel": "Schedule or description of weighted average discount rate"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r129",
      "r130",
      "r131",
      "r176",
      "r225",
      "r226",
      "r227",
      "r229",
      "r233",
      "r238",
      "r240",
      "r421",
      "r442",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Related party service revenue"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate of interest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of options to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Number of Shares, Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Options vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Cancelled / Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options, grants in period, gross",
        "terseLabel": "Granted (Shares)",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price per Share Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price per Share Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price per Share, Cancelled / Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award granted to director under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement, Director [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Employees",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Non-Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Expiration period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Options vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r351",
      "r429"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r38",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r61",
      "r120",
      "r137",
      "r138",
      "r139",
      "r150",
      "r151",
      "r152",
      "r154",
      "r161",
      "r164",
      "r175",
      "r201",
      "r242",
      "r293",
      "r294",
      "r295",
      "r315",
      "r316",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r360",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statements",
        "terseLabel": "LIQUIDITY, GOING CONCERN AND FINANCIAL CONDITION",
        "verboseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r175",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesAdditionalInformationSDetails",
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredTaxAssetsDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r61",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares for cash (in shares)",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Stock issued during period other (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Aggregate shares of common stock",
        "verboseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r61",
      "r68",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Stock options exercised for cash (in shares)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock issued during period for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r61",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares for cash",
        "verboseLabel": "Aggregate proceeds from shares issued under the purchase agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Stock issued during period other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r68",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r61",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r44",
      "r430",
      "r451",
      "r464",
      "r510"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTION PLANS."
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r144",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r242",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r344",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r344",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r344",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r344",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureGrantIncomeDetails",
      "http://www.tapimmune.com/role/DisclosureLegalProceedingsDetails",
      "http://www.tapimmune.com/role/DisclosureNatureOfOperationsDetails",
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails",
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityStockPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Reimbursements",
        "terseLabel": "Reimbursements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureOtherReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureFinancialConditionGoingConcernAndManagementPlansDetails",
      "http://www.tapimmune.com/role/DisclosureRelatedPartyDeferredRevenueDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityDiscretionOfBoardOfDirectorsAndCommonStockTransactionsDetails",
      "http://www.tapimmune.com/role/DisclosureStockholdersEquityUnderwrittenPublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r297",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r178",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureIncomeTaxesSummaryOfExpectedTaxExpenseBenefitBasedOnUsFederalStatutoryRateIsReconciledWithActualTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r352",
      "r429"
     ],
     "calculation": {
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureLeasesQuantitativeInformationAboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureStockOptionPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock purchase warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholdersDilutiveSecuritiesDetails",
      "http://www.tapimmune.com/role/DisclosureWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r167",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of common shares outstanding, diluted",
        "verboseLabel": "Weighted average common shares outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r166",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding, basic",
        "verboseLabel": "Weighted average common shares outstanding, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.tapimmune.com/role/DisclosureNetLossPerShareApplicableToCommonShareholderseComputationOfLossPerShareDetails",
      "http://www.tapimmune.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6806780-109447",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r436": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r437": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r438": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r439": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r441": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001410578-23-000324-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-23-000324-xbrl.zip
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M!32T /5DXG)C!4Z:ON24%J1>URU>AOR'BLA[8WS0C!:VTZ%>*Z <9J6H/9%
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M?:2B@ZQ6TFMY7FLQ0%6/,W2P5,A2S,M$+(&@()>T4WN-])*R%)(2&"JE!7:
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MHX9($<?F%[FQYSLX_+7L$0)_B"WEG_X/4$L#!!0    (  ] =E81,"_-(S<
M +)O P 5    ;7)K<BTR,#(R,3(S,5]D968N>&UL[7U=<^,XDN#[1=Q_X-4]
MS&[$N5QV=<].5W3OABS);NW*DD92=4T_3= D9'&*(M0@Z;+ZUQ\ DA(I B#X
M"<C%B)EJ2TH F<A$ L@O_/Q?KSO7> '(=Z#WR[N;]Q_>&<"SH.UXS[^\"_TK
MT[<<Y]U__>?__E\__Y^KJW_<+:>&#:UP![S L! P V ;WYQ@:ZSA?F]ZQB-
MR'%=XPXY]C,PC)L/[V_??WC_@W%U%?=Q9_JX#?0,VMGM^YOC+\.X/^A],CY>
MW]Y>WWZX_6C<W'SZ\>;3#S\8@\<CY"-&<.,4@[J.]_43^><)#VI@4CW_EW?;
M(-A_NK[^]NW;^]<GY+Z'Z!DW__#Q.@%\%T%^>O6=#/2WCPGLS?4_'J<K:PMV
MYI7C^8'I6:=6I!M6NYN??OKIFOYZ!,7#V\$1-HW-C]?1CQC4=S[Y=*@IM,R
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M+=\!5VS+=:%ZEH3K. \H176#*[(2/V 16ITOO3)DI)<?&WVU:^PN]!T/^/[
MPKNZ'[&3OZ XT%PY$L#K0BSY$P'QP;6P7:D)R+6LO:Z*V0)+HM3YFN*2D%Y
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M*PMX)G(@)T6""<?,%.!"=D92/.YGS]\#R]DXP.8F17!AV:2)H&LE/11-+Y1
MH-,L!P["29J#$%$=PI?)(V)AL(7($=:59 ,7Q.VRP/6@5")4.0]>@MK& Y0%
M,Y^+368CHB@L.8]X/B*9C;#:U3$"R'DQ2?YVRC7X@%$C#ZC?'7X%]C,^+Z8+
MM0A63[7.N/)6O3L5,\E 1[C\N/#<^1"VJ+T :S,/2F+:^0JM2EEZ!0LI4FR3
M((]CRE5Y98'R+0P<8!UH%)<H80)+T]FD;UH\WU &B>[M!DRD,V'^7&05E!4
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M2*JJV=,HLNOMU8)JPH IE)8+K!>U0- "P/;)&XX$/3P98+Y)[:D<!DNT4QX
MUBAO)0C6B*VY8$-B/K20$U4\DHW,/&NDLG!;"ZJ]@%J-N/G6JBK^59$B;J_R
M(C>,Z$S&R!>.3^ZB9-<?FJX5NE$0:E2DB$;++/!I B0OLN#_6H#]UEF3O:NL
MZ];P!:/):;D0)1!]?0]1$N9301DP^E!9!JY;I< @7B/6LQ\#3D6&):]OKR&F
M:0/1#E,R#[8 ^>DR:*2(.3<MH^$Q5-:3:UYT&IZ<UO>=^]"S\475 LX+EFKR
M/#L>,G@@-4:8YB@1N-*Z<TW;GD2$MLX5DAWBA8",2X<\ON))L6 QIJA%M[QI
MURY81*M&^CA9[5^<8#L,_0#N )HZYI/CQOEZ'DD%LN"S)\R#*]=)M[QNW[)6
MDGR-V#\"&X 0L&,LAR'^D%.L1<#=LK-UTQ>/S/:?BHYT1:3263KT#*#;>6_-
M+,4B3:,E(CIKTW-1A0M*W*Y;!K9NAI*@6'^^QH]1EF=LIF&WG%5EA,J0W(D%
MRJ&/C]\#9H[K&4"W/&C?$)0BK<OS_1SMMZ:W0- .K<"G>AI_>$;FKN"8+VK8
M+6]:L\>4(;EUGI5CE#[<:<WD44AG]\8+>;N%"I/%;<<F"VEK16ME)58.OI1M
M' OC,; LDJ9%-C?H.I8#2M:0^)BO(;&:/,PF]Y/A8+8V!L/A_/-L3>I'+.;3
MR7 R;KI6A) 6;F$(F58=)&[&"W2>6*TYF;1L,$UJ/L@S($G09)/3?=ILHA[Q
M:DZ\!MPT60&L!FFQ(CDZFW46!6JO) ^%A?0S$*HS70NE)GV%R&"NV.89I=,2
M8]P0^H$_WWSV]@CB30E3A)=\@)?K^)6$MD7;U& '\7=1]:6[0PQSF"/\U[^
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M*JZJTI2J?)L;!%-\\TQREP?[/::./AT.XU1H\G7\IMC(<<, JXH5L$*,;^F
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MTCQJ%1U/BSE_P^@$P%N$3ZYC)4FD94/D/TJ&R*='-*(AC63,/E#^>PS,:C=
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M!CNBJ=!AY."O$+XH W^]-8,'YP4L'1^LX<IY]IP-/B!XP0(B2MY\,P(8&-$
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MTLWPY^MHJO _)&WX/_\_4$L#!!0    (  ] =E;W<([IFG@   %Y!@ 5
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MOKR4X<M/7P)"^?82#M0?7P"S=7Q+ -SFZATZ?N3"EE%K^E50Q%5=P79EA;^
MPUGMI4QH5OX,WMYR(%R(6]>C=Z?#$PTEXE1![']_%9OI=[_\W>KWE@]>^<Z)
MMP9P1 !:^[X/]-D%M]*/[YR#;+67@V%]9SF[Y6]=AD'XWC(&5-\\AR4 ;.V[
M+_Q-$+*5A)\-'F.VQ<R"DQ^'YUFP5:M!#1:65A@)4U82+0J"SACPHU*A$NJ$
M<&02A"0A0(""-;U:.V^++=NRW)TK0FPUFX<2'DN7:@0H:Y$"&$%_M)RH-(<A
MD3*6[>UGNMVRN8B2_UFZ/OV@%%$*BZ4F&L;+*B(!1% /)1<JU4@@)^D_"."0
ME6]O)4D&GK%_KL)U\.K7"5>$1%:+*M-2I<C!\%3BDH=:A0 $V%X Q;8R\+UM
M%=Z'P8OK;]1^B@H<62T4[$MUXP(63T&DC-1J2>:%I'BV5>4^B&+'^[_=H]:A
ME0,CJXF4=:F2E"#Q5$3"1JV""!S"D&PYJ+!P34/J*!2B_#/"U9.$O>SFJ?";
MW8NGRL"5#\OW X"Q]1WA\MZ[WP>^.C!5!;'_/55LIM_T\G>KWU4^>.7;<C#"
MX>R=#![IYA0RI?KP_=/:C3V9K59![']?%9OI][W\W>KWE0]>^;[\-Q+LR(?O
MOWKZFJ18%C[R.G0@W>GQ?'@*9 )<_&[_\TH93+]MZ4>K'U8R<O6K"A@B@"Q:
M[/QMLV>,4$4H60Z&9[DR=B^MMPB#8L%5!BK?.P4E*:S=4/+L%(;4C\7%%.@F
M<_U/D=)G5(%C.=UZ]LMNMQP6P?'6,:)RO1,<DB$1@67QSB&FD,#DOM ;)W82
M?C0A<3DXWBV#COW+ZP49+,J]@IH1]85"A@/)!TZJ.58OG<.9$]/G(#QKKU4+
M4)A7SQ5FJ[?/&0C2!?3%^+H[Z)"DL-:^^./!\;SK4^3Z-%)O'1=06%]<RFSY
MBY= $+ZX9'S5%^>@)(6U]L7G!QH^LTWH8QB\QOM9<#@ZOMK6%=!8&J!EOJP)
M4E $C=#PH=*,%(4(')(@65"1Q6873D];E]&9QC&-8GXY>>LYSQ+Y=,#V%:2>
M]50_U)!6U:..C8IV+&:W#R3!( 44 CCV=HP]];RZ9:,,A+9?2%B]V"X*$!B[
M165XY68!D*J%H!=.X\*KG&'9'>Y '!P.D,03;'Y_W#ML$E:G&)ZK05!&?:+3
M(J$=C@U$N3@B:S P#LJU["B/RQR3<-0)$<BD@&U/G=C1*W2\A;^E;W^EZL6N
M H>F-'*&+_2D#(2A&C(.E-H@@ F')@S<QH6E.';?NM'&\7ZE3JA^DZ$&1;C(
MK&$[N]14P-F]X-0R4;WL3&)H IX  L8;C9S=6_87V8%9"8GW0D/!].4#C0LP
ME/<94A[4SS.*VL 1K*N">"YDI@PE6&QUD# N5X@"(*)*5+BH58KD(9<MM9BR
ML;><7_EA^>)W^Y]?RF#ZR4L_6OW,DI$KGS:#L77230[9BNO4TJ\('[+*7/89
M\Y_L?L3+<:N?, E;6+H@38:[=</#8JMF./T=[2.6&;SXC.)'C ]9'%GY*0&(
M+&[L?<VT>(R:[QP"[8M>,GGQ3=.?,;YJ>6SE=TW!K)VS?Z&>]U<_>/4?J1,%
M/MTNHNBD>;JDA,<Z=]<(4#Y_*X 1SN%:3E3G<4"Z^AVP2(I&!)XU?;D_/7GN
MYM8+''4.0PD&2R\DC)9UH0" \/TKHZN^N0 D'-+:5_XY\$Y^[(3B$EU]-UV!
MP_K:"H;+7_P"".&K2SE0??D,6.0G=#]([9SHB;-[BJZ>'><H5(!Z<93^)=>%
MY ]_YT]:P/U?[6Y=W_$W+CL/!J(L@Z*F53-4NQK31BQ0HB9XUO2J.5/5T-[J
M[G&U7-Q,U_,;<CU=3N]F<_+XTWR^?D11MVD4T3BJ4:Q+(!P5DK-:5)8RA'6U
MD U?=3PY$/DM!?M_[-YO-N/U\1%7+Y- N)%Z5F QM53!>%59+P"1=%;*A4)U
M)UF*[\ Z_$+#I\!$B\VX3[EV.,Z/*%H]<Z+]U-_"_\S_.+DOCL<XBJ;QS G#
ML^L__^QXI\L@7$-<'*UO)%C1"HP0K5M% ZZJ>L:0>'5,_H\"^H0X,4DI$$X"
M9^WO1;H-_(/FZ%A+@!5AK"P.#Y2M7^XFIEP8^;N%&E@<X]<R7C1V*:!UX]9P
M4=&0'):;\T3U2,&.X;;D'+0;1:/O0WITW.W\[4C]B.HU6@&+H]%:QHL:+06T
MKM$:+BIZD<"2!!A9H]MP3@5PQ%?N+3W"P1MGQ5[%>QH^T UE^\:31Z,[&NN5
M7(> H^GU(A3570UM7>?K6*FH#T<@!8P)83C(^M]2BC#'P#^=FYS-1G$:KSV%
MXYZ^S4[=P^AIH>E#:T9YYPBR*1VS$;7SCFE'@_"1#!Q39]7L5]6W"HNDR2I&
ME$J=(XPFFF0L P.\*FM[JZ#2(?P]Y#K\X7O1U>>_PE^89Q0<:1B?[]F8,3O@
MPN'VR.\<8 =8[QU_%OB,O],&;AT6/H-_#JO/6CO2LFL!O0@.YM&)T""VDW;6
MDN7T],"M)(L0ZO(29\=<$.)LV. GCW?@8@XS\Q[<I(PO^R^/\F=UX$P[!RC9
M\ _QSB[8D>/^'+F07BK4FYR@O9?K$\81\:'E"UON W_+6 +HI^1Q+XD#<@P#
M]F=*GH-@*QSUB(8O[B;QVOT@9G1$ZR"R"\"AB1R/?@.U1;S3ED%M"L+"D,=$
MW&\&61QD*]L07R4E-R&<H&BBDY(DPK<#HF1V(7Y*UZZ7.NP4'+,IH"G)"?%I
M]Z2+5I%YJ0P?PZ"RHAIA($7AZX4HQ=[5X/8C[G6\5(.W"A.9$(Z%%%KO+,91
M8>EV AK,-!THVK.D3D0?W.=]O-I]CBCWC%1'6#T.4EC#1)!29$.'8#^X4<]-
M-3*0XA /D"8D!+2K8'?%MFVQ@R/%.-Z1, :GA#;B/%2XC_"VNLMCCN%I:"S'
M89-C,/KQU_C8BQG.J6571'3\RCD746VU N&JJ%HQD=11JX28BJ=5-T056[K.
MD^NYL4LC=M#A-1GV@;=E&QP<>N)S32#1'!U'39N*5U1D4USKJMZ,L6KMZ1P]
M.XW'9_3TS*Y2+:;7B^5BO9@_DNG=#7E<KV9__6FUO)D_/'Y)YG_[O%C_BFUA
M9KF=.@1T*S+(\E1#8UJ*6<9D <%:TF<3RVB6]^GEB#C)G]/-!F*RT;USAIM;
M9M?L+^&);JLBJ7;/)A207*'F0I;\)7-T^TY54]ZJGE="@20D^(Z3$"$R:T-Z
M&]"?H,>"H$XB:,$0D9S0SO(EGFI+*:VL-C<GN@X>*+_TN7?"^L5%AX"SEM2+
M4%PZU-#65XHZ5JKE7$X4;LT2%)+@("\#C:5(V3\RX#/9TAUET%L2TA?J5W/=
M[5A!PL2#X*'& A3 2-JO9;VD^5)(^UJO8:.J\:EV)-#8NMZ*=TS-+H>ATYWK
MK-?P.J0Q7-:H1%'?UEQB(%_7R-G17'$LQ15'AC>L+32^XC"4A\-F;D_WRI7]
MA!>,3Y'C"2>8A1%&$#YH$#; <?0;^O/I)0>VZUY@VSB)M08'7;?-TEFU")@:
M;YP46E+^466WMI&FF.**'C]3[$JU%]D&>*/R>_17W;5(8_%^:F^7=0[0P!?D
M[7V@6JDNW"">Y@'9L:D9\:YH/=2;ZVUC:;)<C&HC,=Y QK%Q--LPT!VF%LDA
M(_*;ZN4;@2K7*#"FVM8K*[J":M426Q4;YXZ,+UND67[(B#)"&F=+%!&^3#-
MIG$<ND^GF%_LQ '$Y,=P_=U1.,I1</SW^S")FW*6=*6.I)!HE2!43%_4@;@$
MPZ@"(>=!5DDAB6 G?8<X\$24MMVB58)HS'T$H.2*_%_???/==Q_@WHF\"$G^
MA1Q<SX,G%9%HJ>2<XGT0NO]@6'!+^UWZ=Y>+S/\6Y%V7H%+3#=W0PQ,-R0\?
M)@24F0.Q?[#_9)A'REO7>CB!SD+#*6W-L H8UL,D.;OEUTAE&(0G2#(&) ]V
MBAV[AK<<DQI8C3B/!.=5H_GAN\QJ0-4_:(QH0O['-_]<@OX?W_QP":ZRK0C.
MPZ,VK^EVRXNY.MZ]XVX7_LPYNLRM5.63J*"14K#TS)?2K>2@]E.K='Q4LXLR
M: +@\&HN04#*EVK+/90SNF+<;^3<6ZHZ%SNN3[=S)_29=4;3_*WX#=VY&U==
M@JX>$:L>G:E(Y>)T=5@(E>K,6))DX@A$DF*2KPJX)$'^&JN*74NIIJ4R!AQR
M)(=[X\/:> [S9H?X$1S>NQ_:!U'S(^^X-O>WS4[KR@X$W#6Z=MA?-\.4A14,
M/\9.&/?"\C5]=GU_:*YK(X+&_(K 8"0)AV 'JZ4O?.H#H HT]+"V5IPF;\I&
M]Y:LT1LR] !Y$Q$J47-1LV<LQE(.#K%5?17R'AQ;?MR]IR%OG&T465(CCR'
M6">:.N:HPD0.0^K9JH],,GP2A$10$-$6:'8J.J6/(5+96D 1O,S"+^0KMD&+
MR$G%+T>P,=&)?IH%?(SFHHHT!IM2B:*VI4L,9!N2LU-O.P*/Y(ACL)?&P@@[
M<91"H!F'B/DV$#I%&(]1E$6H,P@!/0IC*+)B; CCN=YJ)(0P %?*/)KRK_*
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ML<P;USO%RB?J2NAQ6.<%\SK[3$#1+;3$AY&-)ACCL%(]^S)5WP[(?@M+[4T
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M3KK2/?*N= ZT;=SP#"3RPX<) 6W&.I,UFPH1=]/X/SUZ.F7.YN(LJ"@[;8*
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M7>\=/YF@GVG$9B.=G77 -J%;QPU_AO[-;3_*0,R,='T==.H;K;.#<#*^]79
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MAQ7=\NXA:=I25C]!^=ZA!@DI(]Y(E%*&O!;#?L:\ 3O5#/H$253!+U:J4-5
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M,TSK)M2$K8K>9<A$><A-"&"EE702;QW$S*C$S<*F*!05:)6RWG:L"P[-:S:
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M:2(DA;!KG!HFP= D/ULS&N78$@-X<2/8L^!2*729.YB\-.V[JY#YUY9V$U+
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M,T=:(Y A5:YM\+,)V/P[G0<Y [_TB)S!.*-D:T'/$;'Y^4G'MF4GA0U5EK-
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M<[6_$%-DT.'_A H+YA%JSEU!GTA"<@,AN6@L*RO3CX34<$?*<E_[K8^RD07
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M>P/*\$$\FFFFE%2+BO2@GCJF"RH'=TE(Z!A39);[K'$?%C%TS5PX!ERAKAV
M@R90V/&CMC=MIV^;)D"[UE>P-'2#\%Y6F::4!IJ"R^D1@T#I:S]T)+E^PI4I
M3GKR:-@+H&\LN$YU=G;PH@J9'(Q56T*&,M*J^A[6-[A<MJUOMKEZU2Q_!:T?
M3I[$A#YKW9; 7TI<"0<(:BP*\^(.\JHI1XX:%H!T94@];ZS^?36"#J+C-V1;
MX\I&<VV\"A_-6%M5CH6%F,),N%)JD1H^<5F)<RJZXOT!W+F_W6K.?K(:K%9
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ML3?#PT[8 VE>M65)NT.2)>I*#FM8BSEWIZGA56,<FPREZEUFR-YV:X-RIBW
MG",1CL?"_5TGG//4S>6,\_B*O9CO;2=7O+HKLXEA!&6TR7DJ4M%N,^T8S!<^
M\8&3K>$O&,KJ=*]N6[*=CJ/9L*2S!1O5SL\+>J\=A^GF[]YULAD\4X7,5I-Z
M2W@J-R5)G9EQ=GQV49U+[;J6;67:"9A@%Y,R>M<Y%N6NE7$5U3&LC.,@K*'
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M^DO.XK,3^Q<&Y!*2#3'KKYE V_:I/5"(#!,69Y0MP^%*7G(V&2@PTO*%S*+
M<FW0EJ[2HS=(V.1O=8,= W$15?ZU..K#&X_6/0O"WS_5WR>$P8Z@.;L"DY@L
MYK"8Y;YG$!S8FTKL\50 4-_Q; !W%;!Z,)&/H,&PO=0V5R= G[+]G5ONEI?6
M@91]TN/^^H5@=1<K)'-L:^DOK0R$FO^(YQ38/JGE[.'F%^TE<G2Q'%TL+^@F
MTD6HVTTKB;:0[LCM&$K$VYTX:2G2Z:9Y06!326FEFPAIK=R.<P++)O?:.F1S
M$Y!0]Q(!6##%1=\0"B#2P>VLU2A6Q$:C'>?C\73BL(#:H@/AN3!<E/&GLT?>
M_X)95"?0 A]-/TH3!&L2FFXLTL'Q-F*VQJBCD:L;$4.7:8,*F>ILU!J&FAI0
M=#T#+^C.7TW751\DOX92-_!#7DY0A+8-H-]8EG1V/371P2S5\8,#?835<Y@#
MR54?D75!&,I/) 9T\\I5 ^F91%7WYH5HJH<&1LNF4C-0]$DF\5,93 Z2^[2I
MA*\M8M69+L'P&LPLDI 17:L>03J&.,(J-1B0,+WU83WCR,($U-,AK9]\WX0N
M%D\4W]K$[8!GB)=7?F*RM+<,;89A/#VX PT9J'%%08*8CF5@ ,%PCN6.R#<C
MWDR\&A<,U#[2P;QVR?;I^&T)0"F#BX56(YQL30:CLU,0.(IHAY4AN&*\(>@3
MGN_-S\3%HU"?C)^\B+5T/Z\B4 6QZ$M#D J;U',;FGK"^B1KX2WQ$-;['GP;
M/N,EBG^8-891%2O!D,ZD+&U8;4X@L$ ]0AU/HRBU>B@R/YT,2A#H+%N&M'NP
MFC J\RR7BL(U;'\KM!;DP9N'/RA^U@;_"6R-9GA5S6O%S\09Z+OJ2(7T"1F4
MT#(0"N9S#!=G_?VRL0D'IC8LDK8O829@S='$?KI!=J X0)N/S#X&_<D2DT=S
M3-UP19)=Q_N)>8&&W"$:J1)9:Z9\Z=^G(W0T"6^'O/;4)7X*LS<9)HMOTL^?
M,*#;V8Z/+H"%,$?#Q9/'L,/?]I=MK"_;EJ8,FJCD1*N50GLO_1=\3_B#"Q^V
M1U(>!9BJ ZD9M@F.%E+ 3_UY,#^"),8,;Z?C<66+4I+7# >/X((QM&"K'XG6
MA!<I$^#7A)PMM"GI$^PZH-)%2<>3J:2TM!U(X8.ZJ6R,U/PY[53@P.]0=5*1
M7*(; $FN: U+=D&4!.+(1BO:@LT\W5KEB%;OBU9\Z-!*PTB%.75 <=FHG&+Q
M$B(L8O]H)!+"AD1&MQO!&!.Q^TA;E-:2>*"O100,EK?U>?H8Z:X8)!X&A$)V
M#VOFOM7SC$&UTL4GT+IM$:_9I"18$"@C+72(<]<GS*6A1:- <A\OTL(?\UL6
M86L!F30"#UIQIAYIGA!R!J76(B$ER3;T@+9Y5"Z.O=I\*BXO#&?/9,:69CP=
M^X7QK@]V@:=.8'U<P:A$FT#XCXRPTC^BYA1U4%#;%-FR9*(0"8XCXH40\<1U
M*W"!>=13X[=_\'CJTI[T'U-<VA05Z0HH,R!P@"6NH**%;!.SOB,R'I%Q^_'>
MB_9WM*>-CV.ZX>40@/-B[D#^ R"5!GX*QI[KB@7I0-^S]<:/9<->(G>)8P!9
MD&Q'>*;-?&]D1/L'X]4^KS?7@Y0]K <<$?6(J-L0M0&I/Y V6+S&" 8"F)2V
M!_DBWAJ?=RZ-N4=272*]Q+PH>(BP[L\V\L*)=)65>,\"E_#?+J#26B\<DKDV
M4P-<5#.FI(^Y[;S-#/QD^1C<,1OCF(WQ3#8&YN!^ A//)J(\O\\JC!<Y//Y6
M1SW&MF2\:=;0BO LSW.\P,TX=LBR?'1@]KXQDN;\\ZV .5A?E;^MYV^I.DG'
MZFB&//RUOB:"1P&\"G#[QT#Q&3^%G)#@H^DXS)'Y^?NC@CUYZAXEN8_$FW(2
M].N0C@U+,\0S67S'3&1QBH#G%8*\7*A)4)7%V2U=5WL41 LV622!7B^R2-Q
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M3P*$"2%WTRZ.^/A&?/2S*6A "V-?L*Y>>M3_09<<%XJZ5OM +)M >'U+UEI
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MS]Z[-K=Q9-FB?P71,7VO% >D1>IARY[3$11ENS4C60I)/3[GGC@Q40 *9+6
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M+,%\:@C3FTZVM)A+VZV[9HDCY1KGGGQW\RO'HU^J%FN6M0MLVT*8XJ+BZ*]
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M93P$EKF"3R-EFFQ@%BQN3]6?G6--$DII1D8\K^-1(O0FNM (NX'<0%9'(M<
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M-=*T*0N#L&=,+_,E %3K<>I0CE,W+H*4_^"<9('/0O*@W'' R 3O[63].>[
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M%^HAJ<X1%HN6& 4D-@(IM,X61-S)/?(OOYI3: \OO+ #SHOPO AO:S-K^_K
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MGZ8-O^5VH8&73M^D7_H;TFEJ74$(J'4IS]T.)J6@(0R:#GJ3X\,Y3<=-@H-
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M\:4<GU^2]^7\=',CWHVK:['LW[!P/4I'1VM)QSB%\83J"<O^0'@;0@D8&=4
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M9\I0*N9]Z,AK)O40X\&EI@C&B(-45I[G2 O>,SI#)8R9,G9.Z<C&L?ZJ.FZ
MIH[S<XD=A(IM'%DF$WOV?&Y,%#E:07R)![-7KJI8[1P0;%$W>SH.JB7JFXB5
M5SUQ:BG2 HB%U>2&L/AM^')2&M 13()1#GK,?K?BVPD?LZ\9^EK>OC4M6.R8
M4*@-/6_:0'[#?$AQ!F*O X&@^XZ<_EI* T3;P6#J:'GV1,29CKTJ.@#'+O &
MDECZS2YZ%:9I&1>OA,%S^>$35T$?86[9O=#=ARV9Q>942NL O\(("6+*A@T\
M;3Q>PT4JY&;#?6HP+M=#YH@1BY27)?\H1X%^*"[ @('V"D&GO-7/6A5+YN2R
M<225.#C7;;5EW!*5?7IE.>*:VA#^[7I:O&>I'J5BMN_;4T"O,[T<K9KXOPDR
M+/9+7U_ JJ""6G(@UUVIW:5$#6'1.JPI,@IIQ_FD0HF5+V=O'LV N:Q<0#]@
M-*+W3^F(A@STE@S%H=D%]EOBZDZ_8<"/!:M#ILIVH%^_ORN"6S(VZ7CB:I)M
M'R%J]"U15!%RQ]F#V?30[_M%7,+$&*3+C&YFI=LT&0Y1D+TV):TVI3\D7+(A
MBU-6S5?&W&')WJ!4F;.%D%^:G,T"ZQ$35::SUIV+X#@FS%*E\NA2D(L/=FPD
MKRA^B!_*H;5SM(ON8$\9W.*J0T NR0C %'R]W2-5HFM"D(=.N/&1)\Q@3Y5T
M>9137I8A=FTH!LEVW3@BXLG..2<$$C&Z-:.4(V3+PZ2>INH@V JIWB+4N<:J
MSWLQIJGP97\X0OY[/@(29:)G2U0XK;@P"N%R"7QQ7"?&;KHJK$2[LHJ3G1A>
MHI"(9/Q#0C<(_>U<6, ,Y $K(1E:-RN"LJK\25V("#[$6O"G#\^UX',M^+VL
M!=]<-5(W5+^/J6+[Z--LT&/ F>].>S9R9&>QJ8XL!T%[',BN9(&F="BDCXD+
MHUM5TV7D:466BHZ)J1B6_10!:(4#=X4*A@CZIPZRB<\>]PR#-P.3Z. !?$N=
M*3@ $X0E#MR6U@>'B,T^.X-SL*CX9#&PJ5;TR?QSE97!\EH/"5KOK*]=WP?]
MOAGT]\9 69?<<AY"ZMLI3A 4,%#&ZPP_SJ=OM[R*P[2A3&^"517.ESQ-FZ"B
M@@QMN0.?">6]-YT: >2U-!T^2,LAYUKF_U7OF,]Z/>+STXH]->>Z2K"]L8<:
M'#X2P+]3*^"'$@3^Z'+<[ BFW#8/XB*,!D@1'0D9%X=BR)TPY+ ? 8GO.];[
M][WZB"/BNF[[%,E5Y XM-U6;+OY3T\;[?\?7_=$1MK(7?+EI%I2?3B-Y/T/X
M,FP;LN5-^\9X+.:.W(+RAE>!Q,\OXO'. &FD:83)WQ6QX)'@\_V!^JL=]C?:
MDKA;M?]=&]/9LX^C;W/HYN]6$+M=?$3YP?#\RTJ$4Z4]1C8YM(89%$(FF\S"
M?.(.0L@15IDIF^[<XHMKB*T07FME'@13F4Z1M?<,6]X5JH% ,]K YABD DUX
MYABH;GF,: +YZ6@^Z=QP) 7(_>V0&A6] $E<MF[V,\6?_ "0KV5E93W#HX4F
MV0:?&?)$VBA>YS9]$:Q.]V#VJ@>?,:V<1.NB,X9VDEW8,!0]=>ODP6_\2='Y
MDYV_@[9?QN*/.,!;:Y SOJF\OB@K F\):-R1AKG6M@D0MA0/(%OLLHA.'(!2
MD.111>;2UM6]68GO2EL,4^6< +>ABUD#@QV)=E^!AX:[6P!ZR[P&+L"(TS75
M<??1/\,J[)I-B'[@YO>>4', W[OOUD$JV#?<10U"((-%"'$,K[A#<QG4>,9]
M*.@@)U/D^HWR[D#?\?>CLUQ5$DR; $ZX*4TGV?C8G[T8NXQ95A&5.YU(LF/Q
ME39VBLX'*6,=V#%WTE7304AN3*)TQS-A&]I+A<$H.JMJZRY(<Z&MO*+T8>JM
M&9>5)0M2K_UA298K+D)SJ6F:-3%K75OR<$O@EZ3W*#X.'ZCB\8\Z/+37@A'T
M6%?9KHECMR-^XE+O%&8C'G5K:IQK .-PCT"IL9I/;KHKPAW.1H0=:[8TG72\
MZ(#G1C$Y6&*W)R%;]V:_*.\E'M=XT2@>"!LSH$.1,V5HQT$T)SNRN.;XI;L,
M:S)P1KTWF9G&$Q)MT3F5HY.K: Q+W144#UU<3;V%FZ/C3\&NM):>U(LM\CN[
M-<E9+D-.B)849R\#^2C[^/:S+GZ9PELNF,2#D"+"^;AY4&7&UCZ[:^/B2-CN
M?%@K*9*^3ZE1V3W3.'R6 MDQ2'43L/,^CJI,,'#>VL"<=%UM8H="9]D4#J8M
M'=;S;)\?NWBX=.IVR%H,\;6:[9$C@K@U-_'AOVMNPK40X'7!'F(YV&K.S4@/
M5I!=.X5ZNFR;&Z<U,:(4:*1*P[O@%%/>Z,$*VZ'X''-"!9LSP?"-J^ 6D5HB
MNNU6NB+Q*'PTUMT;OKHM>>XN9%HZ/C-Q')**U^.'3UX2_/5;)E+#KQX]B388
M@<D'%O+?M;('\5EIF,PY4D*1B.\$(0U5B0*7117=<++93@XQ4<RM<= ;4.M.
M:9AR,D@YSHKE_:HD*3HO,(%!H MZCO5!!Z1:Q*\W&LXRIJ5R6:?A4W<NU?7^
M\4G]:H*B]YB9:$#J\P[41)Q$EC[>;HPH9/ <S3<_'H'Q[K;5&']3VFRRT:@1
MQ>VS0TEN4.ZP2LTE8VZE#[)(]NA<)#L7R=[+(IGS>H#<]&<8:D,6"A>X0'%L
M.*+/9F<=CX!_<!83OUK!X,#36:()C.Q4B:+4*"#8*U<!7\93P%B5RW.67YN@
MR%7^4(D(1I1I=,O!W6Z"-+OD P%*F '%Z6UO;GV;\]DWSY\*.P)T7B>88/EU
MN%&+^QR6.,(349(_C(7[=)>I6\^GSA"56A;$"QO9' +\8/9-' -I8T3&56+Q
M\;C%*TBD,W209!BU94B>Y$)&1^(N3&E+@5B79Q$UC^"8#RQSF7HNK'VKR,!@
MB24/'N670MN>M>IH7Q \?^YOXO93H:.8E]M )T$\=Z X'/@=B5]6R6>F=5N9
M7O9=V&4[;MA)0417V-!#."/.[$V=-M" =*TK^+R:1Z)EN&]K;K&-4]A<[L",
MA/HIT<_8=D)(BQ!'*%20K4&F1E#9.3,R7B1C6W*"N<>YH;Q/$MC)IWV+D*Q2
MMO8;Q[*JD520T=U,41?&%])WL/0]ZZO;F/O5SADGZ=1Q<ZCR[CF4<H@$R+Y]
M,@S.NWQR0-^]!7[?G^1Z'=*V9\NL1-C>2L=W')$8X,;'B_=?^A;]G0(N+<6H
M)%82]PC&*[.K$@5EOT0"F]9*U;;H00N.61V!I7_6!!<?/!D]U(:."PKL8L@!
M6A?Z-_C!!)W(E2Z-+WD'(^Z_,'+-N,Y$*Y/S=L(R'H]8XH&W[((2#2JT4*S9
MW/<$SM,+EPY8@Y8JTWBB6IA;&ZY#+:JI0%Q:;QF!>-5OX79Q()&K?;]31)YP
MQ$FMW<$]=JI8MY(RV[H&,9J>,7J,ICK?Q#GL>O0D6>RQE?S!?R8X_L3#ZL#:
MJRZ;O;5*&6^5C],<<7 \N\AN3V&*A/F2F JNFAOV.HB\:=@2I1$GQ@N]6-RO
MM*:X Z<F0X%&)(:2>@BK">>C[!W>FV5Y:NN.4J!Q'($TDNTTO9X$.=L5H+/6
M/ZJ[N=.\SA&2/%W=CA- R6?TASD9;P_]U-3K)@-:6P4?72-H1TON$2]9EU9G
M_>__J?)DGWQV%I=Z%RW/HA6C<X .TE5;W;CTU\#3_+]0_.Z\NGZCU:4.ACOU
MA:+!0$^;:A'^KY2*/R^R=UED!=I@<DXH2B0&*XZPX'!=]G3@QGG:<(H?K<FH
MBJEARTYD\)]2OJ9>])KOLJR!@^LYM(JC6*EF+[]Y_NJ\>L^K][;5ZS*1DJ2Y
M"O$7FYJC.,2J,6X7!]$MPO/B.B^NNYC& 5;+FI\IM5;OA+AVP.^>V.&Y9T %
M.T*]7?1M!WOWA/[V'JW!A^<E^-XM0>ZTW?>'E/8T-<99D@C0O)53K\QZYIEV
MXE<JS]X/F$Z8>!:4=$)G=2OM-1FI<R=Z7J;(YS#]+INCQ9!AS43P1XRHK3+9
M0<GPE>I'!/<\2M\5=[IN*276(B6&4HVO@V3% +EO#C;IM6P "R-=3FIC&)4$
M,HE\LIE>3\532G7#3!4KP<<'0@Z_@L3J0\,'/#[C \[X@/<2'_#N +V?DI,B
MK':Y8Q*4TG2LSMNT>U(&08&=M;02@DT@Q&)QPELT[J*?Z9Z19B_+21&EP_BY
MCR'I2OJ_AJUU8_PO_?:;OHWF+0Y$_#.]/0VG#@?##Y1?8Z-]7LPR-JY+<D-Q
M&M;N0;RHDK_^R+__FH;[J7+>T/%"-[PD7+]]-4T&Q\**@5!YNB379KI(U:P5
M$DS&'K8>F,O5FYJPOZ4/2.%. _=PHZ(Q1+H;#1]*)=?UJG>D/ME8SBWC_TY?
MP[!:*8\E)'>-<$A@=W,9L4H/>1!M'B<MEG0AT9:6NJ[+J._Q8*9&EB.7B8IC
ME#A-X=LK*2>KKTZ^'1YZ>,<'LS]Q:9M*)DGV5VCWNJF-R1T6QIBW.:8J"G#F
M=1O'A1941F;I\.INO&N^$](V_A8U4?0>ZL-&2&?<DZ@12$)ILX_ =VVVX?>Z
MTK:!Q,)MPG21@SM*&$?A#C'SEV<;!<,H;(YU[4_,E_QU0-!%]=S=[!CM?%R4
M\=&BHS2#BKA0QM7MLM]R+Z;CJ:M0S!-RG@3 )/(:] D='2^8\(T-[*>WD+.G
MR7ZLLD_I("AOS,05R&.+$T3[58N53+3"ZCD5_K1HFVJE&Y6>;3 2-L]RLU7!
MNMQKEPRM"EJ#,'V#@?)+DE[FE!8(U#[(\9(W97L TEI"D%!#R2%L!8B2&O0J
M4;^,E_[LCC(C%9#=Q![!K.I&3]2%\.;D\_-*]Z2/1=J*# =VHY(_>JQ/7[XH
M'7Y3\ QP";_2^!"LLB/>OF909Z;N/6C[)9X!UD]05<:/ >.IHHSIZ+3=.CJ3
M4N^\KG0'W/?/A*VXBGLKJS?SO%?YZ+A]DPY9B7F\]4RF:&2(\J?F]YVP.O7:
MW8/9TISIX\J_/A;3J3*=).$O8EB(4S-ARN&\O<$YM:U^;H3":YQ")SFK\$!]
MBH%]3C5UA 13_4^$5)'<_X:.U#J+>,TM>M9LE:CM(ZDML6ZI]L?$$]@%S/8]
M9=7L9D\1*5LG]#?/G_Y^KB,3&-[GQTQD>[B"X%8Z<1\XVN55<(-6FS2<LE.W
M-."IJQ&I@XR\\1\]X58.AH_'(*K6%\A=0EAU8S. 1YSRM1@6Y*2[9.M5MVS@
M,N)$MK X.BJ]ZL!KSM$G/V-PU:QC+L%?E#:>MY1-2W;A0BPQ=5@I3@*D. -P
M':UE/^;L+14>9=2;0)NDVG"2@P@)T-8!3PN0OI6'[M6'O$T4F)LJP3I4M50Z
MF367D3BG^3 88_GNKU%KD=TS#_E>HNCV,F6XGGN2@O_^>'%OP=F[AZ_?=)2!
MK+NKY,6G?!=F*QK,Y9^>OR@S,1QA55/9$'U[*$KF) !!;Z,,&Z>OFG3,&&V<
MBJ1)!:7)T_XF4Z2ZU//9HJ])(,@V$+OOS-4\%B]"8D[4GE60-/%-_+O#;NY5
M,)4?EBK8HTT;:C 7<6A)G_'4S.QFWS7$&Q*'XG5X6W4N#J7>6%;V\[L1Q ;=
MX'H#U^]72BK!96/F#X300TD#[_Q32[Z22TV @\LZ5&D9:8#!3F9T[^ZRW-]Y
MI?\DL$R-<L!NX'D>"9N8W7GJ'A6!5#,F&'_[T8PEPEM%;WL^T<N:G%EU$3?A
MK1RV \+O!!"O@R-8Y^85(8 SYVM [^XS##B<\=('P6-FV//LKN)HLY#*+EN$
M:?+&$[NL]I7ILR;7U;%84&[B@O(#;4_YIP2$EF[O&)3^HZ\9RZF-@>0++2AV
MO8J6H;JD7\1#O"?H>W0QJNX QH1]0VF9]!U>U_0-'.\9E2>M+.-)Y;6[YD[D
MF6,W'=8=5&J3</[J@ENBR;*(LB/R@>$6E<MC4@.KS%5+Q19IM1XH_PR8"3X>
M,*=*NT_<P"4A^K( W F72@M'SJ\:["SU@25 G&H;*JJ6).$3)]H,F5E>:]X_
M9>8_*F[!XP0;;O*([O0$N383>YG2. \77;NP!"IMSY*/6N,HPSB5]^SYC]*C
MX6E! *G000VIPDB-;+FXGX/1NP%UH)]2#K<<L>:Y[ 2FO ENB#W/;F5M64D9
M/ ^L;U%_N;V1R#*5@WIDJ/%Z:<!I'"UQJ,/ACYL,D&YYP-]J/!E%C\FJ#RRW
M,8Q^A/3"8IZ1?A2R7D99L:GZ'76192ATCB#D(NFS1A\27WCEY,7+B#,[GY(6
MQB3W%GW\[5[[L5Q7U[II#D1/<[")'*T$2U%6+),XT/-*G!R<&R![OCD.VHK<
M&>=YHD_R',\-L[EHZ]5E08]+X[ V^'2*A]./+FE4 R45>.FE\SV*&*\/LF3[
MR;ED>R[9OI<EVQ+@8KNOZI(78TQ+(XX0&I3+IEF)$\$NU.XW=)WNK3_(1^'P
MA47O[@X1)"=*O5@[4[,AB+BEU_2"&^A*'8^2^'?GQL ?6GOGL1L :&Z""QVI
MF1#(OG3L<5)@5J*/S,('>#<K5N+07K=TE20()61T_D3)B6<D5+VW&?[JV?/D
MBI2Y,Q' U!C6>0E3"<^!YIE3KB($BQ@$=,]S2];"UQ"!:?5N<S_5G%PNC/CD
MHX7T=)N0-/S8=W8^5FBW[ BSPQ@#,SKE4Y";O(2A@H)(8[#?=E7ONX+??U)0
M4IK!Q<]<B$=BG8R9:,H$V<"$%!&'2ZBMUD2R"HK:454YI6@G'.FG2A;!W@7\
M*(2F_.K2_PZ4F*UF2%*I=J-13GB5;SJ,EU?<NVD-_QUHXZO+-C"U(8:RQV<H
M#O92(_S)1(L[1N7=36/(CV5"EF_0Z4E,PRA$;YKE&U"4,^\!^8??HR8;SZ2.
MU;"NE$?69%$H?E))X3BMO5+<@SM7VJ$EC$:->TFDS_N^[7I*6(%5%\EL**JC
M$BZX"XUB_8=*@8M$)]9[+6\#TMT-,A!29C&R?=;AK*2<OT[WPG+43%N*$Z0@
MTB6."V*>QPEG-^"' QWQ7("5%L4XZ1"KB#%9LQ&Q9T-:[URI*[U4!GWUU+&C
M%1JD9XJ2Q5UC7!78XW&/-+Z_RELV6Y)=GBC.0EAGWW;ALF%->$X(IJ_'?U/J
M@%,OR+X%"51=REKI'W+#XNZ3I*-0&<L.-VBJZTT^,.:Y<G:G[D1]Z,"["1Z
MD%-8=FWN^!WE SB2!F3+?K)RN8;2F>"1O43KG32D"#=CB3U.[*8[8>:.*F;
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MCSZT"<#;$)<Y<4),,T=P@O5.4_1.Z(F,WRS1H#E?<\UM,+9*"^R)[S3\J6D
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MX8JG7(+0X%0'([ESYD!;@UE.QQ4-2PGZC 2:%P#S2<0P"X )#6?\GJV.&O<
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M%IOX>2R_S,DA>RI=F.&!GA#].L3(A:!DV7*!:OTT3%\3KH0^&$E9"SJ36F6
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M%DU+!D^]4WG.&"%HEBO:&W:^[8=DNVB'0R8A['DCFYBX79'*,TQ_Y<10K1"
M.ZL":[AB1S82:O<N'G"LZ*(M2N-$VNV"D)G7U F:I8.G0C+Q!BUR'7TARH^R
M#I?YPEAADO7^Z_NW/_Y0B \Z'2G2@7!TWKJYKT)=(C_4YW:O3*. V^JN=T9)
M+';7+<;.WYB/#>YPW^LU42]LB5&B6CV8$_>]8R8\Z>)"+<P$8&T"$([^\?7W
M1#+M(J:N(JU?<US#Q<B!<.06_=W[B_AN0%K!\JY\RG*RE0LF7.$,[['=9B):
M<CFBK?"N.2HHFEN-+W88"7NR8ESXR*K!FG(B)N*!7G((L[8B5K%B!S22$BM_
MB5BVN'I4XM*GNNB"P=F[7I3.,NQ8E'.[O? T,QB6!&&C>S")RZ34N\3QHL87
M"0?%H0@/HH3@/R^H#Y_=T+6(BH;'ZF/N5(I8ECGA[P>//P0L^RUH0\ I=&@(
MDA:NO+I<_*7E_=W+D,,[/F8,K'2(KYA915,4Q'K%@6SZ7+INJ/(0O,KNFDT6
MT!Q^:GRN6[5SZ/5%)(!1GW?(LXXH:2RK<BH7<ELIVZJ6:ZQF,%G,5HN7"LMK
M!$R5A^D DEQ,H[+D^MQ:S@^9$:7TG7F:1 IUW=+T$ECGW#)_!E Y !7.6BP>
MS0?IF9GHANH>4_E097^ &:FQ.QC3X3FX:1,2&^(V!$3M\H!+D1+>NJ)->S0*
M=7,7;J2V(SPD[GB7#<TD70TQV:?W93.UY.JL9AVOPL7;1NNM6--,/:<^PU16
M4[VJ;F!M<I-.,$(C^4T,XQ+R)L^+=@9_GW?@Z>:4"3\HDO790FZ.DWGS\_(Z
M+Z][+"^GKGI5N9)+>%/FU\N',4(I?#6CL))#H06'0J2I*#U%__+<4J.Z1<SJ
MZ>(6(M3Y-/UY;9_7]LFUG4EU@J/LR*I'(40]+>J;"F&IW$3^<PBV>WHKAMEP
MCISYV_>"CTGDET @3V4&J=@EZJ"&($[V)H($5,<D[T-0%E$@Z!85?0+=PJR6
MORL_A.B7DM5(Y5-6)HU(SMQ'YWWU\4%!%V'T;O53Q8Q*04I@BBQF#!+&DK)I
M!''5K@1 %Q4H+3DSEDN%ID^-)*$TOS'!\#3]MZA/>;$-)P850V\F+J=Z[" Q
M"DO+CG(44*V]I1MNF-=<T'MW]=N=&Y/.6^@_+=NLZGR;<BJ';6=#3%_VS,"^
M+F_:SJ!T^+32\XH!-X?]AE*65T?>AISQ+CB)1NLW)KXC,*8,.YK7O4$]CQZ>
MKVK(?!J"M#<><:<H7C^55JH?DWR"9:A=LM#D,)G_'NG </\+YO8T1<UI]"+1
MUR?I;_"<+IJ*KBZ@9T(-=:I?- K]"*>V(!;#MHF]6@S(*3$0$"0W3=7I7\/U
M4R+V6YCO,< F@A:AHR1>=DLP>4<:'0FC)=4IO+8UVGL8%+$^^I)-"4QPK\G0
M1'PL ;P?AOUA4.P1,V\/;0OTD^MJ&QT$EXOOPP]:,-T3@HXP 8DH;C$"(5B-
M793LJ&"0ERD*Q29.E"LF2VT,^5:DA\>)%2FR+B:N=0ZUS8-5W5)0F&@H8_(U
MI\90!4/\C,!U0#E!<Z%-L*,6S"4)JD)UYS?)1=WZE5AL)3# -4HJXYK-9)*"
M?\ZK?>71K-*L)JO5E0-42R_\M!\,+&\+*$(R?YJMK4[L8;99=+6&VQX)/LQ0
M=NESL^F+NG<*5.1ZI'2%B&.?)#7YR6FYPT8S-DNE+GS?AY*4T_,A>E9,D07$
MM4**F"Q9YM>8Y+-X_10&%+S" TG9Z_Y<M6%_%,RZS_@S9H%F>-RV[3WV!.#'
M^&#3Q4!=PC%5P,LI(<Q.8Q)_BJ0-N=8,.JV2I4A AL@9X;LLJ]C:Z4'FW'[J
M#SF15_X 6\T2N1H;<?=/=J!]HKB:S\^XFC.NYE'B:A* GW@,6I8%%L K&OI"
MBD]26C5% +;N5*56BYK 'F1[5$M0KL2^!R?(J69->91@9%:L1J(=0DM6OR#-
MG%K1JKLVUE6A=JI%'T)]7I6*VT0;G]X=[6=$!=_W6JU2D:#H17!UFPO59,U+
M$="T(I0HD%!\"7T,10K60R_HOV#6-O6^X&BYB.<*98;28P4A^) @KTEC>+$3
M8GXOK\+ZQW+\7=<$3E?.?(7?YQTFH@\;'9'UHJHEPJGBG^E8)>*!H=KMA]Q)
M<1[%[_@2.,( -['DLR'0Q<VU J'BVZ7KN^3V/(%$N)2U^6RD*I+^,)[55U$G
MPT&%4G>:/$@=5GJJNW=('8#1KSNJH*K\*C9/])AX3L 7JNTRL0ERGS&!FBJZ
M*18O%?IT1TN-.OJICU^ZTY,SEUZ?8/(I(J. ^SSK^-!:J5=]X7>9[ LI9S5E
MUQ'X(RDZ0'J=@MRDG* OT'>F9QY('XX$G3/,'[L!6<LMA'FE2X1&!DOEU:%D
M_6BNRLOZI85IC;32]MU>0XN1KD(,: :G%1N96#.J5K_BO#_N'"#@AW?5ZF@-
M*BPCRQ@6EP97GU$%%K(;4Q@H'0K2TY]VCJB+)OX7M$=L750.K6QJK%KFEXYL
M%\M-K$7OQW%W+S],OOB2)<K];.&9*+;"=I;6')-7HR#R1UD6-W6[39NMTUC)
MA&8YFN.07K5U%'"32.VDV0+6QA I$$>(JIWHJJ==12W=6PK84W00#74O:Y9?
MK!XPI\>?P^M-2I%5:&S#DV7ED5(_[6K4Y=4;60B#&?GH8\ODA;>32!OSB[7%
MUAJFT.T_[F<P.+OTG&GF85"M,;I/G)]\ _@Q$F"0\V!%]E3!+3OP&IX<E"2P
MV4&6SC-ZYA@SCKE2"NU0*W0&='46?E /!NQ\SWPFZ7[%\IU+9\1:L$XH;')2
MSY+,Q*%G<ZRMC%E(+4IE#->4T%);Q2;P-3&4\P(U1O ZH'O%JF"@ 4HZVR)&
MF"TE.W)59&D0PO3&.M0X9^HLR%3R+8II1L0@H'.DP1C"C N^)E"F4T=MX3KT
M3CQ8B*'J&X=2G'JL7SQFD2WEH:L72<] *T+52^<>Q+)2IQ]$>'?<:T)^<^;I
M%#[K4-4)(%B@C6F"8WH<2Y1ZHE%QJY6S=.H\B4\E0G$5M1CR;_P>R;2_H- =
M\^]Z3F)5SRW*V0<GQ]#=F*V/9K&6I<-#M!2:@"[#1M\V6=(V<GC1BF?=0]YL
M^/>#F1[T_Q?.(NBS-E7'NP*YK5,PV87('52] 8SCXM$FWS)QLEU<8;&43\0Z
M^<BI1@0F9"$GJVR41P)UFS#?X(/*VH&%,T>/P]^-\?V$'F\9[R+=CCB.M;CC
MO*Q)XY$,QH;1LU0:=TOZC&(V (G_&)$9@MG]MEQ6EXL_XXB3+KQXD$:WW039
M&KX117FQ,W9758-"G7M2FZ6^QC#> Q0?94_N+&8.5Z*!AEM#9R]X7]5V0.-U
M<]%>W1"ZE"E5*'"E2=LA>$H&V4P\%=36HM9V/F9QFNE]47F 7GQPP!I>"4C@
MCOL18@/'L$&081D'WW(I&7LUR[#O*S3TUOVV*O&T$'^#CRNH57<S]!IG_C.G
M^DL"0YD"J\9"J(V4JW":U9"HAC(PU\WGNF XMA.'R1?)J? 1=G'JX2N?C@I.
M1Y!X5UV0_&#=R"&]I[#DFF3P"/%55[?"51%>>5A&!LF-I]=T_/RDNKPFMBR+
MTOW/GLIP_)543ET#28*;:?:H8\UQ#2B\+VCD"HO;\FA[]RB.7 A'21XPM0\S
MJG<_NNC(4//:)J$K41C,DA3_:-TB#2.RJQRZ<D180XYQL$>UYI8DOIZB57#-
M1?QC#0#- F+%TOF*(C"2!\RUB X3M8=)'T%VYII;/FY]H&JCF?'MT0G6VC.-
M.N/O:/JAI@[48H ?S(."\1"&.#I_6^"VI'4'BK^W)16Q2 K=_BYN.[&]5Q2M
MK5E9,HTP1BDUI'GX1)"NGCL>*6$!:TC.(-@70->IFV['; 973HQSJF1T:AQ9
M[U/E&!9]]'9H/)@3F^$.6H7)$E!A4,U<P'>>ED62$BX#PQ$Y'#QARSB8V6L[
MN\5!F2'GJ!O>T"S$DQ*AL^1!J 9&[E"^5<<[=>KH1%0B0L2T\TKJ="J)%A6L
M!>RB=IMRCP.Y.)$$:F8M2YH97Z=]4*0B&DR!J$V["VIU5H.N.]M4:4D#T=$@
MH:9V9H7L\ZIR?6)X-=$- ^Z)IE_JA5KPTXI>ED"+LM3A@\@,,GKL]VR7L^X)
M]X2GJ3+J,-I(E6&T; Y;\&E6\+XX5_#.%;Q?JX+WB_C=R",Z1&\DH=H2-\0Y
M!4:%:$"/$:'80Y*WQ3#49YN-CI(^,U>=J4B#A[%D8(YK&YLA9<,QRW-BP:E$
MK]Z1\WY.HN',O,FISUXP%I:F4WIX9[&PA4NTZ-E@V>>3[=Z3;=',5)/0R$I+
M<UTE$9^&R+[XH$GR(LF:]$5:L>LJ%W7TQ6__[?F7SU[^1SW/A$S*B(-D<HF\
M$M__7?V?'*2D>0,:?@AC+M(P)KR^MW]^5R1?E= K:8C\'<Z[CE@O6_:7-<1)
MZVZ7B[]H7[$O;@.7*3K$^-6)K-?4.5[]7 ,?)3E(Z@1/.M1!Z18I>V="F0CE
M'A?>9[.*S,O.WAE ;WPD]]3ET^TB[,FQ1D39=HXVY)-UP@3L./T&M2E=^M-Y
M-7*.%&WW?L3CG"@56@-% 810(7DX&C;)VB.7@];WN2YM5^-+$0QA!(0]7]D;
MA(-4R!7+6ND,HIOKB1,YM4+OE7VQ<CM4)SSN\N@R;^N*,P.<)HU%C0<SNZ_Z
M"=MBW C5S^&\7/%,(DCU08S6RJTZ%&P.5+Y[5[*:A9*YI+C&&NO42*5N?#RH
M,I3F'U.828K9Q19C6&@%9)SG#Y/,FX(Q@LVMVQ7N4).\/2@?T_YA3V- %=*#
MLD$D"#B*;Z?A-%FWGQ(6"D?6F'':,QE,L?HR]FX&B:GE2ZN3N*+I!"V#,P#E
M^&[(>SA2RE@LOCHQ_V!T#-N8&[B.P;EB^ RM'"V!*@9:^4PN3AE>/!B3,C+\
MLNS3J3VQZ'2Z$:G.,@-Z!VFT]-A'RBOO;,.N.I>+D@R;^A?,E,)&Q?%/%!K'
ML50"/6@EC&=A_[4[W,L*?ZMR%P*)7B"3U0?)Y%3-W]JZ<99:895.,H]WDF$V
M)P-@I8+)GJ!+6W0<82A62E(\B!H>Z/OA\3(1$T]16BL26'FLJGCP-*5(ZX;!
M8?D!QOT/=S[23[ZEE9,04@#US\@HG#@P'0SSVC@+-"U;T4S6?C@A]Z^TZO>(
M$C[*\+_>E,TUYZ[A#3F:'LU)(-6]T>37P36#X6=".RS[.)@P/CNUD.A.\HR2
M\K$0Z+^2A$S%Y3[NZ(0[/B?1 ->:GF*26[IM9M-TJ,X&YPQ,IH)&6/R04,AP
M3.(H9)S?/^WH'Y4PJ.<H) 9_RE[)ZUSHA)!) PJQYU<&MYH@3L23E+;22,/@
MIA*.*4<6ZQ:. QCZ-BDNL@W"W=F%O6=R-^ODB[.@N(S+C:FS)]?C;&[4]RA(
MGC]-ZAFY4>(9"M%1S/&N\M2R/MWH;+]<_(E^%D*F/=43PFIX'^Q"!<:5YU\6
MBQ?/GC]G;^F[JMP<+][O:,&]"E8^O*_%&P !^L6KY0!'-/D._8T0-<)J#&[6
M,(-<$,F^J56C/N%[\<VB2WF#X2+9UE<0E1:>'.T+%QEB.IQ*.7,N5]9U8I4U
M^?FHZBJU6-TCA;.]HVD8+Y@A1)#LG?/+^AX]3F&V/V-?QN,M#+6KOI#B+9AJ
M-09QT6G*?S'M/2E8MV)Y)(NC%(2:UAI1!I&E1D"HPQ7%/[%DXD+>25RRY^*S
M*1925K$)S#H=(^RT(FC)@7$E,8(EL@S _1, %S,)@+:;APYI0<18MU+?:PJ/
MZUCP7S66DU;,D=7SZ<!'_1'3W/=<0DT (@X H(6_<$CQ"Y ^Z(FB3Y'RBA?C
M<:> V+Q[9C;*S,H1)'@3+HF]^OY 7,75XC40==V!94/"N!4"H!!>Q&&LFR8
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M<]2F"P8^Y*DS83R(0=O4+,FAQ)WID*IE(2EKU!!EI+O>@+$-1#:/60X:">U
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M$6B#&Y\>??X]Y*+^Z(@.8GY*5=VILLE#5?\ZOE_""Q*L:RM*TS_*=-GBAG>
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M](+ZL_/B/"_.CUN<Y3(882XP$,BH"K:25Y]KOC)Z@_/Z.J^OT^MKJ<Q6-RE
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M_:0=]K2EKIK@%K9-1,/K P@X\R&A_'"*45_UCK/9<743I1C>C5_64Z^K/!V
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MX-+\>@W^#IZA\#DV/?6I[ZP*XU9:S* ]=$A)DS!^:E9Y^.$[ZO3MNF,XQ0G
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M[5MARW/WM=@M+EA?2VB9@I:M1C#^I B,\"T79N9>"RN<C@=@VD1#RXO&8RS
M1R,GL:)IFJ1@X\!TC!/MATL MGTO/6T-P&X)H1^YBKJ51LLVA0"&U?>?U3N5
MMF'U'[= MLT-SU?TL@>L7M]X@Y?]JGHI/XDW:D!NO>3E('6!%KLC,/W@]K>_
MP1_J.6\DW!@W\D8.GC$2OD1=F_5?GX1=/(&%]VI53E,KS.<E=CK:K.G/__M_
M]-GG%F+5BT91_%;QO+:L&\Y,<XC\UZ(ZB(7[K>H.X<UOW=&=>Y_(97:[-:>I
MSM/;[-S@1EBM6K?[JY7_%;=C;B_'[O>JMF.2V:HC,4S?\E/J(SHGZK,H"1 ?
M[6TL1M1M'<<NC$ID2:/)6\>NM9^(*MJ9I7.K'5K7NHG%\.^__.7R['!1ZC7]
M'0Y>/'9'[_1D0/G1+[]=XAE 0_00O@6:)QE+NNNP97%7%VW79O9 6TV0 H=Z
MA=50:N/,-ME.MDWGXE:$4\:.<*W __LO5[^/OK6<+NAFG7KW%U[LQH_0OZ=)
M&@SOU<3:\Q/[4UA^X%MAE%K7(L3^-L)RPWLKY@E;_C3&1ICIC;#N8=,32X2^
M\*T/PA/D/VC8%<NI.PZ%1>$O\,]8)!/AX>:/[BO<.0<?3]P1NA=B"[9.A F.
M"C2/IK$UB2-_ZJ66AVX''V:0U&BCMK =)Z'5GU[#S^1:[@0LQQ.P%MHCF#E.
MVK6^R"E_@&T:11.$+;3.10([Y-U8[IT;^U:*O41QE>X$%O@]&,/"1O?6*[M1
MLRU8R@A1#[/=.71##[;S"^T[ 2+BAF9#GH0P\W2:TNLOQ7<WJ>!6'GXY/[FL
MP*NL9#J91'%*^_GEQDV$Y5@>O![O0RN- VQK.K0^7U:;=;MFL9+QX6=IR[L3
M78>PV;[UJE%K9@O#1U[9-2?[ -ZN>,I-DL@+7/1&W07I#:\?5V)=QVZ8;HWX
M9Z%U(28I+]YN\.(7\D!&MN,/??BOF^*/;ES?&@@1,OW1U6:]<FKU; =H<85'
M\0JV.^\2ZRR>W(#<E%R56!_II\ V\,SXL>2UAL 9^(84[K*46!.^ \F85E,8
M-YF,</#^YT\U:X8#EC' '*7K&@L_0%C<H8V3]:=D\>/OJ"7** J+21R,\CTB
MC056'X1 ,]<:!.1'M6 1M\ VB>5>QX(P3NGTXO9<\%=6/_^&MN[/8)3 YOX9
MC88UZ\LT3J9(-!A5>RC1G](>L,:N#\0 >9K<6!/WGE@ 'ITF,#$:P!V#5D1L
M\:J;<V@%"&AY$<AF7S8Z(U8"N92Z^& ,?Y) @[,=*\FDUE:S?IB;6K76NMQT
M,;>3-5V!W0'N.LN:1Q_IS:.?6IRMG(EJ8XT(5M,8&52[UH=!@D)D%<6 8+$
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M!1"?G(Q<3Q%.@A3-/J16TR?O0Y(NOE<RZ&U"O-!,?$L$,J5!WZJ"D,-DU<4
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MS$*-IR-I?.)"L<'(P_LGP;&YT01F;^=^QLK2AQA^C'=/W^7M[C!H"]/Q5$(
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MB8:.6$#N&FH0,=8CU"#B"+RA!A%9Q YIZ1CA?5 V4(70ZCET5('F(+9#:2,
M'*$&\?;;&M)\-IUQW]:0%3+9/;^M(3_"NN*6'FR#>7<KQ"4RA]AD6@-LHC%V
MB':MQ.?+$E5CXF^.R+B%B2P4)J P$8Z9)TR%"=@<$>Q,-[SO(5SJXK_#ZQZ
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ML#.Z04#96^9_\1*$IFW(0Z8V=E]V<&8BW6:J!E$C=O<"K'S[LI' T15L,O8
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MT::"NEB#>@W4:X#' (\!'A-MU0*/B<VH@<= O0:828#<,0)@&.HUT= CU&N
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M6S0T,4:/*9!OB<ZMYQ"&?G["+%>ENDE<0?7I#4Y-1-!3Z=4JTAB;V*+MNO(
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MP,BN\UPP(TN?+%0,#B9@9,&Y!(SLVL\%,S(V&AS,V0[FC;4D+WKX+P:$U!N
M<%8._L<02+T$@%-]>_PC+[;'7PP^8O,O.:S/GS7X)H2X6.NL\V+(G]#(94#R
MDGC]@2!YR6<:D-)/9[97332?U6[GM#\N()* 2 (B><'7$Q#)-1#)<3KP[4W0
M%=@P:4EPK=B0>CLRG.(/'=WBE3_JIAD8I=_;Y/"((O9NHDC<L)&+#F7X8*+)
MD7X8E(&T+5V8?%1KXQ^!1^]GKMS->96-#T:3#%X=N"QYA:)*DY?%<( JGX0J
MJ?,K'!^)*X)@JS:9&?<3,.3S$>*K*69$KHSP[\@P_^>_H^F_ B7MRNGAFNUT
M&CGX/AH8[2CQ53CEYV#&GS/)Q WWK;"DR1L45G->L5& +>=0Q[\/MLB.19?C
MI_*>4R1 EP]2R;\/ON21) NR%>#)633U[X,GA9F--=N/4-^_Y#B(D[#)\@JO
M"8CA+:;":S9OK!@NQ$"#L@\EJVMK9OXRJ7VLWO_YVW]3;\#3L] ^OC=>QNPW
MI$TS/+;OM+&#A]$N9I1F<[HZU37HWY19RJ9W%77_$@.]AJ#177^1BCXGX^U<
M@T6K@LPGYOER=KGP-],KUXMO:*='S9NR:=JDM_5NK[QN,ST0<G<M8=)(-"LI
MO95H<3:T9(%^UB$V&0UQ[*%&>=^8HO:<"Q=*LKHVN'S&1$::2_4CF,QKYRU>
M@,.\I5VGW[E(%W*H(V>\,4O88J=:4(N/S_<I*YF.)C*8R\0=+A-PF(##?-K,
M5\A$"UC,Q[&837 2PI)ES?%Z..RF5-:>A+20?F)5O=&T) GSF_SPK.QF7M3%
M:+K1N9V$ZTDA,:VKN?($V$WJU]_15#043Z9"Z=3^*.J Z01,YUQ,)WUX#M(E
MF<[;8/'A@Z3_D.NTD,7+&A+=.3X.N^'L];C4MAX:;"+_W%:$8FG0,]_=C/P@
MNSDZ'RB522]0K-^;L)'>;;G!*NUZ7 &^ WW[HO%$*!)-AV('&,__!IPGX#SG
MXCQ0=GEEG.?*U)U^<67,:GIE.%$C]4E*7"W56O=C><8NJQBN!L^16N=Q,&FS
M"C<0A]%>)PE^%R[VZ^](,A2-Q;":\I)==)VI&W_BZ$V0A8"[BCAS?1/# *IP
M"(S FR/F7QHBDP1T2<)KT(;X,M,RX9-_?#"V_/GXH'#\#=B3$:$?-QE_T-&/
M:-8$PZA+SX54#K;OX5F"XEF=-[! O.<[A<G42+*-N;0<-:N]]>IQ 5- TWO8
MQ> #5_ O'S'[\_))8Q\V).?3BV6O<@;.'_N=\JVI9!1*S8)<X#6[I.3'RZ?,
M'WBV-U2 EXZ/HXG!JCL38C#8R5?F =Y[=Z]5,U5>#G?YV'(I-/CX^KX%+;MA
M-FXH$DF%(JG$.89I79XD/G^8UN7+NCZ,#7QZH>_'L8'W"KO/YP%OUK3V.4 /
M4K1.,8#V0ZP_59-*<J+V^O8:/?2GW!TP@+C#  +B#XC_XA7,7YWZ3[N%.WGC
ML9=;CIXGL[ODO% 8SN\:\4_G!$I>>8H]:06ARU?K>KYEHG%/&&).D/KU=SP2
MBL?2H7B4#=A!P XN7JO]"G9 ID5%/F1[ 79^<>P\W6SM!PBKCYU*^EX!P[&W
MU2D[+#\7^%BZ,%,'4SDID_%0,2IA\+]D_)3"^2/R.ZG;CP"9T:<  9-!2V0(
ML@FS01VOWW>-D'RPH^K:G?V![^JT[XI\V:!44'")X !O&3UB6!19@V4?^'ZC
M&DL-']*1>SKDF(N=T8-U9>1S*57ARL#PP7ZNJ^<B'ZWM7MEQ!EA]%@?.U:-U
MX--YA<K]6A$IA(<#JY<:5 IR1-7GR7M)$P00D9 )&&)3ATH; G82L).OFM(7
M2,D K7]"OMCW=2:]5K)EBZ5<:Q&-=@NS65V.I2;149A=P.#OV,NB[;OFC3$$
M>N$!#UXC :LP2#/)N3+?PB<>)#3]8*<0_,P"8N=\>%TR=/.0VWD1*13BF7GO
MN7O7*=9NE:31RS\/^TEP#25"T<A^ZM^W() @:!2D-_V,]*;#[.  )]!J/"^6
M%_>W$V0]=]7T:M[.+N\Q)XC_^ON,UF_ !;XH%PCRG+ZL3^RU+*%4ZW3NYUI_
MR*Z:\FU4N]/6J  L 9*>0NE$+,3&N( U!*PAR'D*L/,K86>0\_1Y;JK7"AMA
M.!K5\:?%0JX]Z<\6[),N/BZPL"$)4(ZT"?*?*+K4D<4HV*+_.'?5=_53'\UT
MNF"SQRN07E=VW%<4G;DT7EPV<^?2NP^H(J"*2[LTKG#[ 5D$9'%I<_X*M_^F
MIE4?WI?J8[V#1]I45>Y*Y51]&8Y,VIJ0N,O$<V)B_.XFG-AN*&N"KJ(J#0<>
M[5"5R#63:!!7HET^.K2TB&V.E\W[?HITJ(IQH50RA?_M._\^KB%(P'1^.M,Y
MDE]TZ>U?-]/Y6,_.J_E%)!E+W _'Z50W%Y[TBI*J#J4GPB]BK^47WR_7R%G(
M*X<1Y)% 6#XEH2@7HK]\^&""JVUE=X8I!%>EEU]XY,"?9RUH4_YQG>ZP:I?O
MU@LEE.^/A\_W9QLYT)F/;M.I>7Y5"%?'$LO%(I9F+?IIR$U*A:)L,I1*''((
M?Q=:^8%!GL_?\Q4F,UVRQ^5G,(D/[Y'9&<2;?#R3C'9SQ8C4[O#/8S3*8$81
MIXPB8!(!D_AVN4Y?B4N<SGPJ9HNH,3&BJXG=;JSB^/W#AG'>.2-W56&EU..U
M=B$71;8^OJM8: *J10I;*[%(B$W'0XE8). ; =_XXHE0;S/!SMV[_X.<HFA8
MOD_>#T>#2:E5'F.HU1_D[L=RC*.>CCNV(^909<(7<K>U.U3IK[E'PCI([_YT
M*L1Q6.>(Q\_<N_]G$=(/91Y7EZ=V6:7#NNT.VH+.+KM(GZ/8M#<=6]4_2Y%^
M25&HE<J#_'14XPH-FVTO<ZWU;&6 :4'\FM%0.A4/Q=/[Q/X#1Z\>[\A/W#Q!
M<ZZ@.=<;ZS!W)RC\J6NBR@W"L;NV>#M1R\A(/Q7'25GXDY&I[VTL7VBD9\^L
M5BD7'M3G:7*I/_6*D_L^QY*R2S:4B)^QK.+*R.:* JL_"PQ?I'O7)T]I.3^/
M^8QNHO5IM=:K1"6=#2=[A:Y^F]=[F2$PF#AF, %S"9C+YWA, ^[R)]SE!;=I
M8M%"MLGJ!3XGZM$X9Z^2G4_O6ZQHBG2?[=8E-FS=]ZIAO7:7&&> TZ1^_8WW
M'&(39^PA\>/I+& W09.UGWSP ?X'W=C^9.3B9XA(55H:ZW+EOL_RPK*.$G?W
MPVJ/6/MDAB>6D=S)T3'?+S'2U\4_Z,'V!3,9 ]_?1_9@&ZAW1J\_GJY9>;9Z
M3$]M:52[Q\8Z1^9,)D.1^*%$A&] (D$<\8=F.%ZWV7U)I]ZKVV6,'D<E?;Q8
MU@MR)97K-(?K6=G, -. V91!P[: 87RK;,?KYAC7XJA[-?>(S<K#;&:AI5E4
M->1%NY^1S=H]< _2VBT*F0WG]-O]+(+ZH4SDTJF/00^X (V_8Q+>]_6BO5I^
MA1_2^B#Q,"Q-(H6N-2AF>EJCMP#Y1;O%16.Q$,N>FFSW@U+R@FYQ0;>X;W7<
M5Q1FNC1>7!>8@K9R ?D$Y!/TGPOH)Z"?J\H"NC2<KJMGU)\Y.X_49":LUK*;
M;,F(#:=LXS[3TY]KE7<79[VZ\=0Z>U=?S))F;9++\79#N[-SF5D&=@?UF)%T
M*!UE0XET+.A4%["GR[.GH*7=Q?U/K^8LK=O'&(9#:\&&9Y-29Q&=I>KE(>$L
ML==REN^7NN4LY(][VD6^3S7\)_>TVV864<PL1-T>*.@JN,6U-;W[\]P//B7,
M8GSM-L*V!\E>([6*3BOH3Q+'3C>],WN-3JH23PTFB6Y--J/%128?6?2Y*.UZ
M%V/CH>2!/IK?AYHNI;U<FJK>S6+^\4%G[SCO+@V'+]./XC-8RX?WLV@EY3S2
MRME*H31)BEKE;B)/$_? 7N*4O1R*F06L)6 M'^+8O#0@OBUO.9V 5A*U\5.F
MKO'L[+XX7)=J955HGK=OCB!$^G5^MG[N\H/29/9D#M3;QA#X#.FPEPPE8EPH
MD3I4]A)PFX#;?(@;^-* ^#IM^3[(!=Q0)T]U_MX0)WRNDX[>+>/CX1\FNKZZ
M+5\Q^2RVA^MACTU4[U-Z^V%4;.6(8D,FED12(3:6AG]!7[Z Y9R#Y1#7[J4!
M\844G,>B$)5RX[K678URK>?\H)Q?K\_;)[Q;MR+)2EIH=4O2L##M3G+]VIKX
M5L"CRZ5#"98+L0>+9_:Z^?W;XO'!GN'<QK9IR=+*CRH[E$V_\:(%X*M]);%_
M^&(%+!J0L;W6S@@QO  %O;RVPAC.:+J%G\\;^&.-D?$-0X-7F"EO6- DT!HA
M$P&JD) 'ECXB(\D:KPDROLATQ9%Y\X$;. [:US)-49[__1_\P[U/4!!O )<8
M_;5].E%XB<LCV'^>A=*W#R$2<[F@1^C%<,*W;/+SO_Z??_F;D%18T!7=^.WR
M*]^^1I0]1 CK&J+PP$#\),Q+^-6_>67!KTS72YVZB<1<7OC;XWD "29^DTK]
MD]G\"O#8 Z;*+\,^D&U%*^A=[D>$Q[F?Z28Q@7X;2.$M>8[@V5M/)>=BZ=/?
M$>XF<:9CV9%$T<TA_(=G1@9PPO_N-'([:$<? K]CMH,YGO*7GR,['V'* I8#
M-),#QHJ)PL-)_C5XN0W50^#B":?$7%J(LUP,]6,\Q_5C<8'OIV*I9#\E)@0V
M'HT(R23Z1=_Z,5#;DS\OL)A:IG57:#&=VT(KTRQT.^5<VXDLE>LYRBGH5G*-
M>KM1+><SG4*^W<$_:X5ZI]THYC+MVV*U\=#N)Y+11/RBF_&OD=DLDFD4&5@F
M0]9Y'O9]3EGCX!++1Z04)XK]9#*6Z,=0,M)/#3C4%Q*IR& 0%P5)$!WP\ZZ<
MCLZC_-!JM%%W%C%'D?MV7TC&%GU2#[]]I8VQ.%U?+@ML>RQE"^P36JO"HA_9
MO_*VM5@^I,+18G<65=/-=L%,I.:+?G3_RN=*(SFUIHU:8:7V9W>3</1NEA[V
MB8=T^\IU>S[OI.\$KKNJ]5HLNAW?YQXS_5B?W;UR<M^ZR_;[:,'*PU7<FI5[
M%:.0Z<?WKQQ$^T_3YXQ09.V.82BV$KM+9(;XRKUUZKFEV RG9&&2,)0\ZFMV
M>WZ_P%?NK?-V=+\<U88Q9=)HEA^ZB7"M7AP,^XG]MU<+C5BEI)8:DYS,1C-F
MN=^)/MWWD_M7EM)VVV#'+1;;@&:QV1LOC6%FT4_M7SGJY_L*7ZA.NG="3I\(
M1B:<9._[Z?TKC4DK;A?S\UPATJUP3[/R9+5*D:Z%^Y>N13GVF#-[W7"M6WT8
MYBK9N47:CB5V+\W=*S.,2+;43333;2NWRBZF.FFOL/=4OA3N9KNM:9FUI4BI
M*>7R<IHG925[3[7*_6FODN+#DUQ3X'MW;"_/UDEVP-Y3Y56^F'RJ9RS63F?C
M[?$@.4I)1.W<NW0XG-T*<RM1[*J58KN6>8RULWULQ1Y *8//\6'V/C[ISM)/
MF >FPX5R%T/@ $Y%;UEEE'N*#R8S(5]I=!]374[$"SB  &)<;:KU=O217<EB
M>2RN5GS]80B7[D%@-,Y'T8K-RI-$O[O.S3+-8F.!+SV +$8LDLOTUW*8E9.1
M6)0-IVI-V-8!;&D46.&V,WYHL8E(9IVN5#MK&^*?!]"E.[0KG8S%W[$S[JFE
MQ.O5WG*9P=;%_J7KFOEX/T_HU@15[?ES5<@W[M+W_<@!'(@NYL_Y1#)?*LQ*
MBZ>'5&%R:R2&_<B!@[W-=O*I'A^6NXE!OI8M2.)<E?&E!PZV-<J4AU)V.&/#
M2%DA5E9C_!JO]<#!MKM:*MI^C$^[JMY$CXUR-9H?X:<>.-CGF%*<W"[M#+M2
M9]5,?M9)1(:8_1TXV$$GEW]>BW9](BNQ]<C.:MV)-H1+H[N7]NO9),>GZXGN
MPR)=ZBZ;Y4$OCH%UX&!7O3DW"YOA)[9D/#RUJYBKL@I>P(&#G7775GZJV0\8
M![BYE1R'+:F*&?"!TUI)B_: 6W4?V,:L/%SR63[<+]V#Y;AW::09D=+)&=]C
MVU)DK<KU7#M1()?N\4NMK T;RT:WS*Y&^>BXGWEH&>$A7.HR3&+2>3HQM>6Q
M/JSP4Q/]=G_QBU/0(AV]&-0K@:IEK@E %%;>MG3W ZJNDD^VE%I_3@Z]9M]J
ML QW8<X+.2JL7Y=8E.1N8K%3SBF?SNA[OHZ?*2GZPA7T[M]A<'W\IA;  L/I
M1>7;T1_(B]U+^0&V^&P+G5D/W]5H?!>^7IGQ64Y_Z"F*W$3BP4%<P4%@BN""
M@[B&@V!O3C8*" XB8$T_ZR "UG0M!Q&PI@\]B#>FP[^HM7[>KE-OV/59F?#G
M;GG/E_E&&&"C"3[\OU_Q7^^%1^(F<MZ2B-3+(:V3D=*B[I0W6"-$?WE"O&'2
M7PN:B,0_&@86$,&EMWPU1'#!,K$_)9(CA4 !95P;9:3V=OQR>=/^S[VT&H\&
M(N^E 2YRPW)?F@8^L.HM0(,OC0;<1_"]+]"+["50Y'ASQ!2Q:60RDJ&K3&.*
MH!18&S(9 =M#V.)!YN\/)9F+UNI?)$63.A-^X+Z)[?[S]AW@^0_;]]?&\^O4
M^=_7(<'KN'E2Z+G=.+^**G@52/Z"1_P,F_S'A]'F!9/^\4N^=K>6IJ%+LO52
MJQ9C6!GU)W>U98'/9TPYTYR-AK>0-!<]>PNH@/P"\CM%?F?OEL1MT1_79ZUV
MRN+U(<<V'INECB+*JV'_S/27$=MB.=,<WQ<BNF(OYHCC)BJDHB9^_1WC0JED
M"O_;;UKR_D9)7\<$?HMFT$+XH 5,S'0,GBXQFMNYV]+)[P(8S#8,S)/Q]YZU
MS ?6\K>R(CZLG_G%C(,7F&)@%@<(_9T0>MOI_4UM6U+] Z&\J8&5!2JCL/+"
M\*J.-[4F'P0:]=5JU)=R35V\YOV;#,[QTQW^74'P2T83,S[R.Z";W]7$5JP=
MT[3N*J5)M?:8Y[+913]);.-0,I4.<2<'Y01T'-#Q#Z/C\YK4[Z3C^;R5C"ZB
MR6+77J^[;?T9L54E@^DX 73,Q5*A="KZ<0.OOJ"%[>@GQ\;*!T9$8$1<KQ'Q
MK5255\_QLYOSHE1O:SS[("2*L74ZU1P-H8H\^KHI?@$E!Y3\PRGYO,K*JRFY
M^90H9'NWG3NVT:Z7DO',M)J89C E)X"2TPE,R;'4AZLGUZZ+^'4Z!O]'<"6L
M2V';1 QOF@AZ^ 26UI5:6A_,IGX.3SJO=N%EB5819DPMV&I#ZIHH _3DI[C"
M$C@6.L"M)BOKH=X1[69!?7J.Y,8\*RU'F7X:](Y4FL.:QRE3*B#4@%"_!Z&>
M5WGX $*M/5L5^;9\/RPDVD_+6BV7[*W#T#P*JQ5<B.6BH40\'G@]?OT-*1J@
M88BR.=5-7H'L 4E>(O&CU8Q+VPX_U6;Z09G%U\,?SZO(E'A9 [IM:'E"M:3"
MOR$1]FARIQ*NY$>[V\H*MLS.ZN.[6H[3VJW2 MK?050'VUOI4TPQX  !!_@V
M'&!OV/3W]"0 KP#YKH JQ5C(4&4MR+BX;K/D!T9J/R/C^3Q"634FAD\B=S84
MUI"(_6(>"LHFS&ZM+!=CA7:C'--S=4E^4#/0,!;D<#(52J1.ICT')!N0[*5)
M]DP"]0O:T*=KU4>\-L3+V4Z\)ZHZR8)49)[@2I"$_TW4[6\=I#R:LQP@:X"L
M7P99OYNIER++:!IHRLLB@ZA7G(H7$1$'41 NOE[=,8A"795!YWI9RYI@@/V6
M1_3_9<TAL$W4Z:B?];Y:5=MFJ3,LH.[P+KONY6-/;3*Z ]MWL70H?C+X%%!H
M0*%?V,]RWN#P*\AREQH?6VQE5FND^MU&Y&$=+G<KW.*>#)6&.O-((I3D]@=*
M_Z@B<T>#:%@C9# &$I \AYDF0?0WT.^O6[__HD[CX\PL(PB&C<0R-(=$)EZ3
M2XMU9!UR)(?%3+RE+[J%\*PXL/1"6\A)0QC\1<KT8BP72B;V!]-^G"OYT@@>
M$/8W).QOE<WV9AH_:E4D>9W7S.FMV<56Q>UB5FXF[069\D>SVE@V%(56P3\F
M69YJ+1B<&'$MDYGR*S*)C307H##VG"&!=1585X%"\CYF1:BK28D+"HXI:54W
M@:M33$N*E\-B7[T==OEA.UD9K<?%J$[FC8(K)!3%3"L=30?![H!@ T7C#(K&
M:VAWSZB83&.W9I5C"W;U-J^O6WRI:@V!9,%?$N)B7"C&[;?%_($.DQ8,X,):
MQI0WK!4^-@D9!O[30'.DV2@PLKZXD15DSOZ J$[>1AW=(>0FIF/,$W,V)F/M
MD+_E+CRO9Q_"K3';D"+)BE(HM.<3,N><^%OB6)O!9EB00Q]P@I_ ";Y]#CV5
M\OESR?7OCL)!'F[@='B?3'8HKD4)[I1_H2-%B\5)V)RS#]EX.UE\:$K]&9;(
MI%$AAXV51(A+[?<""OP+ 1%?$1%_<T?$/CWO^1SRU:=A(9K-%^[N([U5.6J5
MTHT%D''B%!G_0)\#*2KRR@96@6GQ\:;%!:=$7@5<CID>EX;+#]."MON@N#[;
MU2EMJ**H\]5M:W++RLM\JBS$<T^I9*;/T<Z(7#242I^SL##@(5=#*Y>&2\!#
MKD+S>@</&45LO=M3NK-N>U9[" \%742C(? 0K(I%4ZE0,KV?9/+'Z;)7JW9%
M8F09]=>,40J,RC=QS6MBD1^=4/>SV=QY525,BS "O&GH<UE$8G;5-2&=SN-U
MFRG@)XMT^L/2[</8T+JH)T_Z5L5:#LK8Y"3='".)4#H9"7'Q_8:.@>LHH/*
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M,2+PGT]FN'^]5REV%@]KWZV!?6>H>3)-Q>M:)9OMJMW18[G5ZM>FV]7';^E
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MHC>1],\&04 & 1FD;Z*);P$!DNV[G2C^-:5@ZMN0?^J4<^0P2 9;[_3'!P
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MR3MCU5VE&N-#&%\);$\"#<71_(" :9DR1#E>X2WSI4 ZO@"'Q&C(&)1GUQU
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M=W]DD:>_2Y: W6_/[N]:\L&>OY,&9Q."W0O0*6.!ZJUDZ1KWGW]62 YB7<<
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M1=[ 7;Y5)/:+A%T#?@WX]2OQZW<.^[R<*7[05R=(&?\.)X67=T6^:H0W8.B
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ME*32A13S8=5Z8J7NW<56=;#UV5$ER^B24AS3ZIS+QJ%J%(?B<ZT!3:G$X[%
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MO!.;']!!!)[]X-6.%QP-0"_R"-R_5O5H;3&U:Z2@$V*!2*%#](&;\@2_Q$#
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M<FWSSAED^?4'KW ;!HCML[,;AU?^*Y^>.GZ0A X:,=COI8OM_Q65R_YVFR+
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M@$B[RS3[UL,A[&W=]+7.R, I)#MH@K(W/*OP\L9@&(%*V,.4\(4PY?UI1^=
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M,:W\2C1H("N UT9E#FS>*/L499_"B,DH^Q1EGZ+L$\H^D5\V'G'_[-,Q#U"
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MGM"M1.?%\CIWHY$W; >S1)5#?0 ,0*,KT8:?.7A)U\9TP\$VHH,N/$HZ6)2
M>9R-_>O"M/V)-CNQQ >HF=%,U=B(8E>T5C(OGJ?IAA%L'EU0MI'->OA[#L"J
M83@C$:QY!XT] R1]!FAPEC6QBK+LC%O;*MY-:7U/D3MZE_6 ;?]\6A04 U2A
M@@_/&+R4*NX*H/@'LR >@*CDI-V5TE/DV1!K4_$U@NY7,/]JH&XA"!0,*_@*
MCB,.H-ZR2RSK]N@R+JO+?ER6*7W9!E GGM.O6=-G%-3PXADKN(YKB9B![J!C
MDL7I *@>P HF:T 5.8B-SCDM!S!_W@L "&E9=SE?JEU:O7[6R!#DU3__!?_L
MGN-5L'>H=N=_'\L["KYD5T#!O[YZ<3%V?$R1C.^LAKWF+,3@.<3]NM&___/_
M#M?_$DJ!EWP-Z\?. CC86'#9ED3&@"3&II;(*3%N!M[]@U,];F/OKNFF_4H1
MR+KXL;<B("BPQ',Z_6_LY2,$R DTX?WA Y@=W0_VGSJ^(1Q\9]B(AG\@\2NO
M1#CWT:P(,8YA_B")Y^25\/+*=*->L/!?#IM;4&#\;Z^9.WLT'7X&; 7$@GIT
MQR'X"KC]Z%*V,<-R!KI=;>^)DOL5PCR&ZCEP7>MN_4Z8=<25J+MBP3(TN 4H
MM >R,\\!16R =YY>K8_39INL-DL#9NDNJ:605<JYQ=VNUO_LL&^CV6,P@OJ!
M%3MTHX>5&[EFG=F?_KV#X76RQL];8K=9?5G':%<"OT!SB_#-+:C$.'T#58,(
M:%2 !A3L' !X@,-:EB&X/+37]DEJ[.4X&-2$OKD&*TIPIFD9:V#+.**ZN;B]
MM>>.]($OD=Z[$N52I67*V55"23;<$9N++5,Q4_JP]84J5'0@)$RG.0MV?[#Y
M?=X>;OVL)=5=I%RNU^FR+&GA>+D2&VM<70(ZG7H^+>FW,Z6P&6!7+-?JE'O0
M.+)=TS0LYQ ]D&2(U-\VUIH#RP0C,1[ '/JCF&/)X%^ K7HO%L<)WRKSI_(1
M)-NH'C"\L_=Z<DY8N"M@/6"<I<$I/O!"<<6IT&8 B/=?C'ES$1@C@(1T#)AS
M@$OVLX-I@6>\@6\WP2.B;ZXX@()XUQ$Q;0/ *PN8*KJ*J,G<0:$3(-!%@#'#
M-&014"5@$E'#>%&%J^!TVU3!]/Z.30O@T=I@QG3AES2Q=QLZMTE_#\#.@VL*
MMB(BK\*T1;^6LNT":W %1T']N]ND U2R@]@ ;1<:66 6(=@.!A8E&!JR:2'Q
M6H:*0:5O/D<BZE=6CQ0Z7-.NLC6PN(&:A%X%S]GS%QF%^"4P?&5(:0#!?%#Z
MFG<M5.%FZ8+7S#;PH^]VR =5< "%"N),M"#N+%]EHL,=!TX)9^]_0;@^F0^2
MC_\Z8$YC[9>?T<+@3T#C8D!>Z&"VXU7^9#?V&VO8K6ZW? -R53 '-%H"QG^1
MYO[((VJ 7E!,7L=\-/\HH?],^ITA4[2MX4+AY$*_J(N3TB!.GZ6DSV+]%ZVO
M?U'/\3W)H?_L)23<_M5TRAOQ*=MR)H$.:%J!=WB<PX,X"S)UXT3"E=JMWD2I
MLO1\ZQ*RT4_3G_;_W['CRCJONM! IVU;!/\3>MSZK#XJSHK*ICRKL$R2V)"%
MV)+KS0=MZ&.>EHW> QM0Z!$-'X1;G+UV\4<<4"C8&_H9>:F8KW!V@1YL%^-!
MB/2MCY?R4^KF&?,]W(/8$'8<%CJA[$>)Z""; E&*GQ;N[%GV+,+:IIMLM1.Y
M.$OB@I;MR[;7G7M__$,^4Q]!V.X=3T!XR3P4-B: -_1CA5^03Q#@.@ ,4K/\
M''TW [[K0>SF0'0A>MAA$-B8%4YWH2X&4*3>,#*OS<H48N4 E=1$2(UC1KE;
MXY3!8--1,UQ7ZJ4_B<H"A$,GV CD3X3;L[C$.\TX7>):0[R+%UV5Y)>TLT6X
M/&VM<<86O*75T-2QKF@Z/N<1U!N<=^0AH(7" 84\#?[+ 9)RL#D71&*AN#AX
MF+L2OV8F!.6SZX>D-6MD.\QVIJ>4)ID3::%0V99:GX_6HJGM=SA;*,;4@EHP
M1JQFYS-*?:036051PVEV84\-/J\>@GIOF3<M<P[T<[!G&T.+ (:P 9[1?M>/
MV$OS%XL7_&8"PR?V8GIC=+VVX_NSUL>UV?SC&>6/N(%[#>Q#>@=H!.>6#^:S
MB&Z,'7.5]KR"LFE5$[EQ<JIT-*!S\9^Y@._H7,AC/]6X/U6XW!=5JQ]$3'Q0
MK30-MU-AR59M6JR;XYPN?!PQ+R8WD)IU% L)).;-U1T5B#^D[U[^V(F\KCNU
MQ:4+[Q8 BG%Z&_-8)+[Z/1".+7.+YRF^,E9D(AD33#9>FV\_;LI^5%N6"]MF
M0J[1-#NH=N.XD]>KTO07L.,;)D?:""'L^8HYSM].<%P[#EP3)4ZM<XXC6C:M
M"SF4Y)%$G9=%^S0(7.W)Q?+8&%0!3]K38K8^Z&;[[2L%@=^(29P+ ,"0KZ]>
MB/B/M^IDU)@B7<-:G6:.8?+E1K%[KW!% 9$@F \);?#?8VF@<1MH.YN<Y:!8
M&)"WL@[L9. )&2[ CH@!JI$E/V,'A VL* U3X;X&D"ULZMI@E&T#N8.<?P>J
M_ZFH&M[QBQ3=\%#X2S<P&(Z%FOT)X_Q*OT!EF$!5P#B%"FD$&@R\*,(O;(R3
M.%FWCRR&)S"+!<,2AV^0]96AKOQ !(<!6T &Y#6;(2\"[=1_Z<'<1^_=;Q,%
M+2P1A5+ 8@^7 J;R/1<XX1NQ24$&$M8Q+/L)C)@!>P_XG> ]'/BLRF -\'L+
M\R6Q)-NP&XL OYF*N@B&PQ7:,-L[!U0H6D]PERANN0(3[1 %AL_1+O>;VG57
MVP_<N<6O5K<;=TLSG@;+MZ:RXXN00_C#'/L4$!K@NG-H!C ! EWT)2@@2QU!
MIZP+X"W E>N(D@OL$0-\I%UG;EA OCV!G_EG[$^X81+_NU!N=)!Q2A)__X5-
MH<D/WJ< .K5%44$UIPV?_N57IP*0&>,9V,Q_+QP)34Q?U-N^:V'P?J -T@6)
M$VE SV!+%E+,/,S-6_8N3,3!8/ *!G0!8?+H!':P$O X7)?NQ\[\[_RXF?]Y
MCSH>4+1F8QZD3?\,"IS[8#Y.\O^U1/]ON(5S[Y4/7NVO//4$E#^@MH"ZP0!.
M!8P(?W<0DL!CLJ/ZEM\IF,!:X?:/(.1O <$?0%<753 4O .^<,:MP%,!^P3H
M0# Z<-&"KQ_95C\\B;'KN@1/UCN 8G5Q4Q!%^ZS)D>I7A4%EF-BP@]E2,CON
MO-N$)L?/'70 T4/$/!U(!&1K^R_%9N"MSQB-)/%KZ_LT^18$=@&9\;SE^J[8
ME6UQ8N*4V&F7-_ U*QHK,6[VS853^WS0DH9+%X6:S"$+")@:.<BT.L1%P_!#
MY6\8?PX_=*9&QBTJ75L?U#.=E)%7WL.$'$ + $Y]>2?D51GXPV#GZ&X*<J.F
MG(J"6_9<% ,\W3R>_/YYQP]!&QD!N\+Y9X$ZR@E#MAS36(5,C$:LFHAOU0S]
M#E!YH!$EI-1\,;F[\("\G8,84>J0D ,9 O2NB 2PZ*"C#[X,TV>R%=CF2$8=
M:J@@1ZFCG[NN:0&Y"=C"M5"\ 2K&D6$I>]D'?M&=S>%/K_,>FK$*Y!K/O>AF
MB%#P-;J28V-YV<\K!2_:3=X%9AC8L?[R^^$2C,/=D\'N$5":P 9!7Y+G>'L'
M$\T(##L@& 1TFYA';P<K7''PX*J?K83PN%NZ,-3903]*Z?O;F7,Q#*@]86QR
M)B,*0 %)>P?W,V!&#X =R4CP'BE#^,M.1R*34$#T#)!V15<^LU>3^\]::=!@
MTEE[JPPVVU5S1A:&['$1@%]7DL@E;+V8V%FT5=K?);W?X5Y_:I#7SLH5I>1T
M$C:3V[(:-=K,DZ0L; GZ'4]=UE\L8JP%3_$N7$'RK:2]_@RD.4#=U;H,?1+.
M\5\%<TNTX'E!8"$V9[2ORYLSN-]*L-T=@$\:!2'89EHYS=O8AJ@D>^M2MBQS
M?4)&"3O\-&/W;P 61U81Y>ZA"6D7&MF[R.R>:<CX.:Y!]O@M[$!J0L8/(+_[
MHSPM#J?+E>0RLK%FDC9M-?3E)^U GZ0'G+VC:I^>3B!^2,Q#45A.Y[D-HR1G
MTCHA=6ORF)&@DGS[[/,NJ\8A'H'.NNHB41'0[PNA-U_28?%S(<)3F75?*41,
MX@?YL_@EPHDNRXFE<7)08\CZLLT5D_'&>/M)&?8BI@YM^P#;9]&KU48+I=N8
M+I58RZEW1^/42,J\%U6$AF4POQTXA<B<W^']K.U^8C'M>BW-9+BN?90>?G42
MC3^71MESYA6QG3G =N82V':DJ9-J=G,4XZHT1:;F:2K/?/PDWCZ.:>A23[2T
ME@LD&##H &PT&>6C?J:?,GQID1\ QX;;X FAW%"WX]I[^LEXX53?NJ!"'4!^
MO!/R9'1"/CHA__X)>>Z%CS?#85S(;(6Y0M;T3;KEU&;#)?V'_RYN=W]/*M9J
M@U1Y45)BG3Y?8?5QS]':T 5_/;(32R;&0#PX^(98&LU"?FIK:WI"GHX4)RUW
ME<JM)TR7)T<C=3W/Y;MM:+6\'BG7F+$^G_<U1B2213;OI&H3Q0,C$Z]'-F=R
MNNL8Q2G.-8NU='_&-@:Z!W0L_GKDTJ35K%I7*38Y3\]Z,VKJQ882U,:O1PKZ
MQ.VLTFD93]:IA%Q9<<YR1(.1)V^?;FL+'*\,8DS,Y$R-20C;C@'K>)V\';<E
M;S$=QHO* *\O\76G6!(%;Y(\'<FFNFF.QEL31M3[5DVG,FD:APW,3T9.96M0
MCH\&244>)Y0\T>WTQBP<>;*CPF(J-W,.R2B;-)^NK7K5NF;#D;L=7?\&!4J\
MMV#TOW<09<T#+:X:-O W3O-GMI6LEG"]-E*J;&<1*Z4;S75.\I6NK .+D'9^
M,FX"AQ&ARK8EWLRV=9@:W6/R6(ON]$98KT,WNG2N5VXV;I9V^_O==IB[LQ-!
MJNT%B6?Z8?[6J<6;I'*[_%P47!6XDV^1YAM=,XL*F^&J2[G*N.FQJ$JQU<CA
MHZZ9%^^:N=/>O]<V,X4_IZ[;(^H=P_-@X >ND/]F!8S,32M@A&#+Q',Z_LVV
MG'E.)[_9EB/"_@Y;?ES"_F!!MA#IIAMV%@L+"W]BRQ=HP)=\IJY;@^^]7E#O
MW0>_<H_*B.8?;,L7H_D0]T=[CR>NT67R*S*"!IY4Q3LR0OKUCM_N GC9#H#$
M<^JA*?P#;2$C)#\PDG^OKV,@L^Y0QOPH:I1Z)G>0D'5XG/]'S/_J"!19;J,:
M%I8ST$%@= =/%&1>UB_372)S[WKN=RHT"MW1>^_[$K5$?2\S9-WNJ*/L[KW:
M/KP5$,]N#G]!IQ;@\9%)+KCMVH,7.>C=Z7U86,'GP8 %F[,= P:'&K+U;8-=
M"/DY6YQ,$ZU4LM:A>Y\NP_[&JG='>>$UHL/-P.4=/G*FA&FNN&XW>^69B<O.
MUC4,B<]3[?8D#DL8$T]$G+Q>">-02)>+M%>.Y,RWES-O-72XE9SAO/I@45X:
M&3PW$'*9*L[/^+P4'CFSQ0VVL$US-E-M"4.#5S8*0\*#"4$SL/=: X;3\_R,
MR28;L9[(SW5X6L\R#9^,OD $YEND"KY0<B \LO-2-MKNI">23X#/?#8[X+)=
M?T2259:;02FG+,=5>DH9\]DB]NGJ\9>7E15O;HSB5$U@!T:K:HF9S-Q>>WX;
M50*_8A/5$(1P#RVP2*)$$N6^UMBO2I1"<5),*VI[R&J+5$:176+3J(?(RVNV
M9EJ"*_47K,LUU_R(E*M%J>VW8J7P"S=B?:@(VD!6;4!_ T.=875.=V=@]_[=
MBVM89_=V]D(43+MW.\!02.00PB4\0OQ29J'/XI##CQC\5(JG8[HU<IN"S#33
M<X!+*9<>\"'RH4D!-V82GR+87&$S6U4&O)O+T4%GUV3BBT?J(M$5$KA$HNMF
M]N<OBZXR7I!:VS9/,J*@-!.+XHHTF!")+H]K$QDJ2?18=U8N]%KK5665]?PV
ML&0:_R[!/[\W[$L?#%T &-KWB/@"/OPM!?.].R1>*XUR[WV%1XQ>M^WKY:6<
M1"4+N=E\U<('"T&UNOD,G^UY?C]8XBGQ;K/K1V+[RW6,C[CY>W#S=9NX7B$,
M7RVYI135YI38-J>6ZF0N*\B2W]V5>HI3J8]T=[U2+0A9CP4W!O'G7XBNHR?A
MCS>MS14L:G=?^/#B\+_23TD<AP?7WKQYNV^7XQ?*\2OWP0(>L%;1!EWJ1$7Y
MSI3SX\Y64"1O5B3M]6[_*Q]C W[^(<,N:+P_D0#O%B.F>57)XO6OJJR+/U U
M4/CIY&=_9N1]@=?NCQ$$S;/@'>BW3P[NR[)F<_5=459 OC]=_!__/*,A=X)K
M6<<:QNK@^'I0Z/6@G0B.B*0@3JW]-\?EE-!!4Y^^NB:L_PC_V%OJKT$(8+.K
MZ&-:QDH^O \.9"!J?8>(.GC^I0IA4#-W@_'@!;!B*P>+_)FB!1P]6("5<[
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M8 W![E[>_4'4/&/,"<0!60-8Z\'2$0ON7G, PX KV"ZF 6)![KZ_-C #,%F
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M(^SP$9QEP2.VA3"SPYWP5U(Y<!"]8XK<NS9;PVULMJ -7%=",YWK)GR;()6
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M$K&[0-2!JP60.)!">' "_X'(@I^ ;' G0*X E.+76%I!Y+!VVY!G> 27$,#
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M3BD>-VX2]4-;G=8N9?!-+/\:A05F/ 9B@VD,-^GD#Q!R98MG'[+UJ5U<&(J
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MU5$(_;/2>9QX8A1,]]3PGS#]3?3Y_G##AB#Q590K@X'V]%_+G2ZAW/3BOXX
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MP0H.0;A+)82"8GJLI^+N!<+\3&O,1A*]"E\ 'Z>KJQ]YZ,[)/M2PB(VEW%$
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M,[O3E_C*\1Z6O*] _N0.,J4.6MMGW$U$/XZY/)T8Z>E'/EO+6/$%>PL"9$0
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M;>Y=N@/A7/GK7IN#_-T,[0F6"86.\0L)CUU&N.#UP&7)U"D/QMGN()!'HW+
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M0Z&)ZCF6BE8\&:$H SS^6)=U7ZV6:+H.*']Y6K/@? U8E7T@IJ)#2!YE>D
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M3E"DE(@_WZW1G/A<FX4;3%\\T@Y<F$%FL,A9I)7\\LVDDSR37@IG4Q<#'8T
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M_C1@-C47[7YSL^FK:L1A:KF[BQ.CHE,-8W2$=0].[U,<#E.X0B?K R.H4M+
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M@?'U4W>G,9QEHF#+L<Y>K*LJN9;[S =24Z2SS 2W/X>=>_Z.G5=&0$'-NR%
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M[F44B@&K0!>M4H'<IS^0+.C-ZU>%]W193]4WIB*V9$F_H1@V8DT1UO4>!-L
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M*Y3#=AL,P .P2AOA4D2,^!;&G#EY_-NCTS %VRY/';J:,WYV@=NWR"=F41_
MRK?[)0>'<(J KM3-#5W;7VRU'E_@;,*#W\L=Z0CLN*50;"$BFB.2AQ>A:GA]
M<#9ZQW0[S5\&&,TVYC))*Y*G?=;(((3+E*"D<\]-1<96<8FQ+8%A488U/FOH
M&$9Q%*9LO?R&AMNVS_40"G,\36,$DUHIM?WLOR@]3%L[-'2JI.#W=A=/"_]%
MF\7Z_3\/.*AT?E?]>57EX4$>RU/E2!TAE@D">?N4B*\>7#JK,E9@NZL/U9U1
M',G6+!-8&P]$3\!RUD;(?+G:=F'W?1(\X]B?2AY1ZWO/X74#[!4XVN$R5*&2
M<@ B#3G ORD7&O^YJ5OF\1O-AW9 ^NO5'TQWN8*VZZ7;3CVE:YIZ)"9$2U#W
M R.:+Y^=-28YU0VY@:@RJJ2%D_8HQU$ <RCGZHX)34&FNA,JX_-'#H??&W%J
M?^27,P[W_,#"'V5\1E-[^Q;T0>[G7%Z SG,A,#5SU/980U-H7V7>Z^DWM>F_
M"9XLU2L++[NXV+53W.?[BX'M,NX/+RN+"[E3*A=ME3!WH?PJ/HSZUWG1"FT/
MZK_>?*K#RGJQP=5AI1R'IX<LZ^F7XFR9$;Q7UFZ?<0 [Y(4+01+A/*R+A)NA
M5NQ3_ED_TD2I7APR(W&=J9<NC[+AQFK*,[0&N2;5S5%DC(Y2<%#&J^"0B0@E
MXLP(="=0/]L.VKXS#+U3M[G;;NYF775+T1Q84K$-5%RVG5+4/GKJHVALJ=*2
M;IGEB:J=C;Z>%N*OXEPY7@R*@MD**E(<W2CHQ%B$>%M;<3Y#/NA00AGHHJ$Y
M2#6$@0JF%K3N^O(V9)4C\Y:R/ B[.R'!%0'T\]!I3"_^EBM,O:G=$$\Z$[5W
M]^0$11'I6@STHI [C9I[F)E_3:I2%W/X<1O0W$OA)C#W<4EL3%4%D*$&$^ET
MF?^].!)4^C:M7#!UE_DKJ$:)2@:KYN ,XF//^,:4TL4]!UO)_?;MG50#9*98
M_#J56FI';Y21)$D1[")#SSJ<1] PV?(\-VUKQ]W$Q_F69<7.A.UGR]2=HY]-
M\9!=D&-IJT[#SA'DZ=);G1.,NQ*\"D[]> ZG+FH53]*.FJNPHA,W9"#,SBQJ
M03_)\&<J'(997_MM_:P!HU ^]BU^8H=XTIA[CBU*85#L YKR$LE2_:Q>?;I<
M7]@I).W ^X7Z()\K9&2I7N^0*S?YM,^5-W"6@@'X0'?[!ORWBD.FJ*Y&1T,S
M)-4R=6QK2XF$.8[SZ<*FXA-];[S>8$S/W'G*GG;Z&2[&F<LV^6,UR-F7Z8=Q
M9XK0U$.G;A&]'EG*? *+Z+(CQA#5F4> %;9 K[A7X;-Z^*&S5E.'+59:''&K
M4SEV=E^!_=/OII?>G$K]RJR28RJ ?2@BY(1CUUOD$0!+>_/*+[G>SVN:6V[D
M5?]4GJ)$!]]$;QR=IV8+?J8H*M1JK0/?[H%[0O#>^5WZXF[&9PYW1[&8_',&
M\Q3'BB> 6'F%-QP]4H*!H[ZY7PO]JK#M\>O2=$G<319,Q^C0#QJ.42D9\97.
M$CC2-(N]A_F?R2#&G^W"BA+6N&@&#!+'C'5@L_2- >*TS(LUT8&'TF&O 69F
MKIW4;$]J_SN=*\O[Z?_-%!&R_#"E:T*#C"B;WP?^,$2:3/?RK)V\3)4ME=>9
M$GN8V4TLHA_?7.5VTT5-BKH:/@=V!-,0MZN1MYXX=9S*G70TSGSF^UKNK8&>
MFC $\>KU RUR$ ADG=@^#8,>LJPI2GQ86^)"V]>W;_ -F[F);OC0F^$]_T<U
MW,3Q9+&,0RL0VQ=JR\0.#U.Y.!W5A-K& 1L-P-3:,WAUHT]O^?.L\##U1AK-
M;T\8T.1E^JR7'D8IA,M?/ )L]\5C[I<F9C[H-8'6/I057K@.N,3F>?4+=V&8
M<CX5]LN(Z%FIA43 IP21'Z$Q>S CXQ'J_EPK&_L*YMK4H914C%F]LL$!5\JO
M/"SD1)VYJO<%@L8V?1E%7VT<V?NL*NQNC/[T]D,!:;FG4RU'Y[*^CJ@#ZQ@9
M]CP@*N,*\6FRZM(9=_>!VL+/W1N.&4"I#NFHSY@#ZFV&^Y!H*Q$KH0^]-*14
MDTI1D;8V)EFBCY20*^^RHLIP[(S$4NSVX]  4H6JM"37V3<!5GD'N\H>\.]3
M+DPQ@0V^O1D/A25[PI!4W1R++F>,>-B N#R5_"=7^C6(V'6DNOM<#&#'G^-T
M7^:4],N=3+Z1X?*N"(7S'^"X1@'Q:U%*X7'"HG$[^!B,%<(2&(7CLI_<<E\0
M2#U/R2-@XL9#KY]G>^!$[25X9ICW$2]L25"-(KS+&H"U84WMOBK9D%^RUQQ3
M%5G/Q>P']J4EZ#SM0PT=OJ0[(T_SI=X[/=$^>[)A-N<4=\MK2R&<:V.;,5?N
MPI4_O7[.Q'>4=) 1#=DQQ)PM^)92?4=G@9X!6)*NDPX.*VSKFCUZ,VA)T.^Q
MD,L_*/]@6#_EXP=.,=WD8M7(N9Q$OH+S1-P%WJ2?W)_;LQ4M"H%_[:)^Q4O1
M3TFPM'JQ02P&4Q6])-Z^ZJAE3N$NAK]:H,7?N[$ 91@F5"J\Z.Y&P.PHY!NN
MXY.U^151*BEQ?"K_: (:[/$(" \D-4913K5ST-S;VI.6"!W:?G^63(:RJ7FK
MX/\D*^.U1YW&/W[M_^:.D"/2_%<Z0\E195XUQ._KMWQ(R#,#?3WVDBOFUNEU
MA;YK*9K"G)0"PSX?N*0,A>+G[2N=:I1/@L%N/FNZ3>.%_GTE]L[P0P,E"9E2
M8R#DFF-K6?JHZXC@Y5D)XFD3\.-+!85R\9*U35WCA,,'%F02^$ZVODE</4GA
M)&<.=IK(XRE(?EO\H"^_O,)'\ZU,"G/N>YH:T,^8G5J*%:"-STQTN3Z3:W0#
MQ5P#RVK.U2EZ(+X="!X*!J1L0P*J/&M#PJE^A'6*;F2= 7YTC_10?+H61KBF
MLCS5>8,I8A0^IG2<<?N>2USC,XN:=?.EE&HK4#LY7QLV;C5Q^#!2O$_#V]2>
MJ12J[S%(PN05H^1CB/L'0,8TBCXP:%4(W9J2K5!RZ2K6-8?5: F:I9\>0Z4N
MP]9^U[_B&/T(Q%8WV 6RZJ9IR+J-L@/ ]5^?X@%($WV>-0BNX!DM/&=Y&*F;
M47\$5#1-J<[C-L7\5%L%#ODL&U*]_7E>EL]X<)1=!;NE#OH]'U>MG:_V3:@P
MI[UA\=+YDT%%/#6PAW!1V46PE"%UJ)+6(WQ.(X5<(CZ:7$:JI]Y7V[^E[$YI
MNHZD[E0JJ<10N6QW@ZV.WS$1_O1W*KI:6\XZ [ONM-#%V+=2&-# L_X^IM=;
MQQN#,<HVG;\F]PU'+K&29NE12W%9-32L;&_::'C4]LC@WPC+ONS?!+M&V3C=
M_T9;>2VMD.G#@J;FQJBY9;ZT#&^,*,G?)^SV9SPP 8VH$>43F!*CF*/,GP"B
M=H._0*6I@([*D;-QG-S)WK#&H:32.F$6*$TFP5;@'".D>/EJ0MNB]J<4\-?
M]S=2'_940=3 T*;[$L[E[CU*E1=P25^Q%^#"C;R/X5)\C%-8AQOK9JA)G:.N
M[?@G0I4=!; ]TBGCW67W-D2VA?TJ)I/%U3DDU8&O:[#'HU)M()#"% 6T\';V
M94OZ?9F[T%R>?Z@1$1D@I(X*)3[_MHDJ*N/#5DD^4[Y@J>J$$X^6,R2:ZS+
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M[,-R*J_1$$UCAF2M/$+FR6_Z=.I?M.R_GBG29$6!5W$C$4'8//74A+TH.H;
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ML<J:A?Z,,E#E%NRD0B?AW? N?9CB#]I^PVFJK799RE%R55ZE<Q/58_ EQ#A
MM<+8SIP%X\-.2M7O-7\%5]>U%?P]GA*[<AM7C_@1*F56SZ10ZBLS]ZRGDF'.
M=\RG!\M/3M'R0F4? 1B58(^&JU25*RX;-V*;N-OOU4\B9+,NRTPXVZ7Q[Y38
MIL!KC=,'=(:ND@N"^MZ."Q,6C&8NH%$Y\[6U E!2#X-IZK(:%M?=FUU'_'SV
MVPX/4U>QN%\++6024??H[#&Z:5.>%C:.'5R7OY%8\NCDG ZG'NM'$*^+64-C
MZ55:LY (P,WLO^Y+@L?3!:#>TMGZ?[D$*I<CE/Y=SLF4Z6'I0?(1\)E<@NN5
MC*O'1E/]EZ+?.F;#_2K7U^E/(.:H9M")1P"A%+.=*::_1'/L#Z:6YL9XP]T;
MXY(E]R"7P ,-'C>_G& WX%8'GK]D&S20@?H#/'DN37RN-F^(4URY\98[B38S
M!)7QT@S N9[H'LM!,4O,[N2FJ\@S4M).@ASUAB\QO(_3J,]4A=JD,K4$O'P_
MV>/,PEJ:E1JT)HH:JV9?!1_'7D(6L<RLM]V:) !]$,Z'F0B[%PK,$^\4@E&Z
MY3$1+#GN1LSM#G<<WG9!U%<IU(F*&B/D'^47O?H_F_7K?S5#]+N:[*_24B,_
M].;@AY[W-(<U37.F*C+'WGR,-;H[X[5Y!.C/;(;+T$'3RQIGP[0#33LOX"GO
M^'5F[[<T05=:% 9&2P&Q :)CCN!ZZ&(% SI@B,+%FY>.ZHI\WP@2>1G@],!A
M_&9+Y<V 24WRD'-Q84OZ]Y"HATL%U-!\QEJ+1!P,<.XGV,=]BK:Y?)[Y]\V:
M(^[4X5,T^I;7ZYDC8TM1S]E?CTN$F+0\^RED2#YB+'&"09T-39J&.$ =]F>3
MW+<:V@2%P]CQ7(N'_,J!E6VJ+&L=7SP61I[#&]I)(6BPL\U%C#EAZYYU%ML7
MBRYJ3ELU4@S&N] 'ICEOH OL3:JZ,H*>0._R3>$W[983ET:30.="%W6#.-RJ
MB$OT*<Y*,#?6FR7'2F'2F.=>_/G^E0=M?L^(MZ;]03.5[3R+D/ +0Q5N#*9$
M?8GK*47_%#F"0XTSIX]MNBP2.,#QS1SVMJ0%P]U%;2,7+9C]X<6",JW6W@/1
MI"<UO6':U,6M7U']XED%>Z&4QIUL%LZKTZC1^Y2^AK2J/9T^;O!F^_1Z(K[W
M.?FPL*6E^9TT?Y;(Z'BA&\5*S*5?IJ0U<\NTX"[X4".LL%6F;SR](-B;NA/Q
M0E+!"-YFB' \<?Q^,I<-C_1\E2VKSCMBFSH57_Y1Q!QN'JS?/XN6.?&Q[5:(
M%G3-+MU:/J[D5Q[4>.7Y#VF"N^/JO;@SR2.@6YF3Q[64*0[A2ZZZ _\\M"4\
MRQ#ZB]3U"#^ H^"?,UOH>"Z%% 42VA=$["]6OBN>6DOS"8CZG,I <K2">6S3
MZ8]':0_BC,/7ND81&987&WQ_J=K0@W _"<\LVA,/:&O_GIH&-IM20/SPK[9Y
MI>94.C!<-B;_JA+=?E/"[Y9U-P,166ZX(QXSF])W#=J$S##:.0:.,LVWIBZ]
M"1Z,$5O*2HJN6F+4S4)"NVA$3N[KT+6F+L$VJC-WNL7@\*1B^XT1YV)R&Z[B
MEF]$.'F_PAI2S,(ZO)JFTU:/>QL/P?!$CH7]4_O(M=N9N>[BL U2@G;N)_&4
M66\GBE89N3:)=[S5T8M NH@@/RX>A2234^P[V.9GYHEEVU^<4\IXM^NU+J0\
M% 0N*QS^ QE[K0PGWJ]/Y)8CW0M[0#4[,,L;N:IL/A>NK6_,+CU4#4@H^L_!
M*M)I_R>GE#TYW $Z(V]FJNKVU0B*2NF7@'CW+1]B?C3'0.^]DS^JB3]3[Q;N
M3JA+05WEZ52+O(G[E'0(@<4408 _[!HF!W!^,IU3&2])WKTCOZMEZ&)49$R*
MIK*T^(P.?8OG(H_;QN0J_4SB52GRPUI_6I']U)ZFR9NI^.;6B1%W(FMY-DI!
MZ99KK>"GJ9T )]%1K[W7YCG?MN)I)4%C!_L/'*?$40K"Q>"!L@''(G%5"K+A
M'X,O05^QZ%YLCN&L^FX3_^AX7A0@H#=]V"KK$ ],;(7N$@?#$A.B%S;6%%#(
MQ]_'JO@XQ[2S\71*4^_?7'VYD[XO91]A5*]O83G*T;7^0(C6:YZ_T/AGXM8E
MH!HGY^MLI]PA:\I@9=VZD\NQ8M0K""9UBZ(C_8?;NE==Z'3;@7QG61\;V3G8
ME"(Y6JB(JPX92I% .!HDE)NA_E0B=4KEV2.@CCB1]:,.8]V2-\$WF"_*?M0%
M+AGR5C.NSX20+>CCY #J6:>_Q++#68MC=#=#?/;B.AT>2"IEJ^.9%.[2W>O3
M]X\ 8B</14]*-D_RY3ET/D/P!0H?NN(8*>K11TK Z:?E9FJ;[M(U9VJ8P7ZJ
M)LC[?8N[!$0\Z-B 0Y#5 I<5W6E SGB8U%;:)TS[_5LCIG?OK@P?;.USRG1_
M(XPINRD"4K*J@09RA0^U07BM'8EPIB=,26CYT3POB&++?"2V&E>^T@"F5(N+
ML*7EFKR2U)H2N:25(O4$U[0UE33:C1L_B@3 %:E.-7=S":LN,;$=>AR!9?J[
MZIDM 1]T,PE'[,<TR$-=O%("R<*=Q'52EHHC>0+I%V2=X9C:QE)]_DORPZBX
MFXJCMPW1X9KS<NR+CE2K6ZT+YZ+=.8E_-J\'0RN2:_UW:\ :QD;4H%Y]^(A\
ML-2!8XP?'IF%J!BU GF50LW.(T##E &YWS6W@EG/REW'9;VOH)RI7\DXY)5X
MMDI\K5Q,EW74=2UCM X.,/\^:#W-56 7UB/!5YV,YYV8GQ4KAH"W1XU**F:)
MZ?U3VU4UZ=XB0$7X^^#?(D)LY+*E.D^2H_%\\97E !^M6H618@%L<>BE$.D[
MM;-2YTLQEG2]W3Z3S7X3I](7N7"IX@F-,M,AB=%B?32_--HV+W)%K:L_+[4-
M#9V1;V/%TE3B8\X2SGN7BV?5=O6ON<*!=C ' ZN.%!+]R,4S$<[#Q22=4N)/
MK%8ODZ-#Q2D,VCX3:<CQ_BV3\/]5*D$=!YN!5R/UI4*I:.'>DP-;E/7Q.&%Q
MD9! 0? L.-/ @)*IHS&$ZB 1KN#)7T88#*+F&U-QSV&8,X=ZW"ID8,DXN]4J
M$_J/U)(M!RTQ4B Z8)EK5M HCWUI0CNOF #/XK=S5PT)W)89,]GS&C/)#EDX
MO=#Q0))3X>P"6)TUR<S=)F]_'D1QY<!1NM+7NXJ45'4:D2H%X2HG-\^FL2(&
M/P)^":V;?YQ<X$IVL-;L/:(#X)KAFERV%8(RM6)[%6FHY=%045S3_Y^ZOCHJ
MJK9[>PCI$*53:>GN1DH$!.D!1D&$ >D:ND-26EJZ06"&'+I;6AJ&DF;(H7\^
MS[O>[UOKBW_./V>M^SY[K[//OO9]]KZNS6M?54S1.0QD92A*N]A&A@':%-4C
MTN5V.SNGVL?^^U2;\ND:6K_/AI3N0D-7C-;;D_,YP3UWV?EOC/"OQ>7AD ;
M[\]K/@5GHQ!9LVXU=G%;;YNT&"E@WM+:X9^/(!M"(6K[XI*MK23/^I396B%S
MK+ZWH3>I=&@=_?O V>?R"$-%DZ45$&4$*\UP<1K:@:.6V%4Y/<L)YB6YXZ):
MR;RI<8_"(DWEK[$?3M$E+]8\.L8+.7Q$9RJAXJ.%]W7HF$'X?(M'<GO9MA8?
MF5X\E;AQJ\PH%,J:/+BE:U_X3L&B;_]0,_M0?_]%\,TL5FKAJHTYK^AAPTC-
MLR52N:<,H\901-0#.6MA'L1K4D0 M%1PQ>*_%0K5I%;#/2!"C],!ITILQ]FN
M0XJ?8M=U!.$_S8&#9?:ZGE?=(2,OVX/]B;0"7:EX+G#R_V+ .-V>N;'@B/ 3
M8''>"[&./6?;8]?<-T*(X\)86G>6+IZQ(U#U^U]GS28W]?[&=?^'2.C6'Y_!
M?V&E27@O<:2$;)<_X2/ QB;;<K1GC/M :%B[>?MA[?YWGEE!XO0Y1J+.G2HJ
M/O^.YV3#9J%.C7, @2^);[GJXBOI.V"N6='S '"VC4*!3X;?3\-U_1CO%$C4
M-ZA^%645E!\'*S1(,\;-ZLC<9</Q (GKH&[?SV>F#A&@I[.O[L#.H5S0<[O+
M&[*:70)3>)?,79;:1J$G\2$:@HY'-JKYUS3U[#8EEUW%1KIM(&5-6JW:=2/@
M6<7O38R!ZJ([AXTLXO7^L"/8,0F()2S#(6!L"1[M=V"=G^(N]83LI*IU?=2V
M[Q% )2Q+#FE_"YLZP(OY/-=]4W=MYFK*>#;MR&!.$'R8\V:HLDGZ,':$311V
M13:?+]HE[F\]Y5:JYGX#"L<TBC*"-^#SE#J6!PHY;5R)[.]?9;I=>G3E8*E9
M?"PQDB\&7]7?^.6P9#:()A[HZU\GV%7)Z +X">#U&EY)_C10H*_ Y,.41EO*
M!,([F'3]98-ADB62Z0,9'7^<S77SPZ$,L]GJ$EC"UGJ%^/93'7-M[TMOZ&:!
MC@77SX 6=UYLJ7@39^U,3Y8\"6 F S3E8 "I%2:E@2AW;3JI7I1=IP[:K=R>
M=NW8)1L4'^XIRU.D#JQS8GX>;=#2CRBWAGX$LS:4*EH0Y9!2F]3(SB-B-;[S
MH^=J?_]@F;&:[HC<:@W[RK2"2MCN5ZV9>J;ZZ6>T/&'Y-Q=\G+[9CWVDV=A?
MSLP\UQ\!Z)!P1/W7^T*>G(:N2V6E*.5TCYCC'+0K4HM3E0%)^2=U@R6E8L 5
M=U77_3*BL[IVOW"U=6),L[OW3>02TKVS66L)4E'WGSE=#:8SF'S<K>PM0O@Z
M?=8N*X])[H1.CD.$LW0(GVM,64P**7XY-5Z..1/#P=5UN=*K%1,?MBH4[+IJ
MF-S53_^48&M<6%@XGLH=XB3D>)_$0[%)"7C%A$>9&/C-VP9E)5_W-R""=5)N
MNJRK[CJ%,R4""/;1^NB\$L_0Q9FK,:+/"DG+9C>+ILT>ZN_&ADAW2UDW"U:S
M6\A=[52Z2VG4Z+,</I(UPSH25/NV )]JI.5[O<,[Z!CW-5"05(]X87ASZ^9-
M7L<^+#]6001=^DU9#HK,,[S[$0#X?:>(A(Y>ZOW=W58U2?@,W=ULV8H3NYEM
MQ5$BZ\?<Y&H8]H_JS]#CHZIP(I':1-W\VH=V]/_*P<ZDD2UJ.M%@?NM3J*$"
M; 3'7NSDG"1"@KL:3N2KN[$*+66'Z;:S,PSYJ%Z42CT"+AKSLG#U)PE!#09_
M('KE?:&94W7[$UY9+(^ **@=FU;*P_[[H)4Q<8V6D='3KVB=BK$70Y#N'@F&
M:/A+#]9XA*2A_<% 2WT:V^_7-:<_@H/D-SWV#75 >RD4#:E>&N5:1>.E-&=6
M+_&YTC0J"N@#VD?/Z2]&E:J)R5 ]@M;UZ79=P)]-82R8T"&OQ%^7_51[G,-C
M)XW1TJP(Q.Z@K7=11BUL"E4UDUQUL. EZ0D]PYGQ&U/7/ZR;&Y7I!UH@V7K(
M9>V;X1.6S6ISX[%"R>Z+:,_NVM;:-L;%JL*[S%@:)J30BFS,&.=R/9H5G>=$
MGUF$FRNP2WUKZM><V9PU:+Y8C?AH$*3Z3AWVBX>45W'<?]_8C"Y'Z60NXOB"
M#OC:^V]6CYT]DA1)YEZ&."6X5Q$7[X">JS!$Y.H(9%9ES>S4MF8DULZ [=S;
M8IAJR8 >=^/N=?#P=]"PO05Y;O@ <ZP<#D%Q[G:.T,1B-_.4ZK=NZE1/9C'=
M=P)JT@%DHYU(!H46)6^U;7A$B05+:XM R=5&R3E5%3$B)J4.F:@_>4=6<#V;
MC=T<=>CW8H[1K@B2_)/+XJABYW@3G6(?Y*1"\J;^6WKBJ?_)CC/X8 RWC4[I
MU@B5J(OT[8DK0/$LWC]7H-=?+WL34@[2H''\@Z7#Y_UII]!1E@XN6'4G(X.#
M\K8H'?69<P?-BZ2FZ->R=,U#OS<QV=*-,+VCD0)LT*E55SWO,38+J+&^L8R"
MP2*YFWNMRVH4ROA(U%Y\ HB1=:F?+("H?8"-R $D%;2UIBYR6+76UK1O2(#F
MD-Z&'^VNJ_N)%N6^J=O/&3(9/RU%=H/"5Z>E-C;6WW9G9>AK'SJMV]?I?L+4
MQ?#;4[AG7T++P_J62,:\YUXBF71_":^2&/U>@N39\4QJ<!A^:IJT?$83QB,[
ML9S$MVD9M,&6/@)#22(:JV$YAW3TJX;3#NFOUF:LX/HQK&KXDMEH,29VZ'PT
M;1J\$=PP7QK$WUB*.,Y1/BG;73 >X[8'CJDU!VVE6F]@6LIS-A*YF)'NSGAI
M&/&TSUW3Q:IQAH6>1'5YT-,TS HSMP7K)0@Z^7M[.']\3FLEB-95TN=EZ>P]
M-Y)#U,:(BB2.RC/D,1ONO#RMB)_?]<YKF'[/*H8O&6"D*7-+\ V.8=;B@1@>
M7U WG.)R;>4XG5I?'#+>+<X9TC#;!8!?$$XKP#?]Z:71JI5.PD.$_>E%(X6.
M#\KIGG?7V:"_&BE-6S\=(,1\XEB,)D_888JBC3QG/.1D<3?/2C/71_I'^+$N
M HW!Y/I7(@O>2BZ.9U+UI?CUBO8='SKS^Y9\.F[PKF0QK/'7002&8%S^1G+'
M"C,PC0?)=.!OJQ\'8F79#"<IR>ONS78BRXB$W>2B%/ *F,&Z*VA,K6.P8TQ<
M!O;KG_/H:OGAM&L:W=*Q@WK.P7_@;2)8NIRFG_Y5<*<9]8QP2X@@2X%E"MD^
M9V*(_-&(W)WM>@[)G=$MZ"N/O;"''4B7X.V<P"!;,O[.O0E>P1>]/SC];R^J
M!4DB8^D*9A8E^%!&YCQ3M2JK,UVH#(3LI7TA2U9"9ST6R:B;HYKI_82N<X_'
M>;4@"AN9<&8\^\45/R/-#9_S]R80?%1PQE*?1N'7=6]*Y45^'4C)O!-KT:OF
MC96+G4$[5!:*3XOD^WR&]@BP%3X37['3#\61$CEM?="?VO%>'3ZZ.HVNRK(Y
MC66RM/4YKE[S/@[W>ZE8JD%+44[*RQF!R*9@%;684!7CT/J"/#:5^=&@93-L
M/4@[(K?R".B2C#\&"4)X#[TJ.^M#ZBJJ?K[V? 08&M(3WXIQ^7+N,<TV.Q/T
MU7]4]EL\6 0!'T"EX]D?7GW@5-+Q7M5J.;O':W;/(D]SV%)*83[RI$EQ/U(K
MY\J=+@<,*>-($W*370 9A*QV;WR:OQR3VE-WQ S$7.4YR#^,GU;BG?G30R[5
MZ>0/#JNIAU:6@]2%Y*A8DJ(/3(( @.@<K_R\.^7&>H^D9;42()N O,PDBNZM
M_0]G;#&F'&-D8?KZ[HQKUOG^U-WY(R!,P,T\*TZKK:UABINYJ3GY0Q!_BOL?
M3M;5/J\O1Q@947H6H2G;SR)63WA68SF34*G52;$KJH;24/=]-W*5H8,=FQJ&
M@^A,KY_5LE"DTA8\MR"^B ['7/.X1,I@^:/ 3$1>F6C3&N(,5#Y[:?O)]RF1
ML@ICY#8<0RKASUG/B+$8#[58W1UGJ*0_NM8UV>3<5_V<VHS@/]Y0&V]C&]^N
M2/:*F*C_$-#^VUY@9H=<U6V>;*.TB;$2! ZZ,)-K23A.]'.5Q79<2AJ>O=>W
MR31955BG]V2O*L3/6:#HMO5W<K"T+-L[Z=@6::T))""0[[;CVC/!6);'KK=M
M.-F)@L:1@V/\"U<*1YN?U4:30KX3)+M^$<@QYSP#Z2'=\]R H00O(K'Y>FT'
M#/6(T -S[&'G# >M"/QE[WX)[X')B*,#^\.C5,F0&F72/N"?@X[GXS9(]HT]
MS6+FE!T8$ WG_8Z610/2(W;N_>S;*VW?0M!VV(IVLQCC T-JBZB.[WVY52?H
M*?V8]5M-O[Y)CB4@.0N96M\F=O*+C=@0 ^D-AK"K&U^D3VUM=0K5]+5+V8YM
M.5K,[STB/B6P#\\)W?+1CT3--)@:N=K6PFO(^WCJ!!ES30$O-%#&A&=D?T%[
MQ.K8O</6:B$\KJFL]BJ@?5Y]Z_3L</;!JLVY>,D@ZTX.1;.>0]=U5EA@S-I,
M.4A4\Q&O8.C^*H"?,7OMHEJ1C37R/KZ0Q:KF^LTO5'\? ]Z=T_K^='WS)"]O
M_3/&:2B[,:0(I"]_UN<;1WNB80W.)D9%(2J9P>1>Y)5/ZOK,P1>IM\RJQ,ZX
M2RH_C6]NQ?+%J[FW&CW51*#&BS=S2.'+!!F565=B^EWSR7[025NQ/TOU0.J"
MKK^-FD%T3FKV_'6 \.P?#XEF(R7+(I1H3ZKSBP%1]Z 9HS@V7B8 YQ\X(CIQ
MI<S3%_?8V[UI="!. &5ZXC7<'9E^U/31P06QNY.RN\/U":BS$[&!O47Y#NV#
M@*9GM49>Y+F.MAI/6-#_BUFW_ ^V+"*.%-Q&.,$C;&>\"33J#@ ^2?M]4E(F
M_IDMX(D3M</AD_7A)HM;N]CJ_(7VN]958'$2_!% HF(>O!Q 7V"0XC?7QC8M
M=*@SA%-;?TGMV1JHB9>6+4^5%'=)$?@'*'R&%;?A^_YM:YAEUM8W$=%/Q^9:
M_J#<:F*2V"R.*I)Y^A4:#&IHTU:+S(0,<=LD;/AOMC+CF.:Z.'ZFP6F,LI?\
MDL'-,]&VWT=LA!<T=@_I0#0)(V-*6SQ.X5?<HYNWT6/>]2?.[:'V=R\F>>$:
M)]7OH#'J+&&5+W_&+,:TJ&0\R^Z@B%?Y:))2O 9<%GA/K58O_;MWY$N"LL1Z
M*A6SMUMU)(+C>UGR2SU>YP7WL^N'%)GJE\6AQ;A3&5?5U;OW'DV[,N034%"$
M'\\D3-I] N:]3(25\29E3V$7]S->3_$RF#0N>6  JZ%-&&+;T9P:RN.60RLD
M0I[N:IFJS[LUZI" @].=PAP8VCEX:'(44P:6?>+#X/;7XV\O11Z,%XV-#T='
M!]E>ZO /JQY M ?H;!I"9>CW_<GA\I8;_E_UVS_5PAPD%4XLZ'[-QZUG_W%-
M\''_DV-\^R5C$4Y*SX8X6UF6K9J5412ZY._3VGL$X!VNWMQIL:/<;GF'D4Z:
M,$1+%DC]Q&9DZD\Z]\ITZW=!^UNE,2Q2T7??QX@T1!$[W1GC@=2ZS<'+E7\!
M=[86!TVR)?#W)V?W/HN-4>83/)<]R;G)]N</'-9_ESXW/!;F%3E].+R+D52K
M PGL/5A,BOURN; /<+:-.V'KJK3J66%N0![W3)'-15@,@\WH8QKFK:U]L=78
M^HV(-8-:.1J]]'('A7.WF^OL#W->0@RTYN!6_H0K#99E*\!%59::DW,1@0'1
MN!;F;GNJ>](3SGGR?@1#.(7VM+ 6GHTSF+KD2<B;A%'<>6A+7TBM4VQ_L?#%
MNKNT84Y?1J8![Z4O^5).<7'NLU2!.AGE$ZTHUQ::<$$M'WOW).#KG]_KO3.?
MR"0O[OIAM*"J$9QLT]!1D,+)97:"I,E;PJS>Z6CT$*T-W.@$3<%>7]QMT:NX
M'8U]S6RL+(DRV*+U&/^6S\#X+RG98@A0M6'R/$/L@(N[[_=:A*-DXIZ:5(*G
M<*X2V9\D$\6H=[Y/()57(3P^L@@Q?83C@L4HIY'J)+W1H#]WF%=PX]^2Y/#%
M\T^.CNZ9U&>FWNMC&<*AE[D(.OU'P'M(/ACS=. IL$3\?B$:X/UIKC*@HF2P
M],W@KJWI72LQ@\"/?04>_I;8!OM!K^/6%E<QU<0>V44P[3"[7BI!QT?TX+G3
M FJE1T"DCXFKG< >#0U+XN'[)09>KYH]BPWW@\ .F29$O=4$7$FTVVVVTHU*
M_VSH[&%$6YT26RNCZA">T_<#:"HQISGY 4D:;P1<42>@YHVH.(GCJLU9[NIF
M\#F+OC&HBW(M_Y5DQ6([/\]6IP7FE%D^=(>IC$[F:T]'ZUI6%I;#IG;=RNZ$
M:]V;K%1/^NK*;!?J YT0A WDY/&J<S\["M.VED_/?O&L5@O'Y*+\>]J>3EY8
M/LRTUK35)NOOLH(D)B]?X>(+?3JMC&T+<3'KS4>9S;V>AN&?>[*TMI\^3' 5
M2T96B='5#?:7EM_$A%!7AO8F#SDT9.%)W#)H>=T5><K"[*$%,^ICHR+)&3XM
MQK-3GYJ+O7,LJ7&5/#WKMJ-RGBX!38<=['W*O=WY^BF9+; 3G):NJMJ[S-A;
MGQQS#^/&P/_L>8FI7F')%&KY^^B'1_@1+PT*)7"9?Y:"]0A4O-VX':OL$*--
M9I,)JH (=#^0C(P-?L[8X%=\GN)8DSA&C)ERU./E!)+$YFJ@T$#P)$_!FMFJ
MDYL=IL>RZ:&+:HLC&VX:QA!A\4.+;Q7N.^:E#UP!'CDZ:FS"DR@&O:;6&:%9
MD^N:92ZYG;*G/IWG'6.<.EJ8\E6-D:11H[KWDVJOE''_U+)+3KM2 2(WWO?H
MH+P-K%W+6SA5US_7!SD1IVV+/0*,ML*DHD],3IWZGOCM$HSCQG:=K:\*SUWX
ME8\*]G=L?M]K;-/+,VZ8\#?E?K#Z]>%SFR<RC_=0&Z$&?U7(P=:]_&RSOQ(5
MH$R0.E6Z/3DZ<"W'M!/O%U2-2NRA[N_)PN+%,]L'G<1TEBX5/-\W_O1)ZB=#
MN\/@_7#CFJJ ^!_.>1_A]4K!SN8GL5_SC52*=]WY<3XT1'S@B-O6TM%BGAL>
M(LJHDVF&X:YO#0LYIC,<7*S'$>W.+OB&SE8[6'P^9,DD64DF'^LF&)+;C.\?
MS<8E6[7VHDL-%QIPO9=A8)SE^E88)<@O_MG<DTN+.1OF%SG*7"_>56GT%ZR7
MP6S^T6#6]<"(1V6LJ_G8KHV"5!J2/[:DO4XY>@2XOHVEEUY93+)::,-$5G?=
MJ[R9<6!P^+UE=<9:VR:CFW+0_\WE*E6\FT>>[.JJAYA4-$RH""+BVXQ0)&M/
MN]*]L'*PI)(U(;I8+]_P]KY-$EPQ77E;:\ECSTS4<Q/RP8!^Z;VGT!G.K6$+
M4-'8*+VS3;GJX\.(+#%#=PO<M%QV7DB:E6J'HN[5ZVQ]C:H]8E8A.>6C \BN
M*1$,:3;5<U6[W+D>Z& G_D1C+"]>PS6KP/J-0'!L0.;YX/D4JG"#"JYU,EI9
MW&D(DV2&)_#7BQ\NQW9UHW1K0S\NTH>UZ3?-7(CQ\A0UI1@6@[4R64 ([-SQ
MXD*?(K#6GMI'-IH+C^.M1<5S3;J.;N%H9$)R]J#I^?GJJ<PZZET;]73E5NOD
M@L=T90WIY=50J7"1LL(!* F+-DQ'T5UXI?40ZH&^?/11/7B2/%XQ!T7D J+Q
MD416E:XWK>K6O6O.7#"J?5*K9VPD: ^47<(5"J#OIMO_KD4/UEX>J;8@0UIU
M[QE,I-E;R?:^3'R9RI8MX7Y>[<*9CQVJF>EI8'F=\]W)WHH@AQ\"'LZZ<G#@
MSJE.L&VZJJ$4$R(BA!1W@"(:C%=R64.E>U)G01:V+>([J2,IW+&ES'\_<S'.
M0[K9<@-LA=ZF'D-257UB;W7YDY(-_4%SFQ"*'A ^J*I!0+G-@GGR3837,&VX
M^];%BRW5_<F?/I+Y>]@Z.-R%L49HL>R9=F#:($'H&4R>.;&?[#SY,LNVM'O+
M=+'?B>$=L\G:3? T0Z'+37UPL;6$18S,D.1[QWV"6E;U)+;D)36I\[\5'_+Z
M35[Q5ZWEF-6<8@?.U=$BG:[2:<UM_4H[B[)=_92?O=S=Q@K</=M\YFE\&.@"
ME$'*\AC1!/I862<CRR:]+C:,JDGWUU6B%6S35;_4Z,/)--R^[K@G.N['9*$'
M. 5(ZI\[>)1;>S4;AWM'90FX_2Y.[7CI3_\F^%@O'NG./1=+N#"Z: LLRC;3
M?&AET/#))XQ(R(1Z^8-FHA61$HC.R>[NKC%I"8$5W:O(20V(O.1F!Q.>EN)<
M>Z';"@$JI?G^P.MSH4T]=5*D,?G7*'FG6,TN3P)L22W[D+F1-M;Z9ML=N))#
MK1!X2^ $W0Z#(7"@:G6=RZNHO-(Z99+B)<_LGD#W=BQEGVE<S;KTE<&NFW5O
M[^"1;^67:D(M0@AS DC8$G7]0"Z3D1?).2##]2_U]D^X1N%N\UPXC(;PX[M=
MCZ<")M<Q4,Q^-NF(/>*2RL65KQ?"6_XT;FE<0BWJ/ECUGU+V#!\!.\7)#38Y
M7QK9[A?^Y*OLD^GQ;+MQ>+,W74H1][1C0I>=3V"MAY6;1&L\Q;ZTET%F\TEY
MWS3Y4RG''3FGN:0$P;>2/K)-,W;9JWI(Y2*FGW605+OFE,$8)JI'@&Z[8(U4
MO7B?LM3V8E]SM >ZD975($MD39]T:I%TC6E*<>Z>F? )RWQ-D'J:D'>),&5%
MXC'461D!R:=OO ZZ.9&8_7Z70LFA4ZV(4*]J,Z;S=#='0B)=^7F7[$#%JYN>
MNJ!G\%$%(]99F/JH? $:C+4]X15=Z[M7"Z79D<K\BV3GQ%V@:,**[M+?D*!=
MG*DOO>=>%64UGO5KWQ[,8S%R:>,#%#$"04Q[,H1--02_3(%:UE7OE@8Y^FIN
M57&?4!*5*<N/>BEGK!TJOCD1+JITHJW9]0H=D7"#.^>^=WM6D$A%2:^@)O#Z
M!P.<U-^KC9,KFQ62K68W?<\0Q92Z+E"* !=L5@[OYUWS/!CXQKDWW/]X <\8
M">ZF3DIW$E</2R=-GJJ+4+??=(EMF_G31H?DR4*T"H' J>@0#U*W%^4]&V42
MV7KAN0]ZURL^>J51:3S%WZ$):MNJM252L2L_B#(-ID!U/+G>I:@,G68GQEZ1
MQ.?+Z,Y2XT(1^ S'GA__HLK;-TD)!K*9IYD/1;Q/2\:.'M2UU/TTCY9=Y_ZD
ML^<U$;?]]_<=V?^J6<K*KU+W./X=:I,)\+3J:\?](\,T:<<RPY/2KQT"=T_P
MI/=,-O1!"IDX*/!I,6&BXQROM='=9V[,^JA3)'L6@06#OTU195O2+5!F*=19
M%&WTMW$VH?YBY8$[%3=&V53>S%G'Q%GV;^AR5^;.6D6<&1-2VBZ^LK^/Z(8&
M$RHH$ZDP7@8R?U,6C#=KOR3D4A+6]]CVRIP8M?F56$P8\PB(6N%N0%D6&$(H
MNN<\)/0SBA<K%F*6H=^;OC5),A)/2X6[M!#06M!!UN!TR#>^$I=LD\+JY52_
M,+8TG*^>JGJA<=E[#G9P?6>JJ<R)6<&:%G:H@T1NP<M-S6=G/7DS_8XX2_)/
M+P?\ S_%@0D@R_']5*?2@EVI]2LOH)&J&CTKYAG>ZN[$THL7>C&ZV8+1-6M$
M&GYNL2FLL:^Z)%CR:FY%-,*'R[?*WH/KJXY7*\=S*ZNADEF*FJ@:1).#CWR%
MYJ'M^B. ,$0GW60P*5-!$);AS"\HPU=@X%)\YUZ7]MTF76,L+!8G]M3(HBF0
M\GY5J$]-/O-3?)S7=3?B<UH%A(A\\HA%=D$DY43Y&'>HC\=8K>C5P>2SIO,8
M7]O8D[A(81Q8B[HEIVCF,-8D^ETKCM@>?^9VVT(RZZ[2N+>-O]!GN-S)==8;
M4J&@1.T)H4D[VYG#B4KNV9W?# 1M3P?S]ET@4[W-F68<R)D],NI('NZ*#](O
MZQ2OGE,.N]E?[%YTW&&#@>OZ7[<I^ (Y%CW#N3=Q*55N7"][/69"DC-4YM?W
M;KWXRFU=F!_.2;65U!K_:1;^IX7T/\W11JF7Y#>%2;.ICI6]T.%:U4Q+0R_J
MJ?_.+Y9#IQ3 :D8'PA:OHY7+\OA$0C$"I/G-_)']Z_?C<3(4J[M>(HN^-J-Y
MTT()[>SJ)912'[RLGO@V&.1JOW<7'/.C]_$\J8Z%"Y+GNI0;61L7, U-GU=J
MKG/OU#9JW_98.A.AC1$K\)LI(1L0X]$/KXRU"GUP6MM:;9^X3U]$B9'8T= Q
MAGE0@5WFQ2Z$K3;FHN"B13X?XM2FX=AKJ\^6BS+ WG5Z2G9 '8$E*3.-]"\R
M%B\T>I[_NMPW@X&1B>NS">FQ&995OXU[\PEKC1?E]GY@DR#(='M6Q7$C&GQZ
MB(I)^V2[Z(F;3V2[:.C(]RXWWD__@!JTPAN_P1-'>H1&U'9*[:7%JF0>/#].
M5Z7H6R_Q?]"4XW\$X&)/45;5/,CZR,8J$JR\-/P,A!P5A'ESAD#,X^\:%_2L
M.^-<[GZ(84L9X"/5-SR"[YXXE71NB^23A<0#31>,F$:%!%NG^9))(L;(7N_U
MUD6ORPWCH49N6<N_C^H57+R9/6\![E9>S-5,*9<%U4GRXJNXE JIT]C%)^CK
M;WY\:XEV9Q@WU.:'Y(GQ,\/B?UK_$]\C*E^%\9,JS@4;&[(:HO4W(@E].$N6
M=^T0N$3YI*,.$O=!>T;4EG+;)/6,U'+1E*_;10043FS"&C960]K86NNSM4@6
M>[V]K2Y[6J!GSWV ^#&'/XON(WJ8[G; '=7^X3]KAQS'LJP\U98OZK_ZJ5[P
M>49V3=LOR*)DMST=NBMEWT]7'0K-G$FUM'R'?\]TQ=EG&CPHHZ"Z8&R#6J2P
M3<\%[K;3R%! &+GI-[IK3?<3]JEA17'<T^ZIO(Y!D!75PI?Y2^:, O+RL%A'
M34*OMAHD4[<,/9(N);C49F)A+]7[K>/W@@^BSYY*EB5'-V&R.^.3A Y6.[>"
M;#D+<T>_;Y +Y#GIJ]_<$R5$GCT" A\!I(L;#$&?D!SS4?A&O$>5E;G\([&,
MD?K1%&<D?A;01"@959\SH=<3%_IW>O_J0^O_"Z>+Z3K.VJ-E:#. DWG93P_J
M5UQ=<*;K< K>47709A7JKKF/^NS+A@ISV@5$F#WO7\0,4 Q<=??7A%T*A3\3
MG9[]DDTW60BG<"@R%AX0?_;=P/'.R6R,6 !B[2U2%8N'TM,W&<RDZ'; D/=8
M-U60-IX:F[I@?S9C=T0:S(Q#/*;RSNA[_!*@N-(E_?A@D+S0M=*AJH]1!Z\M
MOYA[M"OPEV?@+Q%)<AW(9OINF\"=A4.(01L16"A\^OS00CME]@&2^97+;J,A
MP:H1/RZ3I[/1;3%!0@_(L$#3[;YZ$C]>O:Q2L+O@#ETPK3SG'W4B1>)[>X:<
M2C!QO?&YLS<G!1#9]O;VB0TV)UNXS'>:(ZE\/!W/&BZV18$H.BO+DST[-GE>
MD1JZ21N%(V1_FJ=C0!7S%P &DP  BX()(_+:ML<?KWBJJD!58S3" .VPFIM%
MH#OSKE'O9<0?O 1BF"]H;7R!N*N-'XG5DH=;/ 6C$]1IG9KE+/?4->4N4SY3
MIR'%T\7%IF*CE.XU>@2$A:+\68^9>EBO\^O#D"E]77M;"53Q9JR,8M]C]O;D
M]CPW@F/ 6O,J*9R*6V=?\K(=]&8K>7V/5MK+[BY_;<M:@<(HS)[#$@W;@X B
M";^-C8S'1(88N>BVXOU#LX*^M<II+Z5?EIWF(F=7WS\"0K;WE2+G="==>0F
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MG:YR@ W7#]XYVE^?#E@0%<FAL5/: \Z9]<B01 E7C/-N0*PFWBT<I6G+X4>
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M608$W^" = 4NS<GX6TK:?G6[W5^EW#/P&JNYG:]N&\3#S#D4F>-D[!/K2)C
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MOX+_[VZ _]X@E_-_G/\?4$L#!!0    (  ] =E80-2/.IZ8  )NY   8
M;7)K<BTR,#(R,3(S,7@Q,&LP,#,N:G!GY+IW5%/_MB\:1 2D=Y"F4@4!Z9VH
M* @("$AO*C7T3JA1$) N(*!4I8J42 E(C73ITJ63T'M""8&$Y/';YYV[[][G
MCKW/>^/^<\?]9GW'R!IKML]WEC7G2(A_B,L >FT-+0T R14 @.3R R#. =0!
MI%>N_'5=KJN7%QD%&=G5JV37R<FO45!?IZ:FNDY%14/+2$]#RT!+147/2L_
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MDSC8+">DC)/GOK(!\PL7196DK4#H%IVSUA(LDC+!V8(-'[PZORIN4RC<3'K
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M6G&%H;OM0+P<*IY0O&3CN)O*8P?(BJB8#Z?6_F>S%UF'4V;XY?HRN0FIU^8
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M\UE$W8O,/O:FAG;/*SNS&OG%VVHLXQ)W94Z#Q%YD 3I8 ^[B0EX/:O%]J=3
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MPGZF6-QD4C:_G_B\>I62OQ=>1M$C:6(*S/*>R9/G2*ZH5H@UJDW5WA-PLJ^
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ME0XIT9U,96G5EEP$3NN*F#:9?NNQX^0AE"T:Q75M7FN#_Q;W4+#FGC5JIY-
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M#ETP>N.B3>5ZU4_G\QT 6.W_8>^]HYKLNGW11P%10% 1!"E1BH@TI?=@H8F
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MH.G3.-@7!IDZ4BH;6ABYC8T+->B\6 W9?X:()PO0.A56N"8OM>A,=M@XY*<
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M54.'5T^S[N5J@6?Q8957;%[3?=']#<<+\S1KGG#+D_A"BR*""- K_XO$L'
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M,:6'?/N6E(G55$!/C,>\X4^PQ0:E/_($' RN(E$*!EP@R^^B-*9%<0/W:E1
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M..[8QT'2H ?*6=HU]\ .B'2P@F:K$\!QFBQ(!*1(<JVH8)&C8^5<&F;] VV
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M<.6&_I27K.*(-K1,6K-P8#FJ60GJ*VM4MT=QO;0&?V>JS?Q*\67K:G]ZQ5N
M+FTLGO$;7A'M^&,IPTPR47U<*!/E$'XM.Y9)T^I5&-4/8.+HUJ6\\=33< SY
ML0$V<5'(U$@2O7L2L:-P@Q*>T[:1MSW5]$*UDU#\Q'CCBN*;35AE7.<0_9:6
M_A26T: V?O#*W^KZ'[71,.]Y-5;?^U9_*!&ZA7#36&A$=AEE $R8JC??"%7
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M+I;8PK*JD)-$,L>A@(.GCCTL3;?^!<?I1^0BKG7E+\?'%;%#Z-%:E[%H8>
MD-&TOWR<K_F;U52A=G-B%]CHX!-H="G(WG#E25C@X2SGCD\P%:=SI6/SF;P'
M\DIT0,^@[VV&(<=*)F*B:.^JNV[UO%&& M(@O S52J>6)'A_[IJX>S[LE7D
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MSYP/S[JR"HS8Z+Y<D4X=(K=86OJZ*<-%=>BK)_!?ZPSUR6&R(->,H>6HBYJ
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M;,)*,;^LS[@S0^:]NL_J$L2MA7^C!]*M.P=P+"]3"I5&?3=<L32ZG=IR<)0
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M6_L(G/YDI3)XZO5KWP1JX=NKW1-B]>,,I$8[S5U34E^6"ZU:W.[N2(6B(_7
M.58(?BZ\KULC"\PQ\8='[IOSYZ<'OXKTQM^FM4N3H8T+%SU@?Q<67X%M3JLK
M<[8X:<?^HXYF-%B1N&$I#Y,]TAEPO &+EZ<N; VYHZVY^]0@L  ,JRP8$[#9
M,+I+E812NTQL1184RZ5]-QVN<M8CSUAY/636]PA8W<RV7L$$[.>CS*\&3IBL
M]H!-.&-6Q.N! 6]^U^)\L3]>_:&5PX#A;K."P9*]XBUWJ2;KLOT(H#D\@:V*
MRJ3D'MB_3.*<3#Z"S#T"#*S(CFQ>-LUJ%:9YX=K(4*Z^E!(/"#WJ2C%!3D-2
M&!Q-N^>/"I<"R";S!]SB(PC/-!*C1Q\!9B<WQC.%! ]\^[T4-:7OX&+T+3]Q
MX<-0+P"2B0']Y6:#-)#%J_#7.EK#ST-Z\F&F?3U_-QR8K3O37;\A/O0" 3+[
M<>"Z9C'<O>4/5I+#3M-48I9](@FIFI_[0<-06GFZY.]C2E5,D-YE%3X)_/[E
MC4J0VK[2?_\73S4!4D2G%-^)SV2=O4U;,]$P"U%7<'*PGN,Z9QKK V;ZB:)(
M(%:TK=6;)V3.--[4+;.V+A*DON\V)5A"FH[E8\]K]V8OTYMD$J?ID2*2FRA9
MFNMO#S]NC=#19M%B4AQY;KAA;]N"V$$AJ6\=D%5X\)T,5+%)*W(Q^3S6U7<L
MY0L'H>G?:-@8FQW=Z7.CZ?$RY53U^@S^+I_J-7,ZUG:QM-WM>!8!O';6# O=
MR"[3FT/9J--J<U>>NF),E>,G%_6*OZ.:C>2(Z1;8I]>SA8YFFN1?BR#DH.JS
MB!K7[UHNTHY9M-:)UC8JM(98/P$81MQC8<QW!HU_PO"=3$]BW5?R/!=>?>HP
MBU&S-7QS]UHI92XC,??,(N"R#,6$F VWW5^0LOLNS]5&)%-^H&@(5"!9Z-I6
M]79C/7EI'^A,"7O1&\>1;28\+"<22'^BW+-PSIL\NV1!]P/[GSC,4I*K"!=0
M<T:N7%P>(JSTT9WP_']BBO]\3T:W;! CY<JI=M\KC>=9LMFOQ(P=U>\4S53L
M\9L]P;[W:74R"K^=J3OJ/E7\U2EZ5_^:I/WW*?&?U/"3JO-,%>POY_+RU=D3
M-/KZ_;=_[HRKP@L@D^L$Y]+0>XW2ED\[69O460T5.TYTT8"+/<F;&_I['J1#
M#"1*AK/$$384/;X@80)1?5_L=:>C[57XM ?;<9UHVVPW]2!WH/)5>[I '&9!
M$1L=M.#S5J&G1+UV'?V%H9I=PV60F D/(6/5G2Y2\9^@?W'^Z7]78E1,0]P^
MV*GMSVSU/U?V]]-N7'XGF9QF@HK&I( ,7<]*M]*<%TT*Q D;LU)[? ZC 3>D
M:LZ;=SI/G9*:"2-*F^Y7'@')W*MA4F%3;L@0M=;Y\P1HDO*@4ZS[&F*3PE1:
M@JP \UAUA3*?G(0S0AV5,T.D-%<LD(X?_5MO"_@#J#O3^P*B5ZG:7/S&].;^
MP>&(]N7YX9_$?>G2\M7MWQLN9H."QW.F2L-&$G'OI?)1IN1H'?*WI4-I%1)N
M&XSWLMPA VMD[;WS&S/-TO@7LD87\8,>= Q;?6-;J57?;=/5,;N6?<M?E&0N
M[;^MIJ*&-DP>-AZA<,"%'']_X;AERPAG9-]YTC O5>SF2@>69.E3<XV<CG0"
MX]>)6= .FT^:(9W-O?.Y _@7-.!P >BJP#,X6S( PU.^0[%O,N@D;GY=N0T
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MV73M(6+E2V14BXHCS:(^;)!=EXR\2'A7M:YMG.GMW584XC#MV+4 J23=.@;
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M<&N"->[=:./#^YWSS9R9.^O.G5O/KO7\L?57NVI7U5[[?NY^!4"F+*\D#\#
M!  P'C[ _0) %H"%B?E/>2#LAX+S" <'&QN'  \/]Q$1 1$1(0$A(3$)!1DQ
M"3D)(2$9-1GY8THJ*BHBTB<TU)0T%)14E/\,@H'UT <;!Q\'!Y^2F)"8\O^:
M[ML!Y(\ ^QCR6!C, $QR#"QRC/MN /!AG3@8_R+ ?Q(&YL,:<?$>X1,0/C2
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MOWHL>+O3*?"_H[D\8.[/%=0"R5NVOX\C?8Z>OGX-Z>O+9$8%AMR(KQZ N^Z
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M1^GZ:RLEKO9^*3:69JM)<?30/]!SNZP4^>@83]^8U $T.DF^G/]QYV65,#+
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MPFV^9P83_?="Y%&HV<PQ=:B6'R&PTM2T5YKH764ZYTHZ8_VHP]7U2L5G#W,
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MS<<< >]08OH2L=-*C_;N&8.,OFN-48EL$HYK^5/$.)<*WV3)Z!./0:@]POX
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MPTL?EAN\C,J<?'NFT</!CPY7%XW;GQ8_A/L+>4]<&/*SFI:G=<T7B=)W4%2
M1WQ4L_B(,M%][]'>HQ\5J?ZZK3);PBJ/@UX:!VAZ64$YJM(5F:$M=T),\YW'
M/JP&O4!+?"8D1TM&E\>=DG:>"VF'%<)S?$&OFH5'*9=7P=S+UY"XCR[5G6.
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M>!5#:L-*_]AF(X/P%I$AVB7I@]\"W*%5X\=I4/EK6^:'G>R83^*9:_DI),T
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MA12NMIV!'BH>PI1(\< ?.]MH10SHO>] 1'U>5B8FUN1H<^EE":?UU3KZF_J
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MA+R/]ECLD*M Q=1D_EA%5Q)/^:.F5@!'T)'%_9$0Y1!(\,D2I?SZ-7.7=JG
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M:%(\\,@=]<LJQ\D*L?=T[JP6ZG3;'<2XKDV[Q]\[3J)(08 "6B<#(!UA9P+
MYDB>U+09H#Q[]\*MR,W6F/TT'#ARYAKN6BL'@TLSSV]Y!'@CG8T"0L=T2_=O
M+,LG9#TBE,$IPBQM5,#N9C 5$*)(1*V8^92<<.FX7]^4= R"*G7-0>QES5JK
M"NOT.]R<JS=*A[6'5^"7:5CP&D?CYR0:WY]EH9'_MEL!4$HH'+H=204(3Y(\
M%&@6_MREU&@?)JSN67S^^W4@YDLCD K00B$/6O\\ZY@,]"=3;NW72_R*!^4T
MMOU=(UIBL)VD(=4AH8F62 )D9\ID+W)YAZ/T-\4A*)1O20+WVTZ")@TR2\)
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M)CXR%N#P*O;WF;MY^B*,I4%U=B*,GY^:BYO9F#8W3C?KZ8KS%IL]\((L4P&
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MG8>IPF!+@QTO(HJ ($4#82.-CD!$QS?81F*YZ^M1*R5^?I*%FHBXY>R/A\P
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M,*I/4+QOF4S=?55#_'>MC9Y;LNW/Q)TN+/6P4PRU:&Z8Z%,CXO*4M[YB;->
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M94]NJ[#T5<Y9A3O('BDD=PCZQ#%XS\T]W3A)*LKX42RGDB5Q!8.)FKI7EZ[
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M/Q-:SC'D\L7#FO@+R\!ET0]\,4MZS_=KZ.=MYI<J8&"/5%"KZM<O55]=(Y_
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M[(S^W<[46\/34/#3]4P*XC;](_.'T %O0\I@/']Z.R^7NYT^U 0O#G#4B0@
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M:J"GT._R"CVWM IM<H_G+1$9! 0,>W%-MLQ[5+MR3GW78XEHRE'N64D#7TB
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M7(#1O&9#T1R 1\;E8\4;0+CD<JB.N*[Q='&=,;A!\:S JN6A^<OC@2PNRQL
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M<2SR+;>0"[,2Q"(.$' *K@<"M>_\ >"O%%M#K4T;""]WWYF2\E@%S'(D9=9
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M0#9U?1/@O!J6MZ'=W<Z:GI_F>=9Q7UY]H2-;9YG@ME5MQC$%R_[J'(Q(1C.
M.BU[P3\._#MKI=Y>2WVG0W.IVT.G"WOKI?L]U<-Y2+$JM^Y$K/A@ %).6Z5Y
M5IW["J:=IJQ?\)5!=WHM+BR%W<Z2&9%FT];0NG[W*NI42*<\9(]Z9X<_8SU:
M74;B\U;Q'#I;0:R]U;'3+<F:Y@%W'.C32%Q\X$7R #]V78Y:@#WI_A9X6FTK
M7K:1;F2+6;F.ZOKEM0F\YI8F4QD2[]R;"BX"D8Q5%O@;X'GD1S932,@)G/\
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MVU6^^MVO8%7_V8SRKOKSQJP4!9.O+F_DOA%QD/ -P#L]:#BO 7V:@%#/,O<
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M3.'$P@0G^[#4I3?I_9E46\%]N9,C"K2:&_&>K7RW'>^$?^N>*VC<;YC&X9(
M/*$&WT<W-6UJMJ4\ES\:$YJ="6W&D.O.[@,E%B&FIB%'I:%B;,'^L/Z^T?#E
MN22AA@ '*,2A3BQ&Y;Q$%!:F^X"4V?C_ (O<T##<+R YCD>QR4^B@-DCD$W?
MW;EH_J=@SO9I0ZJG P77G20K5=]ZGBWB2;<:)ESQY9.'J[O06YTQ-]'91]P_
M6[?#FL7YM9DW#<Q3J<MT'NVJ2X(HH#<CSAO,EYAM4PZ#5FQQABU7.+)FEX_=
M&O)Q)?W1G,0F*&S^K*J-[L"3X_@+78PZ* 0;?72*NLJ-Z=>0[[[P+WJ!B[_D
MQUEOK+E^A+H2CL:.(HB)AP>6U]NK#JQQ::=8;,99[P%2_M1E[G@ZTF#!()G^
M'/RFM%CM6Y'61PH-]K-B I?6(/0(?6/A5]4[\6\B@ M%'1+PJ[I07Z6]657^
MP=*VFZ,=C1C>9I\U;U(W:SAR(,MBUOC%D]I;]/+\HH"T02!\W>37]Y-:^#WZ
M3@V%W"G#5[.=\G.PC#6Q?]Q=Y!'UY4CK73]D<&CBCEA1N^F/__!SP'\F-@AW
M<&=:.&>4Q H#+A4%\PMY%.ENSII>O4G1*1X)^M7[I3JUS?ZT#S-:@Z:;W^V[
M,(KZNKAS4;+GN6Z%%#GG\^Q[]5IM]1:4:KO7-,H:4V:,E"JYXE(L91%/26CT
MO(U1WO/!E*W1Q2L<T&ZI]B%4^R_K;/J0?MCH.QS)OWX 4"!3TQTH7#1&80G\
M+ ("[5=NH<TKO]%J=KBO8T^/%(;!*?R),Y\T/SU2H1JMK;L[:O,N^<9Y.!>\
M+6!0E[E\@),WFU5G@&WG.,/[8!I+,X5Z:#)*9E:-9OYPQ;\$V4EUJZ^0LCX3
MG%9WN!K&M6\AT7:C,;=W*ALO4?5.>7^_^GWB'Q%<Q%'T=/J]5ZSW12=&7G\*
MY7'KI9'X6M,2O'2JZN-7,9GS?&FF'51'6^PF$Y72\MZ.^8BT\Y-Z3^?RPASO
M\?<=I2PV7V2__VW$O7^&J?2H!_-SL\K'VD/OA]/B9D%)RG4[J@'U(NW*29V-
MGO %*:K%?MZ\C9ADU2JE]5A^7@,;1Y_U1Q\7*AN@%"<W6AG!RS5)X-@-L&?=
M:X 9T8#[UT"UNN4-J63IU%^@DR,_V!_H'R*<TA?BL$9,^Q!%&'!C<5$KS%.2
M"%\L_O1;ZX7GC_MC<&+KJ04CU8C.1B6 TQ)EUD_B^Y?S@W:J<_V\PCAMOF3%
M^'<H^ZB6FJ@V8G_-Z#U_&L:#IY> MGP>/7W)%1?3,X=WZT&OE8DC+*7!KO8X
M;1]4)]=NXC6 BK!KBGOY$EWNK]\F__4W)7_SVV/+(C9Z9()D!<^\Y(\O^'G/
M$A@@3!.5'!NL&^\'I?<(D/ ]]60D'!@U'SV[-6DC:T7U3]Y/GVXT<":9?%"3
M[D6H'*8@*95&ZY*K;W)[?%[G'WL-ZU-+=,POV]_/.,V6(E_+SS;QS=?TS.7P
M=1=P(FNBX'14O6'5NQ;67O%0NBSU@,F?>Q3S:1'/$Z0AHVH6Z1#0J5,+YJP+
M](YM8@$R"6)Q1V9%5WL?V\#>G+I)A;:V!C0MN4VR9S@^V^1ZW0K9?L"+K2%,
M SG&O?R'=)+7I$"]%Z3#UF!>X:ECK'3>2P'NISR(&!\V?(/;1,\_?Q++6$)?
M7CZS@>@.F/-R7P.B M&)+FC3((NGK9-_]X0:ITE\8GE0 <TFS^^,6DJ'6/"M
MYD'[-8G;F&IP)*$J<VVFU=T5'G);<TJ9J.,E<[6J;->HS6;15^Q'C3^%NKDL
MRU\EG &5,?N(<KP#3K0"ZES_\"O4@^<)6%'*VVW2BO29#3&5O7C)VQS "4QU
MK^;X$ORU,6?D:ZR3TAF TD&(&-XE1,;1W2TH6%'UKQSL" 'W<(+>LYER&I;-
MDY5"E<K\C^J#LA@__[@&R-X?XB$#_)5PB0-LJM-@SA[B?,N6K;:4O,$LZXM9
M<W*&/L)]]:.XQ0.AA%^# **TB,HO_P DBO^C+TI]X<)X(:QR/UTB@7<ZUZH3
M@XC"RY:"I!()&<*M+UYX* OUB]V5? .(O9626BP2,*AEMZ0-"$U#T;WK4,"Y
M%[H3^#IQSE_PIN-X9>FR4K<YU=*9[].YH&QTYCSBB3K\ 76WP#_*^\7.I$;(
ML^2(_%O30#8\-Z8@RM_FTSZ<1F[H9?:7 ,C'/X@,+N5?QD04)4=P\B<'Y5_H
MWG:NEKKRL7>Z/L424FJ@VY(L?]3F+GN/:GQP-5@P"C&8O*!YZC:E+K\F13?P
M??N,5X SL?1;[)N/^U,#8[)!W V>"6?V'A>7!); =] MT_%K ,:6[AK ]( O
M-R>DYD"%IW5NZZ"'[UPXG_$:\-VVDQ!O_;WSMCIW9V!/#O^%.Q:*51RWMG[X
M$LP";Y!=6.@K%(P3IOI0' '@!FA(;&#FGV^Y_$[H'U(TUK:IK#,X!A:S?=9B
M2'M9UT]6JC^$F%A"7*09:[,<QPQ'_7?%]3\9K^VY.Z2L\;0XYRK(Z!DH]WGC
MU*\[,,]%P<YL<9U[(&ZV,93M7A#;GBUFT!K7CQ'MLV/"8!">UN>P!($=>VG-
MU#45+JEWR1D@CX'ZG%)1T%H]HF+;^6/O]."S:"ED6OIS.*+5/RS8+4BY>PPG
M!HTAR(8:C.-Y7%$T(*/F&2?(Y$[(IWG!!2Z@'K'H^T&T+>V-%H <+G03@-C^
MSG=X-9GWZGSE.^:(N\!62>4Y^GF]88FB7%_V *HGA>%&9$$U!5"7Y-^F:]">
M@B0[9JQ=4\[]R8;Y/ZF^WF$=3Q7D^'OV.-:C@C<*+UFN 6"<P0!GX51#/"C6
MM3^0(#0.5XEM0F0IB]A O#XFUC!5,TQ7+.0-'XDI]D?D"_@M]%6IG3;&3&*]
MN$1[T'=N9SYYONBU)RH3?%!U6+M_2!@'$M7/^B5R7O:97P345O1Z*Y@K/_F)
M/4??*RGC<@@<97D1.?CV<USW9*=[)[4U)#C,H#_K&<[+?B\19-#88"^W81-5
MWP3)-WO\Z'=/M'<6==.M8-<!O.&E'&ZSKT,<*SFU/2Q=@+9]U&LY38RKWN>R
ME9J4\&N*--"+A,U.>7_Z+/>G;K_++L ;2!5J,B4,;YSZ!"H<JP0CE,U5 SHN
MGB]4UR3,3NG[<!L*Z@@(J>L]W^=?_RZ[74 ?O-]\:827Q*R/)'#&)#;\X#T=
MH#&Z]6T4YBXO-_C:ZB$U@WAOT!T=%4&!1ID.90B;(1;>^=XKU,"5[8,TKUAQ
M@]J'(R';B0$G8H?6:JK"?WY1\'/'G8MV%=SN$,"!S&?#>=T)O..*MK8$#G<[
MWNGJZA/R)"[ED$3#T!D1)?G^&$G3:$VQ?;UC+NC\RB"!&1=5BHB6=ICZZY"K
MSP;D1\R4Z-7 //^)YL@\,_2#;#0Y1V6()!0"^E/5.S\1+_G1)2Z38G43O-0E
M2G&9/X_LWI9JN45%GWY8,TO\L2!XY[*;4F+4)VY?XH_W._NZS;@V2C0=J97'
MQZOB1YBPO:4_G&W+PJU-!@6R(GH)K.24WG>LQCY9UF$6'BY27?G^7P<*RQ%O
M? 7>\:I(!G[EV[.L^1UGN[I 8WV@/[GZ[E&,:7LGZY2"W(NG1XT_9DITD7'-
M5$12:;9EW3(\N)E0W[7.Z&L _;["DGT?)PWL:ZEKS;;YP*R4T<_5GY5C1"Z'
MI;I1,Q$.)2R"W'& T[C(TXL%HT9P?.L'F.<446EVC]A0UY#Z&SV^1)"]3/CO
M+-:;N> '%'C1W$>SZ@:E'I0^U>!3:V9]J1[K1]%J#EHMM[DJ!'U&?;U\)B.
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M'4'SE9Y?74'L!G^V+.<7&+NNI6-0[A_@0]"?#8P;,_;A_%A8W%T4R8+> -V
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M@*-?](I$?X5UMU:+#9#OD![Z@(N=X#[]OW (19!4%+0=_ "'#6" #<3;A:W
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MOE 1@ @"4)T9%UN*HQ]2X"YK;5BFB9 3"IU-J7-A84(>;*TN/;[^@D;D[<R
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MW"1S#^9NF2NG<&K SA_B'H_M<?I5,)IK"]06]_45_1H+8@LZ1QS,\'EM1HW
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M?8BCYTL$X <W#+.E6"H?/N8"ZL56'(*5["N&G/_]-'AI5 P%1E<O=U\$L1.
M>-U=RUFEW B\12<L[2 K\_PE3GND%+HKY#$CLU@7^BJ&@^E'A,JS+TSWZ;Q)
M$S5*M,XM_ V4-;%1PQJ M;TOS"G[X&=K#C&/3WJ)>50"X>B(>>3,)WZAU6=
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M,'A<0(Q&!U-QA0"\%VG//A)Q &%%P@E 9.[?D1PVU)('6VP%X>\T/@7M%,'
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M?&+EYN,0@^0(+2\^4))ZI?/ W<\T>Z0E_ZF^DDX:]QB4N&N7P7_O3W-@C0@
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M-N]S"A" KYT$ *T+Q3-8=<*.9!#X:T*(G_'_6=G=YH<$X/9)V7_>TZ8GAG;
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M+I*W'M\+#^([]"K\::KFDN66IC#$$G7&XB\_P5X0ZQ3O)-%K@;\3A-XWM$Q
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M(6V;IQ*;-C6O&*Q('!!>8Q*=U1]'(O<8JBWTQI:??NTX>_=J4:F?5WT)U&H
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M?]%,LQT%@:@<_=E&.]W8:?^^(._3+4W.DY46VT6-G_I?4$L#!!0    (  ]
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M#"8FDZ8O"9LE:K_L2S>#&+K%N;JHE0Y1L>I9G S[*TJP?4>0:UO_"9BHNI,
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MP2I]0F74FV('3'(=+^HXY8C>>ZH1A<S2./+$G'D^@1+KC\+X3C\MM,2U3E_
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M:G4'2HXVLX)]U\V0#R%$"?DF7XR<CDANAWSEW<:O8PN4*'X;0 2Q<O8!\8Z
M7!F': K'QD)?QUG>ED 2SAQ2K0=8H;31(3\=SKWNFS]"3-?1I3BGM3-8?O-'
MS[C_L6/%G<(POP.6FW']Z:^)3D!RKP4F()9;+P_#/AMW=.C#NR'%0V]2R?CZ
MF*W9GS^?,NW-(/54^&# C_:J8IO<I%G;*'BXS*NM[5T1<[9E-M_<NR3=]4A\
MG>XBL:(&YJ0V/W_0(B2VMQ>[M2:K[F/[K=.E,V1Q1/F5J-:FA3QH21"=LV+Q
MZ98%$[BLW9P&*84*KW'T71%/J"X[7P]Y%9JQL@J8C]7DBT-+(&<Z%030,>LW
MYM<"=(JN?%(SFH7M>#TI7CUQ5%G]%)^QZ!/$IXU7[(/?#+.HS-FCUV4DW=HA
M1U,'X_9FLFYG\-T+%NJA1\_S'ZD)J)D=%DR,%2]#0#[9&FB^'F/B3D<2B3(R
MAW@0HTG#,YC^Q@$_A%0:/P>JTKE<5=9!0;0_DR8(6Y>7U9QZ/\N)JJ1;9J(D
M)[\_&GD:A^;NP:3;I., ;YE&KAE!Z==-6 :P9L<J4>5:0Q"%/0*=XG>E+5@4
MC^=RX0(1FMP \$%C#8*Q<UE&1@.IV8D"QN=-2=XFOAQ94%FJZTQF1PFFDU/Q
M8\>RG-]"'3A =.!==*' 0> ]).V/6I02XZJC>N"!I-<VFR<\B+>IS%\%,1*"
M4<]%!^E-.Y9XEKZ+M$?I)+)NQ.: R[XJB 24K?"@34"(E)X7B!3(^MVJ\I9$
MV=O]IID)X8/?"%:-GSL)@PRZLQX@>SJ.HX/P,4*EZ,21SAG?S*'624\&<3\[
MN';C>RI,06[KXWYA[L)B;%>>OG;Q'T$-:>F1SLOG--#%W'50S]2/1K@%7/='
M!F_/4E2DHY#WDD.?&:3R(J!G:FK$09'27S8?W?,24;!5ZNR\)J#Y,&U$R\V_
M;^PIW;MU>CRFD[(XK!AVG%4888#A](6F(H5>3DIHR.I0=:PV4:A>Z6>3_7K3
MX.24)?RLR3T4GP._C,4VJMI@)NC]\D>9+PGA6:<=20NBCWIU$)J=%,,_F.5U
MJ%!?(_R@]Q*K)QH?#-D.IJ25ZDU,#W*EM^MLY%?K1'K7C"?72Y4ES?1>]ONL
MUX2J_DBPC)00/)$%%'VW3M1ZPC?T^QANL.I4"A6,LU]OHG-4RAXP#.G%2Q\5
MN=!: 0VUK'PW7D0E7"E6T7EKV=(5%,T;+O9^CEL0]GKC.OO%]#)6=MJ@2VM.
M<54PXDH>)&9D3Y?BO@M77S(!]5]DJ=+)]P]>7 1GD'I<U++P\9.;?,IB37YO
MO9%I]+@GF1MD?+@<8#SF8!_9;6EE[(% QN30<@\NP9HCE](K]]*>OXDT"M?#
MYTSZ0.BOM:H5TRPQWLP2.%ANLG=,C0Y[E:0YB9G5>5[_23I1G#"#FGQYC>!>
M5C4<U*R '(G$/L98(<CB(NZK3X@?D_5X0N@J(K4=.?BYYK_;]%=&4S]9S&K_
M@@YLDJ[M=U5UE]VO<O"31 5X_CX==1TJ5'OTLZ'!_L=)G.C^O);NKCQ^IZ]%
MY'NRH[B?)GM>EBIAAW05)!R"$%)\<O+;')'C92.*P3C /?^W"$74RU\S'HOF
M< RH/G+7ES55/NWSQ#M[Z]-WWLP#&=;XK0I-?+M"1"88.[0G=-D"O-V9IA7=
MR$2>+'#8-4A7;._I+/K(65!<*0PH*+JH-$)@60:,5R>1R:C.ZR_@Z3Z$")J8
MPXWW4(MFAP%][5O%5/3FZ0VJ#<9CS3/3**^6'RCYO4ATVL#:<H\6M3_'9*#$
M+#A.N1)QW9BXT+$J-3$5#.]YH+\HM;S8=CPLEM!:6NJ^[MP9%-Y"C[F[B@/@
M@Z:S&"<:=5=?G'F9[/,<*1<#13)G./A;>5Z1S"]$ LDM7^=GOC"66Q@^&G,U
M2 P\VO6J]]T#SM,8:R4:))>45.MX:8!@I=_.KFD1-M^0#>L_6A =/<8;"@+C
M_#C *EYCXM+>AGWXA$-)V:=\J@H)O;;^G]R/UQF@>6N*AR9K?//.(?#G266&
M8-[USC1.W^[B,JTW,Y;SO"JIS+(FTM9.BST<2<;J(<C(7 A#MW'5P<:AW2GH
M:-EPKR1]%[3SQXCP0L9)=$I$\;Q)@WTI[/C=C-5!/=_:,7G@1/8]">!G"RJ.
MB=6H+@5>Q.(@GVTIW+Z"TSO%383,A8U72I20&^#=Q\Q\%E3IW:5%A>[H4;7W
M0X8I(3.CX)5#>4/Y++(ZD:8>S^!U=WRSTSGDR*M'3,+*#7WU'":_.))AN0/N
M[;((IL&DA,P'IU.<_ZA:O<U][.L-:JZ'IBK\R(WDVQQQX<F-!/Q')M^ HIW%
M)^YU6,CO&&80<+;ES=2#R<;CRHMY%!&32)UKYJ+[?(&GXCU,$ C1TGJ9'5$F
M8--4\TO/]M/"A\.4N]TO6/:WE]%@Q1 <8.?U=,OQAB)&SQ=,&P71>9S!>Y[[
MV]?Y5.[@G:D07TZ$KT1-2\[9._#(9T5;]U4+.LSK:1P UCR! Y!T'RBA-%JL
M>EUG?);/K^\7^(Q@Y(#M.,!O7I#%^0D0RQOWIRT\7N5]?;O^6"?FRT$6?.Y'
M"TVL0VT)H?USW>0%K^4BV,80$W"VWXRCM85"?$BQV]%Q#4BPK.7WMJ@F@S/T
M*7]Z?R.1INO'X6/C183!04\)V* 3*S]C@P[Q<RU$UX]QU#97EZO[18%"I*D[
MO45#&-@>+GW=;G)31"""[N( HX6E0<N]0>@BQ=45['T<($?7& =HB<<!D'J[
M(TP9D]%Y\CYE05XL[X8O'8=*:^IZZ#=?.6A[U< '<C>O#@O.)?F#K&.\#9%!
MH=7.+/X:S<@82)A3RDGW7-5.:8'H(T+_OLE4UV06G_6?Q;XS!X500W1#IV_9
MA^:'>UF$$QAE5U23ND9-E>K'KQF5G9L?H[-\W><?K]6-_(DAX)_ !ID-FY85
ME(+<.E)F6CJ<3)9-X.?W'^J!+$J/?2Q SGZ'!656NRT4]CH[OBRQV0HY[D5#
MCG>ZSV<^,T#>2'NWXG//&F1A[J/9 JGVL?*3L>77A3=YTX1>0I)1SGP'\]^&
M!X]DFW$ <QF/LH<X0%@PV@(;H@'"8I_B %W:.  %,:+E^D[:S#4F# >(+!,4
M=T6$J+G&)@L,U=1XFZ>A9+/X\![]X63<X7A9'&@V\N.,@MQ>IFH-="C8CWK3
M\"R5;I<#;S=1Q@TT@@/8*0;?!S)CJ!Q7P6?+!V2*A^6FBU]J3E\B?[P(]Q^H
MLB66NQ[K\N'^FQ*B]Y4.92SAT]%0DRG-S,X;Y5W[1;O*ZYY8!5NT.))=#K>H
M(.Z(HP??UQZM*B.SPS)-"K*_ADT=BO\^/9RE?&K]IL8U>(0MK1]Y_Z"RR"%F
MY=!;'7DX'7SCHRCL!PI:PAU+DL=1M/2LUOR=ML!#YNV$">:6OT'D/=&Y+3X>
MF60O>58%TP<M-4V80"#)PZHXP#L-6.X\J#1S>GK*>V%_!O7:[S@XD ^A7[>>
M:64^*:?L O.6Z=H>VGQ1P1^UV6X88C;02YQQ1D]?HOBN%/2J ?W.!PH^.TL?
M(31OZA]ZF%:>_K4BG;V]F9+GI=-%Q(C$( [0T881P@'^^%&- P0]P '6?OXS
MAU;_,X=Z_.8N94ZE37D-<7PU:>8R1O:PMQ+)LJ *=9_WF5-7^U"(.Y("I3>N
MP.;OB3CNM#^[YR2^_ CZNZ7RR&2.G;-S\YS4L1?HL<&S:] LA!W115]UUVO%
M^(NL#;00@'LT/Y82Y3D[P4C$"9+*URWQVKB;I3=81;;_7,5_;;DO(!ND!]QY
M(8ZWA<^TS&-BK,SD]T&46__&#VC3MG>]]W' 3.^Y\V<L_K0_WNKN^^IC^CUS
MB<F'7P?/X9%%[T<0S_-D#6:3T!YEDNC#*Y%]()T"YPY6=+31SW.E5%UCHKF-
M.<6K8+/-A^'KXX3;O?%0Q>XZH;]IM4C1000Z++* 26/I\OFTWU4-;,5,K<[3
M@??S)KC8,_GWZ3*2'<G]X<SB8Q"9_UNA3F=6<.I:2E+9' Y@K001^)(D=T^T
M5Z_U%,C0RE0+^&@25 YI\ULF\B=L9!P4,P1A>:@U7%')#PUS'VVVEU!(WSVU
MNB[1U_J[XIKNMI'X5=%1[SNLI@-*YNZO4GO$62^UU+L!86[.!$_IB4?:"YA?
M[1TMIX(J-7  *\F@.?C$JC.&JU;8(4\7.XD=N5H6D95K$5N&'K<W'+JOB$P'
M2J Y>G" ^<!7B.D,%/ &O\T(7(HOYNK<OR7H!X5F]>;RW^9O2$[351O&W2+_
M.VY>/W6I^2A%,@YE2JWMYX8#2,U-*WICI#>7\17PT7EKUHHTA^\QML5HUO93
M\ZQI[*!A6"QV(47:;%,-QNFDV_M8XK?&^4$Y1*4$PY6M,K6L.1$(K*0OY0P>
M @W-J_)?A8Z_X,Q@;>(+^UM]@A[86*5;%LO$Q[$?U/GV)"S.FPDF^7'G#(7F
MI;R"]#TZ5<">JPPV21RVZ(XYMM@,/%+@]W^"="HLC%'10 9^%1^(89L_.$ER
M>*1@LYYQ@-WI#BC^!+N.*'LW42+'5X31F):P"$5)L:\!R>0K."B97&(@9(G?
M43T31,7_=YWXK] :<,G9N*NO!%##9=R*'U:-%11,97\;DTC66@M8.ID^.KJ>
M"&#-4OFQ&U1Y8F_!?'8<K@VZ\V#RM\>XKIJ)Z6U:/1KA@ 5$IF1<J:M^4/F$
M<> PO*5]&:TNQ?)41R8,!9D5J=Q^/K=YD7$]:.L=F!SW9V[RL*P4JT&7M!)E
M5Q<4. "M-K.F*[FY >+$Y,5U7-A1RTAIC]!!G?EQH!,. %J[P@'(PTQ^!@XR
M9D)B?^, ]\$6/12KUV_%>3R8^C@G=';4J=DAWRAM64TPWW$ 2@+O;7F+@T.$
M,A8/+7/#1;")S&85/!HV.HA:>AG.S,,[:TF/J1MAT:+=P '^MK9HB[9J(Q4-
M?I:QR#R_-(?#+\WFS0MT4XS4RFH^EPKX#D O'4MCK]9;#EH@&,L9\67JW?JS
MX^#&MS>J2UX)(:U\J'IGA9:;X3%;<!]S9![" J4-0]NN[1_3@X.[9,)BY=ZZ
MXIO\X\\IUC^H0N%W16YN\K"7'X@T7/\=T-2I,E3(SL27N4I1SDXS2TL&O]+[
M%X-*9-W-K[UOKJG;H)2X \V>E=@\Q#GV'KG3&;+TYMP+L@U8"!I0%!K<OC[
MTN[*V+8&0P)'*9!B5Z!!LES!N.MOJ/<><U<C8MY7\I+G^^9&?Y<[/0/:#'T=
M7>^MK>:$*_VMJPN#@BH:Q8K=JC54=;-@*FQKZ.%U]%>, /KCRC%:W0>I_RNM
M;%ZQ$@=8GW^?@VG*LAV98.B]U-^.;GG7T*32Z0N,]'^P#FHA M=TJ$>IUDVR
M51FM-X90\BS>$P8@]WS)5Q@W@OY,Q>N@/U=\$;8A4]I=*L $+NFM)K@W;?^S
ME#7-PDW:+<O\]=6-?CH6RT^7[CGN99>W36*!=I=R2_)3Q_XJ!?O ^7A06F1
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MC%-I"V_O?$__QOIB(ZB9 "S>A+<B!J6_9&*. V3!%GYG"JW$1;U!^Y38>>,
M=(W*/F46@]P:7N*Q#ZLY%#GMARFW$QHF""SKCHD"!V0*()V'3#VL4LCKD>@S
M>3I)#?GGF;3Q.JV?QFDX>WWD?;@+)0;^'5Y%WZ$91"M!DRI_;-<FKY>FP9<_
MG:*O+/TNT=7)8+,:NCFAYQG@>>R^U\^WJ?@W/8ULJ41:]%VPQJ%B[UW@ &+_
MGC6*_UQ"_)]>$:KX7[[%_[_B_XP5XS>N->Y":H0.!YCA:?GM8+ 5$IB*G0&>
M.&<)X !0[:"=R;*A.^<5<2OJ,[]51FPM>N(@>^V1/&4>%XC<2![ O\SX#-(L
M0O87%;?T@O%VW)^0Y\8+OXU78LU-^7"')_<_-!6*T2P_,/(-:-M5V6RJ(,L?
MQ9!E4XOZ11_9H]2@Q%\##8EUR?1$V"-??*/4%M) )@<%;B&)J:)=F''TL^6.
M0GZE'WZH6!/E<&9.>XI!9KQSI<706\WO1(J9DPDN$U0WN<_O_Y#Q@E(4#7SK
MTRC.BIM>[\_=A5CM60# SJL; C2(W?JGZCZLF6X(B^6(YD&B/$Y=1U$I+0&J
M66:$K^/CHA0<@$R!&83ES5(Q4;<K*V%<98_3N^MHKPC??F[;^7&*U)X![RGA
ML-=*Y,67SK"B1\?CP=2L/R$M:D'ZR?.ZOCB 6=?9SSEN#?MK+ZYD K?>C]-/
M2E[+,(>V[<D75FF;]631:"L#_G?.O^;SD/A9 U*P#F)/=[O"PF)!!>04NZJ7
M[W7G>]*H=2SH=QBJ]L9[^".=K]VB<(#G!8$>:*'.I^VL(J/5$\ZH\A\63WTV
MB.>V?)R8G Z8;>F'^=KZG<]\W(Z]+SAV*J/D7DK75&#FZ@K]69&"R075O\?F
M%.8Y"B5*I!S.;TV^L+)O;#D*)7Z\0>X:N58\55T6,UV?G/J-*$2<L75T:Y3.
M1["C-7Z 3RZ6DHT+5:Z=TKH?>?*QR_=WYO/L*GTYM:(TT%Q#XKS)@+<[62//
MNRQ;PSSEO<$> $4AFX$VU/\1TN;CVM7(W:'<A<7]E/"*(4=(3EV[,*$A#3''
M%KY"HYYBV-*CX#96T?&SB]^;4T&5^6)=#L?EQJ\@ S:/I>_,&\:BNU6,44 "
M_Z#1,N@;9SKX2,$085.N_%;JEB)<H_H<;DG/]<V%H:W/<<&MFM96GQP1,U9
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M0;"]_ND.X]#HK\2+'YZ)TG.&W0K;*=\K<C\<%<RUOG*QPTYU7@2T_?=7Q^$
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M_S R+7?],HT$5/NB5,PS/"A*.O+MKQJE,_L:.:0X:F_(?2V^*>V/\IFGRP7
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M9S&O6OW[ O#W<B(\4%4^\I@3Q)C&MQC[E1'Z]#.Y B0#_$]._;%>_DN' W>
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M)OW&\*?6:Z8_!+\QN'%U(6"F7>&LVZ-;V=H)8E#H.MU;N*;G^!O[J('$;PR
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MI>*=GOP7[Q%60[L43['FE(%6 W/"C$_A=IA$7<HS*9O CYW5.P$*>ICAO0N
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MAT'^NH6D:KZ[DQKYB6DE<D1MZF-@T(M7:&Q6,S1OL.8"$$%*#O2$8<JZ4-
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M:ZLQKR2F$(%D(^>-\AACTN#!P:+H/"Q^_[A#)BS:(?MFXUO/7V>%BO3V#GE
M%W6U!_R*%P#_LPY:%5%Y=C,'&5"78QQ#AUYGCXQ-D>AT?^'<<QU./91;>R+=
M:>MU_,E?*UN>ZPCEMT=OB,YTH<OX+C;Q[M8$\;;&^G#VC<1RCMN@=&R=E.F
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M+E\_]/.2$E%G)@AZ[(P^[66I)/"A>['0;M@:7J+@8=;*CWCW>_D+T"/GF0N
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MPA[R\RY7)\JNG?V6M0KRY?QOPNI.B6MH,F@V3H)VZ9$#2+YT^V6I=\JLO&>
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M;^8>9+D?%^0$S[\<J??^8LW69@8 ?+4#?*?/>7S#%.6O6X7HC' M7$A2ZYW
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MARZU#\\#=MBU9L-V90BN !B"A1(\GDL#3/"O(081>>4AO3(09TR]1WZW8W^
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M5TW\>HF(A650L 0%++%R<L^F^E)*LWF(3Z!S:<072O]@W54RZ+KG5/?:CRO
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M*&ASSD=Y3&(3@/E[);IU0G!22[\\BB/]-F@?;C\E) CRU:.>E(F^+US^(-[
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M18)(W7?S$$U8.W^3O#5G,F'SZ9U"5<]YW51TR!1M[8.\ALO49B843BL%-5'
MA=!90EF)]D-+CQ\- <H&(K;EWXL7X8/"W3+RE)1T/KN947"QFA=]$%W]]*^7
MB3+P ZDY 3TM!EPWV6,[5 BBZTF4SNB% #0Q<G<$5L.TA44804*C.;A^3?X'
M*8#J+8Y$>I(>X66BE_>2./N%<KZ;Y-& QZ3!9>)7[PI !'">@H)H#6OUZPI3
M:J61"/G9+6D3[4=E:JE?,C@2WS8<-DTMH=(T)&[2X 7G:=D=Q_A#6,IZKP =
MEL(^#:4S#*E7  *0H7ZP_IUFMKEM"#D\0VXL-W5^0?XX6,]RDZK"2(D]^+%G
M^B,QQ[%#<84Q+B==H2FEB@#K';BAAD& &!-;:_X9X.$$^8&;Q W:VQ9I,YZU
MC<"G,#W.?K?,'.'PU7#V(AEBQ:=2(;5%1S/2QAA'><AVWB!/@5GVP8%MR263
M218\SFQ<]Q,F?UP!^LS?WGI^H8&%FNK4+Z_MVL,D5.J1!108FFZM($.LP#6<
MW/]4X%0U(A17.3RNULCX9,?2KYF/C$,EBV5/LN0L0ST>L<8AV%?N'D_5\HPP
M+C:N*FT/4>3N7#T?NG/N$WJP<&<[G:,<R9W#G82;\6(,GI7T)>:Q9H@ZYY>/
MW-H!G6.^L]0#XU(\6UIO^[_IF@L-@QTI^\ 5A;&4?A\^G[I@.RRO0F7D2@]6
MB50SP84'L/E:P_WL9CI5#JO:VYUJV/@R(@]OB;"\(\P:30%VP+4>I-LOG8>4
MP'7#RV>*RGGA;XAF!Q%*<Y1[DS^_WW% CHHHM?# ":&K*A 0GQ/ON_WC(,GA
M.^]TI!V?+"5C:($U4EAK;"_V%F?N).>\ :VPCWS$+C/GHMB75TH >O\/]@,
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MV1S+T')>_WA.]I^IF1TY0%O_8PNU7;4&ID!3:B_V8,8HPW7,9CL%NG!IA 2
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MF3G[%7\H%_A8/H/;2@W"0J9HCK\2.G)NBJ.V)/ UP4_.59K>G[AX/G=<P:-
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M06]VH-E7;#0_&MR?Q=9H5**E1("FU+SIRYW.%+TQ_?26F8]FZ9WD6-W0&XK
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M\?%8PK')G]A:#C<# ;CSX<S24$Q[I&3"5<?B 8=,)IXA83W1A;9 *QI+94-
M5,7]>[=AD4%YHOV=&QW:8R':!JK0K:(*JC_POW/0_QV0OTO_ 5!+ P04
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M:">[L1E$?GZ&A?CMI=>GEW^46Q-O3514N[$1IS92WYOC3A27@L>?Z84,!%8
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MSH]"8NG.O>T-,D"-,#5WSMUG^$0RX/Y0+1GP3CL>#T*R(=?>3)(!6#$4C9;
M/S#0U982=W>= O_%1N!B,%&/#,A>M28#?N;:<'($\L+Z6OX(_"_"S3OO?((3
M52$#WJ]:#Y]!4Q?6<G^/D<R.KQX=PM+/MG9A_S*OSC_- P[)B7<P/#&?"9V>
M(/D?5S7_Z[R"_SQ-!4/4G5C@,LB+Q</\9'YNZ/B?O"0/^Q>?U$F('<F3 8E!
M/7>:0:NP0+7Y?W;2R+\X9:'H?X/]7P!;BR<#<#<X?N"&:M_>AHW&!M#,S MN
M"4T(9W:D=GBZ-+P(Z!R(,+$M=5V,JLS$ "6AN9^BL#RF Y%CRC,7!H.N^!)
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M[:*GIMM^-^NN@8XE?GZ\92K$/TE;OP 2Q+_M#BQ:MTK*]O:@KWF-E?W,G04
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M][EM0M+_+5YG2CGQ_Y$6+%M6@@-D ,MY.BV>);1(WL3)8A.RZ$P,T?9K%\@
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M,K!!^XMPP\O8KLH'[7S!'1]YT+CRI=3_AAE2LE(\RG SN39:;Q%A:26%FK)
M;7OD+I" XR2V(EB(R1]/45"6/T^^MMU$R04@N[:)XYVW-;.?FWAX>,<_8((Z
M9XM3_@&SIGU2P\NG0M*=*QD2!_FST^W8ERHQZ"G";1X7]".G3B9:(?!=@/HD
M!!KPJ$@2JM!>--B>3:UJ_\8W)IO:[2G5H^4]_3-N7KXK\<75MXH@4BB0\ 4
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M(9*<+8J+O[SB'H7C686*1J2"I97#,_"=+4L!)58<8W@<7]IU<)[[@>T';<-
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MVGUP]V"*\><P;$2E*T)$)2J]N&W5"T%.0:,@V;T3A.(B_6])A6U_#[3W+J>
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M3.7Z-6\#-N?_7A#2CQCD"V9RM@B/V"4IL.:P-F$,M6BW%-,0*^@>URS7W^%
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MT6O/X3-',8NSR9B<:/Z)'#T\'QK\%*GDT<7SF0S]S/![,U1)V;K$49D[6^(
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M@+FJHD456F)#;V)L=ZQ^B<[S9]MR$'[.N/J5KLA]7E<#84&4RVN[*XC=1@S
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M)V%RR*H@T^:I&2'>@KBKN5D]\P'>3Z!GMSM#H87^H?E:/=P!:.E#^N/)+0!
MY6G>S]'*ZX=>_)-'NTZ=^SJ37KJVT5!T@1^*@7 KJ>:]5\TRT.@9,6'B4F!I
M(B1L/<WDG5[SJ7[3!?"J^6J(7ET:Z:D6ZQBFU^Q5.N_;?P-(-16=7DL!ULNQ
M !_:^-[7[IYBOF\'Z4)Y=_&OI4/R9F52C.&J3[[]O%\9W=9(W%@")+O*!S[
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M'G?*1VD2'Y]KE(JE\SI4JU,Z/))84FDDIN5DYEWUI;":O@'< S+8K)O^;)Z
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M?]GHH!^WH5E1-XY_-W(75T"C&2&()Y.[R;>Q"P8I#PKG-'NJ)9+M)E58RG"
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MI!;Q/EJUL-PO27427=_+ZWH0[TPKP13VO+WOZ2F'\O%>)LP,$I9RVUS#UTX
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M*_111CI,[6G,-+592^*Z"!.FB8WQ[I]^G1>[#P2Z=N^;]&%EQ;\A*_>+R2<
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MS"%OKM<FZ&O?9N#0RAJ6TJV0B.JY+)W1 PFF.+5U3?X-1EC&(%[N#A&L:$Y
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MHN;'J]XEF=R9F5#-PM]Y/5C2,#GR[SZWZLW./TNU:J=*TAXSUFELY/GF9:(
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M\#ON6EUUCT49=>ZP#>E>9C;OK<<D=]T?!#W/=T9=&&BTT3:,[]0_ R&DFQ-
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M@\=U P?N19.,?$AEYKB+6IGUZ8.ZXK"K"DLZVO%<W)!^5XG_H[OWC&IJ;=J
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M:[(O:@S&F/G(0 +B9*F*@_&FS#4SU&28SB3NXS/U9< TNP.2&7$]VK*HN:!
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MRF[3S/F&6M1W3NZRN3H )95R;T$U-*)#=5H('C\^5%$3^.#SO<XQA^<N@8H
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M0+B#>\,&&FZ-GSF:FVOV*S)@AM+8,GV@Z8V?^9.N<6<Y^M;;.4X/B@R9PZD
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M$LNF/V4R3R:T&.A)=KH2#867:X PF#%@T_J_7CCZ_]MQ.?/_ %!+ P04
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M9:."IO!L>$I%]3]C1R,J*:,[6]#Q:[?F>EM(0M.G3"O;R0<-O\.3^XJ\FYG
M9F]:W]G\>YNR=OEY(]FEYT/B+VD&3F+ON2>'+NRX$KI4=F8Z6AX,W.#L.$R4
MMG.VH6JOO2NZ"Z6]H8;? 5!+ P04    "  /0'96C(=X9)L$  !V$@  &
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M_XS\Z)H%!$22+O<>*-L8*,- -,]MNX $$99'2"O7P>LA^U.#GV^!_U18'&2
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M1A;4*LH",L?"+2#7@L4E$CH=VS_8LEK1YIH:I[@ -S?J_;\!4$L! A0#%
M  @ #T!V5L+A!4 @&0  V_T  !$              ( !     &UR:W(M,C R
M,C$R,S$N>'-D4$L! A0#%     @ #T!V5D=HL\'E#P  W]0  !4
M     ( !3QD  &UR:W(M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    (  ]
M=E81,"_-(S<  +)O P 5              "  6<I  !M<FMR+3(P,C(Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    "  /0'96]W".Z9IX   !>08 %0
M    @ &]8   ;7)K<BTR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ #T!V
M5J-:GT_H5@  6 $& !4              ( !BMD  &UR:W(M,C R,C$R,S%?
M<')E+GAM;%!+ 0(4 Q0    (  ] =E85F:C?QK0# (1R(P 5
M  "  :4P 0!M<FMR+3(P,C(Q,C,Q>#$P:RYH=&U02P$"% ,4    "  /0'96
M@Q_F288\  "\/0  &               @ &>Y00 ;7)K<BTR,#(R,3(S,7@Q
M,&LP,#$N:G!G4$L! A0#%     @ #T!V5J*IV?"@M@  .KH  !@
M     ( !6B(% &UR:W(M,C R,C$R,S%X,3!K,# R+FIP9U!+ 0(4 Q0    (
M  ] =E80-2/.IZ8  )NY   8              "  3#9!0!M<FMR+3(P,C(Q
M,C,Q>#$P:S P,RYJ<&=02P$"% ,4    "  /0'96M3#AVHM'   S20  &
M            @ $-@ 8 ;7)K<BTR,#(R,3(S,7@Q,&LP,#0N:G!G4$L! A0#
M%     @ #T!V5I!"?X-M4P  9%4  !@              ( !SL<& &UR:W(M
M,C R,C$R,S%X,3!K,# U+FIP9U!+ 0(4 Q0    (  ] =E:893 ]<IP  ":O
M   8              "  7$;!P!M<FMR+3(P,C(Q,C,Q>#$P:S P-BYJ<&=0
M2P$"% ,4    "  /0'96W63PNG%>  "M>P  &               @ $9N <
M;7)K<BTR,#(R,3(S,7@Q,&LP,#<N:G!G4$L! A0#%     @ #T!V5D.N&QZ@
M:P  '7$  !@              ( !P!8( &UR:W(M,C R,C$R,S%X,3!K,# X
M+FIP9U!+ 0(4 Q0    (  ] =E:VQ(!EJ#(  #1(   8              "
M 9:"" !M<FMR+3(P,C(Q,C,Q>#$P:S P.2YJ<&=02P$"% ,4    "  /0'96
M'KT7Z@80 0"B(P$ &               @ %TM0@ ;7)K<BTR,#(R,3(S,7@Q
M,&LP,3 N:G!G4$L! A0#%     @ #T!V5B(D]$DK?P$ L(T! !@
M     ( !L,4) &UR:W(M,C R,C$R,S%X,3!K,#$Q+FIP9U!+ 0(4 Q0    (
M  ] =E;E?[P]A0(  '4'   8              "  1%%"P!M<FMR+3(P,C(Q
M,C,Q>&5X,C%D,2YH=&U02P$"% ,4    "  /0'96C(=X9)L$  !V$@  &
M            @ ',1PL ;7)K<BTR,#(R,3(S,7AE>#(S9#$N:'1M4$L! A0#
M%     @ #T!V5F+R+D60"   WRT  !@              ( !G4P+ &UR:W(M
M,C R,C$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    (  ] =E:^^Z BDP@  , N
M   8              "  6-5"P!M<FMR+3(P,C(Q,C,Q>&5X,S%D,BYH=&U0
M2P$"% ,4    "  /0'96>#:%0F\%  " %0  &               @ $L7@L
M;7)K<BTR,#(R,3(S,7AE>#,R9#$N:'1M4$L! A0#%     @ #T!V5KQX;R#&
M!0  )1@  !@              ( !T6,+ &UR:W(M,C R,C$R,S%X97@S,F0R
:+FAT;5!+!08     %P 7 #0&  #-:0L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
